Key,Item Type,Publication Year,Author,Title,Publication Title,ISBN,ISSN,DOI,Url,Abstract Note,Date,Date Added,Date Modified,Access Date,Pages,Num Pages,Issue,Volume,Number Of Volumes,Journal Abbreviation,Short Title,Series,Series Number,Series Text,Series Title,Publisher,Place,Language,Rights,Type,Archive,Archive Location,Library Catalog,Call Number,Extra,Notes,File Attachments,Link Attachments,Manual Tags,Automatic Tags,Editor,Series Editor,Translator,Contributor,Attorney Agent,Book Author,Cast Member,Commenter,Composer,Cosponsor,Counsel,Interviewer,Producer,Recipient,Reviewed Author,Scriptwriter,Words By,Guest,Number,Edition,Running Time,Scale,Medium,Artwork Size,Filing Date,Application Number,Assignee,Issuing Authority,Country,Meeting Name,Conference Name,Court,References,Reporter,Legal Status,Priority Numbers,Programming Language,Version,System,Code,Code Number,Section,Session,Committee,History,Legislative Body
YDC4JGE5,journalArticle,2015,"Taveras, EM; Marshall, R; Sharifi, M; Avalon, E; Fiechtner, L; Horan, C; Orav, J; Price, SN; Sequist, T; Slater, D",Connect for Health: Design of a clinical-community childhood obesity intervention testing best practices of positive outliers,CONTEMPORARY CLINICAL TRIALS,,1551-7144,10.1016/j.cct.2015.09.022,,"Background: The Connect for Health study is designed to assess whether a novel approach to care delivery that leverages clinical and community resources and addresses socio-contextual factors will improve body mass index (BMI) and family-centered, obesity-related outcomes of interest to parents and children. The intervention is informed by clinical, community, parent, and youth stakeholders and incorporates successful strategies and best practices learned from 'positive outlier' families, i.e., those who have succeeded in changing their health behaviors and improve their BMI in the context of adverse built and social environments. Design: Two-arm, randomized controlled trial with measures at baseline and 12 months after randomization. Participants: 2-12 year old children with overweight or obesity (EM >= 85th percentile) and their parents/guardians recruited from 6 pediatric practices in eastern Massachusetts. Intervention: Children randomized to the intervention arm receive a contextually-tailored intervention delivered by trained health coaches who use advanced geographic information system tools to characterize children's environments and neighborhood resources. Health coaches link families to community-level resources and use multiple support modalities including text messages and virtual visits to support families over a one-year intervention period. The control group receives enhanced pediatric care plus non-tailored health coaching. Main outcome measures: Lower age-associated increase in BMI over a 1-year period. The main parent- and child-reported outcome is improved health-related quality of life. Conclusions: The Connect for Health study seeks to support families in leveraging clinical and community resources to improve obesity-related outcomes that are most important to parents and children. (C) 2015 Elsevier Inc. All rights reserved.",2015-11,01/07/2022 10:40,01/07/2022 10:40,,287-295,,,45,,,,,,,,,,,,,,WOS:000367755200023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4MPQNY44,journalArticle,2010,"Cizza, G; Marincola, P; Mattingly, M; Williams, L; Mitler, M; Skarulis, M; Csako, G","Treatment of obesity with extension of sleep duration: a randomized, prospective, controlled trial",CLINICAL TRIALS,,1740-7745,10.1177/1740774510368298,,"Background The prevalence of chronic sleep deprivation is increasing in modern societies with negative health consequences. Recently, an association between short sleep and obesity has been reported. Purpose Primary objectives: To assess the feasibility of increasing sleep duration to a healthy length (approximately 7A1/2 h) and to determine the effect of sleep extension on body weight. Secondary objectives: To examine the long-term effects of sleep extension on endocrine (leptin and ghrelin) and immune (cytokines) parameters, the prevalence of metabolic syndrome, body composition, psychomotor vigilance, mood, and quality of life. Methods One hundred-fifty obese participants who usually sleep less than 6A1/2 h, are being randomized at a 2:1 ratio to either an Intervention or to a Comparison Group. They are stratified by age (above and below 35) and the presence or absence of metabolic syndrome. During the first 12 months (Efficacy Phase) of the study, participants are evaluated at bi-monthly intervals: the Intervention Group is coached to increase sleep by at least 30-60 min/night, while the Comparison Group maintains baseline sleep duration. In the second (Effectiveness) phase, participants converge into the same group and are asked to increase (Comparison Group) or maintain (Intervention Group) sleep duration and are evaluated at 6-month intervals for an additional 3 years. Non-pharmacological and behavior-based interventions are being utilized to increase sleep duration. Endocrine, metabolic, and psychological effects are monitored. The sleep, energy expenditure, and caloric intake are assessed by activity monitors and food recall questionnaires. At yearly intervals, body composition, abdominal fat, and basal metabolic rate are measured by dual energy X-ray absorptiometry (DXA), computerized tomography (CT), and indirect calorimetry, respectively. Results As of January 2010, 109 participants had been randomized, 64 to the Intervention Group and 45 to the Comparison Group (76% women, 62% minorities, average age: 40.8 years; BMI: 38.5 kg/m(2)). Average sleep duration at screening was less than 6 h/night, 40.3 h/week. A total of 28 Intervention and 22 Comparison participants had completed the Efficacy Phase. Limitations The study is not blinded and the sample size is relatively small. Conclusions This proof-of-concept study on a randomized sample will assess whether sleep extension is feasible and whether it influences BMI. Clinical Trials 2010; 7: 274-285. http://ctj.sagepub.com.",2010-06,01/07/2022 10:40,01/07/2022 10:40,,274-285,,3,7,,,,,,,,,,,,,,WOS:000277861400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3GBQ5Z4G,journalArticle,2014,"Qaseem, A; Dallas, P; Owens, DK; Starkey, M; Holty, JEC; Shekelle, P; Amer Coll Phys",Diagnosis of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians,ANNALS OF INTERNAL MEDICINE,,0003-4819,10.7326/M12-3187,,"Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the diagnosis of obstructive sleep apnea in adults. Methods: This guideline is based on published literature on this topic that was identified by using MEDLINE (1966 through May 2013), the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular mortality, nonfatal cardiovascular disease, stroke, hypertension, type 2 diabetes, postsurgical outcomes, and quality of life. Sensitivities, specificities, and likelihood ratios were also assessed as outcomes of diagnostic tests. This guideline grades the evidence and recommendations by using ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends a sleep study for patients with unexplained daytime sleepiness. (Grade: weak recommendation, low-quality evidence) Recommendation 2: ACP recommends polysomnography for diagnostic testing in patients suspected of obstructive sleep apnea. ACP recommends portable sleep monitors in patients without serious comorbidities as an alternative to polysomnography when polysomnography is not available for diagnostic testing. (Grade: weak recommendation, moderate-quality evidence)",05/08/2014,01/07/2022 10:40,01/07/2022 10:40,,210-U169,,3,161,,,,,,,,,,,,,,WOS:000340486000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JK927DEG,journalArticle,2007,"Albert, A; Florath, I; Rosendahl, U; Hassanein, W; Hodenberg, EV; Bauer, S; Ennker, I; Ennker, J",Effect of surgeon on transprosthetic gradients after aortic valve replacement with Freestyle (R) stentless bioprosthesis and its consequences: A follow-up study in 587 patients,JOURNAL OF CARDIOTHORACIC SURGERY,,1749-8090,10.1186/1749-8090-2-40,,"Background: The implantation of stentless valves is technically demanding and the outcome may depend on the performance of surgeons. We studied systematically the role of surgeons and other possible determinants for mid-term survival, postoperative gradients and Quality of Life (QoL) after aortic valve replacement (AVR) with Freestyle (R) stentless bioprostheses. Methods: Between 1996 and 2003, 587 patients (mean 75 years) underwent AVR with stentless Medtronic Freestyle (R) bioprostheses. Follow-up was 99% complete. Determinants of morbidity, mortality, survival time and QoL were evaluated by multiple, time-related, regression analysis. Risk models were built for all sections of the Nottingham Health Profile (NHP): energy, pain, emotional reaction, sleep, social isolation and physical mobility Results: Actuarial freedom from aortic valve re-operation, structural valve deterioration, non-structural valve dysfunction, prosthetic valve endocarditis and thromboembolic events at 6 years were 95.9 +/- 2.1%, 100%, 98.7 +/- 0.5%, 97.0 +/- 1.5%, 79.6 +/- 4.3%, respectively. The actuarial freedom from bleeding events at 6 years was 93.1 +/- 1.9%. Estimated survival at 6 years was similar to the age-matched German population (61.4 +/- 3.8%). Predictors of survival time were: diabetes mellitus, atrial fibrillation, peripheral vascular disease, renal dysfunction, female gender > 80 years and patients < 165 cm with BMI < 24. Predictive models showed characteristic profiles and good discriminative powers (c-indexes > 0.7) for each of the 6 QoL sections. Early transvalvular gradients were identified as independent risk factors for impaired physical mobility (c-index 0.77, p < 0.002). A saturated propensity score identified besides patient related factors (e. g. preoperative gradients, ejection fraction, haematological factors) indexed geometric orifice area, subcoronary implantation technique and individual surgeons as predictors of high gradients. Conclusion: In addition to the valve size (in relation to body size), subcoronary technique (versus total root) and various patient-related factors the risk of elevated gradients after stentless valve implantation depends, considerably on the individual surgeon. Although there was no effect on survival time and most aspects of QoL, higher postoperative transvalvular gradients affect physical mobility after AVR.",2007,01/07/2022 10:40,01/07/2022 10:40,,,,,2,,,,,,,,,,,,,,WOS:000205631000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Z9LZ6XVS,journalArticle,2011,"Lenders, CM; Gorman, K; Lim-Miller, A; Puklin, S; Pratt, J",Practical Approaches to the Treatment of Severe Pediatric Obesity,PEDIATRIC CLINICS OF NORTH AMERICA,,0031-3955,10.1016/j.pcl.2011.09.013,,"Pediatric obesity is a major public health threat. Obese children and adolescents are at increased risk for many medical and surgical conditions. These conditions may affect their quality of life and life expectancy. The rapidly progressive nature of type 2 diabetes mellitus within the first 5 years of obesity diagnosis is particularly concerning. Because health risk increases with degree of obesity, adolescents who may be eligible for more aggressive obesity treatment should be identified and counseled.",2011-12,01/07/2022 10:40,01/07/2022 10:40,,1425-+,,6,58,,,,,,,,,,,,,,WOS:000298311700008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HG43WRT9,journalArticle,2017,"Caperchione, CM; Bottorff, JL; Oliffe, JL; Johnson, ST; Hunt, K; Sharp, P; Fitzpatrick, KM; Price, R; Goldenberg, SL","The HAT TRICK programme for improving physical activity, healthy eating and connectedness among overweight, inactive men: study protocol of a pragmatic feasibility trial",BMJ OPEN,,2044-6055,10.1136/bmjopen-2017-016940,,"Introduction Physical activity, healthy eating and maintaining a healthy weight are associated with reduced risk of cardiovascular disease, type 2 diabetes and cancer and with improved mental health. Despite these benefits, many men do not meet recommended physical activity guidelines and have poor eating behaviours. Many health promotion programmes hold little appeal to men and consequently fail to influence men's health practices. HAT TRICK was designed as a 12-week face-to-face, gender-sensitised intervention for overweight and inactive men focusing on physical activity, healthy eating and social connectedness and was delivered in collaboration with a major junior Canadian ice hockey team (age range 16-20 years). The programme was implemented and evaluated to assess its feasibility. This article describes the intervention design and study protocol of HAT TRICK. Methods and analysis HAT TRICK participants (n=60) were men age 35 years, residing in the Okanagan Region of British Columbia, who accumulate 150 min of moderate to vigorous physical activity a week, with a body mass index of > 25 kg/m(2) and a pant waist size of >38'. Each 90 min weekly session included targeted health education and theory-guided behavioural change techniques, as well as a progressive (ie, an increase in duration and intensity) group physical activity component. Outcome measures were collected at baseline, 12 weeks and 9 months and included the following: objectively measured anthropometrics, blood pressure, heart rate, physical activity and sedentary behaviour, as well as self-reported physical activity, sedentary behaviour, diet, smoking, alcohol consumption, sleep habits, risk of depression, health-related quality of life and social connectedness. Programme feasibility data (eg, recruitment, satisfaction, adherence, content delivery) were assessed at 12 weeks via interviews and self-report. Ethics and dissemination Ethical approval was obtained from the University of British Columbia Okanagan Behavioural Research Ethics Board (reference no H1600736). Study findings will be disseminated through academic meetings, peer-reviewed publication, web-based podcasts, social media, plain language summaries and co-delivered community presentations.",2017-09,01/07/2022 10:40,01/07/2022 10:40,,,,9,7,,,,,,,,,,,,,,WOS:000412650700176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SURWR8Y5,journalArticle,2020,"Papadakis, JL; Anderson, LM; Garza, K; Feldman, MA; Shapiro, JB; Evans, M; Thompson, LG; Weissberg-Benchell, J",Psychosocial Aspects of Diabetes Technology Use The Child and Family Perspective,ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA,,0889-8529,10.1016/j.ecl.2019.10.004,,"This article offers a systematic review of the literature on psychosocial aspects of technology use in children and adolescents with type 1 diabetes and their families, searching for relevant articles published the past 5 years. Topics included continuous subcutaneous insulin infusion, continuous glucose monitoring, predictive low-glucose suspend, and artificial pancreas systems. The review indicates there are positive and negative psychosocial aspects to diabetes technology use among youth and their families. Although consistent findings were revealed, contradictions exist. Discussed are recommendations for future research and implications for how health care providers can collaborate with families to discuss and manage diabetes technology.",2020-03,01/07/2022 10:40,01/07/2022 10:40,,127-+,,1,49,,,,,,,,,,,,,,WOS:000518078700011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UCLGWR9G,journalArticle,2019,"Weghuber, D; Barrientos-Perez, M; Kovarenko, M",Youth-Onset Type 2 Diabetes Manifestations in other Specialties: Its Many Disguises,ANNALS OF NUTRITION AND METABOLISM,,0250-6807,10.1159/000500234,,"Background: Youth-onset type 2 diabetes (T2D) is increasing in many countries, creating large personal and societal burdens. While many primary health-care professionals (HCPs) are aware of the classic symptoms of T2D, there are several other manifestations that could indicate its presence. Summary: This narrative review summarizes information on these symptoms and indicators, focusing on those less well known. The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annulare, necrobiosis lipoidica diabeticorum, and scleredema), gynecological (e.g., polycystic ovary syndrome, oligomenorrhea, and vulvovaginitis), hepatological (e.g., nonalcoholic fatty liver disease), and psychiatric diseases (e.g., psychosis, depression, and autism) could indicate that a patient has T2D or is at increased risk of T2D. Other less well-known indicators include abnormal blood tests (e.g., oxidized lipids, inflammation markers, hepatokines, and adipokines), prescriptions for antipsychotic medications or statins, and disrupted sleep patterns. Key Message: Due to the diversity of T2D manifestations in young people, primary HCPs need to remain alert to its possible presence. (c) 2019 S. Karger AG, Basel",2019,01/07/2022 10:40,01/07/2022 10:40,,339-347,,4,74,,,,,,,,,,,,,,WOS:000470847600009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YZ6N3SLI,journalArticle,2019,"Jung, SW; Lee, KJ; Lee, JH",Does Weekend Catch-up Sleep Affect High-Sensitivity C-Reactive Protein Levels Among Korean Workers? A Cross-Sectional Study Using KNHANES,JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE,,1076-2752,10.1097/JOM.0000000000001657,,"Objective: We sought to determine whether weekend catch-up sleep (CUS) influenced serum high-sensitivity C-reactive protein (hs-CRP) levels in workers. Methods: We analyzed the Korean National Health and Nutrition Examination Survey (2016) data from 3304 workers. Univariate and multivariate logistic regression analyses were used to calculate odds ratios and 95% confidence intervals based on serum hs-CRP cut-off values of 1.0 and 3.0 mg/L, respectively. Results: We found that at least 1-hour and less than 2 hours of weekend CUS reduced the risk of elevated hs-CRP levels (odds ratio 0.80, 95% confidence interval 0.64 to 0.99) in multivariate logistic regression analysis. Conclusion: CUS may reduce serum hs-CRP levels in workers, thereby reducing the risk of cardiovascular disease.",2019-09,01/07/2022 10:40,01/07/2022 10:40,,E367-E373,,9,61,,,,,,,,,,,,,,WOS:000500762900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RZJPQ6LA,journalArticle,2019,"Brouwer, A; van Raalte, DH; Nguyen, HT; Rutters, F; van de Ven, PM; Elders, PJM; Moll, AC; Van Someren, EJW; Snoek, FJ; Beekman, ATF; Bremmer, MA",Effects of Light Therapy on Mood and Insulin Sensitivity in Patients With Type 2 Diabetes and Depression: Results From a Randomized Placebo-Controlled Trial,DIABETES CARE,,0149-5992,10.2337/dc18-1732,,"OBJECTIVE Depression is common in patients with type 2 diabetes and adversely affects quality of life and diabetes outcomes. We assessed whether light therapy, an antidepressant, improves mood and insulin sensitivity in patients with depression and type 2 diabetes. RESEARCH DESIGN AND METHODS This randomized, double-blind, placebo-controlled trial included 83 patients with depression and type 2 diabetes. The intervention comprised 4 weeks of light therapy (10,000 lux) or placebo light therapy daily at home. Primary outcomes included depressive symptoms (Inventory of Depressive Symptomatology [IDS]) and insulin sensitivity (M-value derived from the results of a hyperinsulinemic-euglycemic clamp). Secondary outcomes were related psychological and glucometabolic measures. RESULTS Intention-to-treat analysis showed that light therapy was not superior to placebo in reducing depressive symptoms (-3.9 IDS points [95% CI -9.0 to 1.2]; P = 0.248) and had no effect on insulin sensitivity (0.15 mg/kg*min [95% CI -0.41 to 0.70]; P = 0.608). Analyses incorporating only those participants who accurately adhered to the light therapy protocol (n = 51) provided similar results, but did suggest positive effects of light therapy on depression response rates (>= 50% reduction in IDS points) (26% more response; P = 0.031). Prespecified analysis showed effect moderation by baseline insulin sensitivity (P = 0.009) and use of glucose-lowering medication (P = 0.023). Light therapy did not affect depressive symptoms in participants with higher insulin sensitivity or those who use only oral glucose-lowering medication or none at all, but it did produce a relevant effect in participants with lower insulin sensitivity (-12.9 IDS points [95% CI -21.6 to -4.2]; P = 0.017) and a trend toward effectiveness in those using insulin (-12.2 IDS points [95% CI -21.3 to -3.1]; P = 0.094). Light therapy was well tolerated. CONCLUSIONS Although this trial is essentially inconclusive, secondary analyses indicate that light therapy might be a promising treatment for depression among a subgroup of highly insulin-resistant individuals with type 2 diabetes.",2019-04,01/07/2022 10:40,01/07/2022 10:40,,529-538,,4,42,,,,,,,,,,,,,,WOS:000461816500017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JJ6HSWF9,journalArticle,2008,"Bajaj, JS",Minimal hepatic encephalopathy matters in daily life,WORLD JOURNAL OF GASTROENTEROLOGY,,1007-9327,10.3748/wjg.14.3609,,"Minimal hepatic encephalopathy is a neuro-cognitive dysfunction which occurs in an epidemic proportion of cirrhotic patients, estimated as high as 80% of the population tested. It is characterized by a specific, complex cognitive dysfunction which is independent of sleep dysfunction or problems with overall intelligence. Although named ""minimal"", minimal hepatic encephalopathy (MHE) can have a far-reaching impact on quality of life, ability to function in daily life and progression to overt hepatic encephalopathy. Importantly, MHE has a profound negative impact on the ability to drive a car and may be a significant factor behind motor vehicle accidents. A crucial aspect of the clinical care of MHE patients is their driving history, which is often ignored in routine care and can add a vital dimension to the overall disease assessment. Driving history should be an integral part of care in patients with MHE. The lack of specific signs and symptoms, the preserved communication skills and lack of insight make MHE a difficult condition to diagnose. Diagnostic strategies for MHE abound, but are usually limited by financial, normative or time constraints. Recent studies into the inhibitory control and critical flicker frequency tests are encouraging since these tests can increase the rates of MHE diagnosis without requiring a psychologist. Although testing for MHE and subsequent therapy is not standard of care at this time, it is important to consider this in cirrhotics in order to improve their ability to live their life to the fullest. (C) 2008 WJG. All rights reserved.",21/06/2008,01/07/2022 10:40,01/07/2022 10:40,,3609-3615,,23,14,,,,,,,,,,,,,,WOS:000257580600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LBYFWCJ8,journalArticle,2014,"Pickering, G; Pereira, B; Morel, V; Tiberghien, F; Martin, E; Marcaillou, F; Picard, P; Delage, N; de Montgazon, G; Sorel, M; Roux, D; Dubray, C",Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients,CONTEMPORARY CLINICAL TRIALS,,1551-7144,10.1016/j.cct.2014.06.004,,"The N-methyl-D-aspartate receptor plays an important role in central sensitization of neuropathic pain and N-methyl-D-aspartate receptor antagonists, such as ketamine, memantine and dextromethorphan may be used for persistent pain. However, ketamine cannot be repeated too often because of its adverse events. A drug relay would be helpful in the outpatient to postpone or even cancel the next ketamine infusion. This clinical trial evaluates if memantine and/or dextromethorphan given as a relay to ketamine responders may maintain or induce a decrease of pain intensity and have a beneficial impact on cognition and quality of life. This trial is a multi-center, randomized, controlled and single-blind clinical study (NCT01602185). It includes 60 ketamine responder patients suffering from neuropathic pain. They are randomly allocated to memantine, dextromethorphan or placebo. After ketamine infusion, 60 patients received either memantine (maximal dose 20 mg/day), or dextromethorphan (maximal dose 90 mg/day), or placebo for 12 weeks. The primary endpoint is pain measured on a (0-10) Numeric Rating Scale 1 month after inclusion. Secondary outcomes include assessment of neuropathic pain, sleep, quality of life, anxiety/depression and cognitive function at 2 and 3 months. Data analysis is performed using mixed models and the tests are two-sided, with a type I error set at alpha = 0.05. This study will explore if oral memantine and/or dextromethorphan may be a beneficial relay in ketamine responders and may diminish ketamine infusion frequency. Preservation of cognitive function and quality of life is also a central issue that will be analyzed in these vulnerable patients. (C) 2014 Published by Elsevier Inc.",2014-07,01/07/2022 10:40,01/07/2022 10:40,,314-320,,2,38,,,,,,,,,,,,,,WOS:000340301400019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E3S7YLGM,journalArticle,2019,"Sethakarun, S; Bijaphala, S; Kitiyakara, C; Boongird, S; Phanachet, P; Reutrakul, S; Pirojsakul, K; Nongnuch, A","Effect of bioelectrical impedance analysis-guided dry weight adjustment, in comparison to standard clinical-guided, on the sleep quality of chronic haemodialysis patients (BEDTIME study): a randomised controlled trial",BMC NEPHROLOGY,,1471-2369,10.1186/s12882-019-1405-z,,"Background Sleep disturbance is common among chronic haemodialysis patients, which leads to poor quality of life, in addition to increased instances of morbidity and mortality. Hypervolemia has been linked to sleep problems observed in chronic haemodialysis patients, which suggests that optimising one's fluid status could improve the sleep quality of this patient group. In our study, we subjectively examined and objectively measured sleep parameters, using actigraphy recordings, the Pittsburgh Sleep Quality Index (PSQI) questionnaire, and Epworth Sleepiness Scale (ESS), in order to compare bioelectrical impedance analysis (BIA)-guided and standard clinical-guided dry weight adjustment. Methods We randomly selected 19 chronic haemodialysis patients with subclinical hypervolemia, defined as a clinically euvolemic status, despite the ratio of extracellular water to total body water being more than 0.4 in BIA. Furthermore, these patients, who were poor sleepers (PSQI > 5), were assigned to either a BIA-guided dry weight group (BIA group) or a standard clinical-guided one (clinical group). The primary outcome was changes in sleep actigraphy parameters between the groups at 1, 3, and 6 months. Changes observed in the PSQI and ESS score between the two groups over the same period of time were the secondary endpoints. Results The mean age of the participants was 63.53 +/- 11.12 years, and 42% of them were male. All sleep parameters measured by means of actigraphy were not significantly different between the two groups. Interestingly, at 3 and 6 months, the subjective sleep quality significantly improved in the BIA group, as reflected by a greater decline in the PSQI score, in comparison with the clinical group (3 months: mean difference - 1.82 [- 3.13 to - 0.51], P = 0.006; 6 months: mean difference - 3.16 [- 4.49 to - 1.83], P < 0.001). However, sleepiness assessed by the ESS was not significantly different between the groups throughout the study. Conclusions Optimisation of the fluid status by employing BIA did not improves sleep actigraphy parameter, however, it significantly ameliorates the subjective sleep quality of chronic haemodialysis patients. This observation should be further explored in larger samples and longer clinical trials.",02/09/2019,01/07/2022 10:40,01/07/2022 10:40,,,,1,20,,,,,,,,,,,,,,WOS:000483549900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5JPFMYHW,journalArticle,2016,"Senaratna, CV; English, DR; Currier, D; Perret, JL; Lowe, A; Lodge, C; Russell, M; Sahabandu, S; Matheson, MC; Hamilton, GS; Dharmage, SC","Sleep apnoea in Australian men: disease burden, co-morbidities, and correlates from the Australian longitudinal study on male health",BMC PUBLIC HEALTH,,1471-2458,10.1186/s12889-016-3703-8,,"Background: Obstructive sleep apnoea is a common disorder with under-rated clinical impact, which is increasingly being recognised as having a major bearing on global disease burden. Men are especially vulnerable and become a priority group for preventative interventions. However, there is limited information on prevalence of the condition in Australia, its co-morbidities, and potential risk factors. Methods: We used data from 13,423 adult men included in the baseline wave of Ten to Men, an Australian national study of the health of males, assembled using stratified cluster sampling with oversampling from rural and regional areas. Those aged 18-55 years self-completed a paper-based questionnaire that included a question regarding health professional-diagnosed sleep apnoea, physical and mental health status, and health-related behaviours. Sampling weights were used to account for the sampling design when reporting the prevalence estimates. Odds ratios were used to describe the association between health professional-diagnosed sleep apnoea and potential correlates while adjusting for age, country of birth, and body-mass index (BMI). Results: Prevalence of self-reported health professional-diagnosed sleep apnoea increased from 2.2 % in age 18-25 years to 7.8 % in the age 45-55 years. Compared with those without sleep apnoea, those with sleep apnoea had significantly poorer physical, mental, and self-rated health as well as lower subjective wellbeing and poorer concentration/remembering (p < 0.001 for all). Sleep apnoea was significantly associated with older age (p < 0.001), unemployment (p < 0.001), asthma (p = 0.011), chronic obstructive pulmonary disease/chronic bronchitis (p = 0.002), diabetes (p < 0.001), hypercholesterolemia (p < 0.001), hypertension (p < 0.001), heart attack (p < 0.001), heart failure (p < 0.001), angina (p < 0.001), depression (p < 0.001), post-traumatic stress disorder (p < 0.001), other anxiety disorders (p < 0.001), schizophrenia (p = 0.002), overweight/obesity (p < 0.001), insufficient physical activity (p = 0.006), smoking (p = 0.005), and high alcohol consumption (p < 0.001). Conclusion: Health professional-diagnosed sleep apnoea is relatively common, particularly in older males. Associations between sleep apnoea and cardiovascular, metabolic, respiratory, and psychiatric disorders have important clinical and public health implications. As men are especially vulnerable to sleep apnoea as well as some of its chronic co-morbidities, they are potentially a priority group for health interventions. Modifiable lifestyle related factors such as smoking, alcohol consumption, level of physical activity and BMI are possible key foci for interventions.",31/10/2016,01/07/2022 10:40,01/07/2022 10:40,,,,,16,,,,,,,,,,,,,,WOS:000392422000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LCLUMHHB,journalArticle,2021,"Potratz, M; Sohns, C; Dumitrescu, D; Sommer, P; Fox, H",Phrenic Nerve Stimulation Improves Physical Performance and Hypoxemia in Heart Failure Patients with Central Sleep Apnea,JOURNAL OF CLINICAL MEDICINE,,2077-0383,10.3390/jcm10020202,,"Background: Central sleep apnea (CSA) is a common comorbidity in patients with heart failure (HF) and has been linked to increased morbidity and mortality risk. In addition, CSA is associated with impaired quality of life, reduced physical performance capacity, and hypoxemia. Phrenic nerve stimulation (PNS) is a novel approach to the treatment of CSA and has been shown to be safe and effective in this indication. However, there are currently no data on the effects of PNS on physical performance and hypoxia in CSA HF patients, both of which have been shown to be linked to mortality in HF. Methods: This prospective study enrolled patients with HF and CSA diagnosed using polysomnography. All were implanted with a PNS system (remede(R) system, Respicardia Inc., Minnetonka, MN, USA) for the treatment of CSA. Examinations included polysomnography (to determine hypoxemic burden), echocardiography and a standardized 6-min walk test prior to device implantation (baseline) and after 6 months of follow-up. Results: A total of 24 patients were enrolled (mean age 67.1 +/- 11.2 years, 88% male). The 6-min walk distance was 369.5 +/- 163.5 m at baseline and significantly improved during follow-up (to 410 +/- 169.7 m; p = 0.035). Hypoxemic burden, determined based on time with oxygen saturation < 90% improved from 81 +/- 55.8 min at baseline to 27.9 +/- 42.8 min during PNS therapy (p < 0.01). Conclusion: In addition to safely and effectively treating CSA, PNS is also associated with improved physical performance capacity and reduced hypoxemic burden in patients with HF.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,,,2,10,,,,,,,,,,,,,,WOS:000611310500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HKNQCRQF,journalArticle,2012,"Ponikowski, P; Javaheri, S; Michalkiewicz, D; Bart, BA; Czarnecka, D; Jastrzebski, M; Kusiak, A; Augostini, R; Jagielski, D; Witkowski, T; Khayat, RN; Oldenburg, O; Gutleben, KJ; Bitter, T; Karim, R; Iber, C; Hasan, A; Hibler, K; Germany, R; Abraham, WT",Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure,EUROPEAN HEART JOURNAL,,0195-668X,10.1093/eurheartj/ehr298,,"Periodic breathing with central sleep apnoea (CSA) is common in heart failure patients and is associated with poor quality of life and increased risk of morbidity and mortality. We conducted a prospective, non-randomized, acute study to determine the feasibility of using unilateral transvenous phrenic nerve stimulation for the treatment of CSA in heart failure patients. Thirty-one patients from six centres underwent attempted transvenous lead placement. Of these, 16 qualified to undergo two successive nights of polysomnographyone night with and one night without phrenic nerve stimulation. Comparisons were made between the two nights using the following indices: apnoeahypopnoea index (AHI), central apnoea index (CAI), obstructive apnoea index (OAI), hypopnoea index, arousal index, and 4 oxygen desaturation index (ODI4). Patients underwent phrenic nerve stimulation from either the right brachiocephalic vein (n 8) or the left brachiocephalic or pericardiophrenic vein (n 8). Therapy period was (mean SD) 251 71 min. Stimulation resulted in significant improvement in the AHI [median (inter-quartile range); 45 (3959) vs. 23 (1227) events/h, P 0.002], CAI [27 (1138) vs. 1 (05) events/h, P 0.001], arousal index [32 (2042) vs. 12 (927) events/h, P 0.001], and ODI4 [31 (2236) vs. 14 (720) events/h, P 0.002]. No significant changes occurred in the OAI or hypopnoea index. Two adverse events occurred (lead thrombus and episode of ventricular tachycardia), though neither was directly related to phrenic nerve stimulation therapy. Unilateral transvenous phrenic nerve stimulation significantly reduces episodes of CSA and restores a more natural breathing pattern in patients with heart failure. This approach may represent a novel therapy for CSA and warrants further study. ClinicalTrials.gov identifier: NCT00909259.",2012-04,01/07/2022 10:40,01/07/2022 10:40,,889-894,,7,33,,,,,,,,,,,,,,WOS:000302497800021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9MI5CNP5,journalArticle,2017,"Ratjen, I; Schafmayer, C; di Giuseppe, R; Waniek, S; Plachta-Danielzik, S; Koch, M; Burmeister, G; Nothlings, U; Hampe, J; Schlesinger, S; Lieb, W","Postdiagnostic physical activity, sleep duration, and TV watching and all-cause mortality among long-term colorectal cancer survivors: a prospective cohort study",BMC CANCER,,1471-2407,10.1186/s12885-017-3697-3,,"Background: Lifestyle recommendations for cancer survivors are warranted to improve survival. In this study, we aimed to examine the association of total physical activity, different types of physical activity, hours of sleeping at day and night, and hours spent watching television (TV) with all-cause mortality in long-term colorectal cancer (CRC) survivors. Methods: We assessed physical activity in 1376 CRC survivors (44% women; median age, 69 years) at median 6 years after CRC diagnosis using a validated questionnaire. Multivariable-adjusted Cox regression models were used to estimate hazard ratios (HRs) for all-cause mortality according to categories of physical activities, sleep duration, and TV watching. Results: During a median follow-up time of 7 years, 200 participants had died. Higher total physical activity was significantly associated with lower all-cause mortality (HR: 0.53; 95% CI: 0.36-0.80, 4th vs. 1st quartile). Specifically, sports, walking, and gardening showed a significant inverse association with all-cause mortality (HR: 0.34; 95% CI: 0. 20-0.59, HR: 0.65; 95% CI: 0.43-1.00, and HR: 0.62; 95% CI: 0.42-0.91, respectively for highest versus lowest category). Individuals with >= 2 h of sleep during the day had a significantly increased risk of all-cause mortality compared to individuals with no sleep at day (HR: 2.22; 95% CI: 1.43-3.44). TV viewing of >= 4 h per day displayed a significant 45% (95% CI: 1.02-2.06) higher risk of dying compared to <= 2 h per day of watching TV. Conclusions: Physical activity was inversely related to all-cause mortality; specific activity types might be primarily responsible for this association. More hours of sleep during the day and a higher amount of TV viewing were each associated with higher all-cause mortality. Based on available evidence, it is reasonable to recommend CRC survivors to engage in regular physical activity.",25/10/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,17,,,,,,,,,,,,,,WOS:000413783800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4N3UD9GJ,journalArticle,2004,"Nicholson, B; Verma, S",Comorbidities in chronic neuropathic pain,PAIN MEDICINE,,1526-2375,10.1111/j.1526-4637.2004.04019.x,,"Neuropathic pain arises from a lesion or dysfunction within the nervous system; the specific mechanisms that elicit neuropathic pain symptoms are the subject of ongoing research. It is generally acknowledged that neuropathic pain is extremely difficult to treat, and a major factor impacting outcomes is the presence of comorbidities such as poor sleep, depressed mood, and anxiety. Patients who suffer from chronic pain experience difficulties in initiating and maintaining sleep. Sleep deprivation has been associated with a decreased pain threshold, muscle aches, and stiffness in normal volunteers. The interrelationship of these factors is complex: Many chronic pain patients are depressed and anxious; sleep deprivation can lead to anxiety, and depression can be both the cause and the result of sleep disturbances. Thus, physicians must evaluate all aspects of pain, sleep, and mood in chronic pain patients. Several instruments have been developed to aid physicians in gathering qualitative and quantitative information from chronic pain patients. This triad of chronic pain, sleep disturbances, and depression/anxiety must be fully addressed if the patient is to be restored to optimal functionality. A multidisciplinary team approach allows for treatment of the whole patient. Nonpharmacologic interventions include relaxation therapy, sleep restriction therapy, and cognitive therapy. Strategies for pharmacologic interventions should attempt to maximize outcomes by employing, where possible, agents that address both the pain and the comorbidities. In this way, functionality may be restored and the patient's quality of life improved.",2004-03,01/07/2022 10:40,01/07/2022 10:40,,S9-S27,,,5,,,,,,,,,,,,,,WOS:000220593200003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YIJLKDFN,journalArticle,,"Hart, CN; Hawley, NL; Coffman, DL; Raynor, HA; Carskadon, MA; Jelalian, E; Owens, JA; Spaeth, A; Wing, RR","Randomized controlled trial to enhance children's sleep, eating, and weight",PEDIATRIC RESEARCH,,0031-3998,10.1038/s41390-021-01870-3,,"Background The present study assessed the efficacy of a behavioral intervention to enhance children's sleep and reduce caloric intake and body mass index (BMI) change. Methods Seventy-eight children 8-11 years old who slept 9.5 h/night or less were randomized to the sleep intervention or to no treatment control. The primary outcome was 2-month change in the actigraph-estimated sleep period; changes in reported caloric intake, percent calories from fat, and BMI/BMI z-score (BMIz) were assessed. Results Children randomized to intervention enhanced their sleep period by 40 +/- 7 min/night relative to control (p < 0.001), and were more likely to increase their sleep period by 30 min/night or more (52% versus 15%, p = 0.003). No differences were observed for reported dietary intake or BMI/BMIz. However, in post-hoc analyses collapsing across groups, those who increased sleep by 30 min/night or more had lower BMI (-0.31 kg/m(2), p = 0.01) and BMIz (-0.07, p = 0.03) and reported fewer percent calories from fat at 2 months (-2.2%, p = 0.04). Conclusions A brief behavioral intervention can enhance children's sleep, but did not result in changes in caloric intake or weight status. Enhancing sleep by 30 min/night or more may be beneficial for weight regulation. Impact A brief behavioral intervention improved children's nocturnal sleep relative to no treatment control. Given the many benefits of a good night's sleep across domains of functioning, findings have significant implications for children's health and wellbeing. There were no differences between groups on eating behaviors or BMI. However, across groups, children who increased their sleep period by at least 30 min/night, reported reduced intake from fat and evidenced lower BMI at 2 months. Thus, a brief intervention can improve sleep and may have potential benefits for weight regulation.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000733868900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PWLIWBPV,journalArticle,2019,"Bluher, M",Obesity: global epidemiology and pathogenesis,NATURE REVIEWS ENDOCRINOLOGY,,1759-5029,10.1038/s41574-019-0176-8,,"The prevalence of obesity has increased worldwide in the past similar to 50 years, reaching pandemic levels. Obesity represents a major health challenge because it substantially increases the risk of diseases such as type 2 diabetes mellitus, fatty liver disease, hypertension, myocardial infarction, stroke, dementia, osteoarthritis, obstructive sleep apnoea and several cancers, thereby contributing to a decline in both quality of life and life expectancy. Obesity is also associated with unemployment, social disadvantages and reduced socio-economic productivity, thus increasingly creating an economic burden. Thus far, obesity prevention and treatment strategies - both at the individual and population level - have not been successful in the long term. Lifestyle and behavioural interventions aimed at reducing calorie intake and increasing energy expenditure have limited effectiveness because complex and persistent hormonal, metabolic and neurochemical adaptations defend against weight loss and promote weight regain. Reducing the obesity burden requires approaches that combine individual interventions with changes in the environment and society. Therefore, a better understanding of the remarkable regional differences in obesity prevalence and trends might help to identify societal causes of obesity and provide guidance on which are the most promising intervention strategies.",2019-05,01/07/2022 10:40,01/07/2022 10:40,,288-298,,5,15,,,,,,,,,,,,,,WOS:000464185300012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P7HFW8BD,journalArticle,2021,"Chua, RXY; Tay, MJY; Ooi, DSQ; Siah, KTH; Tham, EH; Shek, LPC; Meaney, MJ; Broekman, BFP; Loo, EXL",Understanding the Link Between Allergy and Neurodevelopmental Disorders: A Current Review of Factors and Mechanisms,FRONTIERS IN NEUROLOGY,,1664-2295,10.3389/fneur.2020.603571,,"Both allergic diseases and neurodevelopmental disorders are non-communicable diseases (NCDs) that not only impact on the quality of life and but also result in substantial economic burden. Immune dysregulation and inflammation are typical hallmarks in both allergic and neurodevelopmental disorders, suggesting converging pathophysiology. Epidemiological studies provided convincing evidence for the link between allergy and neurodevelopmental diseases such as attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Possible factors influencing the development of these disorders include maternal depression and anxiety, gestational diabetes mellitus, maternal allergic status, diet, exposure to environmental pollutants, microbiome dysbiosis, and sleep disturbances that occur early in life. Moreover, apart from inflammation, epigenetics, gene expression, and mitochondrial dysfunction have emerged as possible underlying mechanisms in the pathogenesis of these conditions. The exploration and understanding of these shared factors and possible mechanisms may enable us to elucidate the link in the comorbidity.",15/02/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,11,,,,,,,,,,,,,,WOS:000623209400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T35W9AH4,journalArticle,2017,"Pekel, NB; Yildiz, D; Kahvecioglu, S; Kilic, AK; Yildiz, A; Seferoglu, M; Gunes, A",RESTLESS LEGS SYNDROME AND RELATED FACTORS IN PERITONEAL DIALYSIS PATIENTS,ACTA MEDICA MEDITERRANEA,,0393-6384,10.19193/0393-6384_2017_1_016,,"Introduction: Restless Legs Syndrome (RLS) mostly occurs in hemodialysis (HD) patients but there are limited studies about RLS frequency in peritoneal dialysis (PD) patients. In this study patients who were undergoing PD were screened for RLS and analyzed for associated factors. Material and methods: The study group was consisting of 69 PD patients and 43 healty controls. Beck Depression Inventory was used to analyse for the presence of depression. Sleep disorders were assessed with the Insomnia Severity Index (ISI) and Epworth Sleepiness Scale (ESS). Results: Demographic characteristics of patients and the control group were similar. The rate of RLS tended to be higher in the PD group (p=0.075). There was no difference between PD and control groups in insomnia severity. Logistic regression analysis revealed the only factor independently associated with RLS to be a higher ISI score (p=0.008). Logistic regression analysis revealed the only factor independently associated with at least sub-threshold insomnia as a higher depression score (p=0.002). Being in the PD group and presence of RLS also tended to be independently associated with at least sub-threshold insomnia (p=0.051 and p=0.099, respectively). Linear regression analysis revealed the presence of RLS and a higher depression score as factors independently associated with a higher ISI score (p=0.002 and p=0.013, respectively). Conclusion: The rate of RLS tended to be more common in patients under PD treatment. The main risk factor for the presence of RLS was insomnia. Main risk factors for increased insomnia severity were depression and RLS.",2017,01/07/2022 10:40,01/07/2022 10:40,,101-105,,1,33,,,,,,,,,,,,,,WOS:000397226800016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MTFMML2Q,journalArticle,2003,"O'Brien, PE; Dixon, JB",Laparoscopic adjustable gastric banding in the treatment of morbid obesity,ARCHIVES OF SURGERY,,0004-0010,10.1001/archsurg.138.4.376,,"THE epidemic of obesity requires an intervention that is both effective and broadly acceptable. Conventional medical programs have been ineffective. Traditional surgical approaches, such as gastric bypass and biliopancreatic diversion, are accepted by less than 1% of the severely obese each year. Laparoscopic adjustable gastric banding (LAGB) has been in clinical use for 8 years and it is timely to look at the developments in technique and to look at the outcomes for safety, effectiveness, and acceptability. Data are based on our clinical experiences and research reports derived from 1145 patients treated to date by laparoscopic adjustable gastric banding. We have also drawn on the published literature and on a systematic review of the literature about LAGB published by the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical. Generally reports that have included more than 100 patients and 3 or more years of follow-up have been selected. Laparoscopic adjustable gastric banding has proved to be a safe procedure, 7 to 10 times safer than gastric bypass in terms of mortality, and associated with few perioperative complications. Late events have been more frequent with prolapse of the stomach through the band occurring in 15% of our initial patients and erosion of the band into the stomach in 3.2% of our initial patients. Both complications are treatable laparoscopically and have become less common with modifications of technique. Weight loss is gradual but progressive over the first 2 years and has stabilized at about 50% of excess weight lost for the next 4 years. There are major associated improvements in the multiple comorbidities of obesity including type 2 diabetes mellitus (DM), asthma, hypertension, dyslipidemia, asthma, gastroesophageal reflux disease, sleep disordered breathing, comorbidities of pregnancy, and the quality of life (QOL). Laparoscopic adjustable, gastric banding has several attributes that potentially will enable it to overcome the community's resistance to bariatric surgery. It has proved to be safe. It is highly effective in achieving good weight loss, major improvements in health; and improved QOL. Because of the laparoscopic placement, adjustablity, and the easy reversibility, LAGB can provide these benefits in a gentle and safe way.",2003-04,01/07/2022 10:40,01/07/2022 10:40,,376-382,,4,138,,,,,,,,,,,,,,WOS:000182030500005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NTATRMPI,journalArticle,2016,"Gruver, RS; Bishop-Gilyard, CT; Lieberman, A; Gerdes, M; Virudachalam, S; Suh, AW; Kalra, GK; Magge, SN; Shults, J; Schreiner, MS; Power, TJ; Berkowitz, RI; Fiks, AG",A Social Media Peer Group Intervention for Mothers to Prevent Obesity and Promote Healthy Growth from Infancy: Development and Pilot Trial,JMIR RESEARCH PROTOCOLS,,1929-0748,10.2196/resprot.5276,,"Background: Evidence increasingly indicates that childhood obesity prevention efforts should begin as early as infancy. However, few interventions meet the needs of families whose infants are at increased obesity risk due to factors including income and maternal body mass index (BMI). Social media peer groups may offer a promising new way to provide these families with the knowledge, strategies, and support they need to adopt obesity prevention behaviors. Objective: The aim of this study is to develop and pilot test a Facebook-based peer group intervention for mothers, designed to prevent pediatric obesity and promote health beginning in infancy. Methods: We conducted in-depth semi-structured interviews with 29 mothers of infants and focus groups with 30 pediatric clinicians, to inform the development of a theory-based intervention. We then conducted a single-group pilot trial with 8 mothers to assess its feasibility and acceptability. All participants were recruited offline at pediatric primary care practices. Participants in the pilot trial joined a private Facebook group, moderated by a psychologist, with a weekly video-based curriculum, and also had the option to meet at a face-to-face event. Within the Facebook group, mothers were encouraged to chat, ask questions, and share photos and videos of themselves and babies practicing healthy behaviors. Consistent with the literature on obesity prevention, the curriculum addressed infant feeding, sleep, activity, and maternal well-being. Feasibility was assessed using the frequency and content of group participation by mothers, and acceptability was measured using online surveys and phone interviews. Results: Based on preferences of mothers interviewed (mean BMI 35 kg/m(2), all Medicaid-insured, mean age 27, all Black), we designed the intervention to include frequent posts with new information, videos showing parents of infants demonstrating healthy behaviors, and an optional face-to-face meeting. We developed a privacy and safety plan that met the needs of participants as well as the requirements of the local institutional review board (IRB), which included use of a ""secret"" group and frequent screening of participant posts. Clinicians, 97% (29/30) women and 87% (26/30) pediatricians, preferred no direct involvement in the intervention, but were supportive of their patients' participation. In our 8-week, single group pilot trial, all participants (mean BMI 35 kg/m(2), all Medicaid-insured, mean age 28, all Black) viewed every weekly video post, and interacted frequently, with a weekly average of 4.4 posts/comments from each participant. All participant posts were related to parenting topics. Participants initiated conversations about behaviors related to healthy infant growth including solid food introduction, feeding volume, and managing stress. All 8 pilot group participants reported that they found the group helpful and would recommend it to others. Conclusions: Our methodology was feasible and acceptable to low-income mothers of infants at high risk of obesity, and cou popld be adapted to implement peer groups through social media for underservedulations in varied settings.",2016-07,01/07/2022 10:40,01/07/2022 10:40,,256-270,,3,5,,,,,,,,,,,,,,WOS:000381214600025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5ZJWJVUR,journalArticle,2013,"Daniel, S; Soleymani, T; Garvey, WT",A complications-based clinical staging of obesity to guide treatment modality and intensity,CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY,,1752-296X,10.1097/01.med.0000433067.01671.f5,,"Purpose of reviewThe current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach.Recent findingsAdvancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obese patients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity.SummaryA complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions.",2013-10,01/07/2022 10:40,01/07/2022 10:40,,377-388,,5,20,,,,,,,,,,,,,,WOS:000326587900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GLK6INFP,journalArticle,2020,"Partridge, SR; Raeside, R; Singleton, AC; Hyun, K; Latham, Z; Grunseit, A; Steinbeck, K; Chow, C; Redfern, J","Text Message Behavioral Intervention for Teens on Eating, Physical Activity and Social Wellbeing (TEXTBITES): Protocol for a Randomized Controlled Trial",JMIR RESEARCH PROTOCOLS,,1929-0748,10.2196/16481,,"Background: Obesity is among the most significant health challenges facing today's adolescents. Weight gain during adolescence is related to cardiovascular disease, type 2 diabetes, and some cancers in later life. Presently, adolescents living in Australia have limited access to age-appropriate obesity prevention services. Objective: This study aims to investigate whether a two-way text message program, with optional telephone health counseling, improves body mass index (BMI) z score and lifestyle outcomes in adolescents who are overweight. Methods: This study will be a single-blind randomized controlled trial (N=150) comparing a two-way text message intervention, with optional telephone health counseling, to usual care in adolescents (13-18 years old, inclusive) who are overweight (recruited from a pediatric weight management clinic and the broader community in Sydney, Australia). The intervention group will receive a six-month text message program, which consists of two-way, semipersonalized, lifestyle-focused text messages (four messages/week) in addition to usual care. The control group will be assigned to receive usual care. The study also includes a follow-up at 12-months The primary outcome is a change in BMI z score at six months. Secondary outcomes are changes in waist-to-height ratio, diet, physical and sedentary activity levels, sleep quality, quality of life, self-esteem, self-efficacy, social support, and eating disorder and depression symptoms. Also, we will examine acceptability, utility, and engagement with the program through a study-specific process evaluation questionnaire, semi-structured telephone interviews, and an analysis of health counselor communication logs. The analyses will be performed by the intention-to-treat principle to assess differences between intervention and control groups. Results: The study opened for recruitment in December 2019. Data collection is expected to be completed by December 2021, and the results for the primary outcome are expected to be published in early 2022. Conclusions: This study will test the effectiveness of an interactive two-way text message program compared to usual care in improving BMI z score and lifestyle outcomes in adolescents with overweight. This interactive, innovative, and scalable project also aims to inform future practice and community initiatives to promote obesity prevention behaviors for adolescents.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,,,2,9,,,,,,,,,,,,,,WOS:000518843100023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XWTY8ZIK,journalArticle,2011,"Taylor, BJ; Heath, ALM; Galland, BC; Gray, AR; Lawrence, JA; Sayers, RM; Dale, K; Coppell, KJ; Taylor, RW","Prevention of Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth",BMC PUBLIC HEALTH,,1471-2458,10.1186/1471-2458-11-942,,"Background: Rapid weight gain during the first three years of life predicts child and adult obesity, and also later cardiovascular and other morbidities. Cross-sectional studies suggest that infant diet, activity and sleep are linked to excessive weight gain. As intervention for overweight children is difficult, the aim of the Prevention of Overweight in Infancy (POI.nz) study is to evaluate two primary prevention strategies during late pregnancy and early childhood that could be delivered separately or together as part of normal health care. Methods/Design: This four-arm randomised controlled trial is being conducted with 800 families recruited at booking in the only maternity unit in the city of Dunedin, New Zealand. Mothers are randomised during pregnancy to either a usual care group (7 core contacts with a provider of government funded ""Well Child"" care over 2 years) or to one of three intervention groups given education and support in addition to ""Well Child"" care: the Food, Activity and Breastfeeding group which receives 8 extra parent contacts over the first 2 years of life; the Sleep group which receives at least 3 extra parent contacts over the first 6 months of life with a focus on prevention of sleep problems and then active intervention if there is a sleep problem from 6 months to 2 years; or the Combination group which receives all extra contacts. The main outcome measures are conditional weight velocity (0-6, 6-12, 12-24 months) and body mass index z-score at 24 months, with secondary outcomes including sleep and physical activity (parent report, accelerometry), duration of breastfeeding, timing of introduction of solids, diet quality, and measures of family function and wellbeing (parental depression, child mindedness, discipline practices, family quality of life and health care use). This study will contribute to a prospective meta-analysis of early life obesity prevention studies in Australasia. Discussion: Infancy is likely to be the most effective time to establish patterns of behaviour around food, activity and sleep that promote healthy child and adult weight. The POI.nz study will determine the extent to which sleep, food and activity interventions in infancy prevent the development of overweight.",19/12/2011,01/07/2022 10:40,01/07/2022 10:40,,,,,11,,,,,,,,,,,,,,WOS:000301520600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IF3F8E9L,journalArticle,2014,"Bjorvatn, B; Pallesen, S; Gronli, J; Sivertsen, B; Lehmann, S",PREVALENCE AND CORRELATES OF INSOMNIA AND EXCESSIVE SLEEPINESS IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA SYMPTOMS,PERCEPTUAL AND MOTOR SKILLS,,0031-5125,10.2466/15.06.PMS.118k20w3,,"This study investigated the prevalence and correlates of insomnia and excessive sleepiness in adults presenting symptoms of obstructive sleep apnea (OSA) in the general population. Randomly selected participants (N=1,502; 50.7% men, 49.3% women), ages 40 to 70 yr. (M=53.6, SD=8.5) were interviewed over the telephone. Insomnia and excessive sleepiness (hypersomnia) were assessed with the Bergen Insomnia Scale and the Epworth Sleepiness Scale, respectively. OSA symptoms were identified by self-or spouse reports on snoring, breathing cessations during sleep, and being tired or sleepy. The prevalence of OSA was 6.2%. Among these participants with OSA, 57.6% reported insomnia and 30.1% reported excessive sleepiness. Furthermore, OSA symptoms were associated with self-reported obesity, hypertension, diabetes, and depression, but only in participants with comorbid insomnia or excessive sleepiness.",2014-04,01/07/2022 10:40,01/07/2022 10:40,,571-586,,2,118,,,,,,,,,,,,,,WOS:000334592700019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
K5XVFI4M,journalArticle,2006,"Vergne-Salle, P; Coyral, D; Dufauret, K; Bonnet, C; Bertin, P; Treves, R",Is restless legs syndrome underrecognized? Current management,JOINT BONE SPINE,,1297-319X,10.1016/j.jbspin.2005.03.011,,"Restless legs syndrome (RLS) is a poorly understood sensory-motor neurological disorder whose prevalence in Caucasian populations ranges from 10% to 15%. The patient reports unpleasant sensations in the lower limbs with dysesthesia resulting in an urge to move the legs. The symptoms occur during periods of inactivity, increasing in the evening and at night. Moving the legs provides relief. In 80% of cases, polysomnography shows periodic leg movements during sleep. Patients with idiopathic RLS often report similar symptoms in family members. Secondary RLS may be due to medications, diabetes mellitus, renal failure, iron deficiency, neurological disorders, or rheumatoid arthritis. In secondary RLS, the management rests on treatment of the cause. Symptomatic treatment is warranted in patients with moderate-to-severe symptoms that adversely affect the quality of life. Dopaminergic agents are tried first. When they fail or induce adverse effects, weak opioids, benzodiazepines, anticonvulsants or, if needed, strong opioids, may be used. (c) 2005 Elsevier SAS. All rights reserved.",2006-07,01/07/2022 10:40,01/07/2022 10:40,,369-373,,4,73,,,,,,,,,,,,,,WOS:000239745500006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78BZ76FB,journalArticle,2017,"Goldberg, LR; Ponikowski, P; Javaheri, S; Augostini, R; McKane, S; Holcomb, R; Kao, A; Oldenburg, O; Khayat, R; Stellbrink, C; Abraham, WT; Costanzo, MR","In Heart Failure Patients with CSA, Stimulation of the Phrenic Nerve Improves Sleep and Quality of Life",JOURNAL OF CARDIAC FAILURE,,1071-9164,10.1016/j.cardfail.2017.07.053,,,2017-08,01/07/2022 10:40,01/07/2022 10:40,,S15-S15,,8,23,,,,,,,,,,,,,,WOS:000408403100031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KR9BQL2P,journalArticle,2012,"Hady, HR; Dadan, J; Golaszewski, P","100 obese patients after laparoscopic adjustable gastric banding - the influence on BMI, gherlin and insulin concentration, parameters of lipid balance and co-morbidities",ADVANCES IN MEDICAL SCIENCES,,1896-1126,10.2478/v10039-012-0008-8,,"Purpose: Obesity is a widespread health issue caused by chronic impaired balance between energy supply and its expenditure. It leads to gathering of excessive fat tissue and numerous co-morbidities. The aim of this study is to present the influence of laparoscopic adjustable gastric banding (LAGB) on plasma ghrelin, insulin, glucose, triglycerides, total, HDL- and LDL-cholesterol concentration as well as on alanine and aspartate aminotransferase in obese patients and influence on co-morbidities such as type 2 diabetes mellitus, dislipidemy, hypertension and sleep apnea. Materials and Methods: 100 obese patients underwent LAGB: 34 men -average age 39.18 +/- 12.17 years old and 66 women -average age 37.0 +/- 12.6 years old. During 6 months follow-up, particular measurements have been conducted in different time points. Evaluation of body mass loss (%EWL, %EBL) and the homeostatic model assessment insulin resistance (HOMA IR) was conducted. In the same time ghrelin, insulin, glucose, triglycerides, total cholesterol, HDL- and LDL-cholesterol concentration was determined after 7 days, 1, 3 and 6 months after the surgery. Results: Significant decrease in BMI and HOMA IR was observed as well as in insulin and glucose concentration. Increase in ghrelin concentration in comparison to preoperative values was also stated. Conclusions: LAGB leads to significant body mass loss, improvement in patients' general health state and to normalization of metabolic parameters. Improvement or total resolution of type 2 diabetes (T2DM), hypertension and sleep apnea was also noticed.",2012-06,01/07/2022 10:40,01/07/2022 10:40,,58-64,,1,57,,,,,,,,,,,,,,WOS:000305272600008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3QIVMAWX,journalArticle,2009,"Catenacci, VA; Hill, JO; Wyatt, HR",The Obesity Epidemic,CLINICS IN CHEST MEDICINE,,0272-5231,10.1016/j.ccm.2009.05.001,,"Obesity has reached epidemic proportions in the United States, with 35.1% of adults being classified as obese. Obesity affects every segment of the US population and continues to increase steadily, especially in children. Obesity increases the risk for many other chronic diseases, including diabetes mellitus, cardiovascular disease, and nonalcoholic fatty liver disease, and decreases overall quality of life. The current US generation may have a shorter life expectancy than their parents if the obesity epidemic is not controlled, and there is no indication that the prevalence of obesity is decreasing. Because of the complexity of obesity, it is likely to be one of the most difficult public health issues our society has faced.",2009-09,01/07/2022 10:40,01/07/2022 10:40,,415-+,,3,30,,,,,,,,,,,,,,WOS:000270089200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
V52T7WIE,journalArticle,2015,"Salome, GM; de Almeida, SA; Ferreira, LM","Association of Sociodemographic Factors with Hope for Cure, Religiosity, and Spirituality in Patients with Venous Ulcers",ADVANCES IN SKIN & WOUND CARE,,1527-7941,10.1097/01.ASW.0000459844.07689.02,,"OBJECTIVE: The objective of the study was to evaluate the association of sociodemographic factors with hope for cure and levels of religiosity and spirituality in patients with venous leg ulcers (VLUs). DESIGN: This was a primary, prospective, descriptive, analytical, clinical, nonrandomized study. SETTING: The study was performed at a nursing care and education center of a university hospital in interior Minas Gerais, Brazil. PATIENTS: A convenience sample of 50 adult patients with VLUs and Doppler ankle-brachial index ranging from 0.8 to 1.0 participated in the study. Patients with mixed ulcers, arterial ulcers, and diabetic foot ulcers were excluded from the study. MAIN OUTCOME MEASURES: A questionnaire assessing sociodemographic and clinical characteristics of patients, the Spirituality Self-rating Scale (SSRS), and the Herth Hope Index (HHI) were administered to all patients. MAIN RESULTS: The mean SSRS score was 10.20, and the mean HHI was 25.5, corresponding to low levels of spirituality and moderate hope for cure, respectively. Patients aged between 50 and 59 years, men, nonsmokers, and those who were unemployed had the lowest mean SSRS scores. The lowest mean HHI values were reported by patients whose ulcers had exudate and odor, those aged 20 to 39 years, retired, and living with the wound for 1 year or less. Patients who had no religion or were not practicing a religion and those who considered living with an ulcer as a punishment reported low SSRS scores. CONCLUSION: The results showed that most patients with VLUs had low levels of spirituality, did not perceive divine intervention in their daily life or practice religious activities such as prayer, and had moderate hope for cure.",2015-02,01/07/2022 10:40,01/07/2022 10:40,,76-82,,2,28,,,,,,,,,,,,,,WOS:000348595600005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SJ75SBHF,journalArticle,,"Hwang, JH; Ong, HL; Chen, YC",Surgical treatments for obstructive sleep apnea decrease the risk of erectile dysfunction: A nationwide cohort study,ANDROLOGY,,2047-2919,10.1111/andr.13126,,"Background It has been reported that the risk of erectile dysfunction (ED) is significantly higher in patients with obstructive sleep apnea (OSA), compared with patients without OSA. However, there is limited evidence on whether surgical treatments in patients with OSA could decrease ED risk. Objectives To assess the impact of surgical treatments for OSA on the risk of ED by analysis of claims data from the Taiwan National Health Insurance Research Database between 1997 and 2012. Material and methods We identified 20,675 male adults with newly diagnosed OSA during the study period; 16,040 patients ever received surgical treatments (treated cohort) and 4635 patients never received surgical treatments (untreated cohort). According to 3:1 propensity score matching, we analyzed 8337 patients in the treated cohort and 2779 controls in the untreated cohort. We estimated the incidence rates (IRs) and hazard ratios (HRs) of incident ED in both cohorts through the end of 2012. Results In a total study follow-up of 64,916 person-years, 396 (3.6%) patients developed impotence. The IRs of ED for the treated and untreated cohorts, respectively, were 55.8 (95% confidence interval [CI], 55.6-55.9) and 76.1 (95% CI, 76.0-76.3) per 1000 person-years. Multivariate Cox proportional hazard analysis showed that surgical treatments for OSA patients were associated with a lower risk for ED (adjusted HR, 0.79; 95% CI, 0.64-0.98). Multivariate stratified analysis further verified that significant risk reduction of ED was present in OSA patients without hypertension, diabetes, hyperlipidemia, hyperuricemia, obesity, chronic kidney disease, and chronic liver disease. Conclusions We found that OSA patients who received surgical treatments were associated with a lower risk for developing ED by 21%.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000722463500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YW835T43,journalArticle,2017,"Ramkumar, S; Yang, H; Wang, Y; Nolan, M; Negishi, K; Sanders, P; Marwick, TH",Relation of Functional Status to Risk of Development of Atrial Fibrillation,AMERICAN JOURNAL OF CARDIOLOGY,,0002-9149,10.1016/j.amjcard.2016.10.043,,"Identifying patients at risk is now important as there are demonstrable ways to alter disease progression which could"" potentially prevent atrial fibrillation (AF) and its complications. We sought whether impaired functional capacity was associated with risk of AF, independent of myocardial dysfunction. In this community-based study, asymptomatic participants aged >= 65 years were reCruited if they had >= 1 risk factor (e.g., hypertension, diabetes mellitus, and obesity). Participants underwent baseline echocardiography (including measurement of myocardial mechanics) and six-minute walk test. The CHARGE-AF score was used to calculate 5-year risk of developing AF. Receiver operating characteristic curves were used to assess for independent risk factors for AF. A total of 607 patients (age 71 +/- 5 years, men 47%) were studied at baseline and followed for at least 6. months. Patients in the higher AF risk groups were older and had increased rates of hypertension, diabetes mellitus, and ischemic heart disease (p <0.05). Greater AF risk was associated with lower exercise capacity; independent of lower mean global longitudinal strain, global circumferential strain, greater mean E/e' ratio, indexed left atrial volume and LV mass. Multivariate linear regression confirmed association of LV and functional capacity parameters with AF risk. Although functional capacity is impaired in AF, this association precedes the onset of AF. In conclusion, poor functional status is associated with AF risk, independent of LV function. (C) 2016 Elsevier Inc. All rights reserved.",15/02/2017,01/07/2022 10:40,01/07/2022 10:40,,572-578,,4,119,,,,,,,,,,,,,,WOS:000394725100011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
98QCQ4VA,journalArticle,2021,"Franceschi, R; Micheli, F; Mozzillo, E; Cauvin, V; Liguori, A; Soffiati, M; Giani, E",Intermittently Scanned and Continuous Glucose Monitor Systems: A Systematic Review on Psychological Outcomes in Pediatric Patients,FRONTIERS IN PEDIATRICS,,2296-2360,10.3389/fped.2021.660173,,"Aim: To explore the impact of real-time continuous glucose monitoring (rtCGMs) or intermittently scanned/viewed CGM (isCGM) on psychological outcomes in children and caregivers, and to grade the level of evidence. Method: Systematic review of the literature from PubMed, Embase, Cochrane Library, Web of Science, CINAHL, Nursing reference center, Up to date, Google Scholar, and PsycINFO databases. The studies selected used validated questionnaires for investigating the psychological outcomes. We applied GRADE (Grading of Recommendations Assessment, Development and Evaluation) to rank the quality of a body of evidence. Results: A total of 192 studies were identified in the initial search and after the process of evaluation 25 studies were selected as appropriate to be included in this systematic review. We found in moderate quality studies that isCGM in adolescents can improve diabetes related distress, family conflicts, fear of hypoglycemia, and quality of life, while depression, anxiety, and quality of sleep have not yet been evaluated by validated questionnaires. In moderate-high quality studies, rtCGM technology does not impact on diabetes burden, diabetes specific family conflict, and depressive symptoms. The effect on fear of hypoglycemia, sleep quality, and anxiety is still debated and RCT studies powered to find significant results in psychological outcomes are lacking. RtCGM increases satisfaction and quality of life in parents and patients wearing rtCGM. Conclusion: these data present an interesting point to consider when families are deciding whether or not to start CGM use, choosing between rtCGM to reach a tighter metabolic control, or isCGM which allows greater benefits on psychological outcomes.",05/05/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000651753800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XJB9552X,journalArticle,2004,"Ballantyne, GH; Svahn, J; Capella, RF; Capella, JF; Schmidt, HJ; Wasielewski, A; Davies, RJ","Predictors of prolonged hospital stay following open and laparoscopic gastric bypass for morbid obesity: Body mass index, length of surgery, sleep apnea, asthma and the metabolic syndrome",OBESITY SURGERY,,0960-8923,10.1381/0960892041975460,,"Background: The number of weight reduction operations performed for type II and type III obesity is rapidly escalating. Risk of surgery has been infrequently stratified for patient subgroups. The purpose of this study was to identify patient characteristics that increased the odds of a prolonged hospital length of stay (LOS) following open or laparoscopic Roux-en-Y gastric bypass (RYGBP). Methods: The hospital records of 311 patients who underwent RYGBP in a 6-month period were retrospectively reviewed. Patient characteristics including the presence of significant obesity-related medical conditions were recorded. Analysis was based on intent to treat. Univariate and step-wise logistic regression analysis was used to identify the odds ratio (OR) and adjusted odds ratio (AOR) for predictors of an increased hospital LOS. Results: Datasets for 311 patients were complete. 159 patients underwent open vertical banded gastroplasty-Roux-en-Y gastric bypass (VBG-RYGBP) and 152 laparoscopic RYGBP (LRYGBP). 78% of patients were female. Median age was 40 years (range 18-68). Median BMI was 49 kg /m(2) (range 35-82). 17% of patients had sleep apnea, 18% asthma, 19% type 2 diabetes, 13% hypercholesterolemia and 44% hypertension. Median length of surgery for open VBG-RYGBP (64 minutes) was significantly faster than for LRYGBP (105 minutes). Median length of stay was significantly shorter for LRYGBP (2 days) than open VBG-RYGBP (3 days). Univariate logistic regression analysis identified 6 predictors of increased LOS: open surgery (0.4 OR); increasing BMI (60 kg/m(2) 0.38 OR; BMI 70 kg/m(2) 0.53 OR); increasing length of surgery (120 min 0.33 OR; 180 min 0.48 OR); sleep apnea (2.25 OR); asthma (3.73 OR); and hypercholesterolemia (3.73 OR). Subset analysis identified patients with the greatest odds for a prolonged hospital stay: women with asthma (2.47 AOR) or coronary artery disease (8.65 AOR); men with sleep apnea (5.54 OR) or the metabolic syndrome (6.67 - 10.20 OR); and patients undergoing a laparoscopic operation with sleep apnea (11.53 AOR) or coronary artery disease (12.15 AOR). Conclusions: Open surgery, BMI, length of surgery, sleep apnea, asthma and hypercholesterolemia all increased the odds of a prolonged LOS. Patients with the greatest odds of long LOS were women with asthma or coronary disease, men with sleep apnea or the metabolic syndrome, and patients undergoing laparoscopic surgery with sleep apnea or coronary artery disease. Patients at high-risk for prolonged hospital stay can be identified before undergoing RYGBP. Surgeons may wish to avoid high-risk patients early in their bariatric surgery experience.",2004-09,01/07/2022 10:40,01/07/2022 10:40,,1042-1050,,8,14,,,,,,,,,,,,,,WOS:000224183900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LGLFBJPA,journalArticle,2021,"Gantenbein, KV; Kanaka-Gantenbein, C",Mediterranean Diet as an Antioxidant: The Impact on Metabolic Health and Overall Wellbeing,NUTRIENTS,,2072-6643,10.3390/nu13061951,,"It has been established, worldwide, that non-communicable diseases such as obesity, diabetes, metabolic syndrome, and cardiovascular events account for a high percentage of morbidity and mortality in contemporary societies. Several modifiable risk factors, such as sedentary activities, sleep deprivation, smoking, and unhealthy dietary habits have contributed to this increase. Healthy nutrition in terms of adherence to the Mediterranean diet (MD), rich in fruits, legumes, vegetables, olive oil, herbs, spices, and high fiber intake may contribute to the decrease in this pandemic. The beneficial effects of the MD can be mainly attributed to its numerous components rich in anti-inflammatory and antioxidant properties. Moreover, the MD may further contribute to the improvement of reproductive health, modify the risk for neurodegenerative diseases, and protect against depression and psychosocial maladjustment. There is also evidence highlighting the impact of healthy nutrition in female people on the composition of the gut microbiota and future metabolic and overall health of their offspring. It is therefore important to highlight the beneficial effects of the MD on metabolic, reproductive, and mental health, while shaping the overall health of future generations. The beneficial effects of MD can be further enhanced by increased physical activity in the context of a well-balanced healthy lifestyle.",2021-06,01/07/2022 10:40,01/07/2022 10:40,,,,6,13,,,,,,,,,,,,,,WOS:000666212700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
N9ECK8XR,journalArticle,2015,"Ranque-Gamier, S; Ammar, D; Bouillet, T",Physical activity and breast cancer,CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION,,2100-9619,,,"Physical activity (PA) in this article is adapted to each patient, unlike sport, forcing practitioners to adapt themselves to its rules. It differs from rehabilitation, while remaining complementary. Prescribed by the physician with a specifies dosage (intensity, type, duration, frequency), it is frames by trained sports educators (University Diploma ""Sport and cancer""). Performed under safe conditions and fun,the benefices begin from 150 minutes a week, divided into 3 to 5 times, with a moderate to high intensity (9 MET/h (Metabolic Equivalent of Task] per hour) for at least 6 months. Studies on AP and breast cancer shows that it improves specific cancer fatigue, sleep disturbances, body image, depression, pain, physical function and quality of life at all stages of the disease. Physical activity has shown its positive impact on primary prevention for breast cancer. Cohort studies on large populations are in favor of AP' actions in terms of reduced recurrences and improved overall and specific survivals. Physical activity has metabolic, endocrine, immune and neurobiological effects, that underpin its profits.",2015-12,01/07/2022 10:40,01/07/2022 10:40,,290-296,,10,19,,,,,,,,,,,,,,WOS:000370311000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NX67JZTM,journalArticle,1998,"Stieger, R; Thurnheer, M; Lange, J",Morbid obesity: 130 consecutive patients with laparoscopic gastric banding,SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT,,0036-7672,,,"Morbid obesity causes co-morbidity such as diabetes mellitus, hypertensive heart disease, sleep apnoea, degenerative bone diseases and increased incidence of malignancy. Life expectancy and quality of life are reduced significantly. Without adequate weight loss, treatment of co-morbidity remains symptomatic only. Surgical treatment of morbid obesity is the one therapy promising long-term success, since conservative procedures normally lead to recurrence of overweight. We performed laparoscopic gastric banding on 130 patients between 1.11.95 and 31.10.97. Mean overweight was 63 +/- 12.7 kg (SD), and mean BMI was 46.5 +/- 4.6 kg/m(2). The average hospital stay was 5.5 +/- 1.5 days. 4 patients with postoperative pulmonary embolism were treated with oral anticoagulation. We performed 9 (6.9%) reoperations because of pouch dilatation or dorsal slipping with food intolerance in the first series of 70, and none in the second series of 60 patients. Median weight loss after 3 months was 14.7 +/- 4.2 kg, after six months 24.0 +/- 6.6 kg and after 12 months 33.2 +/- 8.5 kg, corresponding to excessive weight loss (EWL) of 55.9 +/- 14.8% in the first year. 14 (70%) of 20 patients with diabetes mellitus normalised and 6 patients showed improved blood sugar levels. All 36 patients with hypertensive heart disease had normalised blood pressure, 60% of them without further medical antihypertensive treatment after median EWL of 36%. Cholesterol levels normalised in 30 (57%) patients and improved in 20 (38%) after 6 months. Laparoscopic gastric banding is a suitable method for reducing weight in morbid obesity patients and provides a better quality of life in a group of patients who are carefully evaluated and followed. Reducing co-morbidity and improving ability to work have a positive economic impact on health care costs.",22/08/1998,01/07/2022 10:40,01/07/2022 10:40,,1239-1246,,34,128,,,,,,,,,,,,,,WOS:000075527800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UN3ULTL4,journalArticle,2013,"Savini, I; Catani, MV; Evangelista, D; Gasperi, V; Avigliano, L",Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,,1422-0067,10.3390/ijms140510497,,"Obesity represents a major risk factor for a plethora of severe diseases, including diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and cancer. It is often accompanied by an increased risk of mortality and, in the case of non-fatal health problems, the quality of life is impaired because of associated conditions, including sleep apnea, respiratory problems, osteoarthritis, and infertility. Recent evidence suggests that oxidative stress may be the mechanistic link between obesity and related complications. In obese patients, antioxidant defenses are lower than normal weight counterparts and their levels inversely correlate with central adiposity; obesity is also characterized by enhanced levels of reactive oxygen or nitrogen species. Inadequacy of antioxidant defenses probably relies on different factors: obese individuals may have a lower intake of antioxidant-and phytochemical-rich foods, such as fruits, vegetables, and legumes; otherwise, consumption of antioxidant nutrients is normal, but obese individuals may have an increased utilization of these molecules, likewise to that reported in diabetic patients and smokers. Also inadequate physical activity may account for a decreased antioxidant state. In this review, we describe current concepts in the meaning of obesity as a state of chronic oxidative stress and the potential interventions to improve redox balance.",2013-05,01/07/2022 10:40,01/07/2022 10:40,,10497-10538,,5,14,,,,,,,,,,,,,,WOS:000319441500102,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GHC663TW,journalArticle,2012,"Ota, H; Tamaki, S; Itaya-Hironaka, A; Yamauchi, A; Sakuramoto-Tsuchida, S; Morioka, T; Takasawa, S; Kimura, H",Attenuation of glucose-induced insulin secretion by intermittent hypoxia via down-regulation of CD38,LIFE SCIENCES,,0024-3205,10.1016/j.lfs.2011.11.011,,"Aims: Sleep apnea syndrome (SAS) is characterized by recurrent episodes of oxygen desaturation during sleep, the development of daytime sleepiness, and deterioration in the quality of life. Accumulating evidence suggests the association of intermittent hypoxia (IH), a hallmark of SAS, and type 2 diabetes independently on body mass index and waist circumference. In addition to insulin resistance, the progression to type 2 diabetes is dependent on the impairment of glucose-induced insulin secretion (GIS) from pancreatic beta-cells. However, the direct effects of IH on GIS are elusive. Main methods: HIT-T15 hamster beta-cells and isolated rat islets were exposed to 64 cycles/24 h of IH (5 min hypoxia/10 min normoxia) or normoxia for 24 h. Changes of GIS and gene expression in IH-treated beta-cells were analyzed by ELISA and real-time RT-PCR, respectively. Key findings: After IH treatment, GIS both from IH-treated HIT-T15 cells and isolated rat islets were significantly attenuated. The level of insulin mRNA was unchanged by IH. The mRNA levels of glucose transporter 2 (Glut2), glucokinase (GK), sulfonylurea receptor1 (SUR1), and L-type Ca2+ channel1.2 (Cav1.2) in IH-treated-islets were similar to those in normoxia-treated islets. In contrast, the mRNA level of CD38 in IH-treated islets was significantly lower than that in normoxia-treated islets. The reporter gene assay revealed that the transcription of CD38 was attenuated by IH, and the transfection of CD38 expression vector recovered the attenuation of GIS by IH. Significance: These results indicate that IH stress directly attenuates GIS from beta-cells via the down-regulation of CD38. (c) 2011 Elsevier Inc. All rights reserved.",30/01/2012,01/07/2022 10:40,01/07/2022 10:40,,206-211,,05-Jun,90,,,,,,,,,,,,,,WOS:000307487400006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HM22FRXG,journalArticle,2008,"Kroz, M; Feder, G; von Laue, HB; Zerm, R; Reif, M; Girke, M; Matthes, H; Gutenbrunner, C; Heckmann, C",Validation of a questionnaire measuring the regulation of autonomic function,BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE,,1472-6882,10.1186/1472-6882-8-26,,"Background: To broaden the range of outcomes that we can measure for patients undergoing treatment for oncological and other chronic conditions, we aimed to validate a questionnaire measuring self-reported autonomic regulation (aR), i.e. to characterise a subject's autonomic functioning by questions on sleeping and waking, vertigo, morningness-eveningness, thermoregulation, perspiration, bowel movements and digestion. Methods: We administered the questionnaire to 440 participants (: N = 316, : N = 124): 95 patients with breast cancer, 49 with colorectal cancer, 60 with diabetes mellitus, 39 with coronary heart disease, 28 with rheumatological conditions, 32 with Hashimoto's disease, 22 with multiple morbidities and 115 healthy people. We administered the questionnaire a second time to 50.2% of the participants. External convergence criteria included the German version of the Hospital Anxiety and Depression Scale (HADS-D), a short questionnaire on morningness-eveningness, the Herdecke Quality of Life Questionnaire (HLQ) and a short version questionnaire on self-regulation. Results: A principal component analysis yielded a three dimensional 18-item inventory of aR. The subscales orthostatic-circulatory, rest/activity and digestive regulation had internal consistency (Cronbach-alpha: r alpha = 0.65 - 0.75) and test-retest reliability (rrt = 0.70 - 85). AR was negatively associated with anxiety, depression, and dysmenorrhoea but positively correlated to HLQ, self-regulation and in part to morningness (except digestive aR) (0.49 - 0.13, all p < 0.05). Conclusion: An internal validation of the long-version scale of aR yielded consistent relationships with health versus illness, quality of life and personality. Further studies are required to clarify the issues of external validity, clinical and physiological relevance.",05/06/2008,01/07/2022 10:40,01/07/2022 10:40,,,,,8,,,,,,,,,,,,,,WOS:000262744800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZETV5BU4,journalArticle,2015,"Athyros, VG; Pagourelias, ED; Gossios, TD; Vasilikos, VG",Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?,CURRENT VASCULAR PHARMACOLOGY,,1570-1611,10.2174/1570161112666141126150948,,"Heart failure with preserved ejection fraction (HFpEF). Arterial hypertension (AH), arterial stiffness (AS), older age, and female gender are the main determinants of HFpEF, but several cardiac or extra-cardiac pathologies are also possible causes. The combined ventricular-vascular stiffening (abnormal left atrium-left ventricle coupling related to AS) is the main contributor of the increased prevalence of HFpEF in elderly persons, particularly elderly women, and in younger persons with AH. The hospitalization and mortality rates of HFpEF are similar to those of heart failure with reduced EF (HFrEF). However, although the prognosis of HFrEF has been substantially improved during the last 2 decades, the effective treatment of HFpEF remains an unmet need. Regimens effective in HFrEF have no substantial effect on HFpEF, because of different pathophysiologies of the 2 syndromes. Pipeline drugs seem promising, but it will take some years before they are commercially available. Aggressive treatment of noncardiac comorbidities seems to be the only option at hand. Treatment of anaemia, sleep disorders, chronic kidney disease (CKD), non-alcoholic fatty liver (NAFLD), atrial fibrillation, diabetes, and careful use of diuretics to reduce preload are effective to some degree. Statin treatment, despite the presence of dyslipidaemia, deserves special attention because it has been proven, mainly in small studies or post hoc analyses of trials, that it offers a substantial improvement in quality of life and a reduction in mortality rates. We need to urgently utilize these recourses to relieve a considerable part of the general population suffering from HFpEF, a deadly disease.",2015,01/07/2022 10:40,01/07/2022 10:40,,368-380,,3,13,,,,,,,,,,,,,,WOS:000357694900011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58RE8N76,journalArticle,2017,"Selvakumar, PKC; Kabbany, MN; Nobili, V; Alkhouri, N",Nonalcoholic Fatty Liver Disease in Children Hepatic and Extrahepatic Complications,PEDIATRIC CLINICS OF NORTH AMERICA,,0031-3955,10.1016/j.pcl.2017.01.008,,"Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and has become the most common form of chronic liver disease in children and adolescents. The histologic spectrum of NAFLD is broad ranging, from the relatively benign form of simple steatosis to the aggressive form of nonalcoholic steatohepatitis, eventually leading to fibrosis and cirrhosis. NAFLD has also been recognized as an independent risk factor for extrahepatic complications, such as cardiovascular disease, type 2 diabetes mellitus, sleep disorders, and osteoporosis. In this review, we discuss both the hepatic and extrahepatic complications of NAFLD in children.",2017-06,01/07/2022 10:40,01/07/2022 10:40,,659-+,,3,64,,,,,,,,,,,,,,WOS:000403381900014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7F8IR743,journalArticle,2017,"Milla, CE; Ratjen, F; Marigowda, G; Liu, F; Waltz, D; Rosenfeld, M; VX13-809-011 Part B Investigator",Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR,AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,,1073-449X,10.1164/rccm.201608-1754OC,,"Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients. Objectives: In this open-label phase III trial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor combination therapy in patients aged 6-11 years with cystic fibrosis who were homozygous for F508del-CFTR. Methods: Patients (N = 58) received 200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks in addition to their existing cystic fibrosis medications. Measurements and Main Results: Lumacaftor/ivacaftor was well tolerated; the safety profile was generally similar to that observed in larger lumacaftor/ivacaftor trials with older patients. Four patients discontinued (two because of drug-related adverse events: elevated liver transaminases, n = 1; rash, n = 1). No safety concerns were associated with spirometry. No significant changes in percent predicted FEV1 were observed (change from baseline at Week 24, +2.5 percentage points; 95% confidence interval [CI], -0.2 to 5.2; P = 0.0671). At Week 24, significant improvements from baseline were observed in sweat chloride (-24.8 mmol/L; 95% CI, -29.1 to -20.5; P < 0.0001), body mass index z score (+0.15; 95% CI, 0.08 to 0.22; P < 0.0001), Cystic Fibrosis Questionnaire-Revised respiratory domain score ( +5.4; 95% CI, 1.4 to 9.4; P = 0.0085), and lung clearance index based on lung volume turnover required to reach 2.5% of starting N-2 concentration (-0.88; 95% CI, -1.40 to -0.37; P=0.0018). Conclusions: Lumacaftor/ivacaftor was well tolerated in this young population; no new safety concerns were identified. Improvements in lung clearance index, sweat chloride, nutritional status, and health-related quality of life were observed after 24 weeks of treatment.",01/04/2017,01/07/2022 10:40,01/07/2022 10:40,,912-920,,7,195,,,,,,,,,,,,,,WOS:000398017200014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6R7RI7FB,journalArticle,2019,"Sheshadri, A; Kittiskulnam, P; Johansen, KL",Higher Physical Activity Is Associated With Less Fatigue and Insomnia Among Patients on Hemodialysis,KIDNEY INTERNATIONAL REPORTS,,2468-0249,10.1016/j.ekir.2018.10.014,,"Introduction: Patients on hemodialysis experience a heavy burden of symptoms that may be related to the low levels of physical activity reported in this population. We hypothesized that physical activity would be inversely related to symptom severity and that depression might mediate this association. Methods: We designed a cross-sectional study of 48 patients receiving hemodialysis at 3 San Francisco dialysis clinics. Physical activity was measured using pedometers and recorded within 1 week of symptom assessment. Symptoms were assessed using total symptom burden and severity on the Dialysis Symptom Index (DSI; burden 0-29, severity 0-145), individual symptoms on the DSI (0-5), Kidney Disease Quality of Life Vitality scores, (0-100), and the Center for Epidemiologic Study Depression (0-60). Results: Median daily step count was 2631 (25th, 75th percentile 1125, 5278). Seventy-three percent of patients reported fatigue. After adjustment for age, sex, diabetes, and serum albumin, physical activity was associated with 0.2 points lower fatigue severity per 1000 steps per day (95% confidence interval [CI] -0.3 to 0.0), P = 0.04. Physical activity was also associated with higher Vitality score (2.36 points per 1000 steps; 95% CI 0.07-4.65) and lower insomnia scores (-0.1 points per 1000 steps; 95% CI -0.3 to 0.0], P < 0.05) in our adjusted models. Physical activity was not associated with other symptoms. Conclusion: Because the study was cross-sectional, we cannot determine whether physical activity lowers fatigue and insomnia or whether less insomnia and fatigue increase physical activity. However, interventions to increase physical activity should be considered alongside current strategies as a possible approach to managing fatigue and insomnia.",2019-02,01/07/2022 10:40,01/07/2022 10:40,,285-292,,2,4,,,,,,,,,,,,,,WOS:000457641000012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SVQHVNDY,journalArticle,2020,"Hong, SO; Poomkonsarn, S; Millesi, G; Liu, SYC",Upper airway stimulation as an alternative to maxillomandibular advancement for obstructive sleep apnoea in a patient with dentofacial deformity: case report with literature review,INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY,,0901-5027,10.1016/j.ijom.2019.08.008,,"Obstructive sleep apnoea (OSA) is characterized by repeated upper airway collapse leading to oxygen desaturation resulting in cardiovascular and neurocognitive sequelae. Upper airway surgeries such as palatopharyngoplasty, tongue base surgery, and maxillomandibular advancement can improve patient tolerance of continuous positive airway pressure, quality of life, and the severity of OSA. Upper airway stimulation (UAS) of the hypoglossal nerve is a contemporary US Food and Drug Administration-approved treatment modality for OSA with a fundamentally different mechanism. We report the case of a 65-year-old male with a high body mass index, hypertension, diabetes, dentofacial deformity, and severe OSA. He presented with a respiratory distress index (RDI) of 89.1 events per hour, apnoea-hypopnoea index (AHI) of 82.7 events per hour, and minimum oxygen saturation of 75%. He chose to undergo UAS. Initially, complete concentric collapse of the velum was found during drug-induced sedation endoscopy, which was converted by palatopharyngoplasty to meet inclusion criteria for UAS. The patient achieved surgical cure with postoperative RDI and AHI of 2 events per hour with minimum oxygen saturation of 83%, and resolution of daytime somnolence. UAS is an effective surgical option to broaden the surgeon's ability to treat OSA, especially if facial skeletal surgery is contraindicated or declined by the patient with dentofacial deformity.",2020-07,01/07/2022 10:40,01/07/2022 10:40,,908-913,,7,49,,,,,,,,,,,,,,WOS:000546907000011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LLFF49EM,journalArticle,2006,"Smith, MT; Perlis, ML",Who is a candidate for cognitive-behavioral therapy for insomnia?,HEALTH PSYCHOLOGY,,0278-6133,10.1037/0278-6133.25.1.15,,"Chronic insomnia impacts 1 in 10 adults and is linked to accidents, decreased quality of life, diminished work productivity, and increased long-term risk for medical and psychiatric diseases such as diabetes and depression. Recent National Institutes of Health consensus statements and the American Academy of Sleep Medicine's Practice Parameters recommend that cognitive-behavioral therapy for insomnia (CBT-I) be considered the 1st line treatment for chronic primary insomnia. Growing research also supports the extension of CBT-I for patients with persistent insomnia occurring within the context of medical and psychiatric comorbidity. In the emerging field of behavioral sleep medicine, there has yet to be a consensus point of view about who is an appropriate candidate for CBT-I and how this determination is made. This report briefly summarizes these issues. including a discussion of potential contraindications, and provides a schematic decision-to-treat algorithm.",2006-01,01/07/2022 10:40,01/07/2022 10:40,,15-19,,1,25,,,,,,,,,,,,,,WOS:000235123300003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LXJ5TKBR,journalArticle,2017,"Kim, SY; Bang, W; Choi, HG",Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women,PLOS ONE,,1932-6203,10.1371/journal.pone.0185592,,"Background Overactive bladder (OAB) is one of the most prevalent lower urinary tract conditions and has been suggested to be related to various factors. We assessed the prevalence of and factors associated with OAB in women based on a large cross-sectional, population-based study of adult Korean women. Methods The Korean community health survey (KCHS) of 2012 was reviewed, and 107,950 female participants aged 19 to 107 years were identified for inclusion in this study. The overactive bladder symptom score (OABSS) was used to define and classify OAB as mild, moderate, or severe. Numerous variables, including marital status; physical activity; education and income levels; type of occupation; body mass index (BMI); smoking; alcohol; sleep time; and medical history of hypertension, diabetes mellitus, hyperlipidemia, or cerebral stroke, were evaluated. The correlation of these variables with the prevalence of OAB was analyzed using simple and multiple logistic regression analyses with complex sampling. Results The results showed that 5.2% of adult women experienced OAB. Multiple regression analyses showed a significant correlation between the following variables and OAB: older age (adjusted odds ratio [AOR] = 1.44, 95% confidence interval [CI] = 1.39-1.50, P < 0.001 as 10 years older); married status (AOR = 0.83, 95%CI = 0.70-0.96, P = 0.016); lower level of income (AOR = 1.50, 95%CI = 1.34-1.68, P < 0.001); high BMI (AOR = 1.33, 95%CI = 1.23-1.44, P < 0.001); smoking (AOR = 1.24, 95%CI = 1.04-1.47, P < 0.001); long sleep time (AOR = 1.95, 95%CI = 1.69-2.26); and medical history of hypertension (AOR = 1.11, 95%CI = 1.03-1.21, P = 0.011), diabetes mellitus (AOR = 1.38, 95%CI = 1.25-1.53, P < 0.001), hyperlipidemia (AOR = 1.27, 95%CI = 1.16-1.39, P < 0.001), and cerebral stroke (AOR = 2.04, 95%CI = 1.73-2.41, P < 0.001). The level of stress showed a dose-dependent association with OAB (AOR [95%CI] = 3.28 [2.81-3.83] > 2.11 [1.91-2.33] >1.28 [1.16-1.41] for severe > moderate > some stress, respectively, P < 0.001). Conclusion The prevalence of OAB was approximately 5.2% among adult Korean women. Older age; high BMI; stress level; sleep duration; levels of income and education; marital status; smoking; and medical history of hypertension, diabetes mellitus, hyperlipidemia, and cerebral stroke were significantly related to OAB in women.",28/09/2017,01/07/2022 10:40,01/07/2022 10:40,,,,9,12,,,,,,,,,,,,,,WOS:000411985200089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FX5IXVIA,journalArticle,2021,"Fenton, S; Burrows, TL; Collins, CE; Rayward, AT; Murawski, B; Duncan, MJ","Efficacy of a Multi-Component m-Health Diet, Physical Activity, and Sleep Intervention on Dietary Intake in Adults with Overweight and Obesity: A Randomised Controlled Trial",NUTRIENTS,,2072-6643,10.3390/nu13072468,,"This three-arm randomised controlled trial evaluated whether (1) a multi-component weight loss intervention targeting diet, physical activity (PA), and sleep was effective at improving dietary intake over six months and 12 months, compared with a control, and (2) the enhanced diet, PA, and sleep intervention was more effective at improving dietary intake than the traditional diet and PA intervention. A total of 116 adults (70% female, 44.5 years, BMI 31.7 kg/m(2)) were randomised to either traditional diet and PA intervention; enhanced diet, PA, and sleep intervention; or wait-list control. To examine between-group differences, intervention groups were pooled and compared with the control. Then, the two intervention groups were compared. At six months, the pooled intervention group consumed 1011 fewer kilojoules/day (95% CI -1922, -101), less sodium (-313.2 mg/day; 95% CI -591.3, -35.0), and higher %EI from fruit (+2.1%EI; 95% CI 0.1, 4.1) than the controls. There were no differences in intake between the enhanced and traditional groups at six months. At 12 months, the pooled intervention and control groups reported no significant differences. However, compared to the traditional group, the enhanced reported higher %EI from nutrient-dense foods (+7.4%EI; 95% CI 1.3, 13.5) and protein (+2.4%EI; 95% CI 0.1, 4.6), and reduced %EI from fried/takeaway foods (-3.6%EI; 95% CI -6.5, -0.7), baked sweet products (-2.0%EI; 95% CI -3.6, -0.4), and packaged snacks (-1.1%EI; 95% CI -2.2, -0.3). This weight loss intervention reduced total energy and sodium intakes as well as increased fruit intake in adults at six months. The enhanced intervention group reported improved dietary intake relative to the traditional group at 12 months.",2021-07,01/07/2022 10:40,01/07/2022 10:40,,,,7,13,,,,,,,,,,,,,,WOS:000676827200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LM6GHDX7,journalArticle,2018,"Mendelson, M; Bailly, S; Marillier, M; Flore, P; Borel, JC; Vivodtzev, I; Doutreleau, S; Verges, S; Tamisier, R; Pepin, JL","Obstructive Sleep Apnea Syndrome, Objectively Measured Physical Activity and Exercise Training Interventions: A Systematic Review and Meta-Analysis",FRONTIERS IN NEUROLOGY,,1664-2295,10.3389/fneur.2018.00073,,"A systematic review of English and French articles using Pubmed/Medline and Embase included studies assessing objective physical activity levels of obstructive sleep apnea (OSA) patients and exploring the effects of exercise training on OSA severity, body mass index (BMI), sleepiness, and cardiorespiratory fitness [peak oxygen consumption (VO2peak)]. Two independent reviewers analyzed the studies, extracted the data, and assessed the quality of evidence. For objective physical activity levels, eight studies were included. The mean number of steps per day across studies was 5,388 (95% CI: 3,831-6,945; p < 0.001), which was by far lower than the recommended threshold of 10,000 steps per day. For exercise training, six randomized trials were included. There was a significant decrease in apnea-hypopnea-index following exercise training (mean decrease of 8.9 events/h; 95% CI: -13.4 to -4.3; p < 0.01), which was accompanied by a reduction in subjective sleepiness, an increase in VO2peak and no change in BMI. OSA patients present low levels of physical activity and exercise training is associated with improved outcomes. Future interventions (including exercise training) focusing on increasing physical activity levels may have important clinical impacts on both OSA severity and the burden of associated co-morbidities. Objective measurement of physical activity in routine OSA management and well-designed clinical trials are recommended.",22/02/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000425784100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TM32HGS7,journalArticle,2016,"Yildiz, D; Kahvecioglu, S; Buyukkoyuncu, N; Kilic, AK; Yildiz, A; Gul, CB; Seferoglu, M; Tufan, F",Restless-legs syndrome and insomnia in hemodialysis patients,RENAL FAILURE,,0886-022X,10.3109/0886022X.2015.1111118,,"Aim/background: Restless legs syndrome (RLS) is a common neurological movement disorder which is commonly seen in hemodialysis (HD) patients. Insomnia, depression, and anxiety disorders frequently show concurrence. In this study, we aimed to investigate RLS and insomnia prevalence and related factors in HD patients. Subjects and methods: Patients who were under HD treatment and healthy controls with similar mean age, sex ratio, and hypertension and diabetes mellitus frequency were included in this study. Depression, insomnia, and daytime sleepiness assessments were performed by using Beck Depression Inventory, Insomnia Severity Index, and Epworth Sleepiness Scale. The diagnosis of RLS was made using the International RLS Study Group consensus criteria. Results: About 156 HD patients and 35 controls were enrolled. The mean age was 50.6 in the HD group and 49.7 in the control group. Female sex was 43.9% in the HD group and 57.1% in the control group. RLS was significantly more frequent in HD patients compared with controls. The rate of sub-threshold insomnia and insomnia with moderate severity was higher in HD patients. While insomnia severity score and diabetes mellitus were significantly associated with the presence of RLS, depression, RLS, older age, and being under HD treatment were independently associated with insomnia severity. Conclusions: HD patients commonly have RLS and insomnia. Insomnia and diabetes mellitus seem to be major factors underlying RLS in HD patients. Furthermore, depression and RLS seem to be closely related to insomnia in these patients. Treatment of depression, insomnia, and RLS may be beneficial to improve quality of life in HD patients.",2016,01/07/2022 10:40,01/07/2022 10:40,,194-197,,2,38,,,,,,,,,,,,,,WOS:000378052200004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GC8YKD7S,journalArticle,2009,"Dixon, JB",Referral for a Bariatric Surgical Consultation: It is Time to Set a Standard of Care,OBESITY SURGERY,,0960-8923,10.1007/s11695-008-9765-7,,"Indications for bariatric surgery have been clear for some time and many would say that they are conservative. Unfortunately few eligible candidates seek or are referred for bariatric surgery, with less than 1% currently treated annually. In recent years, the evidence base supporting surgical therapy has strengthened with demonstrable improvements in both safety and efficacy. We now have evidence of remarkable improvements in health, quality of life, and increased life expectancy. There is continued frustration with the poor efficacy of non-surgical therapies and no indication that this is about to change. A caring physician should, as best care, refer the seriously ill morbidly obese patient for a surgical opinion. It is no different from their obligation to adequately manage type-2 diabetes, depression or unstable angina. Currently, even discussion of a surgical referral is optional. It is time we articulated and defined a group of patients where referral for a surgical opinion is no longer merely an option but a physician's responsibility as best care for the patient. It is time to provide leadership towards the delivery of better care for these patients.",2009-05,01/07/2022 10:40,01/07/2022 10:40,,641-644,,5,19,,,,,,,,,,,,,,WOS:000266585500018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MSQBVRDS,journalArticle,2021,"Alruwaili, H; Dehestani, B; le Roux, CW",Clinical Impact of Liraglutide as a Treatment of Obesity,CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS,,1179-1438,10.2147/CPAA.S276085,,"Obesity is defined as a chronic, complex, relapsing disease characterized by excessive adipose tissue. Obesity impacts an individual's health by increasing complications such as prediabetes, type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syndrome, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), cancers (eg endometrial), and obstructive sleep apnea (OSA). With the increase of obesity prevalence and its negative influences on individuals' quality of life, there is a great need for therapy with a purpose to produce sustainable weight loss of more than 10% in order to improve or even reverse the progress of obesity related complications. The GLP-1 analogue, liraglutide reduce food consumption, promote weight reduction and improve metabolic functions. The primary mechanism of GLP-1 effect on food intake, metabolism, and weight reduction is mainly due to its actions on peripheral (vagal) and central pathways and activation of hindbrain and hypothalamus. The average weight reduction induced by liraglutide was significant and the weight loss was maintained as long as the patients on therapy. Liraglutide has advantages on weight loss maintenance and promoting cardiovascular disease (CVD) risk reduction, by decreasing systolic blood pressure and glycemic index. In this review, we aim to explain the mechanism of action of Liraglutide, its pharmacokinetic properties, its clinical impact on obesity and its safety and tolerability.",2021,01/07/2022 10:40,01/07/2022 10:40,,53-60,,,13,,,,,,,,,,,,,,WOS:000630318900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XN5B3ID2,journalArticle,2017,"Shin, CH; Grabitz, SD; Timm, FP; Mueller, N; Chhangani, K; Ladha, K; Devine, S; Kurth, T; Eikermann, M",Development and validation of a Score for Preoperative Prediction of Obstructive Sleep Apnea (SPOSA) and its perioperative outcomes,BMC ANESTHESIOLOGY,,1471-2253,10.1186/s12871-017-0361-z,,"Background: Postoperative respiratory complications (PRCs) are associated with significant morbidity, mortality, and hospital costs. Obstructive sleep apnea (OSA), often undiagnosed in the surgical population, may be a contributing factor. Thus, we aimed to develop and validate a score for preoperative prediction of OSA (SPOSA) based on data available in electronic medical records preoperatively. Methods: OSA was defined as the occurrence of an OSA diagnostic code preceded by a polysomnography procedure. A priori defined variables were analyzed by multivariable logistic regression analysis to develop our score. Score validity was assessed by investigating the score's ability to predict non-invasive ventilation. We then assessed the effect of high OSA risk, as defined by SPOSA, on PRCs within seven postoperative days and in-hospital mortality. Results: A total of 108,781 surgical patients at Partners HealthCare hospitals (2007-2014) were studied. Predictors of OSA included BMI > 25 kg* m(-2) and comorbidities, including pulmonary hypertension, hypertension, and diabetes. The score yielded an area under the curve of 0.82. Non-invasive ventilation was significantly associated with high OSA risk (OR 1.44, 95% CI 1.22-1.69). Using a dichotomized endpoint, 26,968 (24.8%) patients were identified as high risk for OSA and 7.9% of these patients experienced PRCs. OSA risk was significantly associated with PRCs (OR 1.30, 95% CI 1.19-1.43). Conclusion: SPOSA identifies patients at high risk for OSA using electronic medical record-derived data. High risk of OSA is associated with the occurrence of PRCs.",30/05/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,17,,,,,,,,,,,,,,WOS:000402593400002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I86QADY9,journalArticle,2016,"Veauthier, C; Paul, F",Therapy of fatigue in multiple sclerosis. A treatment algorithm,NERVENARZT,,0028-2804,10.1007/s00115-016-0128-7,,"Fatigue is one of the most frequent symptoms of multiple sclerosis (MS) and one of the main reasons for underemployment and early retirement. The mechanisms of MS-related fatigue are unknown but comorbid disorders play a major role. Anemia, diabetes, side effects of medication and depression should be ruled out. Moreover, excessive daytime sleepiness (EDS) should be differentiated from fatigue. No approved medicinal therapy of MS fatigue is currently available. Presentation of current treatment strategies with a particular focus on secondary fatigue due to sleep disorders. A review of the literature was carried out. All MS patients suffering from fatigue should be questioned with respect to EDS and if necessary sleep medical investigations should be carried out; however, pure fatigue without accompanying EDS can also be caused by a sleep disorder. Medications, particularly freely available antihistamines, can also increase fatigue. Furthermore, anemia, iron deficits, diabetes and hypothyroidism should be excluded. Self-assessment questionnaires show an overlap between depression and fatigue. Several studies have shown that cognitive behavioral therapy and various psychotherapeutic measures, such as vertigo training, progressive exercise training and individualized physiotherapy as well as fatigue management interventions can lead to a significant improvement of MS-related fatigue. There is currently no medication which is suitable for treatment of fatigue, with the exception of fampridine for the treatment of motor functions and motor fatigue.",2016-12,01/07/2022 10:40,01/07/2022 10:40,,1310-1321,,12,87,,,,,,,,,,,,,,WOS:000389988000010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2IJ544JV,journalArticle,2019,"Iapichino, MC",Tapentadol prolonged release for pain control in a frail obese patient: a case report,EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES,,1128-3602,,,"We present the case of a 59-year-old woman with third-grade obesity and severe comorbidities including osteoporosis, dyslipidemia, diabetes mellitus, hypertension, night eating following bariatric biliary-intestinal by-pass surgery, severe fibromyalgia, poly-arthrosis, lumbar disc herniation in L5S1, sleep disorders and sleep apnea syndrome, and emotional disorders with anxiety and depression, who suffered from chronic pain unresponsive to a combination of multiple analgesics. After a period of metabolic and nutritional rehabilitation. analgesic treatment with tapentadol prolonged release (PR) was started and gradually increased to a daily dose of 300 mg with optimal pain control and a marked improvement in the quality of life and autonomy. Therapy suspension was followed by rebound pain with a worsening in functional capacity, and thus, the patient requested a new rehabilitation treatment, with new benefits. Analgesia is of paramount importance in fragile patients who are undergoing a rehabilitation period, in order to improve compliance with the rehabilitation protocols and increase the success of behavioral therapy. Tapentadol PR can be an effective analgesic therapy for pain control in several settings. Its peculiar tolerability profile improves the acceptability of tapentadol, even in patients with multiple previous analgesic treatments.",2019-11,01/07/2022 10:40,01/07/2022 10:40,,51-54,,,23,,,,,,,,,,,,,,WOS:000498387100009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LD5E7MWP,journalArticle,2021,"Kermansaravi, M; Chiappetta, S; Lainas, P; Kassir, R",Orthostatic Intolerance after Bariatric Surgery: a Systematic Review,OBESITY SURGERY,,0960-8923,10.1007/s11695-021-05266-4,,"Predisposing factors of new-onset orthostatic intolerance (OI) after bariatric surgery (BS) are unknown. The purpose of this study is to summarize current existing data on new-onset OI after BS. Materials and methods were considered for a search of articles that were published by the 30(th) of July 2020. A systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and in line with the protocol agreed by all authors was conducted. Of the 604 initially identified articles, four studies were found to match the established criteria and were extracted for eligibility. 83.3% were female. Hypertension, type 2 diabetes mellitus, and obstructive sleep apnea syndrome were the most frequently reported comorbidities. Surgical intervention such as revision, conversion, or reversal was not documented in these studies. Awareness of this issue must be raised due to the possibility of reduced quality of life and the risk of syncope.",2021-05,01/07/2022 10:40,01/07/2022 10:40,,2250-2254,,5,31,,,,,,,,,,,,,,WOS:000624423500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UB4IVCU3,journalArticle,2008,"Oldenburg, O; Horstkotte, D",Quality of life in patients with chronic heart failure and Cheyne-Stokes respiration,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2007.12.014,,,2008-08,01/07/2022 10:40,01/07/2022 10:40,,601-602,,6,9,,,,,,,,,,,,,,WOS:000259587800003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GGIPV2ED,journalArticle,2006,"Arora, V; Dunphy, C; Chang, VY; Ahmad, F; Humphrey, HJ; Meltzer, D",The effects of on-duty napping on intern sleep time and fatigue,ANNALS OF INTERNAL MEDICINE,,0003-4819,10.7326/0003-4819-144-11-200606060-00005,,"Background: Naps during extended work shifts are effective in reducing fatigue in other industries, but the use of a nap as a countermeasure to prevent fatigue in residents is uncertain. Objective: To assess the effects of a call-night nap on resident sleep and fatigue. Design: 1-year, within-participant, paired trial with crossover at midmonth. Setting: Academic teaching hospital. Participants: 38 of 40 internal medicine interns. Measurements: Sleep was measured by using wristwatch actigraphy. By using the experience sampling method on a personal digital assistant, random alerts prompted interns to rate fatigue on the 7-point Stanford Sleepiness Scale (7 is most tired). Hospital paging logs and structured interviews provided information on use of coverage. Intervention: For 2 weeks of every month, interns were assigned to the nap schedule, which provided coverage to on-duty interns from midnight to 7:00 a.m. so that they could finish their work and take a nap. The other 2 weeks of the month constituted a standard schedule. Results: Interns received 41 more minutes of sleep while on call with the nap schedule (185 minutes vs. 144 minutes; P < 0.001). When interns with the nap schedule used coverage, they received 68 more minutes of sleep (210 minutes vs. 142 minutes; P < 0.001). Despite these small increases in sleep, interns reported less overall fatigue while on the nap schedule than while on the standard schedule (1.74 vs. 2.26; P = 0.017). Postcall fatigue with the nap schedule was lower by nearly 1 point (2.23 vs 3.16; P = 0.036), which is almost equivalent to the difference between oncall and postcall fatigue with the standard schedule (2.06 vs. 3.16). However, use of coverage by interns on the nap schedule was impaired by their desire to care for their patients and concerns about discontinuity of care. Limitations: This was a single-institution study that did not have the power to examine outcomes related to intern or patient wellbeing. Conclusions: Coverage to allow a nap during an extended duty-hour shift can increase sleep and decrease fatigue for residents.",06/06/2006,01/07/2022 10:40,01/07/2022 10:40,,792-798,,11,144,,,,,,,,,,,,,,WOS:000238057000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DFMRM5JQ,journalArticle,2013,"Afsar, B; Elsurer, R",The Relationship Between Sleep Quality and Daytime Sleepiness and Various Anthropometric Parameters in Stable Patients Undergoing Hemodialysis,JOURNAL OF RENAL NUTRITION,,1051-2276,10.1053/j.jrn.2012.06.006,,"Objective: This study evaluates the relationship between sleep quality and daytime sleepiness and body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR), and conicity index in stable patients undergoing hemodialysis (HD). Design and Methods: This was a cross-sectional study. Patients regularly received dialysis treatment in a state hospital. Study participants had a medical history taken and underwent physical examination, measurement of anthropometric factors, and calculations (including BMI, WC, WHR, and confidence interval [CI]) and biochemical analysis. We evaluated quality of life with the 36-item short form survey (SF-36) and depressive symptoms with the Beck Depression Inventory (BDI). Self-reported sleep quality (using the Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (using the Epworth Sleepiness Scale (ESS) was recorded for all patients. Results: In total, 101 patients undergoing HD were enrolled. Stepwise linear regression analysis of factors revealed that BMI (b [partial regression coefficient], 0.405; CI, 0.177-0.632; P, .001), WC (b, 0.082; CI, 0.008-0.157; P, .031), BDI score (b, 0.091; CI, 0.032-0.149; P, .003), presence of diabetes (b, 1.621; CI, 0.175-3.068; P, .028), and presence of cerebrovascular disease (b, 1.944; CI, 0.103-3.785; P, .039) were related to PSQI score (as a dependent variable). Using the same independent parameters, only the physical component summary score of the SF-36 was independently related to the ESS score (b, -0.120; CI, -0.190 to -0.049; P, .001). None of the anthropometric parameters was related to ESS. Conclusions: BMI and WC were the only parameters found to be related to sleep disturbance. None of the anthropometric parameters was related to daytime sleepiness. (C) 2013 by the National Kidney Foundation, Inc. All rights reserved.",2013-07,01/07/2022 10:40,01/07/2022 10:40,,296-301,,4,23,,,,,,,,,,,,,,WOS:000320653100009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H57AP8N3,journalArticle,2020,"Kim, S; Ko, YH; Song, Y; Kang, MJ; Lee, H; Kim, SH; Jeon, JY; Cho, YU; Yi, G; Han, J",Pre-post analysis of a social capital-based exercise adherence intervention for breast cancer survivors with moderate fatigue: a randomized controlled trial,SUPPORTIVE CARE IN CANCER,,0941-4355,10.1007/s00520-020-05363-7,,"Purpose This study assessed the effectiveness of the Better Life After Cancer: Energy, Strength, and Support (BLESS) program, a 12-week social capital-based exercise adherence program for breast cancer survivors (BCS), regarding cancer-related fatigue (CRF), quality of life (QOL), physical activity, and psychosocial characteristics. Methods Forty-eight BCS with moderate or high (>= 4) CRF participated in this randomized control trial (intervention group n = 23, control group n = 25). The intervention group participated in small group sessions to activate social capital while targeting CRF in supervised physical exercises supplemented by home-based physical exercises. The control group was only given written information on exercise. A questionnaire was used to assess CRF, QOL, physical activity, depression, anxiety, sleep quality, and social capital. Results The majority of participants had undergone surgery less than 2 years ago. After participating in BLESS, the CRF behavioral/severity domain significantly decreased (t = 2.642, p = 0.011) and physical activity significantly increased (t = - 2.049, p = 0.046) in the intervention group, in comparison with the control group; there were no significant post-intervention differences in the control group. Both groups showed improvements in sleep quality, depression, anxiety, and QOL. Conclusion The BLESS program decreased behavioral/severity in the CRF and increased physical activity after 12 weeks among BCS. Future research needs to evaluate whether the promising results on physical activity and behavioral fatigue observed in the short term will persist over time. Also, longer-term effects should be examined.",2020-11,01/07/2022 10:40,01/07/2022 10:40,,5281-5289,,11,28,,,,,,,,,,,,,,WOS:000516818800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8J3SGMH9,journalArticle,2012,"Salas, RE; Kwan, AB",The Real Burden of Restless Legs Syndrome: Clinical and Economic Outcomes,AMERICAN JOURNAL OF MANAGED CARE,,1088-0224,,,"Restless legs syndrome (RLS) is a highly prevalent and substantially underdiagnosed sensorimotor disorder. Only relatively recently have the large impact on patient quality of life (QoL) and the economic burden associated with RLS become more widely recognized. QoL in patients with RLS has been shown to be worse than that of many other chronic conditions, including type 2 diabetes, clinical depression, and osteoarthritis. Sleep disturbance, a cardinal feature of RLS, is the most common and most destructive of its symptoms. More than two-thirds of RLS patients experience serious insomnia, and waking up several times per night is typical for this patient population. Moreover, RLS disrupts rest during waking hours, such as when the patient is sitting or relaxing. Thus, whether awake or asleep, the RLS patient finds little opportunity for the general restorative behaviors necessary for healthy human functioning, resulting in high rates of comorbidities including depression, anxiety, and hypertension. The direct and indirect costs related to RLS have been evaluated in a few studies. Although the cost studies are associated with certain limitations (eg, use of questionnaires), the results show that costs related to RLS are substantial. Healthcare utilization, primarily in the form of doctor visits, constitutes the largest proportion of direct expenditures for RLS in the United States. Indirect costs are also large, primarily due to productivity losses, which are as high as 20% in RLS patients. Effective treatment of RLS is necessary to limit the negative effects of RLS on QoL and to reduce costs associated with the condition. (Am J Manag Care. 2012;18:S207-S212)",2012-10,01/07/2022 10:40,01/07/2022 10:40,,S207-S212,,9,18,,,,,,,,,,,,,,WOS:000310997200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PVHB8CV2,journalArticle,2011,"Knight, JA",Diseases and Disorders Associated with Excess Body Weight,ANNALS OF CLINICAL AND LABORATORY SCIENCE,,0091-7370,,,"Excess body weight is a very serious problem, especially in North America and Europe. It has been referred to as a ""pandemic"" since it has progressively increased over the past several decades. Moreover, excess body weight significantly increases the risk of numerous diseases and clinical disorders, including all-cause mortality, coronary and cerebrovascular diseases, various cancers, type 2 diabetes mellitus, hypertension, liver disease and asthma, as well as psychopathology, among others. Unfortunately, overweight and obesity are now common in both young children and adolescents. Although the causes of excess body weight are multi-factorial, the most important factors are excess caloric intake coupled with limited energy expenditure. Therefore, lifestyle modification can significantly reduce the risk of morbidity and mortality and thereby increase longevity and improve the quality of life.",2011,01/07/2022 10:40,01/07/2022 10:40,,107-121,,2,41,,,,,,,,,,,,,,WOS:000294371100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BERPFB78,journalArticle,2007,"Harrington, JM; Wells, CL",Cardiovascular and pulmonary considerations of the obese patient for the rehabilitation clinician,BARIATRIC NURSING AND SURGICAL PATIENT CARE,,1557-1459,10.1089/bar.2007.9951,,"The prevalence of obesity continues to rise worldwide and presents a challenge to all health-care providers. Obesity has pathophysiological effects upon all major systems of the body. Obesity has been linked to an increased risk for many health disorders, including type 2 diabetes, mellitus, hypertension, cardiovascular disease, stroke, and certain cancers. There are changes with basic lung volumes and an increase in incidence of asthma and obstructive sleep apnea for individuals with high body mass index. This article is a review of the cardiovascular and pulmonary physiologic effects of obesity and discusses key components of the evaluation and treatment options that the rehabilitation clinician should consider when delivering care to this patient population.",2007,01/07/2022 10:40,01/07/2022 10:40,,267-280,,4,2,,,,,,,,,,,,,,WOS:000255359900026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WK4KPYUG,journalArticle,,"Phillips, AE; Steel, JL; Amin, A; Wijkstrom, M; Zureikat, A; Tillman, E; Jones, R; Patel, S; Fehrman, N; Starinsky, S; Nalitt, H; Yadav, D; Slivka, A; Bellin, MD; Carroll, A; Humar, A",Psychosocial outcomes 1-year post total pancreatectomy and autologous islet cell transplant,PEDIATRIC TRANSPLANTATION,,1397-3142,10.1111/petr.14167,,"Background A paucity of research regarding the psychosocial outcomes after TPIAT exists. Methods Adults (>18 years), adolescents (13-18 years), and children (5-12 years) with their parents were administered questionnaires at the time of evaluation for TPIAT and 1-year postsurgery to assess psychosocial outcomes. Results A total of 13 adults (6 male, 46%; mean age 35.2 years) and 9 children/adolescents (4 female, 44.4%; mean age 11.78 years) with CP were included in the study. A total of 69.2% of the adults and 66.7% of the children and adolescents were insulin dependent at 1-year postsurgery. In adults, improvements on the SF-36 pain (p = .001) and general health (p = .045) subscales were generally observed 1-year postsurgery. Adult patients who underwent robotic-assisted surgery compared to open surgery specifically reported better general health on the SF-36 (p < .05) at 1 year. For children and adolescents, reductions in average pain in the last week (p < .05), pain interference (p < .001), and fatigue were observed (p < .05) at 1-year postsurgery. For the entire sample, using repeated measures ANOVA and covarying for age, significant differences were found 1-year postsurgery in average pain in the last week (p = .034) and pain interference with the following categories: general activity (p < .001), walking (p = .04), normal work (p = .003), sleep (p = .002), and enjoyment in life (p = .007). Conclusions While few transplant centers offer this treatment, the improvement in quality of life suggests this may be a viable treatment option for those with CP complicated by intractable pain. (IRB Approval PRO 19080302).",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000708855600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PQS7GUNC,journalArticle,2006,"Chevallier, JM; Daoud, F; Szwarcensztein, K; Volcot, MF; Rupprecht, M",Medicoeconomic evaluation of the treatment of morbid obesity by swedish adjustable gastric banding (SAGB),ANNALES DE CHIRURGIE,,0003-3944,10.1016/j.anchir.2005.09.014,,"Introduction: Aim of the present study was to analyze the medicoeconomic impact of each treatment for obesity in France, taking into account morbid obesity-associated comorbidities from a health insurance perspective and to calculate the cost-effectiveness ratio of SAGB compared to the non-surgical treatment for various kinds of patients, as well as the budget impact on a given cohort of patients. Methods: The model studied surgery-eligible patients and compared the effectiveness of the SAGB treatment to the conventional treatment. The follow-up extended from 1 to 5 years. Costs analyzed were treatment-related direct medical costs, as well as potential comorbidities costs. The effectiveness is determined according to the BMI loss and its maintenance over time, together with the level of improved quality of life. Results: An evaluation on a series of 1,000 patients shows that the treatment with SAGB is dominant (less expensive, more effective in terms of loss of BMI and its duration) compared to the conventional treatment for patients suffering from type 11 diabetes or obstructive sleep apnea. The same evaluation in terms of QALYs shows that the treatment with SAGB is dominant compared to the conventional treatment for patients with a BMI >= 35 kg/m(2) and a type II diabetes, as well as for patients whose BMI >= 40 kg/m(2) (with or without type II diabetes mellitus). (c) 2005 Publie par Elsevier SAS.",2006-01,01/07/2022 10:40,01/07/2022 10:40,,Dec-21,,1,131,,,,,,,,,,,,,,WOS:000234763400004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NBK8BDJE,journalArticle,2018,"Papaioannou, O; Karampitsakos, T; Barbayianni, I; Chrysikos, S; Xylourgidis, N; Tzilas, V; Bouros, D; Aidinis, V; Tzouvelekis, A",Metabolic Disorders in Chronic Lung Diseases,FRONTIERS IN MEDICINE,,2296-858X,10.3389/fmed.2017.00246,,"Chronic lung diseases represent complex diseases with gradually increasing incidence, characterized by significant medical and financial burden for both patients and relatives. Their increasing incidence and complexity render a comprehensive, multidisciplinary, and personalized approach critically important. This approach includes the assessment of comorbid conditions including metabolic dysfunctions. Several lines of evidence show that metabolic comorbidities, including diabetes mellitus, dyslipidemia, osteoporosis, vitamin D deficiency, and thyroid dysfunction have a significant impact on symptoms, quality of life, management, economic burden, and disease mortality. Most recently, novel pathogenetic pathways and potential therapeutic targets have been identified through large-scale studies of metabolites, called metabolomics. This review article aims to summarize the current state of knowledge on the prevalence of metabolic comorbidities in chronic lung diseases, highlight their impact on disease clinical course, delineate mechanistic links, and report future perspectives on the role of metabolites as disease modifiers and therapeutic targets.",18/01/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,4,,,,,,,,,,,,,,WOS:000422787400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RU8ZV3ZE,journalArticle,2017,"Kim, SY; Bang, W; Choi, HG",Analysis of the prevalence and associated factors of overactive bladder in adult Korean men,PLOS ONE,,1932-6203,10.1371/journal.pone.0175641,,"Overactive bladder (OAB) is a prevalent condition characterized by lower urinary tract symptoms (LUTS). Age, education, income, marital status, sleep, and emotional problems have been associated with OAB; however, conflicting results exist. The present study was conducted to estimate the prevalence of OAB and comprehensively analyze its associated factors in a large cross-sectional, population-based study. The data of 94,554 participants aged 19- 107 were analyzed from the Korean Community Health Survey (KCHS) of 2012. Data on marital status, physical activity, education level, occupation, body mass index (BMI), income level, sleep time, and stress level were retrieved for all enrolled participants. The overactive bladder symptom score (OABSS) was used to evaluate the presence and degree of OAB. Simple and multiple logistic regression analyses with complex sampling were used for the associations between various factors and the presence of OAB. Overall, OAB was present in approximately 2.9% of the participants. The prevalence of OAB increased with age and steeply increased after 60 years of age (adjusted odds ratio [AOR] for each 10 years = 1.70, 95% confidence interval [CI] = 1.61-1.80, P<0.001). The prevalence of OAB was lower in married than unmarried subjects (AOR = 0.59, 95% CI = 0.48-0.72, P<0.001). The prevalence of OAB was significantly different according to occupation Compared to manager, expert, specialist, clerk group, the prevalence of OAB was highest in unemployed group (AOR = 1.90, 95% CI = 1.55-2.32, P < 0.001). Being underweight was correlated with OAB (AOR = 1.29, 95% CI = 1.08-1.55, P = 0.018). Inadequate sleep showed a significant association with OAB (AOR = 1.13, 95% CI = 1.02-1.25 for <= 6 hours of sleep time and AOR = 1.53, 95% CI = 1.27-1.86 for >= 9 hours of sleep, P<0.001). Stress level showed a dose-dependent positive association with OAB [AOR (95% CI) = 3.91 (3.13-4.89) > 2.16 (1.88-2.48) > 1.39 (1.23-1.57) for severe stress > moderate stress > some stress, respectively, P<0.001]. A medical history of diabetes mellitus, hyperlipidemia, and/or cerebral stroke was significantly related to OAB. Approximately 2.9% of adult Korean men experienced OAB based on the OABSS. Unmarried status; occupation; being underweight; inadequate sleep; stress; and medical history of diabetes mellitus, hyperlipidemia, or cerebral stroke were significantly correlated with OAB.",13/04/2017,01/07/2022 10:40,01/07/2022 10:40,,,,4,12,,,,,,,,,,,,,,WOS:000399955400076,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93YT99YR,journalArticle,2016,"Tauber, M; Diene, G; Molinas, C",Sequelae of GH Treatment in Children with PWS,PEDIATRIC ENDOCRINOLOGY REVIEWS PER,,1565-4753,10.17458/PER.2016.TDM.SequelaeofGH,,"More than 15 years after rGH was granted marketing authorization for children with PWS, a review of the sequelae, side effects and safety issues of rGH therapy is timely. The publications on issues concerning respiratory function, glucose metabolism, fat mass, and scoliosis at baseline and with rGH treatment are herein presented. We discuss the impact of rGH side effects, make proposals to prevent or treat them, and emphasise the remaining questions and perspectives. As a whole, the benefit /risk ratio is positive, although questions are raised about the role of GH in premature pubarche and its long-term effects, particularly the potential long-term oncogenic risk. The organisation of care in dedicated or reference centres at the national and European level will facilitate the collection and analysis of data and serve as a paradigm for long-term follow-up.",2016-12,01/07/2022 10:40,01/07/2022 10:40,,138-146,,2,14,,,,,,,,,,,,,,WOS:000404094000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
S3KWV326,journalArticle,2018,"Bonn, SE; Alexandrou, C; Steiner, KH; Wiklander, K; Ostenson, CG; Lof, M; Lagerros, YT","App-technology to increase physical activity among patients with diabetes type 2-the DiaCert-study, a randomized controlled trial",BMC PUBLIC HEALTH,,1471-2458,10.1186/s12889-018-5026-4,,"Background: Physical activity can decrease the risk of complications related to diabetes type 2. Feasible and scalable strategies to implement support for a healthy lifestyle for patients in primary care are needed. The aim of the DiaCert-study is to evaluate a digital healthcare platform and the effect of a 12-week long smartphone-app physical activity intervention aiming at increasing physical activity (primary outcome) and improve levels of HbA1c (glycated hemoglobin), blood lipids, blood pressure, body composition, as well as other lifestyle factors and overall health in patients with diabetes type 2. Methods/Design: The DiaCert-study is a two-arm, randomized controlled trial that will include 250 patients with diabetes type 2. At baseline, participants are randomized 1:1 to intervention, i.e. use of the smartphone-app, during 12 weeks, or to a control group receiving only standard care. Physical activity and sedentary behavior, is objectively measured using the Actigraph GT3X. Biomarkers including HbA1c and blood lipids are measured in fasting blood samples. Anthropometrics include height, weight, waist circumference and body composition, and a number of lifestyle factors including sleep, diet, self-efficacy, and quality of life, are assessed through an extensive questionnaire. Measurements are made at baseline and at follow-up after 3, 6 and 12 months. Discussion: Using new technology, is one way to bridge the gap between what patients need and what health care can offer. This study evaluates a new digital health care platform and will show if use of a smartphone-app to promote daily steps is an effective and feasible method to increase physical activity and improve clinical markers in patients with diabetes type 2.",10/01/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,18,,,,,,,,,,,,,,WOS:000422802900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SBHER5QV,journalArticle,2010,"Moock, J; Hessel, F; Ziegeler, D; Kubiak, T; Kohlmann, T",Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ),PATIENT-PATIENT CENTERED OUTCOMES RESEARCH,,1178-1653,10.2165/11319510-000000000-00000,,"Objectives: To develop and psychometrically evaluate a domain-specific questionnaire to assess subtle but clinically relevant differences in treatment experiences and satisfaction over a wide range of currently available insulin therapy regimens. The study focussed on patients with type 2 diabetes mellitus and placed particular attention on the impact of different forms of insulin therapy on diabetes self-management. Methods: The development of the Insulin Treatment Experience Questionnaire (ITEQ) was conducted in three steps: (i) a qualitative phase to generate relevant items and identify relevant domains; (ii) a pilot study to reduce the number of generated items; and (iii) a validation study to assess major psychometric properties of the final ITEQ version. Results: The final version of the questionnaire comprised 28 items with the subscales 'leisure activities' (four items), 'psychological barriers' (two items), 'handling' (five items), 'diabetes control' (six items), 'dependence' (five items), 'weight control' (three items), 'sleep' (two items), and one further item assessing general treatment satisfaction. The subscales' internal consistencies (Cronbach's alpha) ranged from 0.52 to 0.83. Motivated by the homogenous structure of inter-scale-correlations (range 0.10-0.46), a summary composite score was calculated (alpha = 0.86). Construct validity showed statistically significant correlations with other scales (ITEQ vs the Problem Areas in Diabetes [PAID] questionnaire total score -0.60, ITEQ vs the Diabetes Treatment Satisfaction Questionnaire [DTSQ] total score 0.52). Conclusion: The newly developed ITEQ displayed satisfactory to good psychometric properties, thereby allowing the assessment of everyday life experience and treatment satisfaction in patients with insulin-treated type 2 diabetes. Additional research is needed to assess test-retest reliability and sensitivity to change.",01/03/2010,01/07/2022 10:40,01/07/2022 10:40,,45-58,,1,3,,,,,,,,,,,,,,WOS:000293127500005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WF63LJAI,journalArticle,2021,"Hynes, M",Beyond Ablation in Atrial Fibrillation: 10 Steps to Better Control,AMERICAN JOURNAL OF LIFESTYLE MEDICINE,,1559-8276,10.1177/1559827620943326,,"The prevention and treatment of atrial fibrillation includes risk factor modification beyond ablation, with lifestyle modifications including treatment of obesity through diet and moderate exercise being at the top of the list. Losing 10% of body weight if obese, a plant-based diet, exercise, maintaining systolic blood pressure below 130 mm Hg, treatment of sleep disorders and obstructive sleep apnea, stress management, and treatment of depression and anxiety should all be included in treatment. Maximizing evidence-based treatment of chronic obstructive pulmonary disease and diabetes is also paramount.",2021-07,01/07/2022 10:40,01/07/2022 10:40,,434-440,,4,15,,,,,,,,,,,,,,WOS:000553071800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XM9VF7YS,journalArticle,2018,"Astell-Burt, T; Feng, XQ",Geographic variation in the impact of a type 2 diabetes diagnosis on behavioural change: A longitudinal study using random effects within-between (REWB) models,HEALTH & PLACE,,1353-8292,10.1016/j.healthplace.2018.07.007,,"A type 2 diabetes (T2DM) diagnosis has been referred to as a ""wake-up call"", but subsequent behavioural change may be influenced by place of residence. Random effects within-between regressions were applied to 130,926 participants in the 45 and Up Study. T2DM diagnoses effected change in the odds of short sleeps and meeting vegetable and alcohol consumption guidelines, but not changes in physical activity. Each of these behaviours varied geographically and were patterned by area disadvantage and geographic remoteness. Impacts of T2DM diagnosis on behavioural change were not found to be geographically contingent, though analysis of specific environmental attributes is warranted.",2018-11,01/07/2022 10:40,01/07/2022 10:40,,164-169,,,54,,,,,,,,,,,,,,WOS:000450111700020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DASIRWIS,journalArticle,2019,"Kass-Iliyya, A; Hashim, H","Nocturnal polyuria: Literature review of definition, pathophysiology, investigations and treatment",JOURNAL OF CLINICAL UROLOGY,,2051-4158,10.1177/2051415818756792,,"Nocturnal polyuria (NP) is characterised by increased urine production overnight in comparison to daytime. It has significant adverse events in adults including reduced quality of life, increased risk of falls and increased mortality. Although NP can be a manifestation of other significant conditions like heart failure and sleep apnoea, there are lots of unanswered questions about NP. What is the underlying pathophysiology? Is NP a physiological manifestation of ageing? Is the circadian change of vasopressin release the primary pathology? Or is it a secondary phenomenon to a low diurnal production of urine? Is the primary pathology at the kidney level or is there another humoral, cardiac, or endovascular element? In this article, we summarise the available English-language literature on the subject of NP, including its epidemiology, pathogenesis, diagnosis and treatment. Level of evidence: Not applicable for this multicentre audit.",2019-01,01/07/2022 10:40,01/07/2022 10:40,,60-71,,1,12,,,,,,,,,,,,,,WOS:000454143600010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IMTLCXSF,journalArticle,2015,"van Dijk, GM; Kavousi, M; Troup, J; Franco, OH",Health issues for menopausal women: The top 11 conditions have common solutions,MATURITAS,,0378-5122,10.1016/j.maturitas.2014.09.013,,"Multiple health issues affect women throughout the life course differently from men, or do not affect men at all. Although attention to women's health is important in all stages in life, health among middle-aged and elderly women has not received sufficient attention by scientists and policy-makers. Related to the menopausal transition and the experiences accumulated until that age, many diseases occur or further develop in middle-aged and elderly women. To improve women's quality of life and guarantee a long-lasting and active role for middle-aged and elderly women in society, prevention of chronic diseases and disability is a key aspect. In this manuscript we give an overview of the major health issues for pen- and post-menopausal women, we summarize risk factors and interventions to improve menopausal health. Based on the available scientific literature and the global burden of disease endeavor, we have selected and herein describe the following top 11 key health issues, selected in terms of burden exerted in women's mortality, morbidity, disability and quality of life: cardiovascular disease, musculoskeletal disorders, cancer, cognitive decline and dementia, chronic obstructive pulmonary disease, diabetes mellitus, metabolic syndrome, depression, vasomotor symptoms, sleep disturbances and migraine. (C) 2014 Elsevier Ireland Ltd. All rights reserved.",2015-01,01/07/2022 10:40,01/07/2022 10:40,,24-30,,1,80,,,,,,,,,,,,,,WOS:000348013900004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BLYKMAMY,journalArticle,2014,"De Cesare, A; Cangemi, B; Fiori, E; Bononi, M; Cangemi, R; Basso, L",Early and long-term clinical outcomes of bilio-intestinal diversion in morbidly obese patients,SURGERY TODAY,,0941-1291,10.1007/s00595-014-0856-x,,"To evaluate the early and long-term postoperative results of malabsorptive surgery in morbidly obese patients. Between 2000 and 2007, 102 morbidly obese patients were referred to the Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Policlinico ""Umberto IA degrees"", Rome, Italy for malabsorptive surgery. All patients underwent derivative biliodigestive surgery after they had been reviewed by a team of surgeons, physicians, dieticians, and psychologists. There were no intra-operative complications, but two patients suffered postoperative pulmonary embolisms, which resolved with medical treatment. The mean postoperative hospital stay was 7 days, with no early or late mortality. Maximum weight loss was reached 12-24 months after surgery, while the mean percentage excess weight loss at 3-5 years ranged from 45 to 64 %. Specific postoperative complications in the first 2 years after surgery were abdominal abscess (n = 2), gastroduodenal reflux (n = 4), and incisional hernia (n = 6). Diabetes resolved in 98 % of the diabetic patients within a few weeks after surgery and blood pressure normalised in 86.4 % of those who had had hypertension preoperatively. Obstructive sleep apnoea and obesity hypoventilation syndrome also improved significantly in 92 % of the patients. Morbidly obese patients can undergo biliodigestive surgery safely with good long-term weight loss and quality of life expectancy.",2014-08,01/07/2022 10:40,01/07/2022 10:40,,1424-1433,,8,44,,,,,,,,,,,,,,WOS:000339379000005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H4UMZ55T,journalArticle,2021,"Barber, TM; Kyrou, I; Randeva, HS; Weickert, MO",Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,,1422-0067,10.3390/ijms22020546,,"Obesity mediates most of its direct medical sequelae through the development of insulin resistance (IR). The cellular effects of insulin occur through two main postreceptor pathways that are the phosphatidylinositol 3-kinase (PI3-K) and the mitogen-activated protein kinase (MAP-K) pathways. Obesity-related IR implicates the PI3-K pathway that confers the metabolic effects of insulin. Numerous and complex pathogenic pathways link obesity with the development of IR, including chronic inflammation, mitochondrial dysfunction (with the associated production of reactive oxygen species and endoplasmic reticulum stress), gut microbiota dysbiosis and adipose extracellular matrix remodelling. IR itself plays a key role in the development of metabolic dysfunction, including hypertension, dyslipidaemia and dysglycaemia. Furthermore, IR promotes weight gain related to secondary hyperinsulinaemia, with a resulting vicious cycle of worsening IR and its metabolic sequelae. Ultimately, IR underlies obesity-related conditions such as type 2 diabetes mellitus (T2D) and polycystic ovary syndrome (PCOS). IR also underlies many obesity-related malignancies, through the effects of compensatory hyperinsulinaemia on the relatively intact MAP-K insulin pathway, which controls cellular growth processes and mitoses. Furthermore, the emergent data over recent decades support an important role of obesity- and T2D-related central IR in the development of cognitive dysfunction, including effects on hippocampal synaptic plasticity. Importantly, IR is largely reversible through the optimisation of lifestyle factors that include regular engagement in physical activity with the avoidance of sedentariness, improved diet including increased fibre intake and sleep sufficiency. IR lies at the key crossroad between obesity and both metabolic and cognitive dysfunction. Given the importance of IR in the pathogenesis of many 21st century chronic diseases and its eminent reversibility, it is important that we all embrace and facilitate optimised lifestyles to improve the future health and wellbeing of the populace.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,,,2,22,,,,,,,,,,,,,,WOS:000611335000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T4CNXRSY,journalArticle,2017,"Osland, E; Yunus, RM; Khan, S; Memon, B; Memon, MA",Changes in Non-Diabetic Comorbid Disease Status Following Laparoscopic Vertical Sleeve Gastrectomy (LVSG) Versus Laparoscopic Roux-En-Y Gastric Bypass (LRYGB) Procedures: a Systematic Review of Randomized Controlled Trials,OBESITY SURGERY,,0960-8923,10.1007/s11695-016-2469-5,,"Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic vertical sleeve gastrectomy (LVSG) have been proposed as cost-effective strategies to manage obesity-related chronic disease. The aim of this systematic review was to study the peer review literature regarding postoperative nondiabetic comorbid disease resolution or improvement reported from randomized controlled trials (RCTs) comparing LVSG and LRYGB procedures. RCTs comparing postoperative comorbid disease resolution such as hypertension, dyslipidemia, obstructive sleep apnea, joint and musculoskeletal conditions, gastroesophageal reflux disease, and menstrual irregularities following LVSG and LRYGB were included for analysis. The studies were selected from PubMed, Medline, EMBASE, Science Citation Index, Current Contents, and the Cochrane database and reported on at least one comorbidity resolution or improvement. The present work was undertaken according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA). The Jadad method for assessment of methodological quality was applied to the included studies. Six RCTs performed between 2005 and 2015 involving a total of 695 patients (LVSG n = 347, LRYGB n = 348) reported on the resolution or improvement of comorbid disease following LVSG and LRYGB procedures. Both bariatric procedures provide effective and almost comparable results in improving or resolving these comorbidities. This systematic review of RCTs suggests that both LVSG and LRYGB are effective in resolving or improving preoperative nondiabetic comorbid diseases in obese patients. While results are not conclusive at this time, LRYGB may provide superior results compared to LVSG in mediating the remission and/or improvement in some conditions such as dyslipidemia and arthritis.",2017-05,01/07/2022 10:40,01/07/2022 10:40,,1208-1221,,5,27,,,,,,,,,,,,,,WOS:000400029400012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
URZ9MKS3,journalArticle,2001,"Visscher, TLS; Seidell, JC",The public health impact of obesity,ANNUAL REVIEW OF PUBLIC HEALTH,,0163-7525,10.1146/annurev.publhealth.22.1.355,,"The increase in obesity worldwide will have an important impact on the global incidence of cardiovascular disease, type 2 diabetes mellitus, cancer, osteoarthritis, work disability, and sleep apnea. Obesity has a more pronounced impact on morbidity than on mortality. Disability due to obesity-related cardiovascular diseases will increase particularly in industrialized countries, as patients survive cardiovascular diseases in these countries more often than in nonindustrialized countries. Disability due to obesity-related type 2 diabetes will increase particularly in industrializing countries, as insulin supply is usually insufficient in these countries. As a result, in these countries, an increase in disabling nephropathy, arteriosclerosis, neuropathy, and retinopathy is expected. Increases in the prevalence of obesity will potentially lead to an increase in the number of years that subjects suffer from obesity-related morbidity and disability. A 1% increase in the prevalence of obesity in such countries as India and China leads to 20 million additional cases of obesity. Prevention programs will stem the obesity epidemic more efficiently than weight-loss programs. However, only a few prevention programs have been developed or implemented, and the success rates reported to date have been low. Obesity prevention programs should be high on the scientific and political agenda in both industrialized and industrializing countries.",2001,01/07/2022 10:40,01/07/2022 10:40,,355-375,,,22,,,,,,,,,,,,,,WOS:000168649000021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HLFT3TW8,journalArticle,2021,"Can, M; Kocabas, M; Cordan, I; Caliskan Burgucu, H; Karakose, M; Kulaksizoglu, M; Karakurt, F",Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population,TURKISH JOURNAL OF MEDICAL SCIENCES,,1300-0144,10.3906/sag-2007-243,,"Background/aim: The presence of comorbidities in patients with acromegaly causes an increase in morbidity and/or mortality and a decrease in quality of life. In this study, we aimed to investigate the demographic, clinical and laboratory features, prevalence of acromegaly-related comorbidities, and factors associated with these comorbidities in patients with acromegaly. Materials and methods: In the study, 96 patients who were followed up with the diagnosis of acromegaly were included. Clinical, laboratory and imaging features, and accompanying comorbidities of the patients were recorded from the patient files. Results: Of the patients included in the study, 63 (65.6%) were female and 33 (34.4%) were male. The mean age of diagnosis was 42.61 +/- 12.08, and the mean follow-up period was 9.97 +/- 7.26 years. Median insulin-like growth factor 1 level was 238.16 ng/mL (30.5-820), median growth hormone level was 2.05 ug/L (0.1-29.4). A total of 60 (62.5%) of the patients were in the well-controlled group, and 36 (37.5%) had active disease at the time of inclusion. Diabetes mellitus (DM) was detected in 30 (31.3%) patients, prediabetes in 19 (28.8%) patients, hypertriglyceridemia in 38 (42.2%) patients, hypertension (HT) in 41 (42.7%) patients, cardiovascular disease in 5 (5.2%) patients, malignancy in 9 (9.4%) patients, obstructive sleep apnea syndrome in 8 (8.3%) patients, carpal tunnel syndrome in 11 (11.5%) patients, arthropathy in 5 (5.2%) patients, hearing loss in 7 (7.3%) patients, thyroid nodule in 56 (67.5%) patients, thyroid cancer in 4 (4.2%) patients, colonic polyp in 19 (38.8%) patients. Conclusion: In this study, we revealed that the most common comorbidities in acromegaly patients in the Turkish population are thyroid nodules, low high-density lipoprotein (HDL cholesterol (HDL-C) level, hypertriglyceridemia, HT, colonic polyps, DM, and prediabetes, and female sex and age at diagnosis are the most important factors associated with comorbidities.",2021,01/07/2022 10:40,01/07/2022 10:40,,1146-1152,,3,51,,,,,,,,,,,,,,WOS:000668244900029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2K4PUW29,journalArticle,2016,"Barat, P; Meiffred, MC; Brossaud, J; Fuchs, D; Corcuff, JB; Thibault, H; Capuron, L","Inflammatory, endocrine and metabolic correlates of fatigue in obese children",PSYCHONEUROENDOCRINOLOGY,,0306-4530,10.1016/j.psyneuen.2016.09.002,,"Alterations in endocrine functions and low-grade systemic inflammation represent fundamental characteristics of obesity. These biological systems have been repeatedly linked to fatigue symptoms. The aim of the study was to assess the relationship between fatigue dimensions and metabolic/inflammatory markers in a sample of non-diabetic obese children. The possibility that inflammation-induced alterations in tryptophan metabolism relates to specific dimensions of fatigue was also investigated in a subsample of patients. The study was conducted in 41 obese children, median aged 12 [9-15] years, recruited in a pediatric tertiary center. Three dimensions of fatigue (e.g., general fatigue, sleep/rest, cognitive fatigue) were assessed using the Pediatric Quality of Life Inventory Multidimentional Fatigue Scale. In addition, a principal component analysis was performed to identify fatigue dimensions that were specific to the population under study. This analysis extracted five relevant dimensions corresponding respectively to concentration, energy, self-perceived cognitive efficiency, 'sleep/rest and motivation/anhedonia. Blood samples were collected for the measurement of inflammatory and metabolic markers, including, high sensitivity C-reactive protein (hs-CRP), insulin, uricemia and glycaemia. Tryptophan, kynurenine and neopterin levels were also determined in a subsample of 17 patients. In the whole population under study, cognitive fatigue and reduced motivation/anhedonia were associated with BMI, independently of sex and age. The dimension of reduced motivation/anhedonia was associated with insulin resistance and inflammatory biomarkers. The association with insulin resistance persisted when the extent of fat mass (BMI-SDS) was taken into account. No association was found between tryptophan metabolism and specific dimensions of fatigue, but kynurenine and the kynurenine/tryptophan ratio correlated with insulin and HOMA-IR. These data indicate that insulin resistance in non diabetic obese children is associated with both cognitive fatigue and reduced motivation/anhedonia and with alterations in tryptophan metabolism. Further investigations are needed to determine whether inflammation-induced alterations in tryptophan metabolism is directly or indirectly implicated in insulin resistance and related fatigue. (C) 2016 Elsevier Ltd. All rights reserved.",2016-12,01/07/2022 10:40,01/07/2022 10:40,,158-163,,,74,,,,,,,,,,,,,,WOS:000387524700018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IH9NVKTL,journalArticle,2021,"Francis, CE; Quinnell, T",Mandibular Advancement Devices for OSA: An Alternative to CPAP?,PULMONARY THERAPY,,2364-1754,10.1007/s41030-020-00137-2,,"Obstructive sleep apnea (OSA) is a prevalent condition causing unrefreshing sleep and excessive daytime sleepiness. It has individual socioeconomic impacts and, through association with increased risk of road traffic accidents, diabetes, and cardiovascular disease, OSA is a public health issue. Continuous positive airway pressure (CPAP) is the first-line treatment for moderate-to-severe OSA. It is effective in improving excessive daytime sleepiness and quality of life. There is also evidence that CPAP therapy has cardiovascular benefits although nature and extent remain uncertain. Despite its benefits, a significant proportion of patients are unable to tolerate CPAP. There are also patients with mild but symptomatic disease, for whom CPAP is usually not available or appropriate, so there is a need for other treatment options. Mandibular advancement devices (MADs) offer an effective alternative to CPAP and can improve daytime symptoms and quality of life. There are many devices available, representing a range of complexity and cost. It is challenging to properly evaluate the effectiveness of this ever-evolving range. The more basic MADs are cheaper and more accessible but are less well tolerated. More complex devices are better tolerated and may be more effective. However, they are more expensive and often require dental expertise, so access is more limited. Efforts continue to try to improve accessibility to effective MAD therapy. Alongside increasing awareness, this may be facilitated by developing and refining devices that could be fitted by non-dental clinicians, and potentially by patients themselves. Research efforts need to focus on determining how to efficiently identify patients who are likely to respond to MAD therapy, so as to improve clinical and cost-effectiveness of OSA therapy overall.",2021-06,01/07/2022 10:40,01/07/2022 10:40,,25-36,,1,7,,,,,,,,,,,,,,WOS:000655084400003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UZ4YGKHS,journalArticle,2019,"Kizilgoz, D; Yeildagli, H; Kabalak, PA; Cengiz, TI; Yilmaz, U",Assesment of symptom burden and related factors of patients with lung cancer in a palliative care unit,EURASIAN JOURNAL OF PULMONOLOGY,,2148-3620,10.4103/ejop.ejop_30_18,,"INTRODUCTION AND AIM: Symptom palliation is important in terms of improving quality of life and therapy compliance in patients diagnosed with lung cancer. In this study, we intend to describe the tumor symptoms and related factors with Edmonton Symptom Assessment Scale (ESAS) in patients who admitted to a palliative care unit. MATERIALS AND METHODS: Two hundred and ninety patients with lung cancer who admitted to our tertiary outpatient palliative clinic were retrospectively reviewed. Pathological diagnosis, stage, demographic features, comorbidities, treatment modalities, and ESAS score were recorded. Survival was analyzed using Kaplan-Meier analysis. RESULTS: There was no relation between stage of disease and ESAS score. The mean sleep variance score was significantly higher in Stage IV patients compared to all other groups (P= 0.038). The scores of cough and how they felt themselves were significantly higher in patients with metastatic lymph node (n = 30: P = 0.016 and P = 0.027, respectively). The presence of diabetes mellitus was found to be significantly related to higher sadness and anxiety score (P = 0.046 and P= 0.023, respectively). Treatment modalities (Group 1: best supportive care [n = 22] and Group 2: others [n = 268]) did not affect the mean ESAS score (P > 0.05). The overall survival and mean ESAS score were not related (P> 0.05). CONCLUSION: ESAS contributes significantly to improve general medical condition of patients with lung cancer. Comorbidities should be considered along with ESAS during cancer management. Symptom score evaluation and proper palliative treatment is important in lung cancer patients. Anyway, the treatment period of lung cancer is already difficult enough, so physicians should facilitate this process for patients.",2019-05,01/07/2022 10:40,01/07/2022 10:40,,93-96,,2,21,,,,,,,,,,,,,,WOS:000484239000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HGZCDEZD,journalArticle,2009,"Schuster, DP",Changes in physiology with increasing fat mass,SEMINARS IN PEDIATRIC SURGERY,,1055-8586,10.1053/j.sempedsurg.2009.04.002,,"Obesity has reached epidemic proportions in the USA with a nearly fourfold rise in the prevalence of childhood obesity. There are many possible etiologies of obesity as the adipose tissue plays a significant, complex role in the physiology of fuel metabolism and hormone regulation. The development of obesity represents a pathophysiologic increase in fat mass in which multiple metabolic pathways are deranged. The consequences of these metabolic derangements, including insulin resistance and inflammation, are reflected in obesity-related comorbidities and can be seen in the setting of pediatric obesity. Obese adolescents demonstrate increased rates of early maturation, orthopedic growth abnormalities, diabetes mellitus, obstructive sleep apnea, hypertension, steatosis, and polycystic ovarian syndrome, placing this group of children at risk for long-term health problems and reduced quality of life. Given the negative short- and long-term impact of obesity on children, careful attention should be paid to the unique health issues of this ""at-risk"" population with both prevention and early intervention strategies. (C) 2009 Elsevier Inc. All rights reserved.",2009-08,01/07/2022 10:40,01/07/2022 10:40,,126-135,,3,18,,,,,,,,,,,,,,WOS:000267953500002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LLSYBWTX,journalArticle,2002,"Iacovides, A; Fountoulakis, KN; Balaskas, E; Manika, A; Markopoulou, M; Kaprinis, G; Tourkantonis, A",Relationship of age and psychosocial factors with biological ratings in patients with end-stage renal disease undergoing dialysis,AGING CLINICAL AND EXPERIMENTAL RESEARCH,,1594-0667,,,"Background and aims: Dialysis is a time-consuming procedure and may cause psychological distress. The aim of the present study was to investigate the relationship between age, emotional state, life satisfaction, sexual functioning and the method of dialysis in patients suffering from end-stage renal failure. Methods: Eighty-two patients Of 97 with end-stage chronic renal failure entered the study; 56 were under hemodialysis (HD), and 26 were under continuous ambulatory peritoneal dialysis (CAPD). Zung Depression Rating Scale (ZDRS), the Life Satisfaction Inventory (LSI), the Lasry Sexual Functioning Scale (LSFS), and a protocol aiming to register sociodemographic variables and variables considering the physical disorders were used. Results: No significant differences between groups were found in the ZDRS (HD patients: 40.7 +/- 8.2, CAPD patients: 41.88 +/- 10.44; p=0.57), LSI scores (HD patients: 87.9 +/- 14.7, CAPD patients: 87.03 +/- 5.25; p=0.7) and LSFS scores. Multiple linear regression analysis showed that LSI scores depended only on gender (females were less satisfied) and individual items on level of albumins and the presence of other physical disorders; ZDRS individual items depended on leukomatine level, gender, diabetes mellitus, albumins, age, creatinine and duration of disease; sexual functioning on age, and urea and sleep on albumin level (all with p<0.001). Discussion: No statistically significant differences were detected in depressive symptomatology, sexual function and life satisfaction between patients undergoing HD or CAPD. Some aspects of depressive symptomatology, sexual functioning and life satisfaction may be influenced by age, the kind of treatment and its effectiveness. Age was positively related with satisfaction from general quality of life, frequency of sexual activity, tiredness and feelings of usefulness. (C) 2002, Editrice Kurtis.",2002-10,01/07/2022 10:40,01/07/2022 10:40,,354-360,,5,14,,,,,,,,,,,,,,WOS:000180994900006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7D4CGX9S,journalArticle,2020,"Chung, MNK; Eckhardt, LL; Chen, LY; Ahmed, HM; Gopinathannair, R; Joglar, JA; Noseworthy, PA; Pack, QR; Sanders, P; Trulock, KM",Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association,CIRCULATION,,0009-7322,10.1161/CIR.0000000000000748,,"Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with substantial morbidity, mortality, and healthcare use. Great strides have been made in stroke prevention and rhythm control strategies, yet reducing the incidence of AF has been slowed by the increasing incidence and prevalence of AF risk factors, including obesity, physical inactivity, sleep apnea, diabetes mellitus, hypertension, and other modifiable lifestyle-related factors. Fortunately, many of these AF drivers are potentially reversible, and emerging evidence supports that addressing these modifiable risks may be effective for primary and secondary AF prevention. A structured, protocol-driven multidisciplinary approach to integrate lifestyle and risk factor management as an integral part of AF management may help in the prevention and treatment of AF. However, this aspect of AF management is currently underrecognized, underused, and understudied. The purpose of this American Heart Association scientific statement is to review the association of modifiable risk factors with AF and the effects of risk factor intervention. Implementation strategies, care pathways, and educational links for achieving impactful weight reduction, increased physical activity, and risk factor modification are included. Implications for clinical practice, gaps in knowledge, and future directions for the research community are highlighted.",21/04/2020,01/07/2022 10:40,01/07/2022 10:40,,E750-E772,,16,141,,,,,,,,,,,,,,WOS:000530123600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
S4T7WJXF,journalArticle,2020,"Beato-Vibora, PI; Gallego-Gamero, F; Lazaro-Martin, L; Romero-Perez, MD; Arroyo-Diez, FJ","Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology",DIABETES TECHNOLOGY & THERAPEUTICS,,1520-9156,10.1089/dia.2019.0400,,"Background:Automatization of insulin delivery by closed-loop systems represents a major step in type 1 diabetes management. The aim of this study was to analyze the effect of the commercialized hybrid closed-loop system, the MiniMed 670G system, on glycemic control, glycemic variability, and patient satisfaction. Methods:A prospective study, including type 1 diabetes patients consecutively starting on the 670G system in one adult and two pediatric hospitals, was performed. Baseline and 3-month visits were documented. Two weeks of data from the system were downloaded. Glycemic variability measures were calculated. Adults and adolescents completed a set of questionnaires (Gold and Clarke scores, Hypoglycemia Fear Survey, Diabetes Quality of Life [DQoL], Diabetes Treatment Satisfaction [DTS], Diabetes Distress Scale, Pittsburgh Sleep Quality Index). Results:Fifty-eight patients were included (age: 28 +/- 15 years [7-63], n = 22], 59% [n = 34] females, previous use of SAP-PLGS [predictive low-glucose suspend]: 60% [n = 35]). HbA1c was reduced from 57 +/- 10 to 53 +/- 7 mmol/L (7.4% +/- 0.9% to 7.0% +/- 0.6%) (P < 0.001) and time in range 70-180 mg/dL was increased from 63.0% +/- 11.4% to 72.7% +/- 8.7% (P < 0.001). In patients with high baseline hypoglycemia risk, time <54 and <70 mg/dL were reduced from 0.9% +/- 1.1% to 0.45% +/- 0.7% (P = 0.021) and from 3.3% +/- 2.8% to 2.1% +/- 2.1% (P = 0.019), respectively. Glycemic variability measures improved. Time in auto mode was 85% +/- 17%, the number of auto mode exits was 0.6 +/- 0.3 per day, and the number of alarms was 8.5 +/- 3.7 per day. Fear of hypoglycemia, DQoL, DTS, and diabetes distress improved, while the percentage of patients with poor sleep quality was reduced. The discontinuation rate was 3%. Conclusion:The commercialized hybrid closed-loop system improves glycemic control and glycemic variability in children and adults, reducing the burden of living with type 1 diabetes.",01/12/2020,01/07/2022 10:40,01/07/2022 10:40,,912-919,,12,22,,,,,,,,,,,,,,WOS:000566008400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCPLQ5N3,journalArticle,2016,"Kovalska, P; Kemlink, D; Nevsimalova, S; Horvat, EM; Jarolimova, E; Topinkova, E; Sonka, K",Narcolepsy with cataplexy in patients aged over 60 years: a case-control study,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2016.05.011,,"Objective: Narcolepsy with cataplexy (NC) is a chronic disabling disease; however, there are insufficient data on older NC subjects. Methods: A cross-sectional evaluation on health and social status, including intensity and progression of NC symptoms, was performed on 42 NC patients (age 71.9 years +/- 7.5) and 46 age-and-sex-matched controls (age 72.2 years +/- 7.0). Results: A greater proportion of patients than controls suffered from hypertension and type 2 diabetes. More controls had a history of treated depression; however, according to the Geriatric Depression Scale, more NC patients scored in the range of depression. There were no significant differences in Addenbrook Cognitive Examination scores. Average physical fitness assessed by the Short Physical Performance Battery was lower in the NC group. The frequency of meeting with family, friends, and participation in hobbies or sports did not differ between the two groups. Conclusions: Symptoms of NC were present throughout life. Comorbidities and lower physical fitness, which are known to be present in young and middle-aged NC subjects, were also present in older patients. Although NC subjects were less professionally active during their lifetime, they did not differ from controls in important social parameters in older age. (C) 2016 Elsevier B.V. All rights reserved.",2016-10,01/07/2022 10:40,01/07/2022 10:40,,79-84,,,26,,,,,,,,,,,,,,WOS:000390720900016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NUYWLFF4,journalArticle,2017,"Bibbins-Domingo, K; Grossman, DC; Curry, SJ; Davidson, KW; Epling, JW; Garcia, FAR; Herzstein, J; Kemper, AR; Krist, AH; Kurth, AE; Landefeld, CS; Mangione, CM; Phillips, WR; Phipps, MG; Pignone, MP; Silverstein, M; Tseng, CW; US Preventive Serv Task Force",Screening for Obstructive Sleep Apnea in Adults US Preventive Services Task Force Recommendation Statement,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,,0098-7484,10.1001/jama.2016.20325,,"IMPORTANCE Based on data from the 1990s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10% for mild OSA and 3.8% to 6.5% for moderate to severe OSA; current prevalence may be higher, given the increasing prevalence of obesity. Severe OSA is associated with increased all-cause mortality, cardiovascular disease and cerebrovascular events, diabetes, cognitive impairment, decreased quality of life, and motor vehicle crashes. OBJECTIVE To issue a new US Preventive Services Task Force (USPSTF) recommendation on screening for OSA in asymptomatic adults. EVIDENCE REVIEW The USPSTF reviewed the evidence on the accuracy, benefits, and potential harms of screening for OSA in asymptomatic adults seen in primary care, including those with unrecognized symptoms. The USPSTF also evaluated the evidence on the benefits and harms of treatment of OSA on intermediate and final health outcomes. FINDINGS The USPSTF found insufficient evidence on screening for or treatment of OSA in asymptomatic adults or adults with unrecognized symptoms. Therefore, the USPSTF was unable to determine the magnitude of the benefits or harms of screening for OSA or whether there is a net benefit or harm to screening. CONCLUSIONS AND RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in asymptomatic adults. (I statement)",24/01/2017,01/07/2022 10:40,01/07/2022 10:40,,407-414,,4,317,,,,,,,,,,,,,,WOS:000392509600022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LULK4ZEW,journalArticle,2016,"Chang, HT; Chen, HC; Chou, P",Factors Associated with Fear of Falling among Community-Dwelling Older Adults in the Shih-Pai Study in Taiwan,PLOS ONE,,1932-6203,10.1371/journal.pone.0150612,,"Background Fear of falling is an important risk indicator for adverse health related outcomes in older adults. However, factors associated with fear of falling among community-dwelling older adults are not well-explored. Objectives To explore the quality of life and associated factors in fear of falling among older people in the Shih-Pai area in Taiwan. Methods This community-based survey recruited three thousand eight hundred and twenty-four older adults aged >= 65 years. The measurements included a structured questionnaire, including quality of life by using Short-Form 36, and information of fear of falling, fall history, demographics, medical conditions, insomnia, sleep quality, depression and subjective health through face-to-face interviews. Results A total of 53.4% of participants reported a fear of falling. The rate of fear of falling was higher in female subjects. Subjects with fear of falling had lower Short Form-36 scores both for men and women. Falls in the previous year, older age, insomnia, depression and worse subjective health were correlates of fear of falling for both sexes. Male-specific associations with fear of falling were the accessibility of medical help in an emergency, diabetes mellitus and stroke. In parallel, cardiovascular diseases were a female-specific correlate for fear of falling. Conclusions Fear of falling is prevalent among community-dwelling older adults. It is seems that there are gender differences in fear of falling with respect to the prevalence and associated factors in older adults. Gender differences should be considered when planning prevention and intervention strategies for fear of falling among older people.",02/03/2016,01/07/2022 10:40,01/07/2022 10:40,,,,3,11,,,,,,,,,,,,,,WOS:000371724200107,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E9GIEJ67,journalArticle,2020,"Sawhney, V; Seethamraju, H; Bourguet, C; Hirshkowitz, M; Bandi, V; Sharafkhaneh, A",Non -respiratory complaints are main reasons for disturbed sleep post lung transplant *,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2019.11.1243,,,2020-06,01/07/2022 10:40,01/07/2022 10:40,,106-110,,,70,,,,,,,,,,,,,,WOS:000539995900016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KUDWP8YQ,journalArticle,2017,"Gulisano, M; Domini, C; Capelli, M; Pellico, A; Rizzo, R",Importance of neuropsychiatric evaluation in children with primary monosymptomatic enuresis,JOURNAL OF PEDIATRIC UROLOGY,,1477-5131,10.1016/j.jpurol.2016.10.019,,"Background Nocturnal enuresis (NE) is an involuntary voiding during sleep. It is a very common disorder in schoolage children. Comorbid psychopathologies are common in patients affected by enuresis. According to the ICCS, the rate of behavioral and emotional disorders in children with enuresis is doubled compared with healthy control (HC) children. Objective The aim of the present study was to investigate the prevalence of neuropsychiatric comorbidities in children affected by NE. Study design Two hundred children with a diagnosis of enuresis were recruited from the Neuropsychiatric Unit of Catania University and 200 age-matched neurologically intact HC children were recruited from local schools. The inclusion criteria were a normal IQ and the absence of other pathological clinical conditions such as diabetes or kidney malformation. The exclusion criteria were failure to complete the initial evaluation or clinical/diagnostic procedures, inability (because of young age) to complete study questionnaires, and severe neurological or physical impairment. Results Age and gender proportions were not significantly different between the groups. In the NE group, 138 subjects (69%) had a familial history of NE, compared with 24 subjects (12%) in the HC group (p < 0.01). The NE group demonstrated significantly higher scores in the Child Behavior Check List, Conners' Multidimensional Anxiety Scale for Children, and the Child Depression Inventory compared than the HC group as well as the Yale Global Tic Severity Score and Child-YaleeBrown Obsessive Compulsive Scale scores (p < 0.01). Quality of life scores were significantly lower in the NE group than in the HCs group; specifically, between-group differences were significant in the relationship and self domains (p > 0.01 for both comparisons) (Figure). Discussion The present case-control study evaluates the prevalence of different neuropsychiatric comorbidities in children with NE as diagnosed according to the new ICCS criteria. An important finding was that neuropsychiatric conditions weremore prevalent in NE patients than in age-matched HC subjects. To the best of our knowledge, this is the first study to report associations between enuresis and obsessive compulsive disorder as well as tic disorder, and is the first to describe the comparative psychopathological profiles of 200 children with enuresis and 200 matched HC children. Conclusion The results suggest that clinicians should not underestimate the effects of enuresis on psychosocial development. Childhood NE should be managed carefully and comprehensively in order to prevent the development of more serious behavioral problems in the future.",2017-02,01/07/2022 10:40,01/07/2022 10:40,,,,1,13,,,,,,,,,,,,,,WOS:000395935900015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L4YY8EEZ,journalArticle,2010,"Newton, JL",Systemic Symptoms in Non-Alcoholic Fatty Liver Disease,DIGESTIVE DISEASES,,0257-2753,10.1159/000282089,,"Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in the Western world and the incidence of the disease is constantly increasing. Most patients with NAFLD do not present with symptoms directly attributable to their underlying liver disease. It is increasingly recognized, however, that those with NAFLD describe a range of nonspecific symptoms, which include fatigue and daytime sleepiness, may be the presenting problem and can impact dramatically upon quality of life in this patient group. The recognition of systemic symptoms in NAFLD has important implications for patients as many are potentially modifiable with targeted interventions. Fatigue appears to be a significant problem in NAFLD and the severity of fatigue is not associated with severity of NAFLD or any parameters of liver damage. Instead, fatigue in these patients shows a strong relationship with the symptom of daytime sleepiness and autonomic dysfunction. Daytime sleepiness can frequently be associated with obstructive sleep apnoea in those with NAFLD and is therefore treatable with evidence-based interventions. Recent studies have confirmed the presence of autonomic nervous system dysfunction in those with early stages of NAFLD. The presence of autonomic nervous system dysfunction leads to symptoms such as postural dizziness and syncope and is also associated with a number of clinical consequences in hepatic and non-hepatic diseases such as cognitive dysfunction, falls and fall-related injuries. On direct questioning, problems with memory and concentration are frequently described by those with NAFLD, with our studies confirming that 50% of NAFLD patients experience mild cognitive symptoms and up to 46% moderate or severe cognitive impairment. There were no positive correlations between cognitive symptoms and biochemical or histological markers of liver damage severity, confirming that cognitive impairment in early-stage NAFLD is not related to hepatic encephalopathy. Falls are also considered a direct consequence of autonomic nervous system dysfunction, and our work suggests that a history of falls is common in NAFLD (43%). The proportion of recurrent fallers is significantly higher in a NAFLD cohort compared to controls (p = 0.001), with injuries (p = 0.009), emergency medical attention (p < 0.001), fracture rates (p < 0.001) and hospital admission (p < 0.001) all significantly more common in the NAFLD group. Falls and the aforementioned associations were unrelated to the presence of diabetes or the severity of liver disease. A range of systemic symptoms appear to affect those with NAFLD, the severity of which is unrelated to the underlying liver disease severity. The presence of autonomic dysfunction may provide a unifying mechanism for these symptoms and a therapeutic target. Consideration of these symptoms affecting patients with NAFLD and, where possible, effective treatment will lead to improvements in quality of life and enhance the ability of those with NAFLD to function in their daily lives. Copyright (C) 2010 S. Karger AG, Basel",2010,01/07/2022 10:40,01/07/2022 10:40,,214-219,,1,28,,,,,,,,,,,,,,WOS:000277578800031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27IQAF7S,journalArticle,2019,"Li, XJ; Zhang, GF; Liu, FQ; Zhang, Y",Effects of individualized nursing on the rehabilitation of patients with cardiovascular diseases after cardiac interventional therapy,INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,,1940-5901,,,"Objective: To study the effects of individualized nursing on rehabilitation of elderly patients with cardiovascular diseases (CVD) after cardiac interventional therapy. Methods: A total of 400 elderly patients that underwent CVD intervention were selected for this study, and were randomly divided into either the individualized nursing group (intervention group, n=200) or the traditional cardiovascular medicine nursing group (control group, n=200). The ratio of males to females in each group was 1:1. Postoperatively, follow-ups were performed to observe and compare the effects of different nursing treatments after interventional therapy. Assessed indicators included the Self-rating anxiety scale (SAS) at 1 day, 3, and 6 months after surgery, the Pittsburgh sleep quality index (PSQI) at 1 day and 1 month after surgery, quality of life scores, and patient satisfaction. Results: There were no significant differences between the control group and the intervention group with regard to general patient demographics (such as gender, age, type of interventional surgery, and the number of patients with hypertension, diabetes, or hyperlipidemia) (all P>0.05). In the intervention group, the SAS scores at 1 day , 3, and 6 months after surgery and the PSQI scores on the 1st day and 1 month after surgery were significantly lower than those in the control group (both P<0.05); the quality of life score was significantly higher than that of the control group (P<0.05); and the patient's satisfaction with the nursing staff was much higher than that of the control group (P<0.05). Conclusion: Individualized nursing is more conducive to rehabilitation of elderly patients with CVD intervention, as it reduces patients' anxiety, and improves their sleep quality and quality of life. It is a feasible intervention.",2019,01/07/2022 10:40,01/07/2022 10:40,,5545-5553,,5,12,,,,,,,,,,,,,,WOS:000469792800113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
V65CK3Z7,journalArticle,2020,"Kahal, H; Kyrou, I; Uthman, OA; Brown, A; Johnson, S; Wall, PDH; Metcalfe, A; Parr, DG; Tahrani, AA; Randeva, HS",The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis,SLEEP AND BREATHING,,1520-9512,10.1007/s11325-019-01835-1,,"Background Obesity is a common risk factor for polycystic ovary syndrome (PCOS) and obstructive sleep apnoea (OSA). Both PCOS and OSA are associated with increased risk of type 2 diabetes and cardiovascular disease. Hence, it is important to determine the burden of OSA in women with PCOS. Methods We searched electronic databases (MEDLINE, Embase, CINAHL, PsycINFO, Scopus, Web of Science, OpenGrey, CENTRAL), conference abstracts, and reference lists of relevant articles, up to January 2019. No restriction for language or publication status. Studies that examined the presence of OSA in women with PCOS using polysomnography and/or level III devices were eligible for inclusion. Results Seventeen studies involving 648 participants were included. Our meta-analysis showed that 35.0% (95% CI 22.2-48.9%) of women with PCOS had OSA. This prevalence was not affected by variation in PCOS definition between studies. Approximately one-tenth of the variation in OSA prevalence was related to differences in study population (higher in adults than adolescents and mixed populations), and around one-tenth was related to sample size (higher in smaller studies). OSA prevalence was markedly higher in obese versus lean women with PCOS, and in women with PCOS compared to controls (odds ratio = 3.83, 95% CI 1.43-10.24, eight studies, 957 participants (349 PCOS and 608 controls)). However, most of the studies were at high risk of selection bias, did not account for important confounders, included predominantly women with class II obesity, and were conducted in one country (USA). Conclusions Future studies need to examine the true prevalence of OSA in a more representative sample of women with PCOS. Nevertheless, our results suggest that the prevalence of OSA in women with PCOS and obesity is high and clinicians should have a high index of suspicion of OSA in these women.",2020-03,01/07/2022 10:40,01/07/2022 10:40,,339-350,,1,24,,,,,,,,,,,,,,WOS:000523299600039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D8XLL2VS,journalArticle,2016,"Dani, H; Esdaille, A; Weiss, JP",Nocturia: aetiology and treatment in adults,NATURE REVIEWS UROLOGY,,1759-4812,10.1038/nrurol.2016.134,,"Nocturia is an extremely common condition that has major sequelae for affected patients. Through disruption of sleep, nocturia impairs quality of life and worsens health outcomes, and is associated with a variety of morbidities including diabetes, coronary artery disease, obstructive sleep apnoea, obesity, metabolic syndrome, and depression. Unsurprisingly, several studies have also linked nocturia with reduced survival. Nocturia is not simply a consequence of lower urinary tract disease; rather, it is a multifactorial disorder that is often a manifestation of an underlying renal or systemic disease. Through the use of the frequency volume chart, clinicians can accurately quantify nocturia and determine its aetiology. Evaluation of quality of life and sleep using simple measures is essential in order to assess the impact of nocturia on a patient. Numerous treatment options for nocturia exist, but most are associated with minor benefit or lack sufficient evidence supporting their use. By systematically analysing an individual's causes of nocturia, clinicians can design appropriate treatment strategies to most effectively treat this condition.",2016-10,01/07/2022 10:40,01/07/2022 10:40,,573-583,,10,13,,,,,,,,,,,,,,WOS:000385477500016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3R29GFV3,journalArticle,2013,"Ananthakrishnan, AN; Long, MD; Martin, CF; Sandler, RS; Kappelman, MD",Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis,CLINICAL GASTROENTEROLOGY AND HEPATOLOGY,,1542-3565,10.1016/j.cgh.2013.01.021,,"BACKGROUND & AIMS: Impairment of sleep quality is common in patients with inflammatory bowel diseases (IBDs) (eg, Crohn's disease [CD] and ulcerative colitis [UC]), even during clinical remission. Sleep impairment can activate inflammatory pathways. Few prospective studies have examined the role of sleep disturbance on risk of relapse in IBD. METHODS: We analyzed data from 3173 patients with IBD (1798 in clinical remission at baseline) participating in the Crohn's and Colitis Foundation of America Partners study, a longitudinal, Internet-based cohort. Sleep disturbance was measured using a subset of questions from the Patient Reported Outcomes Measurement Information Systems sleep disturbance questionnaire. Disease activity was assessed using the short Crohn's Disease Activity Index and the simple clinical colitis activity index for CD and UC, respectively. Logistic regression was used to identify predictors of sleep quality and examine the effect of sleep quality at baseline among patients in remission on risk of active disease at 6 months. RESULTS: Disease activity, depression, female sex, smoking, and use of corticosteroids or narcotics were associated with sleep disturbance at enrollment. Among 1291 patients whose CD was in remission at baseline, those with impaired sleep had a 2-fold increase in risk of active disease at 6 months (adjusted odds ratio, 2.00; 95% confidence interval, 1.45-2.76); however, no effect was observed in patients with UC (odds ratio, 1.14; 95% confidence interval, 0.75-1.74). These findings persisted in a number of sensitivity analyses. CONCLUSIONS: Sleep disturbance was associated with an increased risk of disease flares in CD but not UC. These findings indicate that the evaluation and treatment of sleep disturbance in patients with CD might improve outcomes.",2013-08,01/07/2022 10:40,01/07/2022 10:40,,965-971,,8,11,,,,,,,,,,,,,,WOS:000322707100017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9UTF3T9D,journalArticle,2021,"Tahara, Y; Makino, S; Suiko, T; Nagamori, Y; Iwai, T; Aono, M; Shibata, S",Association between Irregular Meal Timing and the Mental Health of Japanese Workers,NUTRIENTS,,2072-6643,10.3390/nu13082775,,"Breakfast skipping and nighttime snacking have been identified as risk factors for obesity, diabetes, and cardiovascular diseases. However, the effects of irregularity of meal timing on health and daily quality of life are still unclear. In this study, a web-based self-administered questionnaire survey was conducted involving 4490 workers (73.3% males; average age = 47.4 +/- 0.1 years) in Japan to investigate the association between meal habits, health, and social relationships. This study identified that irregular meal timing was correlated with higher neuroticism (one of the Big Five personality traits), lower physical activity levels, and higher productivity loss. Irregular meal timing was also associated with a higher incidence of sleep problems and lower subjective health conditions. Among health outcomes, a high correlation of irregular meal timing with mental health factors was observed. This study showed that irregularity of meal timing can be explained by unbalanced diets, frequent breakfast skipping, increased snacking frequency, and insufficient latency from the last meal to sleep onset. Finally, logistic regression analysis was conducted, and a significant contribution of meal timing irregularity to subjective mental health was found under adjustment for other confounding factors. These results suggest that irregular meal timing is a good marker of subjective mental health issues.",2021-08,01/07/2022 10:40,01/07/2022 10:40,,,,8,13,,,,,,,,,,,,,,WOS:000690031600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X6NIGMPU,journalArticle,2013,"Neff, KJH; le Roux, CW",Bariatric surgery: a best practice article,JOURNAL OF CLINICAL PATHOLOGY,,0021-9746,10.1136/jclinpath-2012-200798,,"Bariatric surgery can effectively reduce body weight and treat obesity associated metabolic diseases such as diabetes mellitus. There are also benefits for an individual's functional status and psychological health. A multi-disciplinary evaluation should be offered to the individual as the first essential step in considering bariatric surgery as a treatment. This evaluation should include a thorough medical assessment, as well as psychological and dietetic assessments. In this best practice article, we outline the current recommendations for referral for bariatric surgery. We also present the data for pre-operative assessment before bariatric surgery, with particular reference to cardiovascular disease and obstructive sleep apnoea. We describe the literature on outcomes after bariatric surgery, including the results for mortality, weight loss, remission of diabetes and associated endocrine disorders such as hypogonadism. Within this review, we will illustrate the impact of bariatric surgery on self-image, psychological health and perceived health and functional status. Finally, we briefly detail the potential complications of bariatric surgery, and offer advice on post-operative care and surveillance.",2013-02,01/07/2022 10:40,01/07/2022 10:40,,90-98,,2,66,,,,,,,,,,,,,,WOS:000314105800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9VSYWXLQ,journalArticle,2013,"Innes, KE; Flack, KL; Selfe, TK; Kandati, S; Agarwal, P","Restless Legs Syndrome in an Appalachian Primary Care Population: Prevalence, Demographic and Lifestyle Correlates, and Burden",JOURNAL OF CLINICAL SLEEP MEDICINE,,1550-9389,10.5664/jcsm.3084,,"distressing sensorimotor disorder of unknown etiology. While the epidemiology of RLS has been examined in several North American and European studies, research on RLS and RLS burden in poor, rural populations, including those residing in Appalachia, remains sparse. In this study, we investigated RLS prevalence in an Appalachian primary care population and examined the association of RLS to demographic factors, lifestyle characteristics, sleep quality, and mood disorders. Methods: Participants of this anonymous survey study were community-dwelling adults aged >= 18 years visiting one of 4 West Virginia primary care clinics. Data gathered included detailed information on sleep patterns, demographic characteristics, lifestyle factors, and health/medical history; the survey also included questions specific to RLS diagnosis and severity. Response rates were excellent, with 68% of eligible adults contacted returning completed surveys (N = 1,424/2,087). Pregnant women (N = 65) and those with missing data on key variables (N = 142) were excluded from the analyses. Results: Of the 1,217 participants included in the final analytic sample, 19.6% (18.2% with symptoms at least once/month) met the 4 IRLSSG diagnostic criteria in the absence of positional discomfort or leg cramps; 14.5% reported RLS symptoms at least once/week and 10.1% indicated symptoms >= 3x/week. Excluding respondents with diabetes, kidney disease, or anemiareduced these rates only slightly. Those with RLS were more likely to be older, female, lower income, unemployed, disabled, non-Hispanic white, and less likely to be college educated than those without RLS. Mood and sleep impairment were significantly elevated in those with RLS; after adjustment for demographic and lifestyle characteristics, health history, and other factors, those with RLS remained significantly more likely to indicate a history of depression (adjusted odds ratio [OR] = 1.9; 95% confidence interval [CI] = 1.4, 2.6) and anxiety (OR = 1.6, CI 1.1, 2.2), to report sleep impairment both 4 (OR = 2.4, CI 1.6, 3.7) and 7 days/week (OR = 1.8, CI 1.3, 2.4), and a mean sleep duration < 5 h/night (OR = 1.7, CI 1.2, 2.3). These associations increased in both strength and magnitude with increasing symptom frequency (p's for trend = 0.01). Conclusions: Findings of this preliminary anonymous survey study suggest that RLS prevalence is high in this Appalachian primary care population and that RLS is associated with significant burden in terms of both mood and sleep impairment.",2013,01/07/2022 10:40,01/07/2022 10:40,,1065-1075,,10,9,,,,,,,,,,,,,,WOS:000325759400012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2WXSDVCL,journalArticle,2016,"Costanzo, MR; Ponikowski, P; Javaheri, S; Augostini, R; Goldberg, L; Holcomb, R; Kao, A; Khayat, RN; Oldenburg, O; Stellbrink, C; Abraham, WT; Remede Syst Pivotal",Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial,LANCET,,0140-6736,10.1016/S0140-6736(16)30961-8,,"Background Central sleep apnoea is a serious breathing disorder associated with poor outcomes. The remede system (Respicardia Inc, Minnetonka, MN, USA) is an implantable device which transvenously stimulates a nerve causing diaphragmatic contraction similar to normal breathing. We evaluated the safety and effectiveness of unilateral neurostimulation in patients with central sleep apnoea. Methods We recruited patients from 31 hospital-based centres in Germany, Poland, and the USA in this prospective, multicentre, randomised trial. Participants had to have been medically stable for at least 30 days and have received appropriate guideline recommended therapy, be aged at least 18 years, be expected to tolerate study procedures, and willing and able to comply with study requirements. Eligible patients with an apnoea-hypopnoea index (AHI) of at least 20 events per h, tested by a polysomnography, underwent device implantation and were randomly assigned (1: 1) by a computer-generated method stratified by site to either stimulation (treatment) or no stimulation (control) for 6 months. The primary eff ectiveness endpoint in the intention-to-treat population was the comparison of the proportions of patients in the treatment versus control groups achieving a 50% or greater AHI reduction from baseline to 6 months, measured by a full-night polysomnography assessed by masked investigators in a core laboratory. The primary safety endpoint of 12-month freedom from serious adverse events related to the procedure, system, or therapy was evaluated in all patients. This trial is active, but not recruiting, and is registered with ClinicalTrials.gov (NCT01816776). Findings Between April 17, 2013, and May 28, 2015, we randomly assigned 151 eligible patients to the treatment (n= 73) or control (n= 78) groups. In the analysis of the intention-to-treat population, significantly more patients in the treatment group (35 [51%] of 68) had an AHI reduction from baseline of 50% or greater at 6 months than had those in the control group (eight [11%] of 73; difference between groups 41%, 95% CI 25-54, p< 0.0001). 138 (91%) of 151 patients had no serious-related adverse events at 12 months. Seven (9%) cases of related-serious adverse events occurred in the control group and six (8%) cases were reported in the treatment group. Seven patients died (unrelated to implant, system, or therapy), four deaths (two in treatment group and two in control group) during the 6-month randomisation period when neurostimulation was delivered to only the treatment group and was off in the control group, and three deaths between 6 months and 12 months of follow-up when all patients received neurostimulation. 27 (37%) of 73 patients in the treatment group reported non-serious therapy-related discomfort that was resolved with simple system reprogramming in 26 (36%) patients, but was unresolved in one (1%) patient. Interpretation Transvenous neurostimulation significantly reduced the severity of central sleep apnoea, including improvements in sleep metrics, and was well tolerated. The clinically meaningful effects of the therapy are supported by the concordant improvements in oxygenation and quality of life, making transvenous neurostimulation a promising therapeutic approach for central sleep apnoea.",03/09/2016,01/07/2022 10:40,01/07/2022 10:40,,974-982,,10048,388,,,,,,,,,,,,,,WOS:000382524400027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CJ9JKT9C,journalArticle,2010,"Nojkov, B; Rubenstein, JH; Chey, WD; Hoogerwerf, WA",The Impact of Rotating Shift Work on the Prevalence of Irritable Bowel Syndrome in Nurses,AMERICAN JOURNAL OF GASTROENTEROLOGY,,0002-9270,10.1038/ajg.2010.48,,"OBJECTIVES: Shift work has been associated with gastrointestinal symptoms such as abdominal pain, constipation, and diarrhea. These symptoms overlap with those reported by patients with functional bowel disorders. Because shift work will lead to misalignment between the endogenous circadian timing system and the external 24 h environment, we hypothesized that nurses participating in shift work will have a higher prevalence of functional bowel disorders when compared with nurses participating in day shifts. METHODS: Nurses engaged in patient care were invited to complete Rome III, irritable bowel syndrome-quality of life measure (IBS-QOL) and modified Sleep-50 questionnaires. Respondents were classified as working day, night, or rotating shifts. The prevalence of IBS, functional constipation, functional diarrhea, and individual gastrointestinal symptoms was determined. RESULTS: Data were available for 399 nurses (214 day shift, 110 night shift, and 75 rotating shift workers). Rotating shift nurses had a significantly higher prevalence of IBS compared to day shift nurses (48% vs. 31%, P < 0.01). Multivariable logistic regression correcting for age, gender, and sleep quality proved this association robust. IBS-QOL scores among groups were similar. Prevalence of functional constipation and functional diarrhea was similar between groups. Rotating shift nurses had a significantly higher prevalence of abdominal pain compared to day shift (81% vs. 54%, P < 0.0001) and night shift workers (61%, P = 0.003). CONCLUSIONS: Participation in shift work, especially rotating shift work, is associated with the development of IBS and abdominal pain that is independent of sleep quality. Circadian rhythm disturbances may have a function in the pathogenesis of IBS and abdominal pain.",2010-04,01/07/2022 10:40,01/07/2022 10:40,,842-847,,4,105,,,,,,,,,,,,,,WOS:000276582300017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9VUP3T6V,journalArticle,2018,"Souche, R; de Jong, A; Nomine-Criqui, C; Nedelcu, M; Brunaud, L; Nocca, D",Complications after bariatric surgery,PRESSE MEDICALE,,0755-4982,10.1016/j.lpm.2018.03.024,,"Bariatric surgery became consensual after the NIH consensus of 1991 and the appearance of laparoscopic approach. This type of operation has a functional role (improvement of quality of life, locomotion and digestive symptoms as gastro-esophageal reflux disease), a prevention role (increase in life expectancy, reduction of risk of cancer and cardiovascular disease) and a curative role (remission of diabetes mellitus, obstructive sleep apnea syndrome and arterial hypertension). The laparoscopic approach for bariatric surgery led to a major reduction of postoperative morbi-mortality. Types and rates of complications after bariatric surgery vary according to the procedure. The efficiency of each technique is closely related to its morbi-mortality rate. This concept explains the disparity concerning the choice of the adequate procedure for the patient according to the bariatric team. The risk/benefits balance evaluation must be analyzed case-bycase by each specialist of the multidisciplinary bariatric staff and explained to the patients before final decision. This preoperative period (6 to 12 months) is crucial to select good candidates for bariatric surgery and contributes to the reduction of postoperative complications. A multidisciplinary surveillance for life is mandatory to prevent and treat late complications of bariatric surgery.",2018-05,01/07/2022 10:40,01/07/2022 10:40,,464-470,,5,47,,,,,,,,,,,,,,WOS:000432465900011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2CZ9LXR6,book,2019,"Arora, T; Grey, I","Sleep, obesity and cardiometabolic disease in children and adolescents",,978-0-12-815374-1,,,,,2019,01/07/2022 10:40,01/07/2022 10:40,,,421,,,,,,SLEEP AND HEALTH,,,,,,,,,,WOS:000483503400032,,,Pages: 433 DOI: 10.1016/B978-0-12-815373-4.00031-9,,,,,,"Grandner, MA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7BY463IW,journalArticle,2014,"Andrade, J; Khairy, P; Dobrev, D; Nattel, S","The Clinical Profile and Pathophysiology of Atrial Fibrillation Relationships Among Clinical Features, Epidemiology, and Mechanisms",CIRCULATION RESEARCH,,0009-7330,10.1161/CIRCRESAHA.114.303211,,"Atrial fibrillation (AF) is the most common arrhythmia (estimated lifetime risk, 22%-26%). The aim of this article is to review the clinical epidemiological features of AF and to relate them to underlying mechanisms. Long-established risk factors for AF include aging, male sex, hypertension, valve disease, left ventricular dysfunction, obesity, and alcohol consumption. Emerging risk factors include prehypertension, increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dysfunction, predisposing gene variants, hypertrophic cardiomyopathy, and congenital heart disease. Potential risk factors are coronary artery disease, kidney disease, systemic inflammation, pericardial fat, and tobacco use. AF has substantial population health consequences, including impaired quality of life, increased hospitalization rates, stroke occurrence, and increased medical costs. The pathophysiology of AF centers around 4 general types of disturbances that promote ectopic firing and reentrant mechanisms, and include the following: (1) ion channel dysfunction, (2) Ca2+-handling abnormalities, (3) structural remodeling, and (4) autonomic neural dysregulation. Aging, hypertension, valve disease, heart failure, myocardial infarction, obesity, smoking, diabetes mellitus, thyroid dysfunction, and endurance exercise training all cause structural remodeling. Heart failure and prior atrial infarction also cause Ca2+-handling abnormalities that lead to focal ectopic firing via delayed afterdepolarizations/triggered activity. Neural dysregulation is central to atrial arrhythmogenesis associated with endurance exercise training and occlusive coronary artery disease. Monogenic causes of AF typically promote the arrhythmia via ion channel dysfunction, but the mechanisms of the more common polygenic risk factors are still poorly understood and under intense investigation. Better recognition of the clinical epidemiology of AF, as well as an improved appreciation of the underlying mechanisms, is needed to develop improved methods for AF prevention and management.",25/04/2014,01/07/2022 10:40,01/07/2022 10:40,,1453-1468,,9,114,,,,,,,,,,,,,,WOS:000335596000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
N9UMC6U5,journalArticle,2008,"Weiner, RA",Obesity - principles of surgical therapy,CHIRURG,,0009-4722,10.1007/s00104-008-1536-4,,"The prevalence of obesity and the number of surgeries for morbid obesity are increasing worldwide. Conservative therapy is largely ineffective in producing maintenance of weight loss in morbidly obese patients, and surgery is therefore increasingly considered as the only available option for these patients. Until approximately 15 years ago, many patients and physicians regarded bariatric surgery as dangerous because it required a large laparotomy and was associated with a relatively high risk of complications. Since laparoscopic techniques have become available, however, the number of patients referred for surgery has been increasing steadily. The principles of standard procedures are independent of access, whether open or laparoscopic. The pathophysiologic mechanisms are restriction, malabsorption, or a combination of both. New findings in the field of endocrine and humoral regulations have shown that surgical procedures can induce complex changes in the regulation of enterohormones. These mechanisms are the basis for metabolic effects, especially in cases of diabetes mellitus type 2. Obesity surgery is known to be the most effective and longest-lasting treatment for morbid obesity and many related conditions, but mounting evidence now suggests that it may also be among the most effective treatments for metabolic diseases and conditions such as type 2 diabetes, hypertension, high cholesterol, nonalcoholic fatty liver disease, and obstructive sleep apnea. Surgery for severe obesity goes far beyond weight loss; benefits include improved quality of life and extended life expectancy.",2008-09,01/07/2022 10:40,01/07/2022 10:40,,826-836,,9,79,,,,,,,,,,,,,,WOS:000259189500003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WLLJH98D,journalArticle,2005,"Adams, TD; Avelar, E; Cloward, T; Crosby, RD; Farney, RJ; Gress, R; Halverson, RC; Hopkins, PN; Kolotkin, RL; LaMonte, MJ; Litwin, S; Nuttall, RT; Pendleton, R; Rosamond, W; Simper, SC; Smith, SC; Strong, M; Walker, JM; Wiebke, G; Yanowitz, FG; Hunt, SC",Design and rationale of the Utah obesity study. A study to assess morbidity following gastric bypass surgery,CONTEMPORARY CLINICAL TRIALS,,1551-7144,10.1016/j.cct.2005.05.003,,"Purpose: This paper details the design and baseline characteristics of a study on the morbidity associated with Roux-en-Y gastric bypass surgery (GBP) in severely obese adults. This study is designed to assess the effectiveness of GBP in reducing morbidity and maintaining weight loss. A wide array of clinical tests and psycho-behavioral questionnaires are included as part of the study. Methods: Three groups (n = 1156 severely obese) have been recruited for this study: cases who were approved for and participated in surgery (n = 415), a control group of GBP seeking individuals who were denied surgery (n = 420) and a control group that was randomly chosen from a population of severely obese participants who were not seeking GBP (n = 32 1). Clinical measures include: a physician interview and detailed medical history, resting electro- and echocardiograms, a submaximal exercise treadmill test and electrocardiogram, pulmonary function, limited polysomnography, resting metabolic rate, anthropometrics, resting and exercise blood pressure, comprehensive blood chemistry and urinalysis and dietary, quality of life and physical activity questionnaires. Most participants (76%) were tested following an overnight stay in a clinical research center. Remaining participants underwent less extensive testing in an outpatient clinic. Results: Baseline characteristics of the 115 6 participants are available for selected measures. Mean +/- S.D. for BMI was 46 +/- 7.5 kg/m(2) (range = 33 to 92) and for age was 44 +/- 11.4 years (range = 18 to 72). The prevalence of diabetes and hypertension was 19% and 35%, respectively. Of the participants who had an echocardiogram or polysomnogram, 92% had left-ventricular hypertrophy and 85% had mild to severe sleep apnea. The two control groups were similar to the surgical group. At approximately 24 months, all participants will have a second clinical examination. Statistical comparisons of changes in morbidity variables will be made between the surgical and control groups. Conclusions: This study design facilitates assessment of risks and benefits of GBP to perform recommendations on whether or not to perform surgery on the severely obese patient. Baseline and 2-year exams provide valuable data for comparison to future long-term follow-up data that can be collected at 5 and 10 years. (c) 2005 Elsevier Inc. All rights reserved.",2005-10,01/07/2022 10:40,01/07/2022 10:40,,534-551,,5,26,,,,,,,,,,,,,,WOS:000232023400004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q5PRFYSQ,journalArticle,2019,"Bliwise, DL; Howard, LE; Moreira, DM; Andriole, GL; Hopp, ML; Freedland, SJ",Nocturia and associated mortality: observational data from the REDUCE trial,PROSTATE CANCER AND PROSTATIC DISEASES,,1365-7852,10.1038/s41391-018-0090-5,,"Background Nocturia (voids arising from sleep) is a ubiquitous phenomenon reflecting many diverse conditions but whether it has significance in its own right remains uncertain. We examined whether nocturia was an independent risk factor for mortality Methods These were observational analyses employing primarily North American and European participants and included 7343 men, aged 50-75 years participating in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial. Cox proportional hazards models were used to test the association between baseline nocturia (voiding >= 3 times per night) and all-cause mortality. Potential confounding variables included: age; race; region of origin; treatment group; self-reported coronary artery disease, diabetes mellitus, hypertension, and peripheral vascular disease; smoking; alcohol use; prostate volume; and diuretics. Self-reported sleep quality, as measured with the Medical Outcomes Study sleep scale, was entered as a final step in the model. Results Nocturia was associated with increased mortality risk (hazard ratio [HR] = 1.72; 95% CI 1.15-2.55) independent from demographics and medical comorbidities. Inclusion of disturbed sleep in the model reduced the magnitude of the association (HR =1.43; 95% CI 0.93-2.19). Conclusions Although the findings are limited to men, half of whom ingested dutasteride, the interruption of sleep by nocturia may have long-term impact on health and may warrant targeted intervention.",2019-03,01/07/2022 10:40,01/07/2022 10:40,,77-83,,1,22,,,,,,,,,,,,,,WOS:000458384600010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P43ZNGWR,journalArticle,,"Hosseini, SF; Rezaei, M; McClements, DJ",Bioactive functional ingredients from aquatic origin: a review of recent progress in marine-derived nutraceuticals,CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION,,1040-8398,10.1080/10408398.2020.1839855,,"There is increasing demand from consumers for healthier and more sustainable foods. The marine biosphere is a rich source of health-promoting substances like bioactive peptides, polysaccharides, polyunsaturated lipids, carotenoids, polyphenolic compounds, minerals, saponins, and phytosterols. These substances display a myriad of potentially beneficial biological functions including antioxidant, antimicrobial, anticancer, anti-diabetic, anti-obesity, anti-Alzheimer, anti-fibrotic, neuroprotective, sleep-enhancing, lipid-lowering, wound healing, and skin protection activities. This review provides an update on recent research on bioactive ingredients derived from aquatic sources and highlights their potential application in the food, supplement, and pharmaceutical industries. Key techno-functional and sensorial attributes of these substances are reviewed, as well as their gastrointestinal fate and potential toxicity. This review should provide academia and industry with new insights into the potential application of marine bioactives in products intended to improve human health and wellbeing.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000585844000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JBIFTFW7,journalArticle,2018,"Deng, NF; Kohn, TP; Lipshultz, LI; Pastuszak, AW",The Relationship Between Shift Work and Men's Health,SEXUAL MEDICINE REVIEWS,,2050-0513,10.1016/j.sxmr.2017.11.009,,"Background: More than 21 million Americans and nearly 20% of the U.S. workforce are shift workers. Non-standard shift work, defined as work that falls outside of 6 AM-6 PM, can lead to poor diet, exercise, and sleep habits that lead to decreased productivity, increased workplace accidents, and a variety of negative health outcomes. Aim: To investigate the associations between shift work exposure and chronic medical conditions such as metabolic syndromes, cardiovascular disease, gastrointestinal disturbances, and depression as well as urologic complications including hypogonadism, male infertility, lower urinary tract symptoms, and prostate cancer with a focus on the effects of shift work sleep disorder (SWSD) on the severity of these negative health outcomes. Methods: We reviewed the literature examining effects of shift work and SWSD on general and urologic health. Outcomes: We produced a summary of effects of shift work on health with focus on the increased risk of negative health outcomes in non-standard shift workers, particularly those with SWSD, when compared to daytime workers or workers without SWSD. Results: Studies have associated non-standard shift work schedules and poor health outcomes, including increased risks of diabetes mellitus, dyslipidemia, hypertension, heart disease, peptic ulcer disease, and depression, in shift workers. However, few studies have focused on the role that shift work plays in men's urologic health. Current evidence supports associations between non-standard shift work and increased hypogonadal symptoms, poor semen parameters, decreased fertility, lower urinary tract symptoms, and prostate cancer. These associations are strengthened by the presence of SWSD, which affects up to 20% of shift workers. Unfortunately, interventions, such as planned naps, timed light exposure, melatonin, and sedative hypnotics, aimed at alleviating excessive nighttime sleepiness and daytime insomnia in non-standard shift workers experiencing SWSD, are limited and lack strong evidence to support their efficacy. Conclusions: Non-standard shift work has been associated with a variety of negative health outcomes and urologic complications, especially with concurrent SWSD. Recognition of these increased risks among shift workers can potentially aid in more effective screening of chronic health and urologic conditions. Non-pharmacologic treatment of SWSD focuses on behavioral therapy and sleep hygiene while melatonin, hypnotics, and stimulants are used to alleviate insomnia and excessive sleepiness of SWSD. Further research into both pharmacologic and non-pharmacologic therapies for SWSD is needed to establish more definitive guidelines in the treatment of SWSD in order to increase productivity, minimize workplace accidents, and improve quality of life for shift workers. Copyright (C) 2018, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.",2018-07,01/07/2022 10:40,01/07/2022 10:40,,446-456,,3,6,,,,,,,,,,,,,,WOS:000508840300011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XWGJSDPE,journalArticle,2009,"Lee, YS",Consequences of Childhood Obesity,ANNALS ACADEMY OF MEDICINE SINGAPORE,,0304-4602,,,"Introduction: The incidence of childhood obesity is rising across the globe, and obesity related co-morbidities are increasing concomitantly in the paediatric population. Materials and Methods: PubMed search for research and review papers on complications of childhood obesity was performed. Results: The consequences of childhood obesity can be broadly classified into medical and psychosocial consequences. Medical consequences include metabolic complications such as diabetes mellitus, hypertension, dyslipidaemia and non-alcoholic fatty liver disease, and mechanical problems such as obstructive sleep apnoea syndrome and orthopaedic disorders. Psychological and social consequences are prevalent but often overlooked. Local data on these complications were also discussed. Conclusion: Childhood obesity is associated with significant morbidities, which not only have immediate impact on the health of the obese children, but also significantly increase the risk of morbidities in adulthood.",2009-01,01/07/2022 10:40,01/07/2022 10:40,,75-81,,1,38,,,,,,,,,,,,,,WOS:000264333500012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GXU5MKSL,journalArticle,2012,"Otani, K; Takegami, M; Fukumori, N; Sekiguchi, M; Onishi, Y; Yamazaki, S; Ono, R; Otoshi, K; Hayashino, Y; Fukuhara, S; Kikuchi, S; Konno, S; Lohas Res Grp","Locomotor dysfunction and risk of cardiovascular disease, quality of life, and medical costs: design of the Locomotive Syndrome and Health Outcome in Aizu Cohort Study (LOHAS) and baseline characteristics of the study population",JOURNAL OF ORTHOPAEDIC SCIENCE,,0949-2658,10.1007/s00776-012-0200-5,,"There is little evidence regarding long-term outcomes of locomotor dysfunction such as cardiovascular events, quality of life, and death. We are conducting a prospective cohort study to evaluate risk of cardiovascular disease, quality of life, medical costs, and mortality attributable to locomotor dysfunction. The present study determined baseline characteristics of participants in the Locomotive Syndrome and Health Outcome in Aizu Cohort Study (LOHAS). Cohort participants were recruited from residents between 40 and 80 years old who received regular health check-ups conducted by local government each year between 2008 and 2010 in Minami-Aizu Town and Tadami Town in Fukushima Prefecture, Japan. Musculoskeletal examination included assessment of physical examination of the cervical and lumbar spine, and upper and lower extremities and of physical function, such as grasping power, one-leg standing time, and time for the 3-m timed up-and-go test. Cardiovascular risk factors, including blood pressure and biological parameters, were measured at annual health check-ups. We also conducted a self-administered questionnaire survey. LOHAS participants comprised 1,289 men (mean age 65.7 years) and 1,954 women (mean age 66.2 years) at the first year. The proportion of obese individuals (body mass index 25.0 kg/m(2)) was 31.9% in men and 34.3% in women, and 41.0% of participants reported being followed up for hypertension, 7.0% for diabetes, and 43.6% for hypercholesterolemia. Prevalence of lumbar spinal stenosis was 10.7% in men and 12.9% in women, while prevalence of low back pain was 15.8% in men and 17.6% in women. The LOHAS is a novel population-based prospective cohort study that will provide an opportunity to estimate the risk of cardiovascular disease, quality of life, medical costs, and mortality attributable to locomotor dysfunction, and to provide the epidemiological information required to develop policies for detection of locomotor dysfunction.",2012-05,01/07/2022 10:40,01/07/2022 10:40,,261-271,,3,17,,,,,,,,,,,,,,WOS:000304462900009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WLSMS7FK,journalArticle,2018,"Oldenburg, O; Fox, H; Wellmann, B; Thiem, U; Horstkotte, D; Bitter, T",IMPROVED QUALITY OF LIFE WITH AUTOMATIC POSITIVE AIRWAY PRESSURE FOR OBSTRUCTIVE SLEEP APNEA IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A RANDOMISED CONTROLLED TRIAL,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,,0735-1097,10.1016/S0735-1097(18)31485-2,,,10/03/2018,01/07/2022 10:40,01/07/2022 10:40,,944-944,,11,71,,,,,,,,,,,,,,WOS:000429659702194,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4DML5DBM,journalArticle,2018,"Duncan, MJ; Brown, WJ; Burrows, TL; Collins, CE; Fenton, S; Glozier, N; Kolt, GS; Morgan, PJ; Hensley, M; Holliday, EG; Murawski, B; Plotnikoff, RC; Rayward, AT; Stamatakis, E; Vandelanotte, C","Examining the efficacy of a multicomponent m-Health physical activity, diet and sleep intervention for weight loss in overweight and obese adults: randomised controlled trial protocol",BMJ OPEN,,2044-6055,10.1136/bmjopen-2018-026179,,"Introduction Traditional behavioural weight loss trials targeting improvements in physical activity and diet are modestly effective. It has been suggested that sleep may have a role in weight loss and maintenance. Improving sleep health in combination with physical activity and dietary behaviours may be one strategy to enhance traditional behavioural weight loss trials. Yet the efficacy of a weight loss intervention concurrently targeting improvements in physical activity, dietary and sleep behaviours remains to be tested. Methods and analysis The primary aim of this three-arm randomised controlled trial is to examine the efficacy of a multicomponent m-Health behaviour change weight loss intervention relative to a waitlist control group. The secondary aims are to compare the relative efficacy of a physical activity, dietary behaviour and sleep intervention (enhanced intervention), compared with a physical activity and dietary behaviour only intervention (traditional intervention), on the primary outcome of weight loss and secondary outcomes of waist circumference, glycated haemoglobin, physical activity, diet quality and intake, sleep health, eating behaviours, depression, anxiety and stress and quality of life. Assessments will be conducted at baseline, 6 months (primary endpoint) and 12 months (follow-up). The multicomponent m-Health intervention will be delivered using a smartphone/tablet 'app', supplemented with email and SMS and individualised in-person dietary counselling. Participants will receive a Fitbit, body weight scales to facilitate self-monitoring, and use the app to access educational material, set goals, self-monitor and receive feedback about behaviours. Generalised linear models using an analysis of covariance (baseline adjusted) approach will be used to identify between-group differences in primary and secondary outcomes, following an intention-to-treat principle. Ethics and dissemination The Human Research Ethics Committee of The University of Newcastle Australia provided approval: H-2017-0039. Findings will be disseminated via publication in peer-reviewed journals, conference presentations, community presentations and student theses.",2018-10,01/07/2022 10:40,01/07/2022 10:40,,,,10,8,,,,,,,,,,,,,,WOS:000454739500199,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HTPEAXTM,journalArticle,,"Moral-Munoz, JA; Salazar, A; Duenas, M; De Sola, H; Failde, I",Smartphone-based exercise intervention for chronic pain: PainReApp randomized clinical trial protocol,JOURNAL OF ADVANCED NURSING,,0309-2402,10.1111/jan.15095,,"Aim To evaluate the effectiveness of PainReApp, an mHealth system, based on physical exercise recommendations for patients with chronic pain (low back pain, fibromyalgia and diabetic neuropathic pain) based on pain intensity, quality of life, anxiety and/or depression, and sleep quality. Design Single-blinded randomized controlled trial. Methods One hundred patients from three different chronic conditions (low back pain, fibromyalgia and neuropathic diabetic pain) will be recruited and randomized into two groups to receive the intervention with a physical activity program guided by the PainReApp system (experimental group) or with the program information in paper format (control group). All patients will attend a first face-to-face session in which the smartphone application usage (experimental group) and exercise execution will be explained (both groups). Data will be collected at baseline, 4, 12 and 24 weeks. Nevertheless, the users of the application will have a daily registry of the exercise performed and the self-perceived difficulty. The primary outcomes of the trial will be the intensity of pain and quality of life. Anxiety and/or depression and sleep quality will be also assessed to evaluate the influence of the physical activity at multiple levels. Discussion Physical exercise is becoming one of the leading evidence-based interventions to treat chronic pain. It needs to be adapted to the necessities of each pain condition. One of the major problems is the low adherence to the proposed program. New strategies that empower the patients, such as the m-Health, are reliable and useful tools to ease this end. Impact To the best of our knowledge, this is the first long-term randomized controlled trial researching the impact of an m-health system on chronic pain from different origin. The intervention is based on international physical exercise recommendations and can be performed without specific material, allowing the home-based practice. Trial registration Australian and New Zealand Clinical Trials Registry (ACTRN12621000783820).",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000722627600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZY34FNW2,journalArticle,2017,"Ryan, DH; Yockey, SR","Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over",CURRENT OBESITY REPORTS,,2162-4968,10.1007/s13679-017-0262-y,,"One begins to see improvement in glycemic measures and triglycerides with small amounts of weight loss, but with greater levels of weight loss there is even greater improvement. In fact, the relationship between weight loss and glycemia is one that is very close. This is fortunate for diabetes prevention; it takes only small amounts of weight loss to prevent progression to type 2 diabetes from impaired glucose tolerance, and after the 10 kg of weight loss, one cannot demonstrate much additional improvement in risk reduction. Modest weight loss (5 to 10%) is also associated with improvement in systolic and diastolic blood pressure and HDL cholesterol. With all these risk factors, more weight loss produces more improvement. Further, for patients with higher BMI levels (> 40 kg/m(2)), the ability to lose the same proportion of weight with lifestyle intervention is equal to that of those with lower BMI levels, and there is equal benefit in terms of risk factor improvement with modest weight loss. For some comorbid conditions, more weight loss is needed-10 to 15%-to translate into clinical improvement. This is true with obstructive sleep apnea and non-alcoholic steatotic hepatitis. There is a graded improvement in improvements in measures of quality of life, depression, mobility, sexual dysfunction, and urinary stress incontinence, whereby improvements are demonstrable with modest weight loss (5-10%) and with further weight loss there are further improvements. For polycystic ovarian syndrome and infertility, modest weight loss (beginning at 2-5%) can bring improvements in menstrual irregularities and fertility. Moderate weight loss (5-10%) has been shown to be associated with reduced health care costs. Reduction in mortality may take more than 10% weight loss, although definitive studies have not been done to demonstrate that weight loss per se is associated with mortality reduction. Clinicians in medical weight management should bear in mind that the target should be health improvement rather than a number on the scale. The individual patient's targeted health goal should be assessed for response rather than a prescribed percentage weight loss.",2017-06,01/07/2022 10:40,01/07/2022 10:40,,187-194,,2,6,,,,,,,,,,,,,,WOS:000402741500011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U5YLUIRX,journalArticle,2015,"Ford, ES; Cunningham, TJ; Giles, WH; Croft, JB",Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2014.12.008,,"Objective: Insomnia is a prevalent disorder in the United States and elsewhere. It has been associated with a range of somatic and psychiatric conditions, and adversely affects quality of life, productivity at work, and school performance. The objective of this study was to examine the trend in self-reported insomnia and excessive daytime sleepiness among US adults. Methods: We used data of participants aged >= 18 years from the National Health Interview Survey for the years 2002 (30,970 participants), 2007 (23,344 participants), and 2012 (34,509 participants). Results: The unadjusted prevalence of insomnia or trouble sleeping increased from 17.5% (representing 37.5 million adults) in 2002 to 19.2% (representing 46.2 million adults) in 2012 (relative increase: +8.0%) (P trend <0.001). The age-adjusted prevalence increased from 17.4% to 18.8%. Significant increases were present among participants aged 18-24, 25-34, 55-64, and 65-74 years, men, women, whites, Hispanics, participants with diabetes, and participants with joint pain. Large relative increases occurred among participants aged 18-24 years (+30.9%) and participants with diabetes (+27.0%). The age-adjusted percentage of participants who reported regularly having excessive daytime sleepiness increased from 9.8% to 12.7% (P trend <0.001). Significant increases were present in most demographic groups. The largest relative increase was among participants aged 25-34 years (+49%). Increases were also found among participants with hypertension, chronic obstructive pulmonary disease, asthma, and joint pain. Conclusions: Given the deleterious effects of insomnia on health and performance, the increasing prevalence of insomnia and excessive daytime sleepiness among US adults is a potentially troubling development. Published by Elsevier B.V.",2015-03,01/07/2022 10:40,01/07/2022 10:40,,372-378,,3,16,,,,,,,,,,,,,,WOS:000351714400013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YIMLU4MG,journalArticle,2015,"Halmo, R; Galuszka, J; Langova, K; Galuszkova, D",Self care in patients with chronic heart failure. Pilot study - self care includes problems,BIOMEDICAL PAPERS-OLOMOUC,,1213-8118,10.5507/bp.2013.044,,"Aim. The goal of this pilot study was to define the scope of therapeutic self-care demand in heart failure (HF) patients according to the concepts of self-care postulated by D.E. Orem and to determine the level of problems experienced and self-care in these patients. Methods. A questionnaire consisting of 7 areas with closed format questions was developed according to the definition. The level of patient problems and level of self-care actions were mapped in each area. The questionnaire was distributed at the hospital outpatient clinic. The study group consisted of 47 heart failure patients (14 women) with following characteristics: average age 68 years, average BMI 29.4, resynchronization therapy 21%, hypertension 69.8%, diabetes mellitus 25.6%, coronary artery disease 46.5%, dilated cardiomyopathy 46.5%, obesity 46.5%, smoking history 39.5% (present and past smoking together), other cardiac disease 16.28%, condition after myocardial infarction 27.8% (NYHA II 41%, NYHA III 56.8%, NYHA IV 2.2%). Results. The greatest problems were in the area of physical activity, sleep and fatigue, the least were in the area of chest pain and blood circulation. The greatest self-care agency was shown in the area of managing problems with physical activities and sleep, the lowest in the area of liquid intake and output. In the patients' subjective opinion, fatigue and sleep problems had the greatest impact on the quality of life. There were no substantial differences in either area based on gender. Conclusions. The data can serve as a foundation for modifying the extent and structure of patient education for more comprehensive and more effective out-patient treatment of HF.",2015,01/07/2022 10:40,01/07/2022 10:40,,124-130,,1,159,,,,,,,,,,,,,,WOS:000351716500020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I4B5CB2K,journalArticle,2016,"Wallstrom, S; Ulin, K; Omerovic, E; Ekman, I",Self-reported symptoms 8 weeks after discharge: A comparison of takotsubo syndrome and myocardial infarction,INTERNATIONAL JOURNAL OF CARDIOLOGY,,0167-5273,10.1016/j.ijcard.2016.09.052,,"Background: Takotsubo syndrome is a form of acute, reversible heart failure that has gained increasing attention. It affects mostly postmenopausal women, and its acute onset and symptoms mimic acute myocardial infarction. The distinct feature of takotsubo syndrome is the ballooning of a ventricle, but the complete pathophysiological mechanisms are not fully understood. Both short-term and long-term survival are affected, but little is known about the illness experience and self-reported residual symptoms after discharge from hospital. Aim: To measure and compare self-reported residual symptoms between patients with takotsubo syndrome and those with acute myocardial infarction. Method: Questionnaire data measuring self-reported symptoms were collected from 48 patients with takotsubo syndrome and 79 patients with acute myocardial infarction 8 weeks after discharge. A multivariate adjusted complete case regression model was used to compare the frequency and severity of symptoms. Results: Self-reported symptoms 8 weeks after discharge differed little between patients with takotsubo syndrome and those with acute myocardial infarction. Both groups reported symptoms, including pain, fatigue, breathlessness, and sleep disturbance. At onset there were significant differences between the groups concerning previous diabetes mellitus, cardiac troponin T, ejection fraction and Killip class. There were no significant between-group differences in frequency or severity of symptoms after adjusting for these differences. Conclusion: Patients with takotsubo syndrome experience residual symptoms after discharge. Symptoms in several cardiovascular diseases predict quality of life, re-admission, and mortality. Symptom management should be integrated into follow-up care for patients with takotsubo syndrome. One way of achieving this is through person-centered care. (C) 2016 Elsevier Ireland Ltd. All rights reserved.",01/12/2016,01/07/2022 10:40,01/07/2022 10:40,,348-352,,,224,,,,,,,,,,,,,,WOS:000390471300064,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6ZELT9BY,journalArticle,2015,"Nimeh, T; Alvarez, P; Mufarreh, N; Lerner, LB",Nocturia: Current Evaluation and Treatment for Urology,CURRENT UROLOGY REPORTS,,1527-2737,10.1007/s11934-015-0533-7,,"Nocturia is a very common yet a highly underreported entity. Recently, there has been an increasing interest in nocturia because of its association with serious adverse health conditions such as diabetes, heart disease, elevated BMI, and mortality. Frequency volume charts are the cornerstone of initial assessment and are pivotal in determining the type of nocturia and associated causes. The diagnostic evaluation is aimed at clarifying the underlying cause: sleep disturbances, reduced bladder capacity (functional or extrinsic), and increased urine production (nocturnal or daily). Obstructive sleep apnea is an important cause of nocturnal polyuria and should always been considered. Management is focused on treating the underlying cause; a range of behavioral and pharmacologic options are available.",2015-09,01/07/2022 10:40,01/07/2022 10:40,,,,9,16,,,,,,,,,,,,,,WOS:000359525500008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GYGMGKXX,journalArticle,1997,"Balsiger, BM; LuquedeLeon, E; Sarr, MG",Surgical treatment of obesity: Who is an appropriate candidate?,MAYO CLINIC PROCEEDINGS,,0025-6196,10.4065/72.6.551,,"The increasing prevalence and far-reaching medical, social, and economical implications of obesity have made it a national health-care crisis in the United States. About one in every three persons is at least 20% above ''ideal'' body weight, and approximately 5% have direct weight-related serious health problems (morbid obesity), including hypertension, hyperlipidemia, coronary artery disease, adult-onset diabetes mellitus, degenerative osteoarthropathy, and obstructive sleep apnea. Morbidly obese patients have an estimated 6- to 12-fold increase in mortality. In addition, they have a substantially diminished quality of life, not only physically but also psychosocially due to overt and occult prejudice. Weight reduction must be aggressively pursued in these patients. Medically supervised weight-control programs have been ineffective because patients cannot maintain pronounced long-term weight loss. In contrast, current operative methods have been proved to be effective in helping patients achieve and maintain permanent weight reduction. Several operations have been designed and assessed; with these procedures, weight loss is achieved by inducing malabsorption, maldigestion, early satiety, or a combination of these outcomes. Although these operations have associated side effects and limitations, the expected benefits outweigh the risks. For optimal results, patients must be carefully selected and treated by a multidisciplinary group.",1997-06,01/07/2022 10:40,01/07/2022 10:40,,551-558,,6,72,,,,,,,,,,,,,,WOS:A1997XC43200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F2B7NM2V,journalArticle,2006,"Crookes, PE",Surgical treatment of morbid obesity,ANNUAL REVIEW OF MEDICINE,,0066-4219,10.1146/annurev.med.56.062904.144928,,"Obesity is a major epidemic in developed countries. It induces or exacerbates hypertension, diabetes mellitus, obstructive sleep apnea, dyslipidemia, and many other disease processes, which cumulatively contribute to premature mortality on a scale rivaling that of smoking. At present, bariatric surgery is the only therapeutic modality that can produce sustained weight loss and halt or resolve comorbidities. This success results from the ability to perform the operation reliably, usually laparoscopically, with low mortality. The most commonly performed operation is Roux-en-Y gastric bypass. Other bypasses discussed in this review include biliopancreatic diversion with and without duodenal switch. Purely restrictive operations, especially adjustable gastric banding, have a lower risk but are somewhat less effective. We focus on the more controversial aspects of commonly accepted operations, including patient selection, the spectrum and frequency of complications, and the long-term outcome.",2006,01/07/2022 10:40,01/07/2022 10:40,,243-264,,,57,,,,,,,,,,,,,,WOS:000235981900016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
62TKKC2I,journalArticle,2021,"Wolnerhanssen, BK; Peterli, R; Hurme, S; Bueter, M; Helmio, M; Juuti, A; Meyer-Gerspach, AC; Slawik, M; Peromaa-Haavisto, P; Nuutila, P; Salminen, P",Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS),BRITISH JOURNAL OF SURGERY,,0007-1323,10.1093/bjs/znaa011,,"Background: Laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (LRYGB) are both effective surgical procedures to achieve weight reduction in patients with obesity. The trial objective was to merge individual-patient data from two RCTs to compare outcomes after LSG and LRYGB. Methods: Five-year outcomes of the Finnish SLEEVEPASS and Swiss SM-BOSS RCTs comparing LSG with LRYGB were analysed. Both original trials were designed to evaluate weight loss. Additional patient-level data on type 2 diabetes (T2DM), obstructive sleep apnoea, and complications were retrieved. The primary outcome was percentage excess BMI loss (%EBMIL). Secondary predefined outcomes in both trials included total weight loss, remission of co-morbidities, improvement in quality of life (QoL), and overall morbidity. Results: At baseline, 228 LSG and 229 LRYGB procedures were performed. Five-year follow-up was available for 199 of 228 patients (87.3 per cent) after LSG and 199 of 229 (87.1 per cent) after LRYGB. Model-based mean estimate of %EBMIL was 7.0 (95 per cent c.i. 3.5 to 10.5) percentage points better after LRYGB than after LSG (62.7 versus 55.5 per cent respectively; P < 0.001). There was no difference in remission of T2DM, obstructive sleep apnoea or QoL improvement; remission for hypertension was better after LRYGB compared with LSG (60.3 versus 44.9 per cent; P = 0.049). The complication rate was higher after LRYGB than LSG (37.2 versus 22.5 per cent; P = 0.001), but there was no difference in mean Comprehensive Complication Index value (30.6 versus 31.0 points; P = 0.859). Conclusion: Although LRYGB induced greater weight loss and better amelioration of hypertension than LSG, there was no difference in remission of T2DM, obstructive sleep apnoea, or QoL at 5 years. There were more complications after LRYGB, but the individual burden for patients with complications was similar after both operations.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,49-57,,1,108,,,,,,,,,,,,,,WOS:000637023600043,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U2CZVJTB,journalArticle,2005,"Andris, DA",Surgical treatment for obesity - Ensuring success,JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING,,1071-5754,10.1097/00152192-200511000-00011,,"In the United States, obesity has reached epidemic proportions. Serious medical complications, impaired quality of life, and premature mortality are all associated with obesity. Medical conditions such as type 2 diabetes mellitus, hypertension, hyperlipidemia, or sleep apnea can improve or be cured with weight loss.' Medical treatment programs focused on diet, behavior modification, and/or pharmacologic intervention have met with limited long-term success. Although surgical treatments for obesity have become popular in recent years, they should only be used as a last resort for weight loss. Not all patients can be considered appropriate candidates for surgery; therefore, guidelines based on criteria from the National Institutes of Health should be used preoperatively to help identify suitable persons.' Most individuals who opt for weight-loss surgery have usually struggled for many years with losing weight and keeping it off, but surgery alone will not ensure successful weight loss. Patient education is imperative for long-term success. Moreover, any such educational regimen should include information on diet, vitamin and mineral supplementation, and lifestyle changes, as well as expected weight-loss results and improvements in comorbid conditions. Patients must be willing to commit to a long-term follow-up program intended to promote successful weight loss and weight maintenance and to prevent metabolic and nutritional complications.",2005-11,01/07/2022 10:40,01/07/2022 10:40,,393-401,,6,32,,,,,,,,,,,,,,WOS:000236347500011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P78IRYDN,journalArticle,2021,"Luppi, F; Kalluri, M; Faverio, P; Kreuter, M; Ferrara, G",Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management,RESPIRATORY RESEARCH,,1465-993X,10.1186/s12931-021-01711-1,,"Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3-5 years after diagnosis. This condition occurs primarily in elderly subjects, and epidemiological studies suggest that the main risk factors, ageing and exposure to cigarette smoke, are associated with both pulmonary and extrapulmonary comorbidities (defined as the occurrence of two or more disorders in a single individual). Ageing and senescence, through interactions with environmental factors, may contribute to the pathogenesis of IPF by various mechanisms, causing lung epithelium damage and increasing the resistance of myofibroblasts to apoptosis, eventually resulting in extracellular matrix accumulation and pulmonary fibrosis. As a paradigm, syndromes featuring short telomeres represent archetypal premature ageing syndromes and are often associated with pulmonary fibrosis. The pathophysiological features induced by ageing and senescence in patients with IPF may translate to pulmonary and extrapulmonary features, including emphysema, pulmonary hypertension, lung cancer, coronary artery disease, gastro-oesophageal reflux, diabetes mellitus and many other chronic diseases, which may lead to substantial negative consequences in terms of various outcome parameters in IPF. Therefore, the careful diagnosis and treatment of comorbidities may represent an outstanding chance to improve quality of life and survival, and it is necessary to contemplate all possible management options for IPF, including early identification and treatment of comorbidities.",17/04/2021,01/07/2022 10:40,01/07/2022 10:40,,,,1,22,,,,,,,,,,,,,,WOS:000641743800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YI9JFNKW,journalArticle,2018,"Bernabeu, I; Aller, J; Alvarez-Escola, C; Fajardo-Montanana, C; Galvez-Moreno, A; Guillin-Amarelle, C; Sesmilo, G","Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus",ENDOCRINOLOGIA DIABETES Y NUTRICION,,2530-0180,10.1016/j.endinu.2018.01.008,,"Acromegaly is a rare disease with many comorbidities that impair quality of life and limit survival. There are discrepancies in various clinical guidelines regarding diagnosis and postoperative control criteria, as well as screening and optimal management of comorbidities. This expert consensus was aimed at establishing specific recommendations for the Spanish healthcare system. The existing recommendations, the scientific evidence on which they are based, and the main controversies are reviewed. Unfortunately, the low prevalence and high clinical variability of acromegaly do not provide strong scientific evidences. To mitigate this disadvantage, a modified Delphi questionnaire, combining the best available scientific evidence with the collective judgment of experts, was used. The questionnaire, generated after a face-to-face debate, was completed by 17 Spanish endocrinologists expert in acromegaly. A high degree of consensus was reached (79.3%), as 65 of the total 82 statements raised were accepted. Some criteria for diagnosis and postoperative control were identified by this procedure. Regarding comorbidities, recommendations have been established or suggested for screening and management of oncological, cardiovascular, respiratory (sleep apnea), metabolic (dystipidemia and diabetes), musculoskeletal, and hypopituitarism-related disorders. Consensus recommendations may facilitate and homogenize clinical care to patients with acromegaly in the Spanish health system. (C) 2018 SEEN y SED. Published by Elsevier Espana, S.L.U. All rights reserved.",2018-05,01/07/2022 10:40,01/07/2022 10:40,,297-305,,5,65,,,,,,,,,,,,,,WOS:000432496100008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
J58JNUB4,journalArticle,2012,"Craig, SE; Kohler, M; Nicoll, D; Bratton, DJ; Nunn, A; Davies, R; Stradling, J",Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial,THORAX,,0040-6376,10.1136/thoraxjnl-2012-202178,,"Background Continuous positive airway pressure (CPAP) for symptomatic obstructive sleep apnoea (OSA) improves sleepiness and reduces vascular risk, but such treatment for the more prevalent, minimally symptomatic disease is contentious. Methods This multicentre, randomised controlled, parallel, hospital-based trial across the UK and Canada, recruited 391 patients with confirmed OSA (oxygen desaturation index > 7.5/h) but insufficient symptoms to warrant CPAP therapy. Patients were randomised to 6 months of auto-adjusting CPAP therapy, or standard care. Coprimary endpoints were change in Epworth Sleepiness Score (ESS) and predicted 5-year mortality using a cardiovascular risk score (components: age, sex, height, systolic blood pressure, smoking, diabetes, cholesterol, creatinine, left ventricular hypertrophy, previous myocardial infarction or stroke). Secondary endpoints included some of the individual components of the vascular risk score, objectively measured sleepiness and self-assessed health status. Results Of 391 patients randomised, 14 withdrew, 347 attended for their follow-up visit at 6 months within the predefined time window, of which 341 had complete ESS data (baseline mean 8.0, SD 4.3) and 310 had complete risk score data. 22% of patients in the CPAP group reported stopping treatment and overall median CPAP use was 2 : 39 h per night. CPAP significantly improved subjective daytime sleepiness (adjusted treatment effect on ESS -2.0 (95% CI -2.6 to -1.4), p < 0.0001), objectively measured sleepiness and self-assessed health status. CPAP did not improve the 5-year calculated vascular risk or any of its components. Conclusions In patients with minimally symptomatic OSA, CPAP can reduce subjective and objective daytime sleepiness, and improve self-assessed health status, but does not appear to improve calculated vascular risk.",2012-12,01/07/2022 10:40,01/07/2022 10:40,,1090-1096,,12,67,,,,,,,,,,,,,,WOS:000311140600013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KN545QGK,journalArticle,2011,"Scholz, H; Benes, H; Happe, S; Bengel, J; Kohnen, R; Hornyak, M",Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study,HEALTH AND QUALITY OF LIFE OUTCOMES,,1477-7525,10.1186/1477-7525-9-73,,"Background: Restless legs syndrome (RLS) is a chronic disorder with substantial impact on quality of life similar to that seen in diabetes mellitus or osteoarthritis. Little is known about the psychological characteristics of RLS patients although psychological factors may contribute to unfavourable treatment outcome. Methods: In an observational cross-sectional design, we evaluated the psychological features of 166 consecutive RLS patients from three outpatient clinics, by means of the Symptom Checklist 90-R (SCL-90-R) questionnaire. Additionally, the Beck Depression Inventory-II (BDI-II) and the International RLS Severity Scale (IRLS) were measured. Both treated and untreated patients were included, all patients sought treatment. Results: Untreated patients (n = 69) had elevated but normal scores on the SCL-90-R Global Severity Index (GSI; p = 0.002) and on the sub-scales somatisation (p < 0.001), compulsivity (p = 0.003), depression (p = 0.02), and anxiety (p = 0.004) compared with a German representative sample. In the treated group, particularly in those patients who were dissatisfied with their actual treatment (n = 62), psychological distress was higher than in the untreated group with elevated scores for the GSI (p = 0.03) and the sub-scales compulsivity (p = 0.006), depression (p = 0.012), anxiety (p = 0.031), hostility (p = 0.013), phobic anxiety (p = 0.024), and paranoid ideation (p = 0.012). Augmentation, the most serious side effect of dopaminergic, i.e. first-line treatment of RLS, and loss of efficacy were accompanied with the highest psychological distress, as seen particularly in the normative values of the sub-scales compulsivity and anxiety. Generally, higher RLS severity was correlated with higher psychological impairment (p < 0.001). Conclusion: Severely affected RLS patients show psychological impairment in multiple psychological domains which has to be taken into account in the treatment regimen.",20/09/2011,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000295806600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
M86AZMGM,journalArticle,2020,"Lenders, NF; McCormack, AI; Ho, KKY",MANAGEMENT OF ENDOCRINE DISEASE Does gender matter in the management of acromegaly?,EUROPEAN JOURNAL OF ENDOCRINOLOGY,,0804-4643,10.1530/EJE-19-1023,,"Gonadal steroids modulate the effects of GH, with oestrogens attenuating and androgens augmenting GH action. Whether these divergent effects influence the clinical manifestation, management and prognosis of acromegaly have not been carefully reviewed. This review examines whether there is a gender difference in epidemiology, presentation, quality of life (QoL), morbidity, treatments and mortality of acromegaly. Acromegaly is more common in women who present at an older age with longer diagnostic delay. At presentation, women have a higher GH relative to IGF-1 level than men. QoL is more adversely affected in women both before and after treatment. Prevalence of hypertension and diabetes are greater in women than in men with acromegaly. Treatment outcomes with SSAs are comparable between sexes, but women may require a higher dose of pegvisomant for equivalent response. Mortality in untreated acromegaly is more profoundly affected in women; however, improved treatments in recent decades have resulted in normalisation of standard mortality ratios in both sexes. We conclude that gender does matter in the management of acromegaly, with women presenting later in life, with greater diagnostic delay, higher prevalence of comorbidities and experiencing worse QoL.",2020-05,01/07/2022 10:40,01/07/2022 10:40,,R67-R82,,5,182,,,,,,,,,,,,,,WOS:000528194900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QMILRSR9,journalArticle,2018,"Gerogianni, G; Kouzoupis, A; Grapsa, E",A holistic approach to factors affecting depression in haemodialysis patients,INTERNATIONAL UROLOGY AND NEPHROLOGY,,0301-1623,10.1007/s11255-018-1891-0,,"Depression in dialysis populations is affected by co-morbid diseases, such as cardiovascular disease, diabetes, and immune dysfunction, and it also includes high suicide risk and frequent hospitalizations. Depressive disorders have a close association with malnutrition and chronic inflammation, as well as with cognitive impairment. Impaired cognitive function may be manifested as low adherence to dialysis treatment, leading to malnutrition. Additionally, chronic pain and low quality of sleep lead to high rates of depressive symptoms in haemodialysis patients, while an untreated depression can cause sleep disturbances and increased mortality risk. Depression can also lead to sexual dysfunction and non-adherence, while unemployment can cause depressive disorders, due to patients' feelings of being a financial burden on their family. The present review provides a holistic approach to the factors affecting depression in haemodialysis, offering significant knowledge to renal professionals.",2018-08,01/07/2022 10:40,01/07/2022 10:40,,1467-1476,,8,50,,,,,,,,,,,,,,WOS:000440607100014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GHDRG93C,journalArticle,2018,"Thong, MSY; Mols, F; van de Poll-Franse, LV; Sprangers, MAG; van der Rijt, CCD; Barsevick, AM; Knoop, H; Husson, O",Identifying the subtypes of cancer-related fatigue: results from the population-based PROFILES registry,JOURNAL OF CANCER SURVIVORSHIP,,1932-2259,10.1007/s11764-017-0641-0,,"Little research has been done to identify possible cancer-related fatigue (CRF) subtypes and to classify cancer survivors accordingly. We aimed to identify CRF subtypes in a large population-based sample of (long term) stage I-III colorectal cancer survivors. We also identified factors associated with the CRF subtypes. Respondents completed the Multidimensional Fatigue Inventory and other validated questionnaires on anxiety and reduced positive affect (anhedonia), sleep quality, and lifestyle factors (body mass index and physical activity). Latent class analysis was used to derive the CRF subtypes. Factors associated with the derived CRF subtypes were determined with multinomial logistic regression. Three CRF classes were identified: class 1 (no fatigue and distress, n = 644, 56%), class 2 (low fatigue, moderate distress, n = 256, 22%), and class 3 (high fatigue, moderate distress, n = 256, 22%). Multinomial logistic regression results show that survivors in class 3 were more likely to be female, were treated with radiotherapy, have comorbid diabetes mellitus, and be overweight/obese than survivors in class 1 (reference). Survivors in classes 2 and 3 were also more likely to have comorbid heart condition, report poorer sleep quality, experience anhedonia, and report more anxiety symptoms when compared with survivors in class 1. Three distinct classes of CRF were identified which could be differentiated with sleep quality, anxiety, anhedonia, and lifestyle factors. The identification of CRF subtypes with distinct characteristics suggests that interventions should be targeted to the CRF subtype.",2018-02,01/07/2022 10:40,01/07/2022 10:40,,38-46,,1,12,,,,,,,,,,,,,,WOS:000423586600005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A4ADKVHA,journalArticle,2010,"Pauly, RP; Maximova, K; Coppens, J; Asad, RA; Pierratos, A; Komenda, P; Copland, M; Nesrallah, GE; Levin, A; Chery, A; Chan, CT; CAN-SLEEP Collaborative Grp",Patient and Technique Survival among a Canadian Multicenter Nocturnal Home Hemodialysis Cohort,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.00300110,,"Background and objectives: As a result of improved clinical and quality-of-life outcomes compared with conventional hemodialysis, interest in nocturnal home hemodialysis (NHD) has steadily increased in the past decade; however, little is known about the flow of patients through NHD programs or about patient-specific predictors of mortality or technique failure associated with this modality. This study addressed this gap in knowledge. Design, setting, participants, & measurements: This study included 247 NHD patients of the Canadian Slow Long nightly ExtEnded dialysis Programs (CAN-SLEEP) cohort from 1994 through 2006 inclusive. The association between program- and patient-specific variables and risk for adverse outcomes was determined using uni- and multivariable Cox regression. Results: A total of 14.6% of the cohort experienced death or technique failure. Unadjusted 1- and 5-year adverse event-free survival was 95.2 and 80.1%, respectively. Significant predictors of a composite of mortality and technique failure included advanced age (P < 0.001), diabetes (P < 0.001), central venous catheter use (P = 0.01), and inability to perform NHD independently (P = 0.009) and were adjusted for center effect. Weekly frequency of NHD was not predictive. Age and diabetes remained significant with multivariable analysis (hazard ratio 1.07 and 2.64, respectively). Unadjusted 1- and 5-year technique survival was 97.9 and 95.2%, respectively. Only age was a significant predictor of technique failure. Conclusions: NHD is associated with excellent adverse event-free survival. This study underscores the importance of modality-specific predictors in the success of home hemodialysis, as well as favorable baseline characteristics such as younger age and the absence of diabetes. Clin J Ant Soc Nephrol 5: 1815-1820, 2010. doi: 10.2215/CJN.00300110",2010-10,01/07/2022 10:40,01/07/2022 10:40,,1815-1820,,10,5,,,,,,,,,,,,,,WOS:000282836400016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FGIWAJQ4,journalArticle,2018,"Uher, I; Bukova, A",Interrelationship between Exercise and Diseases in young people: Review study,PHYSICAL ACTIVITY REVIEW,,2300-5076,10.16926/par.2018.06.25,,"Introduction: Regular physical activity is associated with physical, and mental benefits, whilst insufficient physical activity (PA) is associated with number of negative health outcomes (e.g. metabolic syndrome, brain health, cognitive functions, insulin resistance, prediabetes, type 2 diabetes, sarcopenia, coronary heart disease etc.). In our systematic overview, we look into relationship between participation on regular PA and health of young people. Material and methods: Electronic databases were searched for articles related to connection between PA and correlated diseases in young man. Results: The search resulted in 137 identified records of which 54 records articles were included in the presented review. Conclusions: Based on our findings, we recognize that human body rapidly maladapts to insufficient PA, and if extended for a longer period of time, it will result in substantial decline of health. Altogether, conclusive evidence exists that physical inactivity is one of the most important cause of most chronic diseases. In addition, PA especially in younger age can primarily prevents, or delays chronic diseases, assuming that chronic diseases may not be an inevitable outcome throughout life. Our review suggests that PA exert substantial positive effect on health of young men, however, to reach a true consensus, the mechanism behind these observations must be further elucidated.",2018,01/07/2022 10:40,01/07/2022 10:40,,203-212,,,6,,,,,,,,,,,,,,WOS:000446545800008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UWMV7PR9,journalArticle,2015,"Rodriguez, L; Rodriguez, P; Gomez, B; Ayala, JC; Oxenberg, D; Perez-Castilla, A; Netto, MG; Soffer, E; Boscardin, WJ; Crowell, MD",Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease,SURGERY,,0039-6060,10.1016/j.surg.2014.10.012,,"Background. Lower esophageal sphincter (LES) electrical stimulation therapy (EST) has been shown to improve outcome in gastroesophageal reflux disease (GERD) patients at I year. The aim of this open-label extension trial (NCT01578642) was to study the 2-year safety and efficacy of LES-EST in GERD patients. Methods. GERD patients responsive partially to proton pump inhibitors (PPI) with off-PPI GERD health-related quality of life (HRQL) of >= 20, 24-hour esophageal pH <= 4.0 for > 5 % of the time, hiatal hernia <= 3 cm, and esophagitis LA grade C or lower participated in this trial. Bipolar stitch electrodes and a pulse generator (EndoStim BV, The Hague, The Netherlands) were implanted laparoscopically. LES-EST at 20 Hz, 215,us, 3-8 mAmp was delivered over 30-minute sessions, 6-12 sessions per day, starting on day 1 after implantation. Patients were evaluated using GERD-HRQL, symptom diaries, Short Form-12, and esophageal pH testing at regular intervals. Stimulation sessions were optimized based on residual symptoms and esophageal pH at follow-up. Results. Twenty-five patients (mean age [SD] =52 [12] years; 14 men) were implanted successfully; 23 patients participated in the 2-year extension trial, and 21 completed their 2-year evaluation. At 2 years, there was improvement in their median GERD-HRQL on LES-EST compared with both their on-PPI (9 vs 0; P = .001) and off-PPI (23.5 vs 0; P < .001) baseline scores. Median 24-hour distal esophageal acid exposure improved from 10% at baseline to 4% (per-protocol analysis; P < .001) at 2 years with 71% demonstrating either normalization or a >= 50% decrease in their distal esophageal acid exposure. All except 5 patients (16/21) reported complete cessation of PPI use; only 2 patients were using a PPI regularly (>= 50 % of days). There was significant improvement in sleep quality and daily symptoms of heartburn and regurgitation on IRS-EST At baseline, 92% of the subjects (22/24) reported that they were ""unsatisfied"" with their condition off-PPI and 71% (17/24) on-PPI compared with 0% (0/21) ""unsatisfied"" at the 24-month visits on LES-EST There were no device- or therapy-related serious adverse events and no untoward sensation or dysphagia reported with IRS-EST . Conclusion. IRS-EST is safe and effective for treating patients with GERD over a period of 2 years. LES-EST resulted in a significant and sustained improvement in GERD symptoms, and esophageal acid exposure and eliminated PPI use in majority of patients (16 of 21). Further, LES-EST was not associated with any gastrointestinal side effects or adverse events.",2015-03,01/07/2022 10:40,01/07/2022 10:40,,556-567,,3,157,,,,,,,,,,,,,,WOS:000350839100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B529EFEU,book,2016,"Losso, JN; Losso, JN",Insomnia and Sleep Disorders,,978-1-4822-4822-7,,,,,2016,01/07/2022 10:40,01/07/2022 10:40,,,233,,,,,,MAILLARD REACTION RECONSIDERED: COOKING AND EATING FOR HEALTH,,,,,,,,,,WOS:000381642200016,,,Pages: 247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T4Q4BGYH,journalArticle,2021,"Dendup, T; Feng, XQ; O'Shaughnessy, P; Astell-Burt, T","Perceived built environment and type 2 diabetes incidence: Exploring potential mediating pathways through physical and mental health, and behavioural factors in a longitudinal study",DIABETES RESEARCH AND CLINICAL PRACTICE,,0168-8227,10.1016/j.diabres.2021.108841,,"Aims: The evidence on the pathways through which the built environment may influence type 2 diabetes (T2D) risk is limited. This study explored whether behavioural, physical and mental health factors mediate the associations between perceived built environment and T2D. Methods: Longitudinal data on 36,224 participants aged >= 45 years (The Sax Institute's 45 and Up Study) was analysed. Causal mediation analysis that uses the counterfactual approach to decompose the total effect into direct and indirect effects was performed. Results: The results showed that physical activity, recreational walking, and BMI mediated around 6%, 11%, and 30%, respectively, of the association between perceived lack of access to local amenities and T2D incidence. Physical activity (4.8% for day-time crime), recreational walking (2.3% for day-time crime), psychological distress (5.2% for day-time, 3.7% for night-time crime), and BMI (29.6% for day-time crime, 17.4% for night-time crime) also partially mediated the effect of perceived crime. Mediated effects appeared larger at wave 3 than the same wave 2 mediators. Conclusions: The findings demonstrate that physical activity, psychological distress, and BMI mediate the pathways between the built environment and T2D. Policies aimed to bring amenities closer to homes, prevent crime, and address mental health may help reduce T2D risk. (C) 2021 Elsevier B.V. All rights reserved.",2021-06,01/07/2022 10:40,01/07/2022 10:40,,,,,176,,,,,,,,,,,,,,WOS:000664987800017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U4AGTKXB,journalArticle,2021,"Freire, VAF; Martins, DS; Reis, MEDA; Rosa, TA; Izidoro, LFM; de Rezende, AAA; Calabria, LK","Tracking of risk factors for non-communicable diseases in young shooters, Ituiutaba, MG",ACTA SCIENTIARUM-HEALTH SCIENCES,,1679-9291,10.4025/actascihealthsci.v43i1.54483,,"The aim of this study was to detect early hypertension, diabetes and obesity, as well as their risk factors, in 105 young shooters from Tiro de Guerra 11-002 in the city of Ituiutaba-MG. This is a cross-sectional mixed study. A semi-structured questionnaire that contained questions related to the sociodemographic context, health status, lifestyle, eating habits, and psychosocial variables was applied. Blood pressure, anthropometric indexes, and lipid and glycemic profiles were measured. Descriptive and inferential statistics, including Pearson's correlation test and Spearman's coefficient, considering significative value (p < 0.05). The shooters had an average of 18.9 years old, most educated and brown. Anthropometric indices indicated a mainly eutrophic population, and normotensive and desirable lipid and glycemic profiles. However, overweight, high blood pressure, and self-declaration of family history for chronic diseases were identified. In addition, most shooters affirmed to ingest alcoholics beverages, to have insufficient time of physical activity, and to be aware of their levels of stress, pressure and anxiety and a few hours of sleep. Overall, the shooters showed good anthropometric and biochemical indicators of blood. Risk behavior, such as drinking alcoholic beverages and smoking, low level of physical activity and self-perception of stress, anxiety and pressure were also noted.",2021,01/07/2022 10:40,01/07/2022 10:40,,,,,43,,,,,,,,,,,,,,WOS:000727508400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JXV3EBKS,journalArticle,2020,"Sharma, A; Bajaj, P; Bhandari, A; Kaur, G","From ayurvedic folk medicine to preclinical neurotherapeutic role of a miraculous herb, Tinospora cordifolia",NEUROCHEMISTRY INTERNATIONAL,,0197-0186,10.1016/j.neuint.2020.104891,,"In Ayurveda, the age-old Indian traditional system of medicine, health is considered to be achieved as equilibrium of physical and mental wellbeing and brain related ailments are recognized as 'Vatavyadi'. Rasayana herbs were mainly used for pharmacological treatment of neurological diseases and Tinospora cordifolia is one of the popular Rasayana herbs of Ayurveda. The traditional claims of therapeutic activity of this herb for treatment of fever, diabetes, anxiety, immunodeficiency, memory deficit and psychological problems have been explored by different research groups using reverse pharmacology and advance technological approaches. The aim of current review is to compile and discuss the neurotherapeutic potential of T. cordifolia in the light of various preclinical and clinical studies from literature. This review summarizes the information about different extracts of this herb and decoctions used for various neuro-related problems such as neurodegenerative diseases, neuroinflammation, sleep disorders, neural cancers, memory and cognition deficits and psychological problems besides other potential activities. The review also provides the knowledge of underlying therapeutic mechanism of T. cordifolia and its active phytoconstituents.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,,,,141,,,,,,,,,,,,,,WOS:000594796400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XCGVCS82,journalArticle,2016,"Nielsen, MS; Quist, JS; Chaput, JP; Dalskov, SM; Damsgaard, CT; Ritz, C; Astrup, A; Michaelsen, KF; Sjodin, A; Hjorth, MF","Physical Activity, Sedentary Time, and Sleep and the Association With Inflammatory Markers and Adiponectin in 8-to 11-Year-Old Danish Children",JOURNAL OF PHYSICAL ACTIVITY & HEALTH,,1543-3080,10.1123/jpah.2015-0123,,"Background: Inflammatory markers, adiponectin, and movement/nonmovement behaviors have all been linked to risk factors for cardiovascular disease; however, the association between childhood movement/nonmovement behaviors and inflammatory markers and adiponectin is unknown. Methods: We explored the association between accelerometer determined moderate-to-vigorous physical activity (MVPA), sedentary time, and sleep (7 days/8 nights) and fasting C-reactive protein (CRP), interleukin-6 (IL-6), and adiponectin in 806 school children. A sleep variability score was calculated. Results: MVPA was negatively associated with adiponectin in boys and girls (P < .001) and with CRP and IL-6 in girls (P < .05) independent of sleep duration, sedentary time, age, fat mass index (FMI), and pubertal status. Sedentary time was positively associated with adiponectin in boys and girls (both P < .001), and sleep duration with adiponectin in boys independent of age, FMI, and pubertal status (P < .001); however, these associations disappeared after mutual adjustments for movement behavior. Sleep duration variability was positively associated with CRP in girls independent of all covariates (P < .01). Conclusion: MVPA remained negatively associated with inflammatory markers and adiponectin, and sleep duration variability positively associated with CRP after adjustment for FMI, pubertal status, and other movement behavior. The inverse association between MVPA and adiponectin conflicts with the anti-inflammatory properties of adiponectin.",2016-07,01/07/2022 10:40,01/07/2022 10:40,,733-739,,7,13,,,,,,,,,,,,,,WOS:000381244300006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8UW4LBEQ,journalArticle,2014,"Thompson, AN; Leal, JE; Brzezinski, WA",Olanzapine and Baclofen for the Treatment of Intractable Hiccups,PHARMACOTHERAPY,,0277-0008,10.1002/phar.1378,,"Intractable hiccups are a relatively uncommon condition characterized by involuntary, spasmodic contractions of the diaphragm. This type of hiccups generally has a duration of more than 1 month. We describe a 59-year-old kidney transplant recipient with a complicated medical history (atrial fibrillation, chronic renal failure, type 2 diabetes mellitus, gastroesophageal reflux, gout, hypertension, hyperlipidemia, and obstructive sleep apnea) who developed intractable hiccups that significantly affected his quality of life. Despite an extensive gastrointestinal and pulmonary evaluation, and treatment failures with several different drug regimens-metoclopramide, desipramine, amantadine, cyclobenzaprine, phenytoin, and lorazepam-his hiccups were eventually controlled with a combination of baclofen and low-dose olanzapine therapy. Baclofen is a c-aminobutyric acid (GABA) analog that contains a phenylethylamine moiety. It is hypothesized that having both GABA and phenylethylamine properties activates inhibitory neurotransmitters, most notably GABA, which may in turn block the hiccup stimulus. The exact mechanism through which olanzapine is effective in patients with hiccups is not fully understood. It is thought that the effect is, in part, due to serotonin augmenting phrenic motoneuronal activity on the reflex arcs involved in the generation of hiccups within the spinal cord. In addition, since olanazapine is a dopamine antagonist, particularly a dopamine D2-receptor antagonist, this could also have played a role in its effectiveness in treating our patient. Strong evidence for a specific treatment regimen for intractable hiccups is lacking in the primary literature. Our case report adds to the available literature, as there are currently no published data on the use of combination therapy for the treatment of intractable hiccups, and the combination of baclofen and olanzapine significantly improved our patient's quality of life.",2014-01,01/07/2022 10:40,01/07/2022 10:40,,E4-E8,,1,34,,,,,,,,,,,,,,WOS:000337518800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7UU7IXTT,journalArticle,2017,"Olguin, P; Fuentes, M; Gabler, G; Guerdjikova, AI; Keck, PE; McElroy, SL",Medical comorbidity of binge eating disorder,EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY,,1124-4909,10.1007/s40519-016-0313-5,,"Purpose To gain further understanding of the general medical comorbidity of binge eating disorder (BED) beyond its association with obesity. Method We reviewed studies of general medical comorbidity in people with BED or clinically significant binge eating behavior beyond obesity. We also reviewed studies of BED in specific medical conditions. Results Three broad study categories of medical comorbidity in BED were found: cross-sectional studies of medical conditions in BED; prospective studies of medical conditions in BED; and studies of BED in specific medical conditions. Cross-sectional epidemiologic data suggest that BED is associated with medical conditions related to obesity, including diabetes, hypertension, dyslipidemias, sleep problems/disorders, and pain conditions, and that BED may be related to these conditions independent of obesity and co-occurring psychiatric disorders. Prospective data suggest that BED may be associated with type 2 diabetes and metabolic syndrome. BED or binge eating behavior is also associated with asthma and gastrointestinal symptoms and disorders, and among women, menstrual dysfunction, pregnancy complications, intracranial hypertension, and polycystic ovary syndrome. Conclusions BED is associated with substantial medical comorbidity beyond obesity. Further study of the general medical comorbidity of BED and its relationship to obesity and co-occurring psychiatric disorders is greatly needed.",2017-03,01/07/2022 10:40,01/07/2022 10:40,,13-26,,1,22,,,,,,,,,,,,,,WOS:000396033400003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QH8V28BP,journalArticle,2021,"Moroi, MK; Ruzieh, M; Ahmed, A; Kanjwal, S; Kanjwal, K",Prevention and Management of Supine Hypertension in Patients With Orthostatic Hypotension,AMERICAN JOURNAL OF THERAPEUTICS,,1075-2765,10.1097/MJT.0000000000001054,,"Background: Orthostatic hypotension (OH) is a potentially debilitating condition caused by dysfunction of the autonomic nervous system, which is essential for the physiologic response to orthostatic posture. In addition to OH, autonomic dysfunction may also be associated with the development of concurrent supine hypertension (SH). Areas of Uncertainty: This paradoxical effect speaks to the complexity of the pathogenesis of autonomic disease and greatly complicates management of these patients. Clinicians are faced with a dilemma because aggressive treatment of orthostatic intolerance can worsen supine hypertension and attempts to control supine hypertension can worsen orthostatic intolerance. Data Sources: Systematic review of the published literature. Prevention of Supine Hypertension: Patients should aim to avoid known stressors, perform physical maneuvers (eg, slowly getting up from bed, sleeping with head of bed elevated), manage underlying related conditions (eg, diabetes mellitus), and exercise. Management of Supine Hypertension: With failure of conservative management, patients may advance to pharmacologic therapy. It is important to understand the underlying suspected etiology of the syndrome of supine hypertension and OH (SH-OH) to select promising pharmacologic agents. This article reviews medical treatment options to work toward achieving a better quality of life for patients afflicted with this disease. Although clonidine and beta-blockers can be used to treat hypertension without causing significant hypotension, midodrine, pyridostigmine, and droxidopa may be helpful in preventing OH. Conclusion: The etiology and severity of autonomic dysfunction vary widely between patients, suggesting a need for an individualized treatment approach. Achieving perfect blood pressure control is not a realistic goal. Rather, treatment should be aimed at improving the patient's quality of life and decreasing their risk of injury and organ damage.",2021-03,01/07/2022 10:40,01/07/2022 10:40,,E228-E231,,2,28,,,,,,,,,,,,,,WOS:000656628700009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A4FXRMLJ,journalArticle,2017,"Boyle, T; Vallance, JK; Buman, MP; Lynch, BM","Reallocating Time to Sleep, Sedentary Time, or Physical Activity: Associations with Waist Circumference and Body Mass Index in Breast Cancer Survivors",CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION,,1055-9965,10.1158/1055-9965.EPI-16-0545,,"Background: Moderate-to-vigorous intensity physical activity (MVPA) is inversely associated with waist circumference and body mass index (BMI) among breast cancer survivors. Limited research has focused on behaviors that account for larger portions of the day [sleep, sedentary time, and light-intensity physical activity (LPA)]. We investigated the interdependent associations of self-reported sleep, objectively assessed prolonged and short bouts of sedentary time, total LPA, and total MVPA with waist circumference and BMI. Methods: A cross-sectional sample of breast cancer survivors (N = 256, mean age = 60 years; mean time since diagnosis = 3 years) wore an Actigraph GT3X+ accelerometer during waking hours for 7 days. Participants completed the Pittsburgh Sleep Quality Index and self-reported their waist circumference, height, and weight. An isotemporal substitution approach was used in linear regression models to explore the associations of reallocating time to sleep, sedentary and active behaviors on waist circumference, and BMI, after adjusting for potential confounders. Results: Reallocating 30 minutes to MVPA was significantly associated with lower waist circumference when allocated from sleep (-2.50 cm), prolonged sedentary time (-2.51 cm), or LPA (-2.71 cm). Reallocating 30 minutes of prolonged sedentary time to nonprolonged sedentary time was significantly associated with lower waist circumference (-0.94 cm). Similar results were observed for BMI. Conclusions: Reallocating 30 minutes to MVPA was associated with significantly lower waist circumference and BMI, as was reallocating 30 minutes of prolonged sedentary time to 30 minutes of nonprolonged sedentary time. Impact: Increasing MVPA levels and decreasing time spent in prolonged, unbroken sedentary bouts may be avenues for improving body composition in this population. (C)2016 AACR.",2017-02,01/07/2022 10:40,01/07/2022 10:40,,254-260,,2,26,,,,,,,,,,,,,,WOS:000393909000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87Q22X74,journalArticle,2009,"Ali, MR; Rasmussen, JJ; Monash, JB; Fuller, WD",Depression is associated with increased severity of co-morbidities in bariatric surgical candidates,SURGERY FOR OBESITY AND RELATED DISEASES,,1550-7289,10.1016/j.soard.2008.10.015,,"Background: Depression is prevalent among bariatric surgical patients, and previous studies have suggested a link between depression and quality of life. Our objective was to examine the relationship between depression and other co-morbidities of obesity at a university hospital in the United States. Methods: Data were collected from 1368 consecutive patients evaluated for bariatric surgery. The demographic and co-morbidity profiles of these patients were compared between the depressed and nondepressed individuals. Depression was defined as an Assessment of Obesity-Related Co-morbidities score of >= 3, signifying that the patient required medical treatment for (score of 3) or had complications of (score of 4-5) depression. Results: The prevalence of depression among these patients was 36%. The mean age of the patients with depression was older (44.3 +/- 9.4 versus 42.2 +/- 9.6, P < .05), but the mean body mass index was similar. Depression was more prevalent among the female patients (37.4% versus 29.6%, P < .05). Diabetes mellitus, hypertension, polycystic ovarian syndrome, idiopathic intracranial hypertension, and obesity hypoventilation syndrome occurred with similar frequency and severity in persons with and without depression. The analysis revealed a significantly greater prevalence and severity of dyslipidemia (P < .05), gastroesophageal reflux disease (P < .05), back pain (P < .0001), joint pain (P < .05), sleep apnea (P < .01), stress incontinence (P < .01), and hernia (P < .05) among patients with depression. Overall, patients with depression had more co-morbidities per patient (5.46 versus 4.55) and a greater likelihood of severe or complicated co-morbidifies (2.67 versus 1.89 per patient). Conclusion: This report has characterized a link between depression and other co-morbidities in bariatric surgical patients. This association was independent of the body mass index. Although a causal relationship could not yet be identified, our findings indicate that depression, in this patient population, is associated with a greater prevalence and increased severity of medical co-morbidities that express distinct physical symptoms. (Surg Obes Relat Dis 2009;5:559-564.) (C) 2009 American Society for Metabolic and Bariatric Surgery. All rights reserved.",2009-09,01/07/2022 10:40,01/07/2022 10:40,,559-564,,5,5,,,,,,,,,,,,,,WOS:000270534900010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HAHHEXQ7,journalArticle,2020,"Zaghloul, H; Chagoury, O; Elhadad, S; Ahmed, SH; Suleiman, N; Al Naama, A; El Nahas, K; Al Hamaq, A; Charlson, M; Wells, MT; Al Abdulla, S; Abou-Samra, AB; Taheri, S",Clinical and metabolic characteristics of the Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I) randomised clinical trial cohort,BMJ OPEN,,2044-6055,10.1136/bmjopen-2020-041386,,"Objectives Diabetes Intervention Accentuating Diet and Enhancing Metabolism-I (DIADEM-I) is the first randomised controlled trial (RCT) in the Middle East and North Africa (MENA) region testing the effectiveness of an intensive lifestyle intervention (ILI) for weight loss and diabetes remission. We report on the recruitment process and baseline characteristics of the DIADEM-I cohort based on origin (Middle East vs North Africa), and waist circumference. Design DIADEM-I is an open-label randomised, controlled, parallel group RCT recruiting young individuals (18-50 years) with early type 2 diabetes (<= 3 years since diagnosis) originating from MENA. Individuals from primary care were randomised to usual medical care or ILI (total dietary replacement phase using meal replacement products, followed by staged food reintroduction and physical activity support). The primary outcome is weight loss at 12 months. Other outcomes are glycaemic control and diabetes remission. Setting Primary care, Qatar. Participants 147 (73% men) randomised within DIADEM-I who were included in the final trial data analysis. Outcome measures Recruitment metrics, and baseline clinical and metabolic characteristics. Results Of 1498 people prescreened, 267 (18%) were invited for screening and 209 (78%) consented. 173 (83%) were eligible. 15 (7%) withdrew before randomisation and the remaining 158 were randomised. Mean age was 42.1 (SD 5.6) years and mean body mass index was: 36.3 (5.5) kg/m(2) (women) and 34.4 (5.4) kg/m(2) (men). Mean diabetes duration was 1.8 (1.0) years and mean glycosylated haemoglobin (HbA1c) was 7.0% (1.30) (52.5 mmol/mol (SD 14.3)). Participants originated from 13 countries. Those from North Africa reported greater physical activity and had lower family history of diabetes. 90% of subjects were taking diabetes medications and 31% antihypertensives. Those with greater waist circumference had significantly higher insulin resistance and lower quality of life. Conclusion Recruitment of participants originating from the MENA region into the RCT was successful, and study participation was readily accepted. While DIADEM-I participants originated from 13 countries, there were few baseline differences amongst participants from Middle East versus North Africa, supporting generalisability of RCT results.",2020,01/07/2022 10:40,01/07/2022 10:40,,,,12,10,,,,,,,,,,,,,,WOS:000600203000020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EQD6FAWQ,journalArticle,2011,"Rosenbaum, S; Nguyen, D; Lenehan, T; Tiedemann, A; van der Ploeg, HP; Sherrington, C",Exercise augmentation compared to usual care for Post Traumatic Stress Disorder: A Randomised Controlled Trial (The REAP study: Randomised Exercise Augmentation for PTSD),BMC PSYCHIATRY,,1471-244X,10.1186/1471-244X-11-115,,"Background: The physical wellbeing of people with mental health conditions can often be overlooked in order to treat the primary mental health condition as a priority. Exercise however, can potentially improve both the primary psychiatric condition as well as physical measures that indicate risk of other conditions such as diabetes mellitus and cardiovascular disease. Evidence supports the role of exercise as an important component of treatment for depression and anxiety, yet no randomised controlled trials (RCT's) have been conducted to evaluate the use of exercise in the treatment of people with post traumatic stress disorder (PTSD). This RCT will investigate the effects of structured, progressive exercise on PTSD symptoms, functional ability, body composition, physical activity levels, sleep patterns and medication usage. Methods and design: Eighty participants with a Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD will be recruited. Participants will have no contraindications to exercise and will be cognitively able to provide consent to participate in the study. The primary outcome measures will be PTSD symptoms, measured through the PTSD Checklist Civilian (PCL-C) scale. Secondary outcome measures will assess depression and anxiety, mobility and strength, body composition, physical activity levels, sleep patterns and medication usage. All outcomes will be assessed by a health or exercise professional masked to group allocation at baseline and 12 weeks after randomisation. The intervention will be a 12 week individualised program, primarily involving resistance exercises with the use of exercise bands. A walking component will also be incorporated. Participants will complete one supervised session per week, and will be asked to perform at least two other non-supervised exercise sessions per week. Both intervention and control groups will receive all usual non-exercise interventions including psychotherapy, pharmaceutical interventions and group therapy. Discussion: This study will determine the effect of an individualised and progressive exercise intervention on PTSD symptoms, depression and anxiety, mobility and strength, body composition, physical activity levels, sleep patterns and medication usage among people with a DSM-IV diagnosis of PTSD.",22/07/2011,01/07/2022 10:40,01/07/2022 10:40,,,,,11,,,,,,,,,,,,,,WOS:000293590400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZCMUCN2K,journalArticle,2015,"Swerdlow, DI; Preiss, D; Kuchenbaecker, KB; Holmes, MV; Engmann, JEL; Shah, T; Sofat, R; Stender, S; Johnson, PCD; Scott, RA; Leusink, M; Verweij, N; Sharp, SJ; Guo, YR; Giambartolomei, C; Chung, C; Peasey, A; Amuzu, A; Li, K; Palmen, J; Howard, P; Cooper, JA; Drenos, F; Li, YR; Lowe, G; Gallacher, J; Stewart, MCW; Tzoulaki, I; Buxbaum, SG; Daphne, LV; Forouhi, NG; Onland-Moret, NC; van der Schouw, YT; Schnabel, RB; Hubacek, JA; Kubinova, R; Baceviciene, M; Tamosiunas, A; Pajak, A; Topor-Madry, R; Stepaniak, U; Malyutina, SA; Baldassarre, D; Sennblad, B; Tremoli, E; de Faire, U; Veglia, F; Ford, I; Jukema, JW; Westendorp, RGJ; de Borst, GJ; de Jong, PA; Algra, A; Spiering, W; Maitland-van der Zee, AH; Klungel, OH; de Boer, A; Doevendans, PA; Eaton, CB; Robinson, JG; Duggan, D; Kjekshus, J; Downs, JR; Gotto, AM; Keech, AC; Marchioli, R; Tognoni, G; Sever, PS; Poulter, NR; Waters, DD; Pedersen, TR; Amarenco, P; Nakamura, H; McMurray, JJV; Lewsey, JD; Chasman, DI; Ridker, PM; Maggioni, AP; Tavazzi, L; Ray, KK; Seshasai, SRK; Manson, JE; Price, JF; Whincup, PH; Morris, RW; Lawlor, DA; Smith, GD; Ben-Shlomo, Y; Schreiner, PJ; Fornage, M; Siscovick, DS; Cushman, M; Kumari, M; Wareham, NJ; Verschuren, WMM; Redline, S; Patel, SR; Whittaker, JC; Hamsten, A; Delaney, JA; Dale, C; Gaunt, TR; Wong, A; Kuh, D; Hardy, R; Kathiresan, S; Castillo, BA; van der Harst, P; Brunner, EJ; Tybjaerg-Hansen, A; Marmot, MG; Krauss, RM; Tsai, M; Coresh, J; Hoogeveen, RC; Psaty, BM; Lange, LA; Hakonarson, H; Dudbridge, F; Humphries, SE; Talmud, PJ; Kivimaki, M; Timpson, NJ; Langenberg, C; Asselbergs, FW; Voevoda, M; Bobak, M; Pikhart, H; Wilson, JG; Reiner, AP; Keating, BJ; Hingorani, AD; Sattar, N; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium","HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials",LANCET,,0140-6736,10.1016/S0140-6736(14)61183-1,,"Background Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. Methods We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis. Findings Data were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0.06 mmol/L (95% CI 0.05-0.07) lower LDL cholesterol and higher body weight (0.30 kg, 0.18-0.43), waist circumference (0.32 cm, 0.16-0.47), plasma insulin concentration (1.62%, 0.53-2.72), and plasma glucose concentration (0.23%, 0.02-0.44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1.02, 95% CI 1.00-1.05); the rs12916-T allele association was consistent (1.06, 1.03-1.09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0.92 mmol/L (95% CI 0.18-1.67) at 1-year of follow-up, increased bodyweight by 0.24 kg (95% CI 0.10-0.38 in all trials; 0.33 kg, 95% CI 0.24-0.42 in placebo or standard care controlled trials and 0.15 kg, 95% CI 0.39 to 0.08 in intensive-dose vs moderate-dose trials) at a mean of 4. 2 years (range 1.9-6.7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1.12, 95% CI 1.06-1.18 in all trials; 1.11, 95% CI 1.03-1. 20 in placebo or standard care controlled trials and 1.12, 95% CI 1.04-1. 22 in intensive-dose vs moderate dose trials). Interpretation The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.",24/01/2015,01/07/2022 10:40,01/07/2022 10:40,,351-361,,9965,385,,,,,,,,,,,,,,WOS:000348509000028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TH6FWYVJ,journalArticle,2015,"de Cos, AI; Cardenas, JJ; Pelegrina, B; Roldan, MC; Calvo, I; Vazquez, C; Pallardo, LF",OBESITY ASSOCIATED RISK USING EDMONTON STAGING IN BARIATRIC SURGERY,NUTRICION HOSPITALARIA,,0212-1611,10.3305/nh.2015.31.1.8097,,"With a prevalence of Morbid Obesity of 1,2% of the Spanish population, the current criteria for Bariatric Surgery do not classify patients taking into consideration co-morbidities or functional status. We need new staging systems useful in predicting mortality and able to support prioritizing treatments. Aim: Applying Edmonton staging system to patients awaiting Bariatric Surgery. Method: Data collected from 81 patients from 20112013 after pre-surgery protocol. Weight, height, waist, BMI, biochemical parameters and blood pressure are registered. Also taken down are hepatic, renal, osteoarticular diseases, sleep-apnea syndrome and/or gastro-oesophageal reflux, if present. Edmonton staging of ten variables is applied to each patient. Results: 81 patients: 67% women, average age 47y, 18% below 30y. Average BMI of 47,90% of patients have a BMI >40. 34% of patients show sleep-apnea syndrome and 25% gastro-oesophageal reflux. 9% of the patients have a BMI >45, diabetes mellitus and sleep-apnea syndrome. Applying the Edmonton Staging, nine patients (11%) are in the highest risk range (stage 3), 70% are in the high-risk range (stage 2) and 15 patients (18%) are included in the low-risk range. No patient was found to be in stage 0 without obesity risk factors. Conclusions: The Edmonton staging system provides us with information on presence or extent of co-morbidities that guide decision making in individuals. The mortality-predictive ability of Edmonton proposal could help to assist in determining the urgency of Bariatric Surgery and establish better criteria to prioritize these group of patients.",2015-01,01/07/2022 10:40,01/07/2022 10:40,,196-202,,1,31,,,,,,,,,,,,,,WOS:000348270100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZDDLMGF6,journalArticle,2021,"Thakur, U; Bhansali, A; Gupta, R; Rastogi, A","Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study",OBESITY SURGERY,,0960-8923,10.1007/s11695-020-04850-4,,"Purpose Both laparoscopic sleeve gastrectomy (LSG) and liraglutide cause a significant weight loss. We evaluated the effect of liraglutide in comparison with placebo on total weight loss (TWL) and excess body weight loss (EWL) and when added in initial weight loss period after LSG in obese individuals. Material and Methods Participants with BMI > 30 kg/m(2)undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months. Weight, BMI, %TWL, %EWL, HbA1c, fasting plasma glucose, HOMA-IR, resolution of type 2 diabetes mellitus, hypertension, dyslipidaemia, sleep apnea and quality of life were evaluated. Primary end point was %TWL and % EWL at post-operative 6 months. Results Thirty participants underwent LSG, and 23 were randomised to receive liraglutide (n = 12) or placebo (n = 11).The mean dose of liraglutide in L-L group was 1.41 +/- 0.49 mg/day. Patients in L-L group had %TWL of 28.2 +/- 5.7 and %EWL of 58.7 +/- 14.3 as compared with 23.2 +/- 6.2 (p = 0.116) and 44.5 +/- 8.6 (p = 0.043) in L-P group at 24 weeks, respectively. BMI decreased by 11.7 +/- 3.5 in L-L group compared with 9.5 +/- 4.0 in L-P group (p = 0.287). All patients with diabetes or pre-diabetes had resolution of dysglycemia in the L-L group as compared with 50% in L-P group. However, there was no significant difference in resolution of other obesity-related comorbidities between two groups at 24-week follow-up. Conclusion Liraglutide added early after LSG significantly augments weight loss from LSG in obese individuals.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,84-92,,1,31,,,,,,,,,,,,,,WOS:000547784900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
APEQ9U9R,journalArticle,2019,"Oftedal, S; Kolt, GS; Holliday, EG; Stamatakis, E; Vandelanotte, C; Brown, WJ; Duncan, MJ","Associations of health-behavior patterns, mental health and self-rated health",PREVENTIVE MEDICINE,,0091-7435,10.1016/j.ypmed.2018.11.017,,"Diet quality, physical activity, alcohol use, smoking, sleep and sitting-time are behaviors known to influence health. The aims of this study were to identify how these behaviors co-occur to form distinct health-behavior patterns, and to investigate the relationship between these patterns, and mental and self-rated health. Members of the Australian 10,000 Steps project were invited to participate in an online survey in November-December 2011. The participants self-reported demographic and behavioral characteristics (fruit and vegetable intake, fast food, soft drink and alcohol consumption, smoking, physical activity, sitting-time and sleep), frequency of mental distress and self-rated health. Latent Class Analysis was used to identify health-behavior patterns. Latent class regression was used to examine relationships between behavior patterns, mental and self-rated health, and socio-demographic and economic factors. Data were analyzed in October 2017. Complete datasets were obtained from 10,638 participants. Four latent classes were identified, characterized by 'Low-Risk Behavior', 'Poor Sleep, Low-Risk Daytime Behavior', 'Sound Sleep, High-Risk Daytime Behavior' and 'High-Risk Behavior'. The latter two classes, both characterized by high-risk daytime behaviors, were associated with poor self-rated health. Participants in classes with high-risk daytime behaviors were more likely to be younger, non-partnered, non-university educated, from lower income households and work longer hours. Classes characterized by poor sleep quality were associated with higher frequency of mental distress. Findings suggest that experiencing poor sleep is partly independent of daytime behaviors, demographic and socioeconomic factors, but has a strong association with mental health.",2019-01,01/07/2022 10:40,01/07/2022 10:40,,295-303,,,118,,,,,,,,,,,,,,WOS:000454933300042,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JM4UIWYZ,journalArticle,2019,"Bonn, SE; Lof, M; Ostenson, CG; Lagerros, YT","App-technology to improve lifestyle behaviors among working adults - the Health Integrator study, a randomized controlled trial",BMC PUBLIC HEALTH,,1471-2458,10.1186/s12889-019-6595-6,,"BackgroundMobile health, mHealth is recognized as a strategy to improve lifestyle behaviors. Research targeting specific lifestyle behaviors has shown that interventions using smartphones can be effective. However, few studies have evaluated solutions with multicomponent interventions, tailoring the intervention to the specific needs of the participant using a combination of mHealth and conventional treatment. To accomplish this, we developed Health Integrator, an mHealth platform with services and offers in the areas of diet, physical activity, sleeping habits, stress, alcohol and tobacco use. In the system, the user selects an area of intervention together with a health coach and set weekly goals. This study protocol presents the design and methodology of the Health Integrator Study, a randomized controlled trial to promote improved lifestyle behaviors.MethodsA three-arm parallel randomized controlled trial (1:1:1) is conducted in the Stockholm County, Sweden. In total, 209 employees at a four different companies representing both white and blue collar workers, have been recruited.Participants are randomized to either a control group or to one of two intervention groups receiving a 3-month lifestyle behavior change program including either 1) use of Health Integrator and monthly health coaching sessions or 2) only Health Integrator.At baseline and follow-up after 3- and 6-months, all participants answer questionnaires assessing lifestyle behaviors and quality of life. At baseline and the 3-month follow-up (end of intervention period), weight, height, waist circumference and blood pressure are measured, and all participants wear an Actigraph accelerometer for 7days to assess physical activity. Blood lipid profile and HbA1c are measured among all participants at baseline. If baseline measures fall outside the normal range, a second measurement is done after 3months.DiscussionThe Health Integrator Intervention Study will evaluate if a personalized intervention combining mHealth and conventional programs for lifestyle change, with or without additional health coach sessions, can improve lifestyle behaviors and quality of life. Based on the results from this trial, Health Integrator can easily be implemented within a broad public.Trial registrationClinicalTrials.gov Identifier: NCT03579342. Retrospectively registered, first submitted May 8, 2018.",07/03/2019,01/07/2022 10:40,01/07/2022 10:40,,,,,19,,,,,,,,,,,,,,WOS:000460787400007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LIPAPZV9,journalArticle,2020,"Felsenreich, DM; Bichler, C; Langer, FB; Gachabayov, M; Prager, G","Sleeve Gastrectomy: Surgical Technique, Outcomes, and Complications",SURGICAL TECHNOLOGY INTERNATIONAL-INTERNATIONAL DEVELOPMENTS IN SURGERY AND SURGICAL RESEARCH,,1090-3941,,,"The number of bariatric surgical procedures performed worldwide increases every year and has recently exceeded 685,000. Over 50% of these are laparoscopic sleeve gastrectomy (SG), and Roux-en-Y gastric bypass accounts for an additional 30%. Bariatric/metabolic surgery seeks to achieve not only weight loss and the remission of comorbidities, such as diabetes mellitus type II, arterial hypertension, sleep apnea, risk of cancer, non-alcoholic liver steatosis, etc., but also improvements in the patient's quality of life. SG is mainly a restrictive procedure consisting of the resection and removal of a major part of the stomach, which has an additional impact on hormones such as Ghrelin and Glucagon-like Peptide 1. The first part of this article focuses on patient preparation before a bariatric procedure with mandatory and additional examinations to decrease the patient's risk. Next, the surgical technique itself, including positioning of the patient, positioning of the trocars and related tips and tricks, and the postoperative course are described. The second part discusses the outcomes of SG, including weight loss, remission of comorbidities and quality of life. Further possible acute complications of SG such as leaks, bleeding or stenoses as well as long-term complications (reflux, weight regain and malnutrition) and respective treatments are also described. In conclusion, SG is an effective procedure for weight loss with a low risk for the patient to develop malnutrition. In terms of post-operative care, regular check-ups are vital to ensure a positive outcome as well as for the early detection of possible issues. Reflux and weight regain are common issues with SG in a long-term follow-up; thus, patients should be selected carefully for this procedure.",2020-05,01/07/2022 10:40,01/07/2022 10:40,,,,,36,,,,,,,,,,,,,,WOS:000587503100065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YQ2AZBR6,journalArticle,2020,"Wabitsch, M; Schnurbein, JV; Vollbach, H; Lennerz, B; Weyhreter, H; Wiegand, S; Kiess, W; Hebebrand, J; Brandt, S",Innovative medical care concepts for adolescents with severe obesity,BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ,,1436-9990,10.1007/s00103-020-03167-y,,"There is no convincing, science-based treatment or care concept for adolescents with severe obesity in Germany or other countries. The affected young people have an increased risk of numerous somatic comorbidities (e.g. type 2 diabetes mellitus, orthopaedic disorders and sleep apnoea syndrome), mental disorders (e.g. depression and anxiety disorders, social phobia and self-harming behaviour), as well as social isolation (e.g. avoidance of school and unemployment), which develops due to functional impairments and stigmatisation. Despite the negative effects of severe obesity in adolescence, these young people are medically difficult to reach and treat. Only a small percentage of patients actively seek treatment. Aware of these difficulties, the German multi-centre Youth with Extreme Obesity (YES) Study (funded by the German Ministry of Education and Science; 01 GI 1120 & x202f;A and B) was carried out between 2012 and 2019 with the aim of improving care concepts for this neglected group of young people. In our article, we show possible supply routes. These consist of accompanying the adolescents and treating their comorbidities, sustainable lifestyle interventions in a protected environment and treatment for weight reduction through bariatric surgery. The overriding goals for patients are an increase in self-esteem, early diagnosis and treatment of secondary diseases and integration into the training and labour market.",2020-07,01/07/2022 10:40,01/07/2022 10:40,,831-838,,7,63,,,,,,,,,,,,,,WOS:000539700600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EIK96SQN,journalArticle,2014,"Neff, KJ; Chuah, LL; Aasheim, ET; Jackson, S; Dubb, SS; Radhakrishnan, ST; Sood, AS; Olbers, T; Godsland, IF; Miras, AD; le Roux, CW",Beyond Weight Loss: Evaluating the Multiple Benefits of Bariatric Surgery After Roux-en-Y Gastric Bypass and Adjustable Gastric Band,OBESITY SURGERY,,0960-8923,10.1007/s11695-013-1164-z,,"Background Despite the evidence for benefits beyond weight loss following bariatric surgery, assessments of surgical outcomes are often limited to changes in weight and remission of type 2 diabetes mellitus. To address this shortfall in assessment, the King's Obesity Staging System was developed. This system evaluates the individual in severity stages of physical, psychological, socio-economic and functional disease. These are categorised into disease domains arranged so as to allow an alphabetic mnemonic as Airways, Body Mass Index (BMI), Cardiovascular, Diabetes, Economic, Functional, Gonadal, Health Status (perceived) and (body) Image. Methods In this cohort study, patients were assessed before and 12 months after surgery using the modified King's Obesity Staging Score. We studied 217 consecutive patients undergoing Roux-en-Y gastric bypass (RYGB; N = 148) and laparoscopic adjustable gastric band (LAGB; N = 69) using the modified King's Obesity Staging System to determine health benefits after bariatric surgery. Results Preoperatively, the groups had similar BMI, but the RYGB group had worse Airways, Cardiovascular, and Diabetes scores (p < 0.05). After surgery, RYGB and LAGB produced improvements in all scores. In a subgroup paired analysis matched for preoperative Airways, BMI, Cardiovascular, and Diabetes scores, both procedures showed similar improvements in all scores, except for BMI where RYGB had a greater reduction than LAGB (p < 0.05). Conclusions Both RYGB and LAGB deliver multiple benefits to patients as evaluated by the modified King's Obesity Staging System beyond BMI and glycaemic markers. A validated staging score such as the modified King's Obesity Staging System can be used to quantify these benefits.",2014-05,01/07/2022 10:40,01/07/2022 10:40,,684-691,,5,24,,,,,,,,,,,,,,WOS:000334268000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LW972MY2,bookSection,2006,"Vgontzas, AN; Bixler, EO; Chrousos, GP",Obesity-related sleepiness and fatigue - The role of the stress system and cytokines,"STRESS, OBESITY, AND METABOLIC SYNDROME",0077-8923,,,,"Obesity has epidemic proportions in Western societies and, because of its significant association with morbidity and mortality, is a major public health issue. Excessive daytime sleepiness (EDS) and fatigue (tiredness without increased sleep propensity)-which have been associated with obesity-have a significant impact on individual wellbeing and public safety. In this article, we review data that challenge the belief that sleep apnea and sleep disruption per se are the primary determinants of obesity-related daytime sleepiness and fatigue. Specifically, it appears that obesity per se is associated with objective and subjective daytime sleepiness compared to normal-weight controls regardless of sleep apnea and sleep loss. Indeed, obese patients without sleep apnea are sleepier compared to nonobese controls whereas within the morbidly obese, those who have high sleep efficiency at night are sleepier than those who have low sleep efficiency. In addition, in recent studies based on large random samples of the general population, the primary determinants of subjective EDS were depression and metabolic disturbances, that is, obesity/diabetes, and not sleep apnea or objective sleep disruption. Furthermore, sleepiness and fatigue are very prevalent in conditions associated with insulin resistance, for instance, the polycystic ovary syndrome (PCOS), independently of sleep apnea or obesity, or in conditions of insufficient physical activity. On the basis of these data, we propose that obesity-related objective daytime sleepiness and fatigue are associated primarily with metabolic and psychological factors and less with sleep apnea and sleep disruption per se. Furthermore, we suggest that objective sleepiness is primarily related to metabolic factors, whereas fatigue appears to be related to psychological distress. Finally, based on data from studies in normal controls and patients with sleep disorders, we propose that the interaction of the hypothalamic-pituitary-adrenal (HPA) axis and proinflammatory cytokines determines the level of sleep/arousal within the 24-h cycle, that is, ""hypercortisolemia"" plus hypercytokinemia is associated with low sleep efficiency and fatigue, whereas ""eucortisolemia"" or ""hypocortisolemia"" plus hypercytokinemia is associated with high sleep efficiency and objective sleepiness.",2006,01/07/2022 10:40,01/07/2022 10:40,,329-344,,,1083,,,,,,,,,,,,,,WOS:000244102900021,,,DOI: 10.1196/annals.1367.023,,,,,,"Chrousos, GP; Tsigos, C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EUELKP92,journalArticle,2010,"Xochilcal-Morales, M; Castro, EM; Guajardo-Rosas, J; Obregon, TN; Acevedo, JC; Chucan, JMG; Plancarte-Sanchez, R; Davila, G; Wajsbrot, D; Guerrero, M; Vinueza, R","A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America",INTERNATIONAL JOURNAL OF CLINICAL PRACTICE,,1368-5031,10.1111/j.1742-1241.2010.02389.x,,"P>Aims: The objective of this study was to evaluate the safety and efficacy of pregabalin at flexible doses of 150-600 mg/day in Latin American patients with neuropathic pain. Methods: A prospective, multicentre, open-label, non-comparative study included patients age >= 18 years diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathic pain (PNP), or human immunodeficiency virus-related PNP. Eligible patients (N = 121) had a score of >= 40 mm on the visual analogue scale and a daily pain rating scale (DPRS) score of >= 4 throughout screening. Patients received flexible-dose pregabalin (150-600 mg/day) for 12 weeks, which included a 4-week dose-adjustment phase. The primary efficacy measure was change from baseline to end of treatment/last observation carried forward (EOT/LOCF) in weekly mean pain score on the DPRS. Secondary efficacy measures included pain, anxiety, sleep interference, treatment satisfaction and Patient and Clinician Global Impression of Change. Results: Pregabalin significantly reduced the weekly mean pain score on DPRS from baseline to EOT/LOCF [-3.8 (95% CI: -4.2 to -3.3); p < 0.0001]. Reductions from baseline to EOT/LOCF were observed for all secondary efficacy outcomes (p < 0.0001). Pain and sleep interference were significantly improved compared with baseline across all weeks of the study, as early as 1 week after initiation of pregabalin (p < 0.0001). The most common adverse events (AEs) were somnolence, dizziness, weight gain and peripheral oedema. Nine (7.4%) patients discontinued the study because of AEs and 25 (20.7%) temporarily stopped or reduced their pregabalin dose because of AEs. Conclusions: Flexible-dose pregabalin (150-600 mg/day) significantly reduced pain and anxiety and improved sleep and was generally well tolerated in Latin American patients with neuropathic pain.",2010-08,01/07/2022 10:40,01/07/2022 10:40,,1301-1309,,9,64,,,,,,,,,,,,,,WOS:000279901200022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y59NMJXP,journalArticle,2021,"Shah, AF; Chawla, I; Goel, K; Gollen, R; Singh, R",Impact of Obesity on Female Sexual Dysfunction: A Remiss,CURRENT WOMENS HEALTH REVIEWS,,1573-4048,10.2174/1573404816999200917121519,,"The prevalence of obesity around the globe is increasing at such an alarming rate that WHO designated obesity as a major unattended public health problem worldwide. Obesity is associated with a greater risk of excessive fat related metabolic and endocrinal diseases related to a different set of illnesses and disabilities, including type 2 diabetes, cardiovascular diseases, kidney diseases, sleep apnea, arthritis, lung diseases and sexual disorders. Obesity is found to be associated with male and female sexual dysfunctions and several studies have indicated a positive correlation between obesity and sexual dysfunction among both males and females. The relationship between male obesity and sexual dysfunction has been widely discussed, whereas very little emphasis is laid on relationship between obesity and female sexual dysfunctions. Sexual dysfunctions are common and affects 20-50% of obese women. Particularly, female sexual dysfunction is a multi-factorial problem, including organic and psychological aspects involved. These disorders not only affect physical health of women, but to a greater extent, mental health is also affected. Considering this point of view, present review emphasizes the impact of obesity on female sexual dysfunctions.",2021,01/07/2022 10:40,01/07/2022 10:40,,,,1,17,,,,,,,,,,,,,,WOS:000612994300005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BRSDDGA9,journalArticle,2012,"Sethi, KD; Mehta, SH","A Clinical Primer on Restless Legs Syndrome: What We Know, and What We Don't Know",AMERICAN JOURNAL OF MANAGED CARE,,1088-0224,,,"Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a common sensorimotor disorder that may be idiopathic (primary) or secondary to a diverse group of conditions. The pathophysiology of primary RLS is only partly understood, but a strong association with brain iron deficiency possibly resulting in impaired dopaminergic function has been recognized. Genomic studies have established a genetic basis for primary RLS as well, and at least 42% of people with primary RLS possess a first-degree relative with the disorder. Secondary RLS is often associated with renal insufficiency, pregnancy, iron deficiency anemia, diabetic neuropathy, and Parkinson's disease. Approximately one-fourth of pregnant women experience RLS, with more intense symptoms experienced during the third trimester, and resolution of symptoms typically occurring within a few months after delivery, though RLS may resolve as early as 2 weeks after delivery. Restless legs syndrome is associated with increased prevalence of mood disturbances, sleep disturbances, and an impaired quality of life. The diagnosis of RLS involves 4 essential criteria related to a compelling urge to move the legs with an accompanying unpleasant sensation in the legs that is worse in the evening and at rest and improved by movement. Treatment of RLS incorporates both pharmacologic and nonpharmacologic approaches. Dopamine agonists are the mainstay of RLS treatment, but other therapies, including gabapentin, benzodiazepines, and low-potency opioids, are also commonly employed. (Am J Manag Care. 2012;18:S83-S88)",2012-08,01/07/2022 10:40,01/07/2022 10:40,,S83-S88,,5,18,,,,,,,,,,,,,,WOS:000309036500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39ZHNE7U,journalArticle,2012,"Wolever, RQ; Bobinet, KJ; McCabe, K; Mackenzie, ER; Fekete, E; Kusnick, CA; Baime, M",Effective and Viable Mind-Body Stress Reduction in the Workplace: A Randomized Controlled Trial,JOURNAL OF OCCUPATIONAL HEALTH PSYCHOLOGY,,1076-8998,10.1037/a0027278,,"Highly stressed employees are subject to greater health risks, increased cost, and productivity losses than those with normal stress levels. To address this issue in an evidence-based manner, worksite stress management programs must be able to engage individuals as well as capture data on stress, health indices, work productivity, and health care costs. In this randomized controlled pilot, our primary objective was to evaluate the viability and proof of concept for two mind-body workplace stress reduction programs (one therapeutic yoga-based and the other mindfulness-based), in order to set the stage for larger cost-effectiveness trials. A second objective was to evaluate 2 delivery venues of the mindfulness-based intervention (online vs. in-person). Intention-to-treat principles and 2 (pre and post) x 3 (group) repeated-measures analysis of covariance procedures examined group differences over time on perceived stress and secondary measures to clarify which variables to include in future studies: sleep quality, mood, pain levels, work productivity, mindfulness, blood pressure, breathing rate, and heart rate variability (a measure of autonomic balance). Two hundred and thirty-nine employee volunteers were randomized into a therapeutic yoga worksite stress reduction program, 1 of 2 mindfulness-based programs, or a control group that participated only in assessment Compared with the control group, the mind-body interventions showed significantly greater improvements on perceived stress, sleep quality, and the heart rhythm coherence ratio of heart rate variability. The two delivery venues for the mindfulness program produced basically equivalent results. Both the mindfulness-based and therapeutic yoga programs may provide viable and effective interventions to target high stress levels, sleep quality, and autonomic balance in employees.",2012-04,01/07/2022 10:40,01/07/2022 10:40,,246-258,,2,17,,,,,,,,,,,,,,WOS:000302330900012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9I8VDJB8,journalArticle,2010,"Cherian, D; Sachdeva, P; Fisher, RS; Parkman, HP",Abdominal Pain Is a Frequent Symptom of Gastroparesis,CLINICAL GASTROENTEROLOGY AND HEPATOLOGY,,1542-3565,10.1016/j.cgh.2010.04.027,,"BACKGROUND & AIMS: Although the most commonly recognized symptoms of gastroparesis (GP) are nausea and vomiting, patients also report abdominal pain We aimed to define the prevalence, severity, and quality of abdominal pain in GP and to correlate abdominal pain with gastric emptying (GE) and quality of life. METHODS: Patients presumed to have GP underwent 4-hour GE scintigraphy and upper endoscopy examinations and completed the following patient assessments of gastrointestinal symptoms (Patient Assessment of Upper Gastrointestinal Symptom Severity Index), abdominal pain questionnaires (Short-Form of the McGill Pain Questionnaire), and quality-of-life questionnaires RESULTS: The study group consisted of 68 patients (58 female; 10 male) with delayed GE (18 diabetic gastroparesis [DG] and 50 idiopathic gastroparesis [IG]) Abdominal pain was present in 90% of patients (89% DG, 90% IG) and nausea was present in 96% (100% DG, 94% IG) Abdominal pain was epigastric in 43% and umbilical in 13% Pain occurred daily in 43% and was constant in 38% Pain often was induced by eating (72%), was nocturnal (74%), and interfered with sleep (66%) Severity ranking of symptoms based on the Patient Assessment of Upper Gastrointestinal Symptom Severity Index was as follows abdominal fullness (3 8 +/- 0 2), bloating (3 6 +/- 0 2). nausea (3 6 +/- 0 2), upper abdominal discomfort (3 3 +/- 0 2), upper abdominal pain (3 0 +/- 0 2), and vomiting (2 2 +/- 0 2) Abdominal pain severity did not correlate with GE, but had moderate correlation with quality of life CONCLUSIONS: Abdominal pain is a frequent symptom in patients with GP, comparable with nausea and vomiting. Abdominal pain correlates with impaired quality of life but not with GE.",2010-08,01/07/2022 10:40,01/07/2022 10:40,,676-681,,8,8,,,,,,,,,,,,,,WOS:000280938200011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
USMD8UI4,journalArticle,2013,"Sanchez-Santos, R; Pereferrer, FS; Fernandez, SE; Dejardin, DD; Vilarrasa, N; Bernal, DF; de Adana, JCR; Noguera, CM; Garcia, AT",Is the morbid obesity surgery profitable in times of crisis? A cost-benefit analysis of bariatric surgery,CIRUGIA ESPANOLA,,0009-739X,10.1016/j.ciresp.2013.02.004,,"Morbid obesity is a serious health problem whose prevalence is increasing. Expensive comorbidities are associated to these patients, as well as a reduction in the survival. Bariatric surgery resolves the co-morbidities (type 2 diabetes mellitus, 86.6%; cardiovascular risk, 79.0%; obstructive sleep apnea syndrome, 83.6%; hypertension, 61.7%), reduces the mortality rate (among 31-40%), and increases the morbid obese patients survival over a 10-years period. It provides significant savings for the National Health System. The obese patients consume a 20% plus of health resources and 68% plus of drugs than general population. Bariatric surgery requires an initial investment (diagnosis-related group cost: 7,468 (sic)), but it is recovered in a cost-effectiveness ratio of 2.5 years. Significant savings are obtained from the third year. To the direct economic benefits associated with reduced health expenditures it should be added an increase in tax collection (sick leave and unemployment reduction is estimated in 18%, with a productivity increase of 57% for self-employed people). Bariatric surgery is one of the most cost- effective procedures in the healthcare system. (C) 2012 AEC. Published by Elsevier Espana, S.L. All rights reserved.",2013-10,01/07/2022 10:40,01/07/2022 10:40,,476-484,,8,91,,,,,,,,,,,,,,WOS:000325752200007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GJXNE6AE,journalArticle,2019,"Onakpoya, IJ; Thomas, ET; Lee, JJ; Goldacre, B; Heneghan, CJ",Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials,BMJ OPEN,,2044-6055,10.1136/bmjopen-2018-023600,,"Objective To assess the benefits and harms of pregabalin in the management of neuropathic pain. Design Rapid review and meta-analysis of phase III, randomised, placebo-controlled trials. Participants Adults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria. Interventions Pregabalin or placebo. Primary and secondary outcome measures Our primary outcomes were pain (as measured using validated scales) and adverse events. Our secondary outcomes were sleep disturbance, quality of life, Patient Global Impression of Change, Clinician Global Impression scale, anxiety and depression scores, overall discontinuations and discontinuations because of adverse events. Results We included 28 trials comprising 6087 participants. The neuropathic pain conditions studied were diabetic peripheral neuropathy, postherpetic neuralgia, herpes zoster, sciatica (radicular pain), poststroke pain and spinal cord injury-related pain. Patients who took pregabalin reported significant reductions in pain (numerical rating scale (NRS)) compared with placebo (standardised mean difference (SMD) -0.49 (95% CI -0.66 to -0.32, p< 0.00001), very low quality evidence). Pregabalin significantly reduced sleep interference scores (NRS) compared with placebo (SMD -0.38 (95% CI -0.50 to -0.26, p< 0.00001), moderate quality evidence. Pregabalin significantly increased the risk of adverse events compared with placebo (RR 1.33 (95% CI 1.23 to 1.44, p< 0.00001, low quality evidence)). The risks of experiencing weight gain, somnolence, dizziness, peripheral oedema, fatigue, visual disturbances, ataxia, non-peripheral oedema, vertigo and euphoria were significantly increased with pregabalin. Pregabalin was significantly more likely than placebo to lead to discontinuation of the drug because of adverse events (RR 1.91 (95% CI 1.54 to 2.37, p< 0.00001), low quality evidence). Conclusion Pregabalin has beneficial effects on some symptoms of neuropathic pain. However, its use significantly increases the risk of a number of adverse events and discontinuation due to adverse events. The quality of the evidence from journal publications is low.",2019-06,01/07/2022 10:40,01/07/2022 10:40,,,,1,9,,,,,,,,,,,,,,WOS:000471116800117,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XC6NIG92,journalArticle,2017,"Martinez, CH; Murray, S; Barr, RG; Bleecker, E; Bowler, RP; Christenson, SA; Comellas, AP; Cooper, CB; Couper, D; Criner, GJ; Curtis, JL; Dransfield, MT; Hansel, NN; Hoffman, EA; Kanner, RE; Kleerup, E; Krishnan, JA; Lazarus, SC; Leidy, NK; O'Neal, W; Martinez, FJ; Paine, R; Rennard, SI; Tashkin, DP; Woodruff, PG; Han, MK; Subpopulations & Intermediate Out",Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort,ANNALS OF THE AMERICAN THORACIC SOCIETY,,1546-3222,10.1513/AnnalsATS.201610-815OC,,"Rationale: Ever-smokers without airflow obstruction scores greater than or equal to 10 on the COPD Assessment Test (CAT) still have frequent acute respiratory disease events (exacerbation-like), impaired exercise capacity, and imaging abnormalities. Identification of these subjects could provide new opportunities for targeted interventions. Objectives: We hypothesized that the four respiratory-related items of the CAT might be useful for identifying such individuals, with discriminative ability similar to CAT, which is an eight-item questionnaire used to assess chronic obstructive pulmonary disease impact, including nonrespiratory questions, with scores ranging from 0 to 40. Methods: We evaluated ever-smoker participants in the Subpopulations and Intermediate Outcomes in COPD Study without airflow obstruction (FEV1/FVC >= 0.70; FVC above the lower limit of normal). Using the area under the receiver operating characteristic curve, we compared responses to both CAT and the respiratory symptom-related CAT items (cough, phlegm, chest tightness, and breathlessness) and their associations with longitudinal exacerbations. We tested agreement between the two strategies (kappa statistic), and we compared demographics, lung function, and symptoms among subjects identified as having high symptoms by each strategy. Results: Among 880 ever-smokers with normal lung function (mean age, 61 yr; 52% women) and using a CAT cutpoint greater than or equal to 10, we classified 51.8% of individuals as having high symptoms, 15.3% of whom experienced at least one exacerbation during 1-year follow-up. After testing sensitivity and specificity of different scores for the first four questions to predict any 1-year followup exacerbation, we selected cutpoints of 0-6 as representing a low burden of symptoms versus scores of 7 or higher as representing a high burden of symptoms for all subsequent comparisons. The four respiratory-related items with cutpoint greater than or equal to 7 selected 45.8% participants, 15.6% of whom experienced at least one exacerbation during follow-up. The two strategies largely identified the same individuals (agreement, 88.5%; kappa = 0.77; P< 0.001), and the proportions of high-symptoms subjects who had severe dyspnea were similar between CAT and the first four CAT questions (25.9% and 26.8%, respectively), as were the proportions reporting impaired quality of life (66.9% and 70.5%, respectively) and short walking distance (22.4% and 23.1%, respectively). There was no difference in area under the receiver operating characteristic curve to predict 1-year follow-up exacerbations (CAT score >= 10, 0.66; vs. four respiratory items from CAT >= 7 score, 0.65; P = 0.69). Subjects identified by either method also had more depression/anxiety symptoms, poor sleep quality, and greater fatigue. Conclusions: Four CAT items on respiratory symptoms identified high-risk symptomatic ever-smokers with preserved spirometry as well as the CAT did. These data suggest that simpler strategies can be developed to identify these high-risk individuals in primary care.",2017-05,01/07/2022 10:40,01/07/2022 10:40,,636-642,,5,14,,,,,,,,,,,,,,WOS:000412396800010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I7FE9NLB,journalArticle,2020,"Mutambudzi, M; Henkens, K",Chronic health conditions and work-related stress in older adults participating in the Dutch workforce,EUROPEAN JOURNAL OF AGEING,,1613-9372,10.1007/s10433-020-00554-x,,"The proportion of workers with chronic health conditions (CHCs) will increase over the years as pension reform is increasing the age of retirement in many European countries. This will increase the percentage of older adults with CHCs performing highly demanding work. This study sought to examine the association between common CHCs [cardiovascular disease (CVD), diabetes, arthritis, respiratory and sleep disorders] and three domains of work stress in older Dutch workers. This study used data from the first wave of the NIDI Pension Panel Study for working adults aged 60-65 years (n = 6793). Logistic regression models examined the strength of association between CHCs and (1) general work stress, (2) emotional, and (3) physical demands. All five CHC were independently associated with one or more domains of stress. After including all CHCs in the model, CVD, sleep disorders, and arthritis were significantly associated with general stress. Respiratory disorders, sleep disorders, and arthritis were significantly associated with physical demands. Diabetes (1.25, 95% CI 1.01-1.53), sleep disorders (1.99, 95% CI 1.72-2.31), and arthritis (1.18, 95% CI 1.06-1.31) were significantly associated with emotional demands. Our findings demonstrate that work stress is associated with prevalent CHCs, and these conditions are differentially associated with several domains of work stress in adults approaching retirement. More research is needed to understand the causal relationship between CHCs and work stress. Such research may provide insights for effective workplace and public health interventions to ensure that older workers remain physically and mentally healthy, and productive through their working years.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,499-508,,4,17,,,,,,,,,,,,,,WOS:000520050700002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y6ZA46LH,journalArticle,2010,"Katznelson, L",Approach to the Patient with Persistent Acromegaly after Pituitary Surgery,JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM,,0021-972X,10.1210/jc.2010-0670,,"The approach to a patient with acromegaly and persistent disease after surgery requires a complex diagnostic assessment. Acromegaly is a chronic and insidious disease that is associated with multisystem comorbidities, including cardiovascular disease, hypertension, sleep apnea syndrome, colon polyposis, arthropathy, and metabolic complications including glucose intolerance and type 2 diabetes mellitus. Patients also have a variety of signs and symptoms, including headache, arthralgias, carpal tunnel syndrome, sweating, fatigue, and psychological issues that impact significantly on quality of life. The recommended approach to the evaluation of the postoperative patient includes a biochemical assessment, with measurement of serum IGF-I along with a glucose-suppressed GH value, radiological assessment to determine location of residual tumor and presence of mass effects, a physical examination for evidence of skeletal and soft tissue overgrowth and related signs of acromegaly, and a thorough clinical assessment for the presence of comorbidities. Repeat surgery is indicated if there is residual tumor that is surgically accessible and there may be a chance for surgical cure, or if there are persistent mass effects upon the optic chiasm. Otherwise, medical therapy is indicated, utilizing somatostatin analogs, dopamine agonists, and pegvisomant, a GH receptor antagonist. Radiation therapy is usually relegated to situations where medical therapy is ineffective or poorly tolerated or where patients would prefer not to sustain the cost of long-term medical therapy. The choice of therapy requires close dialog among endocrinologists, neurosurgeons, radiation therapists, and neuroophthalmologists for optimal care of patients. (J Clin Endocrinol Metab 95: 4114-4123, 2010)",2010-09,01/07/2022 10:40,01/07/2022 10:40,,4114-4123,,9,95,,,,,,,,,,,,,,WOS:000281640300023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BZMJQ9NM,journalArticle,2018,"Chiu, HY; Wang, TS; Chen, PH; Hsu, SH; Tsai, YC; Tsai, TF",Psoriasis in Taiwan: From epidemiology to new treatments,DERMATOLOGICA SINICA,,1027-8117,10.1016/j.dsi.2018.06.001,,"Psoriasis is a common, chronic immune-mediated disorder that occurs worldwide. The prevalence of psoriasis in Taiwan is lower than that in Caucasian countries. Nevertheless, an increasing trend in the prevalence of psoriasis and psoriatic arthritis has been observed in Taiwan over the past decade. Accumulating studies have also suggested that psoriasis is not a disease limited to the skin and joints but has far-reaching systemic effects, associated with a higher prevalence of comorbid diseases, such as cardiovascular diseases, diabetes mellitus, metabolic syndrome, depression, and chronic kidney disease, than in the normal population. To date, our understanding of the mechanisms linking psoriasis and comorbidities remains far from complete. Psoriasis and its comorbid diseases confer substantial disease and health care burdens and have a significant negative impact on the quality of life of affected patients. The discovery of new, promising drugs has revolutionized psoriasis treatment, but patients still have unmet needs that require further investigation. Studies specifically on the Taiwanese population with psoriasis remain scarce. Herein, we review the medical literature, with a focus on studies examining the Taiwanese population, with regard to epidemiology, comorbidities, and effects of antipsoriatic agents on comorbidities, as well as the efficacy and safety of novel antipsoriatic treatments for patients with psoriasis. Copyright (C) 2018, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC.",2018-09,01/07/2022 10:40,01/07/2022 10:40,,115-123,,3,36,,,,,,,,,,,,,,WOS:000442419200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HYBWACBH,journalArticle,2013,"Pata, G; Crea, N; Di Betta, E; Bruni, O; Vassallo, C; Mittempergher, F",Biliopancreatic diversion with transient gastroplasty and duodenal switch: Long-term results of a multicentric study,SURGERY,,0039-6060,10.1016/j.surg.2012.06.039,,"Background. Over the years, several modifications of the Scopinaro biliopancreatic diversion (BPD) have been proposed. This retrospective study reported the results of 15 years of follow-up after open. BPD coupled with a type of transient gastroplasty (TG) and duodenal switch (DS), termed BPD-TG with DS. Methods. Data were analyzed for 874 patients operated on between January 1993 and May 2010 in 3 different surgical departments. Results. The median preoperative body mass index (BMI) was 52 kg/m(2) (range, 35-63). Comorbidities present were hypertension (57%), hypercholesterolemia (87%), hypertriglyceridemia (53%), type 2 diabetes (35%), and obstructive sleep apnea syndrome (OSAS; 9%). The mean follow-up was 11.9 3.1 years. The median BMI decreased to 33.9 after 1 year from bariatric surgery, 31.1 after 2-5 years, 30.9 after 5-10 years, and 31.2 kg/m2 after 10-15 years. Overall, 67% of diabetic patients were able to stop insulin and 97% were able to stop oral hypoglycemic drugs within 1 year Blood pressure, triglyceride levels, and cholesterol levels became normal in >96% of patients within I year. OSAS was resolved within 8 months in all cases. One year postoperatively, but absent thereafter we observed severe hypoalbuminemia (serum albumin <3 g/dL) in 1.7% of patients and severe iron-deficiency anemia in 1.9%. Incisional hernias were recorded in 30% and anastomotic ulcers in 2.4% of cases. Mortality was null. Conclusion. Our results suggest considering BPD-TG with DS as a viable bariatric operation, with its excellent long-term outcome in terms of weight loss, improvement of obesity-related diseases, and quality of life. (Surgery 2013;153:413-22.)",2013-03,01/07/2022 10:40,01/07/2022 10:40,,413-422,,3,153,,,,,,,,,,,,,,WOS:000315748000018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LNYGJV5C,journalArticle,2018,"Jambhekar, A; Maselli, A; Robinson, S; Kabata, K; Gorecki, P",Demographics and socioeconomic status as predictors of weight loss after laparoscopic sleeve gastrectomy: A prospective cohort study,INTERNATIONAL JOURNAL OF SURGERY,,1743-9191,10.1016/j.ijsu.2018.04.025,,"Background: Prior studies have established that race and socioeconomic factors may influence weight loss after bariatric surgery. Few studies have focused on laparoscopic sleeve gastrectomy (LSG). The objective of this study is to determine if demographic factors may predict postoperative weight loss following LSG. Methods: Prospectively collected data on 713 consecutive primary LSG operations performed with the same technique between February 2010 and May 2016 by a single surgeon (PG) were analyzed. Multiple regression analysis was done to determine if gender, race, or socioeconomic factors such as insurance and employment status correlated with postoperative weight loss. The presence of chronic comorbidities affecting quality of life such as Type II Diabetes and Obstructive Sleep Apnea (OSA) were also recorded and analyzed. Results: All studied groups had similar preoperative body mass index (BMI) (mean 46 kg/m(2)). Race was not significantly associated with weight loss at any postoperative interval. Male gender was associated with increased weight loss through the first three months (48.2 +/- 12.5 lbs vs. 40.5 +/- 11 lbs; p = 0.0001). Patients with diabetes had significantly less weight loss at the 6 through 18 month intervals (50.4 +/- 17.9 lbs vs. 59.6 +/- 15.6 lbs at six months; p = 0.00032; 53.3 +/- 25.4lbs vs. 80.5 +/- 31.3lbs at 18 months; p = 0.008). Patients with obstructive sleep apnea had significantly less weight loss at the two-year interval (57.5 +/- 29.2 lbs) vs. those without obstructive sleep apnea (69.6 +/- 23.5 lbs; p = 0.047). Those with Medicare compared to Medicaid or commercial insurance had decreased weight loss through the first year (52.8 +/- 20.8 lbs vs. 71.4 +/- 26.4 lbs vs. 68.6 +/- 24.7 lbs; p = 0.0496). Notably, a higher percentage of patients in the Medicare insurance group were also diabetic and had OSA (65% vs. 34% vs. 36%; p = 0.002; 80% vs. 55% vs. 57%; p = 0.01). Finally, those patients who were students had the greatest weight loss at two years postoperatively with the least weight loss seen in refired patients followed by those on disability (108.0 +/- 21.5 lbs vs. 26.0 lbs vs. 46.0 +/- 19.7 lbs; p = 0.04). Conclusions: Several demographic factors including comorbidities, insurance status, and employment may significantly affect weight loss patterns following LSG. Further studies are needed to evaluate whether demographic differences impact long term weight loss. Differences in outcomes based on patient demographics may be beneficial in the planning of the allocation of healthcare resources.",2018-06,01/07/2022 10:40,01/07/2022 10:40,,163-169,,,54,,,,,,,,,,,,,,WOS:000436466400025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F8JPQTYF,journalArticle,2008,"Campos, GM; Rabl, C; Mulligan, K; Posselt, A; Rogers, SJ; Westphalen, AC; Lin, F; Vittinghoff, E",Factors associated with weight loss after gastric bypass,ARCHIVES OF SURGERY,,0004-0010,10.1001/archsurg.143.9.877,,"Background: Gastric bypass (GBP) is the most common operation performed in the United States for morbid obesity. However, weight loss is poor in 10% to 15% of patients. We sought to determine the independent factors associated with poor weight loss after GBP. Design: Prospective cohort study.. We examined demographic, operative, and follow-up data by means of multivariate analysis. Variables investigated were age, sex, race, marital and insurance status, initial weight and body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), comorbidities (diabetes mellitus, hypertension, joint disease, sleep apnea, byperlipidemia, and psychiatric disease), laparoscopic vs; open surgery, gastric pouch area, gastrojejunostomy technique, and alimentary limb length. Setting: University tertiary referral center. Patients: All patients at our institution who underwent. GBP from January 1, 2003, through July 30, 2006. Main Outcome Measures: Weight loss at 12 months. defined as poor (<= 40% excess weight loss) or good (>40% excess weight loss). Results: Follow-up data at 12 months were available for 310 of the 361 patients (85.9%) undergoing GBP during the study period. Mean preoperative BMI was 52 (range, 36-108). Mean BMI and excess weight loss at follow-up were 34 (range, 17-74) and 60% (range, 8%-117%), respectively. Thirty-eight patients (12.3%) had poor weight loss. Of the 4 variables associated with poor weight loss in the univariate analysis (greater initial weight, diabetes, open approach, and larger pouch size), only diabetes (odds ratio, 3.09; 95% confidence interval, 1.35-7.09 [P = .0071) and larger pouch size (odds ratio, 2.77; 95% confidence interval, 1.81-4.22 [P < .0011) remained after the multivariate analysis. Conclusions: Gastric bypass results in substantial weight loss in most patients. Diabetes and larger pouch size are independently associated with poor weight loss after GBP.",2008-09,01/07/2022 10:40,01/07/2022 10:40,,877-883,,9,143,,,,,,,,,,,,,,WOS:000259089200016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DL4WWGCH,journalArticle,2021,"Zhang, SM; Cheng, SJ; Zhang, ZX; Wang, CY; Wang, AR; Zhu, WF",Related risk factors associated with post-stroke fatigue: a systematic review and meta-analysis,NEUROLOGICAL SCIENCES,,1590-1874,10.1007/s10072-020-04633-w,,"Background Post-stroke fatigue (PSF) is one of the most common complications of stroke and has a negative impact on quality of life over time. Although several therapeutic approaches have been explored in the last decade, the risk factors responsible for the occurrence of PSF are still largely unknown. Objective The aim of this meta-analysis was to identify the risk factors contributing to PSF, especially clinical and social risk factors, which may help to prevent PSF. Methods A systematic literature search was performed with PubMed, EMBASE, Cochrane Library, and Web of Science databases from inception until April 2019. Only original studies measuring the association between potential risk factors and PSF were included. All relevant data the included studies were extracted by two independent reviewers using predefined data fields. Results Fourteen studies (n = 3933) were included in this meta-analysis. Female (OR = 1.39;p < 0.01), thalamus (OR = 1.76;p = 0.02), leucoaraiosis (OR = 1.73;p < 0.01), NIHSS score (OR = 1.16; p < 0.01), modified Rankin Scale (OR = 1.63;p < 0.01), depression (OR = 1.75; p < 0.01), and sleeping disturbances (OR = 2.01;p < 0.01) were all significantly associated with PSF. In the subgroup analysis, depression (OR = 2.75;p < 0.01) tended to be associated with Asian patients with PSF. For patients who had a stroke survive for more than half a year, PSF was more likely to occur in stroke survivors with depression (OR = 1.46;p < 0.01), anxiety (OR = 1.13;p < 0.01), or sleeping disturbances (OR = 1.98;p < 0.01). Conclusion Despite some limitations, this study first identified that female and depression conferred an increased susceptibility to PSF, regardless of whether in European or Asian populations. Risk factors associated with PSF included female, thalamic, leucoaraiosis, depression, sleeping disturbances, diabetes mellitus, and anxiety. This meta-analysis shows that chronic PSF appears to be largely attributable to patients with multiple comorbidities. It is necessary to strengthen the treatment for stroke-related complications and improve stroke patient care, which could help to reduce the incidence of PSF.",2021-04,01/07/2022 10:40,01/07/2022 10:40,,1463-1471,,4,42,,,,,,,,,,,,,,WOS:000561777100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VV4CVRID,journalArticle,2005,"Erman, MK; Young, T; Patel, SR; Neubauer, DN; Ginsberg, DL; Hollander, E",The Role of Modified-Release Formulations in Hypnotic Therapy for Insomnia,CNS SPECTRUMS,,1092-8529,,,"In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by Multiple symptoms related to initiating or maintaining sleep. Physiologic Studies Indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include Immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development Include zolpidem MR and indiplon MR.",2005-08,01/07/2022 10:40,01/07/2022 10:40,,Jan-13,,8,10,,,,,,,,,,,,,,WOS:000207076000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DSBB4VEF,journalArticle,2005,"Erman, MK; Young, T; Patel, SR; Neubauer, DN; Ginsberg, DL; Hollander, E",The role of modified-release formulations in hypnotic therapy for insomnia,CNS SPECTRUMS,,1092-8529,,,"In addition to the psychological and medical health risks associated with lack of adequate sleep, effects of insomnia include impaired daytime functioning and decreased quality of life. Many patients experience delayed sleep onset, frequent awakenings, early waking, or nonrestorative sleep. Longitudinal data on insomnia indicate that the prevalence of persistent/chronic insomnia is high and appears to be characterized by multiple symptoms related to initiating or maintaining sleep. Physiologic studies indicate that short-term sleep restriction can cause physiologic problems that lead to long-term health consequences, such as high blood pressure, impaired glucose tolerance, and systemic inflammation. Epidemiologic studies have shown that sleep deprivation is independently associated with increased risk of cardiovascular disease, diabetes, obesity, and mortality. While the available agents are effective, those with a long half life may have carryover effects while short-acting agents may not provide enough sleep continuity. Pharmacologic therapies available for patients who suffer from insomnia include immediate-release nonbenzodiazepine hypnotics, which have a positive benefit/risk profile compared to the benzodiazepines. Modified-release (MR) formulations of these agents may offer the additional benefit of improving sleep continuity throughout the night without sacrificing the rapid elimination properties that minimize next-day residual effects. MR agents in development include zolpidem MR and indiplon MR.",2005-08,01/07/2022 10:40,01/07/2022 10:40,,B1-B13,,8,10,,,,,,,,,,,,,,WOS:000231555700016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X64QNZDK,journalArticle,2011,"Haanpaa, M; Attal, N; Backonja, M; Baron, R; Bennett, M; Bouhassira, D; Cruccu, G; Hansson, P; Haythornthwaite, JA; Iannetti, GD; Jensen, TS; Kauppila, T; Nurmikko, TJ; Rice, ASC; Rowbotham, M; Serra, J; Sommer, C; Smith, BH; Treede, RD",NeuPSIG guidelines on neuropathic pain assessment,PAIN,,0304-3959,10.1016/j.pain.2010.07.031,,"This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50% and 30% pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended. (C) 2010 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.",2011-01,01/07/2022 10:40,01/07/2022 10:40,,14-27,,1,152,,,,,,,,,,,,,,WOS:000285410800008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4WSK3VD5,journalArticle,2021,"Kansra, AR; Lakkunarajah, S; Jay, MS",Childhood and Adolescent Obesity: A Review,FRONTIERS IN PEDIATRICS,,2296-2360,10.3389/fped.2020.581461,,"Obesity is a complex condition that interweaves biological, developmental, environmental, behavioral, and genetic factors; it is a significant public health problem. The most common cause of obesity throughout childhood and adolescence is an inequity in energy balance; that is, excess caloric intake without appropriate caloric expenditure. Adiposity rebound (AR) in early childhood is a risk factor for obesity in adolescence and adulthood. The increasing prevalence of childhood and adolescent obesity is associated with a rise in comorbidities previously identified in the adult population, such as Type 2 Diabetes Mellitus, Hypertension, Non-alcoholic Fatty Liver disease (NAFLD), Obstructive Sleep Apnea (OSA), and Dyslipidemia. Due to the lack of a single treatment option to address obesity, clinicians have generally relied on counseling dietary changes and exercise. Due to psychosocial issues that may accompany adolescence regarding body habitus, this approach can have negative results. Teens can develop unhealthy eating habits that result in Bulimia Nervosa (BN), Binge- Eating Disorder (BED), or Night eating syndrome (NES). Others can develop Anorexia Nervosa (AN) as they attempt to restrict their diet and overshoot their goal of ""being healthy."" To date, lifestyle interventions have shown only modest effects on weight loss. Emerging findings from basic science as well as interventional drug trials utilizing GLP-1 agonists have demonstrated success in effective weight loss in obese adults, adolescents, and pediatric patients. However, there is limited data on the efficacy and safety of other weight-loss medications in children and adolescents. Nearly 6% of adolescents in the United States are severely obese and bariatric surgery as a treatment consideration will be discussed. In summary, this paper will overview the pathophysiology, clinical, and psychological implications, and treatment options available for obese pediatric and adolescent patients.",12/01/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,8,,,,,,,,,,,,,,WOS:000611504400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EPUHHAAH,journalArticle,1999,"Dunford, M; Donoghue, J; Lazaris, M",Case presentation of nurse-managed noninvasive positive pressure ventilation in an acute ward setting,HEART & LUNG,,0147-9563,10.1053/hl.1999.v28.a99956,,"A woman with obstructive sleep apnea who was admitted to the sleep disorders laboratory at St George Hospital in Sydney, Australia, for assessment subsequently experienced respiratory arrest. She was successfully resuscitated and 10 days later was transferred from the critical care unit to the respiratory ward with a cuffed, fenestrated tracheostomy tube in situ. A hoarse voice, oxygen desaturation, and upper airway strider when capping the tracheostomy alerted nursing staff to the existence of an upper airway obstruction. Repositioning of the tracheostomy tube alleviated some of the patient's difficulties, but further investigation revealed large vocal polyps as the underlying factor in her episode of respiratory failure. Removal of the polyps and inception of noninvasive positive pressure ventilation resulted in a range of benefits to the patient's health status, including resolution of her respiratory failure, better management of her diabetes, and a markedly improved quality of life.",1999-09,01/07/2022 10:40,01/07/2022 10:40,,348-351,,5,28,,,,,,,,,,,,,,WOS:000082677200006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QW6ZV9SW,journalArticle,2016,"Corlateanu, A; Covantev, S; Mathioudakis, AG; Botnaru, V; Siafakas, N",Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease,RESPIRATORY INVESTIGATION,,2212-5345,10.1016/j.resinv.2016.07.001,,"The classical definition of Chronic Obstructive Pulmonary Disease (COPD) as a lung condition characterized by irreversible airway obstruction is outdated. The systemic involvement in patients with COPD, as well as the interactions between COPD and its comorbidities, justify the description of chronic systemic inflammatory syndrome. The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies, decreasing the quality of life of patients with COPD and, furthermore, complicating the management of the disease. The most frequently described comorbidities include skeletal muscle wasting, cachexia (loss of fat-free mass), lung cancer (small cell or non-small cell), pulmonary hypertension, ischemic heart disease, hyperlipidemia, congestive heart failure, normocytic anemia, diabetes, metabolic syndrome, osteoporosis, obstructive sleep apnea, depression, and arthritis. These complex interactions are based on chronic low-grade systemic inflammation, chronic hypoxia, and multiple common predisposing factors, and are currently under intense research. This review article is an overview of the comorbidities of COPD, as well as their interaction and influence on mutual disease progression, prognosis, and quality of life. (C) 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.",2016-11,01/07/2022 10:40,01/07/2022 10:40,,387-396,,6,54,,,,,,,,,,,,,,WOS:000417482500003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78HAGEWM,journalArticle,2004,"Jones, DB; Provost, DA; DeMaria, EJ; Smith, CD; Morgenstern, L; Schirmer, B",Optimal management of the morbidly obese patient - SAGES appropriateness conference statement,SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES,,0930-2794,10.1007/s00464-004-8132-6,,"Background: Obesity is a growing health problem that contributes to numerous life-threatening or disabling disorders. including coronary artery disease, hypertension, type 2 diabetes mellitus, hyperlipidemia, degenerative joint disease, and obstructive sleep apnea. Significant weight reduction in the morbidly obese improves or reverses associated illness and benefits wellbeing. The purpose of the SAGES Appropriateness Conference was to summarize the state of the art for open and laparoscopic operations for the morbidly obese. Methods: The English literature comparing bariatric procedures was reviewed and grouped by level of evidence by three surgeons (BS, LV, and CC). From more than 1,500 articles, all conference participants were provided with reprints and table summaries of no less than 50 selected manuscripts. Ten experts were requested to present reviews and make evidence-based arguments for and against the open and laparoscopic approaches in written format. An expert panel of six surgeons, including an ethicist and patient, commented oil implications of data presented. The finalized statement was e-mailed to all participants for approval and comment. Results: Consensus statements were achieved on various aspects of morbid obesity, including indications for surgery, resolution of comorbid illnesses with significant weight loss, and the importance of committed bariatric program. Our panel of experts agreed, in general, to the advantages of laparoscopic approaches compared to open operations in skilled hands. Conclusions: Laparoscopic Roux-en-Y gastric bypass (RYGB) affords improved short-term recovery compared to open gastric bypass. Laparoscopic adjustable banding call be performed with lower average mortality than either RYGB or any of the malabsorptive operations, and it produces variable degrees of short-term weight loss. Prospective randomized trials are needed to compare gastric bypass, malabsorptive, and restrictive procedures.",2004-07,01/07/2022 10:40,01/07/2022 10:40,,1029-1037,,7,18,,,,,,,,,,,,,,WOS:000222826800004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FZ8ZL339,journalArticle,2020,"Seki, Y; Kasama, K; Kikkawa, E; Yokoyama, R; Nabekura, T; Sano, A; Amiki, M; Kurokawa, Y",Five-Year Outcomes of Laparoscopic Sleeve Gastrectomy in Japanese Patients with Class I Obesity,OBESITY SURGERY,,0960-8923,10.1007/s11695-020-04789-6,,"Background Bariatric surgery is being recognized increasingly as an effective treatment for obesity and related comorbidities. In Japan, the cost of laparoscopic sleeve gastrectomy (LSG) is covered by the national health insurance for adults with a body mass index (BMI) >= 35 kg/m(2)and specific comorbidities (type 2 diabetes mellitus (T2DM), hypertension (HT), dyslipidemia (DL), and obstructive sleep apnea syndrome (OSAS)). However, only 0.6% of the adult population have a BMI >= 35 kg/m(2). In contrast, 4.3% have class I obesity (a BMI of 30-34.9 kg/m(2)). The BMI of Asians with central obesity-induced diabetes and other metabolic disorders is much lower than that of Westerners. Objectives To evaluate the medium-term (up to 5 years) outcomes of LSG performed in Japanese patients with class I obesity. Methods One hundred eighteen consecutive patients with class I obesity treated by LSG at our center between August 2007 and December 2018 were included in a retrospective study. Mean preoperative body weight (BW) and BMI were 88.6 +/- 10.3 kg and 32.8 +/- 1.6 kg/m(2), respectively. Weight loss, comorbidity status, and adverse events were assessed. Results Mean BW/BMI at 1, 3, and 5 years after LSG decreased significantly to 66.6 +/- 11.2 kg/24.6 +/- 2.8 kg/m(2), 68.0 +/- 14.0 kg/25.4 +/- 4.0 kg/m(2), and 69.1 +/- 12.9 kg/26.5 +/- 3.0 kg/m(2), respectively. Mean total weight loss at 1, 3, and 5 years was 24.7 +/- 8.2%, 21.8 +/- 12.1%, and 18.5 +/- 9.7%, respectively. Metabolic disorders such as T2DM, HT, and DL improved significantly. There was no mortality. Conclusion LSG is safe, yields excellent weight loss, and improves obesity-related comorbidities in Japanese patients with class I obesity.",2020-11,01/07/2022 10:40,01/07/2022 10:40,,4366-4374,,11,30,,,,,,,,,,,,,,WOS:000542520300002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5FPMH8ZN,journalArticle,2011,"Budhiraja, R; Roth, T; Hudgel, DW; Budhiraja, P; Drake, CL",Prevalence and Polysomnographic Correlates of Insomnia Comorbid with Medical Disorders,SLEEP,,0161-8105,10.5665/SLEEP.1114,,"Study Objectives: To determine the prevalence and polysomnographic correlates of insomnia in subjects with self-reported medical disorders. Design: Prospective cross-sectional study. Participants: Community-based sample of 3282 men and women aged 18 to 65 years old, with a subset who underwent polysomnography. Measurements: Self-reported measures of sleep habits and current health, and polysomnographic sleep variables. Results: The prevalence of insomnia was 21.4%. The adjusted odds of insomnia were 2.2 times as high in persons with any medical disorders as in those without medical disorders. Specifically, odds of insomnia were higher in people with heart disease (OR = 1.6 [95% CI: 1.2-23], P = 0.004), hypertension (1.5 [12-18], P < 0.001), diabetes (1.4 [105-20], P = 0.04), stomach ulcers (2.1 [1.6-2.7], P < 0.001), arthritis (1.8 [1.5-2.2], P < 0.001), migraine (1.8 [1.5-2.1], P < 0.001), asthma (1.6 [1.3-2.0], P = 0.04), COPD (1.9 [1.5-2.5], P < 0.001), neurological problems (2.0 [1.5-2.7], P < 0.001), and menstrual problems (1.7 [1.3-2.1], P < 0.001) than in people without these disorders. Prevalence of insomnia increased with increasing number of medical disorders. However, polysomnographic sleep was not significantly different in persons with or without medical disorders for most disorders assessed. Conclusion: This large population-based study suggests that insomnia is highly prevalent in diverse chronic medical disorders. However, polysomnographic evidence of disturbed sleep is present in only a subset of comorbid insomnia populations.",01/07/2011,01/07/2022 10:40,01/07/2022 10:40,,859-867,,7,34,,,,,,,,,,,,,,WOS:000292926500013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KTF8DSMI,journalArticle,2003,"Kemp, AS",Cost of illness of atopic dermatitis in children - A societal perspective,PHARMACOECONOMICS,,1170-7690,10.2165/00019053-200321020-00003,,"Childhood atopic dermatitis is a disorder with considerable social and financial costs. Consideration of these costs is increasingly important in view of the growing prevalence of atopic dermatitis, particularly in developed countries over recent decades. The family stress related to the care of children with moderate or severe atopic dermatitis is significantly greater than that of the care of children with type I diabetes mellitus. The factors contributing to family stress include sleep deprivation, loss of employment, time taken for care of atopic dermatitis and financial costs. The financial costs for the family and community include medical and hospital direct costs of treatments and indirect costs from loss of employment. There are many interventions utilised in the treatment of childhood atopic dermatitis which involve not only medical practitioners but nurses, pharmacists, dieticians, psychologists and purveyors of so-called alternative therapies such as naturopathy, aromatherapy and bioresonance, all of which contribute to the financial burdens on the parents and the community. It is possible that appropriate interventions directed to reducing trigger factors might produce worthwhile savings, although the cost benefit, of these measures has not been demonstrated. In conclusion, atopic dermatitis should not be regarded as a minor skin disorder but as a condition which ha's the potential to be a major handicap with considerable personal, social and financial consequences both to the family and the community.",2003,01/07/2022 10:40,01/07/2022 10:40,,105-113,,2,21,,,,,,,,,,,,,,WOS:000180641800003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T4GJVEIB,journalArticle,2019,"Bohannon, RW",Grip Strength: An Indispensable Biomarker For Older Adults,CLINICAL INTERVENTIONS IN AGING,,1178-1998,10.2147/CIA.S194543,,"Grip strength has been proposed as a biomarker. Supporting this proposition, evidence is provided herein that shows grip strength is largely consistent as an explanator of concurrent overall strength, upper limb function, bone mineral density, fractures, falls, malnutrition, cognitive impairment, depression, sleep problems, diabetes, multimorbidity, and quality of life. Evidence is also provided for a predictive link between grip strength and all-cause and disease-specific mortality, future function, bone mineral density, fractures, cognition and depression, and problems associated with hospitalization. Consequently, the routine use of grip strength can be recommended as a stand-alone measurement or as a component of a small battery of measurements for identifying older adults at risk of poor health status.",2019,01/07/2022 10:40,01/07/2022 10:40,,1681-1691,,,14,,,,,,,,,,,,,,WOS:000489165400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IYCAR74R,journalArticle,2018,"Blair, HA",Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain,DRUGS,,0012-6667,10.1007/s40265-018-0982-7,,"The adhesive capsaicin dermal patch (Qutenza((R))) delivers a high concentration (8% w/w) of synthetic capsaicin, a highly selective agonist of transient receptor potential vanilloid-1 (TRPV-1), directly to the site of pain. The capsaicin 8% dermal patch is indicated in the EU for the treatment of peripheral neuropathic pain (PNP) in adults, either alone or in combination with other medicinal products for pain. In patients with painful diabetic peripheral neuropathy, a single 30-min application of the capsaicin 8% dermal patch provided 12weeks of pain relief and improved sleep quality compared with placebo. Repeat treatment with the capsaicin 8% dermal patch plus standard of care over 52weeks provided sustained pain relief, with no negative neurological effects compared with standard of care alone. The capsaicin 8% dermal patch was non-inferior to oral pregabalin in relieving pain in patients with non-diabetic PNP, with a faster onset of action and greater treatment satisfaction. A single 60-min application of the capsaicin 8% dermal patch provided rapid and sustained pain relief in patients with postherpetic neuralgia. Results in patients with HIV-associated neuropathy were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8% dermal patch was generally well tolerated; transient application-site reactions were the most common adverse events. In conclusion, the capsaicin 8% dermal patch is a useful addition to the treatment options currently available for patients with PNP.",2018-09,01/07/2022 10:40,01/07/2022 10:40,,1489-1500,,14,78,,,,,,,,,,,,,,WOS:000446539700008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99HFUV2M,journalArticle,2017,"Kim, SY; Bang, W; Kim, MS; Park, B; Kim, JH; Chol, HG",Nocturia Is Associated with Slipping and Falling,PLOS ONE,,1932-6203,10.1371/journal.pone.0169690,,"Several reports have demonstrated associations between falls and nocturia in the elderly. However, little information is available regarding other age groups. This study evaluated the relationship between the frequency of nocturia and falls in men using a large, population-based survey in Korea, and the results were adjusted for various confounding factors. Data from a 2011 Korean community health survey (KCHS) were retrieved for 92,660 men aged 19 to 103 years. Information regarding the history of slips or falls in the past year was collected. The frequency of nocturia was classified as 0, 1, 2, 3, 4, and >= 5 instances a night. Walking during the day, education, income, body mass index (BMI), smoking, alcohol consumption, sleep time, stress level and medical histories of hypertension, diabetes mellitus, hyperlipidemia, cerebral stroke, angina or myocardial infarction, arthritis, and osteoporosis were adjusted using multiple logistic regression analysis with complex sampling. A subgroup analysis was conducted for young (19-30 years), middle-aged (31-60 years), and elderly individuals (61+ years). Approximately 14.6% of the men had a history of falls. Their mean age was 42.9 years, which was significantly higher than that of the non-faller group (P < 0.001). An increased frequency of nocturia was associated with increased adjusted odds ratio (AOR) for falls (AOR for 1 instance of nocturia/night = 1.41 [95% confidence interval, 1.33-1.50]; AOR for 2 instances = 1.41 [1.33-1.50]; AOR for 3 instances = 2.00 [1.75-2.28]; AOR for 4 instances = 2.12 [1.73-2.61]; AOR for-5 instances = 2.02 [1.74-2.36], P < 0.001). In the subgroup analysis, the AORs for falls significantly increased in all age groups as the frequency of nocturia increased.",06/01/2017,01/07/2022 10:40,01/07/2022 10:40,,,,1,12,,,,,,,,,,,,,,WOS:000391641500130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BUYISNHN,journalArticle,2015,"Silverberg, JI; Greenland, P",Eczema and cardiovascular risk factors in 2 US adult population studies,JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY,,0091-6749,10.1016/j.jaci.2014.11.023,,"Background: Eczema is associated with high rates of sleep disturbance and quality-of-life impairment. These factors might have a negative impact on psychosocial development and behavior and could increase cardiovascular risk. Objective: We sought to determine whether adults with eczema have increased cardiovascular risk factors. Methods: We analyzed data for 27,157 and 34,525 adults aged 18 to 85 years from the 2010 and 2012 National Health Interview Survey. Results: Adults with eczema had higher odds of ever smoking 100 cigarettes in their lifetime (survey logistic regression; adjusted odds ratio [aOR], 1.32; 95% CI, 1.18-1.47) and current smoking history (aOR, 1.28; 95% CI, 1.12-1.45), with significantly younger age of onset (survey linear regression; adjusted beta, -0.58; 95% CI, -0.95 to -0.21). Eczema was also associated with greater odds of ever drinking 12 or more alcoholic beverages annually (aOR, 1.16; 95% CI, 1.03-1.31), including current intake of moderate (aOR, 1.33; 95% CI, 1.09-1.62) and heavier (aOR, 1.58; 95% CI, 1.23-2.03) amounts. Adults with a history of eczema had lower odds of daily vigorous activity (aOR, 0.79; 95% CI, 0.63-0.99) and lower frequency of vigorous activity in the past week (adjusted beta, -0.46; 95% CI, -0.72 to -0.21) than did adults without a history of eczema. Those with eczema had a higher body mass index than did those without eczema (adjusted beta, 0.86; 95% CI, 0.37-1.36), particularly a body mass index of 35 or more (aOR, 1.54; 95% CI, 1.16-2.05), and higher odds of hypertension (aOR, 1.48; 95% CI, 1.18-1.85), hypertension on 2 visits (aOR, 1.56; 1.22-1.99), and lifetime prediabetes (aOR, 1.71; 95% CI, 1.19-2.45). Finally, there were significant interactions between eczema and sleep disturbances such that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even higher odds of obesity, hypertension, hypertension on 2 visits, prediabetes, diabetes, and high cholesterol than eczema alone. Conclusions: We found that eczema in adults is a marker for cardiovascular risk, emphasizing the importance of behavioral modification and perhaps more aggressive interventions to better manage eczema.",2015-03,01/07/2022 10:40,01/07/2022 10:40,,721-U219,,3,135,,,,,,,,,,,,,,WOS:000351065000019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EMUG9M7K,journalArticle,1996,"Sklar, AH; Riesenberg, LA; Silber, AK; Ahmed, W; Ali, A",Postdialysis fatigue,AMERICAN JOURNAL OF KIDNEY DISEASES,,0272-6386,10.1016/S0272-6386(96)90256-5,,"To clarify the demographic and clinicolaboratory features of postdialysis fatigue (PDF), we enrolled 85 patients an maintenance hemodialysis in a cross-sectional study using validated questionnaires and chart review. Forty-three patients complained of fatigue after dialysis. On formal testing using the Kidney Disease Questionnaire, the PDF group had statistically greater severity of fatigue and somatic complaints than the group of patients without subjective fatigue (P = 0.03 and 0.04, respectively). On a scare measuring intensity of fatigue (1 = least to 5 = worst), the PDF group average was 3.4 +/- 1.2 PDF subjects reported that 80% +/- 25% of dialysis treatments were followed by fatigue symptoms. In 28 (65%) of patients, the symptoms started with the first dialysis treatment They reported needing an average of 4.8 hours of rest or sleep to overcome the; fatigue symptoms (range, 0 to 24 hours). There were no significant differences between patients with and without PDF in the following parameters: age; sex; type of renal disease; presence of diabetes mellitus, heart disease (congestive, ischemic), or chronic obstructive lung disease; blood pressure response to dialysis; type or adequacy of dialysis regimen; hematocrit; electrolytes; blood urea nitrogen; creatinine; cholesterol; albumin; parathyroid hormone; ejection fraction; and use of antihistamines, benzodiazepines, and narcotics. In the fatigue group, there was significantly greater use of antihypertensive medications known to have fatigue as a side effect (P = 0.007). Depression was more common in the fatigue group by Beck Depression score (11.6 +/- 8.0 v 7.8 +/- 6.3; P = 0.02). We conclude that (1) postdialysis fatigue is a common, often incapacitating symptom in patients on chronic extracorporeal dialysis; (2) no routinely measured parameter of clinical or dialytic function appears to predict postdialysis fatigue; and (3) depression is highly associated with postdialysis fatigue, but the cause-effect relationship is unclear. (C) 1996 by the National Kidney Foundation, Inc.",1996-11,01/07/2022 10:40,01/07/2022 10:40,,732-736,,5,28,,,,,,,,,,,,,,WOS:A1996VY43200011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MUQ3DUER,journalArticle,2016,"Greenfield, R; Busink, E; Wong, CP; Riboli-Sasco, E; Greenfield, G; Majeed, A; Car, J; Wark, PA",Truck drivers' perceptions on wearable devices and health promotion: a qualitative study,BMC PUBLIC HEALTH,,1471-2458,10.1186/s12889-016-3323-3,,"Background: Professional truck drivers, as other shift workers, have been identified as a high-risk group for various health conditions including cardiovascular disease, obesity, diabetes, sleep apnoea and stress. Mobile health technologies can potentially improve the health and wellbeing of people with a sedentary lifestyle such as truck drivers. Yet, only a few studies on health promotion interventions related to mobile health technologies for truck drivers have been conducted. We aimed to explore professional truck drivers' views on health promotion delivered via mobile health technologies such as wearable devices. Methods: We conducted a phenomenological qualitative study, consisting of four semi-structured focus groups with 34 full-time professional truck drivers in the UK. The focus groups were audio-taped, transcribed verbatim and analysed using thematic content analysis. We discussed drivers' perceptions of their health, lifestyle and work environment, and their past experience and expectations from mobile health technologies. Results: The participants viewed their lifestyle as unhealthy and were aware of possible consequences. They expressed the need and wish to change their lifestyle, yet perceived it as an inherent, unavoidable outcome of their occupation. Current health improvement initiatives were not always aligned with their working conditions. The participants were generally willing to use mobile health technologies such as wearable devices, as a preventive measure to avoid prospect morbidity, particularly cardiovascular diseases. They were ambivalent about privacy and the risk of their employer's monitoring their clinical data. Conclusions: Wearable devices may offer new possibilities for improving the health and wellbeing of truck drivers. Drivers were aware of their unhealthy lifestyle. They were interested in changing their lifestyle and health. Drivers raised concerns regarding being continuously monitored by their employer. Health improvement initiatives should be aligned with the unique working conditions of truck drivers. Future research is needed to examine the impact of wearable devices on improving the health and wellbeing of professional drivers.",30/07/2016,01/07/2022 10:40,01/07/2022 10:40,,,,,16,,,,,,,,,,,,,,WOS:000381003600008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6Q527Q8K,journalArticle,2006,"Bray, GA; Bellanger, T","Epidemiology, trends, and morbidities of obesity and the metabolic syndrome",ENDOCRINE,,1355-008X,10.1385/ENDO:29:1:109,,"Obesity has been described as an epidemic because of the rapid increase in the number of overweight and obese individuals over the past 20 yr. This increasing prevalence of obesity is a worldwide phenomenon affecting both children and adults. The metabolic syndrome is a constellation of central adiposity, impaired fasting glucose, elevated blood pressure, and dyslipidemia (high triglyceride and low HDL cholesterol). When three of these five criteria are present, the risk of cardiovascular disease and diabetes is increased 1.5- to 2-fold. As body weight, expressed as the BMI, rises, there are a number of other diseases that are associated with it. First, life span is shortened and the risk of sudden death increases. Second, the risk of diabetes, gall bladder disease, hypertension, heart disease, osteoarthritis, sleep apnea, and certain forms of cancer also increase.",2006-02,01/07/2022 10:40,01/07/2022 10:40,,109-117,,1,29,,,,,,,,,,,,,,WOS:000236772000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EHMV3HVJ,journalArticle,2018,"Flythe, JE; Hilliard, T; Castillo, G; Ikeler, K; Orazi, J; Abdel-Rahman, E; Pai, AB; Rivara, MB; St Peter, WL; Weisbord, SD; Wilkie, C; Mehrotra, R",Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.10850917,,"Background and objectives Individuals receiving in-center hemodialysis experience a high symptom burden that detrimentally affects their quality of life. There are few evidence-based interventions for symptom relief in this population. To stimulate innovation in symptom management, data on patient symptom prioritization and treatment preferences are needed. We undertook this study to (1) identify patient-prioritized symptoms for the development of symptom relief therapies and (2) elicit preferences for treatments among individuals receiving hemodialysis. Design, setting, participants,& measurements We conducted a mixedmethods study that included focus groups in Carrboro, North Carolina; Tucson, Arizona; and Seattle, Washington and a nationally distributed online survey. Focus group transcripts were analyzed for patterns, and the highest priority symptoms were determined on the basis of frequency and report severity. We used focus group findings to inform survey items. Focus group and survey results were crossvalidated and synthesized for final symptom prioritization. Results Therewere 32 participants across three focus groups and 87 survey respondents from 27 states in the United States. The physical symptoms of insomnia, fatigue, muscle cramping, and nausea/vomiting and the mood symptoms of anxiety and depressed mood were reported by participants in all focus groups. Among survey respondents, fatigue (94%), cramping (79%), and body aches (76%) were the most common physical symptoms, and feeling depressed (66%), worried (64%), and frustrated (63%) were the most common mood symptoms. The top-prioritized symptoms were consistent across focus group and survey participants and included the physical symptoms insomnia, fatigue, and cramping and the mood symptoms anxiety, depression, and frustration. Participants indicated that symptom frequency, duration, unpredictability, and social and financial effects factored most heavily into symptom prioritization. Conclusions Patients prioritized the physical symptoms of insomnia, fatigue, and cramping and the mood symptoms of anxiety, depression, and frustration as the top symptoms for which to find new therapies.",07/05/2018,01/07/2022 10:40,01/07/2022 10:40,,735-745,,5,13,,,,,,,,,,,,,,WOS:000432174800012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NLUKP2L6,journalArticle,2018,"Arslanian, S; Bacha, F; Grey, M; Marcus, MD; White, NH; Zeitler, P",Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association,DIABETES CARE,,0149-5992,10.2337/dci18-0052,,,01/12/2018,01/07/2022 10:40,01/07/2022 10:40,,2648-2668,,12,41,,,,,,,,,,,,,,WOS:000450560000036,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4FFDYCHK,journalArticle,2018,"Mahdavian, M; Power, BH; Asghari, S; Pike, JC",Effects of Comorbidities on Asthma Hospitalization and Mortality Rates: A Systematic Review,CANADIAN RESPIRATORY JOURNAL,,1198-2241,10.1155/2018/6460379,,"Background. Recent studies have shown that patients diagnosed with asthma who have other chronic comorbidities have severely worse medical outcomes. However, the number of available published studies in this field is lacking. The aim of this study was to determine the effects of comorbidities in asthmatic patients based on hospitalization and mortality rates. Methods. A systematic review was conducted. Data were obtained from the electronic databases PubMed, CINAHL, and Cochrane until June 15, 2018. The primary objective of this study was to determine the effects of comorbidities on asthma hospitalization and mortality. The secondary objective was to analyze the effects of asthma comorbidity with certain chronic diseases, including COPD, obesity, obstructive sleep apnea, mental illness (anxiety and depression), diabetes mellitus, hypertension, myocardial ischemia, rhinitis, and sinusitis on asthma hospitalization and mortality. Results. From potential 687 articles, only 9 were chosen based on our study inclusion criteria. Almost half of these articles were related to asthma/COPD comorbidity. There were no articles found for hypertension, myocardial ischemia, rhinitis, or sinusitis based on our inclusion/exclusion factors. Each of these 9 published articles had shown an increase in rates of hospitalization, length of stay, and/or mortality, due to asthma-related symptoms, compared to asthma-only patients. Conclusion. There was determined to be a large discrepancy between the available research for various types of comorbid conditions presenting with asthma that focus on hospitalization and mortality rates. The current available literature suggests a large impact that these comorbid diseases can have on asthma-related symptoms when present together, severely affecting a patient's quality of life. We propose that further research on the effects of these comorbidities on asthma mortality and hospitalization can yield beneficial results to improve the management of asthmatic patients.",2018,01/07/2022 10:40,01/07/2022 10:40,,,,,2018,,,,,,,,,,,,,,WOS:000447541900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZU9K55QQ,journalArticle,2013,"Choi, J; Kim, TH; Choi, TY; Lee, MS",Ginseng for Health Care: A Systematic Review of Randomized Controlled Trials in Korean Literature,PLOS ONE,,1932-6203,10.1371/journal.pone.0059978,,"Objective: This systematic review was performed to summarise randomised clinical trials (RCTs) assessing the efficacy and safety of ginseng in the Korean literature. Method: The study involved systematic searches conducted in eight Korean Medical databases. The methodological quality of all of the included studies was assessed using the Cochrane Risk of Bias tool. We included all RCTs on any type of ginseng compared to placebo, active treatment or no treatment in healthy individuals or patients regardless of conditions. Results: In total, 1415 potentially relevant studies were identified, and 30 randomised clinical trials were included. Nine RCTs assessed the effects of ginseng on exercise capacity, cognitive performance, somatic symptoms, quality of life, and sleeping in healthy persons. Six RCTs tested ginseng compared with placebo for erectile dysfunction, while another four studies evaluated the effects of ginseng against no treatment for gastric and colon cancer. Two RCTs compared the effect of red ginseng on diabetes mellitus with no treatment or placebo, and the other nine RCTs assessed the effects of ginseng compared with placebo or no treatment on various conditions. The methodological caveats of the included trials make their contribution to the current clinical evidence of ginseng somewhat limited. However, the 20 newly added trials (66.7% of the 30 trials) may provide useful information for future trials. Ginseng appears to be generally safe, and no serious adverse effects have been reported. Conclusions: The clinical effects of ginseng have been tested in a wide range of conditions in Korea. Although the quality of RCTs published in the Korean literature was generally poor, this review is useful for researchers to access studies that were originally published in languages that they would otherwise be unable to read and due to the paucity of evidence on this subject.",01/04/2013,01/07/2022 10:40,01/07/2022 10:40,,,,4,8,,,,,,,,,,,,,,WOS:000316930900039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ANBXR5R7,journalArticle,2021,"Azuero, J; Santander, J; Trujillo, CG; Caicedo, JI; Zuluaga, L; Becerra, AM; Daza, F; Rondon, M; Plata, M",Potential associations of adult nocturia. Results from a national prevalence study,NEUROUROLOGY AND URODYNAMICS,,0733-2467,10.1002/nau.24624,,"Aim To determine the prevalence of nocturia and associated risk factors in the Colombian population aged >= 18 years old. Methods This is a cross-sectional population-based study conducted in 1060 participants in Colombia. Nocturia was assessed with the Spanish version of the ICIQ-OAB, using the ICS terminology. Descriptive statistics were used to evaluate nocturia prevalence. Logistic regression analysis was carried out to determine the association of nocturia with predefined variables. Results The prevalence of nocturia was 55.9% and it was more common in women than men (53.96% vs. 46.04%; p = .004). At least three episodes of nocturia were observed in 20.37% of the participants who had a severe alteration in their quality of life (p < .01). The bivariate model showed an association between nocturia and obesity (odds ratio [OR], 1.69; 90% confidence interval [CI]: 1.22-2.34), diabetes mellitus (OR, 2.99; 90% CI: 1.86-4.83), high blood pressure (OR, 2.04; 90% CI: 1.52-2.72), cardiovascular disease (OR, 1.75; 90% CI: 1.08 - 2.83), depression (OR, 1.89; 90% CI: 1.23-2.89), obstructive sleep apnea (OR, 1.70; 90% CI: 1.17 - 2.46), and childhood enuresis (OR, 1.45; 90% CI: 1.04-2.02). The multivariate model showed an association with obesity (OR, 2.0; 95% CI: 1.14 - 3.51) in women, as well as age >= 65 years (OR, 3.18; 95% CI: 1.26 - 8.02) and erectile dysfunction (OR, 3.44; 95% CI: 1.21 - 9.72) in men. Childhood enuresis was significantly associated with nocturia in both genders (OR, 1.61; 95% CI: 1.09 - 2.40 in women and OR, 1.66; 95% CI: 1.09-2.52 in men). Conclusion There is a significant prevalence of nocturia in our population and a clear association with impaired quality of life. We consider important to inquire about history of childhood enuresis to define the risk of presenting nocturia in adulthood. Nocturia was associated with multiple comorbidities. Obesity and erectile dysfunction play an important role as modifiable risk factor.",2021-03,01/07/2022 10:40,01/07/2022 10:40,,819-828,,3,40,,,,,,,,,,,,,,WOS:000615701800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I75CM7VI,journalArticle,2015,"Valdes-Rodriguez, R; Mollanazar, NK; Gonzalez-Muro, J; Nattkemper, L; Torres-Alvarez, B; Lopez-Esqueda, FJ; Chan, YH; Yosipovitch, G",Itch Prevalence and Characteristics in a Hispanic Geriatric Population: A Comprehensive Study Using a Standardized Itch Questionnaire,ACTA DERMATO-VENEREOLOGICA,,0001-5555,10.2340/00015555-1968,,"A cross-sectional study of geriatric patients was performed to provide a comprehensive description of the prevalence and clinical characteristics of chronic itch affecting Hispanic geriatric subjects in Mexico. Participants were recruited from both nursing homes and geriatric ambulatory care centers. Patients without dementia were evaluated using an itch intensity and characteristic questionnaire and were assessed for itch-related dermatoses (n=302). Data on medications and underlying systemic diseases were obtained from medical records. The prevalence of chronic itch was 25% in this population. Of those with chronic itch, 69% had xerosis, 28% had itch-related dermatoses, and 96% had documented comorbidities. The most common comorbidities were diabetes mellitus (OR=2.3, 95% CI 1.3-3.9, p=0.003) and chronic venous insufficiency (OR=4.4, 95% CI 1.6-12.2, p=0.002). The most common areas where patients experienced itch were legs (54%), back (45%), scalp (28%) and arms (27%). Patients experienced the greatest amount of itch in the winter (77%) and during the night (65%). Chronic itch is a common problem in the studied Hispanic geriatric population, and its presence significantly correlates with xerosis, diabetes, and venous insufficiency.",2015,01/07/2022 10:40,01/07/2022 10:40,,417-421,,4,95,,,,,,,,,,,,,,WOS:000352751200007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
858T4EZS,journalArticle,2015,"Shalash, AS; Elrassas, HH; Monzem, MM; Salem, HH; Moneim, AA; Moustafa, RR",Restless legs syndrome in Egyptian medical students using a validated Arabic version of the Restless Legs Syndrome Rating Scale,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2015.07.032,,"Objective: Restless legs syndrome (RLS) is a common movement disorder that has a variable prevalence and impact reported from different countries and specific populations. The current study validated an Arabic version of the International Restless Legs Syndrome Study Group (IRLSSG) rating scale (IRLS) and investigated the prevalence and impact of RLS in medical students at Ain Shams University in Cairo. Methods: Translation of IRLS was done according to standard recognized guidelines provided by the publisher. A total of 389 medical students (217 female and 172 male) participated in the study and answered four questions to detect RLS as proposed by the IRLSSG. Subjects who answered positively the first three questions were recruited for face-to-face interview to exclude RLS mimics and to answer the IRLS. Results: A total of 46 subjects (11.8%; 27 female and 19 male) met the four criteria for RLS. Of these, 39 subjects (10%) had idiopathic RLS. Five subjects (1.3%) and two subjects (0.5%) reported association with history of anemia and diabetes mellitus respectively. Their mean total IRLS score was 16.33 +/- 5.3, with moderate severity (11.62 +/- 3.9) and low impact (3.1 +/- 1.8). The prevalence of individuals who had two or more episodes of RLS of at least moderate severity per week was 5.9%. Conclusion: In this specific population of Egyptian medical students, a within-average prevalence of RLS was found with low impact on quality of life similar to worldwide reported populations. RLS sufferers were of high prevalence among this cohort. The Arabic version of IRLS is reliable and valid for further research in Arabic countries. (C) 2015 Elsevier B.V. All rights reserved.",2015-12,01/07/2022 10:40,01/07/2022 10:40,,1528-1531,,12,16,,,,,,,,,,,,,,WOS:000365348900011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
W3A376MA,journalArticle,2020,"James, G; Nyman, E; Fitz-Randolph, M; Niklasson, A; Hedman, K; Hedberg, J; Wittbrodt, ET; Medin, J; Quinn, CM; Allum, AM; Emmas, C","Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study",JOURNAL OF MEDICAL INTERNET RESEARCH,,1438-8871,10.2196/18548,,"Background: Chronic kidney disease (CKD) is a major global health burden, and is associated with increased adverse outcomes, poor quality of life, and substantial health care costs. While there is an increasing need to build patient-centered pathways for improving CKD management in clinical care, data in this field are scarce. Objective: The aim of this study was to understand patient-reported experiences, symptoms, outcomes, and treatment journeys among patients with CKD through a retrospective and qualitative approach based on data available through PatientsLikeMe (PLM), an online community where patients can connect and share experiences. Methods: Adult members (aged >= 18 years) with self-reported CKD within 30 days of enrollment, who were not on dialysis, and registered between 2011 and 2018 in the PLM community were eligible for the retrospective study. Patient demographics and disease characteristics/symptoms were collected from this retrospective data set. Qualitative data were collected prospectively through semistmctured phone interviews in a subset of patients, and questions were oriented to better understand patients' experiences with CKD and its management. Results: The retrospective data set included 1848 eligible patients with CKD, and median age was 56 years. The majority of patients were female (1217/1841, 66.11%) and most were US residents (1450/1661, 87.30%). Of the patients who reported comorbidities (n=1374), the most common were type 2 diabetes (783/1374, 56.99%), hypertension (664/1374, 48.33%), hypercholesterolemia (439/1374, 31.95%), and diabetic neuropathy (376/1374, 27.37%). The most commonly reported severe or moderate symptoms in patients reporting these symptoms were fatigue (347/484, 71.7%) and pain (278/476, 58.4%). In the qualitative study, 18 eligible patients (13 females) with a median age of 60 years and who were mainly US residents were interviewed. Three key concepts were identified by patients to be important to optimal care and management: listening to patient needs, coordinating health care across providers, and managing clinical care. Conclusions: This study provides a unique source of real-world information on the patient experience of CKD and its management by utilizing the PLM network. The results reveal the challenges these patients face living with an array of symptoms, and report key concepts identified by patients that can be used to further improve clinical care and management and inform future CKD studies.",15/07/2020,01/07/2022 10:40,01/07/2022 10:40,,,,7,22,,,,,,,,,,,,,,WOS:000573905500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6ZPSL62Q,journalArticle,2014,"Mihalko, WM; Bergin, PF; Kelly, FB; Canale, ST","Obesity, Orthopaedics, and Outcomes",JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS,,1067-151X,10.5435/JAAOS-22-11-683,,"Obesity, one of the most common health conditions, affects an ever-increasing percentage of orthopaedic patients. Obesity is also associated with other medical conditions, including diabetes, cardiovascular disease, pulmonary disease, metabolic syndrome, and obstructive sleep apnea. These comorbidities require specific preoperative and postoperative measures to improve outcomes in this patient population. Patients who are obese are at risk for increased perioperative complications; however, orthopaedic procedures may L still offer notable pain relief and improved quality of life.",2014-11,01/07/2022 10:40,01/07/2022 10:40,,683-690,,11,22,,,,,,,,,,,,,,WOS:000343855200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ADGZE57C,journalArticle,2021,"Yow, HY; Tiong, JJL; Mai, CW; van Der Werf, E; Zainuddin, ZM; Toh, CC; Ngoo, KS; Goh, EH; Fadzli, AN; Lok, SH; Ong, TA",Prevalence of nocturia among community-dwelling adults: a population-based study in Malaysia,BMC UROLOGY,,1471-2490,10.1186/s12894-021-00860-1,,"Background Nocturia is widely prevalent condition with detrimental effects on quality of life and general health. In Malaysia, there is a lack of up-to-date prevalence study on nocturia. This study aimed to investigate the prevalence of nocturia and awareness pertaining to nocturia among Malaysian adults. Methods A cross-sectional population-based study was conducted among Malaysian adults aged >= 18 years old. The data was collected by mixed mode self-administered questionnaire from May 2019 to September 2019. Nocturia was defined as one or more voids at night. Results There were a total of 4616 respondents with 74.5% of response rate. The overall prevalence of nocturia among Malaysian adults was found to be 57.3%. In multivariate analysis, respondents aged 31-40 (1.91 [1.52-2.40]) or > 60 years old (2.03 [1.48-2.71]), and those who presented with hypertension (2.84 [2.28-3.53]), diabetes mellitus (1.78 [1.42-2.25]), renal disease (3.58 [1.93-6.63]) or overactive bladder (1.61 [1.10-2.35]) were associated with higher prevalence of nocturia. A significantly lower disease prevalence (p < 0.05) was noted among those aged 41-50 (0.73 [0.59-0.91]), male (0.78 [0.69-0.88]) and Chinese (0.47 [0.30-0.74]) or Indian (0.34 [0.21-0.54]) ethnicities. A total of 37.3% of respondents with nocturia reported that they faced sleeping difficulty about half the time or more after waking up in the middle of night. Those who had >= 2 voids per night experienced significantly higher mean bother score than those who had 1 void per night (p < 0.001). Approximately half (56.7%) of all respondents were not aware that night time urination is a medical condition. Only 25.2% of respondents with nocturia had sought medical attention for their nocturia. Conclusions The prevalence of nocturia among Malaysian adults is high and strongly influenced by age, sex, race and comorbidities. However, the general awareness pertaining to nocturia being a health issue remains low among Malaysians. The findings also highlighted the impact of nocturia on sleep and the need for nocturia education to better address this disease.",29/06/2021,01/07/2022 10:40,01/07/2022 10:40,,,,1,21,,,,,,,,,,,,,,WOS:000668161200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CGGFR7T3,book,2015,"Igelstrom, H",Physical Activity and Sedentary Time in Sleep Apnea and Obesity,,978-0-12-420240-5,,,,,2015,01/07/2022 10:40,01/07/2022 10:40,,,297,,,,,,"MODULATION OF SLEEP BY OBESITY, DIABETES, AGE, AND DIET",,,,,,,,,,WOS:000355179600032,,,Pages: 301,,,,,,"Watson, RR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UJAW55CM,journalArticle,2019,"Gonzalez-Chica, DA; Bowden, J; Miller, C; Longo, M; Nelson, M; Reid, C; Stocks, N",Patient-reported GP health assessments rather than individual cardiovascular risk burden are associated with the engagement in lifestyle changes: population-based survey in South Australia,BMC FAMILY PRACTICE,,1471-2296,10.1186/s12875-019-1066-9,,"Background Little is known about whether a more comprehensive health assessment, performed by a general practitioner (GP) during a clinical encounter, could influence patients' lifestyle. We aimed to investigate whether health assessments, performed by GPs, are more important than the presence of cardiovascular disease (CVD) or cardiometabolic risk factors (obesity, diabetes, hypertension, dyslipidaemia) for engagement in lifestyle change. Methods Cross-sectional, population-based survey conducted in South Australia (September-December 2017) using face-to-face interviews and self-reported data of 2977 individuals aged 15+ years. The main outcome was engagement in four lifestyle changes: 1) increasing fruit/vegetable intake, 2) increasing physical activity level, 3) reducing alcohol consumption, and 4) attempts to stop smoking. Health assessments performed by a GP in the last 12 months included clinical/laboratory investigations (weight/waist circumference, blood pressure, glucose levels, lipid levels) and questions about lifestyle/wellbeing (current diet, physical activity, smoking status, alcohol intake, mental health, sleeping problems). Results were restricted to individuals aged 35+ years because of the low prevalence of CVD or their risk factors among younger participants. Logistic regression was used in all associations, adjusted for sociodemographic, lifestyle, mental health, and clinical variables. Results Of the 2384 investigated adults (mean age 57.3 +/- 13.9 years; 51.9% females), 10.2% had CVD and 49.1% at least one cardiometabolic risk factor. Clinical/laboratory assessments performed by the GP were 2-3 times more frequent than assessments of lifestyle, mental health status, or sleeping problems, especially among those with CVD. Individuals with CVD or a cardiometabolic risk factor were no more likely to be increasing their fruit/vegetable consumption (33.6%), physical activity level (40.9%), reducing alcohol consumption (31.1%), or trying to quit smoking (34.0%) than 'healthy' participants. However, lifestyle changes were between 30 and 100% more likely when GPs performed three or more health assessments (either clinical/laboratory or questions about lifestyle/wellbeing) than when individuals did not visit the GP or when GPs performed no any assessment during these clinical encounters (p < 0.05 in all cases). Conclusion More frequent and comprehensive CVD-related assessments by GPs were more important in promoting a healthier lifestyle than the presence of CVD or cardiometabolic risk factors by themselves.",13/12/2019,01/07/2022 10:40,01/07/2022 10:40,,,,1,20,,,,,,,,,,,,,,WOS:000512612800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AXX86HBT,journalArticle,2016,"Platek, AE; Hrynkiewicz-Szymanska, A; Kotkowski, M; Szymanski, FM; Syska-Suminska, J; Puchalski, B; Filipiak, KJ","Prevalence of Erectile Dysfunction in Atrial Fibrillation Patients: A Cross-Sectional, Epidemiological Study",PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY,,0147-8389,10.1111/pace.12753,,"Background: Sexual dysfunctions, especially erectile dysfunction (ED), are a major problem in cardiovascular patients. They are caused by cardiovascular risk factors including low-grade inflammation process, endothelial dysfunction, oxidative stress, and hemodynamic and vascular alterations. The same mechanisms are some of the main causes and/or consequences of atrial fibrillation (AF). To this day, literature provides no cross-sectional data on the prevalence of sexual dysfunction in AF. The study aimed to determine the prevalence of sexual dysfunction in consecutive, young male patients with AF. Material and Methods: A cross-sectional survey of adult male patients with a primary diagnosis of AF was conducted at University Cardiology Departments, during the period of July 2013 to July 2014. During the enrollment process, the study participants were either electively hospitalized with a primary diagnosis of AF, or had a scheduled outpatient visit. Sexual dysfunctions were assessed using the International Index of Erectile Function. Results: A total of 129 consecutive AF patients (mean age 57.0 11.8 years) were analyzed. Hypertension was present in 60.5%, diabetes in 22.5% of patients, 46.5% had dyslipidemia, 18.6% were current smokers, and 45.7% had a family history of cardiovascular disease. At least one kind of sexual dysfunction was found in 86.8% of patients. ED was present in 57.4% of patients, 44.2% of patients had orgasmic dysfunction, 69.0% had lowered sexual desire, 65.1% had lowered intercourse satisfaction, and 55.8% had lowered overall satisfaction. Conclusions: Sexual dysfunctions are highly prevalent in AF patients and are not only limited to ED, but also include dysfunction of orgasmic function, desire, or general satisfaction. In part, the presence of the sexual dysfunctions is probably caused by classical cardiovascular risk factors highly prevalent in AF patients, but the impact of AF itself cannot be underestimated.",2016-01,01/07/2022 10:40,01/07/2022 10:40,,28-35,,1,39,,,,,,,,,,,,,,WOS:000368085000005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89KL2MBQ,journalArticle,2018,"Robinson, D; Suman, S",Managing nocturia: The multidisciplinary approach,MATURITAS,,0378-5122,10.1016/j.maturitas.2018.08.007,,"Nocturia, defined as waking at night to pass urine, is a common condition which increases with age. Whilst nocturia is known to have an important effect on quality of life, more recent evidence has linked the symptom with significant morbidity and mortality due to the effects of sleep deprivation on glucose metabolism and the immune system. The causes of nocturia are multifactorial and may be related to urine overproduction, storage disorders and primary sleep disorders. The commonest underlying pathology, however, is nocturnal polyuria, which may be associated with a number of medical conditions. This review explores the underlying causes of nocturia and nocturnal polyuria and, by doing so, describes a multidisciplinary approach to managing patients effectively.",2018-10,01/07/2022 10:40,01/07/2022 10:40,,123-129,,,116,,,,,,,,,,,,,,WOS:000448094800018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ST97HBSK,journalArticle,2019,"Nsair, A; Hupin, D; Chomette, S; Barthelemy, JC; Roche, F",Factors Influencing Adherence to Auto-CPAP: An Observational Monocentric Study Comparing Patients With and Without Cardiovascular Diseases,FRONTIERS IN NEUROLOGY,,1664-2295,10.3389/fneur.2019.00801,,"Introduction: Obstructive sleep apnea/hypopnea (OSAH) affects more than 15% of the general population and increases the occurrence of cardiovascular (CV) and metabolic events. Continuous positive airway pressure (CPAP) treatment is currently the gold standard treatment of OSAH and could prevent the occurrence of such events. However, long-term adherence to CPAP is a problem where a significant rate stop device treatment use. OSAH patients suffering CV disease could be less compliant due to less diurnal symptoms. Methods: We performed a prospective study of 408 non-CV or CV disease patients suffering severe OSAH syndrome and followed them during the first 5 months as well as a mean of 3 years of CPAP treatment use. Results: We demonstrated that in adult OSAH patients that two variables were associated with a low compliance (<5 h/night): age <60 y and lower maximal positive airway pressure level used. There was no significant impact of the presence of CV disease on compliance of 5 months. After 3 years of CPAP, age <60 y as well as diabetes were independent factors of low compliance. There was no significant association between gender, mask types, 90th centile positive airway pressure level, apnea/hypopnea index and short- or long-term compliance in our population. Conclusions: We did not find lower compliance of CPAP in CV OSAH patients. Most of our population (68-73%) demonstrated an optimal night treatment duration at 3 years of follow-up, allowing a reduction of CV occurrence or recurrence. We hypothesize that an early and short education of OSAH as we routinely proposed could allow a significant increase in the optimal observance of CPAP in at-risk populations.",02/08/2019,01/07/2022 10:40,01/07/2022 10:40,,,,,10,,,,,,,,,,,,,,WOS:000478638000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HCI95P83,journalArticle,2021,"Ammar, A; Trabelsi, K; Brach, M; Chtourou, H; Boukhris, O; Masmoudi, L; Bouaziz, B; Bentlage, E; How, D; Ahmed, M; Mueller, P; Mueller, N; Hammouda, O; Paineiras-Domingos, LL; Braakman-jansen, A; Wrede, C; Bastoni, S; Pernambuco, CS; Mataruna, L; Taheri, M; Irandoust, K; Khacharem, A; Bragazzi, NL; Strahler, J; Adrian, J; Andreeva, A; Glenn, JM; Bott, NT; Gargouri, F; Chaari, L; Batatia, H; Khoshnami, SC; Samara, E; Zisi, V; Sankar, P; Ahmed, WN; Ali, GM; Abdelkarim, O; Jarraya, M; El Abed, K; Moalla, W; Romdhani, M; Aloui, A; Souissi, N; Van Gemert-Pijnen, L; Riemann, BL; Riemann, L; Delhey, J; Gomez-Raja, J; Epstein, M; Sanderman, R; Schulz, S; Jerg, A; Al-Horani, R; Mansi, T; Jmail, M; Barbosa, F; Ferreira-Santos, F; Simunic, B; Pisot, R; Pisot, S; Gaggioli, A; Zmijewski, P; Bailey, SJ; Steinacker, J; Chamari, K; Driss, T; Hoekelmann, A",Effects of home confinement on mental health and lifestyle behaviours during the COVID-19 outbreak: insights from the ECLB-COVID19 multicentre study,BIOLOGY OF SPORT,,0860-021X,10.5114/biolsport.2020.96857,,"Although recognised as effective measures to curb the spread of the COVID-19 outbreak, social distancing and self-isolation have been suggested to generate a burden throughout the population. To provide scientific data to help identify risk factors for the psychosocial strain during the COVID-19 outbreak, an international cross-disciplinary online survey was circulated in April 2020. This report outlines the mental, emotional and behavioural consequences of COVID-19 home confinement. The ECLB-COVID19 electronic survey was designed by a steering group of multidisciplinary scientists, following a structured review of the literature. The survey was uploaded and shared on the Google online survey platform and was promoted by thirty-five research organizations from Europe, North Africa, Western Asia and the Americas. Questions were presented in a differential format with questions related to responses ""before"" and ""during"" the confinement period. 1047 replies (54% women) from Western Asia (36%), North Africa (40%), Europe (21%) and other continents (3%) were analysed. The COVID-19 home confinement evoked a negative effect on mental wellbeing and emotional status (P < 0.001; 0.43 <= d <= 0.65) with a greater proportion of individuals experiencing psychosocial and emotional disorders (+10% to +16.5%). These psychosocial tolls were associated with unhealthy lifestyle behaviours with a greater proportion of individuals experiencing (i) physical (+15.2%) and social (+71.2%) inactivity, (ii) poor sleep quality (+12.8%), (iii) unhealthy diet behaviours (+10%), and (iv) unemployment ( 6%). Conversely, participants demonstrated a greater use (+15%) of technology during the confinement period. These findings elucidate the risk of psychosocial strain during the COVID-19 home confinement period and provide a clear remit for the urgent implementation of technology-based intervention to foster an Active and Healthy Confinement Lifestyle AHCL).",2021,01/07/2022 10:40,01/07/2022 10:40,,Sep-21,,1,38,,,,,,,,,,,,,,WOS:000600062300002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A7JZT88T,journalArticle,2015,"Laurier, V; Lapeyrade, A; Copet, P; Demeer, G; Silvie, M; Bieth, E; Coupaye, M; Poitou, C; Lorenzini, F; Labrousse, F; Molinas, C; Tauber, M; Thuilleaux, D; Jauregi, J","Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France",JOURNAL OF INTELLECTUAL DISABILITY RESEARCH,,0964-2633,10.1111/jir.12140,,"BackgroundPrader-Willi syndrome (PWS) is a developmental genetic disorder characterised by a variable expression of medical, cognitive and behavioural symptoms. In adulthood, the prevalence and severity of these symptoms determine the quality of life of the affected persons. Because of their rare disease condition, data on health and social problems in adults with PWS are scarce. In this research, we present medical, psychological and social features of a large cohort of adults admitted to a specialised PWS centre in France and analyse the differences according to genotype, gender and age. MethodsData from154 patients (68 men/86 women), with a median age of 27 years (range 16-54), were collected during their stay in our centre. Clinical histories were completed using information from parents or main caregivers, and the same medical team performed the diagnosis of different clinical conditions. Statistical analyses were performed to determine the influence of factors such as genotype, age or gender. ResultsPaternal deletion genotype was the most frequent (65%) at all ages. Most patients had mild or moderate intellectual disability (87%). Only 30% had studied beyond primary school and 70% were in some special educational or working programme. Most of them lived in the family home (57%). The most prevalent somatic comorbidities were scoliosis (78%), respiratory problems (75%), dermatological lesions (50%), hyperlipidaemia (35%), hypothyroidism (26%), Type 2 diabetes mellitus (25%) and lymph oedema (22%). Some form of psychotropic treatment was prescribed in 58% of subjects, and sex hormones in 43%. Patients with deletion had a higher body mass index (44 vs. 38.9 kg/m(2)) and displayed higher frequency of sleep apnoeas. Non-deletion patients received insulin treatment (19% vs. 4%) and antipsychotic treatment (54.8% vs. 32.7%) more frequently. No difference was observed in the prevalence of Type 2 diabetes between the two genotype groups. Patients >27 years of age had a higher rate of comorbidities (Type 2 diabetes, hypertension, respiratory problems and lymph oedema). Gender differences were minor. ConclusionsAdult patients with PWS showed high prevalence of comorbid health problems that need to be monitored for early treatment. Some of them are influenced by genotype and age. Another salient problem concerns the lack of adapted structures for better social integration. Further data about the real life and health conditions of adults with PWS are necessary to further our knowledge of the natural history of the disease and to design appropriate care strategies.",2015-05,01/07/2022 10:40,01/07/2022 10:40,,411-421,,5,59,,,,,,,,,,,,,,WOS:000352569300002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VSMDP4HD,journalArticle,2016,"Garvey, C",Recent updates in chronic obstructive pulmonary disease,POSTGRADUATE MEDICINE,,0032-5481,10.1080/00325481.2016.1118352,,"Chronic obstructive pulmonary disease (COPD), characterized by chronic airways inflammation and progressive airflow limitation, is a common, preventable and treatable disease. Worldwide, COPD is a major cause of morbidity and mortality; smoking tobacco is the most important risk factor. This translational review of recent updates in COPD care for the primary care audience, includes recommendations from the 2015 Global Initiative for chronic obstructive lung disease (GOLD) report on diagnosis, pharmacological and non-pharmacological treatment, prevalence of comorbidities, management of exacerbations and the asthma and COPD overlap syndrome, with a focus on the importance and benefit of physical activity and exercise in COPD patients. Exacerbations and comorbidities contribute to the overall severity of COPD in individual patients. Management of exacerbations includes reducing the impact of the current exacerbation and preventing development of subsequent episodes. Healthcare professionals need to be alert to comorbidities, such as cardiovascular disease, anxiety/depression, lung cancer, infections and diabetes, which are common in COPD patients and can have a significant impact on HRQoL and prognosis. Pulmonary rehabilitation is recommended by a number of guidelines for all symptomatic COPD patients, regardless of severity, and involves exercise training, patient education, nutritional advice and psychosocial support. At all stages of COPD, regular physical activity and exercise can aid symptom control, improve HRQoL, reduce rates of hospitalization, and improve morbidity and respiratory mortality. Healthcare professionals play a pivotal role in improving HRQoL and health-related outcomes in COPD patients to meet their specific needs and in providing appropriate diagnosis, management and advice on smoking cessation.",17/02/2016,01/07/2022 10:40,01/07/2022 10:40,,231-238,,2,128,,,,,,,,,,,,,,WOS:000371924000009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9ZBZRC3R,journalArticle,2021,"Cintra, FD; Figueiredo, MJD","Atrial Fibrillation (Part 1): Pathophysiology, Risk Factors, and Therapeutic Basis",ARQUIVOS BRASILEIROS DE CARDIOLOGIA,,0066-782X,10.36660/abc.20200485,,"Atrial fibrillation is the most common sustained arrhythmia in clinical practice, with a preference for older age groups. Considering population ageing, the projections for the next decades are alarming. In addition to its epidemiological importance, atrial fibrillation is evidenced by its clinical repercussions, including thromboernbolic phenomena, hospitalizations, and a higher mortality rate. Its pathophysiological mechanism is complex arid involves an association of hemodynamic, structural, electrophysiological, and autonomic factors. Since the 1990s, the Framingham study of multivariate analyses has demonstrated that hypertension, diabetes, heart failure, and valvular disease are independent predictors of this rhythm abnormality along with age. However, various other risk factors have been recently implicated in an increase of atrial fibrillation cases, such as sedentary behavior, obesity, sleep disorders, tobacco use, and excessive alcohol use. Moreover, changes in quality of life indicate a reduction in atrial fibrillation recurrence, thus representing a new strategy for excellence in the treatment of this cardiac arrhythmia. Therapeutic management involves a broad knowledge of the patient's health state arid habits, comprehending 4 main pillars: lifestyle changes and rigorous treatment of risk factors; prevention of thromboernbolic events; rate control; and rhythm control. Due to the dimension of factors involved in the care of patients with atrial fibrillation, integrated actions performed by interprofessiona I teams are associated with the best clinical results.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,129-139,,1,116,,,,,,,,,,,,,,WOS:000615367300024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
G9AR9N5H,journalArticle,2011,"Auzky, O; Lanska, V; Pitha, J; Roztocil, K",Association between symptoms of chronic venous disease in the lower extremities and cardiovascular risk factors in middle-aged women,INTERNATIONAL ANGIOLOGY,,0392-9590,,,"Aim. The association between chronic venous disease (CVD) and atherosclerosis has been intensively investigated. Because data regarding cardiovascular disease in women are sparse, we evaluated the potential association between the symptoms of CVD and cardiovascular risk factors including markers of preclinical atherosclerosis in middle-aged women. Methods. A questionnaire for chronic lower limb venous insufficiency was completed by 902 women, aged 45-54 years, from the general population. At the same time, all women were examined for the presence of cardiovascular risk factors, including the ankle/brachial systolic blood pressure index (ABI) and carotid intima media thickness of the common carotid arteries measured by ultrasound. Differences in cardiovascular risk factors and markers of preclinical atherosclerosis between women with and without symptoms of CVD were evaluated. Results. Symptoms (cramps, aching, edema, disturbance of sleep) suggestive of CVD in the lower extremities were reported by 606 (67.2%) women and 114 (12.6%) reported that those symptoms were severe enough to limit their usual daily activities. A higher prevalence of ABI of less than 0.91 was observed in women with any (P=0.005) or severe (P=0.029) CVD symptoms. A significantly higher prevalence of the following were observed in women with any or severe CVD symptoms: coronary artery disease, history of diabetes mellitus, increased body mass index, waist circumference, serum triglycerides, serum C-reactive protein and lower serum HDL cholesterol. Conclusion. CVD symptoms were strongly associated with a higher prevalence of pathological values of ABI and several other manageable cardiovascular risk factors. These findings support the data that chronic venous disease might also indicate increased risk for atherosclerosis. [Int Angiol 2011;30:335-41]",2011-08,01/07/2022 10:40,01/07/2022 10:40,,335-341,,4,30,,,,,,,,,,,,,,WOS:000296032500004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4IFQ2BYN,bookSection,2011,"Holdaway, IM",Mortality and Morbidity in Acromegaly: Impact of Disease Control,GROWTH HORMONE RELATED DISEASES AND THERAPY: A MOLECULAR AND PHYSIOLOGICAL PERSPECTIVE FOR THE CLINICIAN,2523-3785,,,,"The excess production of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in patients with acromegaly is associated with a range of complications which have important effects on quality of life and which lead to reduced life expectancy. The increased mortality of the disorder has been recognized in 18 studies, totaling 4,806 individuals with acromegaly and including 1,116 deaths during follow-up, with meta-analyses indicating a standardized mortality estimate of 1.7 (95% CI 1.5-2). Univariate and multivariate analyses within the individual studies have identified the presence of hypertension, diabetes, and cardiac disease as important predictors of survival, as well as estimated duration from onset of the condition to date of effective treatment. However, the most important impact on survival comes from reduction of circulating GH and IGF-I concentrations, with serum GH measured by radioimmunoassay of <2.5 mu g/L and a serum IGF-I measurement within the normal range for age providing mortality estimates indistinguishable from the general population. The major comorbidities of acromegaly, including cardiovascular disease, stroke, diabetes, hypertension, arthropathy, and sleep apnea syndrome, also benefit from biochemical remission following treatment, and management of these complications of the disorder appears to be important in maintaining quality of life as well as assisting with reduction in mortality.",2011,01/07/2022 10:40,01/07/2022 10:40,,317-338,,,,,,,,,,,,,,,,,WOS:000294445100016,,,DOI: 10.1007/978-1-60761-317-6_16,,,,,,"Ho, K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GVHY2K7K,journalArticle,2010,"Symvoulakis, E; Anyfantakis, D; Lionis, C",Restless legs syndrome: literature review,SAO PAULO MEDICAL JOURNAL,,1516-3180,10.1590/S1516-31802010000300008,,"Restless legs syndrome is a distressing condition, with negative effects on sleep and daytime activities that affect personal, family and occupational life. The overall impact of restless legs syndrome on quality of life is comparable to that of chronic and frustrating conditions such as depression and diabetes. Misdiagnosis and inappropriate treatment may increase patients' suffering in terms of uncertainty, overuse or misuse of care services and lack of trust. Presenting a synthesis of the main topics in the literature on restless legs syndrome facilitates for a better understanding and its management in primary care settings.",06/05/2010,01/07/2022 10:40,01/07/2022 10:40,,167-170,,3,128,,,,,,,,,,,,,,WOS:000283255200008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7CCBZUS5,journalArticle,2002,"Hammack, JE; Michalak, JC; Loprinzi, CL; Sloan, JA; Novotny, PJ; Soori, GS; Tirona, MT; Rowland, KM; Stella, PJ; Johnson, JA",Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy,PAIN,,0304-3959,10.1016/S0304-3959(02)00047-7,,"Tricyclic antidepressants have been reported to relieve the paresthesiae associated with peripheral neuropathies of many etiologies. We designed a randomized, double-blind, placebo-controlled, crossover trial to establish the efficacy of nortriptyline in the treatment of cis-diamminedichloroplatinum (CDDP)-induced paresthesiae. The study included 51 evaluable patients with CDDP-induced peripheral neuropathy and painful paresthesiae. The study consisted of two 4 week phases, separated by a 1 week 'wash-out' period, in which patients received escalating dosages of either placebo or nortriptyline. The target maximum dose of nortriptyline was 100 mg/day. Each patient filled out pre-randomization and then weekly questionnaires assessing paresthesiae severity, hours of sleep, quality of life, and adverse effects over the 9 week study. No significant differences in paresthesia were observed in the first treatment period between nortriptyline and placebo (means of 49 and 55 respectively on a 0-100 point scale, P = 0.78). Although some evidence of a modest effect in favor of nortriptyline was observed during the second treatment period (about one patient in five got a 10-point reduction in pain from drug above placebo effect), this occurred in the presence of a strong carryover effect. Linear models analysis and Bayes methods confirmed that the effect of nortriptyline on paresthesia was modest at best. Hours of sleep increased in the nortriptyline phase (P = 0.02). There was no significant difference in measures of quality of life and the effect of paresthesiae on patients' daily activities between nortriptyline and placebo. There was no major toxicity associated with nortriptyline, but dry mouth, dizziness, and constipation were more common with nortriptyline. In summary, nortriptyline failed to demonstrate strong evidence of any effect on paresthesia or pain. The presence of a potential effect which appeared in the second period of the crossover design is questionable due to the observed carryover effect. Cross-validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy-related neuropathy. (C) 2002 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.",2002-07,01/07/2022 10:40,01/07/2022 10:40,,195-203,,01-Feb,98,,,,,,,,,,,,,,WOS:000177204300022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BG345XZS,journalArticle,2007,"Kaplan, G",Impact and outcomes - The public health burden of insomnia and the economic impact of recent pharmacotherapies,FORMULARY,,1082-801X,,,"The clinical and economic burden of insomnia is enormous. Insomnia, with its associated symptoms of sleep disruption, affects about 99 million people in the United States, making it more prevalent than arthritis, diabetes, and cardiovascular disease. This burden is especially great in the elderly. The majority of elderly people who have symptoms of insomnia complain of sleep maintenance problems. Insomnia also has a significant impact on health and healthcare costs. Insomnia is an independent risk factor for diabetes, and is associated with anxiety disorders, depression, and increased risk of falls in the elderly. Insomnia rivals diabetes in terms of annual direct and indirect costs-$92.5 to 107.5 billion in 1994, which is about $147.2 billion in 2006 dollars, using the medical component of the Consumer Price Index (CPI). A cost model developed, suggested that integrating zolpidem tartrate extended-release 000 into a health plan's formulary can result in consistent and significant cost savings to the plan.",2007-03,01/07/2022 10:40,01/07/2022 10:40,,3-+,,,,,,,,,,,,,,,,,WOS:000245475000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L6LI2IXF,journalArticle,2004,"Buchwald, H; Avidor, Y; Braunwald, E; Jensen, MD; Pories, W; Fahrbach, K; Schoelles, K",Bariatric surgery: A systematic review and meta-analysis,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,,0098-7484,10.1001/jama.292.14.1724,,"Context About 5% of the US population is morbidly obese. This disease remains largely refractory to diet and drug therapy, but generally responds well to bariatric surgery. Objective To determine the impact of bariatric surgery on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea). Data Sources and Study Selection Electronic literature search of MEDLINE, Current Contents, and the Cochrane Library databases plus manual reference checks of all articles on bariatric surgery published in the English language between 1990 and 2003. Two levels of screening were used on 2738 citations. Data Extraction A total of 136 fully extracted studies, which included 91 overlapping patient populations (kin studies), were included for a total of 22094 patients. Nineteen percent of the patients were men and 72.6% were women, with a mean age of 39 years (range, 16-64 years). Sex was not reported for 1537 patients (8%). The baseline mean body mass index for 16 944 patients was 46.9 (range, 32.3-68.8). Data Synthesis A random effects model was used in the meta-analysis. The mean (95% confidence interval) percentage of excess weight loss was 61.2% (58.1%-64.4%) for all patients; 47.5% (40.7%-54.2%) for patients who underwent gastric banding; 61.6% (56.7%-66.5%), gastric bypass; 68.2% (61.5%-74.8%), gastroplasty; and 70.1% (66.3%-73.9%), biliopancreatic diversion or duodenal switch. Operative mortality (less than or equal to30 days) in the extracted studies was 0.1% for the purely restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch. Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients. Conclusions Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery. A substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement.",13/10/2004,01/07/2022 10:40,01/07/2022 10:40,,1724-1737,,14,292,,,,,,,,,,,,,,WOS:000224413400032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
67FUKFG7,journalArticle,2019,"Gadelha, MR; Kasuki, L; Lim, DST; Fleseriu, M",Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update,ENDOCRINE REVIEWS,,0163-769X,10.1210/er.2018-00115,,"Acromegaly is a chronic systemic disease with many complications and is associated with increased mortality when not adequately treated. Substantial advances in acromegaly treatment, as well as in the treatment of many of its complications, mainly diabetes mellitus, heart failure, and arterial hypertension, were achieved in the last decades. These developments allowed change in both prevalence and severity of some acromegaly complications and furthermore resulted in a reduction of mortality. Currently, mortality seems to be similar to the general population in adequately treated patients with acromegaly. In this review, we update the knowledge in complications of acromegaly and detail the effects of different acromegaly treatment options on these complications. Incidence of mortality, its correlation with GH (cumulative exposure vs last value), and IGF-I levels and the shift in the main cause of mortality in patients with acromegaly are also addressed.",2019-02,01/07/2022 10:40,01/07/2022 10:40,,268-332,,1,40,,,,,,,,,,,,,,WOS:000460616200011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VW383VBY,book,2013,"Jarvis, S; Toth, C","Impact of chronic pain upon anxiety, sleep, and mood dimensions",,978-1-107-02371-0,,,,,2013,01/07/2022 10:40,01/07/2022 10:40,,,322,,,,,,"NEUROPATHIC PAIN: CAUSES, MANAGEMENT, AND UNDERSTANDING",,,,,,,,,,WOS:000326439500028,,,Pages: 333,,,,,,"Toth, C; Moulin, DE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TY736KKK,journalArticle,2020,"Krupp, K; Wilcox, M; Srinivas, A; Srinivas, V; Madhivanan, P; Bastida, E","Snoring is associated with obesity among middle aged Slum-dwelling women in Mysore, India",LUNG INDIA,,0970-2113,10.4103/lungindia.lungindia_515_19,,"Background: Globally, rates of obesity have trebled in the past four decades. India has more than 9.8 million men and 20 million women classified as obese. While poor diet and sedentary lifestyles are major causes, growing evidence suggests other factors like sleep-disordered-breathing may also be contributors. Methods: A cross-sectional survey was carried out between October 2017 and May 2018 among a nonprobability sample of slum-dwelling women, 40-64 years of age, in government-designated slums in Mysore, India. After the informed consent process, data were collected on sociodemographics, tobacco and alcohol consumption, diet, physical activity, sleep, quality of life, and personal and family history of diagnosed cardiometabolic disorders. Body mass index (BMI) was calculated using anthropometry. The serum was tested for HbA1c and lipid profile. Results: In this sample of slum-dwelling women, snoring was associated with obesity. Habitual snorers had more than double the odds (adjusted odds ratio [aOR] 2.05; 95% confidence interval [CI] 1.26-3.33; P < 0.004) of obesity I, and seven times the odds (aOR 7.71; CI: 3.58-16.62; P < 0.001) of being in the obesity II category compared to nonsnorers after adjustment for age, diabetes, hypertension, hypercholesterolemia, and daytime sleepiness. There was no difference in obesity status among participants reporting abnormal sleep duration, napping, daytime sleepiness, sleep apnea, insomnia, or the use of sleep medication. Conclusion: The relationship between snoring and obesity has not been well explored. This study among slum-dwelling Indian women found a significant relationship between snoring and obesity. Future research should explore the underlying mechanisms connecting snoring to BMI.",2020-05,01/07/2022 10:40,01/07/2022 10:40,,210-219,,3,37,,,,,,,,,,,,,,WOS:000587470800005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WPBB3YCG,journalArticle,2017,"King, CS; Nathan, SD",Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities,LANCET RESPIRATORY MEDICINE,,2213-2600,10.1016/S2213-2600(16)30222-3,,"Despite the development of pharmacological therapies that are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal condition. In addition to the adverse effects caused by pulmonary fibrosis, most patients with IPF have associated comorbid conditions, which might negatively affect functional status, quality of life, and survival. Comorbid conditions can be pulmonary or extrapulmonary. Pulmonary comorbidities include pulmonary hypertension, emphysema, and lung cancer, while non-pulmonary conditions include venous thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression. Although some of these comorbid conditions share risk factors with IPF, the likelihood for their presence or development in patients with IPF is still greater than expected. This might indicate that IPF fosters an environment for the development or perpetuation of comorbid conditions, or alternatively that they share causative factors. Optimal management of IPF therefore requires a comprehensive approach, which includes the identification and treatment of comorbid conditions to optimise patient outcomes.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,72-84,,1,5,,,,,,,,,,,,,,WOS:000396348600028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y5V9N9YI,journalArticle,2017,"Kumar, S; Kelly, AS","Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment",MAYO CLINIC PROCEEDINGS,,0025-6196,10.1016/j.mayocp.2016.09.017,,"Childhood obesity has emerged as an important public health problem in the United States and other countries in the world. Currently 1 in 3 children in the United States is afflicted with overweight or obesity. The increasing prevalence of childhood obesity is associated with emergence of comorbidities previously considered to be ""adult"" diseases including type 2 diabetes mellitus, hypertension, nonalcoholic fatty liver disease, obstructive sleep apnea, and dyslipidemia. The most common cause of obesity in children is a positive energy balance due to caloric intake in excess of caloric expenditure combined with a genetic predisposition for weight gain. Most obese children do not have an underlying endocrine or single genetic cause for their weight gain. Evaluation of children with obesity is aimed at determining the cause of weight gain and assessing for comorbidities resulting from excess weight. Family- based lifestyle interventions, including dietary modifications and increased physical activity, are the cornerstone of weight management in children. A staged approach to pediatric weight management is recommended with consideration of the age of the child, severity of obesity, and presence of obesity- related comorbidities in determining the initial stage of treatment. Lifestyle interventions have shown only modest effect on weight loss, particularly in children with severe obesity. There is limited information on the efficacy and safety of medications for weight loss in children. Bariatric surgery has been found to be effective in decreasing excess weight and improving comorbidities in adolescents with severe obesity. However, there are limited data on the long- term efficacy and safety of bariatric surgery in adolescents. For this comprehensive review, the literature was scanned from 1994 to 2016 using PubMed using the following search terms: childhood obesity, pediatric obesity, childhood overweight, bariatric surgery, and adolescents. (C) 2016 Mayo Foundation for Medical Education and Research",2017-02,01/07/2022 10:40,01/07/2022 10:40,,251-265,,2,92,,,,,,,,,,,,,,WOS:000396902000016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GI6THING,journalArticle,2021,"Tasnim, R; Sujan, MSH; Islam, MS; Ferdous, MZ; Hasan, MM; Koly, KN; Potenza, NM",Depression and anxiety among individuals with medical conditions during the COVID-19 pandemic: Findings from a nationwide survey in Bangladesh,ACTA PSYCHOLOGICA,,0001-6918,10.1016/j.actpsy.2021.103426,,"Background: Coronavirus disease 2019 (COVID-19) disproportionately impacts individuals with medical conditions, including with respect to their mental health. The present study investigated depression and anxiety and their correlates among individuals with medical conditions in Bangladesh. Methods: Subjects were recruited to participate in an internet-based survey. Data were collected from November 2020 to January 2021 using convenience sampling by a semi-structured questionnaire through online platforms. Multiple regression analyses were performed to determine associations applying Bonferroni correction (p < 0.004). The Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder (GAD-7) measured depression and anxiety, respectively. Results: Nine-hundred-and-seventy-one participants (50.1% male; mean age = 42.29 +/- 15.86 years; age range = 18-80 years) with medical conditions were included in final analyses. The most frequently reported conditions were diabetes, hypertension, obesity, heart disease, asthma, and anemia. Estimates of moderate to severe depression and anxiety were 38.9% and 35.2%, respectively. The mean depression and anxiety scores were significantly higher among participants who reported having hypertension, obesity, heart disease, asthma, anemia, cancer and chronic obstructive pulmonary disease (COPD). Using Bonferroni correction (p < 0.004), depression was associated with being female and a student, having poorer quality of life, poorer health status and greater numbers of co-morbidities, not engaging in physical exercise and tobacco smoking. Anxiety was associated with being female and a student, having lower socioeconomic status, poorer quality of life, poorer health status and greater numbers of co-morbidities, less sleep and tobacco smoking. Conclusions: Depression and anxiety are prevalent among individuals with medical conditions and correlate with sociodemographic, quality-of-life and smoking measures. Interventions targeting vulnerable groups should be employed and investigated.",2021-10,01/07/2022 10:40,01/07/2022 10:40,,,,,220,,,,,,,,,,,,,,WOS:000706372300015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X2A2RKRZ,journalArticle,2021,"Perez, RA; Jetelina, KK; Gonzalez, JMR",The Chronic Health Effects of Work-Related Stressors Experienced by Police Communications Workers,SAFETY AND HEALTH AT WORK,,2093-7911,10.1016/j.shaw.2021.05.005,,"Background: Law enforcement communications (i.e., 911 dispatch and call takers) is a challenging and stressful occupation. The purpose of this study is to identify the main stressors associated with employment in law enforcement communications, and to identify and provide context to how these stressors affect workers' health and wellbeing. Methods: This research study included focus groups with 23 call takers and 911 dispatchers employed by a large, urban law enforcement agency in 2018. Thematic analyses were conducted to identify trends. Results: Four themes of stressors emerged (i.e., the high stakes nature of some 911 calls for service, understaffing, supervisor-related stress, and recruiting practice). Two health-related themes emerged as being occupation-related: weight gain and poor sleep patterns/insufficient sleep). Specifically, participants reported negative eating habits resulting in weight gain and obesity, lack of sleep and irregular sleep schedules, and development of hypertension and/or diabetes since beginning their jobs. Conclusion: Law enforcement communications professionals experience a number of the same stressors facing law enforcement officers in patrol. These stressors, combined with the sedentary nature of the job, could result in long-term, chronic health problems. (C) 2021 Occupational Safety and Health Research Institute, Published by Elsevier Korea LLC.",2021-09,01/07/2022 10:40,01/07/2022 10:40,,365-369,,3,12,,,,,,,,,,,,,,WOS:000696954000011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84XADCJB,journalArticle,2010,"Koenig, P; Nagl, C; Neurauter, G; Schennach, H; Brandacher, G; Fuchs, D",Enhanced degradation of tryptophan in patients on hemodialysis,CLINICAL NEPHROLOGY,,0301-0430,,,"Background: Hemodialysis patients often present with increased concentrations of tryptophan catabolites perhaps related to an enhanced activity of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) that is inducible by pro-inflammatory stimuli. The often chronic inflammation and immune activation status in dialysis patients may accelerate tryptophan degradation, which could influence patients' psychological performance. Patients and methods: In this study, plasma concentrations of kynurenine and tryptophan were determined by HPLC in 75 dialysis patients, aged 65.3 +/- 15.0 years. Forty patients were female, 35 male; 21 (28%) had diabetes mellitus Type 1 or 2 and 32 (43%) suffered from sleep disturbances and/or depression. Their dialysis vintage was 4.26 +/- 4.72 years. HPLC results were compared to concentrations obtained from 40 healthy blood donors, to immune activation marker neopterin, and to psychological test results based on INTERMED scores. Results: Compared to those in healthy controls, tryptophan concentrations were decreased in patients. Neopterin, kynurenine and the kynurenine to tryptophan ratio (kyn/trp, an index of tryptophan degradation) were increased in patients (all p < 0.01). Kyn/trp correlated with neopterin concentrations (rs = 0.393, p < 0.01). INTERMED scores were 21.0 + 8.4 and slightly higher in females (U = -1.831, p < 0.07); they correlated with tryptophan concentrations (rs = -0.227, p < 0.05) but with no other parameter studied. Data point to a possible relationship between tryptophan metabolic disturbances and psychologic presentation of patients, although only a rather weak relationship was found. Conclusion: We conclude that tryptophan degradation is increased in dialysis patients. The association with increased neopterin concentrations indicates activated IDO.",2010-12,01/07/2022 10:40,01/07/2022 10:40,,465-470,,6,74,,,,,,,,,,,,,,WOS:000285995200007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YADHYVCU,journalArticle,2016,"Ivkovic, A; Puckett, J",The Psychological and Pharmacological Correlations of Atrial Fibrillation,PSYCHIATRIC ANNALS,,0048-5713,10.3928/00485713-20161110-01,,"Atrial fibrillation (AF) is an arrhythmia characterized by disorganized electrical activity of the atria, secondary to ectopic focal discharge, leading to ineffective contraction and rapid heart rate. AF is the most common cardiac arrhythmia and is seen in approximately 1% to 2% of the population. Risk factors connected with AF include age, male gender, hypertension, valve disease, obesity, heart failure, diabetes, sleep apnea, cardiac surgery, smoking, alcohol consumption, and psychosocial stress. AF is associated with increased morbidity and mortality primarily due to coronary heart disease, heart failure, and stroke and has been associated with cognitive impairment and psychological distress. Treatment of AF should be focused on mitigating stroke risk as well as rate or rhythm control. AF is linked with depression, anxiety, and mood disorders as well as poor quality of life, but evidence suggests that these features can be improved with appropriate management. Further investigation is needed to inform and guide clinicians in therapeutic options and nonpharmacologic interventions for both the physical and psychiatric ramifications of AF.",2016-12,01/07/2022 10:40,01/07/2022 10:40,,702-711,,12,46,,,,,,,,,,,,,,WOS:000393127600009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JFXGK6SE,journalArticle,2019,"Schon, M; Straka, I; Sedliak, M; Ukropec, J; Valkovic, P; Ukropcova, B",The role of physical activity in the management of patients with Parkinson's disease,CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE,,1210-7859,10.14735/amcsnn2019496,,"Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. It is characterized by the progressive deterioration of motor as well as non-motor symptoms, including cognitive dysfunction, disorders of mood and sleep and gastrointenstinal symptoms. Physical activity is a modifiable well-established risk factor for PD and clinical intervention studies with regular exercise undoubtedly point to the beneficial effects of aerobic as well as strength exercise training in patients with PD. Physical training improves 1. motor state, balance and functional capacity of skeletal muscles, thus reducing the risk of falls; 2. physical fitness and general functional capacity of the patient; and 3. energy metabolism, reducing the risk of type 2 diabetes, which often accelerates progression of PD. Moreover, physical activity and physical training improve quality of life by ameliorating both motor and non-motor symptoms, thus slowing down disease progression. Regular physical activity and exercise, based on individualized prescription and performed under the supervision of an experienced physician or exercise physiologist, are recommended as an integral part in the management of a patient with PD.",2019,01/07/2022 10:40,01/07/2022 10:40,,496-504,,5,82,,,,,,,,,,,,,,WOS:000500973400003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
URTLHY9Q,journalArticle,2015,"Muhlbacher, AC; Junker, U; Juhnke, C; Stemmler, E; Kohlmann, T; Leverkus, F; Nubling, M",Chronic pain patients' treatment preferences: a discrete-choice experiment,EUROPEAN JOURNAL OF HEALTH ECONOMICS,,1618-7598,10.1007/s10198-014-0614-4,,"The objective of this study was to identify, document, and weight attributes of a pain medication that are relevant from the perspective of patients with chronic pain. Within the sub-population of patients suffering from ""chronic neuropathic pain"", three groups were analyzed in depth: patients with neuropathic back pain, patients with painful diabetic polyneuropathy, and patients suffering from pain due to post-herpetic neuralgia. The central question was: ""On which features do patients base their assessment of pain medications and which features are most useful in the process of evaluating and selecting possible therapies?"" A detailed literature review, focus groups with patients, and face-to-face interviews with widely recognized experts for pain treatment were conducted to identify relevant treatment attributes of a pain medication. A pre-test was conducted to verify the structure of relevant and dominant attributes using factor analyses by evaluating the most frequently mentioned representatives of each factor. The Discrete-Choice Experiment (DCE) used a survey based on self-reported patient data including socio-demographics and specific parameters concerning pain treatment. Furthermore, the neuropathic pain component was determined in all patients based on their scoring in the painDETECT(A (R)) questionnaire. For statistical data analysis of the DCE, a random effect logit model was used and coefficients were presented. A total of 1,324 German patients participated in the survey, of whom 44 % suffered from neuropathic back pain (including mixed pain syndrome), 10 % complained about diabetic polyneuropathy, and 4 % reported pain due to post-herpetic neuralgia. A total of 36 single quality aspects of pain treatment, detected in the qualitative survey, were grouped in 7 dimensions by factor analysis. These 7 dimensions were used as attributes for the DCE. The DCE model resulted in the following ranking of relevant attributes for treatment decision: ""no character change"", ""less nausea and vomiting"", ""pain reduction"" (coefficient: > 0.9 for all attributes, ""high impact""), ""rapid effect"", ""low risk of addiction"" (coefficient similar to 0.5, ""middle impact""), ""applicability with comorbidity"" (coefficient similar to 0.3), and ""improvement of quality of sleep"" (coefficient similar to 0.25). All attributes were highly significant (p < 0.001). The results were intended to enable early selection of an individualized pain medication. The results of the study showed that DCE is an appropriate means for the identification of patient preferences when being treated with specific pain medications. Due to the fact that pain perception is subjective in nature, the identification of patientsA ' preferences will enable therapists to better develop and implement patient-oriented treatment of chronic pain. It is therefore essential to improve the therapistsA ' understanding of patient preferences in order to make decisions concerning pain treatment. DCE and direct assessment should become valid instruments to elicit treatment preferences in chronic pain.",2015-07,01/07/2022 10:40,01/07/2022 10:40,,613-628,,6,16,,,,,,,,,,,,,,WOS:000356041200005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CQATLDHS,journalArticle,2015,"Kelles, SMB; Diniz, MDHS; Machado, CJ; Barreto, SM",The profile of patients undergoing bariatric surgery in the Brazilian Unified National Health System: a systematic review,CADERNOS DE SAUDE PUBLICA,,0102-311X,10.1590/0102-311X00022714,,"Nearly one million Brazilians were morbidly obese in 2013. Bariatric surgery is an option for sustained weight loss, and the Brazilian Unified National Health System (SUS) had provided 50,000 such procedures as of 2014. The SUS database does not provide anthropometric and comorbidity data on these patients, so the aim of the current study was to perform a systematic review to assess the profile of SUS patients that underwent bariatric surgery from 1998 to 2014. The MEDLINE, LILACS, SciELO, and Scopus databases were searched, and the methodological quality of the included articles was assessed. Of the 1,591 identified studies, 39 were selected, 95% of which were observational. Patients had a mean age of 41.4 years and mean body mass index of 48.6kg/m(2); 21% were males, 61% hypertensive, 22% diabetics, and 31% presented sleep apnea. When compared to international study samples, SUS patients showed similar a anthropometric profile and comorbidities but higher prevalence of hypertension. The studies' low methodological quality suggests caution in interpreting the results.",2015-08,01/07/2022 10:40,01/07/2022 10:40,,1587-1601,,8,31,,,,,,,,,,,,,,WOS:000361551600003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KZPWHWZ6,journalArticle,2017,"Obayashi, K; Saeki, K; Negoro, H; Kurumatani, N",Nocturia increases the incidence of depressive symptoms: a longitudinal study of the HEIJO-KYO cohort,BJU INTERNATIONAL,,1464-4096,10.1111/bju.13791,,"Objectives To evaluate the association between nocturia and the incidence of depressive symptoms. Participants and Methods Of 1 127 participants in the HEIJO-KYO population-based cohort, 866 elderly individuals (mean age 71.5 years) without depressive symptoms at baseline were followed for a median period of 23 months. Nocturnal voiding frequency was logged using a standardized urination diary and nocturia was defined as a frequency of >= 2 voids per night. Depressive symptoms were assessed using the Geriatric Depression Scale. Results During the follow-up period, 75 participants reported the development of depressive symptoms (score >= 6). The nocturia group (n = 239) exhibited a significantly higher hazard ratio (HR) for incident depressive symptoms than the non-nocturia group (n = 627) in the Cox proportional hazard model, which was adjusted for age, gender, alcohol consumption, day length and presence of hypertension and chronic kidney disease (HR 1.69, 95% confidence interval [CI] 1.05-2.72; P = 0.032]. The significance remained after adjustment for sleep disturbances (HR 1.68, 95% CI 1.02-2.75; P = 0.040). Analysis stratified by gender showed that the association between nocturia and the incidence of depressive symptoms was significant in men (HR 2.51, 95% CI 1.27-4.97; P = 0.008) but not in women (HR 1.12, 95% CI 0.53-2.44; P = 0.74). Conclusions Nocturia is significantly associated with a higher incidence of depressive symptoms in the general elderly population, and gender differences may underlie this association.",2017-08,01/07/2022 10:40,01/07/2022 10:40,,280-285,,2,120,,,,,,,,,,,,,,WOS:000405715600018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SEEDYIAP,journalArticle,2011,"Campos, MPO; Hassan, BJ; Riechelmann, R; Del Giglio, A",Cancer-related fatigue: a practical review,ANNALS OF ONCOLOGY,,0923-7534,10.1093/annonc/mdq458,,"Fatigue is an exceedingly common often treatable problem in cancer patients that profoundly affects all aspects of quality of life. Prevalence estimates have ranged from 50% to 90% of cancer patients overall. After addressing reversible or treatable contributing factors, such as hypothyroidism, anemia, sleep disturbance, pain, emotional distress, climacterium, medication adverse events, metabolic disturbances, or organ dysfunction such as heart failure, myopathy, and pulmonary fibrosis, patients may be screened with a brief fatigue self-assessment tool. All cancer patients should be screened regularly for fatigue. Those with moderate or severe fatigue may benefit from both pharmacologic and nonpharmacologic interventions, while mild fatigue that does not interfere with quality of life can be treated with nonpharmacologic measures alone. Physicians often have insufficient knowledge about fatigue and its treatments or underestimate the impact of fatigue on quality of life, while patients may consider it an unavoidable and untreatable side-effect and fear that reporting it may incite a change toward less aggressive cancer treatment. A practical review may therefore be useful to health care professionals in order to avoid the common barriers to its treatment that exist on the sides of both physicians and patients.",2011-06,01/07/2022 10:40,01/07/2022 10:40,,1273-1279,,6,22,,,,,,,,,,,,,,WOS:000291060800005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7FG7SMNM,journalArticle,2017,"Galle, F; Maida, P; Cirella, A; Giuliano, E; Belfiore, P; Liguori, G",Does Post-operative Psychotherapy Contribute to Improved Comorbidities in Bariatric Patients with Borderline Personality Disorder Traits and Bulimia Tendencies? A Prospective Study,OBESITY SURGERY,,0960-8923,10.1007/s11695-017-2581-1,,"Borderline personality disorder (BPD) and eating disorders may affect the outcomes of bariatric surgery. This study was aimed to evaluate the influence of a post-operative dialectical behavioral therapy (DBT) intervention on weight loss and comorbidities in a sample of comorbid obese Italian patients with BPD traits and bulimia tendencies who underwent laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB). One hundred fifty-four LRYGB or LAGB patients showing BPD and bulimia traits and type II diabetes, hypertension, and/or sleep apnea (OSAS) voluntarily adhered to DBT (n = 72) or treatment as usual (n = 82) for 12 months after surgery. Total weight loss (%TWL) and remission/improvement of comorbidities were considered as outcomes. Differences between treatment groups and between LRYGB and LAGB subgroups were evaluated through Student's t test for TWL and chi-square test for comorbidities. DBT was more effective than treatment as usual (TAU) in reducing weight loss (p < .001). Reduction of comorbidities was higher in patients treated with DBT, as for diabetes (p = .68), hypertension (p = .02), and OSAS (p = .03). LRYGB outcomes seem to be significantly better than those of LAGB, mainly in TAU group. Our findings confirm the effectiveness of DBT in enhancing post-bariatric weight loss and reduction of comorbidities in patients showing BPD traits and bulimia tendencies. Further in-depth investigations and a longer follow-up are needed to strengthen these results.",2017-07,01/07/2022 10:40,01/07/2022 10:40,,1872-1878,,7,27,,,,,,,,,,,,,,WOS:000404529600036,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2QU8RM8D,journalArticle,2021,"Torres-Zegarra, C; Sundararajan, D; Benson, J; Seagle, H; Witten, M; Walders-Abramson, N; Simon, SL; Huguelet, P; Nokoff, NJ; Cree-Green, M",Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic,JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY,,1083-3188,10.1016/j.jpag.2021.02.002,,"Study Objective: Based on updated guidelines and expressed patient needs, we created a multidisciplinary clinic including endocrinology, gynecology/adolescent medicine, dermatology, psychology, and nutrition to provide comprehensive care to adolescent girls with polycystic ovary syndrome (PCOS). We describe the patient population presenting to this clinic, and prescribing patterns when a multidisciplinary approach is used. Design: Retrospective chart review. Setting: Tertiary care hospital. Participants: Female patients, aged 11-24 years, presenting for initial assessment in a multidisciplinary PCOS clinic. Interventions: None. Main Outcome Measures: Medical history, physical examination findings, laboratory measurements and prescribed therapies. Results: A total of 92 patients seen from 2014 to 2018 are described (age 15.9 years, range 11-24 years, body mass index 35.6 kg/m(2), range 19.9-53.5). Metabolic syndrome features were common: 26% had a prediabetes hemoglobin A1c (>5.6%), 83% had a high-density lipoprotein (HDL) <50 mg/dL, 40% had a systolic blood pressure >120 mm Hg, and 43% had an alanine aminotransferase level of >30 U/L. Dermatologic findings included acne 93%, hirsutism 38%, acanthosis nigricans 85%, hidradenitis suppurativa 16%, and androgenic alopecia 2%. Of the patients, 33% had a diagnosis of depression or anxiety, 16% of patients had a diagnosis of obstructive sleep apnea, and an additional 59% had symptoms warranting a sleep study The most commonly prescribed medications were topical acne preparations (62%), followed by estrogen-containing hormonal therapy (56%) and metformin (40%). Conclusion: In adolescents with PCOS and obesity, metabolic, dermatologic, and psychologic co-morbidities are common. The use of a multidisciplinary clinic model including dermatology in addition to endocrinology, gynecology, psychology, and lifestyle experts provides care for most aspects of PCOS.",2021-10,01/07/2022 10:40,01/07/2022 10:40,,617-625,,5,34,,,,,,,,,,,,,,WOS:000691540600007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UKSWIUAS,journalArticle,2015,"Chong, VH; Singh, J; Parry, H; Saunders, J; Chowdhury, F; Mancini, DM; Lang, CC",Management of Noncardiac Comorbidities in Chronic Heart Failure,CARDIOVASCULAR THERAPEUTICS,,1755-5914,10.1111/1755-5922.12141,,"Prevalence of heart failure is increasing, especially in the elderly population. Noncardiac comorbidities complicate heart failure care and are increasingly common in elderly patients with reduced or preserved ejection fraction heart failure, owing to prolongation of patient's lives by advances in chronic heart failure (CHF) management. Common comorbidities include respiratory disease, renal dysfunction, anemia, arthritis, obesity, diabetes mellitus, cognitive dysfunction, and depression. These conditions contribute to the progression of the disease and may alter the response to treatment, partly as polypharmacy is inevitable in these patients. Cardiologists and other physicians caring for patients with CHF need to be vigilant to comorbid conditions that complicate the care of these patients. There is now more guidance on management of noncardiac comorbidities in heart failure, and this article contains a comprehensive review of the most recent updates on management of noncardiac comorbidities in CHF.",2015-10,01/07/2022 10:40,01/07/2022 10:40,,300-315,,5,33,,,,,,,,,,,,,,WOS:000361492200008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A396JMU3,journalArticle,2021,"Konttinen, H; Sjoholm, K; Jacobson, P; Svensson, PA; Carlsson, LMS; Peltonen, M","Prediction of Suicide and Nonfatal Self-harm After Bariatric Surgery: A Risk Score Based on Sociodemographic Factors, Lifestyle Behavior, and Mental Health A Nonrandomized Controlled Trial",ANNALS OF SURGERY,,0003-4932,10.1097/SLA.0000000000003742,,"Objective: To identify preoperative sociodemographic and health-related factors that predict higher risk of nonfatal self-harm and suicide after bariatric surgery. Background: Evidence is emerging that bariatric surgery is related to an increased risk of suicide and self-harm, but knowledge on whether certain preoperative characteristics further enhance the excess risk is scarce. Methods: The nonrandomized, prospective, controlled Swedish Obese Subjects study was linked to 2 Nationwide Swedish registers. The bariatric surgery group (N = 2007, per-protocol) underwent gastric bypass, banding or vertical banded gastroplasty, and matched controls (N = 2040) received usual care. Participants were recruited from 1987 to 2001, and information on the outcome (a death by suicide or nonfatal self-harm event) was retrieved until the end of 2016. Subhazard ratios (sub-HR) were calculated using competing risk regression analysis. Results: The risk for self-harm/suicide was almost twice as high in surgical patients compared to control patients both before and after adjusting for various baseline factors [adjusted sub-HR = 1.98, 95% confidence interval (CI) = 1.34-2.93]. Male sex, previous healthcare visits for self-harm or mental disorders, psychiatric drug use, and sleep difficulties predicted higher risk of self-harm/suicide in the multivariate models conducted in the surgery group. Interaction tests further indicated that the excess risk for self-harm/suicide related to bariatric surgery was stronger in men (sub-HR = 3.31, 95% CI = 1.73-6.31) than in women (sub-HR = 1.54, 95% CI = 1.02-2.32) (P = 0.007 for adjusted interaction). A simple-to-use score was developed to identify those at highest risk of these events in the surgery group. Conclusions: Our findings suggest that male sex, psychiatric disorder history, and sleep difficulties are important predictors for nonfatal self-harm and suicide in postbariatric patients. High-risk patients who undergo surgery might require regular postoperative psychosocial monitoring to reduce the risk for future self-harm behaviors.",2021-08,01/07/2022 10:40,01/07/2022 10:40,,339-345,,2,274,,,,,,,,,,,,,,WOS:000670889700043,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
J3TG58ZL,journalArticle,2011,"Lenz, TL; Monaghan, MS",Implementing lifestyle medicine with medication therapy management services to improve patient-centered health care,JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION,,1544-3191,10.1331/JAPhA.2011.10169,,"Objective: To describe a patient-centered medication therapy management (MTM) program that focuses on lifestyle medicine. Setting: Community pharmacy in Omaha, NE, from August 2008 to September 2010. Practice description: Traditional MTM services are combined with lifestyle medicine interventions for employees of a self-insured organization who have dyslipidemia, hypertension, and/or diabetes. Program participants meet one-on-one with a pharmacist 12 times during the first year of the program to ensure proper drug therapy and modify lifestyle behaviors (physical activity, nutrition, weight control, sleep, stress, and alcohol and tobacco use) through individualized programming. Practice innovation: Several patient-centered activities have been developed for the program with an emphasis on modifying lifestyle behaviors in conjunction with medications to manage participants' chronic condition. In addition, a new specialty position in health care is being developed (the ambulatist) that focuses on maintaining the ambulatory status of individuals with chronic medical conditions through appropriate drug therapy, lifestyle medicine, and care coordination. Main outcome measures: Biometric data collection and participant survey data at baseline and after 12 months. Results: Pilot data for 15 participants showed improvements in all measurements, including blood cholesterol, low-density lipoprotein cholesterol, blood glucose, body weight, physical activity level, fruit and vegetable intake, risk for myocardial infarction, risk for any cardiovascular disease event, self-reported unhealthy days, and qualitative survey data. Conclusion: Pharmacists are in an ideal position to implement lifestyle medicine strategies in combination with MTM services to enhance patient-centered health care in a community pharmacy setting.",2011-03,01/07/2022 10:40,01/07/2022 10:40,,184-188,,2,51,,,,,,,,,,,,,,WOS:000297752100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P6QU3MRL,journalArticle,2017,"Zick, SM; Colacino, J; Cornellier, M; Khabir, T; Surnow, K; Djuric, Z",Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial,BREAST CANCER RESEARCH AND TREATMENT,,0167-6806,10.1007/s10549-016-4070-y,,"Fatigue is a prevalent and burdensome effect of breast cancer. Fatigue has been linked to chronic inflammation, and diets high in antioxidant nutrients have been associated with lesser prevalence and severity of fatigue. Studies are needed, however, to test if antioxidant-rich diets could improve fatigue. Pilot, randomized, trial conducted between January 2014 and April 2015, to investigate if a 3-month diet rich in fruit, vegetables, whole grains, and omega-3 fatty acid-rich foods, named the fatigue reduction diet (FRD), improved fatigue and sleep compared to an attention control, named the general health curriculum (GHC). 30 stage 0 to III breast cancer survivors, who had completed cancer treatments, were randomized: 15 receiving the FRD and 15 the GHC. Primary outcome was change in fatigue, as measured by the brief fatigue Inventory, from baseline to 3 months analyzed using linear mixed models. Secondary analyses were changes in sleep quality, serum carotenoids, and fatty acids. From baseline to 3-month fatigue improved by 44 +/- 39% in FRD compared to 8 +/- 34% in GHC (p = 0.01); sleep quality improved by 2.5 +/- 3.3 points in FRD, and diminished by 0.9 +/- 2.3 in GHC (p = 0.03); serum total carotenoids (p < 0.01), beta-cryptoxanthin (p = 0.02), lutein (p = 0.05), zeaxanthin (p = 0.01), lycopene (p = 0.05), omega-3 fatty acids (p < 0.01), and ratio of omega-3:omega-6 fatty acids (p = 0.02) were significantly increased, and percent saturated fatty acids were decreased (p = 0.04) in FRD; gamma-tocopherol was significantly increased in GHC (p = 0.03), and there was a significant visit by group difference for alpha-carotene between the study groups (p = 0.05). The FRD intervention improved fatigue and sleep in breast cancer survivors compared to the GHC. FRD diet could provide a non-toxic treatment strategy for persistent fatigue.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,299-310,,2,161,,,,,,,,,,,,,,WOS:000392385100011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
K9N6SQTR,journalArticle,2019,"Zhang, AY; Li, SH; Zhang, YW; Jiang, F; Jin, XM; Ma, J",Nocturnal enuresis in obese children: a nation-wide epidemiological study from China,SCIENTIFIC REPORTS,,2045-2322,10.1038/s41598-019-44532-5,,"Childhood obesity increases the risk of obstructive sleep apnea syndrome, type 2 diabetes mellitus, cardiovascular abnormalities, and psychological and behavioral disorders. But it is unclear whether obesity is associated with childhood nocturnal enuresis (NE). This study aimed to assess the relationship between childhood obesity and NE in a nationally representative large sample in China. Subjects were enrolled from Urumqi, Chengdu, Xi'an, Hohhot, Wuhan, Canton, Shanghai, and Harbin cities in China in November and December 2005. The survey included 20,987 children aged 5-12 years and they and their caregivers completed questionnaires. Height and weight were measured by school teachers trained in healthcare. According to the WHO child growth standards, obesity was defined as a body mass index >95th percentile of peers with the same age and gender. NE was defined as bed wetting for more than twice a week for 3 consecutive months. Demographic variables were compared among different groups. The prevalence of obesity, asthma, attention-deficit/hyperactivity disorder (ADHD), depressive moods, and snoring were different between the NE and without-NE groups (P < 0.05). The raw odds ratio (OR) for NE and obesity was 1.36 (95%CI = 1.07-1.74; P = 0.013) and the adjusted OR was 1.42 (95%CI = 1.11-1.82; P= 0.005) in the multivariable analysis. When adjusting for co-occurring conditions, the results showed that asthma did not affect the risk of NE (OR = 1.42, 95%CI = 1.11-1.82; P = 0.005), but ADHD (OR = 1.41; 95%CI = 1.10-1.81; P = 0.006) and depressive moods (OR = 1.34; 95%Cl = 1.07-1.76; P = 0.012) slightly weakens the association between NE in children and obesity, while snoring weakens the association between obesity and NE and the risk became non-significant (OR =1.21; 95%CI = 0.94-1.56; P = 0.138). In conclusion, obese children were at a higher risk of incurring NE compared to non-obese children. This association was weaker in children who either snored, had ADHD, or had depressive mood.",10/06/2019,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000470847700011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2E3BDHJU,journalArticle,2019,"Accardi, R; Racaniello, E; Ronchi, S; De Rosa, E; Badiali, S","Gastric Banding, Gastric Bypass, and Comorbidity Reduction: A Five-Year Prospective Study",BARIATRIC SURGICAL PRACTICE AND PATIENT CARE,,2168-023X,10.1089/bari.2019.0014,,"Objective: Analyze if bariatric surgery could induce changes in comorbidity rates and compare the outcomes of two different kinds of bariatric surgery interventions. Materials and Methods: A 5-year before-after study on a cohort of obese patients who were subjected to bariatric surgery in the years 2013-2015 was conducted. Comorbidities considered in this study were arterial hypertension, hyperlipidemia, diabetes, sleep apnea, osteoarthritis, gastroesophageal reflux, urinary incontinence, and lower limb ulcers. Results: One hundred thirty-six subjects were enrolled in the final sample: 110 underwent gastric banding and 26 underwent gastric bypass. Data have shown that both interventions provide an important weight loss and gastric bypass is more effective in permanent weight reduction; bariatric surgery is effective in reduction of sleep apnea, osteoarthritis, gastroesophageal reflux, urinary incontinence, and lower limb ulcers. Frequencies of presentation of hypertension, diabetes, and hypercholesterolemia in patients who underwent gastric banding follow a ""U-shaped trend."" Conclusions: Bariatric surgery for obese subjects is an effective solution for weight loss, but it has also proved to be an effective way to reduce comorbidities, with an important reduction in frequencies of all pathologies and an improvement in blood tests. Gastric bypass is superior to gastric banding in comorbidity reduction.",2019-12,01/07/2022 10:40,01/07/2022 10:40,,150-154,,4,14,,,,,,,,,,,,,,WOS:000488132000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X3JRC5ES,journalArticle,2006,"Bouldin, MJ; Ross, LA; Sumrall, CD; Loustalot, FV; Low, AK; Land, KK",The effect of obesity surgery on obesity comorbidity,AMERICAN JOURNAL OF THE MEDICAL SCIENCES,,0002-9629,10.1097/00000441-200604000-00004,,"Obesity is epidemic in the modern world. It is becoming increasingly clear that obesity is a major cause of cardiovascular disease, diabetes, and renal disease, as well as a host of other comorbidities. There are at present no generally effective long-term medical therapies for obesity. Surgical therapy for morbid obesity is not only effective in producing long-term weight loss but is also effective in ameliorating or resolving several of the most significant complications of obesity, including diabetes, hypertension, dyslipidemia, sleep apnea, gastroesophageal reflux disease, degenerative joint disease, venous stasis, pseudotumor cerebri, nonalcoholic steatohepatitis, urinary incontinence, fertility problems, and others. The degree of benefit and the rates of morbidity and mortality of the various surgical procedures vary according to the procedure.",2006-04,01/07/2022 10:40,01/07/2022 10:40,,183-193,,4,331,,,,,,,,,,,,,,WOS:000237010700004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
754NVZWQ,journalArticle,2016,"Mugisha, JO; Schatz, EJ; Randell, M; Kuteesa, M; Kowal, P; Negin, J; Seeley, J","Chronic disease, risk factors and disability in adults aged 50 and above living with and without HIV: findings from the Wellbeing of Older People Study in Uganda",GLOBAL HEALTH ACTION,,1654-9880,10.3402/gha.v9.31098,,"Background: Data on the prevalence of chronic conditions, their risk factors, and their associations with disability in older people living with and without HIV are scarce in sub-Saharan Africa. Objectives: In older people living with and without HIV in sub-Saharan Africa: 1) to describe the prevalence of chronic conditions and their risk factors and 2) to draw attention to associations between chronic conditions and disability. Methods: Cross-sectional individual-level survey data from people aged 50 years and over living with and without HIV were analyzed from three study sites in Uganda. Diagnoses of chronic conditions were made through self-report, and disability was determined using the WHO Disability Assessment Schedule (WHODAS). We used ordered logistic regression and calculated predicted probabilities to show differences in the prevalence of multiple chronic conditions across HIV status, age groups, and locality. We used linear regression to determine associations between chronic conditions and the WHODAS. Results: In total, 471 participants were surveyed; about half the respondents were living with HIV. The prevalence of chronic obstructive pulmonary disease and eye problems (except for those aged 60-69 years) was higher in the HIV-positive participants and increased with age. The prevalence of diabetes and angina was higher in HIV-negative participants. The odds of having one or more compared with no chronic conditions were higher in women (OR 1.6, 95% CI 1.1-2.3) and in those aged 70 years and above (OR 2.1, 95% CI 1.2-3.6). Sleep problems (coefficient 14.2, 95% CI 7.3-21.0) and depression (coefficient 9.4, 95% CI 1.2-17.0) were strongly associated with higher disability scores. Conclusion: Chronic conditions are common in older adults and affect their functioning. Many of these conditions are not currently addressed by health services in Uganda. There is a need to revise health care policy and practice in Uganda to consider the health needs of older people, particularly as the numbers of people living into older age with HIV and other chronic conditions are increasing.",2016,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000377800800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XL62MMQC,journalArticle,2015,"Connor, CJ; Liu, V; Fiedorowicz, JG",Exploring the Physiological Link between Psoriasis and Mood Disorders,DERMATOLOGY RESEARCH AND PRACTICE,,1687-6105,10.1155/2015/409637,,"Psoriasis is a chronic, immune-mediated skin condition with a high rate of psychiatric comorbidity, which often goes unrecognized. Beyond the negative consequences of mood disorders like depression and anxiety on patient quality of life, evidence suggests that these conditions can worsen the severity of psoriatic disease. The mechanisms behind this relationship are not entirely understood, but inflammation seems to be a key feature linking psoriasis with mood disorders, and physiologic modulators of this inflammation, including the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, demonstrate changes with psychopathology that may be contributory. Cyclical disruptions in the secretion of the sleep hormone, melatonin, are also observed in both depression and psoriasis, and with well-recognized anti-inflammatory and antioxidant activity, this aberration may represent a shared contributor to both conditions as well as common comorbidities like diabetes and cardiovascular disease. While understanding the complexities of the biological mechanisms at play will be key in optimizing the management of patients with comorbid psoriasis and depression/anxiety, one thing is certain: recognition of psychiatric comorbidity is an imperative first step in effectively treating these patients as a whole. Evidence that improvement in mood decreases psoriasis severity underscores how psychological awareness can be critical to clinicians in their practice.",2015,01/07/2022 10:40,01/07/2022 10:40,,,,,2015,,,,,,,,,,,,,,WOS:000363971900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QGFNHW22,journalArticle,2006,"Jassal, SV; Devins, GM; T Chan, C; Bozanovic, R; Rourke, S",Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: A longitudinal pilot study,KIDNEY INTERNATIONAL,,0085-2538,10.1038/sj.ki.5001691,,"Cognitive impairment has been documented in uremia with partial improvement after dialysis. Nocturnal daily hemodialysis (NHD) is a novel dialysis modality with multiple benefits. Previous reports have shown marked improvements in quality of life, cardiac function, resolution of peripheral vascular disease, and reversal of central sleep apnea. We hypothesized that patients maintained on NHD would have better cognitive functioning than those receiving conventional therapy. Using a longitudinal study design, patients were tested at baseline and again after >= 6 months NHD. At each of the two time points, a battery of 10 neuropsychological tests were used to evaluate three domains of cognitive functioning - attention and working memory skills, psychomotor efficiency and processing speed, and learning efficiency. Clinical subjective symptoms for cognitive functioning and depression were measured using the Patients Assessment of Own Functioning inventory and the Beck Depression Index. Twelve patients ( six males, six females) were recruited. Patients were aged 39.6 +/- 3.3 years at the time of first testing. Thirty-three percent were diabetic, with a mean Charlson comorbidity score of 3.5 +/- 2.0. Depression ( defined as 416 on the Beck Depression Index score) was not seen in any patient. Over the 6-month period, a 22% reduction in cognitive symptoms (P = 0.01), 7% improvement in psychomotor efficiency and processing speed (P = 0.02), and 32% improvement in attention and working memory (P = 0.04) was seen. Learning efficiency scores were unchanged. NHD may be associated with improved general cognitive efficiency as measured by psychomotor efficiency and attention and working memory.",2006-09,01/07/2022 10:40,01/07/2022 10:40,,956-962,,5,70,,,,,,,,,,,,,,WOS:000240351100025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RWSQ2CRG,journalArticle,2014,"Sperry, S; Knox, B; Edwards, D; Friedman, A; Rodriguez, M; Kaly, P; Albers, M; Shaffer-Hudkins, E","Cultivating Healthy Eating, Exercise, and Relaxation (CHEER): A Case Study of a Family-Centered and Mindfulness-Based Cognitive-Behavioral Intervention for Obese Adolescents at Risk for Diabetes and Cardiovascular Disease",CLINICAL CASE STUDIES,,1534-6501,10.1177/1534650113507743,,"Attrition from weight management programs and difficulty maintaining success are of significant concern for pediatric overweight patients. Patient and family variables associated with completing and maintaining outcomes from a healthy weight program include understanding and buy-in for treatment, parental motivation, and valuing of weight loss to quality of life. Such findings highlight the need for comprehensive intervention that involves family members and addresses motivation and relapse prevention. The present study describes a family-centered and mindfulness-based cognitive-behavioral intervention implemented with a 15-year old, clinically obese male with associated symptoms including elevated blood pressure and sleep apnea. This pilot implementation resulted in improved pre-post outcomes in regard to weight, blood pressure, and health-promoting behaviors. Improvements in healthy lifestyle were maintained 1-year post-treatment. These results add to the growing literature on ecologically relevant intervention for obese adolescents at risk for future health complications. Technical issues and clinical implications related to recruitment and retention are discussed.",2014-06,01/07/2022 10:40,01/07/2022 10:40,,218-230,,3,13,,,,,,,,,,,,,,WOS:000346588900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DQ2KHATH,journalArticle,2020,"van der Veen, A; Minovic, I; van Faassen, M; Gomes-Neto, AW; Berger, SP; Bakker, SJL; Kema, IP","Urinary Excretion of 6-Sulfatoxymelatonin, the Main Metabolite of Melatonin, and Mortality in Stable Outpatient Renal Transplant Recipients",JOURNAL OF CLINICAL MEDICINE,,2077-0383,10.3390/jcm9020525,,"Melatonin is a multifaceted hormone which rises upon the onset of darkness. Pineal synthesis of melatonin is known to be disturbed in patients with end-stage renal disease, but it is not known if its production is restored to normal after successful renal transplantation. We hypothesized that urinary excretion of 6-sulfatoxymelatonin, the major metabolite of melatonin, is lower in renal transplant recipients (RTRs) compared to healthy controls and that this is associated with excess mortality. Urinary 6-sulfatoxymelatonin was measured via LC-MS/MS in 701 stable outpatient RTRs and 285 healthy controls. Median urinary 6-sulfatoxymelatonin in RTR was 13.2 nmol/24 h, which was 47% lower than in healthy controls. Urinary 6-sufatoxymelatonin appeared undetectable in the majority of 36 RTRs with diabetic nephropathy as primary renal disease. Therefore, this subgroup was excluded from further analyses. Of the remaining 665 RTRs, during 5.4 years of follow-up, 110 RTRs died, of whom 38 died due to a cardiovascular cause. In Cox-regression analyses, urinary 6-sulfatoxymelatonin was significantly associated with all-cause mortality (0.60 (0.44-0.81), p = 0.001) and cardiovascular mortality (0.49 (0.29-0.84), p = 0.009), independent of conventional risk factors and kidney function parameters. Based on these results, evaluation and management of melatonin metabolism could be considered for improvement of long-term outcomes in RTRs.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,,,2,9,,,,,,,,,,,,,,WOS:000518823000237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UQDEWL9B,journalArticle,2015,"Freeman, R; Wallace, MS; Sweeney, M; Backonja, MM","Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin",PAIN MEDICINE,,1526-2375,10.1111/pme.12791,,"ObjectiveTo determine the effect of gastroretentive gabapentin (G-GR) and describe relationships among pain quality, pain impact, and overall-improvement scores in patients with postherpetic neuralgia (PHN). MethodsAnalyses of integrated data from two Phase 3 studies in which PHN patients received once-daily G-GR 1,800 mg (n=356) or placebo (n=363). Neuropathic pain scale (NPS) and brief pain inventory (BPI) were completed at baseline and Week 10; patients' global impression of change (PGIC) at Week 10. Regression analyses described relationships among changes in the NPS, BPI, and PGIC scores. ResultsCompared with placebo, G-GR patients had significant reductions from baseline in individual NPS measures except cold pain (P < 0.05); composite NPS scores (P0.003); BPI pain scores (P<0.05); three individual (mood, sleep, and enjoyment of life) and the average of BPI interference scores (P < 0.05). Clinically significant improvements in BPI interference scores (except walking ability) were positively correlated with reductions in BPI and NPS pain (except dull and cold pain), and with improvements on the PGIC. Reductions in pain qualities at Week 2, especially in NPS pain intensity, were significant (P0.0001) predictors of improvements in three BPI interference scores, total NPS score, and PGIC. ConclusionsFor patients with PHN, G-GR provided significant improvements in multiple measures of pain quality and pain-related functional impairment. There was a positive correlation between pain relief and improvement in patient function, with reduction in pain intensity among predictors of improvements in patients' lives. Such comprehensive analyses give an insight into numerous factors that may contribute to better management of PHN.",2015-10,01/07/2022 10:40,01/07/2022 10:40,,2000-2011,,10,16,,,,,,,,,,,,,,WOS:000362887800017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99WZD5LS,journalArticle,2016,"Abreu, A; Tovar, AP; Castellanos, R; Valenzuela, A; Giraldo, CMG; Pinedo, AC; Guerrero, DP; Barrera, CAB; Franco, HI; Ribeiro-Oliveira, A; Vilar, L; Jallad, RS; Duarte, FG; Gadelha, M; Boguszewski, CL; Abucham, J; Naves, LA; Musolino, NRC; de Faria, MEJ; Rossato, C; Bronstein, MD",Challenges in the diagnosis and management of acromegaly: a focus on comorbidities,PITUITARY,,1386-341X,10.1007/s11102-016-0725-2,,"Acromegaly is a rare, insidious disease resulting from the overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and is associated with a range of comorbidities. The extent of associated complications and mortality risk is related to length of exposure to the excess GH and IGF-1, thus early diagnosis and treatment is imperative. Unfortunately, acromegaly is often diagnosed late, when patients already have a wide range of comorbidities. The presence of comorbid conditions contributes significantly to patient morbidity/mortality and impaired quality of life. We conducted a retrospective literature review for information relating to the diagnosis of acromegaly, and its associated comorbidities using PubMed. The main aim of this review is to highlight the issues of comorbidities in acromegaly, and to reinforce the importance of early diagnosis and treatment. Successful management of acromegaly goes beyond treating the disease itself, since many patients are diagnosed late in disease evolution, they present with a range of comorbid conditions, such as cardiovascular disease, diabetes, hypertension, and sleep apnea. It is important that patients are screened carefully at diagnosis (and thereafter), for common associated complications, and that biochemical control does not become the only treatment goal. Mortality and morbidities in acromegaly can be reduced successfully if patients are treated using a multimodal approach with comprehensive comorbidity management.",2016-08,01/07/2022 10:40,01/07/2022 10:40,,448-457,,4,19,,,,,,,,,,,,,,WOS:000379350000014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GKKF6I8I,journalArticle,2018,"Leiva, AM; Petermann-Rocha, F; Martinez-Sanguinetti, MA; Troncoso-Pantoja, C; Conchas, Y; Garrido-Mendez, A; Diaz-Martinez, X; Lanuza-Rilling, F; Ulloa, N; Martorell, M; Alvarez, C; Celis-Morales, C; Grp Invest ELHOC",Association of a healthy lifestyle index with cardiovascular risk factors in Chileans adults,REVISTA MEDICA DE CHILE,,0034-9887,10.4067/s0034-98872018001201405,,"Background: Healthy lifestyles are associated with a better metabolic- and cardiovascular health profile. Aim: To investigate the association between a lifestyle score and cardiovascular risk in Chilean adults. Material and Methods: A healthy lifestyle score was derived for 2,774 participants in the Chilean National Health Survey 2009-2010 and based on seven modifiable behaviors (salt intake, fruit and vegetable intake, alcohol consumption, sleep duration, smoking, physical activity and sedentary behaviors). A high score represented a healthier lifestyle whereas a low score represents an unhealthy lifestyle. The association between the lifestyle score and cardiovascular risk factors (obesity, hypertension, diabetes, dyslipidemia and metabolic syndrome), was explored using logistic regression models. Results: One quartile increment in the healthy lifestyle score was associated with a lower risk for obesity (Odds ratio (OR): 0.82 [95% confidence intervals (CI): 0.75 to 0.90], p < 0.01), central obesity (OR: 0.88 [95% CI: 0.81 to 0.96], p < 0.01), diabetes (OR: 0.84 95% CI: 0.75 to 0.95], p < 0.04) and dyslipidemia (OR: 0.90 [95% CI: 0.83 to 0.98], p = 0.01). These results were independent of major confounding factors. Conclusions: The adherence to a healthy lifestyle is associated with lower cardiovascular risk.",2018-12,01/07/2022 10:40,01/07/2022 10:40,,1405-1414,,12,146,,,,,,,,,,,,,,WOS:000459046100005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QTCQUTWN,journalArticle,2014,"Moore, RA; Wiffen, PJ; Derry, S; Toelle, T; Rice, ASC",Gabapentin for chronic neuropathic pain and fibromyalgia in adults,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD007938.pub3,,"Background This review is an update of a review published in 2011, itself a major update of previous reviews published in 2005 and 2000, investigating the effects of gabapentin in chronic neuropathic pain (pain due to nerve damage). Antiepileptic drugs are used to manage chronic neuropathic pain and fibromyalgia. Objectives To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia. Search methods We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014). We obtained clinical trial reports and synopses of published and unpublished studies from Internet sources, and searched Clinicaltrials.gov. Searches were run originally in 2011 and the date of the most recent search was 17 March 2014. Selection criteria Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales. Participants were adults. Data collection and analysis Three review authors independently extracted efficacy and adverse event data, examined issues of study quality, and assessed risk of bias. We performed analysis using three tiers of evidence. First tier evidence derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts; at least 200 participants in the comparison, 8 to 12 weeks duration, parallel design), second tier from data that failed to meet one or more of these criteria and were considered at some risk of bias but with adequate numbers in the comparison, and third tier from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both. For efficacy, we calculated the number needed to treat to benefit (NNT), concentrating on at least 50% pain intensity reduction, and Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) definitions of at least moderate and substantial benefit. For harm we calculated number needed to treat for harm (NNH) for adverse effects and withdrawal. Meta-analysis was undertaken using a fixed-effect model. We emphasised differences between conditions now defined as neuropathic pain, and other conditions like masticatory pain, complex regional pain syndrome type 1 (CRPS-1), and fibromyalgia. Main results Seven new studies with 1919 participants were added. Another report (147 participants) provided results for a study already included, but which previously had no usable data. A further report (170 participants) used an experimental formulation of intrathecal gabapentin. Thirty-seven studies (5633 participants) studied oral gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 84% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain. There was no first tier evidence. Second tier evidence for the outcome of at least 50% pain intensity reduction, considered valuable by patients with chronic pain, showed that gabapentin was significantly better than placebo in postherpetic neuralgia (34% gabapentin versus 21% placebo; NNT 8.0, 95% CI 6.0 to 12) and painful diabetic neuropathy (38% versus 21%, NNT 5.9, 95% CI 4.6 to 8.3). There was insufficient information in other pain conditions to reach any reliable conclusion. There was no obvious difference between standard gabapentin formulations and recently-introduced extended-release or gastro-retentive formulations, or between different doses of gabapentin. Adverse events occurred significantly more often with gabapentin. Persons taking gabapentin could expect to have at least one adverse event (62%), withdraw because of an adverse event (11%), suffer dizziness (19%), somnolence (14%), peripheral oedema (7%), and gait disturbance (9%). Serious adverse events (3%) were no more common than with placebo. There were insufficient data for direct comparisons with other active treatments, and only third tier evidence for other painful conditions. Authors' conclusions There was no top tier evidence that was unequivocally unbiased. Second tier evidence, with potentially important residual biases, showed that gabapentin at doses of 1200 mg or more was effective for some people with some painful neuropathic pain conditions. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by patients, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. About 35% achieved this degree of pain relief with gabapentin, compared with 21% for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief. Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited. The levels of efficacy found for gabapentin are consistent with those found for other drug therapies in postherpetic neuralgia and painful diabetic neuropathy.",2014,01/07/2022 10:40,01/07/2022 10:40,,,,4,,,,,,,,,,,,,,,WOS:000335885200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VKSJ79SK,journalArticle,2017,"Mina, TH; Lahti, M; Drake, AJ; Raikkonen, K; Minnis, H; Denison, FC; Norman, JE; Reynolds, RM",Prenatal exposure to very severe maternal obesity is associated with adverse neuropsychiatric outcomes in children,PSYCHOLOGICAL MEDICINE,,0033-2917,10.1017/S0033291716002452,,"Background. Prenatal maternal obesity has been linked to adverse childhood neuropsychiatric outcomes, including increased symptoms of attention deficit hyperactivity disorder (ADHD), internalizing and externalizing problems, affective disorders and neurodevelopmental problems but few studies have studied neuropsychiatric outcomes among offspring born to very severely obese women or assessed potential familial confounding by maternal psychological distress. Method. We evaluated neuropsychiatric symptoms in 112 children aged 3-5 years whose mothers had participated in a longitudinal study of obesity in pregnancy (50 very severe obesity, BMI >= 40 kg/m(2), obese class III and 62 lean, BMI 18.5-25 kg/m(2)). The mothers completed the Conners' Hyperactivity Scale, Early Symptomatic Syndrome Eliciting Neurodevelopmental Clinical Examination Questionnaire (ESSENCE-Q), Child's Sleep Habits Questionnaire (CSHQ), Strengths and Difficulties Questionnaire (SDQ), and Child Behavior Checklist (CBCL) to assess child neuropsychiatric symptoms. Covariates included child's sex, age, birthweight, gestational age, socioeconomic deprivation levels, maternal age, parity, smoking status during pregnancy, gestational diabetes and maternal concurrent symptoms of anxiety and depression assessed using State Anxiety of Spielberger State-Trait Anxiety Index (STAI) and General Health Questionnaire (GHQ), respectively. Results. Children exposed to prenatal maternal very severe obesity had significantly higher scores in the Conners' Hyperactivity Scale; ESSENCE-Q; total sleep problems in CSHQ; hyperactivity, conduct problems and total difficulties scales of the SDQ; higher externalizing and total problems, anxious/depressed, aggressive behaviour and other problem syndrome scores and higher DSM-oriented affective, anxiety and ADHD problems in CBCL. Prenatal maternal very severe obesity remained a significant predictor of child neuropsychiatric problems across multiple scales independent of demographic factors, prenatal factors and maternal concurrent symptoms of anxiety and depression. Conclusions. Prenatal maternal very severe obesity is a strong predictor of increased neuropsychiatric problems in early childhood.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,353-362,,2,47,,,,,,,,,,,,,,WOS:000391320100014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NEEEMPIJ,journalArticle,2021,"Ebied, EME; Eldardery, NE",Lived experiences of homelessness among elderly women: a phenomenological study,PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES,,1996-7195,10.53350/pjmhs211582413,,"Background: Homelessness is a global issue that has a devastating impact on elderly women's health. It is estimated that100 million people are considered homeless worldwide. Aim: to explore the lived experiences of homelessness among elderly women. Research question: What are the lived experiences of homelessness among elderly women? Sample: A purposive sample of 30 homless elderly women. Setting: a selected homelessness shelter. Tools: 1- A structured questionnaire of personal and medical data. 2- Semi-structured interview with open-ended questions. 3- Field notes. Results/Themes: five themes were represented; (1) Living without basic human needs (food, water, sleep &shelter), (2) Self-care deficit. (self-neglect, poor hygiene and bad odor). (3) Bio- psycho- social health problems (fear, aggressive behavior, depression, suicidal ideation, isolation, hopelessness, loss of family role, vision problems, diabetic foot and lack of acces to health care services), (4) Emotional distress (uncertainity, loss of interest, suicidal ideation, bad feeling, feeling lonely), (5) Strategies for resolution (religious and expression of feelings). Conclusion: Majority of homless elderly women experienced living without basic human needs, bio-psychsocial health problems, self-care deficit which predispose them to many devastating health consequences. Recommmendations: Employ urgent interventions to solve the unique and challenging health problems/needs of this vulnerable group; raising community awarness about the nature, and process of homelessness phenomena and conduct bio-psychosocial interventions studies of homeless elderly women.",2021-08,01/07/2022 10:40,01/07/2022 10:40,,2413-2420,,8,15,,,,,,,,,,,,,,WOS:000729240600074,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XP7H5XDB,journalArticle,2018,"Nair, HKR",Microcurrent as an adjunct therapy to accelerate chronic wound healing and reduce patient pain,JOURNAL OF WOUND CARE,,0969-0700,10.12968/jowc.2018.27.5.296,,"Objective: The primary aim is to assess the efficacy of microcurrent, a form of electrical stimulation, as an adjunct therapy in accelerating healing in chronic wounds by reducing wound size and pain level. The secondary aim is to assess the qualitative changes in these parameters: inflammatory symptoms, vasodilation, sleep quality, gait and frequency of bowel movement. Method: Eligible patients with chronic wounds were enrolled between March and June 2016, from the Wound Care Unit, Hospital Kuala Lumpur in this consecutive case series. Standard wound care was performed with microcurrent as an adjunct therapy. Each patient was treated with an anti-inflammatory frequency, followed by a vasodilation frequency, while having their wounds cleansed during each dressing change. Patients were loaned a home-microcurrent device to treat themselves three times daily using a tissue repair frequency for four weeks. Results: A total of 100 patients with chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, were recruited. During the four-week treatment period, all patients had a reduction in wound size, with 16 having complete wound closure. All 89 of the 100 patients who complained of pain, associated with their wound, experienced reduced pain scores, with 11 being pain-free at the end of the four-week period. There was significant reduction (p<0.001) in both mean pain score and mean wound area during the treatment period, as well as improvements in other parameters, such as reduction in inflammatory symptoms (leg swelling, foot stiffness), increased vasodilation (skin discolouration, leg heaviness, early morning erection, sensation), improvement in sleep quality, gait, and frequency of bowel movement. No adverse events were reported. Conclusion: The results of this study show there was significant reduction in wound area and pain score during the treatment period. The ease of use of microcurrent devices would advocate its use in accelerating wound healing.",2018-05,01/07/2022 10:40,01/07/2022 10:40,,296-306,,5,27,,,,,,,,,,,,,,WOS:000431665500007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CKL2K8PQ,journalArticle,,"O'Loughlin, J; Casanova, F; Jones, SE; Hagenaars, SP; Beaumont, RN; Freathy, RM; Watkins, ER; Vetter, C; Rutter, MK; Cain, SW; Phillips, AJK; Windred, DP; Wood, AR; Weedon, MN; Tyrrell, J",Using Mendelian Randomisation methods to understand whether diurnal preference is causally related to mental health,MOLECULAR PSYCHIATRY,,1359-4184,10.1038/s41380-021-01157-3,,"Late diurnal preference has been linked to poorer mental health outcomes, but the understanding of the causal role of diurnal preference on mental health and wellbeing is currently limited. Late diurnal preference is often associated with circadian misalignment (a mismatch between the timing of the endogenous circadian system and behavioural rhythms), so that evening people live more frequently against their internal clock. This study aims to quantify the causal contribution of diurnal preference on mental health outcomes, including anxiety, depression and general wellbeing and test the hypothesis that more misaligned individuals have poorer mental health and wellbeing using an actigraphy-based measure of circadian misalignment. Multiple Mendelian Randomisation (MR) approaches were used to test causal pathways between diurnal preference and seven well-validated mental health and wellbeing outcomes in up to 451,025 individuals. In addition, observational analyses tested the association between a novel, objective measure of behavioural misalignment (Composite Phase Deviation, CPD) and seven mental health and wellbeing outcomes. Using genetic instruments identified in the largest GWAS for diurnal preference, we provide robust evidence that early diurnal preference is protective for depression and improves wellbeing. For example, using one-sample MR, a twofold higher genetic liability of morningness was associated with lower odds of depressive symptoms (OR: 0.92, 95% CI: 0.88, 0.97). It is possible that behavioural factors including circadian misalignment may contribute in the chronotype depression relationship, but further work is needed to confirm these findings.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000658602200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IACKGKKS,journalArticle,2017,"Choi, WS; Moon, OK; Yeum, DM",Latent profile analysis of lifestyle characteristics and health risk behaviors among Koreans who have completed industrial accident care,INDUSTRIAL HEALTH,,0019-8366,10.2486/indhealth.2017-0008,,"This study investigated the characteristics and health behavior profiles of 1,803 workers who had experienced industrial accidents. Average weekly exercise days, average number of cigarettes smoked per day, average daily sleep duration, and number of days of alcohol consumption were selected to investigate health behavior profiles. Specifically, latent profile analysis was applied to identify the health behavior profiles of people who had completed industrial accident care; the latent classes were the health-conscious type (n=240), the potential-risk type (n=850), and the high-risk type (n=713). Comparison of the health-conscious and potential-risk types indicated that younger subjects, the employed, and those with lower social status and life satisfaction were more likely to be the potential-risk type. Comparison of the health-conscious and high-risk types revealed that males, younger subjects, the employed, those without chronic illnesses, and those with lower social status and life satisfaction were more likely to be the high-risk type. The results suggest that industrial accident victims who have completed accident care have different health behaviors and it is necessary to improve health promotion based on health type characteristics.",2017-09,01/07/2022 10:40,01/07/2022 10:40,,460-470,,5,55,,,,,,,,,,,,,,WOS:000412037400008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UL5UDTIV,journalArticle,2014,"Mao, S; Shen, H; Huang, SM; Zhang, AH",Restless legs syndrome in dialysis patients: a meta-analysis,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2014.07.017,,"Background: Restless legs syndrome (RLS) occurs frequently in dialysis patients. However, it remains elusive regarding the risk factors for RLS onset in dialysis patients. Methods: A meta-analysis was performed to investigate the association between clinical measures (age, gender, diabetes mellitus or DM etc.) and RLS in dialysis patients. We searched electronic databases from January 1990 to February 2014 to identify studies that met inclusion criteria. Either a fixed-effects or, in the presence of heterogeneity, a random-effects model was used to calculate the pooled odds ratios (ORs)/standard mean differences (SMDs) and their corresponding confidence intervals (CIs). Results: Twenty-three studies were included in this study. Dialysis patients with RLS demonstrated significantly higher OR of DM compared with non-RLS in Asians (OR: 1.238, 95% CI: 1.032-1.484, P = 0.021). Dialysis patients with RLS showed markedly lower level of hemoglobin (Hb)/iron compared with non-RLS in overall populations/Caucasians (SMD: -0.178/-0.104, 95% CI: -0.352/-0.206 to -0.004/-0.002, P = 0.045/0.045;SMD: -0.283/-0.158, 95% CI: -0.552/-0.304 to -0.013/-0.012, P = 0.04/0.034). No differences of female populations, age, duration of dialysis, body mass index (BMI), blood urea nitrogen (BUN), creatinine, albumin, phosphorus, parathyroid hormone (PTH), and calcium were observed between dialysis patients with RLS and non-RLS in overall populations, Caucasians and Asians. No evidence of publication bias was observed. Conclusions: Our findings indicate that dialysis patients with DM are nearly 24% more susceptible to RLS in Asians. Decreased Hb/iron is a risk factor for RLS onset in dialysis patients in overall populations including Caucasians. (C) 2014 Elsevier B.V. All rights reserved.",2014-12,01/07/2022 10:40,01/07/2022 10:40,,1532-1538,,12,15,,,,,,,,,,,,,,WOS:000346084100016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IKHQ95NA,journalArticle,,"Hernandez, R; Roll, SC; Jin, HM; Schneider, S; Pyatak, EA",Validation of the National Aeronautics and Space Administration Task Load Index (NASA-TLX) adapted for the whole day repeated measures context,ERGONOMICS,,0014-0139,10.1080/00140139.2021.2006317,,"Our objective was to investigate the validity of four-item and six-item versions of the National Aeronautics and Space Administration Task Load Index (NASA-TLX, or TLX for short) for measuring workload over a whole day in the repeated measures context. We analysed data on 51 people with type 1 diabetes from whom we collected ecological momentary assessment and daily diary data over 14 days. The TLX was administered at the last survey of every day. Confirmatory factor analysis fit statistics indicated that neither the TLX-6 nor TLX-4 were a unidimensional representation of whole day workload. In exploratory analyses, another set of TLX items we refer to as TLX-4v2 was sufficiently unidimensional. Raw sum scores from the TLX-6 and TLX-4v2 had plausible relationships with other measures, as evidenced by intra-person correlations and mixed-effects models. TLX-6 appears to capture multiple factors contributing to workload, while TLX-4v2 assesses the single factor of 'mental strain'. Practitioner Summary: Using within-person longitudinal data, we found evidence supporting the validity of a measure evaluating whole-day workload (i.e. workload derived from all sources, not only paid employment) derived from the NASA-TLX. This measure may be useful to assess how day-to-day variations in workload impact quality of life among adults.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000721225000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PD9DHHUD,journalArticle,2012,"Gu, YM; Asayama, K; Liu, YP; Staessen, JA",Renal denervation: time to open Pandora's box,SWISS MEDICAL WEEKLY,,1424-7860,10.4414/smw.2012.13638,,"Depending on the populations studied and the definitions applied, the prevalence of treatment-resistant hypertension varies from 10% to 15%, but is higher in conditions associated with increased sympathetic drive, such as obesity, obstructive sleep apnoea, diabetes or renal dysfunction. The Symplicity studies recently demonstrated that reducing sympathetic tone by intravascular renal denervation is feasible in treatment-resistant hypertension, but failed to provide conclusive evidence on the size and durability of the antihypertensive, renal and sympatholytic effects, long-term safety, quality of life, the possibility to relax antihypertensive drug treatment, cost-effectiveness, and long-term hard cardiovascular-renal outcomes. Renal denervation should therefore only be offered within a clinical research context at highly skilled tertiary referral centres that participate in international registries constructed independent of the manufacturers.",17/07/2012,01/07/2022 10:40,01/07/2022 10:40,,,,,142,,,,,,,,,,,,,,WOS:000306656900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TD82TM6V,journalArticle,2010,"Mols, F; Denollet, J",Type D personality among noncardiovascular patient populations: a systematic review,GENERAL HOSPITAL PSYCHIATRY,,0163-8343,10.1016/j.genhosppsych.2009.09.010,,"Objective: This article reviews all available literature concerning the implications of Type D personality (the conjoint effects of negative affectivity and social inhibition) among patients with noncardiovascular conditions. Methods: Published papers were included if they studied Type D personality among noncardiovascular patient populations. Twelve articles met our inclusion criteria and were subjected to a methodological quality checklist (e.g., sample size, response rate, Type D measurement). Results: The methodological quality of the selected studies was quite good. The noncardiovascular patient populations included chronic pain, asthma, tinnitus, sleep apnea, primary care patients, vulvovaginal candidiasis, mild traumatic brain injury, vertigo, melanoma and diabetic foot syndrome. Type D personality was associated with an increased number or severity of reported health complaints, heightened the perception of negative emotions (e.g., depression and anxiety), had an adverse effect on health-related behaviors, was associated with poor adherence to treatment and significantly reduced effort to perform during diagnostic testing. Conclusion: Type D is a vulnerability factor that not only affects people with cardiovascular conditions but also those with other medical conditions. Type D was associated with poor physical and mental health status and poor self-management of the disease. Consequently, including Type D in future studies seems warranted. (C) 2010 Elsevier Inc. All rights reserved.",2010-01,01/07/2022 10:40,01/07/2022 10:40,,66-72,,1,32,,,,,,,,,,,,,,WOS:000276761200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
V5XRI3C6,journalArticle,2017,"Sharples, AJ; Charalampakis, V; Daskalakis, M; Tahrani, AA; Singhal, R",Systematic Review and Meta-Analysis of Outcomes After Revisional Bariatric Surgery Following a Failed Adjustable Gastric Band,OBESITY SURGERY,,0960-8923,10.1007/s11695-017-2677-7,,"Laparoscopic adjustable gastric band (LAGB)-related complications have been reported in significant numbers of patients often leading to band removal. Increasingly revisional bariatric surgery (RBS) is offered, most commonly either band to Roux-en-Y gastric bypass (B-RYGB) or band to sleeve gastrectomy (B-SG). We conducted a systematic review and meta-analysis of studies to evaluate the efficacy of RBS following failed LAGB. Medline, Embase, The Cochrane Library and NHS Evidence were searched for English language studies assessing patients who had undergone LAGB and who subsequently underwent either B-RYGB or B-SG. Thirty-six studies met the inclusion criteria. There were 2617 patients. B-RYGB was performed in 60.5% (n = 1583). There was one death within 30 days (0.0004%). The overall pooled morbidity rate was 13.2%. There was no difference between the B-RYGB and B-SG groups in morbidity, leak rate or return to theatre. Percentage excess weight loss (%EWL) following the revisional procedure for all patients combined at 6, 12 and 24 months was 44.5, 55.7 and 59.7%, respectively. There was no statistical difference in %EWL between B-RYGB and B-SG at any time point. The rates of remission of diabetes, hypertension and obstructive sleep apnoea were 46.5, 35.9 and 80.8%, respectively. Randomised controlled trials (RCTs) do not exist on this issue but the available observational evidence does suggest that RBS is associated with generally good outcomes similar to those experienced after primary surgery. Further, high-quality research, particularly RCTs, is required to assess long-term weight loss, comorbidity and quality of life outcomes.",2017-10,01/07/2022 10:40,01/07/2022 10:40,,2522-2536,,10,27,,,,,,,,,,,,,,WOS:000411373000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CXU6I3JM,journalArticle,2020,"Munch, M; Wirz-Justice, A; Brown, SA; Kantermann, T; Martiny, K; Stefani, O; Vetter, C; Wright, KP; Wulff, K; Skene, DJ",The Role of Daylight for Humans: Gaps in Current Knowledge,CLOCKS & SLEEP,,2624-5175,10.3390/clockssleep2010008,,"Daylight stems solely from direct, scattered and reflected sunlight, and undergoes dynamic changes in irradiance and spectral power composition due to latitude, time of day, time of year and the nature of the physical environment (reflections, buildings and vegetation). Humans and their ancestors evolved under these natural day/night cycles over millions of years. Electric light, a relatively recent invention, interacts and competes with the natural light-dark cycle to impact human biology. What are the consequences of living in industrialised urban areas with much less daylight and more use of electric light, throughout the day (and at night), on general health and quality of life? In this workshop report, we have classified key gaps of knowledge in daylight research into three main groups: (I) uncertainty as to daylight quantity and quality needed for ""optimal"" physiological and psychological functioning, (II) lack of consensus on practical measurement and assessment methods and tools for monitoring real (day) light exposure across multiple time scales, and (III) insufficient integration and exchange of daylight knowledge bases from different disciplines. Crucial short and long-term objectives to fill these gaps are proposed.",2020-03,01/07/2022 10:40,01/07/2022 10:40,,61-85,,1,2,,,,,,,,,,,,,,WOS:000655526500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BWLXIXBC,journalArticle,2017,"Jennum, P; Thorstensen, EW; Pickering, L; Ibsen, R; Kjellberg, J",Morbidity and mortality of middle-aged and elderly narcoleptics,SLEEP MEDICINE,,1389-9457,10.1016/j.sleep.2017.03.029,,"Objectives: The objective of the study was to evaluate the morbidities and mortality in a national group of middle-aged and elderly narcolepsy patients before and after the first diagnosis of the condition. Methods: From the Danish National Patient Registry (NPR), 1174 patients (45.1% males) aged 20-59 years and 339 patients (44.8% males) aged 60+ who received a diagnosis of narcolepsy between 1998 and 2014 were compared, respectively, with 4716 and 1353 control citizens matched for age, gender and geography, who were randomly chosen from the Danish Civil Registration System Statistics. In the NPR, all morbidities are grouped into major WHO classes. Results: Middle-aged and elderly patients had more health contacts before and after their narcolepsy diagnosis with respect to several disease domains: infections, neoplasm, endocrine/metabolic diseases/diabetes, mental/psychiatric, neurological (including epilepsy), eye, cardiovascular (hypertension, ischemic heart disease), respiratory (upper-airway infections, sleep apnea), gastrointestinal, musculoskeletal (including discopathies) and skin diseases. Narcolepsy patients had lower reproductive rates. Furthermore, patients showed significantly more health contacts due to the evaluation and control contacts for disease and symptoms. Patients suffered from significantly more multiple diseases than did controls. The 17-year hazard ratio mortality rates were 1.35 (95% CI, 0.94-1.95, p = 0.106) among 20-59 year-olds, and 1.38 (1.12-1.69, p = 0.002) among those aged 60+ years. Conclusion: There are higher rates of morbidity in several disease domains before and after a diagnosis of narcolepsy. Elderly narcolepsy patients have higher mortality rates. (C) 2017 Elsevier B.V. All rights reserved.",2017-08,01/07/2022 10:40,01/07/2022 10:40,,23-28,,,36,,,,,,,,,,,,,,WOS:000407742300005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZR3CJ8HX,journalArticle,2010,"Dupuis, J; Langenberg, C; Prokopenko, I; Saxena, R; Soranzo, N; Jackson, AU; Wheeler, E; Glazer, NL; Bouatia-Naji, N; Gloyn, AL; Lindgren, CM; Magi, R; Morris, AP; Randall, J; Johnson, T; Elliott, P; Rybin, D; Thorleifsson, G; Steinthorsdottir, V; Henneman, P; Grallert, H; Dehghan, A; Hottenga, JJ; Franklin, CS; Navarro, P; Song, K; Goel, A; Perry, JRB; Egan, JM; Lajunen, T; Grarup, N; Sparso, T; Doney, A; Voight, BF; Stringham, HM; Li, M; Kanoni, S; Shrader, P; Cavalcanti-Proenca, C; Kumari, M; Qi, L; Timpson, NJ; Gieger, C; Zabena, C; Rocheleau, G; Ingelsson, E; An, P; O'Connell, J; Luan, J; Elliott, A; McCarroll, SA; Payne, F; Roccasecca, RM; Pattou, F; Sethupathy, P; Ardlie, K; Ariyurek, Y; Balkau, B; Barter, P; Beilby, JP; Ben-Shlomo, Y; Benediktsson, R; Bennett, AJ; Bergmann, S; Bochud, M; Boerwinkle, E; Bonnefond, A; Bonnycastle, LL; Borch-Johnsen, K; Bottcher, Y; Brunner, E; Bumpstead, SJ; Charpentier, G; Chen, YDI; Chines, P; Clarke, R; Coin, LJM; Cooper, MN; Cornelis, M; Crawford, G; Crisponi, L; Day, INM; de Geus, EJC; Delplanque, J; Dina, C; Erdos, MR; Fedson, AC; Fischer-Rosinsky, A; Forouhi, NG; Fox, CS; Frants, R; Franzosi, MG; Galan, P; Goodarzi, MO; Graessler, J; Groves, CJ; Grundy, S; Gwilliam, R; Gyllensten, U; Hadjadj, S; Hallmans, G; Hammond, N; Han, XJ; Hartikainen, AL; Hassanali, N; Hayward, C; Heath, SC; Hercberg, S; Herder, C; Hicks, AA; Hillman, DR; Hingorani, AD; Hofman, A; Hui, J; Hung, J; Isomaa, B; Johnson, PRV; Jorgensen, T; Jula, A; Kaakinen, M; Kaprio, J; Kesaniemi, YA; Kivimaki, M; Knight, B; Koskinen, S; Kovacs, P; Kyvik, KO; Lathrop, GM; Lawlor, DA; Le Bacquer, O; Lecoeur, C; Li, Y; Lyssenko, V; Mahley, R; Mangino, M; Manning, AK; Martinez-Larrad, MT; McAteer, JB; McCulloch, LJ; McPherson, R; Meisinger, C; Melzer, D; Meyre, D; Mitchell, BD; Morken, MA; Mukherjee, S; Naitza, S; Narisu, N; Neville, MJ; Oostra, BA; Orru, M; Pakyz, R; Palmer, CNA; Paolisso, G; Pattaro, C; Pearson, D; Peden, JF; Pedersen, NL; Perola, M; Pfeiffer, AFH; Pichler, I; Polasek, O; Posthuma, D; Potter, SC; Pouta, A; Province, MA; Psaty, BM; Rathmann, W; Rayner, NW; Rice, K; Ripatti, S; Rivadeneira, F; Roden, M; Rolandsson, O; Sandbaek, A; Sandhu, M; Sanna, S; Sayer, AA; Scheet, P; Scott, LJ; Seedorf, U; Sharp, SJ; Shields, B; Sigurosson, G; Sijbrands, EJG; Silveira, A; Simpson, L; Singleton, A; Smith, NL; Sovio, U; Swift, A; Syddall, H; Syvanen, AC; Tanaka, T; Thorand, B; Tichet, J; Tonjes, A; Tuomi, T; Uitterlinden, AG; van Dijk, KW; van Hoek, M; Varma, D; Visvikis-Siest, S; Vitart, V; Vogelzangs, N; Waeber, G; Wagner, PJ; Walley, A; Walters, GB; Ward, KL; Watkins, H; Weedon, MN; Wild, SH; Willemsen, G; Witteman, JCM; Yarnell, JWG; Zeggini, E; Zelenika, D; Zethelius, B; Zhai, GJ; Zhao, JH; Zillikens, MC; Borecki, IB; Loos, RJF; Meneton, P; Magnusson, PKE; Nathan, DM; Williams, GH; Hattersley, AT; Silander, K; Salomaa, V; Smith, GD; Bornstein, SR; Schwarz, P; Spranger, J; Karpe, F; Shuldiner, AR; Cooper, C; Dedoussis, GV; Serrano-Rios, M; Morris, AD; Lind, L; Palmer, LJ; Hu, FB; Franks, PW; Ebrahim, S; Marmot, M; Kao, WHL; Pankow, JS; Sampson, MJ; Kuusisto, J; Laakso, M; Hansen, T; Pedersen, O; Pramstaller, PP; Wichmann, HE; Illig, T; Rudan, I; Wright, AF; Stumvoll, M; Campbell, H; Wilson, JF; Bergman, RN; Buchanan, TA; Collins, FS; Mohlke, KL; Tuomilehto, J; Valle, TT; Altshuler, D; Rotter, JI; Siscovick, DS; Penninx, BWJH; Boomsma, DI; Deloukas, P; Spector, TD; Frayling, TM; Ferrucci, L; Kong, A; Thorsteinsdottir, U; Stefansson, K; van Duijn, CM; Aulchenko, YS; Cao, A; Scuteri, A; Schlessinger, D; Uda, M; Ruokonen, A; Jarvelin, MR; Waterworth, DM; Vollenweider, P; Peltonen, L; Mooser, V; Abecasis, GR; Wareham, NJ; Sladek, R; Froguel, P; Watanabe, RM; Meigs, JB; Groop, L; Boehnke, M; McCarthy, MI; Florez, JC; Barroso, I; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten Procardis Consortiu; MAGIC Investigators",New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk,NATURE GENETICS,,1061-4036,10.1038/ng.520,,"Levels of circulating glucose are tightly regulated. To identify new loci influencing glycemic traits, we performed meta-analyses of 21 genome-wide association studies informative for fasting glucose, fasting insulin and indices of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) in up to 46,186 nondiabetic participants. Follow-up of 25 loci in up to 76,558 additional subjects identified 16 loci associated with fasting glucose and HOMA-B and two loci associated with fasting insulin and HOMA-IR. These include nine loci newly associated with fasting glucose (in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and C2CD4B) and one influencing fasting insulin and HOMA-IR (near IGF1). We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes. Within these loci, likely biological candidate genes influence signal transduction, cell proliferation, development, glucose-sensing and circadian regulation. Our results demonstrate that genetic studies of glycemic traits can identify type 2 diabetes risk loci, as well as loci containing gene variants that are associated with a modest elevation in glucose levels but are not associated with overt diabetes.",2010-02,01/07/2022 10:40,01/07/2022 10:40,,105-U32,,2,42,,,,,,,,,,,,,,WOS:000274084400005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NU2V8UQI,journalArticle,2015,"Valdes-Rodriguez, R; Stull, C; Yosipovitch, G","Chronic Pruritus in the Elderly: Pathophysiology, Diagnosis and Management",DRUGS & AGING,,1170-229X,10.1007/s40266-015-0246-0,,"Chronic itch in the elderly is a common problem, with a significant impact on quality of life and sleep in elderly patients. Chronic itch may be attributable to several causes, including dry skin, immunosenescence and neural degeneration. Itch may also be caused by skin diseases, such as seborrhoeic dermatitis and stasis dermatitis; systemic conditions, such as end-stage renal disease and diabetes; and psychogenic conditions, such as depression and anxiety. The use of polypharmacy may also cause itch, with or without a rash. Specifically, thiazides and calcium channel blockers have been known to cause itch in elderly patients. Management should be tailored according to the underlying dermatological or systemic aetiology of itch. Topical treatment is the mainstay of therapy, providing special emphasis on skin hydration and barrier repair. In addition, topical and oral medications that target the nervous system and reduce neuronal hypersensitization, such as gabapentin and selective antidepressants, have a role in treating patients with severe chronic itch. Furthermore, management must account for changes in metabolism and pharmacokinetics of drugs in the aging population in order to prevent the occurrence of adverse effects.",2015-03,01/07/2022 10:40,01/07/2022 10:40,,201-215,,3,32,,,,,,,,,,,,,,WOS:000351531300003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H64Q73PT,conferencePaper,2011,"Debono, M; Ross, RJ",Optimal Glucocorticoid Therapy,,1421-7082,,,,"The rhythmic regulation of human physiology and behaviour is controlled by a central endogenous clock located in the suprachiasmatic nucleus. Most tissues have peripheral clocks that oscillate in time with this central clock. How the central time keeper controls peripheral clocks is not established, however there is evidence to suggest that the cortisol rhythm is one important secondary messenger. Loss of the endogenous cortisol rhythm is associated with sleep disturbance, depression, and metabolic abnormalities. In adrenal insufficiency, current glucocorticoid replacement regimens cannot replace the normal circadian rhythm of cortisol, and patients have an increased mortality and impaired quality of life. We propose that reproducing circadian cortisol levels may improve quality of life in patients with adrenal insufficiency and we have been investigating the impact of circadian hydrocortisone replacement. Using Chronocort, a modified release preparation of hydrocortisone, we have demonstrated that it is possible to simulate the overnight rise in cortisol release and, in preliminary studies in patients with congenital adrenal hyperplasia, control morning androgen levels. Future studies are now required to determine whether Chronocort can improve quality of life in patients with adrenal insufficiency. Copyright (C) 2011 S. Karger AG, Basel",2011,01/07/2022 10:40,01/07/2022 10:40,,173-180,,,20,,,,,,,,,,,,,,WOS:000287122700017,,,,,,,,,"Ghizzoni, L; Cappa, M; Chrousos, G; Loche, S; Maghnie, M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PEDIATRIC ADRENAL DISEASES,,,,,,,,,,,,,,,
5AJDJVEZ,journalArticle,2020,"Washburn, RA; Ptomey, LT; Gorczyca, AM; Smith, PR; Mayo, MS; Lee, R; Donnelly, JE",Weight management for adults with mobility related disabilities: Rationale and design for an 18-month randomized trial,CONTEMPORARY CLINICAL TRIALS,,1551-7144,10.1016/j.cct.2020.106098,,"Adults with mobility related disabilities (MRDs) represent an underserved group with a high prevalence of overweight/obesity and limited options for weight management. We previously demonstrated clinically meaningful 12-month weight loss in adults with MRDs (- 6.2%, 36% >= 5% of baseline weight) using an enhanced Stop Light Diet (eSLD) delivered using at home face-to-face behavioral sessions and optional physical activity. However, the costs/logistics associated with intervention delivery by individual home visits limits the potential for scaling and implementation of this approach. Thus, we will conduct a two-arm randomized trial in 128 overweight/obese adults with MRDs to compare weight loss (6 mos.) and maintenance (12 mos.) between interventions utilizing the eSLD, behavioral counseling, and increased physical activity delivered to individual participants in their homes or delivered to groups of participants in their homes remotely via video conferencing. The primary aim will compare weight loss between interventions arms across 6 months. Secondarily, we will compare weight loss (0-18 mos.), the proportion of participants who achieve clinically meaningful weight loss (>= 5%) from 0 to 6 and 0 to18 months, and changes in quality of life from 0 to 6 and 0 to 18 months between interventions arms. We will also conduct cost, cost-effectiveness and contingent valuation comparisons and explore the influence of behavioral session attendance, compliance with the recommendations for diet and physical activity, self-monitoring of diet and physical activity, barriers to physical activity, sleep quality, and medications on weight change across 6 and 18 months.",2020-09,01/07/2022 10:40,01/07/2022 10:40,,,,,96,,,,,,,,,,,,,,WOS:000571518300003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HDC8Q4MP,journalArticle,2014,"van Deursen, VM; Urso, R; Laroche, C; Damman, K; Dahlstrom, U; Tavazzi, L; Maggioni, AP; Voors, AA",Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey,EUROPEAN JOURNAL OF HEART FAILURE,,1388-9842,10.1002/ejhf.30,,"Aims Co-morbidities frequently accompany heart failure (HF), contributing to increased morbidity and mortality, and an impairment of quality of life. We assessed the prevalence, determinants, regional variation, and prognostic implications of co-morbidities in patients with chronic HF in Europe. Methods and results A total of 3226 European outpatients with chronic HF were included in this analysis of the European Society of Cardiology (ESC) Heart Failure Pilot Survey. The following co-morbidities were considered: diabetes, hyper- and hypothyroidism, stroke, COPD, sleep apnoea, chronic kidney disease (CKD), and anaemia. Prognostic implications of co-morbidities were evaluated using population attributable risks (PARs), and patients were divided into geographic regions. Clinical endpoints were all-cause mortality and HF hospitalization. The majority of patients (74%) had a least one co-morbidity, the most prevalent being CKD (41%), anaemia (29%), and diabetes (29%). Co-morbidities were independently associated with higher age (P < 0.001), higher NYHA functional class (P < 0.001), ischaemic aetiology of HF (P < 0.001), higher heart rate (P = 0.011), history of hypertension (P < 0.001), and AF (P < 0.001). Only diabetes, CKD, and anaemia were independently associated with a higher risk of mortality and/or HF hospitalization. There were marked regional differences in prevalence and prognostic implications of co-morbidities. Prognostic implications of co-morbidities (PARs) were: CKD = 41%, anaemia = 37%, diabetes = 14%, COPD = 10%, and <10% for all other co-morbidities. Conclusion In this pilot survey, co-morbidities are prevalent in patients with chronic HF and are related to the severity of the disease. The presence of diabetes, CKD, and anaemia was independently related to increased mortality and HF hospitalization, with the highest PAR for CKD and anaemia.",2014-01,01/07/2022 10:40,01/07/2022 10:40,,103-111,,1,16,,,,,,,,,,,,,,WOS:000329348900014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6HEG92CT,journalArticle,2010,"Van Kerrebroeck, PEV; Dmochowski, R; FitzGerald, MP; Hashim, H; Norgaard, JP; Robinson, D; Weiss, JP",Nocturia Research: Current Status and Future Perspectives,NEUROUROLOGY AND URODYNAMICS,,0733-2467,10.1002/nau.20913,,"This review summarizes the status of nocturia research, highlighting the condition's distinct nature, as well as areas where further studies are needed. Unlike other LUTS, nocturia has a specific and detrimental effect on the sleep period, and when >= 2 voids per night are experienced it is associated with various sequelae including reduced QoL and productivity, and increased morbidity and perhaps mortality. Many sources suggest that nocturia is associated with chronic medical illness, but little evidence demonstrates that successful treatment of these conditions results in normalization of nocturia, or that improvement in nocturia improves QoL and overall health. To date, management algorithms for LUTS have been based upon reasonable supposition and limited evidence, rather than controlled trials. Whilst a working clinical model is useful until conclusive research is available, a healthy scepticism should be maintained. It is likely that more than one contributory factor is responsible for nocturia, and management ought to better reflect this multifactorial pathophysiology. Indeed, traditional perspectives assuming nocturia to be part of the OAB or BPE symptom complex may have helped to propagate the misconception that therapy for these conditions is sufficient to improve nocturia. In reality, improvements in nocturia with anticholinergics, alpha-blockers and/or 5-alpha reductase inhibitors have been consistently disappointing. Antidiuretic therapy may represent a more tailored approach to management for many nocturia patients, given the high rates of nocturnal polyuria reported. Combination therapy may be required. Further high quality research on pathophysiology, management and patient-reported outcomes with treatment is needed to augment existing limited data. Neurourol. Urodynam. 29:623-628, 2010. (C) 2010 Wiley-Liss, Inc.",2010,01/07/2022 10:40,01/07/2022 10:40,,623-628,,4,29,,,,,,,,,,,,,,WOS:000277306300026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JTAJJ5RD,journalArticle,2016,"Lynch, BM; Mihala, G; Beesley, VL; Wiseman, AJ; Gordon, LG",Associations of health behaviours with return to work outcomes after colorectal cancer,SUPPORTIVE CARE IN CANCER,,0941-4355,10.1007/s00520-015-2855-x,,"Purpose Engaging in positive health behaviours can improve quality of life amongst cancer survivors, whether this facilitates return to work is unknown. We examined associations of health behaviours with return to work outcomes following a diagnosis of colorectal cancer in middle-aged men and women (45-64 years). Methods We recruited 239 participants through the Queensland Cancer Registry between January 2010 and September 2011. Data were collected through telephone-administered interviews and postal questionnaires at 6 and 12 months post-diagnosis. Logistic regression examined likelihood of ceasing or reducing work, and Cox regression examined factors associated with time to return to work. Results No significant associations were observed between health behaviours (fruit and vegetables consumption, alcohol consumption, smoking status, physical activity or sitting time) at 6 months and ceasing or reducing work at 12 months post-diagnosis. Participants who reported excessive sleep (a parts per thousand yen9 h/day) were 2.69 times more likely to reduce work time or retire (relative to those sleeping the recommended 7 to < 9 h/day; 95 % CI 1.06, 6.87, adjusted for cancer treatment). In Cox regression analysis, excessive sleep was associated with a longer work re-entry time (relative to sleeping 7 to < 9 h/day; HR = 0.47; 95 % CI 0.22, 1.00, adjusted for education and cancer treatment). Conclusions Further research into how excessive sleep might be related to return to work amongst colorectal cancer survivors is warranted. Interventions focused on achieving optimal sleep patterns may assist colorectal cancer survivors to return to work and should be tested in future studies.",2016-02,01/07/2022 10:40,01/07/2022 10:40,,865-870,,2,24,,,,,,,,,,,,,,WOS:000367458200042,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GK7MKRV4,journalArticle,2013,"Madnani, N; Khan, K; Chauhan, P; Parmar, G",Polycystic ovarian syndrome,INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY,,0378-6323,10.4103/0378-6323.110759,,"Polycystic ovarian syndrome (PCOS) is a ""multispeciality"" disorder suspected in patients with irregular menses and clinical signs of hyperandrogenism such as acne, seborrhoea, hirsutism, irregular menses, infertility, and alopecia. Recently, PCOS has been associated with the metabolic syndrome. Patients may develop obesity, insulin resistance, acanthosis nigricans, Type 2 diabetes, dyslipidemias, hypertension, non-alcoholic liver disease, and obstructive sleep apnoea. Good clinical examination with hematological and radiological investigations is required for clinical evaluation. Management is a combined effort involving a dermatologist, endocrinologist, gynecologist, and nutritionist. Morbidity in addition includes a low ""self image"" and poor quality of life. Long term medications and lifestyle changes are essential for a successful outcome. This article focuses on understanding the normal and abnormal endocrine functions involved in the pathogenesis of PCOS. Proper diagnosis and management of the patient is discussed.",2013-05,01/07/2022 10:40,01/07/2022 10:40,,310-321,,3,79,,,,,,,,,,,,,,WOS:000321899100005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZPIDDFKZ,journalArticle,2015,"Patel, S",Neuropathic pain guidelines,SA PHARMACEUTICAL JOURNAL,,2221-5875,,,"Neuropathic pain is defined as pain that originates due to a lesion, dysfunction or disease, e.g. diabetes, human immunodeficiency virus infection, herpes zoster, chemotherapy or surgery, and which affects the peripheral or central nervous system. This results in abnormal neural function, often presenting in an individual as sensory pain-related symptoms which are either positive, i.e. hyperaesthesia or hyperalgesia; or negative, i.e. hypoaesthesia or anaesthesia. Patients often describe neuropathic pain as numbness or as a shooting, stabbing, burning, electric, tingling or ""pins and needles"" sensation. The quality of life of patients with neuropathic pain is often compromised as many have difficulty sleeping, lack energy, and experience drowsiness and altered concentration, and this can potentially progress to a stage in which the patient is physically and psychologically distressed.",2015,01/07/2022 10:40,01/07/2022 10:40,,23-26,,5,82,,,,,,,,,,,,,,WOS:000361625400005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
59HBJLRS,journalArticle,2017,"Rohner, A; Widmer, JD; Klasen, J; Scheiwiller, A; Muller, D; Muller, MK",Long-temi outcomes of gastric band removal without additional bariatric surgery,SURGERY FOR OBESITY AND RELATED DISEASES,,1550-7289,10.1016/j.soard.2016.09.010,,"Objective: The outcomes of patients undergoing band removal alone without an additional bariatric procedure after laparoscopic gastric banding are not well reported. We seek to close this gap in the literature. Setting: Cantonal Hospital & University Teaching Hospital, Switzerland Methods: In this retrospective study, we investigated 21 patients who underwent band removal with a mean follow-up of 63 months. Weight regain, co-morbidities, and quality of life were assessed. Results: The laparoscopic gastric bandings were implanted at a mean initial body mass index (BMI) of 44.6 kg/m(2). The bands remained in situ for an average of 87.7 months (range: 14-185 mo). The reasons for band removal included band slippage in 9 cases (42.9%), band penetration in 6 cases (28.6%), leakage, port infection, and patient request in 2 cases (9.5% each). The average BMI at the time of band removal was 34.9 kg/m(2). At 62.9 months after band removal, patients regained an average of 17.3 kg and attained a mean BMI of 41.0 kg/m(2). Co-morbidities such as type 2 diabetes, arterial hypertension, obstructive sleep apnea, and psychiatric disorders worsened during the follow-up period. Thirteen of 21 patients rated their quality of life as bad, 5 as mediocre, and only 3 as good. Only 2 patients said they would undergo a gastric banding procedure again. The patients achieved an average of -.6 points on the Moorehead-Ardelt quality of life score, which indicates a fair quality of life. Conclusion: This study finds that reversal of gastric banding procedures with removal of the banding system alone leads to weight regain, deterioration of physical and psychiatric co-morbidities, and low quality of life scores. (Surg Obes Relat Dis 2017;13:261-266.) (C) 2017 American Society for Metabolic and Bariatric Surgery.",2017-02,01/07/2022 10:40,01/07/2022 10:40,,261-266,,2,13,,,,,,,,,,,,,,WOS:000396802900022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HQTSJTYZ,journalArticle,2020,"Sillars, A; Ho, FK; Pell, GP; Gill, JMR; Sattar, N; Gray, S; Celis-Morales, C",Sex differences in the association of risk factors for heart failure incidence and mortality,HEART,,1355-6037,10.1136/heartjnl-2019-314878,,"Background There are known risk factors associated with the development of heart failure (HF), but it is not fully understood whether these differ by sex. Objectives To investigate sex differences in risk factors for HF incidence and mortality. Methods 468 941 participants (55.9% women, age range 37-73 years) were included. Established CVD risk factors (hypertension, hypercholesterolaemia, diabetes type 1 and 2, adiposity, smoking, physical activity and poor diet) and novel risk factors (grip strength, fitness, TV viewing and sleep duration) were the exposures of interest. HF incidence and mortality were the outcomes. Results Over a mean follow-up of 9.0 years, 1812 participants developed HF and 763 died due to HF. Women with type 1 diabetes (T1DM), type 2 diabetes (T2DM), hypertension, hypercholesterolaemia, low levels of physical activity and fitness, low strength, high levels of TV viewing, sleep duration <7 hours/day, smokers; those who were underweight and who were obese, had high body surface area and those who drink >14 units of alcohol were at higher risk of HF incidence. However, in women T2DM, hypercholesterolaemia, >3 hours/day of TV and sleep <7 hours/day, low level of physical activity and high level of TV viewing were more strongly associated with HF incidence compared with men. Conclusion Several modifiable risk factors (in particular diabetes) appear more strongly associated with HF in women compared with men. The relevance of these findings to HF characteristics and future outcomes needs to be established.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,203-212,,3,106,,,,,,,,,,,,,,WOS:000507910100011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A3PTRFQH,journalArticle,2016,"Rochette, C; Castinetti, F; Brue, T",Acromegaly and Cushing's disease: Persistence of comorbidities after the control of hypersecretion,ANNALES D ENDOCRINOLOGIE,,0003-4266,,,"Acromegaly and Cushing's disease lead to common and distinct comorbidities. Currently available treatments lead to the control of hyper secretion in the majority of cases. However, the prevalence of the comorbidities does not always go back to the one of the normal population after remission. For instance, about 1/3 of acromegalic patients with diabetes and half of patients with Cushing's disease and diabetes will have normal blood glucose values after remission. In contrast, high blood pressure frequently recovers after remission in both diseases. In contrast, while patients with acromegaly improve their lipid profile, patients with Cushing's disease frequently remain hypertriglyceridemic. Many other comorbidities (cardiovascular disease, bone alterations, altered quality of life) may persist after the control of hyper secretion. The aim of this review is to focus on the outcome of patients with acromegaly and Cuhing's disease, and to suggest the optimal follow-up of such patients in a multidisciplinary approach. These points have been discussed during the 2016 European Congress of Endocrinology, notably by J.Romijn and E.Valassi. (C) 2016 Published by Elsevier Masson SAS. All rights reserved.",2016-10,01/07/2022 10:40,01/07/2022 10:40,,S19-S28,,,77,,,,,,,,,,,,,,WOS:000386863000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3YBA5PPG,journalArticle,2021,"Wilson, R; Aminian, A; Tahrani, A",Metabolic surgery: A clinical update,DIABETES OBESITY & METABOLISM,,1462-8902,10.1111/dom.14235,,"Metabolic and bariatric surgery has grown beyond 'experimental' weight-loss surgery. As techniques have advanced over the last few decades, so has the growing body of research and evidence, proving that both weight-loss and metabolic health improvement are induced. Metabolic surgery has become the more appropriate term for weight-loss surgery because of the altered gastrointestinal anatomy and subsequent beneficial metabolic effects. Although the tool of metabolic surgery has been well refined, a large portion of the global population does not have adequate access to it. This clinical update aims to (a) inform healthcare providers from all disciplines about the myriad of benefits of metabolic surgery and (b) equip them with the necessary knowledge to bridge the gap between patients in need of metabolic treatment and the therapies in metabolic surgery available to them.",2021-02,01/07/2022 10:40,01/07/2022 10:40,,63-83,,,23,,,,,,,,,,,,,,WOS:000620716000005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PUPS47U6,journalArticle,2019,"Tabara, Y; Ikezoe, T; Matsumoto, T; Murase, K; Setoh, K; Funada, S; Kawaguchi, T; Nagashima, S; Kosugi, S; Hirai, T; Nakayama, T; Wakamura, T; Chin, K; Ichihashi, N; Tsuboyama, T; Matsuda, F",Association of weak hip abduction strength with nocturia in older women: The Nagahama study,GERIATRICS & GERONTOLOGY INTERNATIONAL,,1444-1586,10.1111/ggi.13761,,"Aim Nocturia is a common phenomenon in older individuals, and is associated with poor quality of life. Nocturia is a multifactorial disorder, wherein the frailty of skeletal muscles, particularly muscle weakness in the lower trunk and hip regions, might be a risk factor in women. We analyzed a dataset of the general Japanese population to clarify the hypothesis. Methods Study participants included 1207 older women (mean age 67.4 +/- 5.2 years). The frequency of nocturnal urination was assessed using a sleep diary for 1 week, and associations with lower muscle strength, skeletal muscle index, sarcopenia and physical performance (one-leg standing time and Timed Up and Go test) were investigated. Results The frequency of nocturnal urination more than one voiding per night was 28.1%; this frequency was inversely associated with hip abduction strength quartiles (Q1: 37.0, Q2: 30.5, Q3: 25.1 and Q4: 19.9%, P < 0.001). When a sleep diary-based nocturnal urination frequency >1.5 times/night (corresponding to a >= 2 times/night frequency obtained by questionnaire) was considered as nocturia, logistic regression analysis adjusted for major covariates identified hip abduction strength as an independent inverse determinant of nocturia (odds ratio 0.75, 95% CI 0.52-0.90, P = 0.002). In contrast, no significant association was observed with knee extension (P = 0.322) and hip flexion (P = 0.603) strengths. Physical performance, skeletal muscle index and sarcopenia did not show significant associations with nocturia. Conclusions Weak hip abduction strength might be a factor associated with nocturnal urination frequency in older women. Geriatr Gerontol Int 2019; center dot center dot: center dot center dot-center dot center dot.",2019-10,01/07/2022 10:40,01/07/2022 10:40,,1010-1016,,10,19,,,,,,,,,,,,,,WOS:000484672400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RW7AC5VB,journalArticle,2016,"Mead, MP; Irish, LA",Spousal Influence on CPAP Adherence: Applications of Health-related Social Control,SOCIAL AND PERSONALITY PSYCHOLOGY COMPASS,,1751-9004,10.1111/spc3.12260,,"Obstructive sleep apnea (OSA) is one of the most prevalent sleep disorders in the United Sates and is a risk factor for poor health outcomes. Continuous positive airway pressure (CPAP) therapy is an effective treatment for OSA, but adherence rates are poor. Although the spouses of patients with OSA have high potential to influence adherence, there has been minimal research to date. The purpose of this review is to summarize key findings regarding spousal influence on health-related behavior change and treatment adherence from other medical fields (e.g., type 2 diabetes and cardiovascular disease) in which this line of inquiry has been more thoroughly developed. Recommendations are presented to guide future research investigating spousal inf luence on CPAP adherence based on findings from other patient populations. In particular, we emphasize the use of spousal health-related social control as it applies to adherence and provide guidance regarding conceptual and methodological moderators.",2016-08,01/07/2022 10:40,01/07/2022 10:40,,443-454,,8,10,,,,,,,,,,,,,,WOS:000381754400003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VP2FXXUN,journalArticle,2016,"Scally, CP; Varban, OA; Carlin, AM; Birkmeyer, JD; Dimick, JB; Michigan Bariatric Surg",Video Ratings of Surgical Skill and Late Outcomes of Bariatric Surgery,JAMA SURGERY,,2168-6254,10.1001/jamasurg.2016.0428,,"IMPORTANCE Measures of surgeons' skills have been associated with variations in short-term outcomes after laparoscopic gastric bypass. However, the effect of surgical skill on long-term outcomes after bariatric surgery is unknown. OBJECTIVE To study the association between surgical skill and long-term outcomes of bariatric surgery. DESIGN, SETTING, AND PARTICIPANTS In this retrospective observational study, 20 surgeons performing bariatric surgery submitted videos; surgeons were ranked on their skill level through blinded peer video review and sorted into quartiles of skill. Outcomes of bariatric surgery were then examined at the patient level across skill levels. The patients (N = 3631) undergoing surgery with these surgeons had 1-year postoperative follow-up data available between 2006 and 2012. The study was conducted using the Michigan Bariatric Surgery Collaborative, a prospective clinical registry of 40 hospitals performing bariatric surgery in the state of Michigan. EXPOSURE Surgeon skill level. MAIN OUTCOMES AND MEASURES Excess body weight loss at 1 year; resolution of medical comorbidities (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional status, and patient satisfaction. RESULTS Surgeons in the top and bottom quartiles had each been practicing for a mean of 11 years. Peer ratings of surgical skill varied from 2.6 to 4.8 on a 5-point scale. There was no difference between the best (top 25%) and worst (bottom 25%) performance quartiles when comparing excess body weight loss (67.2% vs 68.5%; P=.86) at 1 year. There were no differences in resolution of sleep apnea (62.6% vs 62.0%; P=.77), hypertension (47.1% vs 45.4%; P=.73), or hyperlipidemia (52.3% vs 63.4%; P=.45). Surgeons with the lowest skill rating had patients with higher rates of diabetes resolution (78.8%) when compared with the high-skill group (72.8%) (P=.01). CONCLUSIONS AND RELEVANCE In contrast to its effect on early complications, surgical skill did not affect postoperative weight loss or resolution of medical comorbidities at 1 year after laparoscopic gastric bypass. These findings suggest that long-term outcomes after bariatric surgery may be less dependent on a surgeon's operative skill and instead be driven by other factors. Operative technique was not assessed in this analysis and should be considered in future studies.",2016-06,01/07/2022 10:40,01/07/2022 10:40,,,,6,151,,,,,,,,,,,,,,WOS:000377932700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TTNI29UN,journalArticle,2021,"Moustafa, AF; Mohammed, MA; Zeineldin, AA; Elgeiedie, AA; Hafez, AT",Laparoscopic sleeve gastrectomy versus laparoscopic single anastomosis gastric bypass: short-term outcome,EGYPTIAN JOURNAL OF SURGERY,,1110-1121,10.4103/ejs.ejs_335_20,,"Objective To compare laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB) for morbidly obese patients. Both procedures were compared regarding % of excess weight loss (%EWL), resolution of comorbidities, hospital stay, morbidity, mortality, and bariatric analysis and reporting outcome system (BAROS) on short-term basis. Background Bariatric surgery has been proved to be a successful treatment option, leading to long-term weight loss with improvement of obesity-related comorbidities. The LSG is now one of the most popular bariatric procedures worldwide, whereas the LSAGB is now rising worldwide. Patients and methods This prospective study involved 40 patients blindly divided into two groups: 20 of them underwent LSG and 20 of them underwent LSAGB. Written informed consent was obtained from all patients for the procedures and possible complications and conversion. The study was approved by the local ethical committee. All the patients had a 1-year period of follow-up postoperatively and were evaluated for % EWL, resolution of comorbidities, hospital stay, morbidity, mortality, and BAROS. Results A total of 40 obese patients were blindly divided into two groups: LSG included 20 patients, comprising three males and 17 females, with mean BMI of 43.7 kg/m(2). Among them, four had type 2 diabetes mellitus (T2DM), three had hypertension (HTN), five had osteoarthritis, two had obstructive sleep apnea (OSA), five had dyslipidemia, and one had polycystic ovary. LSAGB group included 20 patients, comprising four males and 16 females, having a mean BMI of 45.1 kg/m(2). Of them, 25 had T2DM, four had HTN, three osteoarthritis, one OSA, eight dyslipidemia, and two polycystic ovary. The mean operative time was 66 min in LSG, whereas it was 72.6 min in LSAGB. The mean duration of hospital stay was 2.5 days in LSG, whereas it was 3.5 days in LSAGB. Mean %EWL was 33.4% at 1 month and 77.22% at 12 months in LSG and was 20.13% at 1 month and 80.4% at 12 months in LSAGB. Overall, two patients with T2DM had complete and two had partial resolution in LSG, whereas three patients with T2DM in LSAGB. Moreover, two patients had complete resolution regarding HTN in LSG and all of them in LSAGB. There was resolution of osteoarthritis, OSA, and polycystic ovary in all patients in both groups. Bleeding was seen in one case in LSG. Wound infection was recorded in one case in LSG and in two cases in LSAGB. Postoperative nausea and vomiting was seen in three cases in LSG and in one cases in LSAGB. Symptomatic cholelithiasis was seen in seven patients in LSG group, and two patients needed surgery, whereas in LSAGB, five patients had symptomatic cholelithiasis, and three patients needed surgery. A total of eight patients had dumping symptoms only in LSAGB. According to BAROS, it was revealed that in LSG, 12 of the patients evaluated the quality of life as 'excellent' and two as 'very good,' whereas in LSAGB, 14 of the patients evaluated the quality of life as 'excellent' and three as 'very good.' Conclusion LSG has proved to be a safe and effective bariatric surgery with a rate of success that is similar to the LSAGB. LSAGB appears to reduce obesity-related comorbidities with low complication rate. Both procedures offer a good quality of life according to BAROS.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,300-308,,1,40,,,,,,,,,,,,,,WOS:000656200800039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PEAZ47Q9,journalArticle,2017,"Derry, S; Rice, ASC; Cole, P; Tan, T; Moore, RA",Topical capsaicin (high concentration) for chronic neuropathic pain in adults,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD007393.pub4,,"Background This review is an update of 'Topical capsaicin (high concentration) for chronic neuropathic pain in adults' last updated in Issue 2, 2013. Topical creams with capsaicin are used to treat peripheral neuropathic pain. Following application to the skin, capsaicin causes enhanced sensitivity, followed by a period with reduced sensitivity and, after repeated applications, persistent desensitisation. High-concentration (8%) capsaicin patches were developed to increase the amount of capsaicin delivered; rapid delivery was thought to improve tolerability because cutaneous nociceptors are 'defunctionalised' quickly. The single application avoids noncompliance. Only the 8% patch formulation of capsaicin is available, with a capsaicin concentration about 100 times greater than conventional creams. High-concentration topical capsaicin is given as a single patch application to the affected part. Itmust be applied under highly controlled conditions, often following local anaesthetic, due to the initial intense burning sensation it causes. The benefits are expected to last for about 12 weeks, when another application might be made. Objectives To review the evidence from controlled trials on the efficacy and tolerability of topically applied, high-concentration (8%) capsaicin in chronic neuropathic pain in adults. Search methods For this update, we searched CENTRAL, MEDLINE, Embase, two clinical trials registries, and a pharmaceutical company's website to 10 June 2016. Selection criteria Randomised, double-blind, placebo-controlled studies of at least 6 weeks' duration, using high-concentration (5% or more) topical capsaicin to treat neuropathic pain. Data collection and analysis Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality and potential bias. Where pooled analysis was possible, we used dichotomous data to calculate risk ratio and numbers needed to treat for one additional event, using standard methods. Efficacy outcomes reflecting long-duration pain relief after a single drug application were from the Patient Global Impression of Change (PGIC) at specific points, usually 8 and 12 weeks. We also assessed average pain scores over weeks 2 to 8 and 2 to 12 and the number of participants with pain intensity reduction of at least 30% or at least 50% over baseline, and information on adverse events and withdrawals. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table. Main results We included eight studies, involving 2488 participants, two more studies and 415 more participants than the previous version of this review. Studies were of generally good methodological quality; we judged only one study at high risk of bias, due to small size. Two studies used a placebo control and six used 0.04% topical capsaicin as an 'active' placebo to help maintain blinding. Efficacy outcomes were inconsistently reported, resulting in analyses for most outcomes being based on less than complete data. For postherpetic neuralgia, we found four studies (1272 participants). At both 8 and 12 weeks about 10% more participants reported themselves much or very much improved with high-concentration capsaicin than with 'active' placebo, with point estimates of numbers needed to treat for an additional beneficial outcome (NNTs) of 8.8 (95% confidence interval (CI) 5.3 to 26) with high-concentration capsaicin and 7.0 (95% CI 4.6 to 15) with 'active' placebo (2 studies, 571 participants; moderate quality evidence). More participants (about 10%) had average 2 to 8-week and 2 to 12-week pain intensity reductions over baseline of at least 30% and at least 50% with capsaicin than control, with NNT values between 10 and 12 (2 to 4 studies, 571 to 1272 participants; very low quality evidence). For painful HIV-neuropathy, we found two studies (801 participants). One study reported the proportion of participants who were much or very much improved at 12 weeks (27% with high-concentration capsaicin and 10% with 'active' placebo). For both studies, more participants (about 10%) had average 2 to 12-week pain intensity reductions over baseline of at least 30% with capsaicin than control, with an NNT of 11 (very low quality evidence). For peripheral diabetic neuropathy, we found one study (369 participants). It reported about 10% more participants who were much or very much improved at 8 and 12 weeks. One small study of 46 participants with persistent pain following inguinal herniorrhaphy did not show a difference between capsaicin and placebo for pain reduction (very low quality evidence). We downgraded the quality of the evidence for efficacy outcomes by one to three levels due to sparse data, imprecision, possible effects of imputation methods, and susceptibility to publication bias. Local adverse events were common, but not consistently reported. Serious adverse events were no more common with active treatment (3.5%) than control (3.2%). Adverse event withdrawals did not differ between groups, but lack of efficacy withdrawals were somewhat more common with control than active treatment, based on small numbers of events (six to eight studies, 21 to 67 events; moderate quality evidence, downgraded due to few events). No deaths were judged to be related to study medication. Authors' conclusions High-concentration topical capsaicin used to treat postherpetic neuralgia, HIV-neuropathy, and painful diabetic neuropathy generated more participants with moderate or substantial levels of pain relief than control treatment using a much lower concentration of capsaicin. These results should be interpreted with caution as the quality of the evidence was moderate or very low. The additional proportion who benefited over control was not large, but for those who did obtain high levels of pain relief, there were usually additional improvements in sleep, fatigue, depression, and quality of life. High-concentration topical capsaicin is similar in its effects to other therapies for chronic pain.",2017,01/07/2022 10:40,01/07/2022 10:40,,,,1,,,,,,,,,,,,,,,WOS:000396095800027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VE3BVDQ9,journalArticle,2017,"Anderson, JC; Fritz, ML; Benson, JM; Tracy, BL",Nerve Decompression and restless Legs syndrome: A retrospective Analysis,FRONTIERS IN NEUROLOGY,,1664-2295,10.3389/fneur.2017.00287,,"Introduction: Restless legs syndrome (RLS) is a prevalent sleep disorder affecting quality of life and is often comorbid with other neurological diseases, including peripheral neuropathy. The mechanisms related to RLS symptoms remain unclear, and treatment options are often aimed at symptom relief rather than etiology. RLS may present in distinct phenotypes often described as ""primary"" vs. ""secondary"" RLS. Secondary RLS is often associated with peripheral neuropathy. Nerve decompression surgery of the common and superficial fibular nerves is used to treat peripheral neuropathy. Anecdotally, surgeons sometimes report improved RLS symptoms following nerve decompression for peripheral neuropathy. The purpose of this retrospective analysis was to quantify the change in symptoms commonly associated with RLS using visual analog scales (VAS). Methods: Forty-two patients completed VAS scales (0-10) for pain, burning, numbness, tingling, weakness, balance, tightness, aching, pulling, cramping, twitchy/jumpy, uneasy, creepy/crawly, and throbbing, both before and 15 weeks after surgical decompression. Results: Subjects reported significant improvement among all VAS categories, except for ""pulling"" (P = 0.14). The change in VAS following surgery was negatively correlated with the pre-surgery VAS for both the summed VAS (r = - 0.58, P < 0.001) and the individual VAS scores (all P < 0.01), such that patients who reported the worst symptoms before surgery exhibited relatively greater reductions in symptoms after surgery. Conclusion This is the first study to suggest improvement in RLS symptoms following surgical decompression of the common and superficial fibular nerves. Further investigation is needed to quantify improvement using RLS-specific metrics and sleep quality assessments.",06/07/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,8,,,,,,,,,,,,,,WOS:000404835400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TRA2AET2,journalArticle,2013,"Spitzer, M; Huang, G; Basaria, S; Travison, TG; Bhasin, S",Risks and benefits of testosterone therapy in older men,NATURE REVIEWS ENDOCRINOLOGY,,1759-5029,10.1038/nrendo.2013.73,,"In young men (defined as age <50 years) with classic hypogonadism caused by known diseases of the hypothalamus, pituitary or testes, testosterone replacement therapy induces a number of beneficial effects, for example, the development of secondary sex characteristics, improvement and maintenance of sexual function, and increases in skeletal muscle mass and BMD. Moreover, testosterone treatment in this patient population is associated with a low frequency of adverse events. Circulating testosterone levels decline progressively with age, starting in the second and third decade of life, owing to defects at all levels of the hypothalamic-pituitary-testicular axis. In cohort studies, testosterone levels are associated weakly but consistently with muscle mass, strength, physical function, anaemia, BMD and bone quality, visceral adiposity, and with the risk of diabetes mellitus, coronary artery disease, falls, fractures and mortality. However, the clinical benefits and long-term risks of testosterone therapy-especially prostate-related and cardiovascular-related adverse events-have not been adequately assessed in large, randomized clinical trials involving older men (defined as age >65 years) with androgen deficiency. Therefore, a general policy of testosterone replacement in all older men with age-related decline in testosterone levels is not justified.",2013-07,01/07/2022 10:40,01/07/2022 10:40,,414-424,,7,9,,,,,,,,,,,,,,WOS:000320851700011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HKN28AHT,journalArticle,,"Mygind, L; Elsborg, P; Schipperijn, J; Boruff, B; Lum, JAG; Bolling, M; Flensborg-Madsen, T; Bentsen, P; Enticott, PG; Christian, H","Is vegetation cover in key behaviour settings important for early childhood socioemotional function? A preregistered, cross-sectional study",DEVELOPMENTAL SCIENCE,,1363-755X,10.1111/desc.13200,,"The environmental influences on early childhood development are understudied. The association between vegetation cover (i.e., trees, shrubs, grassed areas) in four key behaviour settings and socioemotional functioning was investigated in 1196 young children (2-5 years). Emotional difficulties were inversely associated with vegetation cover in the home yard (OR: 0.81 [0.69-0.96]) and neighbourhood (OR: 0.79 [0.67-0.94]), but not in early childhood education and care (ECEC) centre outdoor areas or the ECEC neighbourhood. The higher odds of emotional difficulties associated with lower levels of maternal education was reduced with higher percentages of home yard vegetation cover. There was no evidence of mediation of the relationship between emotional difficulties and vegetation cover by time spent playing outside the home, day or nighttime sleep duration, or physical activity. We found no associations between vegetation cover and conduct, hyperactivity and inattention, peer difficulties, or prosocial behaviours.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000727401300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
K5TDT52Y,journalArticle,2002,"O'Brien, PE; Dixon, JB",The extent of the problem of obesity,AMERICAN JOURNAL OF SURGERY,,0002-9610,10.1016/S0002-9610(02)01172-8,,"The prevalence of obesity is increasing worldwide. In the United States, in 1999, 27% of adults had a body mass, index >30 kg/m(2), almost double the prevalence of 20 years earlier. The estimated mortality from obesity-related diseases in the United States is approximately 300,000 annually and growing. In the future, mortality related to obesity is expected to exceed that of smoking. Numerous diseases are caused or made worse by obesity. These include type 2 diabetes; hypertension; dyslipidemia; ischemic heart disease; stroke; obstructive sleep apnea; asthma; nonalcoholic steatohepatitis; gastroesophageal reflux disease; degenerative joint disease of the back, hips, knees, and feet; infertility and polycystic ovary syndrome; various malignancies; and depression. Type 2 diabetes is perhaps the most visible obesity-related problem. Present in at least 14 million Americans, it leads to serious complications and premature death. It is largely caused by obesity, and is generally cured by weight loss. The quality of life of the obese is markedly reduced, and the costs to health care systems are great. Preventive programs have yet to affect the rising prevalence. An effective solution is needed. (C) 2002 Excerpta Medica Inc. All rights reserved.",2002-12,01/07/2022 10:40,01/07/2022 10:40,,4S-8S,,6B,184,,,,,,,,,,,,,,WOS:000180666000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HBIRRB5D,journalArticle,2009,"Binder, A; Bruxelle, J; Rogers, P; Hans, G; Bosl, I; Baron, R","Topical 5% Lidocaine (Lignocaine) Medicated Plaster Treatment for Post-Herpetic Neuralgia Results of a Double-Blind, Placebo-Controlled, Multinational Efficacy and Safety Trial",CLINICAL DRUG INVESTIGATION,,1173-2563,10.2165/00044011-200929060-00003,,"Background and objective: Post-herpetic neuralgia (PHN) is a distressing neuropathic pain condition mainly affecting elderly patients. Neuropathic pain symptoms can be of a burning, shooting and stabbing nature, and may continue for prolonged periods and are often poorly controlled by polymedication. The aim of this study was to evaluate the analgesic efficacy and safety of topical analgesic treatment (5% lidocaine [lignocaine] medicated plaster) compared with placebo plaster in patients with PHN. Methods: This was a double-blind, placebo plaster-controlled, parallel-group, multicentre study employing enriched enrolment with randomized withdrawal methodology. After an initial 8-week open-label, active run-in phase, responders entered a 2-week randomized, double-blind, placebo-controlled phase. The study was conducted at 33 outpatient investigational centres in 12 European countries. Patients with PHN were selected who were aged >= 50 years, had experienced neuropathic pain persisting for >= 3 months after rash healing, and had a mean pain intensity of >= 4 on an 11-point numerical rating scale. A total of 265 patients entered the open-label phase and subsequently a pre-defined number of 71 patients entered the randomized phase. Patients applied up to three 5% lidocaine medicated plasters for up to 12 hours per day. The primary endpoint of the study was time-to-exit due to a >= 2-point reduction in pain relief on two consecutive days of plaster application using a 6-point verbal rating scale. Results: Of the 265 patients entering the run-in phase, 51.7% achieved at least moderate pain relief. In the double-blind phase (full analysis set, n = 71), median times-to-exit were 13.5 (range 2-14) and 9.0 (range 1-14) days for lidocaine and placebo plaster groups, respectively (p = 0.151). For per-protocol patients (n = 34), median time-to-exit was 14.0 (range 3-14) and 6.0 (range 1-14) days for lidocaine and placebo plaster groups, respectively (p = 0.0398). Drug-related adverse events occurred in 13.6% of patients. Treatment with 5% lidocaine medicated plaster was associated with improvements in pain, allodynia, quality of life and sleep measures. Conclusions: This study adds to a growing body of evidence that the 5% lidocaine medicated plaster can be considered a valuable treatment option for patients with PHN, providing beneficial effects on pain, allodynia, quality of life and sleep, with minimal adverse effects.",2009,01/07/2022 10:40,01/07/2022 10:40,,393-408,,6,29,,,,,,,,,,,,,,WOS:000266538900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q5RY2RQW,journalArticle,2016,"Hruby, A; Manson, JE; Qi, L; Malik, VS; Rimm, EB; Sun, Q; Willett, WC; Hu, FB",Determinants and Consequences of Obesity,AMERICAN JOURNAL OF PUBLIC HEALTH,,0090-0036,10.2105/AJPH.2016.303326,,"Objectives. To review the contribution of the Nurses' Health Studies (NHS and NHS II) in addressing hypotheses regarding risk factors for and consequences of obesity. Methods. Narrative review of the publications of the NHS and NHS II between 1976 and 2016. Results. Long-term NHS research has shown that weight gain and being overweight or obese are important risk factors for type 2 diabetes, cardiovascular diseases, certain types of cancers, and premature death. The cohorts have elucidated the role of dietary and lifestyle factors in obesity, especially sugar-sweetened beverages, poor diet quality, physical inactivity, prolonged screen time, short sleep duration or shift work, and built environment characteristics. Genome-wide association and gene-lifestyle interaction studies have shown that genetic factors predispose individuals to obesity but that such susceptibility can be attenuated by healthy lifestyle choices. This research has contributed to evolving clinical and public health guidelines on the importance of limiting weight gain through healthy dietary and lifestyle behaviors. Conclusions. The NHS cohorts have contributed to our understanding of the risk factors for and consequences of obesity and made a lasting impact on clinical and public health guidelines on obesity prevention.",2016-09,01/07/2022 10:40,01/07/2022 10:40,,1656-1662,,9,106,,,,,,,,,,,,,,WOS:000388072300032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FPQRHZXL,journalArticle,2020,"Yang, L; Xie, SH; Tang, B; Wu, X; Tong, ZG; Fang, C; Ding, H; Bao, YY; Zheng, SY; Hong, T",Hypothalamic injury patterns after resection of craniopharyngiomas and correlation to tumor origin: A study based on endoscopic observation,CANCER MEDICINE,,2045-7634,10.1002/cam4.3589,,"The precise understanding of hypothalamic injury (HI) patterns and their relationship with different craniopharyngioma (CP) classifications remains poorly addressed. Here, four HI patterns after CP resection based on endoscopic observation were introduced. A total of 131 CP cases treated with endoscopic endonasal approach (EEA) were reviewed retrospectively and divided into four HI patterns: no-HI, mild-HI, unilateral-HI and bilateral-HI, according to intraoperative findings. The outcomes were evaluated and compared between groups in terms of weight gain, endocrine status, electrolyte disturbance and neuropsychological function before and after surgery. A systematic correlation was found between CP origin and subsequent HI patterns. The majority of intrasellar and suprasellar stalk origins lead to a no-HI pattern, the central-type CP mainly develops a mild or bilateral HI pattern, and the majority of tumors with hypothalamic stalk origins result in unilateral HI and sometimes bilateral HI patterns. The proportion of tumors with a maximum diameter >3 cm in the no-HI group was higher than that in the mild-HI group, BMI and quality of life in the no-HI group showed better results than those in the other groups. The incidence of new-onset diabetes insipidus in the bilateral-HI group was significantly higher than that in the other groups. Memory difficulty was observed mainly in the unilateral-HI and bilateral-HI groups. However, the outcomes of electrolyte disturbance, sleep, and cognitive disorder in the unilateral-HI group were significantly better than those in the bilateral-HI group. This study suggests the possibility of using pre- and intraoperative observation of CP origin to predict four HI patterns and even subsequent outcomes after tumor removal.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,8950-8961,,23,9,,,,,,,,,,,,,,WOS:000583966300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AJ2IS3UG,journalArticle,2019,"Flythe, JE; Hilliard, T; Lumby, E; Castillo, G; Orazi, J; Abdel-Rahman, EM; Pai, AB; Rivara, MB; St Peter, WL; Weisbord, SD; Wilkie, CM; Mehrotra, R; Kidney Hlth Initiative Prioriti","Fostering Innovation in Symptom Management among Hemodialysis Patients Paths Forward for Insomnia, Muscle Cramps, and Fatigue",CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.07670618,,"Individuals receiving in-center maintenance hemodialysis bear a high burden of both physical and mood symptoms. More than half of patients on hemodialysis report sleep disturbance, muscle cramps, and fatigue. Patients describe symptoms as having a deleterious effect on their quality of life, suggesting that symptom alleviation may meaningfully improve patient-reported outcomes. Moreover, patients on hemodialysis have identified symptom management as a key area for research and innovation, prioritizing symptom alleviation over other health outcomes such as mortality and biochemical indices. Despite the importance of symptoms to patients, there has been little research explicitly geared toward improving patient symptoms, and therefore minimal innovation in symptom management. In general, the physiologic underpinnings of symptoms are poorly understood, hampering the development of targeted therapies. In fact, there have been few drugs or devices approved by the US Food and Drug Administration for the indication of improving any patient-reported outcomes for patients on hemodialysis. Recognizing this gap in innovation, the Kidney Health Initiative, a public-private partnership between the American Society of Nephrology and US Food and Drug Administration, convened a workgroup to first prioritize symptoms for the development of therapeutic interventions, and then identify near-term actionable research goals for the prioritized physical symptoms of insomnia, muscle cramps, and fatigue. This paper summarizes the pathophysiology of the three prioritized symptoms, identifies key knowledge gaps, acknowledges factors that challenge development of new therapies, and offers the nephrology community actionable research goals for insomnia, muscle cramps, and fatigue.",07/01/2019,01/07/2022 10:40,01/07/2022 10:40,,150-160,,1,14,,,,,,,,,,,,,,WOS:000455336600026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q3DUZ9UM,journalArticle,2004,"Golomb, BA; Criqui, MH; White, HL; Dimsdale, JE",The UCSD statin study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes,CONTROLLED CLINICAL TRIALS,,0197-2456,10.1016/j.cct.2003.08.014,,"There has been persistent controversy regarding possible favorable or adverse effects of statins or of cholesterol reduction on cognition, mood and behavior (including aggressive or violent behavior), muscle function, and quality of life. The UCSD Statin Study seeks to ascertain the beneficial or adverse effects of statin cholesterol-lowering drugs on a set of noncardiac endpoints, including cognition, behavior, and serotonin biochemistry. The-study will enroll 1000 subjects (minimum 20% female) of mixed ethnicity from San Diego. Subjects must be age 20 and older, postmenopausal if female, without known cardiovascular disease or diabetes, and with LDL-cholesterol between 115 and 190 mg/dl. Subjects will be randomized to a double-blind, placebo-controlled trial with assignment 1/3, 1/3, 1/3 to placebo, simvastatin 20 mg, or pravastatin 40 mg (equipotent LDL-cholesterol-lowering doses for drug arms with simvastatin and pravastatin chosen to represent the extremes of the lipophilicity spectrum) for 6 months of treatment followed by 2 months postcessation follow-up. Primary outcomes are cognition (cognitive battery), irritability/aggression (behavior measure), and serotonin (gauged by whole blood serotonin), assessed as the difference between baseline and 6 months, judging combined statin groups vs. placebo. Secondary outcomes include mood (CES-D and Wakefield depression inventory), quality of life (SF-12V), sleep (Leeds sleep scale, modified), and secondary aggression measures (Conflict Tactics Scale; Overt Aggression Scale, Modified). Cardiovascular reactivity will be examined in a 10% subset. As additional secondary endpoints, primary and selected secondary outcomes will be assessed by statin assignment (lipophilic simvastatin vs. hydrophilic pravastatin). ""Reversibility"" of changes, if any, at 2 months postcessation will be determined. If effects (favorable or unfavorable) are identified, we will seek to ascertain whether there are baseline variables that predict who will be most susceptible to these favorable or adverse noncardiac effects (i.e., effect modification). (C) 2004 Elsevier Inc. All rights reserved.",2004-04,01/07/2022 10:40,01/07/2022 10:40,,178-202,,2,25,,,,,,,,,,,,,,WOS:000220639600004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B3KZAY9K,journalArticle,2017,"Wiffen, PJ; Derry, S; Bell, RF; Rice, ASC; Tolle, TR; Phillips, T; Moore, RA",Gabapentin for chronic neuropathic pain in adults,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD007938.pub4,,"Background Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage). This review updates a review published in 2014, and previous reviews published in 2011, 2005 and 2000. Objectives To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain in adults. Search methods For this update we searched CENTRAL), MEDLINE, and Embase for randomised controlled trials from January 2014 to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trials registries. Selection criteria We included randomised, double-blind trials of two weeks' duration or longer, comparing gabapentin (any route of administration) with placebo or another active treatment for neuropathic pain, with participant-reported pain assessment. Data collection and analysis Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)), or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC). We performed a pooled analysis for any substantial or moderate benefit. Where pooled analysis was possible, we used dichotomous data to calculate risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNT) or harmful outcome (NNH). We assessed the quality of the evidence using GRADE and created ' Summary of findings' tables. Main results We included four new studies (530 participants), and excluded three previously included studies (126 participants). In all, 37 studies provided information on 5914 participants. Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy. Study duration was typically four to 12 weeks. Not all studies reported important outcomes of interest. High risk of bias occurred mainly due to small size (especially in cross-over studies), and handling of data after study withdrawal. In postherpetic neuralgia, more participants (32%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (17%) (RR 1.8 (95% CI 1.5 to 2.1); NNT 6.7 (5.4 to 8.7); 8 studies, 2260 participants, moderate-quality evidence). More participants (46%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (25%) (RR 1.8 (95% CI 1.6 to 2.0); NNT 4.8 (4.1 to 6.0); 8 studies, 2260 participants, moderate-quality evidence). In painful diabetic neuropathy, more participants (38%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (21%) (RR 1.9 (95% CI 1.5 to 2.3); NNT 5.9 (4.6 to 8.3); 6 studies, 1277 participants, moderate-quality evidence). More participants (52%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (37%) (RR 1.4 (95% CI 1.3 to 1.6); NNT 6.6 (4.9 to 9.9); 7 studies, 1439 participants, moderate-quality evidence). For all conditions combined, adverse event withdrawals were more common with gabapentin (11%) than with placebo (8.2%) (RR 1.4 (95% CI 1.1 to 1.7); NNH 30 (20 to 65); 22 studies, 4346 participants, high-quality evidence). Serious adverse events were no more common with gabapentin (3.2%) than with placebo (2.8%) (RR 1.2 (95% CI 0.8 to 1.7); 19 studies, 3948 participants, moderatequality evidence); there were eight deaths (very low-quality evidence). Participants experiencing at least one adverse event were more common with gabapentin (63%) than with placebo (49%) (RR 1.3 (95% CI 1.2 to 1.4); NNH 7.5 (6.1 to 9.6); 18 studies, 4279 participants, moderate-quality evidence). Individual adverse events occurred significantly more often with gabapentin. Participants taking gabapentin experienced dizziness (19%), somnolence (14%), peripheral oedema (7%), and gait disturbance (14%). Authors' conclusions Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by patients, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. Around 3 or 4 out of 10 participants achieved this degree of pain relief with gabapentin, compared with 1 or 2 out of 10 for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief but may experience adverse events. Conclusions have not changed since the previous update of this review.",2017,01/07/2022 10:40,01/07/2022 10:40,,,,6,,,,,,,,,,,,,,,WOS:000408840400063,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2VWR4WMA,journalArticle,2020,"Rajendran, SS; Naik, PK; Asaithambi, N; Arunachalam, SS; Shankar, S; Venkatesan, A",Sociodemographic Status of Breast Cancer Survivors in Chennai,BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS,,0974-6455,,,"Breast cancer is a life-threatening illness and is the type of cancer most often diagnosed in women. While the survival rate increases with the current option of screening and care, this disease is found in one out of four women. Patients' demographic profile has also had a significant influence on patients' morbidity and mortality, and socio-demographic and clinical factors need to be studied. This research is intended to examine breast cancer survivors' socio-demographic and clinical profile in Chennai, Tamil Nadu, India. Descriptive cross-sectional research was performed at a tertiary care hospital that included 150 breast cancer survivors on therapy with a structured questionnaire to collect data. Participants' mean age was 51.57 +/- 9.51 years, 56.67% were overweight, 59.33% had primary education, and 88% were married. Almost all of the participants were semi-urban residents, homemakers and 93.3% received treatment for less than five years and were in the third stage of cancer receiving hormone therapy. Considerably 41.33% of them are living with diabetes as a co-morbid condition. Most of them (76 %) had 4 to 8 hours of sleep. Breast cancer is a public health issue that needs urgent attention. The result will widen the reach for potential researchers and help policymakers prepare exclusive schemes for breast cancer survivors that will increase their quality of life and productivity.",2020,01/07/2022 10:40,01/07/2022 10:40,,315-321,,10,13,,,,,,,,,,,,,,WOS:000640077800051,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4TEYJN9Z,conferencePaper,2017,"Lotfi, A; Langensiepen, C; Wada, YS; Assoc Comp Machinery",Active and Healthy Ageing: Development of a Robotic Platform as an Exercise Trainer,,978-1-4503-5227-7,,10.1145/3056540.3076195,,"In this paper a new robotic system is introduced that will engage, coach, assess and motivate the elderly in physical exercises that are recommended by the National Health Services (NHS) in the UK. With the rise in the population of the elderly which is expected to triple by 2050, this robotic system will aims to improve the quality of life for a significant proportion of the population. Physical activities have tremendous benefit to elderly people. Regular exercise helps the elderly by improving their physical fitness, immune system, sleep and stress levels, not to mention the countless health problems it reduces such as diabetes, cardiovascular disease, dementia, obesity, joint pains etc.. Having a human instructor for each elderly person is not feasible due to the increase in the population of the elderly. The solution to this, therefore, is having a Exercise Trainer Socially Assistive Robot (ETSAR) that engages the elderly in the needed physical activity, coaches, motivates and also assesses their performance.",2017,01/07/2022 10:40,01/07/2022 10:40,,275-279,,,,,,,,,,,,,,,,,WOS:000644308800059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10TH ACM INTERNATIONAL CONFERENCE ON PERVASIVE TECHNOLOGIES RELATED TO ASSISTIVE ENVIRONMENTS (PETRA 2017),,,,,,,,,,,,,,,
8U9HDFIA,journalArticle,2013,"Figueiro, MG; White, RD",Health consequences of shift work and implications for structural design,JOURNAL OF PERINATOLOGY,,0743-8346,10.1038/jp.2013.7,,"The objective of the study was to perform a literature review on the health consequences of working rotating shifts and implications for structural design. A literature search was performed in June 2012 and a selection of the most relevant peer-review articles was included in the present review. Shift workers are more likely to suffer from a circadian sleep disorder characterized by sleepiness and insomnia. Shift work is associated with decreased productivity, impaired safety, diminished quality of life and adverse effects on health. Circadian disruption resulting from rotating shift work has also been associated with increased risk for metabolic syndrome, diabetes, cardiovascular disease and Cancer. This article summarizes the known health effects of shift work and discusses how light can be used as a countermeasure to minimize circadian disruption at night while maintaining alertness. In the context of the lighted environment, implications for the design of newborn intensive care units are also discussed. Journal of Perinatology (2013) 33, S17-S23; doi:10.1038/jp.2013.7",2013-04,01/07/2022 10:40,01/07/2022 10:40,,S17-S23,,,33,,,,,,,,,,,,,,WOS:000316833200003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SF3MYFM9,journalArticle,2010,"Oh, BH",Outline of psychiatric disorders of the elderly,JOURNAL OF THE KOREAN MEDICAL ASSOCIATION,,1975-8456,10.5124/jkma.2010.53.11.953,,"Psychiatric disorders of the elderly are significantly increasing in importance. Moreover, Korea is transitioning more rapidly to an aged society than any other country in the world. Psychiatric disorders of the elderly include typical dementia, depression, anxiety, late-life psychosis, and sleep disorders. Patients also may need to see a geriatric psychiatrist for chronic pain, Parkinson's disease, heart disease, diabetes, stroke, or other medical disorders. Older adults have special physical, emotional, and social needs. The principle therapeutic guidelines for elderly psychiatric disorders are based on comprehensive diagnosis and treatment including co-existing medical illnesses and medications, family, social and environmental issues. An integrated paradigm for prevention, diagnosis, rehabilitation, and multidisciplinary approaches I are essential. We reviewed the literature on the background, classification, diagnosis, and treatment of psychiatric disorders of the elderly. Treatment was classified into pharmacological and non-pharmacological intervention. Psychiatric disorders of the elderly covers from brain to community based on being able to treat elderly disorders successfully and improving quality of life.",2010-11,01/07/2022 10:40,01/07/2022 10:40,,953-957,,11,53,,,,,,,,,,,,,,WOS:000284447800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EUIT2EHN,journalArticle,2012,"Lee, H",Anesthetic management of the bariatric surgery,JOURNAL OF THE KOREAN MEDICAL ASSOCIATION,,1975-8456,10.5124/jkma.2012.55.10.996,,"Obesity, that is, having a body mass index (BMI) >30 kg/m(2), has increased dramatically and became the most single most common preventable cause of death in South Korea. In the end, obesity results in metabolic syndrome, which includes abdominal obesity, increased triglycerides, decreased high-density lipoprotein, hypertension, and impaired glucose tolerance. Nonsurgical methods for obesity treatments include dietary therapy, exercise counseling, behavioral therapy, psychiatric therapy, and pharmacotherapy. Surgical methods for obesity treatments, laparoscopic gastric banding and Roux-en-Y gastric bypass, are commonly performed for obese patients, particularly those with a BMI of 40 kg/m(2) or at BMI more than 30 kg/m(2) with accompanying diseases related to metabolic syndrome such as hypertension, type 2 diabetes, hypercholesterolemia, asthma, angina, other cardiopulmonary diseases, infertility, polycystic ovary, urinary incontinence, severe arthritis, or Pickwickian syndrome. Preoperative evaluation for bariatric surgery should focus on airway management, sleep apnea history, use of a continuous positive airway pressure device, and comorbid systemic diseases. Special consideration and pharmacokinetic knowledge is needed for the choice and dose of the anesthetic agents as well as postoperative pain control, patient monitoring, fluid intake, and surgical complications. Obesity is a disease. Appropriate surgical intervention and pen-operative anesthetic care for bariatric surgery will increase the safety and satisfaction of obese patients and will finally provide a better quality of life for our society.",2012-10,01/07/2022 10:40,01/07/2022 10:40,,996-1002,,10,55,,,,,,,,,,,,,,WOS:000310718900010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3FQDRKTV,journalArticle,2020,"Varughese, S; Rajeev, TP; Rodrigues, DE",Co-morbidities of Nocturia among Adults: A Cross-sectional Study in Southern India,JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH,,2249-782X,10.7860/JCDR/2020/46169.14337,,"Introduction: Night urination severely impacts the quality of life among adults. Coexisting factors such as age, obesity, diabetes, hypertension, cardiac diseases, UTI, asthma, anxiety, and depression are significantly related when voiding episodes exceed two per night. However, understanding its associated factors are essential aspects in the management of Nocturia. Aim: The aim of the study was to determine the association of nocturia with selected demographic variables, co-morbidities, and the precipitating factors among adults with voiding episodes two or more times and adults who void only once at night. Materials and Methods: A descriptive cross-sectional design was carried out among 420 adults of age 35-65 years with voiding over two times (Group I) and 206 adults of age 35-65 years who voided only once (Group II) a night. The data was collected from two selected hospitals of Mangalore between January 2018 and June 2019. The written permission was taken from the concerned authority, after obtaining the informed consent from the subjects. The baseline proforma was assessed by the researcher using structured interview schedule and the questionnaire on co-morbidity and precipitating factors such as regular intake of alcoholism, smoking, consumption of coffee, spicy food, anxiety, urinate before bedtime, use of diuretics, day time frequency, underwent surgeries was filled by the subjects. The data was analysed using frequency, percentage, chi square test, and logistic regression statistics by SPSS V.16. Results: The study observed that the risk of nocturia was significantly higher among Group I subjects with Urinary Tract Infection (UTI), constipation, hypertension, and on medication for various diseases compared with Group II. The precipitating factors of nocturia revealed that Group I subjects who regularly took coffee, spicy food, had anxiety, daytime frequency, and had undergone various surgeries showed significant difference associated with increased risk of nocturia compared with Group II. Conclusion: The study findings demonstrate that nocturia is strongly associated with multiple co-morbidities and precipitating factors. These results therefore provide evidence to establish the primary and secondary preventive strategies among adults with nocturia.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,LC11-LC15,,12,14,,,,,,,,,,,,,,WOS:000600049700060,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CTXSISM5,journalArticle,2014,"Jerath, NU; Lamichhane, D; Jasti, M; Yarlagadda, V; Zilli, E; Nazzal, Y; Granner, M",Treating Epilepsy in the Setting of Medical Comorbidities,CURRENT TREATMENT OPTIONS IN NEUROLOGY,,1092-8480,10.1007/s11940-014-0298-1,,"Treatment of epilepsy in patients with medical comorbidities can be challenging. Comorbidities can affect medical management and quality of life. In this review, we discuss treatment options in patients with epilepsy and medical comorbidities. In our opinion, the best way to manage patients with medical comorbidities and epilepsy is to accurately recognize and diagnose medical comorbidities, and to have adequate knowledge and familiarity with antiepileptic drug (AED) metabolism, dosing, side effects, and drug interactions. We believe the trend should move toward using the newer generation of AEDs given their generally reduced rate of adverse effects and interactions. The primary goal of therapy is seizure freedom without side effects.",2014-07,01/07/2022 10:40,01/07/2022 10:40,,,,7,16,,,,,,,,,,,,,,WOS:000339735000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5NV2GRQI,journalArticle,2015,"Calvino, J; Cigarran, S; Lopez, LM; Martinez, A; Sobrido, MJ",Restless Legs Syndrome in Non-Dialysis Renal Patients: Is It Really That Common?,JOURNAL OF CLINICAL SLEEP MEDICINE,,1550-9389,10.5664/jcsm.4366,,"Background: Sleep disorders are frequent in chronic kidney disease (CKD). Among them, restless legs syndrome (RLS) may affect up to 60% of patients on dialysis, and it has been related to a poor quality of life and higher cardiovascular risk. Despite its high prevalence in advanced stages of renal disease, RLS frequency in non-dialysis CKD has not been clearly established. The aim of this study was to assess the frequency of RLS in non-dialysis CKD patients (stages 2 to 4) followed in a reference nephrology outpatient clinic. Methods: A standardized questionnaire following the international RLS study group diagnostic criteria was self-administered by 110 patients regularly followed in the nephrology clinic. The series comprised 69 men and 41 women, aged 68 +/- 13.2 years, with mean serum creatinine of 1.7 +/- 0.8 mg/dL. Subsequently, patients classified as probable RLS according to the questionnaire underwent a systematic neurological examination. The presence of peripheral artery disease was evaluated by the ankle-brachial index (ABI). Results: The frequency of probable RLS according to the questionnaire results was 21% (17% for men and 27% for women). However, after thorough neurological examination, the diagnosis of RLS was confirmed in only 5 patients. Therefore, the overall definitive RLS frequency was 4.5% (within the prevalence reported for the general population) and was higher among women (9.7% vs 0.2%). In the remaining cases symptoms were due to leg discomfort related with other disorders. Patients with probable and improbable RLS were not significantly different in age, ABI, diabetes, and other comorbid circumstances, except for tricyclic antidepressant prescription, which was more frequent in the probable RLS group (17% vs 2%). Renal function was better in definitive RLS patients than cases classified as probable RLS by the questionnaire but not confirmed after neurological exam. Conclusions: Although RLS can represent an early manifestation of CKD, its prevalence seems very close to that reported for the general population. Diagnostic confirmation of RLS dramatically falls after expert examination, raising the question whether, in the study of RLS cohorts, CKD has a potentially causal relationship or is a confounding factor associated with other causes of leg discomfort.",2015,01/07/2022 10:40,01/07/2022 10:40,,57-60,,1,11,,,,,,,,,,,,,,WOS:000351167800010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99H8ZS4J,journalArticle,2019,"Barton, M; Yanagisawa, M",Endothelin: 30 Years From Discovery to Therapy,HYPERTENSION,,0194-911X,10.1161/HYPERTENSIONAHA.119.12105,,"Discovered in 1987 as a potent endothelial cell-derived vasoconstrictor peptide, endothelin-1 (ET-1), the predominant member of the endothelin peptide family, is now recognized as a multifunctional peptide with cytokine-like activity contributing to almost all aspects of physiology and cell function. More than 30000 scientific articles on endothelin were published over the past 3 decades, leading to the development and subsequent regulatory approval of a new class of therapeutics-the endothelin receptor antagonists (ERAs). This article reviews the history of the discovery of endothelin and its role in genetics, physiology, and disease. Here, we summarize the main clinical trials using ERAs and discuss the role of endothelin in cardiovascular diseases such as arterial hypertension, preecclampsia, coronary atherosclerosis, myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) caused by spontaneous coronary artery dissection (SCAD), Takotsubo syndrome, and heart failure. We also discuss how endothelins contributes to diabetic kidney disease and focal segmental glomerulosclerosis, pulmonary arterial hypertension, as well as cancer, immune disorders, and allograft rejection (which all involve ETA autoantibodies), and neurological diseases. The application of ERAs, dual endothelin receptor/angiotensin receptor antagonists (DARAs), selective ETB agonists, novel biologics such as receptor-targeting antibodies, or immunization against ETA receptors holds the potential to slow the progression or even reverse chronic noncommunicable diseases. Future clinical studies will show whether targeting endothelin receptors can prevent or reduce disability from disease and improve clinical outcome, quality of life, and survival in patients.",2019-12,01/07/2022 10:40,01/07/2022 10:40,,1232-1265,,6,74,,,,,,,,,,,,,,WOS:000497370200005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JJLPZT6N,journalArticle,2017,"Hatori, M; Gronfier, C; Van Gelder, RN; Bernstein, PS; Carreras, J; Panda, S; Marks, F; Sliney, D; Hunt, CE; Hirota, T; Furukawa, T; Tsubota, K",Global rise of potential health hazards caused by blue light-induced circadian disruption in modern aging societies,NPJ AGING AND MECHANISMS OF DISEASE,,2056-3973,10.1038/s41514-017-0010-2,,"Mammals receive light information through the eyes, which perform two major functions: image forming vision to see objects and non-image forming adaptation of physiology and behavior to light. Cone and rod photoreceptors form images and send the information via retinal ganglion cells to the brain for image reconstruction. In contrast, nonimage-forming photoresponses vary widely from adjustment of pupil diameter to adaptation of the circadian clock. nonimage-forming responses are mediated by retinal ganglion cells expressing the photopigment melanopsin. Melanopsin-expressing cells constitute 1-2% of retinal ganglion cells in the adult mammalian retina, are intrinsically photosensitive, and integrate photic information from rods and cones to control nonimage-forming adaptation. Action spectra of ipRGCs and of melanopsin photopigment peak around 480 nm blue light. Understanding melanopsin function lets us recognize considerable physiological effects of blue light, which is increasingly important in our modern society that uses light-emitting diode. Misalignment of circadian rhythmicity is observed in numerous conditions, including aging, and is thought to be involved in the development of age-related disorders, such as depression, diabetes, hypertension, obesity, and cancer. The appropriate regulation of circadian rhythmicity by proper lighting is therefore essential. This perspective introduces the potential risks of excessive blue light for human health through circadian rhythm disruption and sleep deprivation. Knowing the positive and negative aspects, this study claims the importance of being exposed to light at optimal times and intensities during the day, based on the concept of the circadian clock, ultimately to improve quality of life to have a healthy and longer life.",16/06/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,3,,,,,,,,,,,,,,WOS:000411465000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JC6NG4MQ,journalArticle,2015,"Geneen, LJ; Martin, DJ; Adams, N; Clarke, C; Dunbar, M; Jones, D; McNamee, P; Schofield, P; Smith, BH",Effects of education to facilitate knowledge about chronic pain for adults: a systematic review with meta-analysis,SYSTEMATIC REVIEWS,,2046-4053,10.1186/s13643-015-0120-5,,"Background: Chronic pain can contribute to disability, depression, anxiety, sleep disturbances, poor quality of life and increased health care costs, with close to 20 % of the adult population in Europe reporting chronic pain. To empower the person to self-manage, it is advocated that education and training about the nature of pain and its effects and how to live with pain is provided. The objective of this review is to determine the level of evidence for education to facilitate knowledge about chronic pain, delivered as a stand-alone intervention for adults, to reduce pain and disability. Methods: We identified randomised controlled trials of educational intervention for chronic pain by searching CENTRAL, MEDLINE, EMBASE and ongoing trials registries (inception to December 2013). Main inclusion criteria were (1) pain > 3 months; (2) study design that allowed isolation of effects of education and (3) measures of pain or disability. Two reviewers independently screened and appraised each study. Results: Nine studies were analysed. Pooled data from five studies, where the comparator group was usual care, showed no improvement in pain or disability. In the other four studies, comparing different types of education, there was no evidence for an improvement in pain; although, there was evidence (from one study) of a decrease in disability with a particular form of education-pain neurophysiology education (PNE). Post-hoc analysis of psychosocial outcomes reported in the studies showed evidence of a reduction in catastrophising and an increase of knowledge about pain following PNE. Conclusions: The evidence base is limited by the small numbers of studies, their relatively small sample sizes, and the diversity in types of education studied. From that limited evidence, the only support for this type of education is for PNE, though it is insufficiently strong to recommend conclusively that PNE should be delivered as a stand-alone intervention. It therefore remains sensible to recommend that education be delivered in conjunction with other pain management approaches as we cannot confidently conclude that education alone is effective in reducing pain intensity or related disability in chronic pain in adults.",2015,01/07/2022 10:40,01/07/2022 10:40,,,,,4,,,,,,,,,,,,,,WOS:000453134600129,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4JQCYPJ3,journalArticle,2016,"Sarwer, DB; Polonsky, HM",The Psychosocial Burden of Obesity,ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA,,0889-8529,10.1016/j.ecl.2016.04.016,,"Obesity is associated with several comorbidities, including cardiovascular disease, type 2 diabetes, sleep apnea, osteoarthritis, and several forms of cancer. Obesity and its comorbidities also come with a significant psycho social burden, impacting numerous areas of psychosocial functioning. The evaluation of psychosocial functioning is an important part of the assessment and treatment planning for the patient with obesity. This article provides an overview of the psychosocial burden of obesity. It also describes the psychological changes typically seen with weight loss. A particular focus is on the psychosocial functioning of individuals with extreme obesity who present for and undergo bariatric surgery.",2016-09,01/07/2022 10:40,01/07/2022 10:40,,677-+,,3,45,,,,,,,,,,,,,,WOS:000383008200016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GZVTNK3J,journalArticle,2020,"de Ligt, M; Bergman, M; Fuentes, RM; Essers, H; Moonen-Kornips, E; Havekes, B; Schrauwen-Hinderling, VB; Schrauwen, P",No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial,AMERICAN JOURNAL OF CLINICAL NUTRITION,,0002-9165,10.1093/ajcn/nqaa125,,"Background: Effects of resveratrol on metabolic health have been studied in several short-term human clinical trials, with conflicting results. Next to dose, the duration of the clinical trials may explain the lack of effect in some studies, but long-term studies are still limited. Objectives: The objective of this study was to investigate the effects of 6-mo resveratrol supplementation on metabolic health outcome parameters. Methods: Forty-one overweight men and women (BMI: 27-35 kg/m(2); aged 40-70 y) completed the study. In this parallel-group, double-blind clinical trial, participants were randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo. The primary outcome of the study was insulin sensitivity, using the Matsuda index. Secondary outcome measures were intrahepatic lipid (IHL) content, body composition, resting energy metabolism, blood pressure, plasma markers, physical performance, quality of life, and quality of sleep. Postintervention differences between the resveratrol and placebo arms were evaluated by ANCOVA adjusting for corresponding preintervention variables. Results: Preintervention, no differences were observed between the 2 treatment arms. Insulin sensitivity was not affected after 6 mo of resveratrol treatment (adjusted mean Matsuda index: 5.18 +/- 0.35 in the resveratrol arm compared with 5.50 +/- 0.34 in the placebo arm), although there was a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007). The adjusted means showed that postintervention HbA1c was lower on resveratrol (35.8 +/- 0.43 mmol/mol) compared with placebo (37.6 +/- 0.44 mmol/mol). No postintervention differences were found in IHL, body composition, blood pressure, energymetabolism, physical performance, or quality of life and sleep between treatment arms. Conclusions: After 6 mo of resveratrol supplementation, insulin sensitivity was unaffected in the resveratrol arm compared with the placebo arm. Nonetheless, HbA1c was lower in overweight men and women in the resveratrol arm. This trial was registered at clinicaltrials.gov as NCT02565979. Am J Clin Nutr 2020;112:1029-1038.",2020-10,01/07/2022 10:40,01/07/2022 10:40,,1029-1038,,4,112,,,,,,,,,,,,,,WOS:000581138300020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YERM4KK2,journalArticle,2018,"Lainas, P; Dammaro, C; Gaillard, M; Donatelli, G; Tranchart, H; Dagher, I",Safety and short-term outcomes of laparoscopic sleeve gastrectomy for patients over 65 years old with severe obesity,SURGERY FOR OBESITY AND RELATED DISEASES,,1550-7289,10.1016/j.soard.2018.03.002,,"Background: Laparoscopic sleeve gastrectomy (LSG) is a widely accepted, stand-alone bariatric operation. Data on elderly patients undergoing LSG are scarce. Objectives: The aim of this study was to demonstrate that LSG is safe and effective for patients >65 years old with severe obesity. Setting: Department of Minimally Invasive Digestive Surgery, Antoine-Beclere Hospital, AP-HP, Paris-Saclay University, France. Methods: Prospectively collected data from consecutive patients undergoing LSG were retrospectively analyzed. Patients with >1-year follow-up were included in the analysis for weight loss and co-morbidities evaluation. Quality of life was evaluated using the Short-Form 36 questionnaire. Results: Fifty-four patients >65 years old (range, 65-75 yr) underwent LSG. Median weight was 119 kg, and median body mass index was 43 kg/m(2). Median duration of surgery was 86.5 minutes. Two patients (3.7%) suffered a gastric staple-line leak, 1 treated by pure endoscopic internal drainage and 1 by relaparoscopy with subsequent endoscopic internal drainage. Mortality was null. Median length of hospital stay was 5 days. Six, 12, and 24 months after LSG, median body mass index decreased significantly to 35, 32.9, and 30.7 kg/m(2), respectively (P < .0001), with mean excess weight loss of 76.3% at 2 years. Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea syndrome, and arthralgia showed statistically significant remission at 1- and 2-year follow-up, while 6 of 8 SF-36 scale scores of quality of life assessment improved significantly. Conclusions: This study suggests that LSG is effective for patients > 65 years old, resulting in significant weight loss, co-morbidities remission, and quality of life improvement. Careful patient selection after adequate risk versus benefit evaluation by an expert multidisciplinary team is essential for patient safety and optimal results. (C) 2018 American Society for Metabolic and Bariatric Surgery. All rights reserved.",2018-07,01/07/2022 10:40,01/07/2022 10:40,,952-959,,7,14,,,,,,,,,,,,,,WOS:000442976300011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XIAEFA45,journalArticle,2014,"Gesquiere, I; Aron-Wisnewsky, J; Foulon, V; Haggege, S; Van der Schueren, B; Augustijns, P; Bouillot, JL; Clement, K; Basdevant, A; Oppert, JM; Buyse, M",Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients,OBESITY SURGERY,,0960-8923,10.1007/s11695-014-1325-8,,"This study aims to determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-related costs. The study analyzed the types, dosages, and costs of drugs and medical devices prescribed before and after surgery (1, 3, 6, and 12 months and yearly thereafter) in patients who underwent RYGB between June 2004 and May 2010 and had an outpatient visit between December 2009 and May 2010 at Piti,-SalptriSre University Hospital, Paris, France. The cohort included 143 patients (78 % female; mean age, 42.9 years; mean BMI, 48.6 kg/m(2)). Total prescription costs were significantly lower (-32 %, p < 0.001) 1 year after RYGB compared with preoperative costs. However, the cost for medications to prevent RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the first month postsurgery, but then decreased progressively over time. Importantly, the cost related to the treatment of the two most frequent obesity-related diseases significantly decreased 1 year after surgery. Indeed, prescription costs for treatment of type 2 diabetes (T2D) and obstructive sleep apnea (OSA) (namely CPAP therapy considered as the gold standard treatment) were reduced 1 year after surgery by 85 and by 63 % (both p < 0.001), respectively. We also observed a trend toward a decrease in the prescription costs of other obesity-related diseases, although it did not reach significance in our cohort. Considering medication to treat both obesity-related diseases and prevention of secondary effects of bariatric surgery, we observed that overall postoperative medication costs were significantly reduced one year after surgery, especially for T2D and OSA.",2014-11,01/07/2022 10:40,01/07/2022 10:40,,1896-1903,,11,24,,,,,,,,,,,,,,WOS:000343729700010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I26F8UVY,journalArticle,2008,"Shankar, A; Wang, JJ; Rochtchina, E; Mitchell, P",Association between self-rated health and incident severe hypertension among men: a population-based cohort study,SINGAPORE MEDICAL JOURNAL,,0037-5675,,,"Introduction: Self-rated health (SRH) is a consistent predictor of cardiovascular disease and mortality. However, the intermediate biological mechanisms behind this association are not clear. We examined the longitudinal relationship between SRH and incident severe hypertension. Methods: We studied a population-based cohort of 1,298 participants (mean age 62.5 years, range 49-84 years), at the baseline examination (1992 1994) residing in the Blue Mountains region, west of Sydney, Australia, and re-examined after five years (1997-1999). Main outcome-of-interest was incident severe hypertension (systolic blood pressure [BP] 160 mmHg or above, diastolic BP 100 mmHg or above, or a combination of self-reported hypertension diagnosis and use of antihypertensive medications) among baseline individuals without severe hypertension. Results: Among men, those with fair/poor SRH had significantly higher odds of incident severe hypertension, compared to individuals with excellent SRH. Multivariable odds-ratio (OR) (95 percent confidence intervals [CI]) comparing fair/poor SRH to excellent SRH was 1.93 (1.04-3.56) (p-trend was 0.03). This association was not observed in women comparing fair/poor SRH to excellent SRH: OR 0.96, 95 percent CI 0.57-1.62 (p-trend was 0.70). Subgroup analyses stratified by age, smoking, body mass index, diabetes mellitus and BP categories, supported this male gender-specific pattern of association. Conclusion: This data suggests an association between poor SRH and incident hypertension among men, but not among women. These results suggest that at least part of the previously-reported association between poor SRH and mortality may be mediated by its relation to incident severe hypertension.",2008-11,01/07/2022 10:40,01/07/2022 10:40,,860-867,,11,49,,,,,,,,,,,,,,WOS:000261235200004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZQPM9EK5,journalArticle,2020,"Katsiki, N; Stoian, AP; Steiropoulos, P; Papanas, N; Suceveanu, AI; Mikhailidis, DP",Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview,METABOLITES,,2218-1989,10.3390/metabo10110465,,"Chronic obstructive pulmonary disease (COPD) is a common disorder with an increasing prevalence, characterised by persistent respiratory symptoms and airflow limitation. Systemic inflammation is involved in the pathogenesis of COPD and can also predispose to metabolic disorders (e.g., metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD)). Such comorbidities can negatively affect COPD outcomes, cardiovascular risk, and quality of life. Apart from NAFLD, abnormal peri-organ or intra-organ fat (APIFat) could be considered as markers for cardiometabolic diseases and even for COPD. The present narrative review considers the associations of COPD with MetS, NAFLD, and other APIFat, including epicardial, perirenal, peripancreatic, and intramuscular adipose tissue. Further research is needed to define these relationships and identify any potential clinical implications.",2020-11,01/07/2022 10:40,01/07/2022 10:40,,,,11,10,,,,,,,,,,,,,,WOS:000593837300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SWVPSCPI,journalArticle,2010,"Nejat, EJ; Polotsky, AJ; Pal, L",Predictors of chronic disease at midlife and beyond - the health risks of obesity,MATURITAS,,0378-5122,10.1016/j.maturitas.2009.09.006,,"A burgeoning pandemic of obesity is well characterized. 41% of U.S. adults are projected to be obese by 2015 and obesity, a potentially modifiable risk, is emerging as a leading predictor of lifetime health. The wide spectrum of morbidities related to excess body mass includes risks for diabetes, hypertension, coronary artery disease, dyslipidemia, malignancy, venous thrombosis, degenerative joint disease, pulmonary compromise, sleep apnea, cholelithiasis, depression and overall reduced quality of life. Beyond the myriad major and minor morbidities linked to obesity, increased all-cause mortality and cardiovascular mortality is recognized in the obese. Bariatric surgery literature suggests that, in the morbidly obese, increase in the lifespan is achievable with reversal of obesity, reinforcing the realization that sequelae therein are by no means inevitable. Aggressive efforts must be targeted towards population-based strategies to educate and sensitize all generations on contributors to and sequelae of excess body mass as obesity represents one of the few modifiable factors that impact on the quantity and quality of lifespan. (C) 2009 Elsevier Ireland Ltd. All rights reserved.",2010-02,01/07/2022 10:40,01/07/2022 10:40,,106-111,,2,65,,,,,,,,,,,,,,WOS:000274944600005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TJYJSCY8,journalArticle,2017,"Linz, D; Hohl, M; Vollmar, J; Ukena, C; Mahfoud, F; Bohm, M",Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction,EUROPACE,,1099-5129,10.1093/europace/euw092,,"Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with significant morbidity and mortality. Multiple conditions like hypertension, heart failure, diabetes, sleep apnoea, and obesity play a role for the initiation and perpetuation of AF. Recently, a potential association between gastroesophageal reflux disease (GERD) and AF development has been proposed due to the close anatomic vicinity of the oesophagus and the left atrium. As an understanding of the association between acid reflux disease and AF may be important in the global multimodal treatment strategy to further improve outcomes in a subset of patients with AF, we discuss potential atrial arrhythmogenic mechanisms in patients with GERD, such as gastric and subsequent systemic inflammation, impaired autonomic stimulation, mechanical irritation due to anatomical proximity of the left atrium and the oesophagus, as well as common comorbidities like obesity and sleep-disordered breathing. Data on GERD and oesophageal lesions after AF-ablation procedures will be reviewed. Treatment of GERD to avoid AF or to reduce AF burden might represent a future treatment perspective but needs to be scrutinized in prospective trials.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,16-20,,1,19,,,,,,,,,,,,,,WOS:000397055100003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29NWNY9U,journalArticle,2019,"Muscogiuri, G; Formoso, G; Pugliese, G; Ruggeri, RM; Scarano, E; Colao, A; RESTARE",Prader- Willi syndrome: An uptodate on endocrine and metabolic complications,REVIEWS IN ENDOCRINE & METABOLIC DISORDERS,,1389-9155,10.1007/s11154-019-09502-2,,"Prader-Willi syndrome (PWS) is a genetic disorder characterized by short stature, low lean body mass, muscular hypotonia, mental retardation, behavioral abnormalities, dysmorphic features, and excessive appetite with progressive obesity. It is caused by lack of expression of genes on the paternally inherited chromosome 15q11.2-q13. This genetic disorder has an estimated prevalence that ranges between 1/10,000-1/30,000. Hypothalamic dysfunction is a common finding in PWS and it has been implicated in several manifestations of this syndrome such as hyperphagia, temperature instability, high pain threshold, sleep disordered breathing, and multiple endocrine abnormalities. These include growth hormone deficiency, central adrenal insufficiency, hypogonadism, hypothyroidism, and obesity often complicated by type 2 diabetes. The aim of this manuscript is to overview the current literature on metabolic and endocrine complications of PWS, focusing on human studies and providing insights on the physio pathological mechanisms. A careful management of metabolic and endocrine complications can contribute to improve quality of life, prevent complications, and prolong life expectancy of PW patients.",2019-06,01/07/2022 10:40,01/07/2022 10:40,,239-250,,2,20,,,,,,,,,,,,,,WOS:000470792400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VZ376ESU,journalArticle,2015,"Collomb, M; Sens, F; Sanchez, S; Jolivot, A; Pivot, C; Juillard, L; Paillet, C",Long-term benzodiazepine use among dialysis patient: A descriptive study,NEPHROLOGIE & THERAPEUTIQUE,,1769-7255,10.1016/j.nephro.2015.02.004,,"Background. - Dialysis patients frequently have anxiety and sleeping disorders and that explains a benzodiazepine treatment. A significant proportion of dialysis patients are long-term users even though it is not recommended to take benzodiazepine for more than 3 months. Risks of such a use are well identified. Nephrologists frequently have to prescribe benzodiazepines. This prescription is complex and there are few studies regarding the factors of benzodiazepine use among this population. Objectives. - To determine the prevalence and the factors related to a long-term benzodiazepine use by dialysis patients. To determine the prevalence and the motivation of patients to stop taking medication among the long-term users who got information about the risk of such a use. Method. - The study includes 91 dialysis chronic patients. Their characteristics were collected from medical records and interviews with the patients. Results. - The average age of patients is 65,8 years. In all, 50.5% take benzodiazepines. Among benzodiazepine users, the prevalence of long-term use is 78.3%. Long-term benzodiazepine users (a) are older, (b) less active, (c) frequently diabetic, (d) depressive, (e) unable to walk, (f) less often registered on the kidney transplant waiting list, and (g) had less kidney transplant previously. Benzodiazepine doses of long-term users were higher than the doses of short-term users. Moreover, 60% of patients who are chronic users want to take action and stop the treatment. Observation of side effects, impression of ineffectiveness and fear of addiction are the most identified motivation to stop treatment. Conclusion. - The prevalence of benzodiazepine chronic use by dialysis patients is high. Giving information to the patient about the use of these molecules seems to have a positive impact on the decision to stop. (C) 2015 Association Societe de nephrologie. Published by Elsevier Masson SAS. All rights reserved.",2015-07,01/07/2022 10:40,01/07/2022 10:40,,226-233,,4,11,,,,,,,,,,,,,,WOS:000362390000004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WVUDCPEE,journalArticle,2017,"Davenport, MH; Ruchat, SM; Hazell, TJ",Exercise Prescription for Post-Menopausal Women with Obesity,CURRENT WOMENS HEALTH REVIEWS,,1573-4048,10.2174/1573404812666160811120435,,"The transition to menopause is associated with a myriad of physiological changes including unstable hormone levels (estrogen, progesterone) resulting in hot flashes, sleep deprivation, weight gain, mood swings and is associated with increased risk of osteoperosis and cardiometabolic disease. Exercise is a critical component of health and wellbeing at any age; however, it may be especially beneficial during and following menopause. Currently, there are no physical activity guidelines specific to post-menopausal women with obesity. However, strong evidence suggests that greater health benefits may be derived with higher levels of physical activity beyond current recommendations for adults. This review describes the potential benefits of exercise in this population, as well as reviewing current guidelines and considerations for exercise in this population.",2017,01/07/2022 10:40,01/07/2022 10:40,,17-24,,1,13,,,,,,,,,,,,,,WOS:000450922100004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6TAYFNYF,journalArticle,2018,"Lotfi, A; Langensiepen, C; Yahaya, SW",Socially Assistive Robotics: Robot Exercise Trainer for Older Adults,TECHNOLOGIES,,2227-7080,10.3390/technologies6010032,,"Physical activities have tremendous benefit to older adults. A report from the World Health Organization has mentioned that lack of physical activity contributed to around 3.2 million premature deaths annually worldwide. Research also shows that regular exercise helps the older adults by improving their physical fitness, immune system, sleep and stress levels, not to mention the countless health problems it reduces such as diabetes, cardiovascular disease, dementia, obesity, joint pains, etc. The research reported in this paper is introducing a Socially Assistive Robot (SAR) that will engage, coach, assess and motivate the older adults in physical exercises that are recommended by the National Health Services (NHS) in the UK. With the rise in the population of older adults, which is expected to triple by 2050, this SAR will aim to improve the quality of life for a significant proportion of the population. To assess the proposed robot exercise trainer, user's observational evaluation with 17 participants is conducted. Participants are generally happy with the proposed platform as a mean of encouraging them to do regular exercise correctly.",2018-03,01/07/2022 10:40,01/07/2022 10:40,,,,1,6,,,,,,,,,,,,,,WOS:000460468200006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LEBWT2IN,journalArticle,2021,"Frojd, LA; Munkhaugen, J; Moum, T; Sverre, E; Nordhus, IH; Papageorgiou, C; Dammen, T",Insomnia in patients with coronary heart disease: prevalence and correlates,JOURNAL OF CLINICAL SLEEP MEDICINE,,1550-9389,10.5664/jcsm.9082,,"Study Objectives: The aim of this study was to determine the prevalence of insomnia and its association with clinical and psychosocial factors in a large sample of outpatients with coronary heart disease. Methods: The sample comprised 1,082 patients, mean age 62 years (21% female), who participated in the cross-sectional NORwegian CORonary Prevention Study. Patients who were hospitalized with myocardial infarction and/or a coronary revascularization procedure in 2011-2014 responded to a self-report questionnaire and participated in a clinical examination with blood samples 2-36 (mean, 16) months later. Insomnia was assessed using the Bergen Insomnia Scale, a questionnaire based on the criteria for the clinical diagnosis of insomnia as described in the Diagnostic and Statistical Manual of Mental Disorders, fourth version. We performed bivariate logistic regressions for crude analysis and backward stepwise logistic regressions for multiadjusted odds ratios (OR). Results: In total, 488 patients (45%) reported insomnia, and 24% of these patients had used sleep medication in the previous week. Anxiety symptoms (OR: 5.61) were the strongest determinants of insomnia, followed by female sex (OR: 1.88), diabetes (OR: 1.83), eating fish fewer than three times a week (OR: 1.69), type D personality (OR: 1.69), and C-reactive protein >= 2 mg/L (OR:1.58), in multiadjusted analyses. Conclusions: Insomnia was highly prevalent in coronary heart disease outpatients. Psychological factors, lifestyle factors, and subclinical inflammation were associated with insomnia. Our results emphasize the need to identify patients with insomnia and provide appropriate management of insomnia in outpatients with coronary heart disease.",01/05/2021,01/07/2022 10:40,01/07/2022 10:40,,931-938,,5,17,,,,,,,,,,,,,,WOS:000660335600010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3C7JMFIF,journalArticle,2019,"Bhandari, M; Nautiyal, HK; Mathur, W; Kosta, S",OAGB vs BGBP: A retrospective comparative study of a cohort of patients who had bariatric surgery in 2012 at one centre by a single surgeon,CLINICAL OBESITY,,1758-8103,10.1111/cob.12308,,"Two modifications of Roux-en-Y gastric bypass (RYGB), one anastomosis gastric bypass (OAGB) and Roux-en-Y banded gastric bypass (BGBP), are gaining popularity in use because the OAGB is reported to be a simpler operation, and the BGBP is reported to have sustained weight loss compared to standard RYGB. A retrospective review and analysis of data comparing outcomes up to 5 years after BGBP and OAGB from a prospectively maintained database of all bariatric metabolic operations in 2012 was performed. Eighty-two patients underwent a BGBP and 90 an OAGB. The average age and body mass index were 44.12 and 43.97 and 43.57 and 45.79 in the BGBP and OAGB groups, respectively. Postoperative nutrient deficiencies were similar in both groups but were more prominent in the OAGB group. The % excess body weight loss (%EBWL) was 78% and 71.5% at 5 years in the OAGB and BGBP groups, respectively. The % total weight loss (%TWL) was also higher in OAGB compared to the BGBP group, 34.72% and 30.49%, respectively. Resolution of type 2 diabetes (T2DM) was significantly higher in the OAGB group, 79.16%, than in the BGBP group, 71.42%. The resolution of dyslipidaemia and hypertension were similar in both groups, but sleep apnoea resolution was higher in OAGB group. Both operations produced excellent weight loss in the intermediate term. The %EBWL and resolution of T2DM were significantly higher after the OAGB operation at the expense of increased incidence of nutrient deficiencies and hypoproteinemia. Quality of life improvement and patient satisfaction were high after both operations. Long-term follow up and multicentre prospective studies are needed to confirm these intermediate outcomes.",2019-08,01/07/2022 10:40,01/07/2022 10:40,,,,4,9,,,,,,,,,,,,,,WOS:000474933400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2X29V4J6,journalArticle,2017,"Al-Bannay, HR; Jarus, T; Jongbloed, L; Dean, E",Discordance between lifestyle-related health beliefs and behaviours of Saudi women in Dammam,HEALTH EDUCATION JOURNAL,,0017-8969,10.1177/0017896917705160,,"Objective: Women living in the Kingdom of Saudi Arabia including in the Eastern Province have a high prevalence of lifestyle-related conditions for which targeted health education strategies are needed. This study's objective was to explore their self-reported health status and the congruence of their lifestyle-related health beliefs and practices to inform health education programme development. Methods: A cross section of community-living Saudi women (N = 407) living in Dammam (the capital of the Eastern Province) was sampled from regional health centres. Participants completed an interview survey questionnaire about their health status and their lifestyle-related health beliefs and practices. Results: In all, 44% of participants reported having an average but not excellent health. This finding was at odds with their unequivocal, evidence-supported beliefs about the positive relationship between exercise, good nutrition, not smoking and manageable stress, with health (>= 97%). Despite these strong beliefs, participants reported suboptimal levels of exercise, nutritional choices, stress and sleep quality and quantity for maximal health and wellbeing. Conclusion: Studies are warranted to explore and explain marked discrepancy between the positive health beliefs and lifestyle-related health practices of Saudi women living in Dammam, and to design effective health promotion education programmes to address this gap. Improving Saudi women's health by narrowing the lifestyle-related health belief-practice gap may also maximise the health of families, given women's pivotal role in managing the family, as well as individual health.",2017-08,01/07/2022 10:40,01/07/2022 10:40,,569-581,,5,76,,,,,,,,,,,,,,WOS:000408777900005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GP92LQEM,journalArticle,2020,"Davari, M; Amani, B; Amani, B; Khanijahani, A; Akbarzadeh, A; Shabestan, R",Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis,KOREAN JOURNAL OF PAIN,,2005-9159,10.3344/kjp.2020.33.1.3,,"Neuropathic pain after spinal cord injury (SCI) has a significant negative impact on the patients' quality of life. The objective of this systematic review is to examine the safety and efficacy of pregabalin (PGB) and gabapentin (GBP) in the treatment of neuropathic pain due to SCI. PubMed, the Cochrane Library, Embase, Scopus, and the Web of Science were searched up to December 2018. The reference lists of key and review studies were reviewed for additional citations. The quality of the studies was evaluated using the Cochrane Collaboration's tools for assessing the risk of bias. A meta-analysis was performed for primary and secondary outcomes. Eight studies were eligible for inclusion. Meta-analysis of PGB vs. placebo showed that PGB was effective for neuropathic pain (standardized mean difference [SMD] = -0.40; 95% confidence interval [CI]: -0.78, -0.01), anxiety (MD = -0.68; 95% CI: -0.77, -0.59), depression (mean difference [MD] = -0.99; 95% CI: -1.08, -0.89), and sleep interference (MD = -1.08; 95% CI: -1.13, -1.02). Also, GBP was more effective than a placebo for reducing pain. No significant difference was observed between the efficacy of the two drugs (MD = -0.37; 95% CI: -1.67, 0.93). There was no significant difference between the two drugs for discontinuation due to adverse events (risk ratio = 3.00; 95% CI: 0.81, 11.15). PGB and GBP were effective vs. placebos in decreasing neuropathic pain after SCI. Also, there was no significant difference between the two drugs for decreasing pain and adverse events.",2020-01,01/07/2022 10:40,01/07/2022 10:40,,03-Dec,,1,33,,,,,,,,,,,,,,WOS:000505077600002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LSB8HL7U,journalArticle,2014,"Conway, G; Dewailly, D; Diamanti-Kandarakis, E; Escobar-Morreale, HF; Franks, S; Gambineri, A; Kelestimur, F; Macut, D; Micic, D; Pasquali, R; Pfeifer, M; Pignatelli, D; Pugeat, M; Yildiz, BO; ESE PCOS Special Interest Grp",The polycystic ovary syndrome: a position statement from the European Society of Endocrinology,EUROPEAN JOURNAL OF ENDOCRINOLOGY,,0804-4643,10.1530/EJE-14-0253,,"Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.",2014-10,01/07/2022 10:40,01/07/2022 10:40,,P1-P29,,4,171,,,,,,,,,,,,,,WOS:000343671500002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48KGIQQX,journalArticle,2009,"Pratt, JSA; Lenders, CM; Dionne, EA; Hoppin, AG; Hsu, GLK; Inge, TH; Lawlor, DF; Marino, MF; Meyers, AF; Rosenblum, JL; Sanchez, VM",Best Practice Updates for Pediatric/Adolescent Weight Loss Surgery,OBESITY,,1930-7381,10.1038/oby.2008.577,,"The objective of this study is to update evidence-based best practice guidelines for pediatric/adolescent weight loss surgery (WLS). We performed a systematic search of English-language literature on WLS and pediatric, adolescent, gastric bypass, laparoscopic gastric banding, and extreme obesity published between April 2004 and May 2007 in PubMed, MEDLINE, and the Cochrane Library. Keywords were used to narrow the search for a selective review of abstracts, retrieval of full articles, and grading of evidence according to systems used in established evidence-based models. In light of evidence on the natural history of obesity and on outcomes of WLS in adolescents, guidelines for surgical treatment of obesity in this age group need to be updated. We recommend modification of selection criteria to include adolescents with BMI >= 35 and specific obesity-related comorbidities for which there is clear evidence of important short-term morbidity (i.e., type 2 diabetes, severe steatohepatitis, pseudotumor cerebri, and moderate-to-severe obstructive sleep apnea). In addition, WLS should be considered for adolescents with extreme obesity (BMI >= 40) and other comorbidities associated with long- term risks. We identified >1,085 papers; 186 of the most relevant were reviewed in detail. Regular updates of evidence-based recommendations for best practices in pediatric/adolescent WLS are required to address advances in technology and the growing evidence base in pediatric WLS. Key considerations in patient safety include carefully designed criteria for patient selection, multidisciplinary evaluation, choice of appropriate procedure, thorough screening and management of comorbidities, optimization of long-term compliance, and age-appropriate fully informed consent.",2009-05,01/07/2022 10:40,01/07/2022 10:40,,901-910,,5,17,,,,,,,,,,,,,,WOS:000265709800009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T6T2ILGT,journalArticle,2020,"Giustina, A; Barkan, A; Beckers, A; Biermasz, N; Biller, BMK; Boguszewski, C; Bolanowski, M; Bonert, V; Bronstein, MD; Casanueva, FF; Clemmons, D; Colao, A; Ferone, D; Fleseriu, M; Frara, S; Gadelha, MR; Ghigo, E; Gurnell, M; Heaney, AP; Ho, K; Ioachimescu, A; Katznelson, L; Kelestimur, F; Kopchick, J; Krsek, M; Lamberts, S; Losa, M; Luger, A; Maffei, P; Marazuela, M; Mazziotti, G; Mercado, M; Mortini, P; Neggers, S; Pereira, AM; Petersenn, S; Puig-Domingo, M; Salvatori, R; Shimon, I; Strasburger, C; Tsagarakis, S; van der Lely, AJ; Wass, J; Zatelli, MC; Melmed, S",A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update,JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM,,0021-972X,10.1210/clinem/dgz096,,"Objective: The aim of the Acromegaly Consensus Group was to revise and update the consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013. Participants: The Consensus Group, convened by 11 Steering Committee members, consisted of 45 experts in the medical and surgical management of acromegaly. The authors received no corporate funding or remuneration. Evidence: This evidence-based consensus was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence following critical discussion of the current literature on the diagnosis and treatment of acromegaly comorbidities. Consensus Process: Acromegaly Consensus Group participants conducted comprehensive literature searches for English-language papers on selected topics, reviewed brief presentations on each topic, and discussed current practice and recommendations in breakout groups. Consensus recommendations were developed based on all presentations and discussions. Members of the Scientific Committee graded the quality of the supporting evidence and the consensus recommendations using the GRADE system. Conclusions: Evidence-based approach consensus recommendations address important clinical issues regarding multidisciplinary management of acromegaly-related cardiovascular, endocrine, metabolic, and oncologic comorbidities, sleep apnea, and bone and joint disorders and their sequelae, as well as their effects on quality of life and mortality.",2020-04,01/07/2022 10:40,01/07/2022 10:40,,,,4,105,,,,,,,,,,,,,,WOS:000525950100051,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CMK89DKN,journalArticle,2013,"Abed, HS; Wittert, GA",Obesity and atrial fibrillation,OBESITY REVIEWS,,1467-7881,10.1111/obr.12056,,"Atrial fibrillation (AF) is an increasing public health problem, often described as the epidemic of the new millennium. The rising health economic impact of AF, its association with poor quality of life and independent probability of increased mortality, has recently been highlighted. Although population ageing is regarded as an important contributor to this epidemic, obesity and its associated cardiometabolic comorbidities may represent the principal driving factor behind the current and projected AF epidemic. Obesity-related risk factors, such as hypertension, vascular disease, obstructive sleep apnea and pericardial fat, are thought to result in atrial electro-structural dysfunction. In addition, insulin resistance, its associated abnormalities in nutrient utilization and intermediary metabolic by-products are associated with structural and functional abnormalities, ultimately promoting AF. Recent elucidation of molecular pathways, including those responsible for atrial fibrosis, have provided mechanistic insights and the potential for targeted pharmacotherapy. In this article, we review the evidence for an obesity-related atrial electromechanical dysfunction, the mechanisms behind this and its impact on AF therapeutic outcomes. In light of the recently described mechanisms, we illustrate proposed management approaches and avenues for further investigations.",2013-11,01/07/2022 10:40,01/07/2022 10:40,,929-938,,11,14,,,,,,,,,,,,,,WOS:000330106900007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H5ZD4D9F,journalArticle,2003,"Dworkin, RH; Corbin, AE; Young, JP; Sharma, U; LaMoreaux, L; Bockbrader, H; Garofalo, EA; Poole, RM","Pregabalin for the treatment of postherpetic neuralgia - A randomized, placebo-controlled trial",NEUROLOGY,,0028-3878,10.1212/01.WNL.0000055433.55136.55,,"Objective: To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN). Methods: The authors conducted a multicenter, parallel-group, double-blind, placebo-controlled, 8-week, randomized clinical trial in PHN, defined as pain for 3 or more months following herpes zoster rash healing. Patients (n = 173) were randomized to treatment with pregabalin or placebo. Patients randomized to pregabalin received either 600 mg/day (creatinine clearance > 60 mL/min) or 300 mg/day (creatinine clearance 30 to 60 mL/min). The primary efficacy measure was the mean of the last seven daily pain ratings. Secondary endpoints included additional pain ratings, sleep interference, quality of life, mood, and patient and clinician ratings of global improvement. Results: Pregabalin-treated patients had greater decreases in pain than patients treated with placebo (endpoint mean scores 3.60 vs 5.29, p = 0.0001). Pain was significantly reduced in the pregabalin-treated patients after the first full day of treatment and throughout the study, and significant improvement on the McGill Pain Questionnaire total, sensory, and affective pain scores was also found. The proportions of patients with greater than or equal to30% and greater than or equal to50% decreases in mean pain scores were greater in the pregabalin than in the placebo group (63% vs 25% and 50% vs 20%, p = 0.001). Sleep also improved in patients treated with pregabalin compared to placebo (p = 0.0001). Both patients and clinicians were more likely to report global improvement with pregabalin than placebo (p = 0.001). Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity. Conclusions: Treatment of PHN with pregabalin is safe, efficacious in relieving pain and sleep interference, and associated with greater global improvement than treatment with placebo.",22/04/2003,01/07/2022 10:40,01/07/2022 10:40,,1274-1283,,8,60,,,,,,,,,,,,,,WOS:000182489600013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UBBDJAMG,journalArticle,2015,"Sanghera, MK; Sales, SG; Robinson, JL; Song, J; Encarnacion, EV; Stewart, RM",Restless legs syndrome: associated non-motor symptoms and medical comorbidities: a controlled study,JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME,,1927-7733,10.2147/JPRLS.S82392,,"Introduction: Restless legs syndrome (RLS) is a chronic sensorimotor disorder characterized by discomfort or pain, predominantly in the legs, resulting in an urge to move during times of rest. These disturbances are often accompanied by sleep fragmentation, which can significantly increase medical comorbidities over time and can have a detrimental effect on a patient's overall quality of life. In this retrospective study, we examined the temporal relationship between the time of RLS diagnosis and the onset of non-motor symptoms (NMS) and medical comorbidities. Patients and methods: Thirty-six RLS patients were evaluated for age at: symptom onset, time of diagnosis, time of occurrence of NMS, and medical comorbidities. We used structured interviews, validated questionnaires, and past medical records to aggregate and verify patient data. There was no clinical evidence to suggest secondary RLS in any patient at time of diagnosis. Results: Twenty-five patients were diagnosed as having RLS alone and eleven were diagnosed with RLS and Parkinson's disease (RLS + PD). In the RLS + PD group, irrespective of which disorder presented first, we found that patients exhibited symptoms of RLS at a significantly later age than those patients with RLS alone (P<0.05). The incidence and severity of NMS were significantly higher in the RLS + PD group compared to RLS alone and controls (P<0.001). Increased risk of RLS was identified in patients exhibiting mood changes and sleep deficits, and these risk factors manifested 5 and 10 years prior, respectively, to their diagnosis. Conclusion: Primary RLS develops earlier in those patients who only have RLS compared to those who later also develop PD. Mood and sleep impairment can be present years prior to the diagnosis of RLS. Other medical comorbidities associated with RLS included hypertension, hyperlipidemia, arthritis, chronic pain, and diabetes.",2015,01/07/2022 10:40,01/07/2022 10:40,,33-38,,,5,,,,,,,,,,,,,,WOS:000215703800004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XLJTED38,journalArticle,2021,"Yadav, B; Rai, A; Mundada, PS; Singhal, R; Rao, BCS; Rana, R; Srikanth, N",Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial,TRIALS,,1745-6215,10.1186/s13063-021-05326-1,,"Objectives: Primary Objective To assess the efficacy of Ayurveda interventions and Yoga in rehabilitation of COVID-19 cases suffering with long term effects of COVID 19 as compared to WHO Rehabilitation Self-Management after COVID-19- Related Illness. Secondary Objective To assess the safety of Ayurvedic interventions in cases suffering with long term effects of COVID 19 Trial design: Multi-centric, randomized, controlled, parallel group, open-label, exploratory study. The study duration is 9 months and the intervention period is 90 days from the day of enrolment of the participant. Participants: Patients of either sex between 18 to 60 years, ambulatory, willing to participate, with history (not more than 4 weeks) of positive RT-PCR for COVID-19 or IgM antibodies positivity for SARS CoV-2, but having negative RT-PCR for COVID-19 at the time of screening will be considered eligible for enrolment in the study. Critically ill patients with ARDS (acute respiratory distress syndrome), requiring invasive respiratory support in the intensive care unit, known case of any malignancy, immune-compromised state (e.g. HIV), diabetes mellitus, active pulmonary tuberculosis, past history of any chronic respiratory disease, motor neuron disease, multiple sclerosis, stroke, impaired cognition, atrial fibrillation, acute coronary syndrome, myocardial infarction, severe arrhythmia, concurrent serious hepatic disease or renal disease, pregnant or lactating women, patients on immunosuppressive medications, history of hypersensitivity to the trial drugs or their ingredients, depressive illness (before COVID-19), diagnosed psychotic illnesses, substance dependence or alcoholism will be excluded. The trial will be conducted at two medical colleges in Maharashtra, India. Intervention and comparator: Intervention Arm (Group-I): Ayurveda interventions including Agastya Haritaki six gram and Ashwagandha tablet 500 mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days, as per the post-COVID-19 care protocol provided in National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19 published by Ministry of AYUSH, Government of India. Comparator Arm (Group-II): WHO Rehabilitation Self-Management after COVID-19 related illness for 90 days. The trial drugs are being procured from a GMP certified pharmaceutical company. Main outcomes: Primary Outcome: Change in respiratory function to be assessed by San Diego shortness of breath Questionnaire, 6-minutes walk test and pulmonary function test. Secondary Outcomes: Change in High-resolution Computed Tomography (HRCT) Chest Change in Fatigue score assessed by Modified Fatigue Impact Scale Change in Anxiety score assessed by Hospital Anxiety and Depression Scale Score Change in Sleep Quality assessed by Pittsburgh Sleep Quality Index Change in the quality of life assessed by COV19-QoL scale Safety of the interventions will be assessed by comparing hematological and biochemical investigations before and after the intervention period and Adverse Event/Adverse drug reaction Timelines for Outcome assessment: Subjective parameters and clinical assessment will be assessed at baseline, 15th day, 30th day, 60th day and 90th day. Laboratory parameters (CBC, LFT, KFT, HbA1c, Hs-CRP, D-dimer), Pulmonary function test and HRCT Chest will be done at baseline and after completion of study period i.e. 90th day. Randomisation: Statistical package for Social Sciences (SPSS) version 15.0 is used to generate the random number sequences. The participants will be randomized to two study groups in the ratio of 1:1. Blinding (masking): The study is open-label design. However, the outcome assessor will be kept blinded regarding the study group allocation of the participants. Numbers to be randomised (sample size) Sample size: The sample size for the study is calculated assuming improvement in 6-minutes walk test by 40 meter in Group I and a change of 10 meter in Group II with a standard deviation of 50 meter based on the results of the previous studies, with 95% Confidence Level (alpha = 0.05) and 80% power and expecting a dropout rate of 20%. The number of participants to be enrolled in the study should be approximately 55 in each group. Hence, a total of 110 participants will be enrolled in the trial at each study site. Trial Status: Participants' recruitment started on 1st May 2021. Anticipated end of recruitment is August 2021. Protocol number: CCRAS- 01 Protocol version number: 1.1, 13th January 2021. Trial registration: The trial is prospectively registered with the Clinical Trial Registry of India (CTRI) on 03rd March 2021 [CTRI/2021/03/031686]. Full protocol: The full protocol is attached as an additional file, accessible from the Journal website (Additional file 1). This communication serves as a summary of the key elements of the full protocol.",03/06/2021,01/07/2022 10:40,01/07/2022 10:40,,,,1,22,,,,,,,,,,,,,,WOS:000657732200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
69A63NUC,journalArticle,2017,"Abdalla, MI; Sandler, RS; Kappelman, MD; Martin, CF; Chen, WL; Anton, K; Long, MD",Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners,INFLAMMATORY BOWEL DISEASES,,1078-0998,10.1097/MIB.0000000000001017,,"Background: Inflammatory bowel disease (IBD) patients with persistent symptoms despite no or minimal inflammation are frequently described as having an overlap of IBD and irritable bowel syndrome (IBD-IBS). Limited data are available on how IBS impacts the individual patient with IBD. In this study, we aimed to evaluate the prevalence of IBD-IBS and investigate its impact on patient-reported outcomes. Method: We performed a cross-sectional analysis within the CCFA Partners Study. Bivariate analyses and logistic regression models were used to investigate associations between IBD-IBS and various demographic, disease factors, and patient-reported outcomes including anxiety, depression, sleep disturbances, pain interference, and social satisfaction. Results: Of the 6309 participants included, a total of 1279 (20%) reported a coexisting IBS diagnosis. The prevalence of IBD-IBS in this cohort was similar within disease subtypes. A diagnosis of IBD-IBS was associated with higher narcotic use compared with those with no IBS diagnosis for both Crohn's disease, 17% versus 11% (P < 0.001) and ulcerative colitis/indeterminate colitis, 9% versus 5% (P < 0.001). Quality of life, as measured by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was lower in patients with IBD-IBS compared with those without. IBD-IBS diagnosis was associated with anxiety, depression, fatigue, sleep disturbances, pain interference, and decreased social satisfaction. Conclusions: In this sample of patients with IBD, high prevalence of concomitant IBS diagnosis was observed. IBD-IBS diagnosis was associated with increased narcotic use and adverse patient-reported outcome. Appropriate diagnosis, treatment, and counseling may help improve the functional status of IBD-IBS patients and decrease narcotic use.",2017-02,01/07/2022 10:40,01/07/2022 10:40,,325-331,,2,23,,,,,,,,,,,,,,WOS:000393897500023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
M6K9YURW,journalArticle,2021,"Amit, S; Barua, L; Abdulla-Al Kafy",A perception-based study to explore COVID-19 pandemic stress and its factors in Bangladesh,DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS,,1871-4021,10.1016/j.dsx.2021.05.002,,"Background and aims: Worldwide the COVID-19 pandemic has accelerated sufferings of mental health and behaviour attitudes of people. Many countries, including Bangladesh, reported suicide as extreme consequences of the psychological burden influenced by COVID-19. The present study explores human stress and its factor influenced by COVID-19 in Bangladesh, which significantly affect the quality of life. Methods: An online-based questionnaire survey was conducted among 651 adult Bangladeshi pop-ulations by capturing socio-demographic information, possible human stress, and consequences of the pandemic. A set of statistical tools such as Pearson's Correlation Matrix (PCM), T-test, Principal Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA) were applied to identify the rela-tionship between different factors and influential factors increasing human stress. Results: More than 83% of the participants are facing COVID-19 related mental stress, which results in short temper, sleep disorder, and family chaos. PCA and HCA outcomes indicated a significant rela-tionship between the respondents' opinions and human stress factors, which harmonized with the country's existing scenario. PCM results enlighten the relationship between human stress factors and found financial hardship, cutting back daily spending, and food crisis are interconnected together causes stress. Also, hampering students' formal education and future career plans significantly contribute to mental stress. Conclusion: Based on the above findings, it's crucial to introduce a time-oriented strategy and implement precaution monitoring plans for Bangladesh. The rescue plan will help people to manage the pandemic and improve mental health to fight against psychological challenges related to COVID-19 and future pandemics. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.",2021-07,01/07/2022 10:40,01/07/2022 10:40,,,,4,15,,,,,,,,,,,,,,WOS:000684974800017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WEZSNWIN,journalArticle,2009,"Morton, J; Glanville, AR",Lung Transplantation in Patients with Cystic Fibrosis,SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE,,1069-3424,10.1055/s-0029-1238914,,"Cystic fibrosis is one of the most common indications for lung transplantation worldwide and certainly the most common indication for all pediatric lung transplants and for bilateral lung transplantation irrespective of age. Outcomes are outstanding when compared with other indications for lung transplantation, and an increasing number of centers now report mean Survival of greater than 10 years posttransplant. Hence it Is important to concentrate on the broad panoply of potential systemic complications of cystic fibrosis and address proactively issues that may be associated with adverse Outcomes. Optimum management Of infectious, nutritional, diabetic, renal, bone, and gut complications is critical to long-term success so that recipients may realize their full potential. Timing of referral for consideration of active listing should allow sufficient time for the patient and lung transplant team to develop a productive working relationship based on best available evidence and Mutual trust, which will culminate in a long-term successful outcome.",2009-10,01/07/2022 10:40,01/07/2022 10:40,,559-568,,5,30,,,,,,,,,,,,,,WOS:000270175900007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GSR3BVXD,journalArticle,2010,"Perez, C; Navarro, A; Saldana, MT; Masramon, X; Rejas, J",Pregabalin and Gabapentin in Matched Patients With Peripheral Neuropathic Pain in Routine Medical Practice in a Primary Care Setting: Findings From a Cost-Consequences Analysis in a Nested Case Control-Study,CLINICAL THERAPEUTICS,,0149-2918,10.1016/j.clinthera.2010.07.014,,"Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported health outcomes and to analyze health care and nonhealth-care resource consumption and their related costs among patients treated for peripheral neuropathic pain in primary medical care. Methods: A cost-consequences comparison in subjects with refractory (suboptimal response to >= 1 previous analgesic treatment for >6 months) chronic peripheral neuropathic pain was carried out using data extracted from two 12-week, observational, prospective studies in primary medical care. Patients were eligible if they were aged >= 18 years, had a score of >= 4 on the Douleur Neuropathique 4 questionnaire, and were able to complete health questionnaires written in Spanish. A nested-paired case control design was chosen to perform the comparison with 2 controls (pregabalin) per case (gabapentin) matched by age, sex, peripheral neuropathic pain condition, time since diagnosis, number of previous treatments, pain intensity, depressive and anxiety symptom scores, and health state. Adult subjects with refractory chronic pain because of diabetic neuropathy, postherpetic or trigeminal neuralgias, or cervical or lumbosacral radiculopathies were included. Epidemiologic statistical methods were applied for comparing health effects (pain intensity, sleep, anxiety and depressive symptoms, disability, and health state), resources utilization, and related cost variations after 12 weeks. Indirect costs were measured by means of lost-workday equivalent calculations multiplied by the mean national daily salary. Results: Analysis included 44 patients treated with gabapentin (cases) and 88 patients treated with pregabalin (controls) who were matched for age, sex, and other parameters. The mean (SD) gabapentin and pregabalin doses were 1263 (540) and 202 (119) mg/d, respectively. Although there was a greater reduction in last-week mean pain intensity with pregabalin (visual analog scale: 39.1 [22.5] vs 28.0 [22.2] mm; P = 0.008), as well as more patients with a >= 50% reduction in pain rate (60.9% vs 40.5%; P = 0.029), there were no significant differences between groups for sensory, affective, total, or present pain intensity. The significantly higher drug cost associated with pregabalin was offset by a greater reduction in productivity costs compared with gabapentin, yielding similar cost reduction (-(sic)1254 [1479] vs -(sic)1384 [2874], respectively; P = NS). Conclusion: Pregabalin appeared to be associated with greater reduction in mean weekly intensity of pain, but there were no significant differences in cost. (Clin Then 2010;32:1357-1370) (C) 2010 Excerpta Medica Inc.",2010-07,01/07/2022 10:40,01/07/2022 10:40,,1357-1370,,7,32,,,,,,,,,,,,,,WOS:000280829800012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TQFETIAC,journalArticle,2018,"Eisenga, MF; Gomes-Neto, AW; van Londen, M; Ziengs, AL; Douwes, RM; Stam, SP; Oste, MCJ; Knobbe, TJ; Hessels, NR; Buunk, AM; Annema, C; Siebelink, MJ; Racz, E; Spikman, JM; Bodewes, FAJA; Pol, RA; Berger, SP; Drost, G; Porte, RJ; Leuvenink, HGD; Damman, K; Verschuuren, EAM; de Meijer, VE; Blokzijl, H; Bakker, SJL",Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients,BMJ OPEN,,2044-6055,10.1136/bmjopen-2018-024502,,"Introduction In the past decades, short-term results after solid organ transplantation have markedly improved. Disappointingly, this has not been accompanied by parallel improvements in long-term outcomes after transplantation. To improve graft and recipient outcomes, identification of potentially modifiable risk factors and development of biomarkers are required. We provide the rationale and design of a large prospective cohort study of solid organ transplant recipients (TransplantLines). Methods and analysis TransplantLines is designed as a single-centre, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. Data will be collected from transplant candidates before transplantation, during transplantation, at 3 months, 6 months, 1 year, 2 years and 5 years, and subsequently every 5 years after transplantation. Data from living organ donors will be collected before donation, during donation, at 3 months, 1 year and 5 years after donation, and subsequently every 5 years. The primary outcomes are mortality and graft failure. The secondary outcomes will be cause-specific mortality, cause-specific graft failure and rejection. The tertiary outcomes will be other health problems, including diabetes, obesity, hypertension, hypercholesterolaemia and cardiovascular disease, and disturbances that relate to quality of life, that is, physical and psychological functioning, including quality of sleep, and neurological problems such as tremor and polyneuropathy. Ethics and dissemination Ethical approval has been obtained from the relevant local ethics committee. The TransplantLines cohort study is designed to deliver pioneering insights into transplantation and donation outcomes. The study design allows comprehensive data collection on perioperative care, nutrition, social and psychological functioning, and biochemical parameters. This may provide a rationale for future intervention strategies to more individualised, patient-centred transplant care and individualisation of treatment.",2018-12,01/07/2022 10:40,01/07/2022 10:40,,,,12,8,,,,,,,,,,,,,,WOS:000455309300148,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A3EU2VVS,journalArticle,2020,"Tate, DF; Quesnel, DA; Lutes, L; Hatley, KE; Nezami, BT; Wojtanowski, AC; Pinto, AM; Power, J; Diamond, M; Polzien, K; Foster, G",Examination of a partial dietary self-monitoring approach for behavioral weight management,OBESITY SCIENCE & PRACTICE,,2055-2238,10.1002/osp4.416,,"Introduction Dietary self-monitoring in behavioral weight loss programmes traditionally involves keeping track of all foods and beverages to achieve a calorie deficit. While effective, adherence declines over time. WW (TM) (formerly Weight Watchers), a widely available commercial weight management programme, sought to pilot an approach that permitted participants to consume over 200 foods without monitoring them. Methods The current study used a pre-post evaluation design with anthropometric, psychosocial and physical health assessments at baseline, 3 and 6 months. Results Participants (N = 152) were, on average, 48.4 (+/- 12.3) years old, with body mass index (BMI) of 32.8 (+/- 4.8) m/kg(2) and 94% female. Mean weight loss was 6.97 + 5.55 kg or 7.9 +/- 6.1% of initial body weight (ps < .0001) at 6 months. One third (32.6%) of the sample lost 10% or more of initial body weight. Significant improvements in hunger, cravings, happiness, sleep, quality of life, aerobic stamina, flexibility and blood pressure were observed. Attendance at group meetings, as well as decreases in hunger, and fast food cravings from baseline to 3 months were associated with achieving 10% weight loss at 6 months (p < .01). Conclusions Using an approach that does not require self-monitoring of all foods and beverages produced significant weight losses and other physical and psychosocial improvements.",2020-08,01/07/2022 10:40,01/07/2022 10:40,,353-364,,4,6,,,,,,,,,,,,,,WOS:000528567500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YJRYKLR9,journalArticle,2012,"Yoshimura, K",Correlates for nocturia: A review of epidemiological studies,INTERNATIONAL JOURNAL OF UROLOGY,,0919-8172,10.1111/j.1442-2042.2011.02956.x,,"Traditionally, nocturia was considered to be one of the symptoms of prostatism. However, this symptom has unusual characteristics compared with other lower urinary tract symptoms; for example, there is only a mild benefit for nocturia from treatment for benign prostatic hyperplasia. In the past decade, nocturia has been investigated as a separate symptom in epidemiological studies. These types of studies have shown various correlates for nocturia other than benign prostatic hyperplasia, as well as the prevalence of this symptom. These correlates include age, race/ethnicity, medical problems (such as hypertension, diabetes and stroke) psychological aspects, tasting habits, quality of life and even mortality. The cause-and-effect associations are not always obvious between nocturia and its correlates. In the present article, the author attempts to comprehensively review the correlates for nocturia shown by epidemiological studies.",2012-04,01/07/2022 10:40,01/07/2022 10:40,,317-329,,4,19,,,,,,,,,,,,,,WOS:000302013400006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
847PNESK,journalArticle,2020,"Bianchi, A; Pagan-Pomar, A; Jimenez-Segovia, M; Martinez-Corcoles, JA; Gonzalez-Argente, FX",Biliopancreatic Diversion in the Surgical Treatment of Morbid Obesity: Long-Term Results and Metabolic Consequences,OBESITY SURGERY,,0960-8923,10.1007/s11695-020-04777-w,,"Purpose In the multidisciplinary therapeutic approach to obesity, bariatric surgery is considered the most effective treatment in weight reduction and the decrease in associated comorbidities. The objective of this work is to describe the long-term clinical and metabolic results in obese patients undergoing biliopancreatic diversion (BPD) according to Scopinaro's technique. Materials and Methods Patients undergoing surgery were followed by the same multidisciplinary team in a study period of 15 years (1999-2015). A retrospective study based on a prospective database was designed, where data on the evolution of obesity-related diseases and nutritional parameters were studied. Results Two hundred seventy-seven patients were collected; 75.5% were women. The preoperative body mass index (BMI) decreased from 52.5 kg/m(2)to 34.9 kg/m(2)10 years after surgery. A resolution or improvement of diabetes has been observed in 85.38% of the patients; a decrease in arterial hypertension and obstructive sleep apnea syndrome were in 65.61% and 89.14%, respectively. Throughout the monitoring of the sample, protein malnutrition increased, from 1.8% after the first year of surgery to 4.5% 10 years after the operation. Conclusion Even if Scopinaro's technique is beginning to be replaced by other malabsorptive techniques, it can still be considered as an effective surgical procedure in terms of weight loss, quality of life, and evolution of obesity-related diseases. In order to avoid nutritional deficiencies, the operated patients need a strict follow-up and a supplementation adjusted to the technique.",2020-11,01/07/2022 10:40,01/07/2022 10:40,,4234-4242,,11,30,,,,,,,,,,,,,,WOS:000541331100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YAAXR6TS,journalArticle,2020,"Urits, I; Orhurhu, V; Powell, J; Murthy, A; Kiely, B; Shipon, S; Kaye, RJ; Kaye, AD; Arron, BL; Cornett, EM; Viswanath, O",Minimally Invasive Therapies for Osteoarthritic Hip Pain: a Comprehensive Review,CURRENT PAIN AND HEADACHE REPORTS,,1531-3433,10.1007/s11916-020-00874-8,,"Purpose of Review Osteoarthritis (OA) is a highly prevalent cause of chronic hip pain, affecting 27% of adults aged over 45 years and 42% of adults aged over 75 years. Though OA has traditionally been described as a disorder of ""wear-and-tear,"" recent studies have expanded on this understanding to include a possible inflammatory etiology as well, damage to articular cartilage produces debris in the joint that is phagocytosed by synovial cells which leads to inflammation. Recent Findings Patients with OA of the hip frequently have decreased quality of life due to pain and limited mobility though additional comorbidities of diabetes, cardiovascular disease, poor sleep quality, and obesity have been correlated. Initial treatment with conservative medical management can provide effective symptomatic relief. Physical therapy and exercise are important components of a multimodal approach to osteoarthritic hip pain. Patients with persistent pain may benefit from minimally invasive therapeutic approaches prior to consideration of undergoing total hip arthroplasty. The objective of this review is to provide an update of current minimally invasive therapies for the treatment of pain stemming from hip osteoarthritis; these include intra-articular injection of medication, regenerative therapies, and radiofrequency ablation.",06/06/2020,01/07/2022 10:40,01/07/2022 10:40,,,,7,24,,,,,,,,,,,,,,WOS:000540450900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I8UCD24L,journalArticle,2021,"Annerino, A; Gouma, PI",Future Trends in Semiconducting Gas-Selective Sensing Probes for Skin Diagnostics,SENSORS,,1424-8220,10.3390/s21227554,,"This paper presents sensor nanotechnologies that can be used for the skin-based gas ""smelling"" of disease. Skin testing may provide rapid and reliable results, using specific ""fingerprints"" or unique patterns for a variety of diseases and conditions. These can include metabolic diseases, such as diabetes and cholesterol-induced heart disease; neurological diseases, such as Alzheimer's and Parkinson's; quality of life conditions, such as obesity and sleep apnea; pulmonary diseases, such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease; gastrointestinal tract diseases, such as irritable bowel syndrome and colitis; cancers, such as breast, lung, pancreatic, and colon cancers; infectious diseases, such as the flu and COVID-19; as well as diseases commonly found in ICU patients, such as urinary tract infections, pneumonia, and infections of the blood stream. Focusing on the most common gaseous biomarkers in breath and skin, which is nitric oxide and carbon monoxide, and certain abundant volatile organic compounds (acetone, isoprene, ammonia, alcohols, sulfides), it is argued here that effective discrimination between the diseases mentioned above is possible, by capturing the relative sensor output signals from the detection of each of these biomarkers and identifying the distinct breath print for each disease.",2021-11,01/07/2022 10:40,01/07/2022 10:40,,,,22,21,,,,,,,,,,,,,,WOS:000726657300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KTXBD3RC,journalArticle,2019,"Ferri, GM; Cavone, D; Intranuovo, G; Macinagrossa, L",Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers,CURRENT MEDICINAL CHEMISTRY,,0929-8673,10.2174/0929867324666170720160632,,"Background: The large increase in epidemiological studies on night shift work is due to the important effects of night shift work on workers' health and psychophysical wellbeing. The short-term effects-insomnia, difficulties in managing work and private life, lower work performance, and more work and extra-work accidents-are easily studied. However, there are several long-term effects that are difficult to study because of the need for detailed exposure assessment and the long latency periods of these diseases. Objective: The aim was to collect epidemiologic evidence of diseases in night shift workers, describing their biological pathways and a set of dietary guidelines. Methods: This is a review on diet and health effects in night shift workers. Results: Significant increases in the rate ratios and hazard ratios of different diseases were associated with modified eating behaviours and poor eating habits among night shift workers. Night shift work is a risk factor for disruption of the circadian rhythms and for some genetic deregulation because it produces the inversion of the sleep/wake cycle and modifies the alternation between activity and rest. Conclusion: A healthy diet and improved dietary practices, together with other factors, can reduce shift workers' chronic disease risk. The literature showed the importance of eating behaviour in order to prevent diseases in these workers; therefore, educational programmes are necessary to encourage several important lifestyle changes. The target of our future research will be the role of food components in some dietetic habits for the prevention of disease in night shift workers.",2019,01/07/2022 10:40,01/07/2022 10:40,,3521-3541,,19,26,,,,,,,,,,,,,,WOS:000485782800011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QY352RYM,journalArticle,2021,"Lazar, RM; Howard, VJ; Kernan, WN; Aparicio, HJ; Levine, DA; Viera, AJ; Jordan, LC; Nyenhuis, DL; Possin, KL; Sorond, FA; White, CL; Amer Heart Assoc Stroke Council",A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association,STROKE,,0039-2499,10.1161/STR.0000000000000367,,"A healthy brain is critical for living a longer and fuller life. The projected aging of the population, however, raises new challenges in maintaining quality of life. As we age, there is increasing compromise of neuronal activity that affects functions such as cognition, also making the brain vulnerable to disease. Once pathology-induced decline begins, few therapeutic options are available. Prevention is therefore paramount, and primary care can play a critical role. The purpose of this American Heart Association scientific statement is to provide an up-to-date summary for primary care providers in the assessment and modification of risk factors at the individual level that maintain brain health and prevent cognitive impairment. Building on the 2017 American Heart Association/American Stroke Association presidential advisory on defining brain health that included ""Life's Simple 7,"" we describe here modifiable risk factors for cognitive decline, including depression, hypertension, physical inactivity, diabetes, obesity, hyperlipidemia, poor diet, smoking, social isolation, excessive alcohol use, sleep disorders, and hearing loss. These risk factors include behaviors, conditions, and lifestyles that can emerge before adulthood and can be routinely identified and managed by primary care clinicians.",2021-06,01/07/2022 10:40,01/07/2022 10:40,,e295-e308,,6,52,,,,,,,,,,,,,,WOS:000653963600018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95DX7V3X,bookSection,2015,"Rueda-Clausen, CF; Ogunleye, AA; Sharma, AM",Health Benefits of Long-Term Weight-Loss Maintenance,"ANNUAL REVIEW OF NUTRITION, VOL 35",0199-9885,,,,"Obesity is a chronic and complex medical condition associated with a large number of complications affecting most organs and systems through multiple pathways. Strategies for weight management include behavioral, pharmacological, and surgical interventions, all of which can result in a reduction in obesity-related comorbidities and improvements in quality of life. However, subsequent weight regain often reduces the durability of these improvements. The objective of this article is to review evidence supporting the long-term effects of intentional weight loss on morbidity, mortality, quality of life, and health-care cost. Overall, considerable evidence suggests that intentional weight loss is associated with clinically relevant benefits for the majority of obesity-related comorbidities. However, the degree of weight loss that must be achieved and sustained to reap these benefits varies widely between comorbidities.",2015,01/07/2022 10:40,01/07/2022 10:40,,475-516,,,35,,,,,,,,,,,,,,WOS:000358259600016,,,DOI: 10.1146/annurev-nutr-071714-034434,,,,,,"Bowman, BA; Stover, PJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
W37832Q6,journalArticle,2001,"Weiner, DK; Hanlon, JT",Pain in nursing home residents - Management strategies,DRUGS & AGING,,1170-229X,10.2165/00002512-200118010-00002,,"Pain is prevalent and undertreated in nursing home residents, despite the existing wide array of effective pharmacological and nonpharmacological treatment modalities. In order to improve the quality of life of these vulnerable individuals, practitioners require education about the correct approach to assessment anti management. Assessment should be comprehensive, taking into account the basic underlying pathology (e.g. osteoarthritis, osteoporosis, peripheral neuropathy, fibromyalgia, cancer) as well as other contributory pathology (e.g. muscle spasm, myofascial pain) and modifying comorbidities (e.g. depression, anxiety, fear, sleep disturbance). Pharmacological management should be guided by a stepped-care approach, modelled after that recommended by the World Health Organization for treatment of cancer pain. Nonopioid and opioid analgesics are the cornerstone of pharmacological pain management. Tricyclic antidepressants and anticonvulsants can be very effective for the treatment of certain types of neuropathic pain. In addition to treating the pain per se, attention should be given to prevention of disease progression and exacerbation, as maintaining function is of prime importance. Nursing home residents with severe dementia challenge the practitioner's pain assessment skills: an empirical approach to treatment may sometimes be warranted. The success of treatment should be measured by improvement in pain intensity as well as physical, psychosocial and cognitive function. Effective pain management may impact any or all of these functional domains and, therefore, substantially improve the nursing home resident's quality of life.",2001,01/07/2022 10:40,01/07/2022 10:40,,13-29,,1,18,,,,,,,,,,,,,,WOS:000167131800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KGEGRQV4,journalArticle,2015,"Manna, P; Jain, SK","Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies",METABOLIC SYNDROME AND RELATED DISORDERS,,1540-4196,10.1089/met.2015.0095,,"Obesity is gaining acceptance as a serious primary health burden that impairs the quality of life because of its associated complications, including diabetes, cardiovascular diseases, cancer, asthma, sleep disorders, hepatic dysfunction, renal dysfunction, and infertility. It is a complex metabolic disorder with a multifactorial origin. Growing evidence suggests that oxidative stress plays a role as the critical factor linking obesity with its associated complications. Obesity per se can induce systemic oxidative stress through various biochemical mechanisms, such as superoxide generation from NADPH oxidases, oxidative phosphorylation, glyceraldehyde auto-oxidation, protein kinase C activation, and polyol and hexosamine pathways. Other factors that also contribute to oxidative stress in obesity include hyperleptinemia, low antioxidant defense, chronic inflammation, and postprandial reactive oxygen species generation. In addition, recent studies suggest that adipose tissue plays a critical role in regulating the pathophysiological mechanisms of obesity and its related co-morbidities. To establish an adequate platform for the prevention of obesity and its associated health risks, understanding the factors that contribute to the cause of obesity is necessary. The most current list of obesity determinants includes genetic factors, dietary intake, physical activity, environmental and socioeconomic factors, eating disorders, and societal influences. On the basis of the currently identified predominant determinants of obesity, a broad range of strategies have been recommended to reduce the prevalence of obesity, such as regular physical activity, ad libitum food intake limiting to certain micronutrients, increased dietary intake of fruits and vegetables, and meal replacements. This review aims to highlight recent findings regarding the role of oxidative stress in the pathogenesis of obesity and its associated risk factors, the role of dysfunctional adipose tissue in development of these risk factors, and potential strategies to regulate body weight loss/gain for better health benefits.",01/12/2015,01/07/2022 10:40,01/07/2022 10:40,,423-444,,10,13,,,,,,,,,,,,,,WOS:000364631700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YS7XBX5S,journalArticle,2004,"Klesius, AA; Dzemali, O; Simon, A; Kleine, P; Abdel-Rahman, U; Herzog, C; Wimmer-Greinecker, G; Moritz, A",Successful treatment of deep sternal infections following open heart surgery by bilateral pectoralis major flaps,EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY,,1010-7940,10.1016/j.ejcts.2003.11.019,,"Objective: Severe sternum necrosis requiring extended resection necessitates plastic reconstruction of the resulting defect and stabilization of the chest. We analyzed the outcome of patients undergoing bilateral pectoralis major flap repair on functional and cosmetic results, chest stabilization and pulmonary function. Methods: Twelve patients undergoing cardiac surgery between 1997 and 2001 suffered from a deep mediastinal wound infection and sternum necrosis. After a mean of two attempts of extensive wound debridement, all 12 patients underwent complete sternal resection with plastic reconstruction by bilateral pectoralis major flaps. Risk factors were obesity (n = 10) and diabetes (n = 11). Six months postoperatively patients underwent physical examination, pulmonary function testing and functional CT scan. Results: Three patients died in hospital (two septic multiorgan failure, one heart failure) and nine were discharged with complete wound closure. One patient suffered a lethal stroke during follow-up. At 6-month follow-up no recurrent sternum infection had occurred. Chest stability was satisfactory without impairment of pulmonary function (VC 77.5 +/- 12.1% at follow-up vs 77.8 +/- 12.5% preoperatively). Mobility and force of arms and shoulder were adequate; at CT scan the maximum distance change between the former stemoclavicular joint in inspiration versus expiration was minimal. Quality of life questionnaires showed no significant limitations except a disturbed sleep and mild restriction of executing hobbies and social activities. Conclusions: Bilateral pectoralis major flap repair is a safe technique to cure severe mediastinitis necessitating complete sternal resection. Wounds close without extensive reconstructive surgery. Cosmetic results as well as stabilization of the chest were good. Patients reported an almost uncompromised quality of life without respiratory impairment. (C) 2003 Elsevier B.V. All rights reserved.",2004-02,01/07/2022 10:40,01/07/2022 10:40,,218-223,,2,25,,,,,,,,,,,,,,WOS:000189040900014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW8WQAT2,journalArticle,2017,"DeFerio, JJ; Govindarajulu, U; Brar, A; Cukor, D; Lee, KG; Salifu, MO",Association of restless legs syndrome and mortality in end-stage renal disease: an analysis of the United States Renal Data System (USRDS),BMC NEPHROLOGY,,1471-2369,10.1186/s12882-017-0660-0,,"Background: Objective of the study is to assess prevalence and survival among end stage renal disease patients with restless legs syndrome (RLS) within a national database (USRDS). Methods: A case-control, retrospective analysis was performed. Differences in characteristics between the groups, RLS and those with no sleep disorder (NSD), were determined using chi(2) tests. Cox proportional hazard regression was used to assess survival between those with RLS and propensity score matched controls. Results: Cases of restless legs syndrome were defined as patients that had received an ICD-9 code of 333.94 at any point during their treatment (n = 372). RLS group demonstrated a significantly higher proportion of patients with major depressive disorder, dysthymic disorder, anxiety, depression, minor depressive disorder, and psychological disorder. The difference between the survival was not statistically significant in those without sleep disorder as compared to those with RLS (HR = 1.16 +/- 0.14, p = 0.3). Conclusions: True prevalence of RLS in dialysis patients can only be estimated if knowledge gap for care providers in diagnosis of RLS is addressed. RLS patients also have increased incidence of certain psychological disorders which needs to be addressed.",01/08/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,18,,,,,,,,,,,,,,WOS:000406869400003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TIJTA7DP,journalArticle,2014,"Lasselin, J; Capuron, L",Chronic Low-Grade Inflammation in Metabolic Disorders: Relevance for Behavioral Symptoms,NEUROIMMUNOMODULATION,,1021-7401,10.1159/000356535,,"The ability of cytokines to influence cerebral functions and to induce the development of behavioral alterations is well established in conditions of acute or chronic high-grade activation of the innate immune system. Recent evidence suggests that the release of these immune mediators during chronic low-grade endogenous inflammatory processes may also contribute to the development of behavioral alterations. Metabolic disorders, including obesity, type 2 diabetes and the metabolic syndrome, represent examples of those conditions which are both characterized by a chronic low-grade inflammatory state and an increased prevalence of behavioral disorders. In metabolic disorders, the increased production of acute-phase proteins and cytokines (e.g. C-reactive protein, interleukin-6 and tumor necrosis factor-a), but at relatively low levels, may promote and contribute to the development of behavioral symptoms, including depressive symptoms, cognitive impairment, fatigue, sleep problems and pain. This hypothesis is supported by a growing literature referring both to experimental and clinical findings that will be reviewed here. (C) 2014 S. Karger AG, Basel",2014,01/07/2022 10:40,01/07/2022 10:40,,95-101,,02-Mar,21,,,,,,,,,,,,,,WOS:000331488100005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DW82TNKX,journalArticle,2003,"O'Brien, PE; Dixon, JB",Lap-Band((R)): Outcomes and results,JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES-PART A,,1092-6429,10.1089/109264203322333593,,"Introduction: Laparoscopic adjustable gastric banding was first introduced in the early 1990s as a potentially safe, controllable, and reversible method for achieving significant weight loss in the severely obese. The Bioenterics Lap-Band(R) system (Inamed Health, Santa Barbara, California) is the device most commonly used. After 10 years of experience in treating more than 100,000 patients with the Lap-Band, it is timely for us to review the outcomes. Methods: Data for the review are derived from the experience of our unit in the treatment of 1250 patients to date, from an independent systematic review of the published literature up to September 2001, and from major studies published after the date of closure of the systematic review. Results: Lap-Band placement has proved to be a very safe procedure with a mortality rate in the published reports of I in 2000, only 10% of the published mortality rate of gastric bypass. The early complication rate has been very low, but late complications of prolapse or erosions have been more frequent, particularly during the early experience. Weight is lost during the first 2 to 3 years after surgery. The systematic review reports 56% excess weight loss (EWL) at 5 years (three reports). In comparison, Roux-en-Y gastric bypass (RYGB) is reported to have achieved 59% EWL at 5 years (four reports). Major improvements in comorbid conditions have been reported in association with weight loss after Lap-Band placement. Most importantly, type 2 diabetes is usually cured, and insulin resistance and reduced pancreatic beta-cell function are reversed. Gastroesophageal reflux, obstructive sleep apnea, and depression are other diseases in which marked improvement is noted. Quality-of-life scores return to normal values. Conclusions: Lap-Band placement is proving to be safe and effective. In view of the attributes of adjustability, safe laparoscopic placement, and reversibility, it should be considered the optimal initial approach for the control of obesity and its comorbid conditions.",2003-08,01/07/2022 10:40,01/07/2022 10:40,,265-270,,4,13,,,,,,,,,,,,,,WOS:000185165400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D3WHWNV5,journalArticle,2020,"Viigimaa, M; Vlachopoulos, C; Doumas, M; Wolf, J; Imprialos, K; Terentes-Printzios, D; Ioakeimidis, N; Kotsar, A; Kiitam, U; Stavropoulos, K; Narkiewicz, K; Manolis, A; Jelakovic, B; Lovic, D; Kreutz, R; Tsioufis, K; Mancia, G; Dysfunction, ESHWGS",Update of the position paper on arterial hypertension and erectile dysfunction,JOURNAL OF HYPERTENSION,,0263-6352,10.1097/HJH.0000000000002382,,"Sexual health is an integral part of overall health, and an active and healthy sexual life is an essential aspect of a good life quality. Cardiovascular disease and sexual health share common risk factors (arterial hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking) and common mediating mechanisms (endothelial dysfunction, subclinical inflammation, and atherosclerosis). This generated a shift of thinking about the pathophysiology and subsequently the management of sexual dysfunction. The introduction of phosphodiesterase type 5 inhibitors revolutionized the management of sexual dysfunction in men. This article will focus on erectile dysfunction and its association with arterial hypertension. This update of the position paper was created by the Working Group on Sexual Dysfunction and Arterial Hypertension of the European Society of Hypertension. This working group has been very active during the last years in promoting the familiarization of hypertension specialists and related physicians with erectile dysfunction, through numerous lectures in national and international meetings, a position paper, newsletters, guidelines, and a book specifically addressing erectile dysfunction in hypertensive patients. It was noted that erectile dysfunction precedes the development of coronary artery disease. The artery size hypothesis has been proposed as a potential explanation for this observation. This hypothesis seeks to explain the differing manifestation of the same vascular condition, based on the size of the vessels. Clinical presentations of the atherosclerotic and/or endothelium disease in the penile arteries might precede the corresponding manifestations from larger arteries. Treated hypertensive patients are more likely to have sexual dysfunction compared with untreated ones, suggesting a detrimental role of antihypertensive treatment on erectile function. The occurrence of erectile dysfunction seems to be related to undesirable effects of antihypertensive drugs on the penile tissue. Available information points toward divergent effects of antihypertensive drugs on erectile function, with diuretics and beta-blockers possessing the worst profile and angiotensin receptor blockers and nebivolol the best profile.",2020-07,01/07/2022 10:40,01/07/2022 10:40,,1220-1234,,7,38,,,,,,,,,,,,,,WOS:000546781800003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TFIX9XLT,journalArticle,2016,"Goveas, JS; Rapp, SR; Hogan, PE; Driscoll, I; Tindle, HA; Smith, JC; Kesler, SR; Zaslavsky, O; Rossom, RC; Ockene, JK; Yaffe, K; Manson, JE; Resnick, SM; Espeland, MA",Predictors of Optimal Cognitive Aging in 80+Women: The Women's Health Initiative Memory Study,JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES,,1079-5006,10.1093/gerona/glv055,,"Background. Independent predictors of preserved cognitive functioning and factors associated with maintaining high preserved cognitive function in women >= 80 years remain elusive. Methods. Two thousand two hundred twenty-eight women with a mean age of 85 years who participated in the Women's Health Initiative Memory Study were classified as cognitively normal (n = 1,905, 85.5%), mild cognitive impairment (n = 88, 3.9%), dementia (n = 121, 5.4%) or other cognitive impairment (n = 114, n = 5.1%) by central adjudication. Global cognitive functioning was assessed using telephone interview for cognitive status-modified in those women who did not meet cognitive impairment criteria. Differences between women grouped by cognitive status with respect to each potential risk factor were assessed using chi-squared tests and t-tests. Backward stepwise logistic regression was used to select factors that were independently associated with cognitive status. Results. Factors associated with preserved cognitive functioning were younger age, higher education, and family incomes, being non-Hispanic white, better emotional wellbeing, fewer depressive symptoms, more insomnia complaints, being free of diabetes, and not carrying the apolipoprotein E-epsilon 4 allele. Cognitively normal women who demonstrated sustained high preserved cognition were younger, more educated, and endorsed better self-reported general health, emotional wellbeing, and higher physical functioning. Conclusions. Addressing sociodemographic disparities such as income inequality, and targeting interventions to improve depressive symptoms and vascular risk factors, including diabetes, may play an important role in preserving cognition among women who survive to 80 years of age. Person-centered approaches that combine interventions to improve physical, cognitive, and psychosocial functioning may promote maintenance of high preserved cognitive health in the oldest-old.",2016-03,01/07/2022 10:40,01/07/2022 10:40,,S62-S71,,,71,,,,,,,,,,,,,,WOS:000374213500008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H46Z4ACE,journalArticle,2009,"Debono, M; Ross, RJ; Newell-Price, J",Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy,EUROPEAN JOURNAL OF ENDOCRINOLOGY,,0804-4643,10.1530/EJE-08-0874,,"Patients with adrenal insufficiency need lifelong glucocorticoid replacement, but many suffer from poor quality of life, and overall there is increased mortality. Moreover, it appears that use of glucocorticoids at the higher end of the replacement dose range is associated with increased risk for cardiovascular and metabolic bone disease. These data highlight some of the inadequacies of current regimes. The cortisol production rate is estimated to be equivalent to 5.7-7.4 mg/m(2) per day. and a major difficulty for replacement regimes is the inability to match the distinct circadian rhythm of circulating cortisol levels, which are low at the time of sleep onset, rise between 0200 and 0400 h, peaking just after waking and then fall during the day. Another issue is that current dose equivalents of glucocorticoids used for replacement are based on anti-inflammatory potency, and few data exist as to doses needed for equivalent cardiovascular and bone effects. Weight-adjusted, thrice-daily dosing using hydrocortisone (HQ reduces glucocorticoid overexposure and represents the most refined regime for current oral therapy, but does not replicate the normal cortisol rhythm. Recently, proof-of-concept studies have shown that more physiological circadian glucocorticoid therapy using HC infusions and newly developed oral formulations of HC have the potential for better biochemical control in patients with adrenal insufficiency. Whether such physiological replacement will have an impact on the complications seen in patients with adrenal insufficiency will need to be analysed in future clinical trials.",2009-05,01/07/2022 10:40,01/07/2022 10:40,,719-729,,5,160,,,,,,,,,,,,,,WOS:000272934500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32Z97WYS,journalArticle,2020,"Doan, S; Zagorski, Z; Palmares, J; Yagmur, M; Kaercher, T; Benitez-Del Castillo, JM; Van Dooren, B; Jonckheere, P; Jensen, PK; Maychuk, DY; Bezditko, P",Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries,OPHTHALMOLOGY AND THERAPY,,2193-8245,10.1007/s40123-020-00268-4,,"Purpose Anecdotal evidence suggests that eyelid disorders are common, although estimates of prevalence vary. The current study determines the prevalence of eyelid disorders, meibomian gland dysfunction (MGD) and related diseases (specifically ocular surface disease) in a population of patients presenting for routine ophthalmologic consultations. Methods This cross-sectional epidemiologic survey evaluated patients presenting for routine ophthalmic visits. During the consultation an ophthalmologist completed a questionnaire, and each patient underwent an ophthalmic examination and completed a quality of life questionnaire. Results Three hundred forty-nine ophthalmologists, recruited from 11 countries, provided data on 6525 patients. Patients were predominantly females (61.6%). The mean age of the study population was 57.0 +/- 17.6 years. Eyelid disorders were diagnosed in 5109 (78.3%) patients and were statistically associated with: atopic dermatitis, seborrheic dermatitis, dry eye, age-related macular degeneration, diabetes, cataract, allergy and MGD (P < 0.05, all associations). Eyelid abnormalities were identified in 59.6% of patients; conjunctival or corneal abnormalities were observed in 64.9% and 28.1% of patients, respectively. MGD was diagnosed in 54.3% patients and was statistically significantly associated with the presence of eyelid disorders and eyelid margin abnormalities (P < 0.001, both comparisons). Dry eye was diagnosed in 61.8% of patients. Concurrent dry eye and MGD were present in 67.6% of patients. Most patients reported some degree of impaired vision and daily/work activities related to dry eye. Impact on contact lens usage, emotions and quality of sleep was also reported. The effects on daily life were associated with the presence of MGD. Conclusion In conclusion, eyelid disorders were highly prevalent in this 'real-world' population of patients from ophthalmology clinics. Routine ophthalmologic consultations provide an opportunity to improve patient quality of life and to modify topical therapy in patients who may be predisposed to eyelid disorders.",2020-09,01/07/2022 10:40,01/07/2022 10:40,,597-608,,3,9,,,,,,,,,,,,,,WOS:000544876400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DQTXVV97,journalArticle,2016,"Butterworth, J; Deguara, J; Borg, CM","Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility",JOURNAL OF OBESITY,,2090-0708,10.1155/2016/1871594,,"Background. Polycystic ovary syndrome (PCOS) is the commonest cause of female infertility. Visceral obesity and insulin resistance are key pathophysiological mechanisms behind PCOS. Women suffering from this syndrome and infertility often seek bariatric surgery hoping that they would be able to conceive postoperatively. Objective. At present, there is no consensus on the role of bariatric surgery in the management of PCOS-associated infertility within the medical community, making it difficult to give specific advice to these women, so a review of the literature was necessary. Results. A detailed review of the literature was performed. Only 6 manuscriptswere relevant and contained quantitative data. They demonstrated that bariatric surgery results in postoperative conception rates varying from 33% to 100%. Surgery is also associated with amelioration of menstrual irregularities, hormonal abnormalities, and hirsutism that are associated with PCOS. These studies were retrospective and only had a small number of participants with infertility. Conclusions. Bariatric surgery has been shown to conclusively improve life expectancy, quality of life, and comorbidities like type 2 diabetes and obstructive sleep apnea. However, further research is required to identify whether weight loss surgery results in significant improvement in fertility of women with PCOS and to investigate which operation has the best results.",2016,01/07/2022 10:40,01/07/2022 10:40,,,,,2016,,,,,,,,,,,,,,WOS:000388852700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
W236B8TW,journalArticle,2021,"Patel, S",Guidelines for the treatment of neuropathic pain in South Africa,SA PHARMACEUTICAL JOURNAL,,2221-5875,,,"Neuropathic pain is defined as pain that originates due to a lesion, dysfunction or disease, e.g. diabetes, HIV infection, herpes zoster, chemotherapy or surgery, and which affects the peripheral or central nervous system. This results in abnormal neural function, often presenting in an individual as sensory pain-related symptoms which are either positive, i.e. hyperaesthesia or hyperalgesia; or negative, i.e. hypoaesthesia or anaesthesia. The quality of life of patients with neuropathic pain is often compromised as many have difficulty sleeping, lack energy, and experience drowsiness and altered concentration, and this can potentially progress to a stage in which the patient is physically and psychologically distressed. In 2012, an expert panel proposed clinical guidelines for the treatment of neuropathic pain in the South African context. These guidelines shifted from traditional pain management, primarily comprised of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, to alternative therapeutic agents including pregabalin, gabapentin, tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors (SNRIs) and opioids. Recent studies have suggested that melatonin, a neurohormone responsible for regulating the circadian rhythm, may be a potential therapeutic agent for symptoms associated with neuropathic pain. The guidelines reviewed in this article offer healthcare providers with a concise stepwise approach with which to diagnose and treat neuropathic pain.",2021,01/07/2022 10:40,01/07/2022 10:40,,21-25,,3,88,,,,,,,,,,,,,,WOS:000668562100004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
36W3LRC2,journalArticle,2018,"Patel, S",Guidelines for the treatment of neuropathic pain in South Africa,SA PHARMACEUTICAL JOURNAL,,2221-5875,,,"Neuropathic pain is defined as pain that originates due to a lesion, dysfunction or disease, e.g. diabetes, HIV infection, herpes zoster, chemotherapy or surgery, and which affects the peripheral or central nervous system. This results in abnormal neural function, often presenting in an individual as sensory pain-related symptoms which are either positive, i.e. hyperaesthesia or hyperalgesia; or negative, i.e. hypoaesthesia or anaesthesia. The quality of life of patients with neuropathic pain is often compromised as many have difficulty sleeping, lack energy, and experience drowsiness and altered concentration, and this can potentially progress to a stage in which the patient is physically and psychologically distressed. In 2012, an expert panel proposed clinical guidelines for the treatment of neuropathic pain in the South African context. These guidelines shifted from traditional pain management, primarily comprised of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, to alternative therapeutic agents including pregabalin, gabapentin, tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors (SNRIs) and opioids. Recent studies have suggested that melatonin, a neurohormone responsible for regulating the circadian rhythm, may be a potential therapeutic agent for symptoms associated with neuropathic pain. The guidelines reviewed in this article offer healthcare providers with a concise step-wise approach with which to diagnose and treat neuropathic pain. (c) Medpharm",2018,01/07/2022 10:40,01/07/2022 10:40,,40-47,,2,85,,,,,,,,,,,,,,WOS:000435495600007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AM43PKH9,journalArticle,2005,"Harris, M; Smith, B; Veale, A",Printed patient education interventions to facilitate shared management of chronic disease: a literature review,INTERNAL MEDICINE JOURNAL,,1444-0903,10.1111/j.1445-5994.2005.00955.x,,"Background: Printed materials for patient self-education are a comparatively low cost, flexible and potentially useful aid for dealing with the growing burden of chronic disease in our society. A comprehensive review of existing trials is required. Aims: We conducted a comprehensive review which aimed to (i) evaluate the evidence for effectiveness of print-only interventions in increasing patient participation in chronic disease management and (ii) identify disease or intervention characteristics associated with success. Methods: Medline, the Cochrane Central Register of Controlled Trials, EMBASE and CINAHL were searched for the period 1992 to January 2005 for reports of controlled trials of printed patient materials in chronic disease. The quality of both studies and interventions was assessed. Results: Seven studies were found. They focussed on inflammatory bowel disease, arthritis, asthma and diabetes. Few studies named primary outcomes, continued beyond 6 months or included process evaluations. Few reports gave the behaviour-change rationale of the intervention. Few interventions were reported as having been designed using testing and improvement, psychosocial theory, checks of patient understanding or other patient input. A variety of outcomes was measured. Statistically significant change was found for few. Knowledge improved in three studies, adherence improved in two and quality of life declined in one. Conclusions: We found that printed interventions as currently designed appear to produce, at best, modest benefits. The design of interventions, studies and study reports all need improvement before decisions can be made about effectiveness and characteristics associated with success.",2005-12,01/07/2022 10:40,01/07/2022 10:40,,711-716,,12,35,,,,,,,,,,,,,,WOS:000233408600006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BERZRAQA,journalArticle,2019,"Liou, TG",The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein Its Role and Function in Extrapulmonary Disease,CHEST,,0012-3692,10.1016/j.chest.2018.10.006,,"Normal cystic fibrosis (CF) transmembrane regulator (CFTR) protein has multiple functions in health and disease. Many mutations in the CFTR gene produce abnormal or absent protein. CFTR protein dysfunction underlies the classic CF phenotype of progressive pulmonary and GI pathology but may underlie diseases not usually associated with CF. This review highlights selected extrapulmonary disease that may be associated with abnormal CFTR. Increasing survival in CF is associated with increasing incidence of diseases associated with aging. CFTR dysfunction in older individuals may have novel effects on glucose metabolism, control of insulin release, regulation of circadian rhythm, and cancer cell pathophysiology. In individuals who have cancers with acquired CFTR suppression, their tumors may more likely exhibit rapid expansion, epithelial-to-mesenchymal transformation, abnormally reduced apoptosis, and increased metastatic potential. The new modulators of CFTR protein synthesis could facilitate the additional exploration needed to better understand the unfolding clinical biology of CFTR in human disease, even as they revolutionize treatment of patients with CF.",2019-03,01/07/2022 10:40,01/07/2022 10:40,,605-616,,3,155,,,,,,,,,,,,,,WOS:000460160800025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TDM6XGU5,journalArticle,2015,"Combs, SA; Teixeira, JP; Germain, MJ",Pruritus in Kidney Disease,SEMINARS IN NEPHROLOGY,,0270-9295,10.1016/j.semnephrol.2015.06.009,,"Pruritus is a common and distressing symptom in patients with chronic kidney disease. The most recent epidemiologic data have suggested that approximately 40% of patients with end-stage renal disease experience moderate to severe pruritus and that uremic pruritus (UP) has a major clinical impact, being associated strongly with poor quality of life, impaired sleep, depression, and increased mortality. The pathogenesis of UP remains largely unclear, although several theories on etiologic or contributing factors have been proposed including increased systemic inflammation; abnormal serum parathyroid hormone, calcium, and phosphorus levels; an imbalance in opiate receptors; and a neuropathic process. UP can present somewhat variably, although it tends to affect large, discontinuous, but symmetric, areas of skin and to be most symptomatic at night. A variety of alternative systemic or dermatologic conditions should be considered, especially in patients with asymmetric pruritus or other atypical features. Treatment initially should focus on aggressive skin hydration, patient education on minimizing scratching, and optimization of the aspects of chronic kidney disease care that are most relevant to pruritus, including dialysis adequacy and serum parathyroid hormone, calcium, and phosphorus management. Data for therapy specifically for UP remain limited, although topical therapies, gabapentin, type B ultraviolet light phototherapy, acupuncture, and opioid-receptor modulators all may play a role. (C) 2015 Elsevier Inc. All rights reserved.",2015-07,01/07/2022 10:40,01/07/2022 10:40,,383-391,,4,35,,,,,,,,,,,,,,WOS:000361421700009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TXVRMNFT,journalArticle,2020,"Butler, CR; Reese, PP; Perkins, JD; Hall, YN; Curtis, JR; Tamura, MK; O'Hare, AM","End-of-Life Care among US Adults with ESKD Who Were Waitlisted or Received a Kidney Transplant, 2005-2014",JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1046-6673,10.1681/ASN.2020030342,,"Background The care of patients in the United States who have ESKD is often shaped by their hopes and prognostic expectations related to kidney transplant. Little is known about how patients' engagement in the transplant process might relate to patterns of end-of-life care. Methods We compared six measures of intensity of end-of-life care among adults in the United States with ESKD who died between 2005 and 2014 after experiencing differing exposure to the kidney transplant process. Results Of 567,832 decedents with ESKD, 27,633 (5%) had a functioning kidney transplant at the time of death, 14,653 (3%) had a failed transplant, 16,490 (3%) had been removed from the deceased donor waitlist, 17,010 (3%) were inactive on the waitlist, 11,529 (2%) were active on the waitlist, and 480,517 (85%) had never been waitlisted for or received a transplant (reference group). In adjusted analyses, compared with the reference group, patients exposed to the transplant process were significantly more likely to have been admitted to an intensive care unit and to have received an intensive procedure in the last 30 days of life; they were also significantly more likely to have died in the hospital. Those who died on the transplant waitlist were also less likely than those in the reference group to have been enrolled in hospice and to have discontinued dialysis before death. Conclusions Patients who had engaged in the kidney transplant process received more intensive patterns of end-of-life care than other patients with ESKD. These findings support the relevance of advance care planning, even for this relatively healthy segment of the ESKD population.",2020-10,01/07/2022 10:40,01/07/2022 10:40,,2424-2433,,10,31,,,,,,,,,,,,,,WOS:000577091000020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SSBFMA2C,journalArticle,2019,"Sebo, P; Haller, DM; Cerutti, B; Maisonneuve, H",A prospective observational study of the main features of nocturnal leg cramps in primary care,SWISS MEDICAL WEEKLY,,1424-7860,10.4414/smw.2019.20048,,"OBJECTIVE: There are few data available regarding the characteristics of nocturnal leg cramps in primary care. However, this condition is particularly common among older adults and often causes sleep disturbances, which can seriously affect quality of life. We aimed to investigate the main characteristics of nocturnal leg cramps occurring over a two-week period in patients visiting primary care physicians. METHODS: This prospective observational study was conducted in western Switzerland from January 2015 until June 2016. Twenty primary care physicians were asked to recruit up to 20 consecutive patients over the age of 50 who had suffered from cramps in the previous three months. Patients completed a daily log during a two-week period, reporting the number and duration (in minutes) of their cramps. They also reported the severity of the cramps and their level of cramp-related sleep disturbance on a scale from 0 to 10. Crude and adjusted associations between the number of cramps and patient characteristics were computed using a generalised mixed effects model (Poisson). RESULTS: Of 550 consecutive patients, 233 agreed to be contacted for participation. Of these, 129 signed the consent to participation form and all completed the questionnaire and the daily log (men: 67%; mean age: 71 years; follow-up rate: 100%). Overall, 41% of patients were suffering from hypertension, 20% from dyslipidaemia, 19% from sleep disturbances and depression, and 6% from diabetes. Half the patients reported having already used a treatment against nocturnal leg cramps in the past, and 25% were currently using magnesium. Most of them also used medication for other health problems (mean number 3.7 per patient; psychotropic drugs: 36%). Patients had a median of two cramps per week, which were generally mild (median rating of 0.7 on a 10-point scale) and short (median: 0.4 min), leading to mild sleep disturbances (median rating of 0.8 on a 10-point scale). Multivariate analysis showed that older age and previous cramp treatment were associated with more cramps per day, while the use of magnesium and/or psychotropic drugs was associated with fewer cramps per day. CONCLUSIONS: Although nocturnal leg cramps are common among older patients in primary care, the disease burden of nocturnal leg cramps only appears to be severe in a minority of patients.",11/03/2019,01/07/2022 10:40,01/07/2022 10:40,,,,,149,,,,,,,,,,,,,,WOS:000462153900009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L3Y26ISJ,journalArticle,2009,"Ghorayeb, I; Tison, F",Epidemiology of restless legs syndrome,REVUE NEUROLOGIQUE,,0035-3787,10.1016/j.neurol.2009.02.006,,"Introduction. - Restless legs syndrome (RLS) is a chronic sensorimotor disorder where patients complain of an almost irresistible urge to move their legs. This urge can often be accompanied by pain or other unpleasant sensations, it either occurs or worsens with rest particularly at night, and improves with activity. The International Restless Legs Syndrome Study Group has established four essential criteria for clinical diagnosis of RLS. State of art. - Affecting an estimated 7.2 to 11.5% of the adult population, the symptoms of RLS may be associated with significant sleep disturbance and may have a negative impact on quality of life. The prevalence of RLS increases with age, and women are more frequently affected than men. In France, the estimated prevalence is 8.5%. Among sufferers, 4.4% complain of very severe symptoms. Although RLS is mainly idiopathic, several clinical conditions have been associated with it, especially iron deficiency with or without anemia, end-stage renal disease and pregnancy. These conditions may share a common pathophysiological mechanism involving a disorder of iron metabolism. By contrast, controversy persists as to whether polyneuropathy, particularly when associated with diabetes, is to be considered as an important cause of secondary RLS. This association is difficult to demonstrate as conventional electromyography is not adequate to detect small fiber neuropathy often associated with diabetes. Conclusion and perspectives. - RLS is often underdiagnosed and few subjects receive recommended RLS drug treatment. There is a clear need for complementary education to improve the accurate diagnosis of RLS. Indeed, better knowledge of this syndrome is a prerequisite to prompt an appropriate therapeutic management. (c) 2009 Elsevier Masson SAS. All rights reserved.",2009-08,01/07/2022 10:40,01/07/2022 10:40,,641-649,,08-Sep,165,,,,,,,,,,,,,,WOS:000270673600004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SJWJJZRN,journalArticle,2015,"Willmer, M; Berglind, D; Thorell, A; Sundbom, M; Udden, J; Raoof, M; Hedberg, J; Tynelius, P; Ghaderi, A; Naslund, E; Rasmussen, F",Changes in BMI and Psychosocial Functioning in Partners of Women Who Undergo Gastric Bypass Surgery for Obesity,OBESITY SURGERY,,0960-8923,10.1007/s11695-014-1398-4,,"There is very little research exploring the effects of Roux-en-Y gastric bypass surgery (RYGB) on the patient's partner. The aim of the present study was to investigate longitudinally whether male partners of female RYGB patients were affected in terms of BMI, sleep quality, body dissatisfaction, depression, and anxiety. Thirty-seven women, with partners who were willing to participate, were recruited from RYGB waiting lists at five Swedish hospitals. Data collection took place during two home visits, 3 months before and 9 months after RYGB surgery. Anthropometrical data were documented, and both women and men completed the Hospital Anxiety and Depression Scale (HADS) and the Karolinska Sleep Questionnaire (KSQ). The men also completed the Male Body Dissatisfaction Scale (MBDS). The men's BMI changes between the two time points that were analysed using general estimating equation (GEE) regression. Their BMI decreased significantly (beta = -0.9, p = 0.004). The change was more pronounced in the 26 men who had a baseline BMI of a parts per thousand yen25 (beta = -1.4, p < 0.001). Fixed-effects regression showed a statistically significant association between the men's weight loss and that of the women (beta = 0.3, p = 0.004). There were no significant changes in the men's HADS, KSQ, or MBDS scores. Overweight/obese male partners of RYGB patients also lose weight during the first 9 months post-operatively. However, symptoms of body dissatisfaction, anxiety, and depression remain unchanged, as does self-reported sleep quality.",2015-02,01/07/2022 10:40,01/07/2022 10:40,,319-324,,2,25,,,,,,,,,,,,,,WOS:000348111000018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MN7GUF9Q,journalArticle,2014,"Liu, WQ; Kanungo, A; Toth, C",Equivalency of tricyclic antidepressants in open-label neuropathic pain study,ACTA NEUROLOGICA SCANDINAVICA,,0001-6314,10.1111/ane.12169,,"ObjectivesTo compare adverse effects, tolerability and efficacy of the tricyclic antidepressants (TCAs) amitriptyline and nortriptyline in management of neuropathic pain due to peripheral neuropathy (PN). Materials & MethodsWe performed a prospective open-label flexible-dosing comparison of monotherapy or adjuvant therapy using amitriptyline or nortriptyline in PN-associated neuropathic pain. Primary outcomes were quantitative adverse effects and discontinuation rates. Secondary outcomes assessed changes in pain severity, quality of life, disability, sleep efficacy, mood and anxiety, and global improvement. Assessments occurred at 3 and 6months after initiation. Our hypothesis was that nortriptyline would have better tolerance than amitriptyline. ResultsA total of 228 PN patients were enrolled approximately equally for monotherapy and adjuvant therapy. Adverse effects and discontinuation rates were similar between amitriptyline and nortriptyline interventions. Weight gain was more common with amitriptyline, while nortriptyline use was associated with greater prevalence of dry mouth. Secondary outcome measures were similar in both groups, demonstrating improvement from baseline. ConclusionsAmitriptyline and nortriptyline are equivalent for overall adverse effects and discontinuation rates. Either TCA should be equally considered for use in neuropathic pain due to PN. When used as monotherapy or as part of adjuvant therapy, either TCA can be expected to provide approximately 23-26% visual analog scale pain reduction if tolerated. Discontinuations due to inefficacy or adverse effects can be anticipated in 26-37% of patients initiated on either TCA for PN-associated neuropathic pain.",2014-02,01/07/2022 10:40,01/07/2022 10:40,,132-141,,2,129,,,,,,,,,,,,,,WOS:000329458800011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KE7BN75D,journalArticle,2003,"Rose, SR",Endocrinopathies in childhood cancer survivors,ENDOCRINOLOGIST,,1051-2144,10.1097/01.ten.0000098611.49230.10,,"One in every 900 individuals between ages 15 and 45 years is a cancer survivor. Endocrine late effects depend on tumor location, surgery, and other treatment modalities used. Cranial irradiation can cause growth hormone (GH), gonadotropin, adrenocorticotropin, and thyrotropin deficiency. Spinal irradiation can result in poor growth of the spine with relative sparing of limb growth. Mantle irradiation or total-body irradiation affects thyroid and gonads. Craniospinal irradiation for medulloblastoma affects hypothalamus and thyroid. Chemotherapy has more generalized and transient effects, but can affect the gonads or hypothalamus. Symptoms of endocrinopathy include failure to show catch-up growth, slow growth rate, failure to thrive, weight loss, anorexia, obesity, hypoglycemia, fatigue, poor stamina, increased sleep, dry skin, thin hair, cold intolerance, constipation, fractures, or altered timing of puberty. The most frequent endocrine late effects are growth hormone deficiency, primary or central hypothyroidism, altered timing of puberty, corticotropin deficiency, osteopenia, and obesity. Cancer survivors require yearly surveillance for endocrine effects, including accurate height and weight, arm span (if there was total-body or spinal radiation or scoliosis), pubertal staging, assessment of dietary calcium and vitamin D intake, free T4, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and testosterone or estradiol (if puberty is delayed or interrupted), and insulin-like growth factor 1 (IGF-I) and IGF-binding protein 3 (IGFBP3; if growth rate is slow). Early identification and treatment of endocrinopathy can lead to enhanced growth rate, adult height, stamina, and quality of life.",2003-11,01/07/2022 10:40,01/07/2022 10:40,,488-495,,6,13,,,,,,,,,,,,,,WOS:000186770800010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49SBA9UK,journalArticle,2019,"Srivastava, G; Fox, CK; Kelly, AS; Jastreboff, AM; Browne, AF; Browne, NT; Pratt, JSA; Bolling, C; Michalsky, MP; Cook, S; Lenders, CM; Apovian, CM",Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity,OBESITY,,1930-7381,10.1002/oby.22385,,"A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration-approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off-label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.",2019-02,01/07/2022 10:40,01/07/2022 10:40,,190-204,,2,27,,,,,,,,,,,,,,WOS:000456722000004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4TNAWCYV,journalArticle,2021,"Liu, ZF; Li, CAY",A Predictive Model for the Risk of Cognitive Impairment in Patients with Gallstones,BIOMED RESEARCH INTERNATIONAL,,2314-6133,10.1155/2021/3792407,,"Objectives. Gallstones can cause malnutrition in patients and further lead to cognitive impairment. This study is aimed at constructing a validated clinical prediction model for evaluating the risk of developing cognitive impairment from gallstones. Methods. The study was a single-centre crosssectional study. Four models or methods (SVM-RFE, random forest model, Lasso model, and logistics analysis) were analyzed and compared regarding their predictive performance. The model with the best classification performance and predictive power was selected. The AUC index, C-index, and calibration curves were applied to the chosen model to further evaluate its classification and prediction performance. Finally, the nomogram was plotted, and the clinical usability, efficacy, and safety of the nomogram were assessed using decision curve analysis (DCA). Results. This study included a total of 294 patients with gallstones, of which 110 had cognitive impairment. Factors such as gender, age, education, place of birth, history of alcohol consumption, abdominal circumference, sarcopenia, diabetes, anaemia, depression, and Pittsburgh Sleep Quality Index (PSQI) were incorporated into the model for nomogram construction. The calibration curve showed that the nomogram had good classification performance. Furthermore, the C-index of the model was 0.778 (95% CI, 0.674-0.882) in the test group. The DCA curves indicated that the constructed model had strong clinical applicability, efficacy, and safety. Conclusions. This study constructed a cognitive impairment risk prediction model for patients with gallstones with good classification and predictive power. The constructed predictive model allows us to screen patients with gallstones and at high risk of cognitive impairment. These efforts might also help to further increase patient compliance, assist healthcare professionals to better manage patients with gallstones, and ultimately improve their overall health status and quality of life. Future clinical studies should further evaluate the accuracy and clinical usability of this model.",19/07/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,2021,,,,,,,,,,,,,,WOS:000683449200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YK7Z52W4,journalArticle,2019,"Manera, KE; Johnson, DW; Craig, JC; Shen, JI; Ruiz, L; Wang, AYM; Yip, T; Fung, SKS; Tong, M; Lee, A; Cho, Y; Viecelli, AK; Sautenet, B; Teixeira-Pinto, A; Brown, EA; Brunier, G; Dong, J; Dunning, T; Mehrotra, R; Naicker, S; Pecoits, R; Perl, J; Wilkie, M; Tong, A",Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis Multinational Nominal Group Technique Study,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.05380518,,"Background and objectives The absence of accepted patient-centered outcomes in research can limit shared decision-making in peritoneal dialysis (PD), particularly because PD-related treatments can be associated with mortality, technique failure, and complications that can impair quality of life. We aimed to identify patient and caregiver priorities for outcomes in PD, and to describe the reasons for their choices. Design, setting, participants, & measurements Patients on PD and their caregivers were purposively sampled from nine dialysis units across Australia, the United States, and Hong Kong. Using nominal group technique, participants identified and ranked outcomes, and discussed the reasons for their choices. An importance score (scale 0-1) was calculated for each outcome. Qualitative data were analyzed thematically. Results Across 14 groups, 126 participants (81 patients, 45 caregivers), aged 18-84 (mean 54, SD 15) years, identified 56 outcomes. The ten highest ranked outcomes were PD infection (importance score, 0.27), mortality (0.25), fatigue (0.25), flexibility with time (0.18), BP (0.17), PD failure (0.16), ability to travel (0.15), sleep (0.14), ability to work (0.14), and effect on family (0.12). Mortality was ranked first in Australia, second in Hong Kong, and 15th in the United States. The five themes were serious and cascading consequences on health, current and impending relevance, maintaining role and social functioning, requiring constant vigilance, and beyond control and responsibility. Conclusions For patients on PD and their caregivers, PD-related infection, mortality, and fatigue were of highest priority, and were focused on health, maintaining lifestyle, and self-management. Reporting these patient-centered outcomes may enhance the relevance of research to inform shared decision-making.",07/01/2019,01/07/2022 10:40,01/07/2022 10:40,,74-83,,1,14,,,,,,,,,,,,,,WOS:000455336600013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
THCS5ZE6,journalArticle,2017,"Shirazian, S; Grant, CD; Aina, O; Mattana, J; Khorassani, F; Ricardo, AC","Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management",KIDNEY INTERNATIONAL REPORTS,,2468-0249,10.1016/j.ekir.2016.09.005,,"Depression is highly prevalent and is associated with poor quality of life and increased mortality among adults with chronic kidney disease (CKD), including those with end-stage renal disease ( ESRD). However, there are several important differences in the diagnosis, epidemiology, and management of depression between patients with non-dialysis-dependent CKD and ESRD. Understanding these differences may lead to a better understanding of depression in these 2 distinct populations. First, diagnosing depression using self-reported questionnaires may be less accurate in patients with ESRD compared with CKD. Second, although the prevalence of interview-based depression is approximately 20% in both groups, the risk factors for depression may vary. Third, potential mechanisms of depression might also differ in CKD versus ESRD. Finally, considerations regarding the type and dose of antidepressant medications vary between CKD and ESRD. Future studies should further examine the mechanisms of depression in both groups, and test interventions to prevent and treat depression in these populations.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,94-107,,1,2,,,,,,,,,,,,,,WOS:000405958900015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CEWAVJ7K,journalArticle,2016,"Innes, KE; Kandati, S; Flack, KL; Agarwal, P; Selfe, TK",The Relationship of Restless Legs Syndrome to History of Pregnancy-Induced Hypertension,JOURNAL OF WOMENS HEALTH,,1540-9996,10.1089/jwh.2015.5484,,"Background: Restless legs syndrome (RLS), a burdensome sleep disorder, has been associated with cardiovascular disease (CVD), hypertension, diabetes, and related disorders. However, the relationship of RLS to history of pregnancy-induced hypertension (PIH), a predictor of subsequent CVD, diabetes, and associated conditions, remains little explored. In this study, we investigated the relationship of RLS to history of PIH in a sample of primary care patients. Methods: Participants were women aged 40 years drawn from an anonymous survey study of West Virginia primary care patients. Data collected included detailed information on demographics, lifestyle factors, sleep patterns, and reproductive/medical history; the survey also included an RLS diagnostic questionnaire. Women who were pregnant or unsure about their pregnancy status were excluded from the analyses. Results: Of the 498 participants in the final analytic sample, 24.5% met diagnostic criteria for RLS (17.9% with symptoms once/week, 11.9% with symptoms 3 times/week); 73 (16.5% of parous women) reported a history of PIH, defined as physician-diagnosed preeclampsia or gestational hypertension. After adjustment for demographics, lifestyle characteristics, obesity, reproductive history, health conditions, and other factors, those reporting a history of PIH were approximately twice as likely to meet criteria for RLS (odds ratio [OR]=1.9; 95% confidence interval [CI]=1.1, 3.6). These associations increased in magnitude with increasing symptom frequency (adjusted OR for RLS with symptoms 3 times/week=3.8; CI 1.9, 7.6; p for trend=0.003). Conclusions: History of PIH was strongly and positively related to current RLS in this study of primary care patients; these findings further support a possible role for metabolic dysregulation in RLS etiology.",2016-04,01/07/2022 10:40,01/07/2022 10:40,,397-408,,4,25,,,,,,,,,,,,,,WOS:000374648800102,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6IU7KFD7,journalArticle,2020,"Charoenwoodhipong, P; Harlow, SD; Marder, W; Hassett, AL; McCune, WJ; Gordon, C; Helmick, CG; Barbour, KE; Wang, L; Mancuso, P; Somers, EC; Zick, SM",Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program,ARTHRITIS CARE & RESEARCH,,2151-464X,10.1002/acr.23925,,"Objective To examine associations between dietary intake of omega-3 (n-3; generally antiinflammatory) and omega-6 (n-6; generally proinflammatory) fatty acids and patient-reported outcomes in systemic lupus erythematosus (SLE). Methods This study was based on the population-based Michigan Lupus Epidemiology and Surveillance cohort. Estimates of n-3 and n-6 intake were derived from Diet History Questionnaire II items (past year with portion size version). Patient-reported outcomes included self-reported lupus activity (Systemic Lupus Activity Questionnaire [SLAQ]). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n-3 and n-6, as well as the n-6:n-3 ratio, and patient-reported outcomes. Results Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4%) were African American, and the mean +/- SD age was 52.9 +/- 12.3 years. Controlling for potential confounders, the average SLAQ score was significantly higher by 0.3 points (95% confidence interval [95% CI] 0.1, 0.6;P= 0.013) with each unit increase of the n-6:n-3 ratio. Both lupus activity and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scores were lower with each 1-gram/1,000 kcal increase of n-3 fatty acids (SLAQ regression coefficient beta = -0.8 [95% CI -1.6, 0.0];P= 0.055; PROMIS sleep beta = -1.1 [95% CI -2.0, -0.2];P= 0.017). Higher n-3 intakes were nonsignificantly associated with lower levels of depressive symptoms and comorbid fibromyalgia, and with higher quality of life, whereas results for the n6:n3 ratio trended in the opposite direction. Conclusion This population-based study suggests that higher dietary intake of n-3 fatty acids and lower n-6:n-3 ratios are favorably associated with patient-reported outcomes in SLE, particularly self-reported lupus activity and sleep quality.",2020-07,01/07/2022 10:40,01/07/2022 10:40,,874-881,,7,72,,,,,,,,,,,,,,WOS:000543900000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QUVV8SXJ,journalArticle,2017,"Juodeikis, Z; Brimas, G",Long-term results after sleeve gastrectomy: A systematic review,SURGERY FOR OBESITY AND RELATED DISEASES,,1550-7289,10.1016/j.soard.2016.10.006,,"Sleeve gastrectomy (SG) has become one of the most commonly used bariatric procedures worldwide. However, data regarding long-term results remain insufficient. The aim of this study was to review the long-term results after SG. We conducted a comprehensive literature search of Medline and the Cochrane Library for articles published until May 2016 on the long-term results ( > 5 yr) after SG. Studies representing outcomes of SG were included if they reported >= 5-year results that contained at least one outcome of interest-weight loss, co-morbidities, long-term complications, or quality of life-and SG was performed as a primary procedure. Of the 297 initially identified articles, 277 studies met the exclusion criteria, and 20 met the inclusion criteria. SG was performed on 2713 patients and 1626 patients reached the >= 5-year follow-up point. Among the patients, 71.3% were women and 28.7% were men. The mean preoperative body mass index was 46.9 kg/m(2). The duration of follow-up ranged 5 to 11 years. The mean 5-year follow-up rate was 66% (range, 57%-100%). The mean percentage excess weight loss was 58.4%, 59.5%, 56.6%, 56.4%, and 62.5% at 5, 6, 7, 8, and 11 years, respectively. Five years after SG, the resolution or improvement of type 2 diabetes was observed in 77.8% of patients, and arterial hypertension, dyslipidemia, obstructive sleep apnea, gastroesophageal reflux disease, and degenerative joint diseases had improved or resolved in 68.0%, 65.9%, 75.8%, 30.6%, and 55.7% of patients, respectively. This systematic review suggests that SG can lead to substantial and lasting excess weight loss and significant improvement in obesity-related co-morbidities. However, the lack of randomized clinical trials, low follow-up rates, and poorly reported data regarding co-morbidities and quality of life in many of the studies indicate that these findings should be interpreted with caution. (C) 2017 American Society for Metabolic and Bariatric Surgery. All rights reserved.",2017-04,01/07/2022 10:40,01/07/2022 10:40,,693-699,,4,13,,,,,,,,,,,,,,WOS:000402021700027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PSD2SHMD,journalArticle,2021,"Wu, SI; Wu, CC; Tsai, PJ; Cheng, LH; Hsu, CC; Shan, IK; Chan, PY; Lin, TW; Ko, CJ; Chen, WL; Tsai, YC","Psychobiotic Supplementation of PS128 (TM) Improves Stress, Anxiety, and Insomnia in Highly Stressed Information Technology Specialists: A Pilot Study",FRONTIERS IN NUTRITION,,2296-861X,10.3389/fnut.2021.614105,,"Background: Information technology (IT) is an industry related to the production of computers, information processing, and telecommunications. Such industries heavily rely on the knowledge and solutions provided by IT specialists. Previous reports found that the subjective stress scores were higher in IT specialists who developed diabetes, hypertension, and depression. Specific probiotics, known as psychobiotics, may alleviate stress and mood symptoms. This study aimed to examine whether an 8-week intervention of a novel psychobiotic, Lactobacillus plantarum PS128 (TM) (PS128 (TM)), improved self-perceived stress and mood symptoms among high-stress IT specialists. Methods: This open-label, single-arm, baseline-controlled study included IT specialists from a large IT company in Northern Taiwan. Participants with a Perceived Stress Scale (PSS) 10-item version score of 27 or higher were included. Participants were asked to take two capsules containing PS128 (TM) powder, equivalent to 20 billion colony-forming units, daily. Self-report measures, such as the Job Stress Scale, Visual Analog Scale of Stress, the Insomnia Severity Index, the State and Trait Anxiety Index, the Questionnaire for Emotional Trait and State, the Patient Health Questionnaire, the Quality of Life Enjoyment and Satisfaction Questionnaire, and Gastrointestinal Severity Index were compared at baseline and at the end of the trial period. The primary outcome was a 20% reduction in the PSS score at endpoint. Objective measures included salivary levels of stress biomarkers, including cortisol, a-amylase, immunoglobulin A, lactoferrin, and lysozymes, as well as results of the Test of Attentional Performance. Results: Of the 90 eligible IT specialists, 36 met the inclusion criteria. After the 8-week trial period, significant improvements in self-perceived stress, overall job stress, job burden, cortisol level, general or psychological health, anxiety, depression, sleep disturbances, quality of life, and both positive and negative emotions were found. Conclusion: Our results suggest that PS128 (TM) has the distinct advantage of providing stress relief and can improve mental health for people with a high-stress job. Future placebo-controlled studies are warranted to explore the effect and underlying mechanisms of action of PS128 (TM).",26/03/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,8,,,,,,,,,,,,,,WOS:000638195900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WXI2RKE9,journalArticle,2020,"Barak, S; Anikster, Y; Sarouk, I; Stern, E; Eisenstein, E; Yissar, T; Sherr-Lurie, N; Raas-Rothschild, A; Guttman, D",Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings,DIAGNOSTICS,,2075-4418,10.3390/diagnostics10020108,,"Enzyme replacement therapy (ERT) is one of the available therapies for mucopolysaccharidosis (MPS). This study presents a follow-up of two siblings with MPS IVA (Morquio A disease) that received ERT. Both siblings received weekly intravenous infusions of elosulfase alfa for 4.5 years. One sibling (patient 1, P1; male) started therapy at 54 months of age, and the other sibling (patient 2, P2; female) started at 11 months of age. ERT was well-tolerated. In comparison to P1, P2's growth curves deviated less from the norm. The orthopedic deformities of P1 were more severe than those of P2 and required several surgical corrections. P1's sleep test at 48 months revealed obstructive sleep apnea, while by the age of 102 months, parameters were normal. P2 never had sleep apnea. Only P1 demonstrated ear, nose, and throat clinical illnesses. In comparison to P1, P2's physical function was better maintained. In conclusion, ERT was safe in both patients during a 4.5-year follow-up. Although the typical characteristics of this disease were similar in both patients, P1 had a complex clinical course in comparison to P2, which influenced function and quality of life. Therefore, in order to make the most of ERT, it may be more beneficial when initiated at a relatively young age.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,,,2,10,,,,,,,,,,,,,,WOS:000519541300037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
P6LZKB48,journalArticle,2020,"Moodi, M; Firoozabadi, MD; Kazemi, T; Payab, M; Ghaemi, K; Miri, MR; Sharifzadeh, G; Fakhrzadeh, H; Ebrahimpur, M; Arzaghi, SM; Zarban, A; Mirimoghadam, E; Sharifi, A; Hosseini, MS; Esmaeili, A; Mohammadifard, M; Ehsanbakhsh, A; Ahmadi, Z; Yaghoobi, GH; Hosseinirad, SA; Davari, MH; Heydari, B; Nikandish, M; Norouzpour, A; Naseri, S; Khorashadizadeh, M; Mohtashami, S; Mehdizadeh, K; Ahmadi, G; Soltani, H; Khodbakhshi, H; Sharifi, F; Larijan, B","Birjand longitudinal aging study (BLAS): the objectives, study protocol and design (wave I: baseline data gathering)",JOURNAL OF DIABETES AND METABOLIC DISORDERS,,2251-6581,10.1007/s40200-020-00504-5,,"ObjectivesThe pace of population aging is growing rapidly around the world. Aging is associated with the emergence of different health status including geriatric syndrome such as frailty, diabetes, cardiovascular diseases, and dementia. These conditions are the most prominent challenges for health care systems and also elderly people. Therefore, understanding these changes can help scientists to prevent and treat significant health issues and also improve the functional ability of older adults.MethodsThis is a protocol of the first wave of Birjand Longitudinal Aging Study that is an ongoing community-based prospective cohort study with a following up at least 10 years. This study carries out on aged population >= 60 years which were residents in Birjand County (urban and rural older subjects). The selection of the participants of this study in urban areas is based on an age group weighted multistage stratified random sample while in the rural region the sample was selected from all ten rural regions of Birjand County by simple random sampling. The rural region sampling was based on the list of the aged population which were under the coverage of the rural health center. Sociodemographic, past medical history, lifestyle, sleep, activities of daily living, cognitive function, quality of life, and social capital were evaluated by interviewing with the participants and one of the informants. Anthropometric measures, electrocardiography, and interpretation of ophthalmologic examination were carried out by experts. Fasting Blood samples were collected and bio-banked in-80 degrees C. then finally biochemical and hematologic markers were measured.ResultsThis is the protocol of stage one baseline of Birjand Longitudinal Aging Study (BLAS). The BLAS is an enjoining study, the first phase of its baseline was carried out on a community- dwelling aged population sample >= 60 years who were residents in urban and rural regions of Birjand County. This is a community based prospective cohort study with at least 10 years follow up of participants. The data for 65% of older subjects (response rate=65%) that lived in clusters were collected.ConclusionsThis study can help scientists to recognize some risk factors related to the aging process and also aware policymakers about the necessity to create heath care services at regional and even national levels.",2020-06,01/07/2022 10:40,01/07/2022 10:40,,551-559,,1,19,,,,,,,,,,,,,,WOS:000571450700062,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LMAFR369,journalArticle,2020,"Suojanen, LU; Ahola, AJ; Kupila, S; Korpela, R; Pietilainen, KH","Effectiveness of a web-based real-life weight management program: Study design, methods, and participants' baseline characteristics",CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS,,2451-8654,10.1016/j.conctc.2020.100638,,"Obesity is an important public health concern with limited effective treatment options. Internet-based technologies offer a cost-effective means to treat obesity. However, most of the online programs have been of short duration, have focused on a limited number of treatment modalities, and have not utilized the potential of coaching as part of the intervention. In this paper, we present the design, methods and participants' baseline characteristics in a real-life internet-based weight management program. Healthy Weight Coaching (HWC) is a 12-month web-based intervention for the management of obesity. The program is based on the Acceptance and Commitment Therapy and includes themes important for weight loss, including diet, physical activity, psychological factors, and sleep. In addition to the automated, interactive program, a personal coach is allocated to each participant. The participants are nationally enrolled through referrals from primary care, occupational health, hospitals, and private health care units. Adult individuals with BMI >= 25 kg/m(2) without severe complications are included. On a weekly basis, participants submit their weight logs, training sessions, and lifestyle targets to the internet portal and are scheduled to have online discussions with their coaches 26 times over the course of a year. Questionnaires on lifestyle, diet, physical activity, psychological factors, sleep, and quality of life are completed at baseline, 3, 6, 9, and 12 months, and thereafter yearly until 5 years. Additionally, log data on the use of the service and discussions with the coach are collected. The main outcome is weight change from baseline to 12 months. Recruitment to the HWC is ongoing. Baseline data of the participants recruited between Oct 2016 and Mar 2019 (n = 1189) are provided. This research will bring insight into how internet-based technologies can be implemented in the virtual management of obesity.",2020-09,01/07/2022 10:40,01/07/2022 10:40,,,,,19,,,,,,,,,,,,,,WOS:000594377800024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MDE3Q3VQ,journalArticle,2017,"Casilimas, GAG; Martin, DA; Martinez, MA; Merchan, CR; Mayorga, CA; Barragan, AF",Pathophysiology of hypertension secondary to obesity,ARCHIVOS DE CARDIOLOGIA DE MEXICO,,1405-9940,10.1016/j.acmx.2017.02.001,,"The obesity is a problem with a high morbidity and mortality all over the world. It has now been designated as a cardiovascular risk factor. It often predisposes the development of many diseases that reduce quality of life, such as hypertension, dyslipidaemia, and diabetes. These diseases are associated with some of the criteria that should be considered in the diagnosis of metabolic syndrome. During this review, explanations will be presented on the relationship between obesity, metabolic syndrome, and the development of hypertension from neurohumoral, biochemical and mechanical concepts. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.",2017-10,01/07/2022 10:40,01/07/2022 10:40,,336-344,,4,87,,,,,,,,,,,,,,WOS:000417354300010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EZFAPCNN,journalArticle,2013,"Peltzer, K; Phaswana-Mafuya, N",ARTHRITIS AND ASSOCIATED FACTORS IN OLDER ADULTS IN SOUTH AFRICA,TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI,,1304-2947,,,"Introduction: Arthritis is one of the more prevalent chronic conditions and a leading cause of disability in the elderly. The objective of this study is to assess the prevalence and to identify the factors associated with arthritis in a national probability sample of older South Africans who participated in the Study of Global Ageing and Adults Health (SAGE) in 2008. Materials and Method: We conducted a national population-based cross-sectional study with a sample of 3840 aged 50 years or older in South Africa in 2008. The questionnaire included socio-demographic characteristics, health variables, anthropometric and blood pressure measurements. Multivariable regression analysis was performed to assess the association of socio-demographic factors, health variables and arthritis. Results: Overall 24.7% had self-reported diagnosed arthritis, 28.4% symptom-based arthritis; and of those who had self-reported diagnosed arthritis 77.3% were undergoing routine ongoing therapy in the past 12 months and 67.6% were under current therapy (in past 2 weeks) for arthritis. In multivariable analysis female gender, Coloured, Indian or Asian population group, other illness or chronic conditions (Stroke, Depression, Sleeping problem, Diabetes and Obesity), poorer subjective health status, greater activity limitations and low quality of life were associated with self-reported arthritis. Conclusion: Considering the paucity of similar studies addressing the impact of arthritis in Africa, these findings may be applied to similar communities and support better planning of resource allocations to minimize the effects of arthritis among the elderly.",2013,01/07/2022 10:40,01/07/2022 10:40,,389-394,,4,16,,,,,,,,,,,,,,WOS:000328934700006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
K7M8GEUB,journalArticle,2017,"Batul, SA; Gopinathannair, R",Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times,KOREAN CIRCULATION JOURNAL,,1738-5520,10.4070/kcj.2017.0040,,"Atrial fibrillation (AF) and heart failure (HF) are growing cardiovascular disease epidemics worldwide. There has been an exponential increase in the prevalence of AF and HF correlating with an increased burden of cardiac risk factors and improved survival rates in patients with structural heart disease. AF is associated with adverse prognostic outcomes in HF and is most evident in mild-to-moderate left ventricular (LV) dysfunction where the loss of ""atrial kick"" translates into poorer quality of life and increased mortality. In the absence of underlying structural heart disease, arrhythmia can independently contribute to the development of cardiomyopathy. Together, these 2 conditions carry a high risk of thromboembolism due to stasis, inflammation and cellular dysfunction. Stroke prevention with oral anticoagulation (OAC) remains a mainstay of treatment. Pharmacologic rate and rhythm control remain limited by variable efficacy, intolerance and adverse reactions. Catheter ablation for AF has resulted in a paradigm shift with evidence indicating superiority over medical therapy. While its therapeutic success is high for paroxysmal AF, it remains suboptimal in persistent AF. A better mechanistic understanding of AF as well as innovations in ablation technology may improve patient outcomes in the future. Refractory cases may benefit from atrioventricular junction ablation and biventricular pacing. The value of risk factor modification, especially with regard to obesity, sleep apnea, hypertension and diabetes, cannot be emphasized enough. Close interdisciplinary collaboration between HF specialists and electrophysiologists is an essential component of good long-term outcomes in this challenging population.",2017-09,01/07/2022 10:40,01/07/2022 10:40,,644-662,,5,47,,,,,,,,,,,,,,WOS:000413842200003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AGXJLAEN,journalArticle,2009,"Yermilov, I; McGory, ML; Shekelle, PW; Ko, CY; Maggard, MA",Appropriateness Criteria for Bariatric Surgery: Beyond the NIH Guidelines,OBESITY,,1930-7381,10.1038/oby.2009.78,,"Careful selection of bariatric patients is critical for successful outcomes. In 1991, the NIH first established patient selection guidelines; however, some surgeons operate on individuals outside of these criteria, i.e., extreme age groups. We developed appropriateness criteria for the spectrum of patient characteristics including age, BMI, and severity of eight obesity-related comorbidities. Candidate criteria were developed using combinations of patient characteristics including BMI: >= 40 kg/m(2), 35-39, 32-34, 30-31, <30; age: 12-18, 19-55, 56-64, 65+ years old; and comorbidities: prediabetes, diabetes, hypertension, dyslipidemia, sleep apnea, venous stasis disease, chronic joint pain, and gastroesophageal reflux (plus severity level). Criteria were formally validated on their appropriateness of whether the benefits of surgery clearly outweighed the risks, by an expert panel using the RAND/UCLA modified Delphi method. Nearly all comorbidity severity criteria for patients with BMI >= 40 kg/m(2) or BMI = 35-39 kg/m(2) in intermediate age groups were found to be appropriate for surgery. In contrast, patients in the extreme age categories were considered appropriate surgical candidates under fewer conditions, primarily the more severe comorbidities, such as diabetes and hypertension. For patients with a BMI of 32-34, only the most severe category of diabetes (Hgb A1c >9, on maximal medical therapy), is an appropriate criterion for those aged 19-64, whereas many mild to moderate severity comorbidity categories are ""inappropriate."" There is overwhelming agreement among the panelists that the current evidence does not support performing bariatric surgery in lower BMI individuals (BMI <32). This is the first development of appropriateness criteria for bariatric surgery that includes severity categories of comorbidities. Only for the most severe degrees of comorbidities were adolescent and elderly patients deemed appropriate for surgery. Patient selection for bariatric procedures should include consideration of both patient age and comorbidity severity.",2009-08,01/07/2022 10:40,01/07/2022 10:40,,1521-1527,,8,17,,,,,,,,,,,,,,WOS:000268374200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
EF6YAGW4,journalArticle,2010,"Penza, P; Majorana, A; Lombardi, R; Camozzi, F; Bonadeo, S; Sapelli, P; Lauria, G","""Burning Tongue"" and ""Burning Tip"": The Diagnostic Challenge of the Burning Mouth Syndrome",CLINICAL JOURNAL OF PAIN,,0749-8047,10.1097/AJP.0b013e3181e15b83,,"Objective: To investigate the clinical features of burning mouth syndrome (BMS) in a large cohort of patients and to correlate them with the results of tongue biopsy. Methods: We screened 98 patients complaining of oral burning pain for at least 6 months. Forty-two patients were excluded after screening for contact sensitivity to dental materials, food allergies, tongue injuries, malignancies, connective tissue and metabolic disorders, oral infectious diseases, vitamin deficiencies, and other systemic diseases known to cause neuropathy. Fifty-six patients underwent neurologic examination and assessment of pain intensity, depression, anxiety, quality of sleep, and quality of life. Tongue biopsy with the quantification of epithelial nerve fibers (ENF) was performed in 51 patients. Results: Compared with 9 healthy participants (4.13 +/- 1.85 SD), epithelial innervation density was significantly reduced in 38 patients (1.35 +/- 1.46 SD; P < 0.0001) and normal in 13 patients (6.1 +/- 2.19 SD). The clinical features differed in the two groups: patients with reduced ENF density complained of pain in the whole tongue, lips, hard palate, and alveolar ridges, reported dysgeusia and xerostomia in 29% of cases (P < 0.001), and 24% of them were depressed. Patients with normal innervation complained of pain on the tip of the tongue, reported dysgeusia and xerostomia in 7.7% of cases, and 54% of them were depressed (P < 0.017). Discussion: The diagnostic criteria for BMS are not defined yet and the relationship with depression and anxiety is debated. We proposed a biopsy-supported approach for the diagnosis. Our study shows that BMS can present with two distinct clinical pictures and that tongue biopsy can contribute to the assessment of the diagnosis. Mood disorders occur frequently and should be considered when approaching patients and treatment options. These observations could help physicians in identifying patients with BMS and addressing them with the appropriate diagnostic work-up and treatment.",2010-07,01/07/2022 10:40,01/07/2022 10:40,,528-532,,6,26,,,,,,,,,,,,,,WOS:000278823500009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3WFM8HFD,journalArticle,2012,"Robinson, S; Yardy, K; Carter, V",A narrative literature review of the development of obesity in infancy and childhood,JOURNAL OF CHILD HEALTH CARE,,1367-4935,10.1177/1367493512443908,,"This narrative review explains the development of excess weight gain in babies and children. It takes a life course approach which includes genetics, pre-conception, pregnancy, infancy and childhood. The paper focuses on feeding behaviours, physical activity, parental influences and the wider social and environmental context. Risk factors which can cumulatively lead to excess childhood weight gain include: under- or overweight during pregnancy; the presence of diabetes during pregnancy; low or high birth weight; having obese parents; early weaning; prolonged formula feeding; rapid weight gain in the first year; disinhibited eating patterns and the consistent availability of energy dense food at home; feeding practices which are not responsive to the child's cues; insufficient sleep among preschool children; sedentary parents; low parental education; living in poor socio-economic circumstances; absence, or perceived absence, of safe play areas; parents who lack time or confidence to authoritatively parent; environments where there is poor access to affordable lower energy dense foods; and parents who do not accept that excess weight is a health problem. Recommendations for health professionals are made.",2012-12,01/07/2022 10:40,01/07/2022 10:40,,339-354,,4,16,,,,,,,,,,,,,,WOS:000314410600004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KP8E5MJT,journalArticle,2019,"Wood, MH; Carlin, AM; Ghaferi, AA; Varban, OA; Hawasli, A; Bonham, AJ; Birkmeyer, NJ; Finks, JF",Association of Race With Bariatric Surgery Outcomes,JAMA SURGERY,,2168-6254,10.1001/jamasurg.2019.0029,,"IMPORTANCE The outcomes of bariatric surgery vary considerably across patients, but the association of race with these measures remains unclear. OBJECTIVE To examine the association of race on perioperative and 1-year outcomes of bariatric surgery. DESIGN, SETTING, AND PARTICIPANTS Propensity score matching was used to assemble cohorts of black and white patients from the Michigan Bariatric Surgery Collaborative who underwent a primary bariatric operation (Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastric banding) between June 2006 and January 2017. Cohorts were balanced on baseline characteristics and procedure. Conditional fixed-effects models were used to evaluate the association of race on outcomes within hospitals and surgeons. Data analysis occurred from June 2006 through August 2018. MAIN OUTCOMES AND MEASURES Thirty-day complications and health care resource utilization measures, as well as 1-year weight loss, comorbidity remission, quality of life, and satisfaction. RESULTS In each group, 7105 patients were included. Black patients had a higher rate of any complication (628 [8.8%] vs 481 [6.8%]; adjusted odds ratio, 1.33 [95% CI, 1.17-1.51]; P =.02), but there were no significant differences in the rates of serious complications (178 [2.5%] vs 135 [1.9%]; adjusted odds ratio, 1.32 [95% CI, 1.05-1.66]; P =.29) or mortality (5 [0.10%] vs 7 [0.10%]; adjusted odds ratio, 0.73 [95% CI, 0.23-2.31]; P =.54). Black patients had a greater length of stay (mean [SD], 2.2 [3.0] days vs 1.9 [1.7] days; adjusted odds ratio, 0.30 [95% CI, 0.20-0.40]; P <.001), as well as a higher rate of emergency department visits (541 [11.6%] vs 826 [7.6%]; adjusted odds ratio, 1.60 [95% CI, 1.43-1.79]; P <.001) and readmissions (414 [5.8%] vs 245 [3.5%]; adjusted odds ratio, 1.73 [95% CI, 1.47-2.03]; P <.001). At 1 year, black patients had lower mean total body weight loss and as a percentage of weight (32.0 kg [26%]; vs 38.3 kg [29%]; P <.001) and this held true across procedures. Remission of hypertension was lower for black patients (564 [40.0%] vs 1096 [56.0%]; P <.001), but the rate of sleep apnea remission (467 [62.6%] vs 615 [56.1%]; P =.005) and gastroesophageal reflux disease (309 [78.6%] vs 453 [75.4%]; P =.049) were higher. There were no significant differences in remission of diabetes with insulin dependence, diabetes without insulin dependence, or hyperlipidemia hyperlipidemia. Fewer black patients than white patients reported a good or very good quality of life (1379 [87.2%] vs 2133 [90.4%]; P =.002) and being very satisfied with surgery (1908 [78.4%] vs 2895 [84.2%]; P <.001) at 1 year. CONCLUSIONS AND RELEVANCE Black patients undergoing bariatric surgery in Michigan had significantly higher rates of 30-day complications and resource utilization and experienced lower weight loss at 1 year than a matched cohort of white patients. While sleep apnea and gastroesophageal reflux disease remission were higher and hypertension remission lower in black patients, comorbidity remission was otherwise similar between matched cohorts. Racial and cultural differences among patients should be considered when designing strategies to optimize outcomes with bariatric surgery.",2019-05,01/07/2022 10:40,01/07/2022 10:40,,,,5,154,,,,,,,,,,,,,,WOS:000472166100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Z5C9J4RQ,journalArticle,2018,"Nyenhuis, SM; Dixon, AE; Ma, J","Impact of Lifestyle Interventions Targeting Healthy Diet, Physical Activity, and Weight Loss on Asthma in Adults: What Is the Evidence?",JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE,,2213-2198,10.1016/j.jaip.2017.10.026,,"Unhealthy lifestyle factors such as poor diet quality, sedentary lifestyle, and obesity are associated with negative health consequences in asthma including poor asthma control, impaired quality of life, and greater health care utilization. Lifestyle modification is the cornerstone of behavioral treatments and has been effective in chronic diseases such as atherothrombotic vascular disease and diabetes. There is a critical need for lifestyle interventions in asthma care that address obesity and its intimately linked risk behaviors in terms of poor diet and physical inactivity. We present in this commentary the promising lifestyle interventions emerging in asthma care that target poor diet, physical inactivity and weight loss, the proposed mechanisms of these lifestyle interventions, and the critical need for guideline-concordant lifestyle interventions in asthma care. (C) 2017 American Academy of Allergy, Asthma & Immunology.",2018-05,01/07/2022 10:40,01/07/2022 10:40,,751-763,,3,6,,,,,,,,,,,,,,WOS:000432461800005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y6SSV7NH,journalArticle,2014,"Bruno, A; Pace, E; Cibella, F; Chanez, P",Body Mass Index and Comorbidities in Adult Severe Asthmatics,BIOMED RESEARCH INTERNATIONAL,,2314-6133,10.1155/2014/607192,,"Both severe asthma and obesity are growing health problems. Severe asthma leads to a poor quality of life. The relationship among BMI, comorbidities, and severe asthma control in adults is still unclear. The aim of the study is to better understand the effect of the comorbidities as atopy, type II diabetes, OSAS, gastroesophageal reflux, hypertension, cardiovascular diseases, osteoporosis, infections, and psychological factors with BMI on asthma control in a cohort of adult severe asthmatics. One hundred and two patients were enrolled in a cross-sectional study assessing asthma control, treatments, pulmonary function, inflammatory markers, and comorbidities. Patients were divided into 3 classes according to BMI: normal weight, overweight, and obese. We found that the optimal state of asthma control is lower. whereas the score of Asthma Control Questionnaire, the number of asthma exacerbations during last year, the oral corticosteroids requirement during the previous year, and the LABA treatments are higher in obese than in overweight and normal weight severe asthmatics. The number of subjects with type II diabetes and OSAS are higher among obese and overweight patients than in normal weight asthmatics. In conclusion, BMI represents per se a factor for the deterioration in disease control in severe asthma.",2014,01/07/2022 10:40,01/07/2022 10:40,,,,,2014,,,,,,,,,,,,,,WOS:000337481700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5FKGQS4K,journalArticle,2016,"Lai, HH; Vetter, J; Jain, S; Andriole, GL",Systemic Nonurological Symptoms in Patients with Overactive Bladder,JOURNAL OF UROLOGY,,0022-5347,10.1016/j.juro.2016.02.2974,,"Purpose: We compare the systemic (nonurological) symptoms between patients with overactive bladder and subjects without overactive bladder. We also compare the urinary symptoms, quality of life and psychosocial measures between the 2 subgroups of patients with overactive bladder with a high vs low systemic symptom burden. Materials and Methods: Patients diagnosed with overactive bladder (51) and age matched individuals without overactive bladder (30) were administered the polysymptomatic, polysyndromic questionnaire to assess the numbers and distribution of systemic symptoms across multiple organ systems. Validated instruments were administered to evaluate urinary symptoms (ICIQ-UI, ICIQOAB, OAB-q, USS), quality of life (UDI-6, IIQ-7, OAB-q) and psychosocial difficulties (depression, anxiety, stress, sexual trauma, sleep, fatigue). Patients with overactive bladder were divided into 2 subgroups (with and without widespread systemic symptoms) and their responses were compared. Results: Patients with overactive bladder reported significantly more systemic (nonurological) symptoms compared to controls (mean +/- SD 17.5 +/- 12.3 vs 6.4 +/- 7.9 symptoms, p <0.001). Differences were observed across multiple organ systems (neurologic, cardiopulmonary, gastrointestinal, sexual, musculoskeletal and gynecologic, p <0.05). About a third of patients with overactive bladder (31.4%) reported widespread systemic symptoms across multiple organ systems (mean 32.0 symptoms). The presence of widespread systemic symptoms among patients with overactive bladder was correlated with worse incontinence/overactive bladder symptoms (ICIQ-UI, OAB-q), poorer quality of life (UDI-6, IIQ-7, OAB-q) and more psychosocial difficulties (depression, anxiety, fatigue and higher stress, p <0.05). Conclusions: The increased presence of nonurological symptoms in overactive bladder suggests an underlying systemic etiology and pathogenetic mechanisms that may contribute to overactive bladder. This study highlights the importance of understanding systemic factors in urological conditions otherwise thought to be organ specific.",2016-08,01/07/2022 10:40,01/07/2022 10:40,,467-472,,2,196,,,,,,,,,,,,,,WOS:000379266400075,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L953QENH,journalArticle,2017,"Gilron, I; Tu, DS; Holden, R; Towheed, T; Vandenkerkhof, E; Milev, R","Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid -Pregabalin Combination for the Treatment of Fibromyalgia Pain",JMIR RESEARCH PROTOCOLS,,1929-0748,10.2196/resprot.8001,,"Background: Fibromyalgia is a clinical disorder commonly presenting with chronic widespread pain as well as sleep disturbance, fatigue, depression, and cognitive dysfunction. There is an urgent need for treatment strategies that provide better pain relief and fewer adverse effects (AEs). Efforts to develop rational combinations of specific fibromyalgia treatments have demonstrated potential for measurable improvements in pain relief, quality of life, and health care utilization. More than half of fibromyalgia patients receive 2 or more analgesics but current combination use is based on limited evidence. As an early proof-of-concept project from the Canadian Institutes of Health Research-Strategy on Patient-Oriented Research Chronic Pain Network, this trial protocol is expected to advance the field by rigorously evaluating a new treatment combination for fibromyalgia. Objective: We will test the hypothesis that analgesic combinations containing at least one nonsedating agent would be as safe but more effective than either monotherapy because of additive pain relief without increasing overall AEs. Pregabalin (PGB), a sedating anticonvulsant, is proven effective for fibromyalgia, and the antioxidant, alpha-lipoic acid (ALA), one of the only nonsedating systemic agents proven effective for neuropathic pain, is currently being evaluated in fibromyalgia. Thus, we will conduct a clinical trial to compare a PGB+ALA combination to each monotherapy for fibromyalgia. Methods: Using a double-blind, double-dummy, crossover design, 54 adults with fibromyalgia will be randomly allocated to 1 of 6 sequences of treatment with PGB, ALA, and PGB+ALA combination. During each of 3 different treatment periods, participants will take 2 sets of capsules containing (1) ALA (or placebo) and (2) PGB (or placebo) for 31 days, followed by an 11-day taper/washout period. The primary outcome will be mean daily pain intensity (0 to 10 scale) at maximal tolerated doses (MTDs) during each period. Secondary outcomes, assessed at MTD, will include global improvement, adverse events, mood, and quality of life. Results: This trial attained ethics approval March 6, 2017 (Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board protocol number ANAE-313-17), and recruitment is set to start in August 2017. Conclusions: This trial will provide rigorous evidence comparing the efficacy of a PGB-ALA combination to PGB alone and ALA alone in the treatment of fibromyalgia.",2017-08,01/07/2022 10:40,01/07/2022 10:40,,,,8,6,,,,,,,,,,,,,,WOS:000406901300005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JKXZQ7JR,journalArticle,2019,"Marczuk, P; Kubisa, MJ; Swiech, M; Waledziak, M; Kowalewski, P; Major, P; Pedziwiatr, M; Pasnik, K; Janik, MR",Effectiveness and Safety of Roux-en-Y Gastric Bypass in Elderly PatientsSystematic Review and Meta-analysis,OBESITY SURGERY,,0960-8923,10.1007/s11695-018-3546-8,,"IntroductionAs the population ages, there is more interest in bariatric surgery for older patients. There are controversies regarding the safety and effectiveness of surgical weight loss in this population.AimThe aim of this study was to compare the safety and efficacy of Roux-en-Y gastric bypass in patients over the age of 60years with younger patients.MethodsThe available literature was searched for eligible studies up to February 2018. Inclusion criteria were reports on mortality, morbidity, percentage excess weight loss (%EWL), remission of diabetes, remission of hypertension, and remission of obstructive sleep apnea. Random effects meta-analyses were performed.ResultsThe initial search yielded 2000 references. The final meta-analysis involved nine studies and revealed significant differences in mortality (odds ratio 4.38, 95% confidence interval [1.25, 15.31], p=0.02), morbidity (OR 1.88, CI [1.07, 3.30], p=0.03), %EWL (mean difference -5.86, 95% CI [-9.15, -2.56], p<0.001), and remission of comorbidities.ConclusionHigher mortality and morbidity were found in the group of older patients. The analysis suggested lower effectiveness of Roux-en-Y gastric bypass for weight loss and improvement in comorbidity in older patients when compared with younger patients.",2019-02,01/07/2022 10:40,01/07/2022 10:40,,361-368,,2,29,,,,,,,,,,,,,,WOS:000458263000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I643TIQC,journalArticle,2012,"Persu, A; Renkin, J; Thijs, L; Staessen, JA",Renal Denervation Ultima Ratio or Standard in Treatment-Resistant Hypertension,HYPERTENSION,,0194-911X,10.1161/HYPERTENSIONAHA.112.195263,,"Depending on studied populations and applied definitions, the prevalence of treatment-resistant hypertension (rHT) varies from 10% to 15%, but is higher in conditions associated with increased sympathetic drive, such as obesity, obstructive sleep apnea, diabetes or renal dysfunction. The SYMPLICITY studies recently demonstrated that reducing sympathetic tone by intravascular renal denervation (IRD) is feasible in rHT, but did not provide conclusive evidence on the size and durability of the antihypertensive, renal and sympatholytic effects, long-term safety, quality of life, the possibility to relax antihypertensive drug treatment, cost-effectiveness, and benefit in terms of long-term hard cardiovascular-renal outcomes. At the time of writing of this report, 28 IRD trials in various indications were registered at http://www.clinicaltrials.gov, but only seven had a randomized controlled design. In the US, IRD remains an investigational procedure that cannot be used in clinical practice, but in Europe, CE-label certification of electrical safety is permitting to market catheter systems to any interventional facility for regular clinical use. IRD should not be routinely applied as a substitute for the skilful management of resistant patients, which includes documentation of adherence to antihypertensive drugs, implementation of lifestyle measures and the use of recommended combinations of antihypertensive agents at the highest tolerated daily dose. For now, IRD should therefore remain the ultima ratio in adherent patients with severe rHT, in whom all other efforts to reduce blood pressure have failed. IRD should only be offered within a clinical research context at highly skilled tertiary referral centers that participate in international registries constructed independent of the manufacturers.",2012-09,01/07/2022 10:40,01/07/2022 10:40,,596-+,,3,60,,,,,,,,,,,,,,WOS:000307951900014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BXMRRNAS,journalArticle,2017,"Gibbons, E; Casey, AF; Brewster, KZ",Bariatric surgery and intellectual disability: Furthering evidence-based practice,DISABILITY AND HEALTH JOURNAL,,1936-6574,10.1016/j.dhjo.2016.09.005,,"Background: Rates of morbid obesity are higher for individuals with intellectual disability (ID). Individuals with ID may find nutritional guidelines difficult to follow and many face personal and environmental barriers for physical activity. Bariatric surgery may reduce obesity related health comorbidities while promoting sustained weight loss in diverse populations. Yet no study has reviewed the feasibility of conducting bariatric surgery on individuals with ID. Objectives: To conduct a scoping review of literature on bariatric procedures performed on individuals with D. Methods: Authors searched electronic database via PubMED, Science Direct, Wiley and Medline (1975-2014). Extracted articles were evaluated independently following scoping reviews guidelines. Results: Reviewers included sixteen studies. Nine surgical interventions were reported on 49 patients with ID. Studies followed either case report or case series design. The most common procedure patients received was biliopancreatic diversion (n = 24) followed by Roux en -Y Gastric Bypass (n = 12). Degree of weight loss was the primary outcome in each study. Excess weight loss (%EWL) ranged from 12% to 86%. Further benefits included improved quality of life, decreased psychological tension within family and resolution of sleep apnea, hypertension, respiratory distress and type II diabetes. Six studies included a post-operative follow-up period below two years. Conclusions: Bariatric surgery may be a viable option to treat obesity in individuals with ID but there is no consensus which procedure is preferred and which associated interventions should be in place to warrant long lasting results. Further research featuring randomized control trials may be beneficial. (C) 2016 Elsevier Inc. All rights reserved.",2017-01,01/07/2022 10:40,01/07/2022 10:40,,03-Oct,,1,10,,,,,,,,,,,,,,WOS:000390293100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U6LFBGHG,journalArticle,2009,"Salihu, HM; Bonnema, S; Alio, AP",Obesity: What is an elderly population growing into?,MATURITAS,,0378-5122,10.1016/j.maturitas.2009.02.010,,"Objectives: Obesity is currently a major public health concern; however, there is little data available on the prevalence and impact of obesity within the elderly population. This review examines the prevalence and health effects of obesity among individuals aged >= 50. Methods: PubMed (1996-2008) and PsychInfo (2002-2008) search engines were used to retrieve qualified peer-reviewed articles focusing on obesity or a health condition correlated with obesity using BMI or other weight index as a defining variable; and studies limited to the elderly (age 60+) or pre-elderly (50+). Results: Worldwide, the elderly Population is increasingly becoming obese regardless of socio-economic status. Among elderly persons, obesity increases the risks for a variety of morbidity conditions including cancers, diabetes, hypertension, stroke, heart disease, metabolic syndrome, obstructive sleep apnea syndrome, osteoarthritis, depression, disability, and lower scores on quality of life measures. In some reports, obesity has been linked to Alzheimer's disease and other forms of cognitive decline. Obesity significantly increases healthcare costs and nursing homes are currently ill equipped to address the needs of the rising number of obese residents. Conclusions: Obesity is increasing in the elderly Population worldwide and is expected to continue to rise. Obesity is associated with disease and disability in addition to escalating healthcare costs, and hospitals and nursing homes are ill equipped to serve the obese elderly. It is imperative that research efforts and funding be devoted to studying the effects and the reduction of obesity in the elderly population. (C) 2009 Elsevier Ireland Ltd. All rights reserved.",20/05/2009,01/07/2022 10:40,01/07/2022 10:40,,07-Dec,,1,63,,,,,,,,,,,,,,WOS:000267462300003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D3PTRLDJ,journalArticle,2019,"Siwek, M; Wasik, A; Krupa, A",Agomelatine - pharmacological properties and use in psychiatric practice,PSYCHIATRIA I PSYCHOLOGIA KLINICZNA-JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY,,1644-6313,10.15557/PiPK.2019.0019,,"Although a plethora of studies have been conducted and guidelines for clinical practice have been delineated and are conscientiously implemented, the outcomes of depression treatment still do not meet the expectations. Only 60-70% of patients respond to treatment and 30% achieve remission after the first course of antidepressant pharmacotherapy. Others remain fraught with residual symptoms and, as a result, aren't able to reach their optimal level of occupational, family and social functioning, and the overall quality of life. The adverse effects of antidepressant treatment, which diminish patients' adherence, are an another troublesome issue. This leads to a search of new antidepressant drugs, not only efficacious in relieving depression symptoms, but also well tolerated. Agomelatine was first registered as an antidepressant in Europe in 2009. It has a distinct mechanism of action (5-TH2C antagonism and MT1, MT2 agonism) and an extraordinary treatment tolerance. Furthermore, the profile of adverse effects differs from selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. This raises hope that agomelatine will help improve the results of mood disorders treatment. Numerous studies, both observational and clinical, have compared agomelatine to placebo and other antidepressants proving its efficacy in reducing depressive symptoms, especially anhedonia, the co-occurring anxiety and sleep difficulties. Agomelatine is efficient in treatment of depression comorbid with somatic disease (type 2 diabetes, chronic kidney disease, Parkinson's disease and cardiovascular conditions). Although sparse, there is data suggesting that agomelatine is useful in the treatment of depressive episodes in bipolar and seasonal affective disorder, anxiety disorders, fibromyalgia and migraine.",2019,01/07/2022 10:40,01/07/2022 10:40,,188-203,,2,19,,,,,,,,,,,,,,WOS:000475435300008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66CT8F7B,journalArticle,2014,"Ades, PA; Savage, PD",Potential Benefits of Weight Loss in Coronary Heart Disease,PROGRESS IN CARDIOVASCULAR DISEASES,,0033-0620,10.1016/j.pcad.2013.09.009,,"The prevalence of overweight, obesity and insulin resistance in patients with coronary heart disease (CHD) exceeds that of the general population. Obesity is associated with a constellation of coronary risk factors that predispose to the development and progression of CHD. Intentional weight loss, accomplished through behavioral weight loss and exercise, improves insulin sensitivity and associated cardio-metabolic risk factors such as lipid measures, blood pressure, measures of inflammation and vascular function both in healthy individuals and patients with CHD. Additionally, physical fitness, physical function and quality of life all improve. There is evidence that intentional weight loss prevents the onset of CHD in high risk overweight individuals. While weight loss associated improvements in insulin resistance, fitness and related risk factors strongly supports favorable prognostic effects in individuals with established CHD, further study is needed to determine if long-term clinical outcomes are improved. (C) 2014 Elsevier Inc. All rights reserved.",2014-01,01/07/2022 10:40,01/07/2022 10:40,,448-456,,4,56,,,,,,,,,,,,,,WOS:000330255900011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3XFTBBDN,journalArticle,2007,"Gilron, I",Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions,CURRENT OPINION IN ANESTHESIOLOGY,,0952-7907,10.1097/ACO.0b013e3282effaa7,,"Purpose of review Gabapentin and pregabalin bind to the alpha-2-delta calcium channel subunit and represent a novel analgesic drug class. The evidence base supporting their use for chronic neuropathic and early postsurgical pain is reviewed. Recent findings Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain. Treatment-related improvement of pain and sleep positively impact upon quality of life. Sedation, dizziness and ataxia are important and relatively common adverse effects, however. Accumulating evidence indicates that gabapentin, and possibly pregabalin, also exert important effects following surgery. Multiple high-quality trials have demonstrated analgesic and opioid-sparing efficacy with gabapentin following various surgical procedures. Gabapentin and pregabalin reduce movement-evoked pain and this can lead to enhanced functional postoperative recovery. Postoperative opioid sparing is of questionable relevance since few trials have shown reduced opioid-related adverse effects. Sedation, dizziness and ataxia have been reported in only a few trials. Future larger-scale perioperative trials focused on safety assessment are needed, however. Summary Gabapentin and pregabalin are efficacious treatments for neuropathic and postsurgical pain. Future research addressing several specific questions would serve to better delineate their optimal roles in treating these and other pain conditions.",2007-10,01/07/2022 10:40,01/07/2022 10:40,,456-472,,5,20,,,,,,,,,,,,,,WOS:000209632800009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QU9MLMWB,journalArticle,2018,"Roumie, CL; Patel, NJ; Munoz, D; Bachmann, J; Stahl, A; Case, R; Leak, C; Rothman, R; Kripalani, S",Design and outcomes of the Patient Centered Outcomes Research Institute coronary heart disease cohort study,CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS,,2451-8654,10.1016/j.conctc.2018.03.001,,"Background: The Patient Centered Outcomes Research Institute (PCORI) established Clinical Data Research Networks (CDRNs) to support pragmatic research. The objective was to electronically identify, recruit, and survey coronary heart disease (CHD) patients and describe their characteristics, health status, and willingness to participate in future research. Methods: We developed a computable phenotype and assembled CHD patients 30 years or older and had visits or hospitalizations between 2009 and 2015. A sample of patients was surveyed between August 2014 and September 2015. Survey administration included the following methods: face-to-face, telephone, paper or web portal. Survey items covered broad domains including: health literacy and numeracy, and socio-demographics, physical and mental health, health behaviors, access to medical care, and willingness to participate in future research. Results: Of 5517 approached patients, 2605 completed the survey. Participants were mostly white (similar to 88%), male (68%) and had a median age of 69 years (interquartile range [IQR] 61-76 years). Most respondents' health literacy and numeracy were adequate (83.2% and 84.3%, respectively). Only 4% of respondents reported that their overall health or physical health was excellent. The majority (similar to 58%) reported that their health was good or very good, while 40% reported that their general and physical health were fair or poor. The majority reported that their quality of life was good to excellent (81%). Limitations in physical health and function were common, including often/always having fatigue (25%), pain (38.7%), or sleep difficulty (19.7%). A patient sample (n = 1936) was provided with a trial summary which would randomize their aspirin dose; and 63% reported that they would consider participating. Conclusion: Many patients with CHD had limitations in physical health. However, the majority reported a good or excellent quality of life.",2018-06,01/07/2022 10:40,01/07/2022 10:40,,42-49,,,10,,,,,,,,,,,,,,WOS:000433315000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2I8W3UIM,journalArticle,2010,"Goldberg, E; Beitz, JM",The Lived Experience of Diverse Elders With Chronic Wounds,OSTOMY WOUND MANAGEMENT,,0889-5899,,,"A previous study described the phenomenon of 16 financially stable Caucasian elders living with a chronic wound The purpose of this study was to extend this research and describe the phenomenon of living with a chronic nonhealing wound in elders of color and in financially fragile circumstances A purposive sample of 11 elders (nine older than and two disabled persons younger than 65 years of age) was selected who met the following inclusion criteria having a chronic nonhealing wound present longer than 8 weeks, absence of mental health issues or cognitive deficits, able to communicate in English, and being from a diverse racial/ethnic background (not Caucasian) Seven male and four female elders were interviewed Interviews were tape recorded and transcribed Using phenomenological analysis, the researchers derived 10 themes and 24 associated subthemes incorporating physiological, psychological, and social concerns Diverse elders had some experiences in common with Caucasian elders - notably, tolerating pain, missing normal mobility, living with chronic illness, and explaining causes of wounds They also had different experiences including encountering losses, considering costs (both emotional and financial), and changed social roles Unlike wealthier white elders, the diverse elders did not describe distrust of caregivers or altered sleeping or eating patterns The results of this study provide a window on the lived experience of having a chronic wound",2010-11,01/07/2022 10:40,01/07/2022 10:40,,36-+,,11,56,,,,,,,,,,,,,,WOS:000285078600009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NTNGK5SL,journalArticle,2020,"Rozich, JJ; Holmer, A; Singh, S",Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases,AMERICAN JOURNAL OF GASTROENTEROLOGY,,0002-9270,10.14309/ajg.0000000000000608,,"Various lifestyle factors including physical activity and obesity, stress, sleep, and smoking may modify the risk of developing inflammatory bowel diseases (IBDs). In patients with established IBD, these lifestyle factors may significantly impact the natural history and clinical outcomes. Recreational exercise decreases the risk of flare and fatigue in patients with IBD. In contrast, obesity increases the risk of relapse and is associated with higher anxiety, depression, fatigue, and pain and higher health care utilization. Obesity also modifies pharmacokinetics of biologic agents unfavorably and is associated with a higher risk of treatment failure. Sleep disturbance is highly prevalent in patients with IBD, independent of disease activity, and increases the risk of relapse and chronic fatigue. Similarly, stress, particularly perceived stress rather than major life events, may trigger symptomatic flare in patients with IBD, although its impact on inflammation is unclear. Cigarette smoking is associated with unfavorable outcomes including the risk of corticosteroid dependence, surgery, and disease progression in patients with Crohn's disease; in contrast, smoking does not significantly impact outcomes in patients with ulcerative colitis, although some studies suggest that it may be associated with a lower risk of flare. The effect of alcohol and cannabis use in patients with IBD is inconsistent, with some studies suggesting that cannabis may decrease chronic pain in patients with IBD, without a significant effect of biological remission. Although these lifestyle factors are potentially modifiable, only a few interventional studies have been conducted. Trials of structured exercise and psychological therapy including mindfulness-based therapies such as meditation and yoga and gut-directed hypnotherapy have not consistently demonstrated benefit in clinical and/or endoscopic disease activity in IBD, although may improve overall quality of life.",2020-06,01/07/2022 10:40,01/07/2022 10:40,,832-840,,6,115,,,,,,,,,,,,,,WOS:000552998400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5Y4253TU,journalArticle,2021,"Kurlawala, Z; Shadowen, PH; McMillan, JD; Beverly, LJ; Friedland, RP",Progression of Nonmotor Symptoms in Parkinson's Disease by Sex and Motor Laterality,PARKINSONS DISEASE,,2090-8083,10.1155/2021/8898887,,"Nonmotor symptoms (NMS) in Parkinson's disease (PD) can start up to a decade before motor manifestations and strongly correlate with the quality of life. Understanding patterns of NMS can provide clues to the incipient site of PD pathology. Our goal was to systematically characterize the progression of NMS in PD (n = 489), compared to healthy controls, HC (n = 241), based on the sex of the subjects and laterality of motor symptom onset. Additionally, NMS experienced at the onset of PD were also compared to subjects with scans without dopaminergic deficit, SWEDD (n = 81). The Parkinson's Progression Markers Initiative (PPMI) database was utilized to analyze several NMS scales. NMS experienced by PD and SWEDD cohorts were significantly higher than HC and both sex and laterality influenced several NMS scales at the onset of motor symptoms. Sex Differences. PD males experienced significant worsening of sexual, urinary, sleep, and cognitive functions compared to PD females. PD females reported significantly increased thermoregulatory dysfunction and anxious mood over 7 years and significantly more constipation during the first 4 years after PD onset. Laterality Differences. At onset, PD subjects with right-sided motor predominance reported significantly higher autonomic dysfunction. Subjects with left-sided motor predominance experienced significantly more anxious mood at onset which continued as Parkinson's progressed. In conclusion, males experienced increased NMS burden in Parkinson's disease. Laterality of motor symptoms did not significantly influence NMS progression, except anxious mood. We analyzed NMS in a large cohort of PD patients, and these data are valuable to improve PD patients' quality of life by therapeutically alleviating nonmotor symptoms.",02/04/2021,01/07/2022 10:40,01/07/2022 10:40,,,,,2021,,,,,,,,,,,,,,WOS:000640313400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3KUUTZIV,journalArticle,2017,"Nelson, RJ; DeVries, AC",Medical hypothesis: Light at night is a factor worth considering in critical care units,ADVANCES IN INTEGRATIVE MEDICINE,,2212-9588,10.1016/j.aimed.2017.12.001,,"Exposure to light at night is not an innocuous consequence of modernization. There are compelling data linking long-term exposure to occupational and environmental light at night with serious health conditions, including heart disease, obesity, diabetes, and cancer. However, far less is known about the physiological and behavioral effects of acute exposure to light at night. Among healthy volunteers, acute night-time light exposure increases systolic blood pressure and inflammatory markers in the blood, and impairs glucose regulation. Whether critically ill patients in a hospital setting experience the same physiological shifts in response to evening light exposure is not known. This paper reviews the available data on light at night effects on health and wellbeing, and argues that the data are sufficiently compelling to warrant studies of how lighting in intensive care units may be influencing patient recovery. (C) 2017 Published by Elsevier Ltd.",2017-12,01/07/2022 10:40,01/07/2022 10:40,,115-120,,3,4,,,,,,,,,,,,,,WOS:000428127300007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TUQT9FUD,journalArticle,2015,"Andersen, J; Gjengedal, E; Sandberg, S; Raheim, M","A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda",BRITISH JOURNAL OF DERMATOLOGY,,0007-0963,10.1111/bjd.13198,,"BackgroundPorphyria cutanea tarda (PCT) is characterized by fragile skin with blistering on sun-exposed areas. Symptoms typically develop in late adulthood and can be triggered by iron overload, alcohol intake, oestrogens and various liver diseases. Treatment consists of phlebotomy to reduce iron, or increasing urinary porphyrin excretion by administering chlorochin. To optimize patient care, health personnel need to understand the subjective experiences of PCT. ObjectivesTo explore the experiences of persons with PCT with regard to symptoms, treatment, follow-up and prevention of the disease. MethodsInterpretive description was used as a qualitative approach. Twenty-one participants attended three focus groups. All participants had experienced PCT symptoms during the last 5years. ResultsParticipants' experiences varied from trivializing symptoms and fragile skin to what was described as a desperate situation, with huge blisters, skin falling off and feeling as if one was in a horror movie'. For some, itching was very troublesome, preventing sleep and delaying skin healing. In managing PCT a shift in focus from skin to blood was described. PCT was perceived as a chronic and systemic disease causing a range of health problems. Strategies for preventing symptoms ranged from doing nothing to frequent controls and check-ups. ConclusionsParticipants had a systemic perception of PCT, and a tendency to attribute a range of health problems to the condition. This study adds insight into the experiences patients have with PCT.",2015-01,01/07/2022 10:40,01/07/2022 10:40,,223-229,,1,172,,,,,,,,,,,,,,WOS:000347726500033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FYI2BFIQ,journalArticle,1995,"WISE, TN",CONSULTATION-LIAISON RESEARCH - THE USE OF DIFFERING PERSPECTIVES,PSYCHOTHERAPY AND PSYCHOSOMATICS,,0033-3190,10.1159/000288932,,"Slavney and McHugh have discussed the four perspectives in psychiatry in respect to their strengths and weaknesses. Research in consultation-liaison psychiatry is reviewed by considering the various perspectives that such studies utilize. Early studies utilized the life story methodology and the disease model. The life history approach considers each patient as a unique subject whose developmental vicissitudes have meaningful associations. These studies were often viewed through a psychoanalytic theory. The disease model demands syndromal identification so that etiologic factors, whether biological, psychological or social, may eventually be discovered. More contemporary investigations use the dimensional measurement of intersubject differences that allow better designation of personality. The fourth perspective of motivated behavior offers a method of studying goal-directed activity such as substance abuse, eating pathology, and sleep disorders. Consultation-liaison studies using each framework are reviewed.",1995,01/07/2022 10:40,01/07/2022 10:40,,Sep-21,,1,63,,,,,,,,,,,,,,WOS:A1995QH72900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3JSASUCI,journalArticle,2020,"Mathur, K; Vuppalanchi, V; Gelow, K; Vuppalanchi, R; Lammert, C",Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis,DIGESTIVE DISEASES AND SCIENCES,,0163-2116,10.1007/s10620-019-05756-7,,"Background and Aims Utilization and safety of cannabidiol (CBD) in patients with autoimmune hepatitis (AIH) are currently unknown. We aimed to identify the frequency of CBD use, impact on symptoms, and safety profile. Methods An invitation to complete a CBD-specific questionnaire was posted every other day to well-established autoimmune hepatitis Facebook communities (combined membership of 2600 individuals) during a 10-day study period. Age >= 18 years and an AIH diagnosis by a physician were the eligibility criteria for participation in the survey. Results In total, 371 AIH patients (median age 49 years, 32% reported advanced fibrosis) completed the questionnaire. Respondents were 91% women, 89% Caucasian, and 89% from North America. Ninety-three (25%) respondents were ever CBD users, with 55 of them (15% of the survey responders) identified as current users. Among ever users, 45.7% reported their treating doctors were aware of their CBD use. The most common reason cited for CBD use was pain (68%), poor sleep (62%), and fatigue (38%). Most respondents using CBD for these symptoms reported a significant improvement in pain (82%), sleep (87%), and fatigue (61%). In ever CBD users, 17.3% were able to stop a prescription medication because of CBD use: pain medication (47%), immunosuppression (24%), and sleep aids (12%). Side effects attributed to CBD use were reported in 3% of CBD users, yet there were no reported emergency department visits or hospitalizations. Conclusion CBD use was not uncommon in patients with AIH, and its use was associated with reports of improvement in extrahepatic symptoms.",2020-01,01/07/2022 10:40,01/07/2022 10:40,,322-328,,1,65,,,,,,,,,,,,,,WOS:000511968600040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7DA89ITN,journalArticle,2019,"Yaffe, K; Barnes, DE; Rosenberg, D; Dublin, S; Kaup, AR; Ludman, EJ; Vittinghoff, E; Peltz, CB; Renz, AD; Adams, KJ; Larson, EB",Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol,JOURNAL OF ALZHEIMERS DISEASE,,1387-2877,10.3233/JAD-180634,,"This article describes the protocol for the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT), a single-blind randomized pilot trial to test a personalized, pragmatic, multi-domain Alzheimer's disease (AD) risk reduction intervention in a US integrated healthcare delivery system. Study participants will be 200 higher-risk older adults (age 70-89 years with subjective cognitive complaints, low normal performance on cognitive screen, and >= two modifiable risk factors targeted by our intervention) who will be recruited from selected primary care clinics of Kaiser Permanente Washington, oversampling people with non-white race or Hispanic ethnicity. Study participants will be randomly assigned to a two-year Alzheimer's risk reduction intervention (SMARRT) or a Health Education (HE) control. Randomization will be stratified by clinic, race/ethnicity (non-Hispanic white versus non-white or Hispanic), and age (70-79, 80-89). Participants randomized to the SMARRT group will work with a behavioral coach and nurse to develop a personalized plan related to their risk factors (poorly controlled hypertension, diabetes with evidence of hyper or hypoglycemia, depressive symptoms, poor sleep quality, contraindicated medications, physical inactivity, low cognitive stimulation, social isolation, poor diet, smoking). Participants in the HE control group will be mailed general health education information about these risk factors for AD. The primary outcome is two-year cognitive change on a cognitive test composite score. Secondary outcomes include: 1) improvement in targeted risk factors, 2) individual cognitive domain composite scores, 3) physical performance, 4) functional ability, 5) quality of life, and 6) incidence of mild cognitive impairment, AD, and dementia. Primary and secondary outcomes will be assessed in both groups at baseline and 6, 12, 18, and 24 months.",2019,01/07/2022 10:40,01/07/2022 10:40,,S207-S220,,,70,,,,,,,,,,,,,,WOS:000481670800016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
V5J3PDVS,journalArticle,2016,"Koebele, SV; Bimonte-Nelson, HA",Modeling menopause: The utility of rodents in translational behavioral endocrinology research,MATURITAS,,0378-5122,10.1016/j.maturitas.2016.01.015,,"The human menopause transition and aging are each associated with an increase in a variety of health risk factors including, but not limited to, cardiovascular disease, osteoporosis, cancer, diabetes, stroke, sexual dysfunction, affective disorders, sleep disturbances, and cognitive decline. It is challenging to systematically evaluate the biological underpinnings associated with the menopause transition in the human population. For this reason, rodent models have been invaluable tools for studying the impact of gonadal hormone fluctuations and eventual decline on a variety of body systems. While it is essential to keep in mind that some of the mechanisms associated with aging and the transition into a reproductively senescent state can differ when translating from one species to another, animal models provide researchers with opportunities to gain a fundamental understanding of the key elements underlying reproduction and aging processes, paving the way to explore novel pathways for intervention associated with known health risks. Here, we discuss the utility of several rodent models used in the laboratory for translational menopause research, examining the benefits and drawbacks in helping us to better understand aging and the menopause transition in women. The rodent models discussed are ovary-intact, ovariectomy, and 4-vinylcylohexene diepoxide for the menopause transition. We then describe how these models may be implemented in the laboratory, particularly in the context of cognition. Ultimately, we aim to use these animal models to elucidate novel perspectives and interventions for maintaining a high quality of life in women, and to potentially prevent or postpone the onset of negative health consequences associated with these significant life changes during aging. (C) 2016 Elsevier Ireland Ltd. All rights reserved.",2016-05,01/07/2022 10:40,01/07/2022 10:40,,May-17,,,87,,,,,,,,,,,,,,WOS:000374606600003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YNJWL7VS,journalArticle,2012,"Jermendy, G; Nadas, J; Hegyi, I; Vasas, I; Hidvegi, T",Assessment of cardiometabolic risk among shift workers in Hungary,HEALTH AND QUALITY OF LIFE OUTCOMES,,1477-7525,10.1186/1477-7525-10-18,,"Aim: Shift workers may be at risk of different diseases. In order to assess cardiometabolic risk in shift workers, a cross-sectional study was performed among active workers. Methods: A total of 481 workers (121 men, 360 women) were investigated; most of them were employees in light industry (58.2%) or in public services (23.9%). Past medical history was recorded and physical examination was performed. Questionnaires were used to characterize daily activity. Fasting venous blood sample was collected for measuring laboratory parameters. Data from shift workers (n = 234, age: 43.9 +/- 8.1 years) were compared to those of daytime workers (n = 247, age: 42.8 +/- 8.5 years), men and women were analyzed separately. Results: In men, systolic blood pressure was higher in shift workers compared to daytime workers (133 +/- 8 vs 126 +/- 17 mmHg; p < 0.05). In women, weight (73.6 +/- 15.5 vs 67.7 +/- 13.2 kg; p < 0.001), body mass index (27.5 +/- 5.7 vs 25.0 +/- 4.3 kg/m(2); p < 0.001) and the prevalence rate of hypertension in the past medical history (24.4 vs 13.4%; p < 0.01) were higher in shift workers compared to daytime workers. In addition, the proportion of current smokers was higher (37.7 vs 21.7%; p < 0.001) and HDL-cholesterol level was lower (1.56 +/- 0.32 vs 1.68 +/- 0.36 mmol/l; p < 0.01) in female shift workers than in female daytime workers. Both in men and in women, rotating shift workers spent less time sleeping both on working days and on non-working days, spent less time with sport activity, drank more coffee and they spent less time working per day, especially in light physical work, compared to daytime workers. In addition, low and middle educational levels were most frequently found among rotating shift workers as opposed to the daytime workers where high educational level was more common. Conclusion: Middle-aged active shift workers, especially women, have a less healthy lifestyle and are at higher cardiometabolic risk as compared to daytime workers. Our study highlights the importance of measures for identifying and preventing cardiometabolic risk factors in shift workers.",01/02/2012,01/07/2022 10:40,01/07/2022 10:40,,,,,10,,,,,,,,,,,,,,WOS:000302066900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DRJMRBMA,bookSection,2013,"Allgulander, C; Baldwin, DS",Pharmacotherapy of Generalized Anxiety Disorder,ANXIETY DISORDERS,1662-2685,,,,"Generalized anxiety disorder (GAD) is chiefly characterized by a cognitive focus on threats and risks towards the individual and/or the immediate family. It is accompanied by a sense of tension, worry, muscle pain, disturbed sleep and irritability. The condition impairs work capacity, relations, and leisure activities, and aggravates concurrent somatic diseases. Due to its chronic course, GAD increases costs for the individual, the family, and health care services, and reduces work and educational performance. In cardiovascular or cerebrovascular disease, pulmonary disease, diabetes and neurological diseases, GAD is a risk factor for somatic complications and for lowered adherence to somatic treatments. There is evidence that GAD can be treated with cognitive behavioural therapy (CBT), and/or with medications. First-line pharmacotherapies are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and pregabalin. If such therapies fail, one may reconsider the diagnosis, question adherence with the prescribed schedule, and determine the adverse influence of comorbidity (such as depression, substance use, and physical ill-health) as well as the influence of social stressors. Second-line pharmacotherapies are largely not supported by controlled trials, and so leave much to clinical judgment and careful monitoring. One may attempt treatments with benzodiazepine anxiolytics, with quetiapine, or with pregabalin as an adjunct therapy in patients with partial response to SSRI or SNRI treatment. CBT is a valid alternative to pharmacotherapy, depending on patient preference. Copyright (C) 2013 S. Karger AG, Basel",2013,01/07/2022 10:40,01/07/2022 10:40,,119-127,,,29,,,,,,,,,,,,,,WOS:000388841200010,,,DOI: 10.1159/000351955,,,,,,"Baldwin, DS; Leonard, BE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I45NZHAV,journalArticle,2011,"Higa, K; Ho, TC; Tercero, F; Yunus, T; Boone, KB",Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up,SURGERY FOR OBESITY AND RELATED DISEASES,,1550-7289,10.1016/j.soard.2010.10.019,,"Background: The short-term benefits of bariatric surgery are well documented; however, few reports with data beyond 10 years exist. Those that have been published have described only open procedures. We present our 10-year follow-up results with laparoscopic Roux-en-Y gastric bypass with hand-sewn gastrojejunal anastomosis in a group private practice. Methods: We performed an institutional review board-approved retrospective review of a prospectively maintained database, combined with office visits and telephone questionnaires, for patients who underwent laparoscopic Roux-en-Y gastric bypass between February 1998 and April 1999. Results: A total of 242 patients underwent surgery from February 1998 to April 1999. The office follow-up rate was 33% at 2 years and 7% at 10 years. An additional 19% had telephone follow-up at 10 years. The mean excess weight loss was 57% at 10 years. Of the 242 patients, 65(33.2%) failed to achieve an excess weight loss of > 50%; 86 (35%) had >= 1 complication during follow-up. However, 83%, 87%, 67%, and 76% of patients with diabetes, hypertension, dyslipidemia, and obstructive sleep apnea, respectively, experienced improvement or resolution. The internal hernia rate was 16%, and the gastrojejunal stenosis rate was 4.9%. No surgery-related deaths occurred. Of the 242 patients, 136 (51%) had nutritional testing at least once after postoperative year 1. Of these 136 patients, only 24 (18%) had remained nutritionally intact during follow-up. Conclusion: The obstacles to follow-up have continued to impede the collection of accurate long-term data. Of the 26% of patients with data, laparoscopic Roux-en-Y gastric bypass provided sustainable weight loss and resolution of co-morbidities. However, nutritional deficiencies presented sporadically over time and underscore the importance of routine testing. (Surg Obes Relat Dis 2011; 7:516-525.) (C) 2011 American Society for Metabolic and Bariatric Surgery. All rights reserved.",2011-07,01/07/2022 10:40,01/07/2022 10:40,,516-525,,4,7,,,,,,,,,,,,,,WOS:000294196300014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6FQBYIBJ,journalArticle,2015,"Ambrose, KR; Golightly, YM",Physical exercise as non-pharmacological treatment of chronic pain: Why and when,BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY,,1521-6942,10.1016/j.berh.2015.04.022,,"Chronic pain broadly encompasses both objectively defined conditions and idiopathic conditions that lack physical findings. Despite variance in origin or pathogenesis, these conditions are similarly characterized by chronic pain, poor physical function, mobility limitations, depression, anxiety, and sleep disturbance, and they are treated alone or in combination by pharmacologic and non-pharmacologic approaches, such as physical activity (aerobic conditioning, muscle strengthening, flexibility training, and movement therapies). Physical activity improves general health, disease risk, and progression of chronic illnesses such as cardiovascular disease, type 2 diabetes, and obesity. When applied to chronic pain conditions within appropriate parameters (frequency, duration, and intensity), physical activity significantly improves pain and related symptoms. For chronic pain, strict guidelines for physical activity are lacking, but frequent movement is preferable to sedentary behavior. This gives considerable freedom in prescribing physical activity treatments, which are most successful when tailored individually, progressed slowly, and account for physical limitations, psychosocial needs, and available resources. (C) 2015 Elsevier Ltd. All rights reserved.",2015-02,01/07/2022 10:40,01/07/2022 10:40,,120-130,,1,29,,,,,,,,,,,,,,WOS:000360419500013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SEH36XI4,journalArticle,2014,"Zoli, M; Mazzatenta, D; Valluzzi, A; Marucci, G; Acciarri, N; Pasquini, E; Frank, G",Expanding indications for the extended endoscopic endonasal approach to hypothalamic gliomas: preliminary report,NEUROSURGICAL FOCUS,,1092-0684,10.3171/2014.7.FOCUS14317,,"Object. In the last decade the indications for the endoscopic endonasal approach have been progressively expanded to include lesions that have not been traditionally considered amenable to resection through the transsphenoidal route. In this study, the authors analyze their experience with hypothalamic gliomas treated via the endoscopic endonasal approach. Methods. Consecutive cases of hypothalamic gliomas treated since 2007 via an endoscopic endonasal approach were reviewed. Preoperative and postoperative neuroimaging as well as endocrinological, neurological, and visual symptoms were analyzed to assess the surgical outcome. Signs and symptoms of hypothalamic dysfunction including body mass index (BMI), memory, sleep-wake rhythm, and polyphagia were prospectively collected pre-and post-operatively to assess hypothalamic function. Quality of life was evaluated using the Katz scale. Results. In the initial phase the endoscopic endonasal approach was adopted in 3 cases with a palliative intent, to obtain a biopsy sample or for debulking of the mass followed by radio-or chemotherapy. In 2 later cases it was successfully adopted to achieve gross-total tumor resection. Complications consisted of 2 postoperative CSF leaks, which required an endoscopic endonasal reintervention. Visual deficit improved in 3 cases and normalized in the other 2. Four patients developed diabetes insipidus, and 3 an anterior panhypopituitarism. All patients had a moderate increase in BMI. No patients presented with any other signs of hypothalamic damage, and their quality of life at follow-up is normal. Conclusions. Despite the limitations of a short follow-up and small sample, the authors' early experience with the endoscopic endonasal approach has revealed it to be a direct, straightforward, and safe approach to third ventricle astrocytomas. It allowed the authors to perform tumor resection with the same microsurgical technique: dissecting the tumor with 2 hands, performing a central debulking, and controlling the bleeding with bipolar coagulation. The main limitations were represented by some anatomical conditions, such as the position of the chiasm and the anterior communicating artery complex and, finally, by the challenge of watertight plastic repair. To definitively evaluate the role of this approach in hypothalamic gliomas, a comparison with transcranial series would be necessary, but due to the rarity of these cases such a study is still lacking. The authors observed that more aggressive surgery is associated with a worse endocrinological outcome; thus they consider it to be an open question (in particular in prepubertal patients)",2014-10,01/07/2022 10:40,01/07/2022 10:40,,,,4,37,,,,,,,,,,,,,,WOS:000343230900012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ACIPNKJR,journalArticle,2017,"Lai, HH; Jemielita, T; Sutcliffe, S; Bradley, CS; Naliboff, B; Williams, DA; Gereau, RW; Kreder, K; Clemens, JQ; Rodriguez, LV; Krieger, JN; Farrar, JT; Robinson, N; Landis, JR; MAPP Res Network",Characterization of Whole Body Pain in Urological Chronic Pelvic Pain Syndrome at Baseline: A MAPP Research Network Study,JOURNAL OF UROLOGY,,0022-5347,10.1016/j.juro.2017.03.132,,"Purpose: We characterized the location and spatial distribution of whole body pain in patients with urological chronic pelvic pain syndrome using a body map. We also compared the severit y of urinary symptoms, pelvic pain, nonpelvic pain and psychosocial health among patients with different pain patterns. Materials and Methods: A total of 233 women and 191 men with urological chronic pelvic pain syndrome enrolled in a multicenter, 1-year observational study completed a battery of baseline measures, including a body map describing the location of pain during the last week. Participants were categorized with pelvic pain if they reported pain in the abdomen and pelvis only. Participants who reported pain beyond the pelvis were further divided into 2 subgroups based on the number of broader body regions affected by pain, including an intermediate group with 1 or 2 additional regions outside the pelvis and a widespread pain group with 3 to 7 additional regions. Results: Of the 424 enrolled patients 25% reported pelvic pain only and 75% reported pain beyond the pelvis, of whom 38% reported widespread pain. Participants with a greater number of pain locations had greater nonpelvic pain severity (p < 0.0001), sleep disturbance (p = 0.035), depression (p = 0.005), anxiety (p = 0.011), psychological stress (p = 0.005) and negative affect scores (p = 0.0004), and worse quality of life (p <= 0.021). No difference in pelvic pain and urinary symptom severity was observed according to increasing pain distribution. Conclusions: Three-quarters of the men and women with urological chronic pelvic pain syndrome reported pain outside the pelvis. Widespread pain was associated with greater severity of nonpelvic pain symptoms, poorer psychosocial health and worse quality of life but not with worse pelvic pain or urinary symptoms.",2017-09,01/07/2022 10:40,01/07/2022 10:40,,622-631,,3,198,,,,,,,,,,,,,,WOS:000407448300090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
T9XD72R5,journalArticle,2003,"Rowbotham, MC; Twilling, L; Davies, PS; Reisner, L; Taylor, K; Mohr, D",Oral opioid therapy for chronic peripheral and central neuropathic pain,NEW ENGLAND JOURNAL OF MEDICINE,,0028-4793,10.1056/NEJMoa021420,,"BACKGROUND: Although opioids are commonly used to treat chronic neuropathic pain, there are limited data to guide their use. Few controlled trials have been performed, and many types of neuropathic pain remain unstudied. METHODS: Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0.75-mg) or low-strength (0.15-mg) capsules of the potent (mu)-opioid agonist levorphanol for eight weeks under double-blind conditions. Intake was titrated by the patient to a maximum of 21 capsules of either strength per day. Outcome measures included the intensity of pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitive function, the number of capsules taken daily, and blood levorphanol levels. RESULTS: Among the 81 patients exposed to the study drug, high-strength levorphanol capsules reduced pain by 36 percent, as compared with a 21 percent reduction in pain in the low-strength group (P=0.02). On average, patients in the high-strength group took 11.9 capsules per day (8.9 mg per day) and patients in the low-strength group took close to the 21 allowed (18.3 capsules per day; 2.7 mg per day). Affective distress and interference with functioning were reduced, and sleep was improved, but there were no differences between the high-strength group and the low-strength group in terms of these variables. Noncompletion of the study was primarily due to side effects of the opioid. Patients with central pain after stroke were the least likely to report benefit. CONCLUSIONS: The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses. Higher doses produced more side effects without significant additional benefit in terms of other outcome measures.",27/03/2003,01/07/2022 10:40,01/07/2022 10:40,,1223-1232,,13,348,,,,,,,,,,,,,,WOS:000181790800004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
36DQEHCE,bookSection,2006,"Vadalouca, A; Siafaka, I; Argyra, E; Vrachnou, E; Moka, E",Therapeutic management of chronic neuropathic pain - An examination of pharmacologic treatment,NEUROENDOCRINE AND IMMUNE CROSSTALK,0077-8923,,,,"Neuropathic pain is defined as pain caused by a lesion in the nervous system and is common in clinical practice. Diagnosis can be difficult. Recommendations for first-line pharmacologic treatments are based on positive results from multiple, randomized, controlled trials, and recommendations for second-line pharmacologic treatments are based on the positive result of a single, randomized, controlled trial or inconsistent results of multiple, randomized, controlled trials. The results of published trials and clinical experience provide the foundation for specific recommendations for first-line treatments, which include gabapentin, 5% lidocaine patch, opioid analgesics, tramadol hydrochloride, and tricyclic antidepressants (TCAs). Gabapentin (up to 3,600 mg/day) significantly reduced pain compared with placebo; improvements in sleep, mood, and quality of life were also demonstrated. Adverse effects of gababentin include somnolence and dizziness, and, less commonly, gastrointestinal symptoms and mild peripheral edema. Thus, monitoring and dosage adjustment are required, without discontinuation of the drug. Gabapentin combined with morphine achieved better analgesia at lower doses of each drug than each drug alone, with only mild adverse effects. The first medication that proved effective for neuropathic pain in placebo-controlled trials was TCAs. Treatment decisions for patients with neuropathic pain can be difficult. Interest in the mechanisms and treatment of chronic neuropathic pain has increased during the past years, resulting in significant treatment advances in the future. In this article all recent knowledge on therapeutic management of chronic neuropathic pain is presented.",2006,01/07/2022 10:40,01/07/2022 10:40,,164-186,,,1088,,,,,,,,,,,,,,WOS:000244734200013,,,DOI: 10.1196/annals.1366.016,,,,,,"Chrousos, GP; Kaltsas, GA; Mastorakos, G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4UHMNNHJ,journalArticle,2011,"Donald, GK; Tobin, I; Stringer, J",Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy,ACUPUNCTURE IN MEDICINE,,0964-5284,10.1136/acupmed.2011.010025,,"Aim To clinically evaluate the effectiveness of acupuncture when used in the management of chemotherapy-induced peripheral neuropathy (PN). Background During cancer treatment, certain chemotherapies can cause varying degrees of PN. Patients' quality of life can be seriously impaired through loss of sensation, pain or mobility problems. Conventional medications routinely used to manage neuropathic symptoms have poor side-effect profiles and there is little or no evidence justifying their use to treat chemotherapy-related neurotoxicities. There are studies suggesting that acupuncture may be an effective therapy in treating PN across a number of different aetiologies. Design A retrospective service evaluation. Method Patients (n=18) were referred for acupuncture by the medical staff and/or nurse specialists or they self-referred for treatment. A course of six weekly acupuncture sessions was offered to them, and their details were recorded on an evaluation form prior to session one. Points were selected by acupuncturists, based on patient presentation, and needles remained in situ for 30-45 min. Treatments took place in outpatient clinics, chemotherapy day case ward or a drop-in clinic based in a physiotherapy gym. The evaluation form was completed at the end of session 6 by a therapist who had not been involved in patient care. Results 82% (n=14) of patients reported an improvement in symptoms following their course of acupuncture; one patient with advanced disease died during the 6 weeks. Some patients derived additional benefits from the treatment including a reduction in analgesic use and improved sleeping patterns. The most common acupoints used were SP6 (n=18), ST36 (n=18) and LV3 (n=14). Conclusion Although these results are encouraging, they are uncontrolled. They suggest that acupuncture could be an option for these patients and controlled trials using validated patient-reported outcome measures are justified.",2011-09,01/07/2022 10:40,01/07/2022 10:40,,230-233,,3,29,,,,,,,,,,,,,,WOS:000294326700013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LYHBA426,journalArticle,2018,"Kim, S; McMaster, M; Torres, S; Cox, KL; Lautenschlager, N; Rebok, GW; Pond, D; D'Este, C; McRae, I; Cherbuin, N; Anstey, KJ",Protocol for a pragmatic randomised controlled trial of Body Brain Life-General Practice and a Lifestyle Modification Programme to decrease dementia risk exposure in a primary care setting,BMJ OPEN,,2044-6055,10.1136/bmjopen-2017-019329,,"Introduction It has been estimated that a 10%-25% reduction in seven key risk factors could potentially prevent 1.1-3.0 million Alzheimer's disease cases globally. In addition, as dementia is preceded by more subtle cognitive deficits which have substantial social and economic impact, effective preventative interventions would likely have more extensive benefits. The current study evaluates in primary care a multidomain risk reduction intervention targeting adults with high risk of developing dementia. Methods and analysis A randomised controlled trial (RCT) is being conducted to evaluate three intervention programmes using a pragmatic approach suitable to the clinic: (1) a 12-week online and face-to-face dementia risk-reduction intervention (Body Brain Life-General Practice (BBL-GP)); (2) a 6-week face-to-face group lifestyle modification programme (LMP); and (3) a 12 week email-only programme providing general health information. We aim to recruit 240 participants, aged 18 and over, to undergo a comprehensive cognitive and physical assessment at baseline and follow-ups (postintervention, 18, 36 and 62 weeks). The primary outcome is dementia risk measured with the modified version of the Australian National University-Alzheimer's Disease Risk Index Short Form. Secondary outcomes are cognitive function measured with Trails A and B, and the Digit Symbol Modalities Test; physical activity with moderate-vigorous physical activity and the International Physical Activity Questionnaire; depression with the Centre for Epidemiological Studies Depression; cost evaluation with the 12-item Short Form Health Survey, Framingham Coronary Heart Disease Risk Score and Australian Type 2 Diabetes Risk Assessment Tool; diet quality with the Australian Recommended Food Score; and sleep quality with the Pittsburgh Sleep Quality Index. Ethics and dissemination This RCT is a novel pragmatic intervention applied in a primary care setting to reduce the dementia risk exposure in adults at high risk. If successful, BBL-GP and LMP will provide a versatile, evidence-based package that can be easily and quickly rolled out to other primary care settings and which can he scaled up at relatively low cost compared with other strategies involving intensive interventions.",2018-03,01/07/2022 10:40,01/07/2022 10:40,,,,3,8,,,,,,,,,,,,,,WOS:000433881200112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q2IIBH3X,journalArticle,2021,"Nash, Y; Sitty, M",Non-Motor Symptoms of Amyotrophic Lateral Sclerosis: A Multi-Faceted Disorder,JOURNAL OF NEUROMUSCULAR DISEASES,,2214-3599,10.3233/JND-210632,,"Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor pathways. A growing body of evidence from recent years suggests that ALS results in a wide range of non-motor symptoms as well, which can have a significant impact on patients' quality of life. These symptoms could also, in turn, provide useful information as biomarkers for disease progression, and can shed insight on ALS mechanisms. Here we aim to review a wide range of non-motor symptoms of ALS, with emphasis on their importance to research and clinical treatment of patients.",2021,01/07/2022 10:40,01/07/2022 10:40,,699-713,,4,8,,,,,,,,,,,,,,WOS:000680742800025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y3MNTX9U,journalArticle,2016,"Wong, JA; Quinn, FR; Gillis, AM; Burland, L; Chen, GM; Wyse, G; Wilton, SB",Temporal Patterns and Predictors of Rate vs Rhythm Control in Patients Attending a Multidisciplinary Atrial Fibrillation Clinic,CANADIAN JOURNAL OF CARDIOLOGY,,0828-282X,10.1016/j.cjca.2016.01.014,,"Background: Contemporary trends in the selection of and persistence with rate vs rhythm control for atrial fibrillation (AF) are not well studied, particularly in the context of multidisciplinary AF clinics. Methods: The initial arrhythmia management strategy in 1031 consecutive patients attending a multidisciplinary AF clinic from 20052012 was analyzed. Results: The 397 (38.5%) patients initially treated with rhythm control were younger (57.4 +/- 14 years vs 65.6 +/- 13 years; P < 0.0001) and more likely to be men (64.5% vs 56.9%; P = 0.019). They also had fewer comorbidities, lower CHADS(2) (Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack) scores, and greater symptom burden. The proportion treated with rhythm control declined from 46.9% in 2005-2006 to 28.4% in 2012 ( P for trend < 0.0001). Compared with those initially selecting rate control, patients treated with rhythm control required more frequent clinic encounters (7 [interquartile range {IQR}, 3-12] vs 3 [IQR, 2-7]; P < 0.001) and longer follow-up (266 days [IQR, 84-548 days] vs 99 days [IQR, 0-313 days]; P < 0.001). Younger age, absence of diabetes and sleep apnea, earlier treatment year, higher symptom burden, and rural residence were independently associated with rhythm control. Persistence with the initial treatment strategy was reduced in the rhythm-control group (P = 0.003). Conclusions: Use of rhythm control as the initial arrhythmia management strategy for AF in a specialty AF clinic is declining. Rhythm control requires more intensive follow-up and was more likely to lead to a change in arrhythmia management strategy.",2016-10,01/07/2022 10:40,01/07/2022 10:40,,,,10,32,,,,,,,,,,,,,,WOS:000388298100027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DHU8AYDS,journalArticle,2019,"Youssef, MK",Efficacy of neuromuscular electric stimulation versus aerobic exercise on uraemic restless legs syndrome,INTERNATIONAL JOURNAL OF THERAPY AND REHABILITATION,,1741-1645,10.12968/ijtr.2017.0132,,"Background The prevalence of restless legs syndrome in haemodialysis patients is approximately -30%, and it is significantly higher than in the general population. Restless legs syndrome is a sensory-motor disorder with negative effects on sleep and daytime activities that affect personal, family and occupational life. The overall impact of restless legs syndrome on quality of life is comparable to that of chronic and frustrating conditions such as depression and diabetes. The present study was conducted to compare the effect of neuromuscular electric stimulation with aerobic exercise on cases of uraemic restless legs syndrome. Methods A total of 60 chronic renal failure patients with uraemic restless legs syndrome aged 20 to 65 years participated in this study. Participants were allocated to receive neuromuscular electric stimulation or aerobic exercises. All participants were evaluated before the first session of treatment and after 3 months, at the end of the treatment. Normal and fast walk gait speed tests and the Five Times Sit-to-Stand Test and 60 second Sit-to-Stand Test were used to assess participants' physical status. The Restless Legs Syndrome Rating Scale was used to determine the level of restless legs syndrome severity. Results Neuromuscular electric stimulation resulted in significant improvements in all measures of physical performance and in Restless Legs Syndrome Rating Scale score when compared to baseline. Aerobic exercise produced significant improvements in all tests. At the end of the study, aerobic exercise had greater responses than neuromuscular electric stimulation in all parameters measured except the Five Times Sit-to-Stand Test. Conclusions Neuromuscular electrical stimulation may be used as an alternative to aerobic exercise to improve physical performance in cases of less severe restless legs syndrome in those unable or unwilling to participate in physical training.",02/10/2019,01/07/2022 10:40,01/07/2022 10:40,,,,10,26,,,,,,,,,,,,,,WOS:000495382500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
W53235V6,journalArticle,2000,"Sayenko, VF; Lavryk, AS; Stetsenko, OP",Report on bariatric surgery in the Ukraine,OBESITY SURGERY,,0960-8923,10.1381/09608920060674120,,"Background: Morbid obesity (MO) is a problem internationally, including in the Ukraine. We present the surgical treatment of MO in the Ukraine over the last 15 years, during which Intestinal bypasses and various gastric reduction procedures were performed. Methods: 198 patients with MO underwent: jejunoileal (JI) bypass 64, non-adjustable gastric banding (NGB) 34, Roux-en-Y gastric bypass (RYGBP) 1, horizontai gastroplasty 1, vertical banded gastroplasty (VBG) 2, and abdominal lipectomy 96. The 96 men and 102 women weighed 160-290 kg (mean 210+/-SD18 kg). Mean body mass index was >60 kg/m(2). These patients had a high incidence of hypertension, diabetes, sleep apnea, menstrual disorders, impotency in men and infertility in women. Results: At 1 year, after JI bypass 61 patients lost a mean of 62+/-17 kg and after NGB II kg. After JI bypass, 1 patient died in the early postoperative period from acute respiratory insufficiency and 2 died in the first year from acute liver insufficiency. The JI bypass was reversed in 2 patients due to uncontrollable malabsorption syndrome; 1 year after reversal, the weight of these patients exceeded their preoperative weight. In the early postoperative period, 1 patient died after NGB and 1 after RYGBP, from acute respiratory insufficiency. Postoperative weight loss was associated with decrease in the co-morbidities of MO, but after JIB, there was a high incidence of bypass enteritis, excessive malabsorption, formation of renal stones and gallstones. After NGB, no complications have been identified. Isolated lipectomy was performed in 44 patients, lipectomy combined with a bariatric operation in 31, and lipectomy after loss of the excess body weight in 21. Conclusions: Bariatric surgery was very effective in weight loss, accompanied by reduction or disappearance of the co-morbidities of MO with considerable improvement in quality of life.",2000-02,01/07/2022 10:40,01/07/2022 10:40,,54-57,,1,10,,,,,,,,,,,,,,WOS:000085962400013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XM2LTFDJ,journalArticle,2015,"Davison, KK; Falbe, J; Taveras, EM; Gortmaker, S; Kulldorff, M; Perkins, M; Blaine, RE; Franckle, RL; Ganter, C; Baidal, JW; Kwass, JA; Buszkiewicz, J; Smith, L; Land, T; MA-CORD Study Grp",Evaluation Overview for the Massachusetts Childhood Obesity Research Demonstration (MA-CORD) Project,CHILDHOOD OBESITY,,2153-2168,10.1089/chi.2014.0059,,"Background: The Massachusetts Childhood Obesity Research Demonstration (MA-CORD) project is a 2-year, multilevel, multisector community intervention to prevent and control obesity among children 2-12 years of age from two predominantly low-income communities in Massachusetts. MA-CORD includes evidence-based interventions in multiple sectors, including community health centers, early care and education centers, schools, afterschool programs, the Special Supplemental Nutrition Program for Women, Infants and Children, and the broader community. Currently, implementation of MA-CORD is complete and the final year of data collection is in progress. Here, the MA-CORD evaluation plan is described and baseline data are presented. Methods/Design: The impact of MA-CORD on children's BMI, lifestyle behaviors, obesity-related care, and quality of life will be assessed using sector-specific, pre/post, time-series, and quasi-experimental designs. Change in the primary outcomes will be compared for intervention and comparison communities. Additionally, change in mean BMI and obesity prevalence in intervention school districts will be compared to similar districts throughout the state. Results: At baseline in 2012, approximately 16% of preschool-aged and 25% of school-aged children were obese. Moreover, 15-40% of children consumed no vegetables on the previous day, 25-75% drank a sugar-sweetened beverage on the previous day, up to 87% had insufficient physical activity, 50-75% had a television in the room where they slept, and 50-80% obtained insufficient sleep. Conclusions: There is ample room for improvement in BMI and health behaviors in children in MA-CORD communities. If successful, MA-CORD may serve as a model for multilevel, multisector approaches to childhood obesity prevention and control.",01/02/2015,01/07/2022 10:40,01/07/2022 10:40,,23-36,,1,11,,,,,,,,,,,,,,WOS:000349317000004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VT9M8AT5,journalArticle,2000,"Semenchuk, MR; Sherman, S",Effectiveness of tizanidine in neuropathic pain: An open-label study,JOURNAL OF PAIN,,1526-5900,10.1054/jpai.2000.9435,,"The purpose of this research trial is to assess the effectiveness and tolerability of tizanidine in neuropathic pain. In an open-label study, patients with neuropathic pain received 1 to 4 mg of tizanidine once daily for 7 days, followed by weekly dose escalation of 2 to 8 mg to his/her effective or maximum tolerated dose or a maximum of 36 mg over an 8-week period. Treatment effects were assessed, using average weekly pain scores as well as biweekly scores for patient global assessment of pain relief, the Neuropathic Pain Scale, and Wisconsin Brief Pain Inventory. Frequency and severity of adverse events were examined also. Twenty-three patients were enrolled. The mean average weekly pain score at baseline was 6.9, which decreased by 1.7 points at the end of week 8 to 5.2 (P less than or equal to .01). A total of 15 patients (68%) reported that their pain relief was improved or much improved with tizanidine therapy, and 2 of these patients became completely pain-free. The following neuropathic pain qualities were significantly lower at week 8 compared with baseline: intense, sharp, hot, dull, cold, sensitive, unpleasant, and deep pain. There was a significant decline in pain quantity and interference of pain on quality of life from baseline to week 8. The mean effective or maximum tolerated dose was 23 mg/day (range 6 to 36 mg/day). Side effects consisted primarily of dizziness/lightheadedness (52%), drowsiness (48%), fatigue/weakness (43%), dry mouth (39%), gastrointestinal upset (30%), and sleep difficulty (22%). One patient developed significant elevation in liver function tests (LFTs) with symptoms at week 4. Tizanidine therapy was discontinued. LFTs returned to normal in 3 weeks. Tizanidine might be an effective treatment for neuropathic pain, offering an alternative for patients poorly responsive to other medications. A larger, randomized placebo-controlled trial is recommended. In addition, comparative studies with alternative agents should be sought.",2000,01/07/2022 10:40,01/07/2022 10:40,,285-292,,4,1,,,,,,,,,,,,,,WOS:000165873400008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
S6SJTNSC,journalArticle,2009,"Niederer, I; Kriemler, S; Zahner, L; Burgi, F; Ebenegger, V; Hartmann, T; Meyer, U; Schindler, C; Nydegger, A; Marques-Vidal, P; Puder, JJ",Influence of a lifestyle intervention in preschool children on physiological and psychological parameters (Ballabeina): study design of a cluster randomized controlled trial,BMC PUBLIC HEALTH,,1471-2458,10.1186/1471-2458-9-94,,"Background: Childhood obesity and physical inactivity are increasing dramatically worldwide. Children of low socioeconomic status and/or children of migrant background are especially at risk. In general, the overall effectiveness of school-based programs on health-related outcomes has been disappointing. A special gap exists for younger children and in high risk groups. Methods/Design: This paper describes the rationale, design, curriculum, and evaluation of a multicenter preschool randomized intervention study conducted in areas with a high migrant population in two out of 26 Swiss cantons. Twenty preschool classes in the German (canton St. Gallen) and another 20 in the French (canton Vaud) part of Switzerland were separately selected and randomized to an intervention and a control arm by the use of opaque envelopes. The multidisciplinary lifestyle intervention aimed to increase physical activity and sleep duration, to reinforce healthy nutrition and eating behaviour, and to reduce media use. According to the ecological model, it included children, their parents and the teachers. The regular teachers performed the majority of the intervention and were supported by a local health promoter. The intervention included physical activity lessons, adaptation of the built infrastructure; promotion of regional extracurricular physical activity; playful lessons about nutrition, media use and sleep, funny homework cards and information materials for teachers and parents. It lasted one school year. Baseline and post-intervention evaluations were performed in both arms. Primary outcome measures included BMI and aerobic fitness (20 m shuttle run test). Secondary outcomes included total (skinfolds, bioelectrical impedance) and central (waist circumference) body fat, motor abilities (obstacle course, static and dynamic balance), physical activity and sleep duration (accelerometry and questionnaires), nutritional behaviour and food intake, media use, quality of life and signs of hyperactivity (questionnaires), attention and spatial working memory ability (two validated tests). Researchers were blinded to group allocation. Discussion: The purpose of this paper is to outline the design of a school-based multicenter cluster randomized, controlled trial aiming to reduce body mass index and to increase aerobic fitness in preschool children in culturally different parts of Switzerland with a high migrant population. Trial Registration: Trial Registration: clinicaltrials.gov NCT00674544",31/03/2009,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000265927100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X5EL3Z3V,journalArticle,2005,"Nathan, A; Rose, JB; Guite, JW; Hehir, D; Milovcich, K",Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment,PEDIATRICS,,0031-4005,10.1542/peds.2004-1395,,"Erythromelalgia is a rare, chronic, debilitating condition characterized by redness, warmth, and severe burning pain of the distal extremities. The feet are more commonly affected than the hands. Pain is precipitated by increases in temperature and by exercise. Patients often obtain relief by immersing the affected extremity in cold water. The pain is often refractory to treatment. For many patients, multiple pain medications have been useless in achieving complete relief of pain symptoms. Previous reports of erythromelalgia among adolescents indicated prolonged relief of pain with sodium nitroprusside infusions, epidural infusions of local anesthetics, or gabapentin treatment. We present a case of an 11-year-old, white, male child with primary erythromelalgia, whose initial symptoms started in his preschool years and whose childhood was marked by escalating episodes of pain with warmth and redness of his feet, precipitated especially by increases in temperature and by activity. All conventional pain management techniques had failed to relieve our patient of his symptoms, and he obtained some relief only by soaking his affected extremities in ice water. He had experienced minimal benefit from seeing a pain psychologist, who helped him develop techniques to cope with the pain. At the time of presentation, the patient's episodes of pain had increased to 15 to 20 per day, and there was evidence of chronic immersion injury to the skin of his feet. Before his most recent hospitalization, the pain had spread to involve his hands as well. The patient was overwhelmed with anxiety and could not participate in school or social activities at the time of admission. During his current hospitalization, he did show some therapeutic response to sodium nitroprusside infusion, which unfortunately had to be discontinued because of side effects and because his family desired to leave the ICU environment, which was stressful to the patient. He also had some response to lumbar epidural infusion of local anesthetics, which could not be continued because he found the motor blockade that accompanied his analgesia intolerable. However, intravenous lidocaine infusion, with subsequent transition to oral mexiletine therapy, proved very effective in reducing the frequency and severity of the pain episodes. The patient was discharged from the hospital with oral mexiletine therapy and has been monitored at the pain management clinic. He returned to and completed school, attended summer camp, and enjoys an active happy life. He walks without precipitating pain in his feet and sleeps 9 to 10 hours every night. He has needed to soak his feet on only 4 occasions in the 6 months since his discharge from the hospital. His quality of life has improved significantly. He has shown no evidence of liver toxicity, and his mexiletine levels have been stable.",2005-04,01/07/2022 10:40,01/07/2022 10:40,,,,4,115,,,,,,,,,,,,,,WOS:000228107900019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MQ76VV3Y,journalArticle,2006,"Yitzhak, A; Mizrahi, S; Avinoach, E",Laparoscopic gastric banding in adolescents,OBESITY SURGERY,,0960-8923,10.1381/096089206778663823,,"Background: Adolescent obesity has undesirable short- and long-term effects. Laparoscopic adjustable gastric banding has been considered a procedure of choice for adolescent morbid obesity. We retrospectively evaluated our single-team banding experience in the adolescent population. Methods: We reviewed the medical and clinic records and conducted telephone questionnaire interviews, to evaluate the results of banding using the Swedish adjustable gastric band (SAGB(R)) in the 60 adolescents at our institution who had been followed >= 3 years. Results: An average of 39.5 months of follow-up has been conducted in the patients who have been followed >= 3 years. Mean age at the time of the operation was 16 years (9 to 18).60% reported a family history of obesity. Associated co-morbidities included hypertension, diabetes, sleep apnea and asthma. Mean preoperative BMI was 43 (35-61) kg/m(2). Mean postoperative BMI after 39.5 months follow-up was 30 (20-39) kg/m(2). No co-morbidities have existed after the operation. 6 patients (10%) underwent band repositioning and 2 patients underwent band removal, due to slippage; 7 of the 8 slippages occurred with an earlier perigastric technique which transgressed lesser sac. There was no mortality. Average postoperative hospital stay was 24 hours. Conclusions: Gastric banding in adolescents is a safe, satisfactory and reversible weight reduction procedure.",2006-10,01/07/2022 10:40,01/07/2022 10:40,,1318-1322,,10,16,,,,,,,,,,,,,,WOS:000241209200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BTQNIZLB,journalArticle,2020,"Doumouras, AG; Lee, Y; Babe, G; Gmora, S; Tarride, JE; Hong, D; Anvari, M",The hidden cost of an extensive preoperative work-up: predictors of attrition after referral for bariatric surgery in a universal healthcare system,SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES,,0930-2794,10.1007/s00464-019-06894-9,,"Background Bariatric surgery is in high demand and patients generally undergo an extensive work-up process to maximize the success of surgery, especially in universal healthcare systems. Although valuable, this work-up process can lead to attrition before surgery. Therefore, we aim to assess patient and health system factors associated with attrition after bariatric surgery referral in a universal healthcare system. Methods This was a population-based study of all patients aged >= 18 referred for bariatric surgery in Ontario, Canada from 2009 to 2015. Primary outcome was patients who dropped out of bariatric surgery after referral. Predictors of attrition after referral included patient demographics, clinical, institutional, and socioeconomic variables. Odds ratios and 95% CIs were estimated by multilevel logistic regression models. Results From 17,703 patients that were referred for bariatric surgery, 4122 patients dropped after the initial referral. Male patients, increasing age, and longer wait times for surgery were significantly (P < 0.0001) associated with higher odds of attrition. Additionally, smoker status, immigration status, unemployment, and disability were significant factors (P < 0.0001) predicting attrition. Patients who lived in lowest income quintile neighborhoods, when compared to those from the richest neighborhoods, had significantly higher odds of attrition (P = 0.02). Sleep apnea was associated with lower odds of attrition while diabetes and heart failure both with higher odds of attrition. Conclusion Even in a universal healthcare system, there are various factors that could lead to increased odds of attrition before bariatric surgery. Clear disparities exist for certain marginalized populations. Further studies are warranted to ensure equitable utilization of bariatric surgery for all patients.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,988-995,,2,34,,,,,,,,,,,,,,WOS:000512824800058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IXW85D3N,journalArticle,2020,"Kirwan, R; McCullough, D; Butler, T; de Heredia, FP; Davies, IG; Stewart, C",Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss,GEROSCIENCE,,2509-2715,10.1007/s11357-020-00272-3,,"The COVID-19 pandemic is an extraordinary global emergency that has led to the implementation of unprecedented measures in order to stem the spread of the infection. Internationally, governments are enforcing measures such as travel bans, quarantine, isolation, and social distancing leading to an extended period of time at home. This has resulted in reductions in physical activity and changes in dietary intakes that have the potential to accelerate sarcopenia, a deterioration of muscle mass and function (more likely in older populations), as well as increases in body fat. These changes in body composition are associated with a number of chronic, lifestyle diseases including cardiovascular disease (CVD), diabetes, osteoporosis, frailty, cognitive decline, and depression. Furthermore, CVD, diabetes, and elevated body fat are associated with greater risk of COVID-19 infection and more severe symptomology, underscoring the importance of avoiding the development of such morbidities. Here we review mechanisms of sarcopenia and their relation to the current data on the effects of COVID-19 confinement on physical activity, dietary habits, sleep, and stress as well as extended bed rest due to COVID-19 hospitalization. The potential of these factors to lead to an increased likelihood of muscle loss and chronic disease will be discussed. By offering a number of home-based strategies including resistance exercise, higher protein intakes and supplementation, we can potentially guide public health authorities to avoid a lifestyle disease and rehabilitation crisis post-COVID-19. Such strategies may also serve as useful preventative measures for reducing the likelihood of sarcopenia in general and in the event of future periods of isolation.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,1547-1578,,6,42,,,,,,,,,,,,,,WOS:000574340100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZQ6QULCA,journalArticle,2013,"Hartman, ML; Xu, R; Crowe, BJ; Robison, LL; Erfurth, EM; Kleinberg, DL; Zimmermann, AG; Woodmansee, WW; Cutler, GB; Chipman, JJ; Melmed, S; Int HypoCCS Advisory Board",Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients,JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM,,0021-972X,10.1210/jc.2012-2684,,"Context: In clinical practice, the safety profile of GH replacement therapy for GH-deficient adults compared with no replacement therapy is unknown. Objective: The objective of this study was to compare adverse events (AEs) in GH-deficient adults who were GH-treated with those in GH-deficient adults who did not receive GH replacement. Design and Setting: This was a prospective observational study in the setting of US clinical practices. Patients and Outcome Measures: AEs were compared between GH-treated (n = 1988) and untreated (n = 442) GH-deficient adults after adjusting for baseline group differences and controlling the false discovery rate. The standardized mortality ratio was calculated using US mortality rates. Results: After a mean follow-up of 2.3 years, there was no significant difference in rates of death, cancer, intracranial tumor growth or recurrence, diabetes, or cardiovascular events in GH-treated compared with untreated patients. The standardized mortality ratio was not increased in either group. Unexpected AEs (GH-treated vs untreated, P <= .05) included insomnia (6.4% vs 2.7%), dyspnea (4.2% vs 2.0%), anxiety (3.4% vs 0.9%), sleep apnea (3.3% vs 0.9%), and decreased libido (2.1% vs 0.2%). Some of these AEs were related to baseline risk factors (including obesity and cardiopulmonary disease), higher GH dose, or concomitant GH side effects. Conclusions: In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabetes, or cardiovascular events, although the follow-up period was of insufficient duration to be conclusive for these long-term events. The identification of unexpected GH-related AEs reinforces the fact that patient selection and GH dose titration are important to ensure safety of adult GH replacement. (J Clin Endocrinol Metab 98: 980-988, 2013)",2013-03,01/07/2022 10:40,01/07/2022 10:40,,980-988,,3,98,,,,,,,,,,,,,,WOS:000316417200045,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5KZHENCB,journalArticle,2019,"Chen, YF; Lin, CS; Hong, CF; Lee, DJ; Sun, CM; Lin, HH",Design of a Clinical Decision Support System for Predicting Erectile Dysfunction in Men Using NHIRD Dataset,IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS,,2168-2194,10.1109/JBHI.2018.2877595,,"Erectile dysfunction (ED) affects millions of men worldwide. Men with ED generally complain failure to attain or maintain an adequate erection during sexual activity. The prevalence of ED is strongly correlated with age, affecting about 40% of men at age 40 and nearly 70% at age 70. A variety of chronic diseases, including diabetes, ischemic heart disease, congestive heart failure, hypertension, depression, chronic renal failure, obstructive sleep apnea, prostate disease, gout, and sleep disorder, were reported to be associated with ED. In this study, data retrieved from a subset of the National Health Insurance Research Database of Taiwan were used for designing the clinical decision support system (CDSS) for predicting ED incidences in men. The positive cases were male patients aged 20-65 who were diagnosed with ED between January 2000 and December 2010 confirmed by at least three outpatient visits or at least one inpatient visit, while the negative cases were randomly selected from the database without a history of ED and were frequency (1:1), age, and index year matched with the ED patients. Data of a total of 2832 ED patients and 2832 non-ED patients, each consisting of 41 features including index age, 10 comorbidities, and 30 other comorbidity-related variables, were retrieved for designing the predictive models. Integrated genetic algorithm and support vector machine was adopted to design the CDSSs with two experiments of independent training and testing (ITT) conducted to verify their effectiveness. In the 1st ITT experiment, data extracted from January 2000 till December 2005 (61.51%, 1742 positive cases and 1742 negative cases) were used for training and validating and the data retrieved from January 2006 till December 2010 were used for testing (38.49%), whereas in the 2nd ITT experiment, data in the training set (77.78%) were extracted from January 2000 till Deceber 2007 and those in the testing set (22.22%) were retrieved afterward. Tenfold cross validation and three different objective functions were adopted for obtaining the optimal models with best predictive performance in the training phase. The testing results show that the CDSSs achieved a predictive performance with accuracy, sensitivity, specificity, g-mean, and area under ROC curve of 74.72%-76.65%, 72.33%-83.76%, 69.54%-77.10%, 0.7468-0.7632, and 0.766-0.817, respectively. In conclusion, the CDSSs designed based on cost-sensitive objective functions as well as salient comorbidity-related features achieve satisfactory predictive performance for predicting ED incidences.",2019-09,01/07/2022 10:40,01/07/2022 10:40,,2127-2137,,5,23,,,,,,,,,,,,,,WOS:000489729400032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39TVJN96,journalArticle,2017,"Sauerbier, A; Jitkritsadakul, O; Titova, N; Klingelhoefer, L; Tsuboi, Y; Carr, H; Kumar, H; Banerjee, R; Erro, R; Bhidayasiri, R; Schrag, A; Zis, P; Lim, SY; Al-Hashel, JY; Kamel, WA; Martinez-Martin, P; Chaudhuri, KR",Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations,NEUROEPIDEMIOLOGY,,0251-5350,10.1159/000478702,,"Background: Ethnic variations have been described in medical conditions, such as hypertension, diabetes, and multiple sclerosis. Whether ethnicity plays a role in Parkinson's disease (PD), particularly with regard to non-motor symptoms (NMS), remains unclear. Existing literature is diverse, controversial, and inadequately documented. This review aims to analyse and report the currently available literature on NMS, specifically in Asian PD patients. Summary: We conducted a literature review using PubMed, searching for articles and currently available publications that reference and assess NMS in PD patients living in Asia using the validated NMS Questionnaire (NMS Quest) and NMS Scale (NMSS). In total, 24 articles were included: 12 using the NMS Quest and 12 using the NMSS. Symptoms of constipation, memory impairment, and nocturia were the most frequently self-reported symptoms (NMS Quest) in selected Asian populations, while symptoms within the domains sleep/fatigue, attention/memory, and mood/apathy were most prevalent when applying the health-professional completed NMSS. Key Messages: NMS are generally prevalent and highly burdensome within selected Asian PD populations living in countries included in this review. Our review suggests that NMS-driven phenotypic heterogeneity is present in Asian patients, and compared to Western PD populations there might be variations in assessed NMS. (C) 2017 S. Karger AG, Basel",2017,01/07/2022 10:40,01/07/2022 10:40,,Jan-17,,01-Feb,49,,,,,,,,,,,,,,WOS:000412968900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D2C26C73,journalArticle,2015,"Dean, E; Soderlund, A",What is the role of lifestyle behaviour change associated with non-communicable disease risk in managing musculoskeletal health conditions with special reference to chronic pain?,BMC MUSCULOSKELETAL DISORDERS,,1471-2474,10.1186/s12891-015-0545-y,,"Background: Other than activity and exercise, lifestyle practices such as not smoking and healthy nutrition, well established for preventing and managing lifestyle-related non-communicable diseases (i.e., heart disease, cancer, hypertension, stroke, obstructive lung disease, diabetes, and obesity), are less emphasized in the physical therapy guidelines for addressing chronic pain, e.g., back pain. This state-of-the-art review examines the relationships between lifestyle behaviours and musculoskeletal health, with special reference to chronic pain, and their clinical and research implications. Discussion: A state-of-the-art review was conducted to synthesize evidence related to lifestyle factors (not smoking, healthy diet, healthy weight, optimal sleep and manageable stress, as well as physical activity) and musculoskeletal health, with special reference to chronic pain. The findings support that health behaviour change competencies (examination/assessment and intervention/treatment) may warrant being included in first-line management of chronic pain, either independently or in conjunction with conventional physical therapy interventions. To address knowledge gaps in the literature however three lines of clinical trial research are indicated: 1) to establish the degree to which traditional physical therapy interventions prescribed for chronic pain augment the benefits of lifestyle behaviour change; 2) to establish the degree to which adopting healthier lifestyle practices, avoids or reduces the need for conventional physical therapy; and 3) to establish whether patients/clients with healthier lifestyles and who have chronic pain, respond more favourably to conventional physical therapy interventions than those who have less healthy lifestyles. Summary: Lifestyle behaviour change is well accepted in addressing lifestyle-related non-communicable diseases. Compelling evidence exists however supporting the need for elucidation of the role of negative lifestyle behaviours on the incidence of chronic pain, and the role of positive lifestyle behaviours on its incidence and effective management. Addressing lifestyle behaviour change in patients/clients with chronic pain, e.g., back pain, as a first-line intervention might not only constitute a novel approach, but also reduce the socioeconomic burden related to chronic pain as well as non-communicable diseases.",13/04/2015,01/07/2022 10:40,01/07/2022 10:40,,,,,16,,,,,,,,,,,,,,WOS:000352840600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MT3TPUQH,journalArticle,2003,"Parisi, L; Pierelli, F; Amabile, G; Valente, G; Calandriello, E; Fattapposta, F; Rossi, P; Serrao, M",Muscular cramps: proposals for a new classification,ACTA NEUROLOGICA SCANDINAVICA,,0001-6314,10.1034/j.1600-0404.2003.01289.x,,"Muscle cramps are involuntary, painful, sudden contractions of the skeletal muscles. They are present in normal subjects under certain conditions (during a strong voluntary contraction, sleep, sports, pregnancy) and in several pathologies such as myopathies, neuropathies, motoneuron diseases, metabolic disorders, hydroelectrolyte imbalances or endocrine pathologies. There has been considerable uncertainty in the literature regarding the classification and nomenclature of muscle cramps, both because the term ""cramp"" is used to indicate a variety of clinical features of muscles, leading to its use as an imprecise ""umbrella"" term that includes stiffness, contractures and local pain, and because the spectrum of the diseases in which it appears is wide. The purpose of the present study is to propose a simple classification to provide a framework to better recognize the full spectrum of phenomenology of muscle cramps.",2003-03,01/07/2022 10:40,01/07/2022 10:40,,176-186,,3,107,,,,,,,,,,,,,,WOS:000181329400002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZPK399CG,journalArticle,2016,"Couture, M","A Single-center, Retrospective Study of Cryopreserved Umbilical Cord for Wound Healing in Patients Suffering From Chronic Wounds of the Foot and Ankle",WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE,,1044-7946,,,"Objective. Chronic wounds are a significant issue not only in wound care facilities, but also in daily practice for general practitioners and specialists across a wide variety of disciplines. These wounds are primarily foot or lower extremity ulcers and can result from a combination of factors including neuropathy, vascular insufficiency, and impaired wound healing. In addition to a significant health care cost, ulcerations have a devastating impact on virtually every aspect of the affected patient's daily life such as extensive pain, sleep impairment, restricted mobility, and work capacity. The objective of this single-center, retrospective study was to evaluate the clinical effectiveness of a human cryopreserved umbilical cord (cUC) allograft as an advanced therapeutic treatment modality for chronic, nonhealing lower extremity wounds. Materials and Methods. Following Institutional Review Board approval, data from all qualifying patients who had received cUC tissue treatment during a period of 16 months was collected retrospectively. A total of 57 patients presenting with 64 chronic wounds who received treatment with cUC and were treated by the same surgeon at a single wound care center were analyzed. Results. The average initial wound area was 6.85 cm(2) +/- 16.29 cm(2). Overall, 51 of 64 wounds achieved complete healing, resulting in an overall wound-healing rate of 79.7%. For wounds that healed, the average wound-healing time was 5.53 +/- 3.93 weeks, and an average of 3.43 +/- 2.42 applications of cUC were used to achieve healing. Conclusion. Overall, these results demonstrate cUC may be effective in promoting the healing of chronic, lower extremity ulcers. In addition, this study suggests cUC may be a useful advanced tissue treatment modality with the potential not only to improve patient quality of life, but also positively impact rising health care costs associated with long-term treatment of such ulcers. Further exploration, including prospective, randomized controlled trials, is warranted to better understand the effectiveness of cUC.",2016-07,01/07/2022 10:40,01/07/2022 10:40,,217-225,,7,28,,,,,,,,,,,,,,WOS:000385870700002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YLCZIC9Z,journalArticle,2009,"Roth, T",Comorbid Insomnia: Current Directions and Future Challenges,AMERICAN JOURNAL OF MANAGED CARE,,1088-0224,,,"Insomnia is a leading cause of absenteeism, presenteeism (lost productivity when employees are at work), accidents, and errors in the workplace. Overall direct and indirect costs exceed $30 billion annually. A significant portion of these costs are attributable to patients with comorbid insomnia, making these conditions a significant clinical public health issue. These comorbid conditions include mood and anxiety disorders; chronic pain; respiratory, urinary, and neurologic conditions; diabetes; and cardiovascular diseases. Traditional treatment for insomnia with comorbid conditions has focused on treating the comorbid condition with the expectation that the insomnia will resolve. Recent studies, however, suggest this approach is not the most appropriate. Instead, treating both conditions simultaneously may improve the outcomes for each. (Am J Manag Care. 2009; 15: S6-S13)",2009-02,01/07/2022 10:40,01/07/2022 10:40,,S6-S13,,1,15,,,,,,,,,,,,,,WOS:000207835200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IHG9J6XM,journalArticle,2019,"Flythe, JE; Dorough, A; Narendra, JH; Wingard, RL; Dalrymple, LS; DeWalt, DA",Development and content validity of a hemodialysis symptom patient-reported outcome measure,QUALITY OF LIFE RESEARCH,,0962-9343,10.1007/s11136-018-2000-7,,"PurposeTo describe the process and preliminary qualitative development of a new symptom-based patient-reported outcome measure (PROM) intended to assess hemodialysis treatment-related physical symptoms.MethodsExperienced interviewers conducted concept elicitation and cognitive debriefing interviews with individuals receiving in-center hemodialysis in the United States. Concept elicitation interviews involved eliciting spontaneous reports of symptom experiences and probing to further explore and confirm concepts. We used patient-reported concepts to generate a preliminary symptom PROM. We conducted 3 rounds of cognitive debriefing interviews to evaluate symptom relevance, item interpretability, and draft item structure. We iteratively refined the measure based on cognitive interview findings.ResultsForty-two adults receiving in-center hemodialysis participated in the concept elicitation interviews. A total of 12 symptoms were reported by >10% of interviewees. We developed a 13-item initial draft instrument for testing in 3 rounds of cognitive interviews with an additional 52 hemodialysis patients. Participant responses and feedback during cognitive interviews led to changes in symptom descriptions, division of the single item nausea/vomiting into 2 distinct items, removal of daily activity interference items, addition of instructions, and clarification about the recall period, among other changes.ConclusionsSymptom Monitoring on Renal Replacement Therapy-Hemodialysis (SMaRRT-HD) is a 14-item PROM intended for use in hemodialysis patents. SMaRRT-HD uses a single treatment recall period and a 5-point Likert scale to assess symptom severity. Qualitative interview data provide evidence of its content validity. SMaRRT-HD is undergoing additional testing to assess measurement properties and inform measure scoring.",2019-01,01/07/2022 10:40,01/07/2022 10:40,,253-265,,1,28,,,,,,,,,,,,,,WOS:000456282400023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7IQVICIB,journalArticle,2016,"Shechter, A",Effects of continuous positive airway pressure on energy balance regulation: a systematic review,EUROPEAN RESPIRATORY JOURNAL,,0903-1936,10.1183/13993003.00689-2016,,"Obesity is both a cause and a possible consequence of obstructive sleep apnoea (OSA), as OSA seems to affect parameters involved in energy balance regulation, including food intake, hormonal regulation of hunger/satiety, energy metabolism and physical activity. It is known that weight loss improves OSA, yet it remains unclear why. continuous positive airway pressure (CPAP) often results in weight gain. The goal of this systematic review is to explore if and how CPAP affects the behaviour and/or metabolism involved in regulating energy balance. CPAP appears to correct for a hormonal profile characterised by abnormally high leptin and ghrelin levels in OSA, by reducing the circulating levels of each. This is expected to reduce excess food intake. However, reliable measures of food intake are lacking, and not yet sufficient to make conclusions. Although studies are limited and inconsistent, CPAP may alter energy metabolism, with reports of reductions in resting metabolic rate or sleeping metabolic rate. CPAP appears to not have an appreciable effect on altering physical activity levels. More work is needed to characterise how CPAP affects energy balance regulation. It is clear that promoting CPAP in conjunction with other weight loss approaches should be used to encourage optimal outcomes in OSA patients.",2016-12,01/07/2022 10:40,01/07/2022 10:40,,1640-1657,,6,48,,,,,,,,,,,,,,WOS:000392462500018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KGLV8I3F,journalArticle,2015,"Kantor, D; Panchal, S; Patel, V; Bucior, I; Rauck, R","Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes",JOURNAL OF PAIN,,1526-5900,10.1016/j.jpain.2015.08.011,,"To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed. There were widespread, networked, positive correlations among efficacy end points-pain qualities on the visual analog scale (VAS) and Brief Pain Inventory (BPI), measures of pain interference on the BPI, and Patient Global Impression of Change (PGIC)-most likely characterized by positive feedback loops, in which pain interferes with patient functioning, and poor functioning enhances pain. VAS scores at baseline or at week 2 were the strongest predictors of being ""much"" or ""very much"" improved on the PGIC; BPI sleep interference scores were the strongest predictors of percent changes in BPI pain qualities and in the average of BPI interference scores, whereas age, sex, and race were not important predictors. In addition to VAS, BPI sleep interference and PGIC assessments appeared to be key co-strategic factors important for successful treatment outcomes, and should be considered as co-primary end points in future clinical trials of PHN. This could improve detection of true positive efficacy responses and guide successful transition to real-world clinical practice. Perspective: This study describes complex relationships among measures of pain intensity, pain interference with daily activities, and demographics of patients with PHN treated with G-GR. Such comprehensive characterization provides important insight into how different variables contribute to successful treatment, and may lead to better management of neuropathic pain. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).",2015-12,01/07/2022 10:40,01/07/2022 10:40,,1300-1311,,12,16,,,,,,,,,,,,,,WOS:000366443000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RAVXSMZ9,journalArticle,2020,"Fayne, RA; Borda, LJ; Egger, AN; Tomic-Canic, M",The Potential Impact of Social Genomics on Wound Healing,ADVANCES IN WOUND CARE,,2162-1918,10.1089/wound.2019.1095,,"Significance: Human skin wounds carry an immense epidemiologic and financial burden, and their impact will continue to grow with an aging population and rising incidence of comorbid conditions known to affect wound healing. To comprehensively address this growing clinical issue, physicians should also be aware of how conditions of the human social environment may affect wound healing. Here we provide a review of the emerging field of social genomics and its potential impact on the wound healing. Recent Advances: Multiple studies using human and animal models have correlated social influences and their contributing effects to acute and chronic stress with delays in wound healing. Furthermore, observations between nongenetic factors such as nutrition, socioeconomic, and educational status have also shown to have a direct or indirect impact on clinical outcomes of wound healing. Critical Issues: Nutrition, financial burden, socioeconomic and education status, and acute and chronic stress are variables that have either direct (epigenetic) or indirect impact on wound healing and patients' quality of life. Wound care is costly and remains a challenge placing economic burden on patients. Furthermore, poor clinical outcomes and complications including loss of mobility and disability may lead to job loss, further contributing to socioeconomic related stress. Thus, the economic burden and inadequate wound healing are intertwined, making each other worse. Future Directions: Although some evidence regarding the specific changes in genetic pathways imparted by conditions of the social environment exists, further studies are warranted to identify potential mechanisms, interventions, and prevention approaches.",01/06/2020,01/07/2022 10:40,01/07/2022 10:40,,325-331,,6,9,,,,,,,,,,,,,,WOS:000515350100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NQTNMP9M,journalArticle,2013,"Derry, S; Sven-Rice, A; Cole, P; Tan, T; Moore, RA",Topical capsaicin (high concentration) for chronic neuropathic pain in adults,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD007393.pub3,,"Background Topical creams with capsaicin are used to treat peripheral neuropathic pain. Following application to the skin capsaicin causes enhanced sensitivity, followed by a period with reduced sensitivity and, after repeated applications, persistent desensitisation. High-concentration (8%) capsaicin patches were developed to increase the amount of capsaicin delivered; rapid delivery was thought to improve tolerability because cutaneous nociceptors are 'defunctionalised' quickly. The single application avoids noncompliance. Only the 8% patch formulation of capsaicin is available, with a capsaicin concentration about 100 times greater than conventional creams. High-concentration topical capsaicin is given as a single patch application to the affected part. It must be applied under highly controlled conditions, normally under local anaesthetic, due to the initial intense burning sensation it causes. The benefits are expected to last for about 12 weeks, when another application might be made. Objectives To review the evidence from controlled trials on the efficacy and tolerability of topically applied, high-concentration (8%) capsaicin in chronic neuropathic pain in adults. Search methods We searched CENTRAL, MEDLINE, EMBASE and clinicaltrials.gov to December 2012. Selection criteria Randomised, double-blind, placebo-controlled studies of at least six weeks' duration, using topical capsaicin to treat neuropathic pain. Data collection and analysis Two review authors independently assessed trial quality and validity, and extracted data on numbers of participants with pain relief (clinical improvement) after at least six weeks, and with local skin reactions. We calculated risk ratio and numbers needed to treat to benefit (NNT) and harm (NNH). We sought details of definition of pain relief and specific adverse events. Efficacy outcomes reflecting long-duration pain relief after a single drug application were from the patient global impression of change (PGIC) at specific points, usually eight and 12 weeks. We regarded these outcomes as first-tier evidence. We regarded average pain scores over weeks 2 to 8 and 2 to 12 and the number and/or percentage of participants with pain intensity reduction of at least 30% or at least 50% over baseline as second-tier evidence. Main results We included six studies, involving 2073 participants; they were of generally good reporting quality; the control was 0.04% topical capsaicin to help maintain blinding. Efficacy outcomes were inconsistently reported between studies, however, resulting in analyses for most outcomes being based on less than complete data. Four studies involved 1272 participants with postherpetic neuralgia. All efficacy outcomes were significantly better than control. At both eight and 12 weeks there was a significant benefit for high-concentration over low-concentration topical capsaicin for participants reporting themselves to be much or very much better, with point estimates of the NNTs of 8.8 (95% confidence interval (CI) 5.3 to 26) and 7.0 (95% CI 4.6 to 15) respectively. More participants had average 2 to 8-week and 2 to 12-week pain intensity reductions over baseline of at least 30% and at least 50% with active treatment than control, with NNT values between 10 and 12. Two studies involved 801 participants with painful HIV-neuropathy. In a single study the NNT at 12 weeks for participants to be much or very much better was 5.8 (95% CI 3.8 to 12). Over both studies more participants had average 2 to 12-week pain intensity reductions over baseline of at least 30% with active treatment than control, with an NNT of 11. Local adverse events were common, but not consistently reported. Serious adverse events were no more common with active treatment (4.1%) than control (3.2%). Adverse event withdrawals did not differ between groups, but lack of efficacy withdrawals were somewhat more common with control than active treatment, based on small numbers of events. No deaths were judged to be related to study medication. Authors' conclusions High-concentration topical capsaicin used to treat postherpetic neuralgia and HIV-neuropathy generates more participants with high levels of pain relief than does control treatment using a much lower concentration of capsaicin. The additional proportion who benefit over control is not large, but for those who do obtain high levels of pain relief there are additional improvements in sleep, fatigue, depression and an improved quality of life. High-concentration topical capsaicin is therefore similar to other therapies for chronic pain. In this case, the high cost of single and repeated applications suggest that high-concentration topical capsaicin is likely to be used when other available therapies have failed, and that it should probably not be used repeatedly without substantial documented pain relief. Even when efficacy is established, there are unknown risks, especially on epidermal innervation, of repeated application of long periods.",2013,01/07/2022 10:40,01/07/2022 10:40,,,,2,,,,,,,,,,,,,,,WOS:000315461200014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WWW6DYRH,journalArticle,2019,"Zhuang, S; Na, MZ; Winkelman, JW; Ba, D; Liu, CF; Liu, GD; Gao, X",Association of Restless Legs Syndrome With Risk of Suicide and Self-harm,JAMA NETWORK OPEN,,2574-3805,10.1001/jamanetworkopen.2019.9966,,"IMPORTANCE Restless legs syndrome (RLS) is a common neurologic disorder that has been previously found to be associated with higher odds of suicidal ideation. In the context of the increasing suicide rate in the United States, the evidence regarding the association between RLS and the risk of suicide and self-harm is limited. OBJECTIVE To investigate the association between RLS and risk of suicide and self-harm. DESIGN, SETTING, AND PARTICIPANTS This cohort study was performed using Truven Health MarketScan national claims data from 2006 to 2014; the baseline data were from 2006 to 2008, and the follow-up data covered 6 years (January 1, 2009, to December 31, 2014). Included were 24 179 nonpregnant participants with RLS and 145 194 age- and sex-matched participants without RLS at baseline (2006-2008), who were free of suicide, self-harm, cardiovascular disease, or cancer at study baseline. Data analysis was performed from February 1, 2018, to January 1, 2019. EXPOSURE Diagnosis of RLS, as identified by the International Classification of Diseases, Ninth Revision code. MAIN OUTCOMES AND MEASURES Incident suicide and self-harm event, identified by the International Classification of Diseases, Ninth Revision diagnosis code. RESULTS Among 169 373 participants in the current analysis, the mean (SD) age was 49.4 (9.1) years; 53 426 (31.5%) participants were men. During a mean (SD) follow-up duration of 5.2 (2.2) years, 119 incident suicide and self-harm cases were identified. Individuals with RLS had a higher risk of suicide or self-harm compared with those without RLS (adjusted hazard ratio, 2.66; 95% CI, 1.70-4.15), after adjusting for lifestyle factors (eg, alcohol and obesity), presence of chronic diseases (eg, depression, insomnia, diabetes, chronic kidney disease, peripheral neuropathy, iron-deficiency anemia, and Parkinson disease), and use of medications. Excluding those with depression, insomnia, obstructive sleep apnea, and other common chronic conditions, the significant association between RLS and suicide or self-harm persisted (adjusted hazard ratio, 4.14; 95% CI, 2.17-7.92). CONCLUSIONS AND RELEVANCE Restless legs syndrome was associated with a high risk of suicide and self-harm, and the risk was independent of most identified diseases and conditions.",2019-08,01/07/2022 10:40,01/07/2022 10:40,,,,8,2,,,,,,,,,,,,,,WOS:000513151100033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WP5BQUAL,journalArticle,2017,"Zheng, YW; Zhou, YB; Hu, JS; Zhu, JP; Hua, Q; Tao, MF",Prediction of risk of depressive symptoms in menopausal women based on hot flash and sweating symptoms: a multicentre study,CLINICAL INTERVENTIONS IN AGING,,1178-1998,10.2147/CIA.S148688,,"Objective: The present study aimed to des chip a symptom-based (namely, hot flashes and sweating) scarring system for predicting the risk of depressive symptoms in menopausal women via a multicentre cross-sectional survey. Methods: The data examined in the present study were obtained from 1,004 women aged 40 60 years A,who underwent physical examination at A hospital. The basic information was obtained using a questionnaire-based survey. A self-rating depression scale was used tar obtain the depressive symptom scores, while the Kupperman Menopausal Index was used to obtain the scores for the frequency of hot flashes and sweating. A logistic regression model was also established. The resulting beta coefficient was employed to calculate and predict the risk of depressive symptoms in these women and a risk scoring system was established. The scoring system xi ass using samples from 2 other centers (validation sample 1: B Hospital, 440 women; validation sample 2: C Hospital, 247 women). Results: The scarring system developed to predict the risk of depressive symptoms in menopausal women was based on hart flash and sweating symptoms and associated with menopausal status, hart flash scores, education level (high school education and below) and being diabetic. The scoring system yielded a total score of 0 54 points. For women in the study sample, the area under the curve (AUC) of depressive symptom risk score was 0.75(1 (95% Cl 0.708-0.793). Validation sample Iliad an AUC 0.731 (95% Cl, 0.667-1.794), while validation sample 2 had an AUC of 0.744 (95% CI, 0.669-0.820). The optimal cut-off score to assess depressive symptoms in women participating in the present study was 31 points. The sensitivity and specificity for predicting depressive symptoms in the study sample were 0.667 and 0.701, respectively. In contrast, the sensitivity was 0.840 in validation sample 1 and 0.879 in validation sample 2. Conclusion: The hot flash and sweating symptom-based scoring system developed to predict the risk of depressive symptoms in menopausal women relies on non-laboratory survey data. The system is simple, practical, and convenient to use. For Chinese huge population of menopausal women, the scoring system should he considered a reliable screening tool for depressive symptoms.",2017,01/07/2022 10:40,01/07/2022 10:40,,1993-2001,,,12,,,,,,,,,,,,,,WOS:000416116100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XUPHY2AC,journalArticle,2010,"Jedel, E; Waern, M; Gustafson, D; Landen, M; Eriksson, E; Holm, G; Nilsson, L; Lind, AK; Janson, PO; Stener-Victorin, E",Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index,HUMAN REPRODUCTION,,0268-1161,10.1093/humrep/dep384,,"Anxiety and depression are more prevalent in women with polycystic ovary syndrome (PCOS) than in those without this disorder. Possible confounding effects of overweight and obesity are suggested. The aim was to compare symptoms of anxiety and depression in women with PCOS and controls matched for age, body weight and body mass index (BMI). Women with PCOS (n = 30) and controls (n = 30) were recruited from the community. Persons with ongoing psychotropic medication were excluded. All potential participants underwent gynecological examination to confirm case-control status. Participants completed the self-reported versions of the Brief Scale for Anxiety (BSA-S) and Montgomery Asberg Depression Rating Scale (MADRS-S). Women with PCOS had a higher BSA-S score compared with controls (median, range: 10.5, 1-24 versus 5.0, 0-28, P < 0.001). They scored higher on the following four individual symptoms: reduced sleep (2.0, 0-5 versus 0, 0-2, P < 0.001), worry (1.5, 0-4 versus 0, 0-6, P = 0.004), phobias (1, 0-4 versus 0, 0-3, P < 0.001), and pain (1, 0-3 versus 0, 0-2, P < 0.001). No statistical difference was demonstrated regarding MADRS-S scores (10.0, 0-27 versus 5.5, 0-24, P = 0.053). Only one of the nine MADRS-S symptoms, reduced sleep, which is also included in the BSA-S, differed between cases and controls. Several anxiety symptoms distinguished women with PCOS from a control group matched on BMI. A better understanding of the symptoms is needed to identify and alleviate anxiety symptoms in this vulnerable group.",2010-02,01/07/2022 10:40,01/07/2022 10:40,,450-456,,2,25,,,,,,,,,,,,,,WOS:000273703400023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AHM4VRJI,journalArticle,2010,"Scozzari, G; Toppino, M; Famiglietti, F; Bonnet, G; Morino, M",10-year Follow-up of Laparoscopic Vertical Banded Gastroplasty Good Results in Selected Patients,ANNALS OF SURGERY,,0003-4932,10.1097/SLA.0b013e3181fd35b0,,"Objective: To evaluate the long-term results of laparoscopic vertical banded gastroplasty (VBG) for morbid obesity. Background: Laparoscopic VBG, a safe and straightforward bariatric procedure characterized by good short-term results, has been progressively replaced by other more complex procedures on the basis of a presumed high rate of long-term failure. Nevertheless, some authors have recently reported long-term efficacy in selected patients. Methods: All patients who underwent laparoscopic VBG were included in a prospective database. Patients reaching 10-year follow-up received a complete evaluation including clinical, endoscopic, and biochemical examinations. Results: Between January 1996 and March 1999, 266 morbidly obese patients underwent bariatric procedures. Among them, 213 were selected for laparoscopic VBG; exclusion criteria were as follows: contraindications to pneumoperitoneum, gastroesophageal reflux disease, and psychological contraindications to restrictive procedures. Mean age, preoperative weight, and body mass index were 36.9 years, 123.6 kg, and 45.4 kg/m(2), respectively. Intraoperative complication rate and conversion rate were 0.9% and 0.9%, respectively. Early postoperative complication rate was 4.2% and early reoperation rate was 0.5%. Mean hospital length of stay was 6.3 days. Mortality was nil. The 10-year follow-up rate was 70.4% (150 patients). Late postoperative complication rate was 14.7%, and 10-year revisional surgery rate was 10.0%. The excess weight loss percentages at 3, 5, and 10 years were 65.0%, 59.9%, and 59.8%, respectively. The resolution and/or improvement rate for comorbidity were 47.5% for hypertension, 55.6% for diabetes, 75% for sleep apnea, and 47.4% for arthritis. Mean Moorehead-Ardelt Quality of Life Questionnaire and BAROS values were 1.4 and 3.8, respectively. Conclusions: The present study demonstrates that laparoscopic VBG in carefully selected patients leads to long-term results comparable with more complex and invasive procedures. Given the low postoperative morbidity for laparoscopic VBG, its present clinical role should be, in our opinion, reevaluated.",2010-11,01/07/2022 10:40,01/07/2022 10:40,,831-838,,5,252,,,,,,,,,,,,,,WOS:000283646000015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QHDV3TSN,journalArticle,2011,"Low, Y; Preud'homme, X; Goforth, HW; Omonuwa, T; Krystal, AD",The Association of Fatigue with Depression and Insomnia in HIV-Seropositive Patients: A Pilot Study,SLEEP,,0161-8105,10.5665/sleep.1446,,"Objective: Fatigue is a pervasive symptom associated with HIV, resulting in significant functioning impairment; but little is known about its etiology or treatment. In patients with primary insomnia, data have shown improvement in fatigue following successful treatment of insomnia. However, little is known about the role of insomnia in patients with fatigue in HIV. This manuscript seeks to test the hypothesis that insomnia severity is correlated with increased fatigue in HIV-seropositive patients. Methods: Fifty-seven ambulatory HIV-seropositive patients, aged 18-60 years, with a DSM-IV-TR diagnosis of insomnia, were administered the Insomnia Severity Index (ISI), Piper Fatigue Scale (PFS), Hospital Anxiety and Depression scale, and Hamilton Depression Rating Scale (HAM-D). Their most recent CD4 count and time since diagnosis of HIV were recorded. Regression analysis was carried out with PFS as the dependent variable. Results: A higher ISI score correlated with higher PFS score, (R-2 = 0.1713, P = 0.0042). Overall depression severity was not significantly correlated with PFS score, except in the most severely depressed subgroup, in which the HADS depression score was the strongest predictor of PFS (R2 = 0.182, P = 0.0009). In participants without depression, ISI accounted for most of the variance in fatigue (R-2 = 0.6035, P = 0.0011). Conclusions: Greater insomnia severity is associated with greater fatigue severity in HIV seropositive patients. Depression may contribute to both fatigue and insomnia. In the absence of depression, the treatment of insomnia may emerge as a treatment strategy to help alleviate fatigue. Further studies are needed to confirm these data.",01/12/2011,01/07/2022 10:40,01/07/2022 10:40,,1723-1726,,12,34,,,,,,,,,,,,,,WOS:000297689800019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VL2DXEXW,journalArticle,2021,"Althumiri, NA; Basyouni, MH; AlMousa, N; AlJuwaysim, MF; Almubark, RA; BinDhim, NF; Alkhamaali, Z; Alqahtani, SA","Obesity in Saudi Arabia in 2020: Prevalence, Distribution, and Its Current Association with Various Health Conditions",HEALTHCARE,,2227-9032,10.3390/healthcare9030311,,"The global prevalence of obesity is increasing. Obesity is associated with many chronic diseases and health conditions. This study aims to estimate the current prevalence of obesity in Saudi Arabia and described the current national-level status of the association between obesity and various health conditions. This study is a nationwide cross-sectional survey conducted over phone-interviews in June 2020. In this study, a proportional quota-sampling technique was used to obtain equal distributions of participants, stratified by age and gender, across the 13 regions of Saudi Arabia. Weight and height were self-reported, and the obesity was determined as BMI >= 30. Logistic regression adjusted for age and gender was used for exploring current associations between obesity and health conditions. Of the 6239 participants contacted, 4709 participants responded and completed the interview with a response rate of 75.48%. Of them, 50.1% were female, the mean age was 36.4 +/- 13.5 (Range: 18-90), and the median age was 36. The national weighted prevalence of obesity (BMI >= 30) was 24.7%, and the prevalence in the sample (unweighted) was 21.7%. Obesity was significantly associated with type 2 diabetes [Odd ratio, (OR) = 1.52], hypercholesterolemia (OR = 1.69), hypertension (OR = 1.61), lung diseases (OR = 1.69), rheumatoid arthritis (OR = 1.57), sleep apnea (OR = 1.82), colon diseases (OR = 1.31), and thyroid disorders (OR = 1.8). This study provides an update on the recent prevalence of obesity in Saudi Arabia. It also shows the variation in prevalence rates between different regions, which might be explored further. Although obesity shows a decreasing trend, almost one-quarter of this study sample were obese. Obesity is currently associated with many health conditions that can affect the individuals' quality of life, impose stress on the healthcare system and impose an economic burden on the country. This evidence highlights the need for action to focus more on obesity in Saudi Arabia.",2021-03,01/07/2022 10:40,01/07/2022 10:40,,,,3,9,,,,,,,,,,,,,,WOS:000633694000001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3WDQGT9V,journalArticle,2018,"Pols, AD; Schipper, K; Overkamp, D; van Marwijk, HWJ; van Tulder, MW; Adriaanse, MC",Patients' and practice nurses' perceptions of depression in patients with type 2diabetes and/or coronary heart disease screened for subthreshold depression,BMC FAMILY PRACTICE,,1471-2296,10.1186/s12875-018-0870-y,,"BackgroundComorbid depression is common in patients with type 2 diabetes (DM2) and/or coronary heart disease (CHD) and is associated with poor quality of life and adverse health outcomes. However, little is known about patients' and practice nurses' (PNs) perceptions of depression. Tailoring care to these perceptions may affect depression detection and patient engagement with treatment and prevention programs. This study aimed to explore patients' and PNs' perceptions of depression in patients with DM2/CHD screened for subthreshold depression.MethodsA qualitative study was conducted as part of a Dutch stepped-care prevention project. Using a purposive sampling strategy, data were collected through semi-structured interviews with 15 patients and 9 PNs. After consent, all interviews were recorded, transcribed verbatim and analyzed independently by two researchers with Atlas.ti.5.7.1 software. The patient and PN datasets were inspected for commonalities using a constant comparative method, from which a final thematic framework was generated.ResultsMain themes were: illness perception, need for care and causes of depression. Patients generally considered themselves at least mildly depressed, but perceived severity levels were not always congruent with Patient Health Questionnaire 9 scores at inclusion. Initially recognizing or naming their mental state as a (subthreshold) depression was difficult for some. Having trouble sleeping was frequently experienced as the most burdensome symptom. Most experienced a need for care; psycho-educational advice and talking therapy were preferred. Perceived symptom severity corresponded with perceived need for care, but did not necessarily match help-seeking behaviour. Main named barriers to help-seeking were experienced stigma and lack of awareness of depression and mental health care possibilities. PNs frequently perceived patients as not depressed and with minimal need for specific care except for attention. Participants pointed to a mix of causes of depression, most related to negative life events and circumstances and perceived indirect links with DM2/CHD.ConclusionData of the interviewed patients and PNs suggest that they have different perceptions about (subthreshold) depressive illness and the need for care, although views on its causes seem to overlap more.",23/12/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,19,,,,,,,,,,,,,,WOS:000454215200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3CZGSS8F,journalArticle,2013,"Qiu, L; Cheng, XQ; Wu, J; Liu, JT; Xu, T; Ding, HT; Liu, YH; Ge, ZM; Wang, YJ; Han, HJ; Liu, J; Zhu, GJ",Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces,BMC PUBLIC HEALTH,,1471-2458,10.1186/1471-2458-13-664,,"Background: Hyperuricemia (HUA) is a potential risk factor for developing insulin resistance, hypertension, dyslipidemia and cardiovascular disease. Therefore, we studied the prevalence of HUA and associated risk factors in the population of two provinces in northern China. Methods: Based on the research of Chinese Physiological Constant and Health Conditions conducted in 2008-2010, we enrolled 29,639 subjects in a randomized, stratified study in four sampling areas in Heilongjiang Province and the Inner Mongolia Autonomous Region. We collected 13,140 serum samples to determine biochemical indicators including uric acid(UA), glucose, blood lipids, liver function, and renal function, and finally a representative sample of 8439 aged 18 years and older was determined. We also defined and stratified HUA, hypertension, diabetes, obesity and lipid abnormalities according to international guidelines. Results: There were significant differences in the UA levels between different genders and regions. The total prevalence of HUA is 13.7%. Men had a higher prevalence of HUA than women (21% vs. 7.9%; P < 0.0001). As age increased, HUA prevalence decreased in men but rose in women. The suburbs of big cities had the highest HUA prevalence (18.7%), and in high-prevalence areas the proportion of women with HUA also increased. A stepwise logistic regression model was used to filter out twelve HUA risk factors, including age, gender, residence, hypercholesterolemia, hypertriglyceridemia, impaired fasting glucose, hypertension, obesity, abdominal obesity, CKD, drinking and sleeping. After adjusting for these factors, the odds ratio of HUA was 1.92 times higher in men than in women. Compared with agricultural and pastoral areas, the odds ratio of having HUA was 2.14 for participants in the suburbs of big cities and 1.57 in the center of big cities. Conclusions: The prevalence of HUA is high in northern China. The differences in HUA prevalence by geographic region suggested that unbalanced economic development and health education, therefore HUA prevention measures should be strengthened to improve quality of life and reduce health care costs.",17/07/2013,01/07/2022 10:40,01/07/2022 10:40,,,,,13,,,,,,,,,,,,,,WOS:000322132700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3TV2MNX6,journalArticle,2018,"Eller-Smith, OC; Nicol, AL; Christianson, JA",Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions,FRONTIERS IN CELLULAR NEUROSCIENCE,,1662-5102,10.3389/fncel.2018.00035,,"Centralized pain syndromes are associated with changes within the central nervous system that amplify peripheral input and/or generate the perception of pain in the absence of a noxious stimulus. Examples of idiopathic functional disorders that are often categorized as centralized pain syndromes include fibromyalgia, chronic pelvic pain syndromes, migraine, and temporomandibular disorder. Patients often suffer from widespread pain, associated with more than one specific syndrome, and report fatigue, mood and sleep disturbances, and poor quality of life. The high degree of symptom comorbidity and a lack of definitive underlying etiology make these syndromes notoriously difficult to treat. The main purpose of this review article is to discuss potential mechanisms of centrally-driven pain amplification and how they may contribute to increased comorbidity, poorer pain outcomes, and decreased quality of life in patients diagnosed with centralized pain syndromes, as well as discuss emerging non-pharmacological therapies that improve symptomology associated with these syndromes. Abnormal regulation and output of the hypothalamic-pituitary-adrenal (HPA) axis is commonly associated with centralized pain disorders. The HPA axis is the primary stress response system and its activation results in downstream production of cortisol and a dampening of the immune response. Patients with centralized pain syndromes often present with hyper- or hypocortisolism and evidence of altered downstream signaling from the HPA axis including increased Mast cell (MC) infiltration and activation, which can lead to sensitization of nearby nociceptive afferents. Increased peripheral input via nociceptor activation can lead to ""hyperalgesic priming"" and/or ""wind-up"" and eventually to central sensitization through long term potentiation in the central nervous system. Other evidence of central modifications has been observed through brain imaging studies of functional connectivity and magnetic resonance spectroscopy and are shown to contribute to the widespreadness of pain and poor mood in patients with fibromyalgia and chronic urological pain. Non-pharmacological therapeutics, including exercise and cognitive behavioral therapy (CBT), have shown great promise in treating symptoms of centralized pain.",13/02/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,12,,,,,,,,,,,,,,WOS:000424940400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BSTQAW9A,journalArticle,2006,"Lee, WJ; Wang, W; Wei, PL; Huang, MT",Weight loss and improvement of obesity-related illness following laparoscopic adjustable gastric banding procedure for morbidly obese patients in Taiwan,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,,0929-6646,10.1016/S0929-6646(09)60174-1,,"Background/Purpose: Laparoscopic adjustable gastric banding (LAGB) is a newly developed minimally invasive surgical procedure for the treatment of morbid obesity. This study was conducted to evaluate body weight loss, surgical complications, and comorbidities after LAGB surgery. Methods: Ninety-one morbidly obese patients (mean age, 31.2 years; mean preoperative weight, 120.8 kg) underwent LAGB in a private Taiwan hospital setting within a comprehensive multidisciplinary bariatric program. Patients were followed up to 36 months. Comorbidities were assessed in 55 patients who completed more than 12 months of follow-up by comparing each comorbid condition before surgery and during follow-up. Results: All procedures were performed laparoscopically with no conversion. Mean operation time was 88.7 +/- 32.9 minutes. There were no intraoperative or major postoperative complications. Minor complication of stoma stenosis occurred in three (3.3%) patients. At 36 months after surgery mean body mass index had decreased from 42.7 to 33.9 kg/m(2), and mean percentage of excess weight loss was 44.8%. Late complications were as follows: intractable vomiting requiring band removal in one (1.1%) patient, tubing problems requiring revision surgery in four (4.3%), and stoma obstruction in two (2.1%). There was no mortality. Resolution or improvement of comorbidities was significant for hyperglycemia and diabetes-related index, dyslipidemia, abnormal liver function, hyperuricemia, sleep apnea, and arthralgia, but not for hypertension. Conclusion: LAGB provides good weight loss and significant reduction in comorbidities with few minor complications.",2006-11,01/07/2022 10:40,01/07/2022 10:40,,887-894,,11,105,,,,,,,,,,,,,,WOS:000242328000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LSJGRGJJ,journalArticle,2013,"Heins, MJ; Korevaar, JC; Rijken, PM; Schellevis, FG",For which health problems do cancer survivors visit their General Practitioner?,EUROPEAN JOURNAL OF CANCER,,0959-8049,10.1016/j.ejca.2012.07.011,,"Primary health care use of cancer patients is increased, even years after active treatment. Insight into the reasons for this could help in developing and improving guidelines and planning of health care, which is important given the expected increase in cancer survivors. Using data from the Netherlands Information Network of Primary Care, we selected 1256 adult breast cancer, 503 prostate cancer and 487 colorectal cancer patients diagnosed between 2001 and 2006. We compared diseases and complaints for which they contacted their General Practitioner (GP) 2-5 years after diagnosis to age and sex matched non-cancer controls from the same practice. Cancer patients consulted their GP more often than controls for acute symptoms such as abdominal pain and fatigue (18% more in breast cancer, 26% more in prostate cancer) and infections, such as cystitis or respiratory infections (45% in breast cancer and 17% in colorectal cancer). Consultations for chronic diseases and psychosocial problems were slightly increased: breast cancer patients had more contacts related to diabetes (55%), sleep disturbance (60%) and depression (64%), prostate cancer patients had more contacts related to hypertension (53) and chronic obstructive pulmonary disease (COPD, 34%). Adverse drug effects were almost twice as often observed in prostate and colorectal cancer patients than in controls. Fear of cancer recurrence was noted as the reason for consulting the GP in only 20 patients. Concluding, increased primary health care use in cancer survivors is mostly related to common infections and acute symptoms, which may be due to direct effects of cancer treatment or increased health concerns. (C) 2012 Elsevier Ltd. All rights reserved.",2013-01,01/07/2022 10:40,01/07/2022 10:40,,211-218,,1,49,,,,,,,,,,,,,,WOS:000312896700025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BXNDXIS6,journalArticle,2019,"LaVela, SL; Etingen, B; Miskevics, S; Heinemann, AW",What determines low satisfaction with life in individuals with spinal cord injury?,JOURNAL OF SPINAL CORD MEDICINE,,1079-0268,10.1080/10790268.2018.1466480,,"Objective: To examine variables associated with satisfaction with life (SWL) in individuals with a spinal cord injury (SCI). Design: Cross-sectional, national survey to assess SWL, demographic and injury characteristics, health care utilization, chronic conditions (obesity, diabetes, heart problems, lung problems, hypertension, high cholesterol), symptoms (poor sleep, pain, depression), social support, grief/loss, and independence. Setting/Participants: Community-dwelling Veterans with SCI. Outcome Measures/Analyses: Bivariate analyses were conducted to assess differences in demographics, injury characteristics, chronic conditions, symptoms, social support, grief/loss, and independence in individuals who reported low SWL (<= 20) vs. average/high SWL (21-35). Multivariate logistic regression assessed factors independently associated with low SWL. Results: 896 Veterans with SCI (62%) responded. Average age was 62 years, the majority were male (94%), Caucasian (77%), and had paraplegia (61%). Odds of low SWL were 2.4 times greater for individuals experiencing pain (OR = 2.43, CI95: 1.47-4.02, P = 0.0005). Odds of low SWL were increased for individuals reporting greater grief/loss due to their SCI (OR = 1.14, CI95: 1.10-1.18, P < 0.0001). Lesser odds of low SWL were seen for individuals reporting greater emotional social support (OR = 0.97, CI95: 0.96-0.99, P < 0.0001) and independence (OR = 0.94, CI95: 0.90-0.97, P < 0.0001). Conclusions: Pain and feelings of grief/loss due to injury were associated with low SWL. Self-perceived independence and good social support were associated with better SWL. Along with addressing pain and facilitating independence and social support, these findings suggest that interventions to improve SWL should focus on helping individuals deal with grief/loss due to injury.",2019,01/07/2022 10:40,01/07/2022 10:40,,236-244,,2,42,,,,,,,,,,,,,,WOS:000474485900013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CUUM9MU4,journalArticle,2021,"Taguchi, T; Nakano, S; Nozawa, K",Effectiveness of Pregabalin Treatment for Neuropathic Pain in Patients with Spine Diseases: A Pooled Analysis of Two Multicenter Observational Studies in Japan,JOURNAL OF PAIN RESEARCH,,1178-7090,10.2147/JPR.S293556,,"Purpose: Neuropathic pain (NeP) is common among patients with chronic pain associated with spine diseases. Practical effectiveness of pregabalin, one of the first-line treatments for NeP, has not been evaluated in an entire population of patients with spine diseases, including various pathophysiological conditions. This pooled analysis aimed to evaluate the therapeutic value of pregabalin for chronic pain with NeP component in patients with spine diseases in routine primary care settings. Patients and Methods: We pooled data from two 8-week prospective observational cohort studies for patients with chronic low back pain with accompanying lower limb pain (NeP component), and patients with chronic cervical pain and accompanying upper limb radiating pain (NeP component) in routine primary care settings in Japan. For both studies, patients were treated for 8 weeks with pregabalin (alone/with other analgesics) or usual care with conventional analgesics (eg, non-steroidal anti-inflammatory drugs). Changes in pain numerical rating scale (NRS), Pain-Related Sleep Interference Scale (PRSIS), and EuroQol 5-dimension 5-level (EQ-5D-5L) scores from baseline to week 8 were summarized and compared between the pregabalin and usual care groups, and also for subgroups of primary diagnosis. Safety was evaluated by adverse events (AEs) in the pregabalin group. Results: The pooled dataset comprised 700 patients (pregabalin group: 302; usual care group: 398). All patient-reported outcomes (PRO) scores significantly improved from baseline to week 8 in the pregabalin than in the usual care group (NRS: P<0.0001; PRSIS: P<0.0001, and EQ-5D-5L: P=0.0006). Overall, all three PRO measures showed greater improvement in the pregabalin than in the usual care group, irrespective of the primary diagnosis. AEs were reported in 36.1% of the pregabalin group. Conclusion: This analysis suggested multi-faceted effectiveness of treatment with pregabalin from the patient's perspectives under a ""real-world"" practice in all patients with chronic NeP from various spine diseases.",2021,01/07/2022 10:40,01/07/2022 10:40,,757-771,,,14,,,,,,,,,,,,,,WOS:000629993600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZLHSZHR3,journalArticle,2015,"Bawa, FLM; Mercer, SW; Atherton, RJ; Clague, F; Keen, A; Scott, NW; Bond, CM",Does mindfulness improve outcomes in patients with chronic pain? Systematic review and meta-analysis,BRITISH JOURNAL OF GENERAL PRACTICE,,0960-1643,10.3399/bjgp15X685297,,"Background Chronic pain and its associated distress and disability are common reasons for seeking medical help. Patients with chronic pain use primary healthcare services five times more than the rest of the population. Mindfulness has become an increasingly popular self-management technique. Aim To assess the effectiveness of mindfulness-based interventions for patients with chronic pain. Design and setting Systematic review and meta-analysis including randomised controlled trials of mindfulness-based interventions for chronic pain. There was no restriction to study site or setting. Method The databases MEDLINE (R), Embase, AMED, CINAHL, PsycINFO, and Index to Theses were searched. Titles, abstracts, and full texts were screened iteratively against inclusion criteria of: randomised controlled trials of mindfulness-based intervention; patients with non-malignant chronic pain; and economic, clinical, or humanistic outcome reported. Included studies were assessed with the Yates Quality Rating Scale. Meta-analysis was conducted. Results Eleven studies were included. Chronic pain conditions included: fibromyalgia, rheumatoid arthritis, chronic musculoskeletal pain, failed back surgery syndrome, and mixed aetiology. Papers were of mixed methodological quality. Main outcomes reported were pain intensity, depression, physical functioning, quality of life, pain acceptance, and mindfulness. Economic outcomes were rarely reported. Meta-analysis effect sizes for clinical outcomes ranged from 0.12 (95% confidence interval [CI] = -0.05 to 0.30) (depression) to 1.32 (95% CI = -1.19 to 3.82) (sleep quality), and for humanistic outcomes 0.03 (95% CI = -0.66 to 0.72) (mindfulness) to 1.58 (95% CI = -0.57 to 3.74) (pain acceptance). Studies with active, compared with inactive, control groups showed smaller effects. Conclusion There is limited evidence for effectiveness of mindfulness-based interventions for patients with chronic pain. Better-quality studies are required.",2015-06,01/07/2022 10:40,01/07/2022 10:40,,E387-E400,,635,65,,,,,,,,,,,,,,WOS:000356967000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TIPK85L6,journalArticle,2016,"Broussard, JL; Devkota, S","The changing microbial landscape of Western society: Diet, dwellings and discordance",MOLECULAR METABOLISM,,2212-8778,10.1016/j.molmet.2016.07.007,,"Background: The last 50-100 years has been marked by a sharp rise in so-called ""Western-diseases"" in those countries that have experienced major industrial advances and shifts towards urbanized living. These diseases include obesity, type 2 diabetes, inflammatory bowel diseases, and food allergies in which chronic dysregulation of metabolic and/or immune processes appear to be involved, and are likely a byproduct of new environmental influences on our ancient genome. What we now appreciate is that this genome consists of both human and co-evolved microbial genes of the trillions of microbes residing in our body. Together, hostemicrobe interactions may be determined by the changing diets and behaviors of the Western lifestyle, influencing the etiopathogenesis of ""new-age"" diseases. Scope of review: This review takes an anthropological approach to the potential interplay of the host and its gut microbiome in the post-industrialization rise in chronic inflammatory and metabolic diseases. The discussion highlights both the changes in diet and the physical environment that have co-occurred with these diseases and the latest evidence demonstrating the role of hostemicrobe interactions in understanding biological responses to the changing environment. Major conclusions: Technological advances that have led to changes in agriculture and engineering have altered our eating and living behaviors in ways never before possible in human history. These changes also have altered the bacterial communities within the human body in ways that are seemingly linked with the rise of many intestinal and systemic metabolic and inflammatory diseases. Insights into the mechanisms of this reciprocal exchange between the environment and the human gut microbiome may offer potential to attenuate the chronic health conditions that derail quality of life. This article is part of a special issue on microbiota. (C) 2016 Published by Elsevier GmbH.",2016-09,01/07/2022 10:40,01/07/2022 10:40,,737-742,,9,5,,,,,,,,,,,,,,WOS:000386882600002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JYAL7L64,journalArticle,2004,"Zacharin, M; Kanumakala, S",Pamidronate treatment of less severe forms of osteogenesis imperfecta in children,JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM,,0334-018X,,,"Background. Bisphosphonate therapy improves bone quality in children with severe osteogenesis imperfecta (OI). Children with milder phenotypes also have prepubertal fractures, bone pain and reduced bone mass, predisposing them to adult osteoporosis. Objective: To evaluate treatment effects of pamidronate in children with mild phenotypes of OI. Methods: Open label, 2-year observational study of 18 patients, using pamidronate, with clinical, biochemical and radiological monitoring. Results: Over 2 years, bone pain decreased from 16 to 1 patient and disturbed sleep from 12 children to 0. Independent mobility improved from 10 to 17 children. Fracture incidence decreased from 1.6 to 0.5 fractures/child/year. Surgical interventions decreased from a mean 1.3 procedures/patient to 0 in the second year of treatment. Growth velocity remained stable at a mean 4.8 cm/year. Mean lumbar vertebral bone mineral density improved by 40.8%, from 0.375 to 0.528 g/cm(2) (p <0.0001), z-score from -3.77 to -2.44 (p <0.0001). Mean vertebral height improved by 17.3%, from 15.6 to 18.38 mm (p = 0.07); plasma alkaline phosphatase decreased from 222 to 169 U/l (p = 0.0009) and urinary deoxypyridinoline crosslinks decreased from 26.7 to 21.8 nmol/mmol creatinine (p = 0.21). Two children with vitamin D insufficiency were concurrently treated. A significant association (r = -0.6, p = 0.008) was shown between age at start of treatment and percentage change in BMD after 2 years. Conclusions: Pamidronate treatment improves bone quality in children with mild types of OI. It ameliorates clinical symptoms, improves mobility, reduces fracture frequency and thus improves quality of life and in future is likely to reduce the severity and consequences of adult osteoporosis by improved peak bone mass in these children.",2004-11,01/07/2022 10:40,01/07/2022 10:40,,1511-1517,,11,17,,,,,,,,,,,,,,WOS:000225095600007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DG4PXLG7,journalArticle,2020,"Di Rosa, C; Lattanzi, G; Taylor, SF; Manfrini, S; Khazrai, YM","Very low calorie ketogenic diets in overweight and obesity treatment: Effects on anthropometric parameters, body composition, satiety, lipid profile and microbiota",OBESITY RESEARCH & CLINICAL PRACTICE,,1871-403X,10.1016/j.orcp.2020.08.009,,"According to the World Health Organization (WHO) the prevalence of obesity tripled worldwide since 1975. Obesity prevention and treatment is based upon lifestyle changes involving eating habits, physical activity and behaviour therapy. Various dietary patterns have been used as nutritional strategies and, in recent years, interest has been shown in very low calorie ketogenic diets (VLCKD) that provide less than 800 calories (kcal), no more than 20-50 g/day of carbohydrates and 0.8-1.5 g/kg ideal body weight of protein. We conducted a literature review of all clinical trials published between January 2014-November 2019 on people with obesity (PWO) that evaluated VLCKD effects on anthropometric parameters, body composition, satiety, lipid profile and microbiota. Findings from literature showed that VLCKD could be useful to ameliorate the quality of life and sleep of PWO. It leads to a rapid weight loss and results in improvements in body mass index (BMI = kg/m(2)), waist circumference and fat mass reduction preserving lean body mass and resting metabolic rate. This eating pattern reduced the desire to eat and increased satiety. Little is known regarding the effects of VLCKD on the microbiota of PWO for which it is important to conduct further studies. (c) 2020 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.",2020-11,01/07/2022 10:40,01/07/2022 10:40,,491-503,,6,14,,,,,,,,,,,,,,WOS:000595340200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IUEYUITI,bookSection,2011,"Byrne, LN; Avila, D; Seftel, AD; Khera, M; Parikh, PT",Etiology and Risk Factors of Erectile Dysfunction,CONTEMPORARY TREATMENT OF ERECTILE DYSFUNCTION: A CLINICAL GUIDE,2523-3785,,,,"A wide variety of risk factors contribute to erectile dysfunction (ED). Many of these risk factors are treatable yet go unrecognized. Further, many of the treatments of these risk factors have also been implicated in causing the disease. Thus, the treatment of ED may be a complicated issue for the general practitioner. The majority of this chapter focuses on the correlation between cardiovascular disease and erectile dysfunction. A major benefit of screening for ED is that it may lead to early diagnosis of subclinical cardiovascular disease, alerting the clinician to potential treatment intervention in these patients.",2011,01/07/2022 10:40,01/07/2022 10:40,,51-67,,,,,,,,,,,,,,,,,WOS:000286014900005,,,DOI: 10.1007/978-1-60327-536-1_5,,,,,,"McVary, KT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KST3YRIV,journalArticle,2007,"Paran, H; Shargian, L; Shwartz, I; Gutman, M",Long-term follow-up on the effect of silastic ring vertical gastroplasty on weight and co-morbidities,OBESITY SURGERY,,0960-8923,10.1007/s11695-007-9136-9,,"Background: Silastic ring vertical gastroplasty (SRVG) is a simple, effective and reproducible restrictive operation for the treatment of morbid obesity. Over the last years, it has lost its popularity due to the development of adjustable gastric banding systems performed laparoscopically. In order to evaluate the long-term effect of SRVG on weight loss and co-morbidities, we reviewed the results of SRVG operations in our institution. Methods: We reviewed SRVG operations performed in our University-affiliated General Hospital. Data was collected from the patients' in-patient records, their outpatient-clinic files, and from a telephone interview. Results: Between 1989 and 2001, 162 patients were operated upon. Complete follow-up was obtained of 115 patients (71%). The mean follow-up was 7.1 +/- 3 years (range 4 to 16 years). Mean preoperative BMI was 47 kg/m(2) (range 34 to 69 kg/m(2)). Maximal weight loss was obtained within 1 year to a mean BMI of 29 kg/m(2), with a mean excess BMI loss of 67%. Subsequently, there was a small increase in BMI, which stabilized at 34 kg/m(2) up to 15 years after the operation. A rapid, significant improvement in obesity-related co-morbidities was observed regarding hypertension (81%), diabetes (100%), sleep disorders (90%), osteoarthritis (83%) and ischemic heart disease (75%). There was no peri-operative mortality. Early complication rate was 10%. Late complications included postoperative ventral hernia (18%), esophagitis (31%), ring stricture (19%), ring erosion (2 patients), failure of staple line (13%) and obstruction of the pouch with food (19%). 35 patients (30%) required another procedure, 8 of them were eventually converted to other bariatric operations, and 2 patients had the ring removed and refused another bariatric procedure. The overall satisfaction rate was 86%. Conclusions: SRVG is a simple, safe and effective bariatric operation in selected patients with morbid obesity. It results in a rapid, excellent effect on obesity-related co-morbidities and good long-term effect in weight loss, which compares positively with other, more complicated bariatric operations.",2007-06,01/07/2022 10:40,01/07/2022 10:40,,737-741,,6,17,,,,,,,,,,,,,,WOS:000246911800007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Z5SZFJAC,journalArticle,2012,"Fanous, M; Carlin, A",Surgical resident participation in laparoscopic Roux-en-Y bypass: Is it safe?,SURGERY,,0039-6060,10.1016/j.surg.2012.02.014,,"Background. The majority of bariatric surgeons use dedicated surgical assistants when performing laparoscopic Roux-en-Y gastric bypass (LGBP) because of the technical difficulty and steep learning curve involved in the operation. At our institution, either a senior surgical resident (SSR) or a physician assistant (PA) participates in LGBP cases. The PA's role is confined to assisting, whereas the SSR progressively acts as the operating surgeon. We were interested in evaluating patient outcomes to determine whether any differences existed between the LGBP operations in which either the PA or the SSR participated. Methods. All patients undergoing LGBP between January 2007 and December 2009 in our prospectively collected bariatric database were reviewed. Demographics, baseline measures, intraoperative parameters, and outcomes were compared. Results. A total of 711 patients were identified. The group involving PAs included 343 patients, and the group involving SSRs included 368 patients. Preoperative comorbidities, including diabetes, hypertension, coronary artery disease, asthma, sleep apnea, hyperlipidemia, musculoskeletal disability, and depression, were similar in both groups. Personal histories of venous thromboembolism were higher in the PA group (5.1% vs 2.5%; P = .075). The mean body-mass indexes (BMI) (53 +/- 9 vs 51 +/- 8 kg/m(2); P = .006) and weights (323 +/- 67 vs 306 +/- 59 lbs; P < .001) in the PA group were significantly higher than in the SSR group. The proportion of males was higher in the PA group (24% vs 16%; P = .008). The operative time was significantly shorter in the PA group (121 +/- 36 vs 164 +/- 30 minutes; P < .001). There was no significant difference between the groups in intraoperative complications, length of hospital stay, 30-day complications, or reoperations within 1 year There were no mortalities in either group. The 1-year percent excess weight loss (64% vs 66%) was similar in the PA and SSR groups, respectively. Conclusion. SSR participation in LGBP prolongs operative time but does not increase complications, mortality rates, or length of stay. Therefore, SSR participation in LGBP is safe and produces outcomes comparable to those performed with PAs. (Surgery 2012;152:21-5.)",2012-07,01/07/2022 10:40,01/07/2022 10:40,,21-25,,1,152,,,,,,,,,,,,,,WOS:000305853800004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3HJUINQH,book,2014,"Chapman, DG; Suratt, BT; Dixon, AE",Respiratory Diseases in Obesity,,978-1-62703-770-9,,,,,2014,01/07/2022 10:40,01/07/2022 10:40,,,295,,,,,,"ADIPOSE TISSUE AND ADIPOKINES IN HEALTH AND DISEASE, 2ND EDITION",,,,,,,,,,WOS:000340098400021,,,Pages: 314 DOI: 10.1007/978-1-62703-770-9_19,,,,,,"Fantuzzi, G; Braunschweig, C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ARNFYBXL,journalArticle,2014,"Al-Hashel, JY; Ahmed, SF; Alroughani, R; Goadsby, PJ",Migraine among medical students in Kuwait University,JOURNAL OF HEADACHE AND PAIN,,1129-2369,10.1186/1129-2377-15-26,,"Medical students routinely have triggers, notably stress and irregular sleep, which are typically associated with migraine. We hypothesized that they may be at higher risk to manifest migraine. We aimed to determine the prevalence of migraine among medical students in Kuwait University. This is cross-sectional, questionnaire-based study. Participants who had two or more headaches in the last 3 months were subjected to two preliminary questions and participants with at least one positive response were asked to perform the validated Identification of Migraine (ID Migraine (TM)) test. Frequency of headache per month and its severity were also reported. Migraine headache was suggested in 27.9% subjects based on ID-Migraine (TM). Migraine prevalence (35.5% and 44%, versus 31.1%, 25%, 21.1%, 14.8%, 26.5%, p < 0.000), frequency (5.55 + 1.34 and 7.23 + 1.27, versus 3.77 +/- 0.99, 2.88 +/- 0.85, 3.07 +/- 0.96, 2.75 +/- 0.75, 4.06 +/- 1.66, p < 0.000); and severity of headache (59.1% and 68.2%, versus 28.3%,8.3%, 6.7%,16.7%, p < 0.000; were significantly increased among students in the last 2 years compared to first five years of their study. Stress 43 (24.9%), irregular sleep 36 (20.8%), and substantial reading tasks 32 (18.5%), were the most common triggering factors cited by the students. The prevalence of migraine is higher among medical students in Kuwait University compared to other published studies. The migraine prevalence, frequency and headache severity, all increased in the final two years of education.",10/05/2014,01/07/2022 10:40,01/07/2022 10:40,,01-Jun,,,15,,,,,,,,,,,,,,WOS:000336396800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A3T85E6J,journalArticle,2018,"Parsons, B; Pan, XP; Xie, L; Chen, YX; Ortiz, M; Whalen, E",Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients,JOURNAL OF PAIN RESEARCH,,1178-7090,10.2147/JPR.S157856,,"Purpose: Pregabalin is indicated for postherpetic neuralgia (PHN) in multiple countries, including China. This analysis compared pregabalin efficacy and safety in Chinese and international patients with PHN. Patients and methods: Data from Chinese and international randomized, double-blind, placebo-controlled trials were compared. Pregabalin was administered at fixed (150, 300, or 600 mg/day) or flexible (150-600 mg/day) doses. The main efficacy measure was mean pain score change at endpoint on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. Secondary efficacy measures included proportions of 30% and 50% pain responders, pain-related sleep interference (PRSI) scores, and proportions of Patient Global Impression of Change (PGIC) responders. The incidences of serious adverse events (SAES) and adverse events (AEs) were used to assess safety. The effect of baseline pain severity on efficacy was tested. The proportions of patients with severe baseline pain who had moderate or mild pain at endpoint were also assessed. Results: A total of 1166 patients were analyzed: 312 Chinese and 854 international. Overall, results were similar between Chinese and international patients. Pregabalin statistically significantly improved mean pain score versus placebo (least squares mean difference [95% CIs]: Chinese, -0.8 [-1.2, -0.5]; international, -1.3 [-1.6, -1.0]; both p<0.001). Pregabalin Was statistically significantly better than placebo in Chinese and international patient groups in the proportions of 30% and 50% pain responders, PRSI scores, and proportions of PGIC responders. Baseline pain severity did not affect efficacy, except for some measures in Chinese patients with moderate baseline pain. Similar proportions of pregabalin-treated patients with severe baseline pain had moderate or mild pain at endpoint in both groups. SAE and AE profiles were comparable in Chinese and international patient groups, except incidences were commonly higher in international patients. Conclusion: Chinese and international patients with PHN exhibit comparable pregabalin efficacy and safety, highlighting the utility of pregabalin for diverse PHN patient populations.",2018,01/07/2022 10:40,01/07/2022 10:40,,1699-1708,,,11,,,,,,,,,,,,,,WOS:000443450200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
S7TLHPFZ,journalArticle,2018,"Sharma, G; Nor-Hanipah, Z; Haskins, IN; Punchai, S; Strong, AT; Tu, C; Rodriguez, JH; Schauer, PR; Kroh, M",Comparative Outcomes of Bariatric Surgery in Patients with Impaired Mobility and Ambulatory Population,OBESITY SURGERY,,0960-8923,10.1007/s11695-018-3132-0,,"Purpose This study aims to characterize complications, metabolic improvement, and change in ambulation status for patients with impaired mobility undergoing bariatric surgery. Material and Methods Individuals undergoing primary sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) from February 2008 to December 2015 were included. Impaired mobility (WC) was defined as using a wheelchair or motorized scooter for at least part of a typical day. The WC group was propensity score matched to ambulatory patients (1:5 ratio). Comparisons were made for 30-day morbidity and mortality and 1-year improvement in weight-related comorbidities. Results There were 93 patients in the WC group matched to 465 ambulatory controls. The median operative time (180 vs 159 min, p = 0.003) and postoperative length of stay (4 vs 3 days, p <= 0.001) was higher in the WC group. There were no differences in readmission or all-cause morbidity within 30 days. The median percent excess weight loss (%EWL) at 1 year was similar (WC group, 65% available, 53% EWL vs AMB group, 73% available, 54% EWL); however, patients with impaired mobility were less likely to experience improvement in diabetes (76 vs 90%, p = 0.046), hypertension (63 vs 82%, p < 0.005), and obstructive sleep apnea (53 vs 71%, p < 0.001). Within the WC group, 62% had improvement in their mobility status, eliminating dependence on wheelchair or scooter assistance. Conclusion Patients with both obesity and impaired mobility experience similar rates of perioperative morbidity and weight loss at 1 year compared to ambulatory controls. However, improvement in weight-related comorbidities may be less likely with impaired mobility.",2018-07,01/07/2022 10:40,01/07/2022 10:40,,2014-2024,,7,28,,,,,,,,,,,,,,WOS:000436300100028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5294LIGB,conferencePaper,2009,"Imamura, M; Cassius, DA; Fregni, F",Fibromyalgia: From treatment to rehabilitation,,,,10.1016/j.eujps.2009.08.011,,"Fibromyalgia is a clinical syndrome of chronic widespread pain and reduced pain thresholds to palpation. The pathophysiology remains unknown, but there is increasing evidence that peripheral and central sensitization cause an amplification of sensory impulses that may alter pain perception in fibromyalgia patients. Interventions to treat fibromyalgia should aim at different targets simultaneously in order to reduce peripheral and central sensitization. There are both pharmacologic and non-pharmacologic approaches with evidence for effectiveness in the treatment of fibromyalgia and its associated symptoms. Evidence from randomized trials and meta-analyses shows that partial and short-term improvements in fibromyalgia symptoms can be achieved with low doses of antidepressants and with physical activity such as aerobic and strengthening exercises. A multidimensional approach which emphasizes education and integration of exercise and cognitive behavior therapy improves quality of life and reduces pain, fatigue and depressive symptoms when measured on a short term basis. More recently, trials have shown the neuromodulators gabapentin and pregabalin to be effective in reducing pain and improving quality of sleep in fibromyalgia. In addition, small trials of noninvasive brain stimulation have also shown benefits in reducing pain in fibromyalgia. It is essential to keep in mind that some important clinical conditions can mimic and overlap with fibromyalgia and should always be ruled out by a complete history, physical examination and appropriate laboratory testing. (C) 2009 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.",2009,01/07/2022 10:40,01/07/2022 10:40,,117-+,,,,,,,,,,,,,,,,,WOS:000282721600018,,,,,,,,,"Allegri, M; Bonezzi, C; Braschi, A; Fanelli, G; Redi, CA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ACUTE AND CHRONIC PAIN: WHERE WE ARE AND WHERE WE HAVE TO GO,,,,,,,,,,,,,,,
HWQUDMSA,journalArticle,2021,"Selph, SS; Skelly, AC; Wasson, N; Dettori, JR; Brodt, ED; Ensrud, E; Elliot, D; Dissinger, KM; McDonagh, M","Physical Activity and the Health of Wheelchair Users: A Systematic Review in Multiple Sclerosis, Cerebral Palsy, and Spinal Cord Injury",ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION,,0003-9993,10.1016/j.apmr.2021.10.002,,"Objective: To understand the benefits and harms of physical activity in people who may require a wheelchair with a focus on people with multiple sclerosis (MS), cerebral palsy (CP), and spinal cord injury (SCI). Data Sources: Searches were conducted in MEDLINE, Cumulative Index to Nursing and Allied Health, PsycINFO, Cochrane CENTRAL, and Embase (January 2008 through November 2020). Study Selection: Randomized controlled trials, nonrandomized trials, and cohort studies of observed physical activity (at least 10 sessions on 10 days) in participants with MS, CP, and SCI. Data Extraction: We conducted dual data abstraction, quality assessment, and strength of evidence. Measures of physical functioning are reported individually where sufficient data exist and grouped as ""function"" where data are scant. Data Synthesis: No studies provided evidence for prevention of cardiovascular conditions, development of diabetes, or obesity. Among 168 included studies, 44% enrolled participants with MS (38% CP, 18% SCI). Studies in MS found walking ability may be improved with treadmill training and multimodal exercises; function may be improved with treadmill, balance exercises, and motion gaming; balance is likely improved with balance exercises and may be improved with aquatic exercises, robot-assisted gait training (RAGT), motion gaming, and multimodal exercises; activities of daily living (ADL), female sexual function, and spasticity may be improved with aquatic therapy; sleep may be improved with aerobic exercises and aerobic fitness with multimodal exercises. In CP, balance may be improved with hippotherapy and motion gaming; function may be improved with cycling, treadmill, and hippotherapy. In SCI, ADL may be improved with RAGT. Conclusions: Depending on population and type of exercise, physical activity was associated with improvements in walking, function, balance, depression, sleep, ADL, spasticity, female sexual function, and aerobic capacity. Few harms of physical activity were reported in studies. Future studies are needed to address evidence gaps and to confirm findings. Archives of Physical Medicine and Rehabilitation 2021;102:2464-81 (c) 2021 The Authors. Published by Elsevier Inc. on behalf of The American Congress of Rehabilitation Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)",2021-12,01/07/2022 10:40,01/07/2022 10:40,,2464-+,,12,102,,,,,,,,,,,,,,WOS:000726577100020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5S4468XU,journalArticle,2012,"Reid, WD; Yamabayashi, C; Goodridge, D; Chung, F; Hunt, MA; Marciniuk, DD; Brooks, D; Chen, YW; Hoens, AM; Camp, PG",Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews,INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,1178-2005,10.2147/COPD.S29750,,"Introduction: The prescription of physical activity for hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can be complicated by the presence of comorbidities. The current research aimed to synthesize the relevant literature on the benefits of exercise for people with multimorbidities who experience an AECOPD, and ask: What are the parameters and outcomes of exercise in AECOPD and in conditions that are common comorbidities as reported by systematic reviews (SRs)? Methods: An SR was performed using the Cochrane Collaboration protocol. Nine electronic databases were searched up to July 2011. Articles were included if they (1) described participants with AECOPD, chronic obstructive pulmonary disease (COPD), or one of eleven common comorbidities, (2) were an SR, (3) examined aerobic training (AT), resistance training (RT), balance training (BT), or a combination thereof, (4) included at least one outcome of fitness, and (5) compared exercise training versus control/sham. Results: This synthesis examined 58 SRs of exercise training in people with AECOPD, COPD, or eleven chronic conditions commonly associated with COPD. Meta-analyses of endurance (aerobic or exercise capacity, 6-minute walk distance - 6MWD) were shown to significantly improve in most conditions (except osteoarthritis, osteoporosis, and depression), whereas strength was shown to improve in five of the 13 conditions searched: COPD, older adults, heart failure, ischemic heart disease, and diabetes. Several studies of different conditions also reported improvements in quality of life, function, and control or prevention outcomes. Meta-analyses also demonstrate that exercise training decreases the risk of mortality in older adults, and those with COPD or ischemic heart disease. The most common types of training were AT and RT. BT and functional training were commonly applied in older adults. The quality of the SRs for most conditions was moderate to excellent (>65%) as evaluated by AMSTAR scores. Conclusion: In summary, this synthesis showed evidence of significant benefits from exercise training in AECOPD, COPD, and conditions that are common comorbidities. A broader approach to exercise and activity prescription in pulmonary rehabilitation may induce therapeutic benefits to ameliorate clinical sequelae associated with AECOPD and comorbidities such as the inclusion of BT and functional training.",2012,01/07/2022 10:40,01/07/2022 10:40,,297-320,,,7,,,,,,,,,,,,,,WOS:000319053100031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2TFDTHMJ,journalArticle,2019,"Taft, TH; Bedell, A; Craven, MR; Guadagnoli, L; Quinton, S; Hanauer, SB",Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients,INFLAMMATORY BOWEL DISEASES,,1078-0998,10.1093/ibd/izz032,,"Background: Post-traumatic stress (PTS), or the psycho-physiological response to a traumatic or life-threatening event, is implicated in medical patient outcomes. Emerging evidence suggests a complex relationship between PTS, the brain-gut axis, the gut microbiome, and immune function. Inflammatory bowel disease (IBD) may be susceptible to PTS and its subsequent impacts. To date, no study has evaluated PTS in IBD in the United States. Methods: Adult patients with IBD were recruited from an outpatient gastroenterology practice, via social media, and via a research recruitment website. Patients with irritable bowel syndrome (IBS) were recruited as a comparison group. Participants completed demographic and disease information, surgical and hospitalization history, and the PTSD Checklist-Civilian Version (PCL-C). Statistical analyses evaluated rates of PTS in IBD and IBS, including differences between groups for PTS severity. Regression analyses determined potential predictors of PTS. Results: One hundred eighty-eight participants (131 IBD, 57 IBS) completed the study. Thirty-two percent of IBD and 26% of IBS patients met the criteria for significant PTS symptoms based on PCL-C cutoffs. Inflammatory bowel disease patients are more likely to attribute PTS to their disease than IBS patients. Crohn's disease (CD) patients appear to be the most likely to experience PTS, including those being hospitalized or undergoing ileostomy surgery. Symptom severity is the greatest predictor of PTS for ulcerative colitis and IBS. Conclusions: Although PTS is relevant in both IBS and IBD, IBD patients are seemingly more susceptible to PTS due their disease experiences, especially CD patients. The nature of PTS symptoms may contribute to IBD disease processes, most notably through sleep disturbance and ANS arousal. Clinicians should assess for PTS in IBD patients as standard of care, especially after a hospitalization or surgery.",2019-09,01/07/2022 10:40,01/07/2022 10:40,,1577-1585,,9,25,,,,,,,,,,,,,,WOS:000493081500024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7UTRF66N,journalArticle,2019,"Adie, S; Harris, I; Chuan, A; Lewis, P; Naylor, JM",Selecting and optimising patients for total knee arthroplasty,MEDICAL JOURNAL OF AUSTRALIA,,0025-729X,10.5694/mja2.12109,,"The minimum requirements for total knee arthroplasty (TKA) are significant, prolonged symptoms with supporting clinical and radiological signs. Despite interest in screening tools, there is limited evidence for a specific symptom threshold that justifies surgery. Non-operative treatments including medications, exercise and weight loss are unlikely to reverse radiographic changes, but they may improve symptoms and delay the need for surgery. Many patient factors such as mental health and obesity affect both the level of symptomatic improvement after surgery and risks of surgery, but none have been identified as contraindications for the procedure as significant health gains can still be achieved. Although age and sex are associated with patient-reported outcomes and risk of revision, these factors cannot be used to restrict access to TKA, and age cut-offs are not recommended. Evidence regarding pre-operative optimisation of patients to improve post-operative TKA outcomes is limited by the few interventional trials available, particularly in the areas of patient expectation, diabetes, obesity and vascular disease. There is good evidence from randomised controlled trials that pre-operative rehabilitation primarily focusing on exercises for the joint or limb has minimal effect on post-operative TKA outcomes, and there is some evidence from randomised controlled trials that an intensive smoking cessation program before surgery may improve post-operative outcomes. Detailed international guidelines exist on the optimisation of the cardiorespiratory status of surgical patients, and these should be followed for TKA surgery.",2019-02,01/07/2022 10:40,01/07/2022 10:40,,135-141,,3,210,,,,,,,,,,,,,,WOS:000458732900011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WJVCH48S,journalArticle,2006,"Gudmundsson, G; Gislason, T; Lindberg, E; Hallin, R; Ulrik, CS; Brondum, E; Nieminen, MM; Aine, T; Bakke, P; Janson, C",Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity,RESPIRATORY RESEARCH,,1465-993X,10.1186/1465-9921-7-109,,"Background: The aim of this study was to analyse mortality and associated risk factors, with special emphasis on health status, medications and co-morbidity, in patients with chronic obstructive pulmonary disease ( COPD) that had been hospitalized for acute exacerbation. Methods: This prospective study included 416 patients from each of the five Nordic countries that were followed for 24 months. The St. George's Respiratory Questionnaire (SGRQ) was administered. Information on treatment and co-morbidity was obtained. Results: During the follow-up 122 (29.3%) of the 416 patients died. Patients with diabetes had an increased mortality rate [HR = 2.25 (1.28 - 3.95)]. Other risk factors were advanced age, low FEV1 and lower health status. Patients treated with inhaled corticosteroids and/or long-acting beta-2-agonists had a lower risk of death than patients using neither of these types of treatment. Conclusion: Mortality was high after COPD admission, with older age, decreased lung function, lower health status and diabetes the most important risk factors. Treatment with inhaled corticosteroids and long-acting bronchodilators may be associated with lower mortality in patients with COPD.",16/08/2006,01/07/2022 10:40,01/07/2022 10:40,,,,,7,,,,,,,,,,,,,,WOS:000240486200001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5V7JUNIC,journalArticle,2020,"Salvi, P; Kosta, S; Fobi, M; Bhandari, M; Reddy, M; Gusani, R; Khurana, M; Benamro, F; Mathur, W; Bhandari, M",Banded Sleeve Gastrectomy and One Anastomosis Gastric Bypass/Mini-gastric Bypass for Treatment of Obesity: a Retrospective Cohort Comparative Study with 6 years follow-up,OBESITY SURGERY,,0960-8923,10.1007/s11695-019-04369-3,,"Background Banded sleeve gastrectomy (BSG), a modification of the laparoscopic sleeve gastrectomy (SG), and one anastomotic gastric bypass/mini-gastric bypass (OAGB/MGB), a modification to the Roux-en-Y gastric bypass (RYGB), have been reported to enhance weight loss and minimize significant weight regain when compared with the SG and RYGB respectively. However, there has not been any report or study comparing these two operations. Objective We did a retrospective cohort study comparing these two operations and present a review and analysis with follow-up for 6 years. Method A review of all the operations performed at MBRSC in 2011 from a prospectively maintained database was done. Patients who had either a BSG or OAGB/MGB were identified. Data on the patients' profile, co-morbid conditions, perioperative complications, late complications, weight loss, resolution of comorbidities, and changes in quality of life (QLF) were collected reviewed and analyzed. Result Sixty-eight patients were identified who had a primary BSG and 55 who had an OAGB/MGB in 2011. The follow-up rate, the age, BMI, and gender composition were similar in both groups. There were more patients with type 2 diabetes (T2D) in the BSG group than in the OAGB/MGB group (44.1% vs. 27.2%). The incidences of hypertension (HTN) and obstructive sleep apnea (OSA) were higher in the OAGB/MGB group (62% vs. 36% and 96.3% vs. 2.9% respectively). The weight loss was faster in the OAGB/MGB group in the first year, but by the sixth year, the weight loss was slightly higher in the BSG group (84% vs. 79%). Resolution rate of T2D and HTN was higher after the OAGB/MGB group, 86.6% vs. 75.7% and 85.3% vs. 64.0% respectively. There was a 20% incidence of nutrient deficiencies in OAGB/MGB group and none in the BSG group. Conclusion Both operations produced excellent weight loss and maintenance in the short to intermediate term. There was better resolution of T2D and HTN after OAGB/MGB at the expense of a higher incidence of nutrient deficiency and some protein caloric malnutrition. There is need for prospective and larger series studies to confirm these findings.",2020-04,01/07/2022 10:40,01/07/2022 10:40,,1303-1309,,4,30,,,,,,,,,,,,,,WOS:000505347200004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JQ6G4KZE,journalArticle,2015,"Prystowsky, EN; Padanilam, BJ; Fogel, RI",Treatment of Atrial Fibrillation,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,,0098-7484,10.1001/jama.2015.7505,,"IMPORTANCE Atrial fibrillation is a common arrhythmia that affects more than 2.5 million people in the United States and causes substantial morbidity and mortality, especially regarding the increased risk of stroke. OBJECTIVE To summarize atrial fibrillation treatment exclusive of stroke prevention. EVIDENCE REVIEW An Ovid MEDLINE comprehensive literature search was performed on atrial fibrillation therapy excluding anticoagulation and emphasizing studies published within the last 5 years through April 2015 (N = 5044 references). The 2014 atrial fibrillation guideline from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society also was reviewed. FINDINGS Reversible causes of atrial fibrillation should be identified. Risk factor modification, including weight loss and treatment of hypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation episodes. Appropriate anticoagulation is necessary for patients at substantial stroke risk regardless of rate or rhythm treatment strategy. Sinus rhythm is often needed to control symptoms; however, an alternative strategy for atrial fibrillation is appropriate rate control. Rate control is safe in older patients (those who are about age >= 65 years) followed up for a few years, but no such safety data exist for patients younger than 60 years or for those followed up for longer periods. Thus, selection of therapy is individualized, taking into account present and future medical problems for the patient. Choice of an antiarrhythmic drug is based on safety first vs efficacy. Catheter ablation is an effective nonpharmacological alternative that is often, but not always, the second-line treatment. Reduction of the frequency and duration of atrial fibrillation episodes that result in a significant improvement in quality of life is a good marker of drug treatment success and complete elimination of atrial fibrillation is not required in many patients. Rate control is usually achieved with a beta-blocker or non-dihydropyridine calcium channel blockers. It is important to assess adequate rate control during both rest and activity. If the ventricular rate goes uncontrolled for a prolonged period, tachycardia-mediated cardiomyopathy can occur. CONCLUSIONS AND RELEVANCE Therapy for atrial fibrillation includes prevention and modification of inciting causes and appropriate anticoagulation. Rate control is necessary for all patients. Maintenance of sinus rhythm with drugs or catheter ablation should be considered based on the individual needs of each patient.",21/07/2015,01/07/2022 10:40,01/07/2022 10:40,,278-288,,3,314,,,,,,,,,,,,,,WOS:000358228000022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4YA6YCNI,journalArticle,2018,"Moreau, KL",Intersection between gonadal function and vascular aging in women,JOURNAL OF APPLIED PHYSIOLOGY,,8750-7587,10.1152/japplphysiol.00117.2018,,"Vascular aging, characterized by endothelial dysfunction and large elastic arterial stiffening, is a major risk factor for age-associated cardiovascular disease (CVD). Although women have a lower prevalence of CVD until midlife, prevalence rates increase rapidly coincident with the menopausal transition to match those observed in men. The menopausal transition, or perimeno-pause, is a chaotic period that is associated with increased symptoms (e.g., hot flashes, depressed mood, anxiety, sleep disturbances) and CVD risk factors due to changes in the hormonal environment. Because these quality of life factors and CVD risk factors also change with aging, the arteries of women appear to endure a double insult. Our laboratory has been investigating how changes in gonadal function and hormone levels with the menopause transition impacts the vascular aging process in healthy women. Our work has shown that vascular endothelial function progressively declines, and large elastic arterial stiffness is greater across the stages of the menopausal transition. This acceleration in vascular aging may be due to the loss of vasodilatory, antioxidant, anti-inflammatory, and antiproliferative effects of estradiol on the vascular wall. This minireview discusses the impact of changes in gonadal function and hormones with the menopausal transition on vascular aging in women and areas for investigations to further our understanding of the intersection between gonadal function and vascular aging.",2018-12,01/07/2022 10:40,01/07/2022 10:40,,1881-1887,,6,125,,,,,,,,,,,,,,WOS:000454529900025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2PITVZM7,journalArticle,2008,"Nocca, D; Krawczykowsky, D; Bomans, B; Noel, P; Picot, MC; Blanc, PM; de Hons, CD; Millat, B; Gagner, M; Monnier, L; Fabre, JM",A prospective multicenter study of 163 sleeve gastrectomies: Results at 1 and 2 years,OBESITY SURGERY,,0960-8923,10.1007/s11695-007-9288-7,,"Background Good results obtained after laparoscopic sleeve gastrectomy (LSG), in terms of weight loss and morbidity, have been reported in few recent studies. Our team has designed a multicenter prospective study for the evaluation of the effectiveness and feasibility of this operation as a restrictive procedure. Methods From January 2003 to September 2006, 163 patients (68% women) with an average age of 41.57 years, were operated on with a LSG. Indications for this procedure were morbid obese [body mass index (BMI)> 40 kg/m(2)] or severe obese patients (BMI> 35 kg/m(2)) with severe comorbidities (diabetes, sleep apnea, hypertension.) with high-volume eating disorders and superobese patients (BMI> 50 kg/m(2)). Results The average BMI was 45.9 kg/m(2). Forty-four patients (26.99%) were superobese, 84 (51.53%) presented with morbid obesity, and 35 (21.47%) were severe obese patients. Prospective evaluations of excess weight loss, mortality, and morbidity have been analyzed. Laparoscopy was performed in 162 cases (99.39%). No conversion to laparotomy had to be performed. There was no operative mortality. Perioperative complications occurred in 12 cases (7.36%). The reoperation rate was 4.90% and the postoperative morbidity was 6.74% due to six gastric fistulas (3.66%), in which four patients (2.44%) had a previous laparoscopic adjustable gastric banding. Long-term morbidity was caused by esophageal reflux symptoms (11.80%). The percentage of loss in excessive body weight was 48.97% at 6 months, 59.45% at 1 year (120 patients), 62.02% at 18 months, and 61.52% at 2 years (98 patients). No statistical difference was noticed in weight loss between obese and extreme obese patients. Conclusions The sleeve gastrectomy seems to be a safe and effective restrictive bariatric procedure to treat morbid obesity in selected patients. LSG may be proposed for volume-eater patients or to prepare superobese patients for laparoscopic gastric bypass or laparoscopic duodenal switch. However, weight regained, quality of life, and evolution of morbidities due to obesity need to be evaluated in a long-term follow up.",2008-05,01/07/2022 10:40,01/07/2022 10:40,,560-565,,5,18,,,,,,,,,,,,,,WOS:000255630900013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5RSH8J9S,journalArticle,2021,"Koyanagi, A; Smith, L; Shin, JI; Oh, H; Kostev, K; Jacob, L; Abduljabbar, AS; Haro, JM",Multimorbidity and Subjective Cognitive Complaints: Findings from 48 Low- and Middle-Income Countries of the World Health Survey 2002-2004,JOURNAL OF ALZHEIMERS DISEASE,,1387-2877,10.3233/JAD-201592,,"Background: Data on the association between multimorbidity and subjective cognitive complaints (SCC) are lacking from low- and middle-income countries (LMICs). Objective: To assess the association between multimorbidity and SCC among adults from 48 LMICs. Methods: Cross-sectional, community-based data were analyzed from the World Health Survey 2002-2004. Ten chronic conditions (angina, arthritis, asthma, chronic back pain, depression, diabetes, edentulism, hearing problems, tuberculosis, visual impairment) were assessed. Two questions on subjective memory and learning complaints in the past 30 days were used to create a SCC scale ranging from 0 (No SCC) to 100 (worse SCC). Multivariable linear regression and mediation analyses were conducted to explore the associations. Results: A total of 224,842 individuals aged >= 18 years [mean (SD) age 38.3 (16.0) years; 49.3% males] constituted the final sample. Compared to no chronic conditions, the mean SCC score was higher by 7.13 (95%CI = 6.57-7.69), 14.84 (95%CI = 13.91-15.77), 21.10 (95%CI = 19.49-22.70), 27.48 (95%CI = 25.20-29.76), and 33.99 (95%CI = 31.45-36.53) points for 1, 2, 3, 4, and >= 5 chronic conditions. Estimates by sex and age groups (18-44, 45-64, >= 65 years) were similar. Nearly 30% of the association between multimorbidity (i.e., >= 2 chronic conditions) and SCC was explained by psychological factors (i.e., perceived stress, sleep problems, anxiety symptoms). Conclusion: Multimorbidity is associated with SCC among adults in LMICs. Future studies should investigate whether addressing psychological factors in people with multimorbidity can improve cognitive function, and whether screening for SCC in individuals with multimorbidity can be a useful tool to identify individuals at particularly high risk for future cognitive decline.",2021,01/07/2022 10:40,01/07/2022 10:40,,1737-1747,,4,81,,,,,,,,,,,,,,WOS:000663926600032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZRZBQTFS,journalArticle,2017,"Salminen, AV; Garrett, L; Schormair, B; Rozman, J; Giesert, F; Niedermeier, KM; Becker, L; Rathkolb, B; Racz, I; Klingenspor, M; Klopstock, T; Wolf, E; Zimmer, A; Gailus-Durner, V; Torres, M; Fuchs, H; de Angelis, MH; Wurst, W; Holter, SM; Winkelmann, J; German Mouse Clinic Consortium",Meis1: effects on motor phenotypes and the sensorimotor system in mice,DISEASE MODELS & MECHANISMS,,1754-8403,10.1242/dmm.030080,,"MEIS1 encodes a developmental transcription factor and has been linked to restless legs syndrome (RLS) in genome-wide association studies. RLS is a movement disorder leading to severe sleep reduction and has a substantial impact on the quality of life of patients. In genome-wide association studies, MEIS1 has consistently been the gene with the highest effect size and functional studies suggest a disease-relevant downregulation. Therefore, haploinsufficiency of Meis1 could be the system with the most potential for modeling RLS in animals. We used heterozygous Meis1-knockout mice to study the effects of Meis1 haploinsufficiency on mouse behavioral and neurological phenotypes, and to relate the findings to human RLS. We exposed the Meis1-deficient mice to assays of motor, sensorimotor and cognitive ability, and assessed the effect of a dopaminergic receptor 2/3 agonist commonly used in the treatment of RLS. The mutant mice showed a pattern of circadian hyperactivity, which is compatible with human RLS. Moreover, we discovered a replicable prepulse inhibition (PPI) deficit in the Meis1-deficient animals. In addition, these mice were hyposensitive to the PPI-reducing effect of the dopaminergic receptor agonist, highlighting a role of Meis1 in the dopaminergic system. Other reported phenotypes include enhanced social recognition at an older age that was not related to alterations in adult olfactory bulb neurogenesis previously shown to be implicated in this behavior. In conclusion, the Meis1-deficient mice fulfill some of the hallmarks of an RLS animal model, and revealed the role of Meis1 in sensorimotor gating and in the dopaminergic systems modulating it.",01/08/2017,01/07/2022 10:40,01/07/2022 10:40,,981-991,,8,10,,,,,,,,,,,,,,WOS:000406796600005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BYDGX3B4,journalArticle,2021,"Swiatkiewicz, I; Mila-Kierzenkowska, C; Wozniak, A; Szewczyk-Golec, K; Nuszkiewicz, J; Wroblewska, J; Rajewski, P; Eussen, SJPM; Faerch, K; Manoogian, ENC; Panda, S; Taub, PR",Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome,NUTRIENTS,,2072-6643,10.3390/nu13020346,,"Metabolic syndrome (MetS) and erratic eating patterns are associated with circadian rhythm disruption which contributes to an increased cardiometabolic risks. Restricting eating period (time-restricted eating, TRE) can restore robust circadian rhythms and improve cardiometabolic health. We describe a protocol of the Time-Restricted Eating on Metabolic and Neuroendocrine homeostasis, Inflammation, and Oxidative Stress (TREMNIOS) pilot clinical trial in Polish adult patients with MetS and eating period of >= 14 h/day. The study aims to test the feasibility of TRE intervention and methodology for evaluating its efficacy for improving metabolic, neuroendocrine, inflammatory, oxidative stress and cardiac biomarkers, and daily rhythms of behavior for such population. Participants will apply 10-h TRE over a 12-week monitored intervention followed by a 12-week self-directed intervention. Changes in eating window, body weight and composition, biomarkers, and rhythms of behavior will be evaluated. Dietary intake, sleep, activity and wellbeing will be monitored with the myCircadianClock application and questionnaires. Adherence to TRE defined as the proportion of days recorded with app during the monitored intervention in which participants satisfied 10-h TRE is the primary outcome. TREMNIOS will also provide an exploratory framework to depict post-TRE changes in cardiometabolic outcomes and behavior rhythms. This protocol extends previous TRE-related protocols by targeting European population with diagnosed MetS and including long-term intervention, validated tools for monitoring dietary intake and adherence, and comprehensive range of biomarkers. TREMNIOS trial will lay the groundwork for a large-scale randomized controlled trial to determine TRE efficacy for improving cardiometabolic health in MetS population.",2021-02,01/07/2022 10:40,01/07/2022 10:40,,,,2,13,,,,,,,,,,,,,,WOS:000622909600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BP56C8RE,journalArticle,2017,"El Masri, A; Kolt, GS; Astell-Burt, T; George, ES",Lifestyle behaviours of Lebanese-Australians: Cross-sectional findings from The 45 and Up Study,PLOS ONE,,1932-6203,10.1371/journal.pone.0181217,,"Little is known regarding the health and lifestyle behaviours of Australians of Lebanese ethnicity. The available evidence suggests that Australians of Lebanese ethnicity who were born in Lebanon reportedly have higher rates of cardiovascular disease-related and type 2 diabetes-related complications when compared with the wider Australian population. The aim of this study is to compare lifestyle behaviours of middle-aged to older adults of Lebanese ethnicity born in Lebanon, Australia, and elsewhere to those of Australian ethnicity. Participants were 37,419 Australians aged >= 45 years, from the baseline dataset of The 45 and Up Study which included 4 groups of interest: those of Australian ethnicity (n = 36,707) [Reference]; those of Lebanese ethnicity born in Lebanon (n = 346); 302 those of Lebanese ethnicity born in Australia (n = 302); and those of Lebanese ethnicity born elsewhere (n = 64). Multilevel logistic regression was used to examine the odds of those of Lebanese ethnicity reporting suboptimal lifestyle behaviours (insufficient physical activity, prolonged sitting, smoking, sleep duration, and various diet-related behaviours) relative to those of Australian ethnicity. Multilevel linear regression was used to examine the clustering of suboptimal lifestyle behaviours through a 'lifestyle index' score ranging from 0-9 (sum of all lifestyle behaviours for each subject). The lifestyle index score was lower among Lebanese-born (-0.36, 95% CI -0.51, -0.22, p<0.001) and Australian- born (-0.17, 95% CI -0.32, -0.02, p = 0.031) people of Lebanese ethnicity in comparison to those of Australian ethnicity. Those of Lebanese ethnicity born in Lebanon had higher odds of reporting suboptimal lifestyle behaviours for physical activity, smoking, and sleep duration, and lower odds of reporting optimal lifestyle behaviours for sitting time, fruit, processed meat, and alcohol consumption, when compared with those of Australian ethnicity. Differences in the individual lifestyle behaviours for those of Lebanese ethnicity born in Australia and elsewhere compared with those of Australian ethnicity were fewer. Lifestyle behaviours of those of Lebanese ethnicity vary by country of birth and a lower level of suboptimal lifestyle behaviour clustering was apparent among Lebanese-born and Australian- born middle-aged to older adults of Lebanese ethnicity.",13/07/2017,01/07/2022 10:40,01/07/2022 10:40,,,,7,12,,,,,,,,,,,,,,WOS:000405649700108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3M9CSZVW,journalArticle,2019,"Guimbellot, J; Solomon, GM; Baines, A; Heltshe, SL; VanDalfsen, J; Joseloff, E; Sagel, SD; Rowe, SM; GOALe Investigators",Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations,JOURNAL OF CYSTIC FIBROSIS,,1569-1993,10.1016/j.jcf.2018.04.004,,"Background: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator ivacaftor is approved for patients with CF with gating and residual function CFTR mutations. We report the results of an observational study investigating its effects in CF patients with non-G551D gating mutations. Methods: Patients with non-G551D gating mutations were recruited to an open-label study evaluating ivacaftor. Primary outcomes included: lung function, sweat chloride, weight gain, and quality of life scores. Results: Twenty-one subjects were enrolled and completed 6 months follow-up on ivacaftor; mean age was 25.6 years with 52% <18. Baseline ppFEVI was 68% and mean sweat chloride 89.6 mEq/L. Participants experienced significant improvements in ppFEVi (mean absolute increase of 10.9% 95% CI = [2.6,19.3], p = 0.0134), sweat chloride (-48.6 95% CI = [-67.4,-29.9], p < 0.0001), and weight (5.1 kg, 95% CI = [2.8, 7.3], p = 0.0002). Conclusions: Patients with non-G551D gating mutations experienced improved lung function, nutritional status, and quality of life. This study supports ongoing use of ivacaftor for patients with these mutations. (C) 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.",2019-01,01/07/2022 10:40,01/07/2022 10:40,,102-109,,1,18,,,,,,,,,,,,,,WOS:000457820400014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BQN6M7BQ,journalArticle,2013,"Bennett, MI; Laird, B; van Litsenburg, C; Nimour, M",Pregabalin for the Management of Neuropathic Pain in Adults with Cancer: A Systematic Review of the Literature,PAIN MEDICINE,,1526-2375,10.1111/pme.12212,,"ObjectiveTo systematically identify and appraise the current literature of pregabalin in the treatment of neuropathic pain resulting from cancer or cancer treatment. DesignA systematic review of the literature was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Interventions and SubjectsStudies reporting pregabalin data for adult (>18 years) patients with cancer experiencing neuropathic pain due to cancer or cancer treatment/surgery were considered eligible for inclusion. MethodsA literature search was conducted in PubMed on February 22, 2012 using the following search terms: neuropath* AND pain AND cancer OR oncology OR tumor OR tumour AND pregabalin. Open access journals were also searched. Abstracts were screened and reviewed for eligibility based on predetermined criteria for inclusion. Data reporting pain intensity, pain interference, quality of life, symptom quality and intensity, global impression of change, treatment satisfaction, and adverse effects were the predefined factors for analysis. Data were summarized descriptively due to variations in study outcome measures. ResultsFive articles were eligible for inclusion; one double-blind National Cancer Institute common toxicity criteria controlled trial, one single-arm open-label study, two observational analyses, and one case report. ConclusionsThere were limited published data reporting efficacy and safety outcomes for pregabalin in the treatment of neuropathic pain in adult patients with cancer. Due to limitations within the studies included in this review, it is not possible to draw any conclusions on the descriptive summary of pregabalin for the treatment of cancer-related neuropathic pain, and further studies are required.",2013-11,01/07/2022 10:40,01/07/2022 10:40,,1681-1688,,11,14,,,,,,,,,,,,,,WOS:000327011600013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
S98NPYIA,journalArticle,2019,"Robert, M; Espalieu, P; Pelascini, E; Caiazzo, R; Sterkers, A; Khamphommala, L; Poghosyan, T; Chevallier, JM; Malherbe, V; Chouillard, E; Reche, F; Torcivia, A; Maucort-Boulch, D; Bin-Dorel, S; Langlois-Jacques, C; Delaunay, D; Pattou, F; Disse, E","Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial",LANCET,,0140-6736,10.1016/S0140-6736(19)30475-1,,"Background One anastomosis gastric bypass (OAGB) is increasingly used in the treatment of morbid obesity. However, the efficacy and safety outcomes of this procedure remain debated. We report the results of a randomised trial (YOMEGA) comparing the outcomes of OAGB versus standard Roux-en-Y gastric bypass (RYGB). Methods This prospective, multicentre, randomised non-inferiority trial, was held in nine obesity centres in France. Patients were eligible for inclusion if their body-mass index (BMI) was 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, or arthritis), and were aged 18-65 years. Key exclusion criteria were a history of oesophagitis, Barrett's oesophagus, severe gastro-oesophageal reflux disease resistant to proton-pump inhibitors, and previous bariatric surgery. Participants were randomly assigned (1:1) to OAGB or RYGB, stratified by centre with blocks of variable size; the study was open-label, with no masking required. RYGB consisted of a 150 cm alimentary limb and a 50 cm biliary limb and OAGB of a single gastrojejunal anastomosis with a 200 cm biliopancreatic limb. The primary endpoint was percentage excess BMI loss at 2 years. The primary endpoint was assessed in the per-protocol population and safety was assessed in all randomised participants. This study is registered with ClinicalTrials.gov, number NCT02139813, and is now completed. Findings From May 13, 2014, to March 2, 2016, of 261 patients screened for eligibility, 253 (97%) were randomly assigned to OAGB (n=129) or RYGB (n=124). Five patients did not undergo their assigned surgery, and after undergoing their surgery 14 were excluded from the per-protocol analysis (seven due to pregnancy, two deaths, one withdrawal, and four revisions from OAGB to RYGB) In the per-protocol population (n=117 OAGB, n=117 RYGB), mean age was 43.5 years (SD 10.8), mean BMI was 43.9 kg/m2 (SD 5.6), 176 (75%) of 234 participants were female, and 58 (27%) of 211 with available data had type 2 diabetes. After 2 years, mean percentage excess BMI loss was 87.9% (SD 23.6) in the OAGB group and 85.8% (SD 23.1) in the RYGB group, confirming non-inferiority of OAGB (mean difference 3.3%, 95% CI 9.1 to 2.6). 66 serious adverse events associated with surgery were reported (24 in the RYGB group vs 42 in the OAGB group; p=0.042), of which nine (21.4%) in the OAGB group were nutritional complications versus none in the RYGB group (p=0.0034). Interpretation OAGB is not inferior to RYGB regarding weight loss and metabolic improvement at 2 years. Higher incidences of diarrhoea, steatorrhoea, and nutritional adverse events were observed with a 200 cm biliopancreatic limb OAGB, suggesting a malabsorptive effect. Funding French Ministry of Health. Copyright (C) 2019 Elsevier Ltd. All rights reserved.",30/03/2019,01/07/2022 10:40,01/07/2022 10:40,,1299-1309,,10178,393,,,,,,,,,,,,,,WOS:000462967700026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2QRUC3HU,journalArticle,2020,"Gudivada, SD; Rajasurya, V; Spector, AR",Qualifying Patients for Noninvasive Positive Pressure Ventilation Devices on Hospital Discharge,CHEST,,0012-3692,10.1016/j.chest.2020.08.014,,"When and how do I qualify inpatients with acute on chronic hypercapnic respiratory failure for home noninvasive positive-pressure ventilation at the time of discharge? A 44-year-old woman with morbid obesity (BMI, 48) was brought to the hospital by her boyfriend for 1 day of confusion and reduced alertness. She had a history of chronic dyspnea on exertion and 10-pack-years of smoking. She also had history of well-treated diabetes and hypertension. In the ER, she was found to be somnolent but arousable and following commands appropriately. Her oxygen saturation was 86% on room air, and arterial blood gases indicated a pH of 7.16 with a Paco(2) of 87 mm Hg, a Pao(2) of 60 mm Hg, and a bicarbonate of 42 mEq/L. Chest radiograph showed mild pulmonary vascular congestion. She was started on continuous bilevel positive airway pressure and medical therapy, with clinical improvement.",2020-12,01/07/2022 10:40,01/07/2022 10:40,,2524-2531,,6,158,,,,,,,,,,,,,,WOS:000600577700023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6AFHUZMM,journalArticle,2013,"Huang, JS; Barlow, SE; Quiros-Tejeira, RE; Scheimann, A; Skelton, J; Suskind, D; Tsai, P; Uko, V; Warolin, JP; Xanthakos, SA; NASPGHAN Obesity Task Force",Childhood Obesity for Pediatric Gastroenterologists,JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION,,0277-2116,10.1097/MPG.0b013e31826d3c62,,"Obesity in childhood is one of the major health issues in pediatric health care today. As expected, the prevalence of obesity-related comorbidities has risen in parallel with that of obesity. Consultation regarding these concomitant diseases and subsequent management by subspecialists, including pediatric gastroenterologists, is now common and has resulted in obesity being recognized as a chronic disease requiring coordination of care. Although medications and even surgery may provide effective, though often temporary, treatments for obesity and its comorbidities, behavioral interventions addressing healthy dietary and physical activity habits remain a mainstay in the obesity treatment paradigm. Therefore, the issue of weight management must be addressed by both general practitioner and subspecialist alike. In this report, we review select aspects of pediatric obesity and obesity-related management issues because it relates in particular to the field of pediatric gastroenterology and hepatology.",2013-01,01/07/2022 10:40,01/07/2022 10:40,,99-109,,1,56,,,,,,,,,,,,,,WOS:000313028400028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8LNQUFDS,journalArticle,2013,"Melmed, S; Casanueva, FF; Klibanski, A; Bronstein, MD; Chanson, P; Lamberts, SW; Strasburger, CJ; Wass, JAH; Giustina, A",A consensus on the diagnosis and treatment of acromegaly complications,PITUITARY,,1386-341X,10.1007/s11102-012-0420-x,,"In March 2011, the Acromegaly Consensus Group met to revise and update the guidelines on the diagnosis and treatment of acromegaly complications. The meeting was sponsored by the Pituitary Society and the European Neuroendocrinology Association and included experts skilled in the management of acromegaly. Complications considered included cardiovascular, endocrine and metabolic, sleep apnea, bone diseases, and mortality. Outcomes in selected, related clinical conditions were also considered, and included pregnancy, familial acromegaly and invasive macroadenomas. The need for a new disease staging model was considered, and design of such a tool was proposed.",2013-09,01/07/2022 10:40,01/07/2022 10:40,,294-302,,3,16,,,,,,,,,,,,,,WOS:000322704500002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E5I37Q9E,journalArticle,2014,"Kappelman, MD; Long, MD; Martin, C; DeWalt, DA; Kinneer, PM; Chen, WL; Lewis, JD; Sandler, RS",Evaluation of the Patient-Reported Outcomes Measurement Information System in a Large Cohort of Patients With Inflammatory Bowel Diseases,CLINICAL GASTROENTEROLOGY AND HEPATOLOGY,,1542-3565,10.1016/j.cgh.2013.10.019,,"BACKGROUND & AIMS: Patient-reported outcomes (PROs) convey important aspects of health status, complementing physician-reported measures. The PRO Measurement Information System (PROMIS) provides valid, widely available measures applicable to patients with chronic illness and the general population. We sought to evaluate these measures in a large cohort of patients with inflammatory bowel disease (IBD). METHODS: By using data from the Crohn's and Colitis Foundation Association Partners internet cohort, we performed cross-sectional and longitudinal analyses to evaluate associations between PROMIS measures and validated disease activity indices (Short Crohn's Disease Activity Index and Simple Clinical Colitis Activity Index) and the Short IBD Questionnaire quality-of-life instrument. RESULTS: A total of 10,634 individuals (6689 with Crohn's disease and 3945 with ulcerative colitis or indeterminate colitis) completed PRO testing. Compared with the general population (mean PROMIS score, 50), IBD patients in this cohort reported more depression (mean, 54), anxiety (mean, 52), fatigue (mean, 56), sleep disturbance (mean, 52), and pain interference (mean, 53); and they had less social satisfaction (mean, 48). In each PROMIS domain, there was worse functioning with increasing levels of disease activity and worsening Short IBD Questionnaire scores (P < .001 for all). Longitudinal analyses showed improved PROMIS scores with improved disease activity and worsening PROMIS scores with worsening disease (P < .001 for all comparisons). CONCLUSIONS: In a cross-sectional and longitudinal study, we observed differences between patients with IBD and the general population in several important aspects of health. The improvement in diverse health outcome measures with improved disease control provides strong support for the construct validity of PROMIS measures in the IBD population. Their use should advance patient-centered outcomes research in IBD.",2014-08,01/07/2022 10:40,01/07/2022 10:40,,1315-+,,8,12,,,,,,,,,,,,,,WOS:000341119700019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3YDI8XS3,journalArticle,2016,"Garvey, WT; Mechanick, JI; Brett, EM; Garber, AJ; Hurley, DL; Jastreboff, AM; Nadolsky, K; Pessah-Pollack, R; Plodkowski, R; AACE ACE Obesity Clinical Practice",AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY,ENDOCRINE PRACTICE,,1530-891X,10.4158/EP161365.GL,,"Objective: Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology (ACE) Board of Trustees and adheres to published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent review of clinical evidence with transparent incorporation of subjective factors. Results: There are 9 broad clinical questions with 123 recommendation numbers that include 160 specific statements (85 [53.1%] strong [Grade A]; 48 [30.0%] intermediate [Grade B], and 11 [6.9%] weak [Grade C], with 16 [10.0%] based on expert opinion [Grade D]) that build a comprehensive medical care plan for obesity. There were 133 (83.1%) statements based on strong (best evidence level [BEL] 1 = 79 [49.4%]) or intermediate (BEL 2 = 54 [33.7%]) levels of scientific substantiation. There were 34 (23.6%) evidence-based recommendation grades (Grades A-C = 144) that were adjusted based on subjective factors. Among the 1,790 reference citations used in this CPG, 524 (29.3%) were based on strong (evidence level [EL] 1), 605 (33.8%) were based on intermediate (EL 2), and 308 (17.2%) were based on weak (EL 3) scientific studies, with 353 (19.7%) based on reviews and opinions (EL 4). Conclusion: The final recommendations recognize that obesity is a complex, adiposity-based chronic disease, where management targets both weight-related complications and adiposity to improve overall health and quality of life. The detailed evidence-based recommendations allow for nuanced clinical decision-making that addresses real-world medical care of patients with obesity, including screening, diagnosis, evaluation, selection of therapy, treatment goals, and individualization of care. The goal is to facilitate high-quality care of patients with obesity and provide a rational, scientific approach to management that optimizes health outcomes and safety.",2016-07,01/07/2022 10:40,01/07/2022 10:40,,1-203,,,22,,,,,,,,,,,,,,WOS:000384279500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VEI3YHCV,journalArticle,2020,"Eisengart, JB; King, KE; Shapiro, EG; Whitley, CB; Muenzer, J",The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome,MOLECULAR GENETICS AND METABOLISM REPORTS,,2214-4269,10.1016/j.ymgmr.2019.100549,,"In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.",2020-03,01/07/2022 10:40,01/07/2022 10:40,,,,,22,,,,,,,,,,,,,,WOS:000514810400026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
996HA8GE,journalArticle,2012,"Kutner, NG; Zhang, R; Huang, YJ; Bliwise, DL",Racial differences in restless legs symptoms and serum ferritin in an incident dialysis patient cohort,INTERNATIONAL UROLOGY AND NEPHROLOGY,,0301-1623,10.1007/s11255-011-0108-6,,"Purpose Restless legs syndrome (RLS), a debilitating sleep disorder that is frequently reported by CKD patients on dialysis, may be more common in whites than in non-whites. Iron deficiency is associated with RLS, and serum ferritin is higher among African Americans compared to Caucasians in the general population. No prior studies have compared restless legs symptoms and serum ferritin levels of African-American and those of the Caucasian patients on dialysis. Methods In a multicenter observational study that included in-person interviews and medical chart review, we studied 210 patients who had recently started renal dialysis. Predictors of restless legs symptoms were examined in a multivariable logistic regression model. Results African Americans had a reduced risk of restless legs complaint compared to Caucasian patients (OR, 0.44 [95% CI 0.21-0.93]; P = 0.03). African-American patients were also less likely than Caucasian patients to have low serum ferritin values (<100 ng/ml), and among patients with serum ferritin >= 100 ng/ml, the average serum ferritin of African-American patients was higher than that of Caucasian patients. Conclusions Further study of racial and iron status relationships could advance the understanding of RLS pathophysiology, and RLS is an important patient outcome to monitor, as revised anemia and iron protocols are implemented in the clinical setting.",2012-12,01/07/2022 10:40,01/07/2022 10:40,,1825-1831,,6,44,,,,,,,,,,,,,,WOS:000313523000030,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X56MRLC5,journalArticle,2010,"Koyama, H; Fukuda, S; Shoji, T; Inaba, M; Tsujimoto, Y; Tabata, T; Okuno, S; Yamakawa, T; Okada, S; Okamura, M; Kuratsune, H; Fujii, H; Hirayama, Y; Watanabe, Y; Nishizawa, Y",Fatigue Is a Predictor for Cardiovascular Outcomes in Patients Undergoing Hemodialysis,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.08151109,,"Background and objectives: Despite potential significance of fatigue and its underlying components in the occurrence of cardiovascular diseases, epidemiologic data showing the link are virtually limited. This study was designed to examine whether fatigue symptoms or fatigue's underlying components are a predictor for cardiovascular diseases in high-risk subjects with ESRD. Design, setting, participants, & measurements: 788 volunteer patients under hemodialysis therapy (506 male, 282 female) completed the survey between October and November 2005, with the follow-up period up to 26 months to monitor occurrence of fatal or nonfatal cardiovascular events. The questionnaire consisted of 64 questions, and promax rotation analysis of the principal component method conceptualized eight fatigue-related factors: fatigue itself, anxiety and depression, loss of attention and memory, pain, overwork, autonomic imbalance, sleep problems, and infection. Results: 14.7% of the patients showed fatigue scores higher than twice the SD of the mean for healthy volunteers. These highly fatigued patients exhibited a significantly higher risk for cardiovascular events (hazard ratio: 2.17; P < 0.01), with the relationship independent of the well-known risk factors, including age, diabetes, cardiovascular disease history, and inflammation and malnutrition markers. Moreover, comparisons of the risk in key subgroups showed that the risk of high fatigue score for cardiovascular events was more prominent in well-nourished patients, including lower age, absence of past cardiovascular diseases, higher serum albumin, and high non-HDL cholesterol. Conclusions: Fatigue can be an important predictor for cardiovascular events in patients with ESRD, with the relationship independent of the nutritional or inflammatory status. Clin J Am Soc Nephrol 5: 659-666, 2010. doi: 10.2215/CJN.08151109",2010-04,01/07/2022 10:40,01/07/2022 10:40,,659-666,,4,5,,,,,,,,,,,,,,WOS:000276585000016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y62MQ9TU,journalArticle,2018,"Helfand, BT; Smith, AR; Lai, HH; Yang, CC; Gore, JL; Erickson, BA; Kreder, KJ; Cameron, AP; Weinfurt, KP; Griffith, JW; Lentz, A; Talaty, P; Andreev, VP; Kirkali, Z; LURN",Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study,JOURNAL OF UROLOGY,,0022-5347,10.1016/j.juro.2018.02.075,,"Purpose: Male urinary incontinence is thought to be infrequent. We sought to describe the prevalence of urinary incontinence in a male treatment seeking cohort enrolled in the LURN (Symptoms of Lower Urinary Tract Dysfunction Research Network). Materials and Methods: Study inclusion and exclusion criteria, including men with prostate cancer or neurogenic bladder, were previously reported. LURN participants prospectively completed questionnaires regarding lower urinary tract symptoms and other clinical variables. Men were grouped based on incontinence type, including 1) no urinary incontinence, 2) post-void dribbling only and 3) urinary incontinence. Comparisons were made using ANOVA and multivariable regression. Results: Of the 477 men 24% reported no urinary incontinence, 44% reported post-void dribbling only and 32% reported urinary incontinence. African American men and those with sleep apnea were more likely to be in the urinary incontinence group than in the no urinary incontinence group (OR 3.2, p = 0.02 and OR 2.73, p = 0.003, respectively). Urinary incontinence was associated with significantly higher bother compared to men without leakage (p < 0.001). Compared to men without urinary incontinence and men with only post-void dribbling those with urinary incontinence were significantly more likely to report higher scores (more severe symptoms) on the PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaires regarding bowel issues, depression and anxiety than men without urinary incontinence (p < 0.01). Conclusions: Urinary incontinence is common among treatment seeking men. This is concerning because the guideline recommended questionnaires to assess male lower urinary tract symptoms do not query for urinary incontinence. Thus, clinicians may be missing an opportunity to intervene and improve patient care. This provides a substantial rationale for a new or updated symptom questionnaire which provides a more comprehensive symptom assessment.",2018-08,01/07/2022 10:40,01/07/2022 10:40,,397-403,,2,200,,,,,,,,,,,,,,WOS:000438718000104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7XLS6WV8,journalArticle,2021,"Shao, JM; Elhage, SA; Prasad, T; Gersin, K; Augenstein, VA; Colavita, PD; Heniford, BT",Best reoperative strategy for failed fundoplication: redo fundoplication or conversion to Roux-en-Y gastric diversion?,SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES,,0930-2794,10.1007/s00464-020-07800-4,,"Background Failed fundoplication is a difficult reoperative challenge, with limited evidence differentiating outcomes of a redo fundoplication versus conversion to Roux-en-Y anatomy with a gastric diversion (RYGD). The aim of this study was to determine the impact of these reoperative strategies on symptom resolution. Methods A retrospective single institution study of patients with failed fundoplications undergoing conversion to RYGD or redo fundoplication between 2006 and 2019 was conducted. Patient characteristics, preoperative evaluation, operative findings, and postoperative outcomes were recorded and analyzed. Results 180 patients with symptomatic, failed fundoplications were identified: 101 patients (56.1%) underwent conversion to RYGD, and 79 patients (43.9%) underwent redo fundoplication. Body mass index (BMI) was significantly higher for the patients undergoing RYGD with mean BMI of 34.3 +/- 6.9 vs 27.7 +/- 3.9 kg/m(2)(p < 0.001). Patients undergoing conversion to RYGD were also more comorbid than their counterparts, with higher rates of obstructive sleep apnea (17.8% vs 5.1%,p = 0.01), but similar rates of hypertension (54.5% vs 44.3%,p = 0.18, asthma/COPD (25.7% vs 16.5%,p = 0.13), diabetes (10.9% vs 10.1%,p = 0.87), and hyperlipidemia (29.7% vs 36.7%,p = 0.32). Mean operative times were significantly higher for the RYGD (359.6 +/- 90.4 vs 238.8 +/- 75.6 min,p < 0.0001), as was mean estimated blood loss (168.8 +/- 207.5 vs 81.0 +/- 145.4,p < 0.0001). Conversion rates from minimally invasive to open were similar (10.9% vs 11.4%,p = 0.92). The incidence of recurrent reflux symptoms was not significantly different (p = 0.46) between RYGD (16.8%) and redo fundoplication (12.8%), at an average follow-up of 50.6 +/- 140.7 vs 34.7 +/- 39.2 months, (p = 0.03). For the RYGD cohort, patients also had resolution of other comorbidities including obesity 35.6%, OSA 16.7%, hyperlipidemia 10.0%, hypertension 9.1%, and diabetes 9.1%. On average, patients decreased their BMI by 6.8 +/- 5.5 kg/m(2)and lost 69.6% of their excess body weight. Mean length of stay was higher in patients undergoing RYGD (5.3 +/- 7.3 vs 3.0 +/- 1.9 days,p = 0.01). Thirty-day readmission rates were similar (9.9% vs 3.8%,p = 0.12). The reoperation rate was higher in the RYGD cohort (17.8% vs 2.5%,p = 0.001). Conclusions RYBG and redo fundoplication are equivalent in terms of resolution of reflux. RYGD resulted in significant loss of excess body weight.",2021-07,01/07/2022 10:40,01/07/2022 10:40,,3865-3873,,7,35,,,,,,,,,,,,,,WOS:000549281000004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I9MLQER5,journalArticle,2013,"Kim, KH; Cho, YY; Shin, DW; Lee, JH; Ko, YJ; Park, SM",Comparison of physical and mental health status between cancer survivors and the general population: a Korean population-based survey (KNHANES II-IV),SUPPORTIVE CARE IN CANCER,,0941-4355,10.1007/s00520-013-1939-8,,"To compare the physical and mental health status of the general population with that of cancer survivors in South Korea. We analyzed 19,035 subjects (age a parts per thousand yen40 years), who participated in the 2001-2009 Korea National Health and Nutrition Examination Survey II-IV. We compared metabolic syndrome components, health behaviors, and mental health outcomes between cancer survivors and non-cancer controls. Cancer survivors accounted for 1.68 % (n = 316) of total population. Cancer survivors did not show low occurrence of hypertension and diabetes compared to the control group. Both cancer survivors and the general population had high risks of physical inactivity (75.4 % and 75.5 %, respectively) and inadequate sleep (52.5 % and 60.7 %, respectively). In the unadjusted model, depression was more common in cancer survivors (odds ratio [OR], 1.61; 95 % CI, 1.22-2.74), so was suicidal ideation (OR, 1.51; 95 % CI, 0.16-1.96) than non-cancer controls. After adjustment for attributable socioeconomic factors, the elevated adjusted odds ratios (aORs) among cancer survivors were reduced by 23 % in depression and 45 % in suicidal thought. Cancer survivors at < 5 years from diagnosis showed a high occurrence of depression (aOR, 1.77; 95 % CI, 1.09-2.85) while the magnitude of aOR decreases after a parts per thousand yen5 years from cancer diagnosis (aOR, 1.38; 95 % confidence interval, 0.97-1.98, respectively). The physical and mental health of South Korean cancer survivors was not optimal. Their control rates of modifiable risk factors were similar or even lower than those for the non-cancer groups. Depression was highly prevalent in cancer survivors which can be ascribed, at least in part, to socioeconomic environment. A better-targeted intervention to improve the health of this population may be needed.",2013-12,01/07/2022 10:40,01/07/2022 10:40,,3471-3481,,12,21,,,,,,,,,,,,,,WOS:000326892100029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
V3BZ7TBD,journalArticle,2009,"Pene, P; Touitou, Y",Sport and health,BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE,,0001-4079,10.1016/S0001-4079(19)32592-0,,"The report of the National Academy of Medicine named ""Sport and Health"" underlines the medical, social and educational dimensions of sporting activities. Various kinds of sporting practices are described: they concern the approximately 7,000 high level athletes, around 8,000 professional (licensed) sportsmen, and sporting club members (approximately 15 millions people). A large number of amateurs do not practice in any structure and therefore are neither managed in their activities nor medically followed. Some characteristics of sporting practice at various stages of life have been documented. Around 50% of the teenagers from 12 to 17 years have a sporting practice out-of-school besides the weekly three hours applied at school or college; however, the withdrawal of sporting practice by a high number of teenagers results in a sedentary lifestyle with overweight and obesity, major risks factors for health. Elderly people take a profit from a regular and medically controlled physical activity. Functional capacities are thus improved, cardiovascular risks factors among other, which results in better quality of life of the aged and delays their dependence. The benefit upon public health of sporting practice has been pointed out in the primary prevention of cardiovascular and respiratory diseases, osteoporosis, obesity, diabetes, breast and colon cancer, and mood disturbances. It is currently well acknowledged that sporting practice is an important component of public health in both primary and secondary prevention of many diseases. Deleterious effects of which the most serious is the sudden death related to a cardiovascular anomaly, which generally occurs during an important physical effort. An important sport drift is the practice of doping to improve performances through the use of hormones, anabolics, EPO, transfusions, ... When a person exceeds his/her capacities of adaptation, because of a badly adapted or a too intense drive, this overtraining results in a reduction in physical capabilities, stress, behavioral issues and sleep-wake disorders. All of those issues often lead sportsmen to doping with the aim to improve their capabilities, rapidly installing an overtiredness state resulting in a fall of performances. A major aim from the view point of public health is to reinforce the fight against doping since it concerns a large number of people, sportsmen and amateurs, with teenagers among them. Lastly, this report underlines that sport medicine is practically not taught in the initial training of medical doctors. The qualification of sport physician is obtained through a diploma named sport medicine capacity.",2009-02,01/07/2022 10:40,01/07/2022 10:40,,415-429,,2,193,,,,,,,,,,,,,,WOS:000268553500020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TG2PSGA3,journalArticle,2005,"Cvetkovic, RS; Plosker, GL",Desmopressin - In adults with nocturia,DRUGS,,0012-6667,10.2165/00003495-200565010-00008,,"Desmopressin, a synthetic antidiuretic hormone analogue, is the only drug currently approved for the treatment of nocturia associated with nocturnal polyuria or multiple sclerosis (MS). Compared with vasopressin, desmopressin has a longer lasting and more potent antidiuretic effect and is devoid of vasopressor and uterotonic effects. In two large, randomised, double-blind phase III trials in adults with nocturia associated with nocturnal polyuria, 3 weeks of oral desmopressin therapy was significantly more effective than placebo in reducing the mean number of nocturnal voids and in normalising the rate of nocturnal urine production. Beneficial effects of desmopressin on nocturia were maintained and increased in patients completing 10 or 12 months of further treatment in a nonblind extension of short-term trials. In randomised, double-blind trials in MS patients with nocturia, nasal desmopressin reduced the mean number of nocturnal voiding episodes by 31-54%. In both patient populations, desmopressin increased the initial sleep period or mean maximum period of uninterrupted sleep by approximate to2 hours, an outcome significantly greater than that achieved with placebo. In trials of less than or equal to6 weeks duration in adults with nocturia, desmopressin was generally well tolerated. Most desmopressin-related adverse events were transient and mild or moderate in severity. Clinically significant hyponatraemia was reported in approximate to5% and required withdrawal from studies in less than or equal to3% of patients.",2005,01/07/2022 10:40,01/07/2022 10:40,,99-107,,1,65,,,,,,,,,,,,,,WOS:000226503500008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
QTCMTB9I,journalArticle,2021,"de Graaf, JP; de Vries, F; Dirkson, A; Hiort, O; Pereira, AM; Korbonits, M; Cools, M; Res Sci Work Package Endo-ERN",Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research,ENDOCRINE,,1355-008X,10.1007/s12020-021-02618-z,,"Purpose European Reference Network on Rare Endocrine Conditions' (Endo-ERN) mission is to reduce and ultimately abolish inequalities in care for patients with rare endocrine conditions in Europe. This study assesses which themes related to rare endocrine conditions are prioritized by patients for clinical research. Methods A survey was developed, translated into 22 different European languages, and distributed to patients with rare endocrine conditions. Patients were asked to give priority scores to listed prespecified topics: fertility, heritability, tiredness, daily medicine intake, sleep quality, physical discomfort, and ability to work, partake in social life, and sports. They were also asked to suggest further important areas for research in open fields. Results After data cleaning, 1378 survey responses were analyzed. Most responses were received from Northern (47%) and Western Europeans (39%), while Southern (11%) and Eastern Europe (2%) were underrepresented. Respondents were most interested in research concerning ability to participate in social life and work. Patients suggested key areas to work: long-term side effects of medical treatments and quality of life. Some priorities differed between disease groups, both for prespecified and open topics and reflected aspects of patients' individual conditions. Conclusions With this large survey, Endo-ERN gained insight into patients' unmet needs in scientific research. Patients prioritized research on ability to work and participation in social activities, though needs differ between the disease groups. Clinical experts should incorporate the results of this survey into the design of future studies on rare endocrine conditions. We aim to utilize these results in designing patient-reported outcome measures for the disease areas covered by Endo-ERN.",2021-03,01/07/2022 10:40,01/07/2022 10:40,,561-568,,3,71,,,,,,,,,,,,,,WOS:000614307700003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VMPIG9Q3,journalArticle,2021,"Shteinberg, M; Taylor-Cousar, JL; Durieu, I; Cohen-Cymberknoh, M",Fertility and Pregnancy in Cystic Fibrosis,CHEST,,0012-3692,10.1016/j.chest.2021.07.024,,"People with cystic fibrosis (pwCF) have experienced increased survival and wellbeing in recent decades, such that more than half of those living with CF are adults. Consequently, sexual and reproductive health is increasingly important for pwCF, because many are considering parenthood. Most men and some women with CF (wwCF) will have reduced fertility, which in both sexes is multifactorial. However, unplanned pregnancies in women are not rare, and contraception and its interaction with CF complications need to be addressed by the CF team. Reduced fertility may be overcome in most pwCF through use of assisted reproductive technologies; however, the risk of having offspring with CF must be considered. Most wwCF will have normal pregnancies, but premature birth is common, especially in the setting of reduced lung function and CF-related diabetes (CFRD); optimization of treatment is recommended during pregnancy planning. Parenting imposes an increased burden on pwCF, with the challenges of caring for the newborn, postpartum physiologic changes, and maintaining CF treatments. Most drugs used to treat CF are considered safe in pregnancy and lactation, but exceptions need to be acknowledged, including the limited data regarding safety of CF transmembrane conductance regulator (CFTR) modulators during conception, pregnancy, and lactation. Because most pwCF are eligible for highly effective CFTR modulators, fertility, contraception, and pregnancy in people with CF is changing. Prospective studies regarding these issues in people treated with CFTR modulators are paramount to provide evidence-based guidance for management in the current era of CF care. CHEST 2021; 160(6):2051-2060",2021-12,01/07/2022 10:40,01/07/2022 10:40,,2051-2060,,6,160,,,,,,,,,,,,,,WOS:000728782000038,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PP2Z8WS2,journalArticle,2016,"Sweeney, J; Patterson, CC; Menzies-Gow, A; Niven, RM; Mansur, AH; Bucknall, C; Chaudhuri, R; Price, D; Brightling, CE; Heaney, LG; British Thoracic Soc Difficult Ast",Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry,THORAX,,0040-6376,10.1136/thoraxjnl-2015-207630,,"Objective To determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma. Design Cross-sectional observational study. Setting The primary care Optimum Patient Care Research Database and the British Thoracic Society Difficult Asthma Registry. Participants Optimum Patient Care Research Database (7195 subjects in three age- and gender-matched groups)-severe asthma (Global Initiative for Asthma (GINA) treatment step 5 with four or more prescriptions/year of oral corticosteroids, n=808), mild/moderate asthma (GINA treatment step 2/3, n=3975) and nonasthma controls (n=2412). 770 subjects with severe asthma from the British Thoracic Society Difficult Asthma Registry (442 receiving daily oral corticosteroids to maintain disease control). Main outcome measures Prevalence rates of morbidities associated with systemic steroid exposure were evaluated and reported separately for each group. Results 748/808 (93%) subjects with severe asthma had one or more condition linked to systemic corticosteroid exposure (mild/moderate asthma 3109/3975 (78%), non-asthma controls 1548/2412 (64%); p<0.001 for severe asthma versus non-asthma controls). Compared with mild/moderate asthma, morbidity rates for severe asthma were significantly higher for conditions associated with systemic steroid exposure (type II diabetes 10% vs 7%, OR=1.46 (95% CI 1.11 to 1.91), p<0.01; osteoporosis 16% vs 4%, OR=5.23, (95% CI 3.97 to 6.89), p<0.001; dyspeptic disorders (including gastric/duodenal ulceration) 65% vs 34%, OR=3.99, (95% CI 3.37 to 4.72), p<0.001; cataracts 9% vs 5%, OR=1.89, (95% CI 1.39 to 2.56), p<0.001). In the British Thoracic Society Difficult Asthma Registry similar prevalence rates were found, although, additionally, high rates of osteopenia (35%) and obstructive sleep apnoea (11%) were identified. Conclusions Oral corticosteroid-related adverse events are common in severe asthma. New treatments which reduce exposure to oral corticosteroids may reduce the prevalence of these conditions and this should be considered in cost-effectiveness analyses of these new treatments.",2016-04,01/07/2022 10:40,01/07/2022 10:40,,339-346,,4,71,,,,,,,,,,,,,,WOS:000372285700008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43K7HM6R,journalArticle,2016,"Lai, HH; Morgan, CD; Vetter, J; Andriole, GL",Impact of childhood and recent traumatic events on the clinical presentation of overactive bladder,NEUROUROLOGY AND URODYNAMICS,,0733-2467,10.1002/nau.22872,,"Aims(1) To describe the Prevalence of childhood and recent trauma in patients with overactive bladder (OAB), and (2) assess the impact of traumatic events on the clinical presentation and the severity of OAB symptoms, quality of life, and psychosocial health. MethodsPatients diagnosed with OAB (n=51) and age-matched healthy controls (n=30) were administered the Childhood Traumatic Events Scale and Recent Traumatic Events Scale, assessing exposure and perceived impact of common traumatic events. Among OAB patients, validated instruments were administered to correlate traumatic exposure to evaluate adult urinary symptoms (ICIQ-UI, ICIQ-OAB, OAB-q, UDI-6, IIQ-7, USS), mood dysregulation (HADS), sleep and fatigue (PROMIS), and Psychological stress (PSS). ResultsChildhood sexual trauma was more prevalent in patients with OAB compared to controls (29.4% vs. 6.7%, P=0.041). OAB patients also rated their childhood sexual exposure as more traumatic compared to controls (mean ratings of 1.7 vs. 0.4, P=0.050). There was no difference in childhood deaths (P=0.24), parental upheaval (P=0.87), violence (P=0.099), illness/injury (P=0.683), or any recent traumatic events between OAB and control subjects. Childhood trauma predicted worse bladder pain (P=0.005), worse non-urologic pain (P=0.017), poorer mood (P=0.001), higher anxiety (P=0.029), higher physical symptom burden (P<0.001), and higher psychological stress (P<0.039). However, childhood trauma did not correlate with the severity of OAB symptoms (urgency, frequency, incontinence). ConclusionsThirty percent of OAB patients reported childhood sexual trauma. These patients report more pain symptoms, poorer mood, and greater somatic burden. These data highlight the potentiating role of psychosocial stressors from childhood in the adult suffering from OAB. Neurourol. Urodynam. 35:1017-1023, 2016. (c) 2015 Wiley periodicals, Inc.",2016-11,01/07/2022 10:40,01/07/2022 10:40,,1017-1023,,8,35,,,,,,,,,,,,,,WOS:000385842000027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U68UUSTP,journalArticle,2009,"Coyne, KS; Kaplan, SA; Chapple, CR; Sexton, CC; Kopp, ZS; Bush, EN; Aiyer, LP; EpiLUTS Team",Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS,BJU INTERNATIONAL,,1464-4096,10.1111/j.1464-410X.2009.08438.x,,"To explore the risk factors and comorbid conditions associated with subgroups of lower urinary tract symptoms (LUTS) in men and women aged >= 40 years in three countries, using data from the EpiLUTS study, as LUTS are common amongst men and women and increase in prevalence with age. This cross-sectional, population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Participants were asked to rate how often they experienced individual LUTS during the past 4 weeks on a 5-point Likert scale. Eight LUTS subgroups were created. Descriptive statistics and logistic regressions within each LUTS subgroup were used to assess the data. The survey response rate was 59%. The final sample was 30 000 (men and women). The voiding + storage + postmicturition (VSPM) group reported the highest rates of comorbid conditions for both men and women, and the fewest were reported in the no/minimal LUTS and the postmicturition-only groups. Increasing age was associated with increasing LUTS in men, but not in women. Comorbid conditions significantly associated with the VSPM group were arthritis, asthma, chronic anxiety, depression, diabetes (men only), heart disease, irritable bowel syndrome, neurological conditions, recurrent urinary tract infection, and sleep disorders. Risk factors, such as body mass index, exercise level and smoking, played less of a role, except for childhood nocturnal enuresis, which was significantly associated with most LUTS subgroups. In this large population study, many comorbid conditions and risk factors were significantly associated with LUTS among both men and women. Further longitudinal investigations of the associations noted here would help physicians to understand the pathophysiology of LUTS and comorbid conditions, and provide clinical guidelines for patient management of comorbid conditions sharing common pathophysiological pathways.",2009-04,01/07/2022 10:40,01/07/2022 10:40,,24-32,,,103,,,,,,,,,,,,,,WOS:000264372500004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y8PUFPJS,journalArticle,2015,"Madhu, C; Coyne, K; Hashim, H; Chapple, C; Milsom, I; Kopp, Z",Nocturia: risk factors and associated comorbidities; findings from the EpiLUTS study,INTERNATIONAL JOURNAL OF CLINICAL PRACTICE,,1368-5031,10.1111/ijcp.12727,,"ObjectiveTo evaluate the risk factors and comorbidities associated with nocturia in men and women aged 40years. Material and methodsThe EpiLUTS study was an Internet-based cross-sectional, population-representative survey involving 30,000 men and women from the USA, UK and Sweden evaluating lower urinary tract symptoms (LUTS) using the LUTS Tool. A secondary analysis of the EpiLUTS data using participants with nocturia was performed. Descriptive statistics were used to examine the data. Logistic regressions were used to analyse associations of comorbid conditions and risk factors in men and women with nocturia 2. ResultsWith a 59% response rate, nocturia 1 was quite common at 69% in men and 76% in women; 28% men and 34% women had nocturia 2. Age, body mass index (in women), Hispanic and Black responders, diabetes, high blood pressure, anxiety and depression and a history of bed-wetting were significantly associated with nocturia 2. Arthritis, asthma, diabetes, heart disease, inflammatory bowel disease, bladder infection, uterine prolapse, hysterectomy and menopausal status were all significantly associated with nocturia 2 in women. Prostatitis and prostate cancer were significant in men with nocturia 2. British and Swedish participants had a lesser risk of nocturia 2. ConclusionNocturia is a highly prevalent condition associated with various risk factors and comorbidities. Treatment of nocturia should be aimed at these causes in a multidisciplinary fashion. Further studies are needed to look specifically at these conditions in the pathophysiology of nocturia.",2015-12,01/07/2022 10:40,01/07/2022 10:40,,1508-1516,,12,69,,,,,,,,,,,,,,WOS:000366359700012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RR84GCTN,journalArticle,2013,"Rogal, SS; Winger, D; Bielefeldt, K; Szigethy, E",Pain and Opioid Use in Chronic Liver Disease,DIGESTIVE DISEASES AND SCIENCES,,0163-2116,10.1007/s10620-013-2638-5,,"Background Pain is common in patients with liver disease, difficult to treat, and poorly understood. Aims The aim of this study was to determine factors associated with pain and prescription opioid use in a large cohort of patients with confirmed chronic liver disease. Methods This was a retrospective cohort study of consecutive patients with chronic liver disease visiting a tertiary-care hepatology clinic. Pain was determined by self-report and rated numerically from 0 to 10. Symptoms of mood and sleep disorders and emotional distress were based on a symptom checklist. Etiology and stage of liver disease and use of prescribed opioids were abstracted from the electronic medical record. Logistic regression was used to establish factors associated with pain and prescription opioid use. Results Among 1,286 patients with chronic liver disease, 34 % had pain and 25 % used opioids. The strongest predictor of pain in multivariate modeling was emotional distress (OR 3.66, 95 % CI 2.40-5.64), followed by non-white race (OR 1.87, 95 % CI 1.24-2.79), mood symptoms (OR 1.47, 95 % CI 1.04-2.07), sleep disturbance/fatigue (OR 1.70, 95 % CI 1.24-2.32), and advanced liver disease (Child class B: OR 1.73, 95 % CI 1.15-2.60; Child class C: OR 2.78, 95 % CI 1.49-5.24) compared to no cirrhosis. Emotional distress, mood-related symptoms, and advanced liver disease were also significant predictors of prescription opioid use, as were age, nicotine use, and etiology of liver disease. Conclusions This large cohort study demonstrates the high prevalence of pain and opioid use in chronic liver disease. While disease variables contribute to pain, psychological symptoms were most strongly associated with pain and opioid use, providing rationale and target for therapeutic interventions.",2013-10,01/07/2022 10:40,01/07/2022 10:40,,2976-2985,,10,58,,,,,,,,,,,,,,WOS:000324778900002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SETXZW97,journalArticle,2016,"Cordero, MJA; Blanque, RR; Garcia, JCS; Lopez, AMS; Garcia, LB; Contreras, GL",Influence of SWEP (Study Pregnant Water Exercise) program in perinatal outcomes: Study protocol,NUTRICION HOSPITALARIA,,0212-1611,,,"Introduction: Moderate exercise training during the pregnancy benefits both the pregnant woman and the fetus. The research papers consulted have linked physical activity with the reduction of the number of cesareans, instrumental delivery and with a more physiological delivery. It also prevents excessive weight gain in women and decreases the risk of gestational diabetes and high blood pressure. Aims: The aim of this research is to know if an exercise program of moderate character with Water Study Exercise Pregnant (SWEP) method, performed in an aquatic environment, contributes to have more favorable results in the perinatal period, both for women and baby. Material and methods: The design is a randomized clinical trial. The sample will consist of 364 pregnant women, with a total universe of 6,579 births occurred in Granada (Spain) during 2014. The sample was divided into two groups, intervention group and control group. The activity will be carried out in the water sporting facilities of the Faculty of Sports Science of the University of Granada, which have two pools suitable for our purposes: a 25-meter polyvalent pool and a 12.5-meter pool for training. Results: The exercise program designed specifically for the project called SWEP is performed from 20 to 37 weeks of gestation (SG), and it consists of three weekly sessions, with duration of 60 minutes each. Sessions will include three phases: warm-up phase, the main phase in which the exercise is divided into an aerobic phase and strength training and endurance training phase and a final phase of stretching and relaxation. The variables that will be studied are: a) Maternal: weight, BMI, blood pressure, O'Sullivan test, postpartum depression, level of self-rated health, sleep quality and perceived exertion during physical activity; b) fetal: weight, Apgar scores, head circumference and GA (Gestational age); c) peripartum: time dilation, expulsion and delivery, type of delivery, episiotomy, type of feed received by the RN and time of exclusive breasffeeding; and d) descriptive: age, occupation, education level, type of exercise done before and OF (obstetric formula). Conclusion: With aquatic moderate physical activity during pregnancy (method SWEP), we intended to improve the variables above.",2016-01,01/07/2022 10:40,01/07/2022 10:40,,162-176,,1,33,,,,,,,,,,,,,,WOS:000373752400027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H5QCN5GT,journalArticle,2012,"Carlin, BW",COPD and Associated Comorbidities: A Review of Current Diagnosis and Treatment,POSTGRADUATE MEDICINE,,0032-5481,10.3810/pgm.2012.07.2582,,"Health care utilization and costs associated with chronic obstructive pulmonary disease (COPD) continue to increase, notwithstanding evidence-based management strategies described by major respiratory societies. Cardiovascular diseases, asthma, diabetes and its precursors (obesity and metabolic syndrome), depression, cognitive impairment, and osteoporosis arc examples of common comorbidities that can affect or be affected by COPD. Appropriate diagnosis and management (from a pharmacologic and nonpharmacologic perspective) of COPD and its associated comorbidities are important to ensure optimal patient care. An evolving understanding of COPD as a multimorbid disease that affects an aging population, rather than just a lung-specific disease, necessitates an integrated, tailored disease-management approach to improve prognoses and reduce costs.",2012-07,01/07/2022 10:40,01/07/2022 10:40,,225-240,,4,124,,,,,,,,,,,,,,WOS:000307201700023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DNW4C5QF,journalArticle,2012,"Ludwig, DS",Weight Loss Strategies for Adolescents A 14-Year-Old Struggling to Lose Weight,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,,0098-7484,10.1001/jama.2011.2011,,"With prevalence approaching 20% in the United States, adolescent obesity has become a common problem for patients, parents, and clinicians. Obese adolescents may experience physical and psychosocial complications, as illustrated by the case of Ms K, a 14-year-old girl with a body mass index of 40. Unfortunately, the effectiveness of pediatric obesity treatment is modest in younger children and declines in older children and adolescents, and few interventions involving adolescents have produced significant long-term weightloss. Nevertheless, novel strategies to alter energy balance have shown preliminary evidence of benefit in clinical trials, including a diet focused on food quality rather than fat restriction and a lifestyle approach to encourage enjoyable physical activity throughout the day rather than intermittent exercise. Parents can have an important influence on weight-related behaviors in adolescents despite typically complicated emotional dynamics at this age, especially through the use of noncoercive methods. A key parenting practice applicable to children of all ages is to create a protective environment in the home, substituting nutritious foods for un-healthful ones and facilitating physical activities instead of sedentary pursuits. Other behaviors that may promote successful long-term weight management include good sleep hygiene, stress reduction, and mindfulness. Ultimately, the obesity epidemic can be attributed to changes in the social environment that hinder healthful lifestyle habits, and prevention will require a comprehensive public health strategy. JAMA. 2012;307(5):498-508",01/02/2012,01/07/2022 10:40,01/07/2022 10:40,,498-508,,5,307,,,,,,,,,,,,,,WOS:000299728000031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TLTW6DT2,journalArticle,,"Palazzuoli, A; Ruocco, G; Gronda, E",Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door,HEART FAILURE REVIEWS,,1382-4147,10.1007/s10741-020-09972-6,,"Heart failure is associated with a range of comorbidities that have the potential to impair both quality of life and clinical outcome. Unfortunately, noncardiac diseases are underrepresented in large randomized clinical trials, and their management remains poorly understood. In clinical practice, the prevalence of comorbidities in heart failure is high. Although the prognostic impact of comorbidities is well known, their prevalence and impact in specific heart failure settings have been overlooked. Many studies have described specific single noncardiac conditions, but few have examined their overall burden and grading in patients with multiple comorbidities. The risk of comorbidities in patients with heart failure rises with more advanced disease, older age, and increased frailty-three conditions that are poorly represented in clinical trials. The pathogenic links between comorbidities and heart failure involve many pathways and include neurohormonal overdrive, inflammatory activation, oxidative stress, and endothelial dysfunction. Such interactions may worsen prognoses, but details of these relationships are still under investigation. We propose a shift from cardiac-focused care to a more systemic approach that considers all noncardiac diseases and related medications. Some new drugs class such as ARNI or SGLT2 inhibitors could change prognosis by acting directly or indirectly on metabolic disorders and related vascular consequences.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000530958800002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FCUQZR85,journalArticle,2017,"Khan, NA; Donatelli, CV; Tonelli, AR; Wiesen, J; Neto, MLR; Sahoo, D; Culver, DA",Toxicity risk from glucocorticoids in sarcoidosis patients,RESPIRATORY MEDICINE,,0954-6111,10.1016/j.rmed.2017.09.003,,"Background: Glucocorticoids (GC) are considered first-line therapy for treating sarcoidosis, but there are few data about the adverse consequences of GC. Although there are several steroid-sparing medications available for treatment, a large proportion of patients are treated with prolonged courses of GC. The toxicities of GC in sarcoidosis populations have not been carefully evaluated. Methods: We performed a retrospective cohort study of all newly diagnosed sarcoidosis patients who had the entirety of their medical care in a single health system. We analyzed the time to development of a composite toxicity end-point, including diabetes, hypertension, weight gain, hyperlipidemia, low bone density and ocular complications of GC using Cox proportional hazards analysis. Results: One hundred and five patients were ever treated with GC, whereas 49 were not treated during a median follow-up of 101 months. GC-treated patients developed 1.3 +/- 1.1 toxicities during therapy, versus 0.6 +/- 1.0 in the non-treated group. After adjustment for age, gender, race and preexisting conditions, the hazard ratio for ever-treated patients was 2.37 (1.34-4.17) for the composite end-point. Age and the presence of preexisting conditions also were associated with reaching the end-point. Similar effects were seen when analyzed for cumulative GC dose and for duration of GC use. For individual end-points, weight gain (HR 2.04) and new hypertension (HR 3.36) were associated with any use of GC. Conclusions: Our data suggest that GC are associated with clinically important toxicities in sarcoidosis patients, associated with both the cumulative dose and duration of treatment. (c) 2017 Elsevier Ltd. All rights reserved.",2017-11,01/07/2022 10:40,01/07/2022 10:40,,Sep-14,,,132,,,,,,,,,,,,,,WOS:000418239100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76ZHCE2G,journalArticle,2019,"Dougherty, JP; Springer, DA; Cullen, MJ; Gershengorn, MC",Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays,BEHAVIOURAL BRAIN RESEARCH,,0166-4328,10.1016/j.bbr.2018.12.011,,"Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention. To identify and develop such interventions, and to better understand fatigue, additional preclinical research is necessary. However, despite numerous mouse behavioral assays reportedly detecting fatigue-like behavior, the assumption that fatigue-like behavior is detected in many assays has not been validated through a cross-assay study. Thus, we modeled fatigue in mice by administering 5-fluorouracil, a chemotherapy drug known to cause fatigue in humans and fatigue-like behavior in mice, then evaluated its effects via voluntary wheel running activity (VWRA), locomotor activity in the open field test (OFT), immobility in the forced swim test (FST), and distance run in the treadmill fatigue test (TFT) and treadmill exercise capacity test. Additionally, taltirelin or methylphenidate was administered to alleviate fatigue-like behavior. As a result of 5-fluorouracil treatment, VWRA and the TFT were markedly reduced, indicating fatigue. The OFT, FST, and treadmill exercise capacity test, however, failed to detect fatigue-like behavior. Interestingly, both taltirelin and methylphenidate alleviated fatigue-like behavior in TFT. These data suggest that, of the current assays, only the TFT and VWRA should be expected to detect fatigue-like behavior. Moreover, this study provides additional evidence that taltirelin may provide a novel treatment for chemotherapy-induced fatigue and warrants further evaluation as an anti-fatigue therapeutic.",15/03/2019,01/07/2022 10:40,01/07/2022 10:40,,255-261,,,360,,,,,,,,,,,,,,WOS:000456352900026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZJ6Y5T7I,journalArticle,2011,"Smith, EML; Bakitas, MA; Homel, P; Piehl, M; Kingman, L; Fadul, CE; Bookbinder, M",Preliminary Assessment of a Neuropathic Pain Treatment and Referral Algorithm for Patients With Cancer,JOURNAL OF PAIN AND SYMPTOM MANAGEMENT,,0885-3924,10.1016/j.jpainsymman.2011.03.017,,"Context. The purpose of this case series study was to pilot test an evidence-based neuropathic pain (NP) treatment and referral algorithm for use by oncology nurses when managing cancer-related NP. Objectives. The primary study objective was to assess patient-reported outcomes (pain severity, changes in activities of daily living, and satisfaction) resulting from algorithm use. Methods. Outpatients (n = 20) with cancer-related NP scores >= 4 on a 0-10 numeric rating scale participated in the study. NP assessment, treatment, and referral to ancillary providers were guided by an evidence-based NP algorithm that was implemented by oncology nurse practitioners. Based on efficacy evidenced through randomized clinical trials published at the time of study implementation, the following drugs were included in the algorithm: lidocaine patch, gabapentin, oxycodone, tramadol, morphine, methadone, duloxetine, pregabalin, and nortriptyline. Recommendations for starting dose, dose escalation, drug combinations, treatment duration, and contraindications were included for first-tier drugs. Patient-reported outcomes (pain severity, functional capacity, and satisfaction) were assessed monthly over 12 weeks. Results. Average NP severity (P = 0.001), general activity (P < 0.001), mood (P = 0.002), walking ability (P = 0.01), ability to perform normal work (P = 0.002), relationships (P = 0.002), sleep (P = 0.01), life enjoyment (P < 0.001), and patient satisfaction (P = 0.003) all improved by 12 weeks. Conclusion. Evidence from this pilot study suggests that NP evidence-based treatment may result in improved symptoms, function, and patient satisfaction. A randomized controlled trial is needed to further assess algorithm efficacy. J Pain Symptom Manage 2011;42:822-838. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.",2011-12,01/07/2022 10:40,01/07/2022 10:40,,822-838,,6,42,,,,,,,,,,,,,,WOS:000298342400006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
J8AVZC4G,journalArticle,2008,"Bult, MJF; van Dalen, T; Muller, AF",Surgical treatment of obesity,EUROPEAN JOURNAL OF ENDOCRINOLOGY,,0804-4643,10.1530/EJE-07-0145,,"More than half of the European population are overweight (body mass index (BMI) > 25 and < 30kg/m(2))and upto 30% are obese (BMI >= 30kg/m(2)). Being overweight and obesity are becoming endemic, particularly because of increasing nourishment and a decrease in physical exercise. Insulin resistance, type 2 diabetes, dyslipidemia, hypertension, cholelithiasis, certain forms of cancer, steatosis hepatis, gastroesophageal reflux, obstructive sleep apnea, degenerative joint disease, gout, lower back pain, and polycystic ovary syndrome are all associated with overweight and obesity. The endemic extent of overweight and obesity with its associated comorbidities has led to the development of therapies aimed at weight loss. The long-term effects of diet, exercise, and medical therapy on weight are relatively poor. With respect to durable weight reduction, bariatric surgery is the most effective long-term treatment for obesity with the greatest chances for amelioration and even resolution of obesity-associated complications. Recent evidence shows that bariatric surgery for severe obesity is associated with decreased overall mortality. However, serious complications can occur and therefore a careful selection of patients is of utmost importance. Bariatric surgery should at least be considered for all patients with a BMI of more than 40 kg/m(2) and for those with a BMI of more than 3 5 kg/m(2) with concomitant obesity-related conditions after failure of conventional treatment. The importance of weight loss and results of conventional treatment will be discussed first. Currently used operative treatments for obesity and their effectiveness and complications are described. Proposed criteria for bariatric surgery are given. Also, some attention is devoted to more basic insights that bariatric surgery has provided. Finally we deal with unsolved questions and future directions for research.",2008-02,01/07/2022 10:40,01/07/2022 10:40,,135-145,,2,158,,,,,,,,,,,,,,WOS:000253380800001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MZHBU7Z8,book,2009,"Oh, KH; Ahn, C",Advances in the Peritoneal Dialysis and Future Prospects,,978-1-60741-736-1,,,,"Peritoneal dialysis (PD) has been widely used as one of the major renal replacement therapies for end-stage renal disease (ESRD) patients. A new PD fluid is instilled into the peritoneal cavity via peritoneal catheter after the previously instilled fluid has been drained out. Exchange of solutes and water between the body and the peritoneal fluid occurs during PD. PD system has three major components 1) peritoneal fluid compartment, 2) peritoneal microcirculation and 3) peritoneal membrane. Basic mechanism employed in PD lies in diffusion and convection for removing uremic toxins, and ultrafiltration (UF) for water removal. PD fluid contains a high concentration of glucose, which generates an osmotic gradient between the peritoneal fluid and peritoneal microcirculation, resulting in water movement into the peritoneal cavity. There is a wide inter-individual variation in the speed of solute and water transport through the peritoneal membrane. Peritoneal equilibration test (PET) and other tests for the assessment of the peritoneal solute and water transport have been developed. Fast transporters are likely to dissipate osmotic gradient earlier than slow transporters because they absorb glucose more rapidly through the peritoneal membrane. Suspected factors determining the peritoneal solute transport rate (PSTR) are age, diabetes, comorbidity, peritonitis, chronic inflammation and frequent use of bio-incompatible PD fluid containing high glucose and glucose degradation products (GDP). Interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), nitric oxide(NO), cancer antigen 125 (CA 125) and transforming growth factor-beta (TGF-beta) have been associated with PSTR. The role of the genetic polymorphism of the above molecules is under investigation. We have seen remarkable technical advances in the prevention of peritonitis by allowing less chance of contamination during PD fluid exchange (connectology), along with the development of diagnosis and management protocols. Automated PD facilitating fluid exchange during sleep provides improved quality of life for the patients. Continuous flow PD (CFPD) through potential application of sorbents is also under intensive research. However, long-term PD is associated with progressive loss of UF capacity, resulting in ultimate discontinuation of PD. This is related to the inflammation, new vessel formation (neoangiogenesis) and fibrotic thickening of the peritoneal membrane (PM). Bio-incompatible PD fluid, along with peritonitis, is the major contributor to the PM change. IL-6, VEGF, TGF-beta, connective tissue growth factor (CTGF) are suspected as mediators of the PM injury. There has been recent development of newer biocompatible fluids characterized by neutral pH, non-glucose or low GDP content. Further research will follow in order to develop a more biocompatible PD fluid.",2009,01/07/2022 10:40,01/07/2022 10:40,,,55,,,,,,NEPHROLOGY - DIALYSIS - TRANSPLANTATION,,,,,,,,,,WOS:000278693400003,,,Pages: 73,,,,,,"Kruger, E; Hahn, K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
M5FM83IB,journalArticle,2016,"Posadzki, P; Mastellos, N; Ryan, R; Gunn, LH; Felix, LM; Pappas, Y; Gagnon, MP; Julious, SA; Xiang, LM; Oldenburg, B; Car, J",Automated telephone communication systems for preventive healthcare and management of long-term conditions,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD009921.pub2,,"Background Automated telephone communication systems (ATCS) can deliver voice messages and collect health-related information from patients using either their telephone's touch-tone keypad or voice recognition software. ATCS can supplement or replace telephone contact between health professionals and patients. There are four different types of ATCS: unidirectional (one-way, non-interactive voice communication), interactive voice response (IVR) systems, ATCS with additional functions such as access to an expert to request advice (ATCS Plus) and multimodal ATCS, where the calls are delivered as part of a multicomponent intervention. Objectives To assess the effects of ATCS for preventing disease and managing long-term conditions on behavioural change, clinical, process, cognitive, patient-centred and adverse outcomes. Search methods We searched 10 electronic databases (the Cochrane Central Register of Controlled Trials; MEDLINE; Embase; PsycINFO; CINAHL; Global Health; WHOLIS; LILACS; Web of Science; and ASSIA); three grey literature sources (Dissertation Abstracts, Index to Theses, Australasian Digital Theses); and two trial registries (www.controlled-trials.com; www.clinicaltrials.gov) for papers published between 1980 and June 2015. Selection criteria Randomised, cluster-and quasi-randomised trials, interrupted time series and controlled before-and-after studies comparing ATCS interventions, with any control or another ATCS type were eligible for inclusion. Studies in all settings, for all consumers/carers, in any preventive healthcare or long term condition management role were eligible. Data collection and analysis We used standard Cochrane methods to select and extract data and to appraise eligible studies. Main results We included 132 trials (N = 4,669,689). Studies spanned across several clinical areas, assessing many comparisons based on evaluation of different ATCS types and variable comparison groups. Forty-one studies evaluated ATCS for delivering preventive healthcare, 84 for managing long-term conditions, and seven studies for appointment reminders. We downgraded our certainty in the evidence primarily because of the risk of bias for many outcomes. We judged the risk of bias arising from allocation processes to be low for just over half the studies and unclear for the remainder. We considered most studies to be at unclear risk of performance or detection bias due to blinding, while only 16% of studies were at low risk. We generally judged the risk of bias due to missing data and selective outcome reporting to be unclear. For preventive healthcare, ATCS (ATCS Plus, IVR, unidirectional) probably increase immunisation uptake in children (risk ratio (RR) 1.25, 95% confidence interval (CI) 1.18 to 1.32; 5 studies, N = 10,454; moderate certainty) and to a lesser extent in adolescents (RR 1.06, 95% CI 1.02 to 1.11; 2 studies, N = 5725; moderate certainty). The effects of ATCS in adults are unclear (RR 2.18, 95% CI 0.53 to 9.02; 2 studies, N = 1743; very low certainty). For screening, multimodal ATCS increase uptake of screening for breast cancer (RR 2.17, 95% CI 1.55 to 3.04; 2 studies, N = 462; high certainty) and colorectal cancer (CRC) (RR 2.19, 95% CI 1.88 to 2.55; 3 studies, N = 1013; high certainty) versus usual care. It may also increase osteoporosis screening. ATCS Plus interventions probably slightly increase cervical cancer screening (moderate certainty), but effects on osteoporosis screening are uncertain. IVR systems probably increase CRC screening at 6 months (RR 1.36, 95% CI 1.25 to 1.48; 2 studies, N = 16,915; moderate certainty) but not at 9 to 12 months, with probably little or no effect of IVR (RR 1.05, 95% CI 0.99, 1.11; 2 studies, 2599 participants; moderate certainty) or unidirectional ATCS on breast cancer screening. Appointment reminders delivered through IVR or unidirectional ATCS may improve attendance rates compared with no calls (low certainty). For long-term management, medication or laboratory test adherence provided the most general evidence across conditions (25 studies, data not combined). Multimodal ATCS versus usual care showed conflicting effects (positive and uncertain) on medication adherence. ATCS Plus probably slightly (versus control; moderate certainty) or probably (versus usual care; moderate certainty) improves medication adherence but may have little effect on adherence to tests (versus control). IVR probably slightly improves medication adherence versus control (moderate certainty). Compared with usual care, IVR probably improves test adherence and slightly increases medication adherence up to six months but has little or no effect at longer time points (moderate certainty). Unidirectional ATCS, compared with control, may have little effect or slightly improve medication adherence (low certainty). The evidence suggested little or no consistent effect of any ATCS type on clinical outcomes (blood pressure control, blood lipids, asthma control, therapeutic coverage) related to adherence, but only a small number of studies contributed clinical outcome data. The above results focus on areas with the most general findings across conditions. In condition-specific areas, the effects of ATCS varied, including by the type of ATCS intervention in use. Multimodal ATCS probably decrease both cancer pain and chronic pain as well as depression (moderate certainty), but other ATCS types were less effective. Depending on the type of intervention, ATCS may have small effects on outcomes for physical activity, weight management, alcohol consumption, and diabetes mellitus. ATCS have little or no effect on outcomes related to heart failure, hypertension, mental health or smoking cessation, and there is insufficient evidence to determine their effects for preventing alcohol/substance misuse ormanaging illicit drug addiction, asthma, chronic obstructive pulmonary disease, HIV/AIDS, hypercholesterolaemia, obstructive sleep apnoea, spinal cord dysfunction or psychological stress in carers. Only four trials (3%) reported adverse events, and it was unclear whether these were related to the interventions. Authors' conclusions ATCS interventions can change patients' health behaviours, improve clinical outcomes and increase healthcare uptake with positive effects in several important areas including immunisation, screening, appointment attendance, and adherence to medications or tests. The decision to integrate ATCS interventions in routine healthcare delivery should reflect variations in the certainty of the evidence available and the size of effects across different conditions, together with the varied nature of ATCS interventions assessed. Future research should investigate both the content of ATCS interventions and the mode of delivery; users' experiences, particularly with regard to acceptability; and clarify which ATCS types are most effective and cost-effective.",2016,01/07/2022 10:40,01/07/2022 10:40,,,,12,,,,,,,,,,,,,,,WOS:000391317600008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AEBJ5SX6,journalArticle,2013,"Aulinas, A; Casanueva, F; Goni, F; Monereo, S; Moreno, B; Pico, A; Puig-Domingo, M; Salvador, J; Tinahones, FJ; Webb, SM",Adrenal insufficiency and adrenal replacement therapy. Current status in Spain,ENDOCRINOLOGIA Y NUTRICION,,1575-0922,,,"Adrenal insufficiency (AI) is a rare endocrine disease, associated to increased mortality if left untreated. It can be due to a primary failure of the adrenal glands (primary AI) or malfunctioning of the hypothalamic-pituitary-adrenal axis (HPA) (secondary AI). The lack of data on incidence/prevalence of adrenal insufficiency in Spain complicates any evaluation of the magnitude of the problem in our country. Initial symptoms are non-specific, so often there is a delay in diagnosis. Current therapy with available glucocorticoids is associated with decreased quality of life in patients with treated AI, as well as with increased mortality and morbidity, probably related to both over-treatment and lack of hydrocortisone, associated with non-physiological peaks and troughs of the drug over the 24 hours. The availability of a new drug with a modified dual release (immediate and retarded), that requires one only daily dose, improves and simplifies the treatment, increases compliance as well as quality of life, morbidity and possibly mortality. This revision deals with the knowledge on the situation both globally and in Spain, prior to the availability of this new drug. (C) 2012 SEEN. Published by Elsevier Espana, S.L. All rights reserved.",2013-03,01/07/2022 10:40,01/07/2022 10:40,,136-143,,3,60,,,,,,,,,,,,,,WOS:000209714400005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NL6QYEIE,journalArticle,2017,"Chapple, ILC; Bouchard, P; Cagetti, MG; Campus, G; Carra, MC; Cocco, F; Nibali, L; Hujoel, P; Laine, ML; Lingstrom, P; Manton, DJ; Montero, E; Pitts, N; Range, H; Schlueter, N; Teughels, W; Twetman, S; Van Loveren, C; Van der Weijden, F; Vieira, AR; Schulte, AG","Interaction of lifestyle, behaviour or systemic diseases with dental caries and periodontal diseases: consensus report of group 2 of the joint EFP/ORCA workshop on the boundaries between caries and periodontal diseases",JOURNAL OF CLINICAL PERIODONTOLOGY,,0303-6979,10.1111/jcpe.12685,,"Periodontal diseases and dental caries are the most common diseases of humans and the main cause of tooth loss. Both diseases can lead to nutritional compromise and negative impacts upon self-esteem and quality of life. As complex chronic diseases, they share common risk factors, such as a requirement for a pathogenic plaque biofilm, yet they exhibit distinct pathophysiologies. Multiple exposures contribute to their causal pathways, and susceptibility involves risk factors that are inherited (e.g. genetic variants), and those that are acquired (e.g. socio-economic factors, biofilm load or composition, smoking, carbohydrate intake). Identification of these factors is crucial in the prevention of both diseases as well as in their management. Aim: To systematically appraise the scientific literature to identify potential risk factors for caries and periodontal diseases. Methods: One systematic review (genetic risk factors), one narrative review (role of diet and nutrition) and reference documentation for modifiable acquired risk factors common to both disease groups, formed the basis of the report. Results & Conclusions: There is moderately strong evidence for a genetic contribution to periodontal diseases and caries susceptibility, with an attributable risk estimated to be up to 50%. The genetics literature for periodontal disease is more substantial than for caries and genes associated with chronic periodontitis are the vitamin D receptor (VDR), Fc gamma receptor IIA (Fc-gamma RIIA) and Interleukin 10 (IL10) genes. For caries, genes involved in enamel formation (AMELX, AMBN, ENAM, TUFT, MMP20, and KLK4), salivary characteristics (AQP5), immune regulation and dietary preferences had the largest impact. No common genetic variants were found. Fermentable carbohydrates (sugars and starches) were the most relevant common dietary risk factor for both diseases, but associated mechanisms differed. In caries, the fermentation process leads to acid production and the generation of biofilm components such as Glucans. In periodontitis, glycaemia drives oxidative stress and advanced glycation end-products may also trigger a hyper inflammatory state. Micronutrient deficiencies, such as for vitamin C, vitamin D or vitamin B12, may be related to the onset and progression of both diseases. Functional foods or probiotics could be helpful in caries prevention and periodontal disease management, although evidence is limited and biological mechanisms not fully elucidated. Hyposalivation, rheumatoid arthritis, smoking/tobacco use, undiagnosed or sub-optimally controlled diabetes and obesity are common acquired risk factors for both caries and periodontal diseases.",2017-03,01/07/2022 10:40,01/07/2022 10:40,,S39-S51,,,44,,,,,,,,,,,,,,WOS:000418237200004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PD2KMUUI,journalArticle,2016,"Ong, T; Ramsey, BW",New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator,PEDIATRIC CLINICS OF NORTH AMERICA,,0031-3955,10.1016/j.pcl.2016.04.006,,"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are clinically available personalized medicines approved for some individuals with cystic fibrosis (CF) to target the underlying defect of disease. This review summarizes strategies used to develop CFTR modulators as therapies that improve function and availability of CFTR protein. Lessons learned from dissemination of ivacaftor across the CF population responsive to this therapy and future approaches to predict and monitor treatment response of CFTR modulators are discussed. The goal remains to expand patient-centered and personalized therapy to all patients with CF, ultimately improving life expectancy and quality of life for this disease.",2016-08,01/07/2022 10:40,01/07/2022 10:40,,751-+,,4,63,,,,,,,,,,,,,,WOS:000381954000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R5RGPLTX,journalArticle,2020,"Ruark, J; Mullane, E; Cleary, N; Cordeiro, A; Bezerra, ED; Wu, V; Voutsinas, J; Shaw, BE; Flynn, KE; Lee, SJ; Turtle, CJ; Maloney, DG; Fann, JR; Bar, M",Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy,BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,,1083-8791,10.1016/j.bbmt.2019.09.037,,"CD19-targeted chimeric antigen receptor (CAR) modified T cell immunotherapy is a novel treatment with promising results in patients with relapsed/refractory lymphoid malignancies. CAR T cell therapy has known early toxicities of cytokine release syndrome and neurotoxicity, but little is known about long-term neuropsychiatric adverse effects. We have used patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS) measures, to assess neuropsychiatric and other patient-reported outcomes of 40 patients with relapse/refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute lymphoblastic leukemia 1 to 5 years after treatment with CD19-targeted CART cells. Mean T scores of PROMIS domains of global mental health, global physical health, social function, anxiety, depression, fatigue, pain, and sleep disturbance were not clinically meaningfully different from the mean in the general US population. However, 19 patients (47.5%) reported at least 1 cognitive difficulty and/or clinically meaningful depression and/or anxiety, and 7 patients (17.5%) scored <= 40 in global mental health, indicating at least 1 standard deviation worse than the general population mean. Younger age was associated with worse long-term global mental health (P=.02), anxiety (P=.001), and depression (P=.01). Anxiety before CAR T cell therapy was associated with increased likelihood of anxiety after CAR T cell therapy (P=.001). Fifteen patients (37.5%) reported cognitive difficulties after CAR T cell therapy. Depression before CART cell therapy was statistically significantly associated with higher likelihood of self-reported post-CART cognitive difficulties (P=.02), and there was a trend for an association between acute neurotoxicity and self-reported post-CAR T cognitive difficulties (P=.08). Having more post-CAR T cognitive difficulties was associated with worse global mental health and global physical health. Our study demonstrates overall good neuropsychiatric outcomes in 40 long-term survivors after CAR T cell therapy. However, nearly 50% of patients in the cohort reported at least 1 clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty), indicating that a significant number of patients would likely benefit from mental health services following CAR T cell therapy. Younger age, pre-CAR T anxiety or depression, and acute neurotoxicity may be risk factors for long-term neuropsychiatric problems in this patient population. Larger studies are needed to confirm these findings. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.",2020-01,01/07/2022 10:40,01/07/2022 10:40,,34-43,,1,26,,,,,,,,,,,,,,WOS:000507718100005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LQPDAGWA,journalArticle,2015,"Lakshman, R; Whittle, F; Hardeman, W; Suhrcke, M; Wilson, E; Griffin, S; Ong, KK",Effectiveness of a behavioural intervention to prevent excessive weight gain during infancy (The Baby Milk Trial): study protocol for a randomised controlled trial,TRIALS,,1745-6215,10.1186/s13063-015-0941-5,,"Background: Infancy is a period of rapid growth and habit formation and hence could be a critical period for obesity prevention. Excess weight gain during infancy is associated with later obesity and formula-fed babies are more likely to gain excess weight compared to breastfed babies. The primary trial outcome is a change in the weight standard deviation score from birth to 1 year. Methods/Design: We will recruit 650 to 700 parents who introduce formula-milk feeds within 14 weeks of their baby's birth to a single (assessor) blind, parallel group, individually randomised controlled trial. The focus of the intervention is the caregiver (usually the mother), and the focus of the primary outcome is the infant. The intervention group will receive the behavioural intervention, which aims to reduce formula-milk intake, promote responsive feeding and healthy weaning, and prevent excessive weight gain during infancy. The intervention is based on Social Cognitive Theory and action planning ('implementation intentions'). It consists of three components: (1) a motivational component to strengthen parents' motivation to follow the Baby Milk feeding guidelines, (2) an action planning component to help translate motivation into action, and (3) a coping planning component to help parents deal with difficult situations. It will be delivered by trained facilitators (research nurses) over 6 months through three face-to-face contacts, two telephone contacts and written materials. The control group will have the same number of contacts with facilitators, and general issues about feeding will be discussed. Anthropometric outcomes will be measured by trained research staff, blind to group allocation, at baseline, 6 months and 12 months following standard operating procedures. Validated questionnaires will assess milk intake, temperament, appetite, sleep, maternal quality of life and maternal psychological factors. A 4-day food diary will be completed at 8 months. Discussion: The results of the trial will help to inform infant feeding guidelines and to understand the links between infant feeding, behaviour, appetite and growth.",06/10/2015,01/07/2022 10:40,01/07/2022 10:40,,,,,16,,,,,,,,,,,,,,WOS:000362249700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LPUWAPX7,journalArticle,2001,"Bhana, N; Perry, CM",Olanzapine - A review of its use in the treatment of bipolar I disorder,CNS DRUGS,,1172-7047,10.2165/00023210-200115110-00005,,"Olanzapine, a thienobenzodiazepine derivative, is a psychotropic agent that has shown efficacy in the treatment of patients with bipolar 1 disorder. Olanzapine has a multireceptorial binding profile including a greater affinity for serotonin 5-HT2A than for dopamine D-2 receptors. Olanzapine 5 to 20 mg/day demonstrated significantly greater antimanic efficacy than placebo in two double-blind, randomised 3- or 4-week trials of patients with bipolar 1 disorder of either manic or mixed episodes, with or without psychotic features. Additionally, in one of these trials, improvements in cognitive function and hostility were superior with olanzapine. In cohorts of severely depressed and rapid cycling patients, improvements in manic and depressive symptoms and in manic symptoms only, were superior with olanzapine compared with placebo. Significant improvements from baseline in symptoms of mania, depression, cognitive functioning and hostility were seen with olanzapine in a 49-week extension phase study. In double-blind trials, olanzapine 10 mg/day appeared to have similar antimanic efficacy to oral lithium 400mg twice daily in the treatment of patients with pure mania (4-week small study). In patients with acute manic or mixed episodes olanzapine 5 to 20 mg/day appeared to be more effective than oral valproate semisodium (divalproex sodium) 500 to 2500 mg/day (3-week study) and at least as effective as oral haloperidol 3 to 15 mg/day (12-week study). Preliminary results from a large 6-week placebo-controlled study suggest that olanzapine 5 to 20 mg/day in combination with mood stabilisers (lithium or valproate semisodium) provides effective augmentation of antimanic treatment of patients with bipolar 1 disorder, with benefits seen in the first week. Adverse events reported significantly more often with olanzapine than with placebo were somnolence, dry mouth, dizziness and bodyweight gain, and in comparison with valproate semisodium were somnolence, dry mouth, increased appetite and bodyweight gain. Olanzapine was generally well tolerated with no clinically relevant abnormalities in laboratory tests, vital signs or electrocardiogram results. Conclusion: Olanzapine demonstrated superior efficacy compared with placebo in the short-term treatment of patients with bipolar 1 disorder with manic or mixed episodes, with or without psychotic features, and was generally well tolerated. According to preliminary data the antimanic efficacy of olanzapine appears similar to that of haloperidol and better than that of valproate semisodium in patients with bipolar 1 disorder experiencing a manic or mixed episode; among nonpsychotic patients with manic or mixed episodes olanzapine appears to be superior to haloperidol. Available data support the choice of olanzapine as an option in the short-term management of mania in patients with bipolar 1 disorder with manic or mixed episodes, with or without psychotic features. Olanzapine, a thienobenzodiazepine derivative, is a psychotropic agent which has binding affinity for a broad range of neurotransmitter receptors. In vitro olanzapine is a potent antagonist at serotonin 5-HT2A-C, alpha (1)-adrenergic and histamine H-1 receptors, a relatively modest antagonist at dopamine D-1 and all five subtypes of the muscarinic receptor, and is devoid of agonist activity at any of these receptors. The mixed receptor activity of olanzapine is similar to that of clozapine, as is its greater affinity for 5-HT2A than for D-2 receptors. Olanzapine exhibits a preclinical behavioural profile that is indicative of antipsychotic activity. Inhibition of a number of dopamine and serotonin agonist-induced animal behaviours was demonstrated in vivo, confirming in vitro evidence of its receptor affinity profile. Olanzapine blocked conditioned avoidance at lower doses than those inducing catalepsy and reduced behaviours predictive of positive and negative symptoms. Olanzapine increased noradrenaline and dopamine release in cortical areas which may contribute to its effects against negative symptoms. In electrophysiological studies, olanzapine demonstrated mesolimbic (A10) over nigrostriatal (A9) selectivity, which may be predictive of a low potential for the induction of extrapyramidal symptoms (EPS). Olanzapine is not associated with cognitive dysfunction but may improve neurocognitive deficits, as seen in patients with schizophrenia. Spatial memory capacity (a cognitive indicator) was not impaired after a morning dose of olanzapine 5mg alone or in combination with imipramine 75mg in healthy volunteers and short-term effects on alertness and motor effects showed rapid adaptation to treatment. In healthy volunteers olanzapine showed sleep-promoting effects. Olanzapine was not associated with clinically significant prolonged rate-corrected QT (QTc) interval or hyperprolactinaemia in clinical trials of patients with acute psychosis or bipolar 1 disorder. There are a number of case reports of treatment-emergent diabetes mellitus and a few of diabetic ketoacidosis or hyperosmolar states. Bodyweight gain with olanzapine in short-term clinical trials was significantly greater than that seen with placebo or valproate semisodium (divalproex sodium). Olanzapine is well absorbed after oral administration in healthy volunteers and the absolute oral bioavailability (60 to 80%) is unaffected by food. Mean peak plasma concentrations (C-max) Of 11 mug/L after a single oral dose of 12.5mg are achieved in approximately 5 hours (t(max)). Steady-state plasma concentrations are seen after about 7 days' treatment with olanzapine. The volume of distribution is 22 L/kg and the drug is highly (93%) protein bound in plasma. In vitro about 5 to 14% of olanzapine crosses the placenta. Olanzapine is extensively metabolised by glucuronidation (facilitated by uridine diphosphate glucuronyltransferase) and oxidation [by the cytochrome P450 (CYP) 1A2 and 2D6 isoenzymes and the flavin-containing mono-oxygenase-3 system] to the major metabolites 10-N-glucuronide and 4'-N-desmethyl olanzapine and about 8 other inactive metabolites. The elimination half-life (t(1/2)beta) of olanzapine is about 30 hours for healthy volunteers and is prolonged in female and elderly individuals. The clearance (CL) of olanzapine ranges from 12 to 47 L/h in healthy volunteers but is decreased in females and elderly individuals. The pharmacokinetics of olanzapine were not significantly altered in patients with renal or hepatic dysfunction. Some inhibitors of CYP1A2 (fluvoxamine, ciprofloxacin) and CYP2D6 (fluoxetine) increase the plasma concentration of olanzapine by 40 to 100%, and some CYP1A2 inducers, such as cigarette smoking and carbamazepine, increase the apparent CL of olanzapine by about 23 to 46%, respectively. Olanzapine (5, 10, 15 or 20 mg once daily for 3 or 4 weeks) significantly improved manic symptoms in two double-blind trials of patients (n = 254) aged 18 to 70 years with bipolar I disorder of either manic or mixed episodes with or without psychotic features. Improvements from baseline Young-Mania Rating Scale (Y-MRS) scores to endpoint, according to last observation-carried-forward analysis, were significantly greater with olanzapine than placebo (36 and 51% vs 18 and 28%, p < 0.05). In the 4-week trial, superiority compared with placebo was seen as early as week 1; the starting dosage in this trial was 15 mg/day compared with 10 mg/day in the 3-week trial. No significant difference in improvements was seen between patients experiencing manic or mixed episodes or those with or without psychotic features. Additionally, clinical response (defined as <greater than or equal to>50% improvement from baseline to endpoint Y-MRS total score) was seen in more olanzapine than placebo recipients in both trials (49 and 65% vs 24 and 43%, p < 0.05). Secondary efficacy measures showed significantly greater improvements in cognitive functioning and hostility with olanzapine than with placebo in the 3-week trial. Post hoc analysis of a cohort of patients (n = 68) from these trials with depression of at least moderate severity showed that improvements from baseline to endpoint in Y-MRS (40 vs 15%) and Hamilton Depression Rating Scale (HAM-D) [44 vs 27%] scores (rating manic and depressive symptoms, respectively) were significantly greater with olanzapine 5 to 20 mg/day than placebo. Similarly, in a cohort of patients with rapid cycling bipolar I disorder (n = 44), improvements in mania were superior with olanzapine compared with placebo (-14 vs -4, p < 0.05). Significantly more olanzapine than placebo recipients showed 30% improvement from baseline Y-MRS scores (84 vs 36%. p = 0.002). During nonblind treatment with olanzapine (n = 113), in the extension phase (49 weeks) of the 3-week acute phase study, superior (p < 0.001) improvements from baseline were observed for symptoms of mania (71%), depression (47%), cognitive functioning (36%) and hostility (42%). Olanzapine 10 mg/day was as effective as lithium 400mg twice daily in a 4-week double-blind trial of patients (n = 30) with bipolar I disorder experiencing a pure manic episode. No significant between-treatment difference was seen in improvements from baseline scores on the Brief Psychiatric Rating Scale or the Mania Rating Scale, although superior improvements were seen with olanzapine on the Clinical Global Impressions severity score (51 vs 38%, p < 0.05). Important limitations of this trial include the low mean serum lithium concentration (0.74 mmol/L), the doses of both lithium and olanzapine were low compared with other relevant studies and the study was small. Compared with valproate semisodium 500 to 2500 mg/day (in divided doses) olanzapine 5 to 20 mg/day improved symptoms of mania (according to Y-MRS total score) to a significantly greater extent (49 vs 37%, p < 0.05) in a 3-week double-blind trial of patients (n = 251) with either manic or mixed episodes. In these preliminary results (poster presentation) there was no significant between-treatment difference in the percentage of responders; however, improvements of depressive symptoms were greater with olanzapine, and significantly more olanzapine than valproate semisodium recipients achieved remission (defined as having a Y-MRS score <less than or equal to> 12) [47 vs 34%, p < 0.05]. Chart reviews showed olanzapine 5 to 30 mg/day to be beneficial as adjunctive therapy in patients with treatment-resistant bipolar disorder. Additionally, a few case reports and one noncomparative study have suggested some efficacy in the treatment of children with bipolar disorder. According to retrospective chart reviews and case reports olanzapine, when combined with mood stabilisers (mostly lithium and valproate semisodium), provides effective augmentation of mood stabilising and antimanic treatment of patients with bipolar I disorder and preliminary results from a large (n = 344) 6-week, double-blind study support these findings. Addition of olanzapine 5 to 20 mg/day to an existing treatment regimen of valproate semisodium (50 to 125 <mu>g/ml serum concentration) or lithium (0.6 to 1.2 mmol/L serum concentration) improved Y-MRS total scores to a significantly greater extent than the mood stabilisers alone (-13 vs -9, p = 0.003) and superiority was seen as early as week 1. In a subgroup of patients with concurrent depressive symptoms, response rates (68 vs 45%, p < 0.001) and improvements in depressive symptoms (assessed using HAM-D scores, -10.3 vs -1.57; p < 0.001) were greater with olanzapine adjunctive therapy than each study drug alone. In the two placebo-controlled 3- or 4-week, double-blind trials in patients (n 254) with bipolar I disorder, the most common adverse events (reported by at least 10% of patients treated with olanzapine 5 to 20 mg/day in either trial) were somnolence, dry mouth, dizziness, asthenia, headache, bodyweight gain, constipation, dyspepsia and anxiety; only somnolence (33 vs 17%), dry mouth (26 vs 9%), dizziness (23 vs 6%) and bodyweight gain (11 vs 1%) occurred in significantly more olanzapine than placebo recipients in at least one of the trials (p < 0.05). In comparison with valproate semisodium (500 to 2500 mg/day in divided doses), the incidence of somnolence, dry mouth and increased appetite was significantly higher with olanzapine. In these trials treatment termination due to adverse events was similar between olanzapine and placebo or valproate semisodium. Clinically relevant changes in vital signs, laboratory tests, electrocardiogram results (including QTc interval prolongation) or haematological parameters in olanzapine recipients were not observed in either placebo-controlled study with the exception of supine systolic blood pressure in one trial. Hepatic serum transaminase levels were elevated in significantly more olanzapine than placebo recipients in both trials (18 and 17 vs 0%), although the increases were transient and clinical signs of hepatic dysfunction were not apparent. Mean bodyweight gain with olanzapine treatment was significantly greater than that seen with placebo (1.7 and 2.1 vs -0.4 and 0.4kg) in 3- or 4-week clinical trials, and valproate semisodium in two short-term trials (2.5 and 4 vs 0.9 and 2.5kg). The incidence of EPS (assessed by standard rating scales) was comparable to that seen with placebo or valproate semisodium. There were no reports of tardive dyskinesia in 3- to 4-week placebo-controlled trials or in preliminary results of a 49-week extension phase study. Pharmacoeconomic comparisons of olanzapine and placebo generally suggest that olanzapine does not add to the overall treatment cost of patients with bipolar I disorder, and may even furnish small cost savings. Among 139 patients with bipolar I disorder treated with olanzapine 5 to 20 mg/day or placebo in a 3-week double-blind trial, total monthly outpatient ($US298 vs $US462) and inpatient costs ($US 11 543 vs $US 13 420) were lower with olanzapine. Moreover, during the 49-week noncomparative extension phase, total outpatient ($US89 vs $US330) and inpatient costs ($US852 vs $US1159) per month during olanzapine treatment were markedly lower than those over the previous 12 months. Health-related quality of life tended to be comparable between patients treated with olanzapine or placebo during a 3-week double-blind trial but were superior compared with baseline in the 49-week noncomparative extension phase. Olanzapine is indicated in the US for the short-term treatment of acute mania associated with bipolar I disorder in patients with manic or mixed episodes with or without psychotic features. Available formulations for this indication include oral tablets and orally disintegrating tablets. The recommended starting dosage of oral olanzapine in patients with bipolar I disorder is 10 to 15mg once daily, regardless of meals. If clinically indicated, 5mg increments or decrements at intervals <greater than or equal to>24 hours may be implemented within the effective therapeutic range of 5 to 20 mg/day. The safety of dosages >20 mg/day has not been assessed. In patients predisposed to orthostatic hypotension, the risk can be minimised by dosage initiation at 5 mg/day with careful titration. Dosage modification should also be considered for patients with a combination of factors associated with slower olanzapine metabolism.",2001,01/07/2022 10:40,01/07/2022 10:40,,871-904,,11,15,,,,,,,,,,,,,,WOS:000172474400005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TYZNFNCW,journalArticle,2010,"Geddes, J; Ratcliff, R; Allerhand, M; Childers, R; Wright, RJ; Frier, BM; Deary, IJ",Modeling the Effects of Hypoglycemia on a Two-Choice Task in Adult Humans,NEUROPSYCHOLOGY,,0894-4105,10.1037/a0020074,,"Objective: Previous research has demonstrated that hypoglycemia causes reaction times to be slower and more variable. Reaction time tests, however, use multiple cognitive and noncognitive processes. This study is the first to use a validated sequential sampling model (diffusion model) applied to results obtained from a simple 2-choice task in adult humans to assess the effects of hypoglycemia on the basic parameters of decision making. Method: Fourteen adult volunteers were tested on a numerosity discrimination task with and without reduced blood glucose concentrations. The results were analyzed with a model that dissects the components of processing that underlie decisions: the quality of the information on which a decision is based (drift rate), the critical amount of evidence that must be accumulated before a decision is made (boundary separation). and the time taken by nondecision processes. Results: Hypoglycemia resulted in a reduction of mean drift rate from 0.290 to 0.211, t(13) = 4.10, p < .05. No effect of experimental state was observed on the amount of evidence required to make a decision or peripheral and motor processes. Conclusion: This study locates the precise processing deficit associated with hypoglycemia and provides further understanding of the precise cognitive effect of hypoglycemia. Further research into the amelioration of these effects is required.",2010-09,01/07/2022 10:40,01/07/2022 10:40,,652-660,,5,24,,,,,,,,,,,,,,WOS:000281338200011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23T77GWT,journalArticle,2013,"Mora, M; Aranda, GB; de Hollanda, A; Flores, L; Puig-Domingo, M; Vidal, J",Weight loss is a major contributor to improved sexual function after bariatric surgery,SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES,,0930-2794,10.1007/s00464-013-2890-y,,"The relative contribution of anthropometric, hormonal, and metabolic changes after bariatric surgery (BS) on sexual function (SF) in severely obese subjects is not well established. Prospective observational case series study of 39 men undergoing BS. SF was assessed by means of the international index of erectile function (IIEF) before and at 1 year after surgery. At the same time points, anthropometric (body mass index, waist circumference), hormonal (testosterone, sex hormone binding globulin, estradiol, gonadotropins, inhibin B, prolactin, leptin), and metabolic parameters (insulin sensitivity, C-reactive protein, lipid profile, hemoglobin A1c, presence of hypertension or sleep apnea) were assessed. BS was associated with marked weight loss (77.18 % excess weight loss), improved IIEF score (baseline: 54.85 +/- A 16.59, 1 year: 61.21 +/- A 14.10; p < 0.01), gonadal function (testosterone: baseline 256.36 +/- A 120.98, 1 year: 508.01 +/- A 161.90; p < 0.001), and improved metabolic profile. However, on multivariate regression analysis whereas changes in body mass index (beta: -0.677, p = 0.001), and baseline IIEF score (beta: -0.397, p = 0.023), were independent predictors of the changes in the IIEF score at 1 year after surgery, changes in hormonal and metabolic factors were not. Variables in the model accounted for 66 % of the postsurgical variation in the IIEF score. Similar results were found when the different IIEF-sexual domains were evaluated, except for intercourse satisfaction for which no independent predictor was identified. Weight loss's beneficial effects on SF occurring after BS are beyond the parallel improvement in gonadal and metabolic profiles.",2013-09,01/07/2022 10:40,01/07/2022 10:40,,3197-3204,,9,27,,,,,,,,,,,,,,WOS:000323621500018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2Z4Y3A7K,journalArticle,2009,"Nesrallah, GE; Suri, RS; Moist, LM; Cuerden, M; Groeneweg, KE; Hakim, R; Ofsthun, NJ; McDonald, SP; Hawley, C; Caskey, FJ; Couchoud, C; Awaraji, C; Lindsay, RM",International quotidian dialysis registry: Annual report 2009,HEMODIALYSIS INTERNATIONAL,,1492-7535,10.1111/j.1542-4758.2009.00391.x,,"The International Quotidian Dialysis Registry (IQDR) is a global initiative designed to study practices and outcomes associated with the use of hemodialysis regimens of increased frequency and/or duration. Several small studies suggest that compared with conventional hemodialysis (HD), short-daily, nocturnal, and long conventional HD regimens may improve surrogate endpoints and quality of life. However, methodologically robust comparisons on hard outcomes are sorely lacking. The IQDR represents the first-ever attempt to aggregate long-term follow-up data from centers utilizing alternative HD regimens worldwide, and will have adequate statistical power to examine the effects of these regimens on multiple clinical endpoints, including mortality. To date, the IQDR has enrolled patients from Canada, the United States, Australia, and New Zealand, with plans in place to begin linking with additional commercial databases and national registries. This fifth annual report of the IQDR describes (1) a proposed governance structure that will facilitate international collaboration, stakeholder input and funding; (2) data sources and participating registries; (3) recruitment to date and patient baseline characteristics; and (4) an agenda for future research.",2009-07,01/07/2022 10:40,01/07/2022 10:40,,240-249,,3,13,,,,,,,,,,,,,,WOS:000269057200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94IGBS6D,journalArticle,2014,"Pleasants, RA; Ohar, JA; Croft, JB; Liu, Y; Kraft, M; Mannino, DM; Donohue, JF; Herrick, HL",Chronic Obstructive Pulmonary Disease and Asthma - Patient Characteristics and Health Impairment,COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,1541-2555,10.3109/15412555.2013.840571,,"Background: Persons with chronic obstructive pulmonary disease (COPD) and/or asthma have great risk for morbidity. There has been sparse state-specific surveillance data to estimate the impact of COPD or COPD with concomitant asthma (overlap syndrome) on health-related impairment. Methods: The North Carolina (NC) Behavioral Risk Factor Surveillance System (BRFSS) was used to assess relationships between COPD and asthma with health impairment indicators. Five categories [COPD, current asthma, former asthma, overlap syndrome, and neither] were defined for 24,073 respondents. Associations of these categories with health impairments (physical or mental disability, use of special equipment, mental or physical distress) and with co-morbidities (diabetes, coronary heart disease, stroke, arthritis, and high blood pressure) were assessed. Results: Fifteen percent of NC adults reported a COPD and/or asthma history. The overall age-adjusted prevalence of any self-reported COPD and current asthma were 5.6% and 7.6%, respectively; 2.4% reported both. In multivariable analyses, adults with overlap syndrome, current asthma only, and COPD only were twice as likely as those with neither disease to report health impairments (p < 0.05). Compared to those with neither disease, adults with overlap syndrome and COPD were more likely to have co-morbidities (p < 0.05). The prevalence of the five co-morbid conditions was highest in overlap syndrome; comparisons with the other groups were significant (p < 0.05) only for diabetes, stroke, and arthritis. Conclusions: The BRFSS demonstrates different levels of health impairment among persons with COPD, asthma, overlap syndrome, and those with neither disease. Persons reporting overlap syndrome had the most impairment and highest prevalence of co-morbidities.",2014-06,01/07/2022 10:40,01/07/2022 10:40,,256-266,,3,11,,,,,,,,,,,,,,WOS:000336507800003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8NNEHTI3,book,2010,"Panossian, LA; Avidan, AY",Narcolepsy and Other Comorbid Medical Illnesses,,978-1-4419-0853-7,,,,,2010,01/07/2022 10:40,01/07/2022 10:40,,,105,,,,,,NARCOLEPSY: A CLINICAL GUIDE,,,,,,,,,,WOS:000272515300012,,,Pages: 113 DOI: 10.1007/978-1-4419-0854-4_10,,,,,,"Goswami, M; PandiPerumal, SR; Thorpy, MJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
J64SWL6F,journalArticle,2016,"Sundh, J; Montgomery, S; Hasselgren, M; Kampe, M; Janson, C; Stallberg, B; Lisspers, K",Change in health status in COPD: a seven-year follow-up cohort study,NPJ PRIMARY CARE RESPIRATORY MEDICINE,,2055-1010,10.1038/npjpcrm.2016.73,,"Health status is a prognostic factor included in the assessment of chronic obstructive pulmonary disease (COPD). The aim of our study was to examine the associations of clinical factors with change in health status over a 7-year follow-up period. In 2005, 970 randomly selected primary and secondary care patients with a COPD diagnosis completed questionnaires including the Clinical COPD Questionnaire (CCQ); and in 2012, 413 completed the CCQ questionnaire again. Linear regression used difference in mean total CCQ score between 2005 and 2012 as the dependent variable. Independent variables were CCQ score at baseline 2005, sex, age, educational level, body mass index (BMI), smoking status, heart disease, diabetes, depression, number of exacerbations in the previous 6 months, dyspnoea (modified Medical Research Council (mMRC)). Health status worsened from mean total CCQ (s.d.) 2.03 (1.26) in 2005 to 2.16 (1.37) in 2012 (P = 0.011). In linear regression with adjustment for baseline CCQ; older age, lower education, higher mMRC and BMI below 25 kg/m(2) at baseline were associated with worsened health status in 2012. When sex, age and all statistically significant measures were included simultaneously in the analysis of the main study group, higher mMRC and BMI below 25 kg/m(2) were were associated with deteriorated health status (P<0.0001). A higher level of dyspnoea and lower weight were associated with worse health status in COPD. Strategies for decreasing dyspnoea and awareness of the possible increased risk of worsening disease in under- and normal-weight COPD patients are clinically important.",20/10/2016,01/07/2022 10:40,01/07/2022 10:40,,,,,26,,,,,,,,,,,,,,WOS:000386853900004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YI7PQL28,journalArticle,2018,"Mundi, MS; Patel, J; McClave, SA; Hurt, RT",Current perspective for tube feeding in the elderly: from identifying malnutrition to providing of enteral nutrition,CLINICAL INTERVENTIONS IN AGING,,1178-1998,10.2147/CIA.S134919,,"With the number of individuals older than 65 years expected to rise significantly over the next few decades, dramatic changes to our society and health care system will need to take place to meet their needs. Age-related changes in muscle mass and body composition along with medical comorbidities including stroke, dementia, and depression place elderly adults at high risk for developing malnutrition and frailty. This loss of function and decline in muscle mass (ie, sarcopenia) can be associated with reduced mobility and ability to perform the task of daily living, placing the elderly at an increased risk for falls, fractures, and subsequent institutionalization, leading to a decline in the quality of life and increased mortality. There are a number of modifiable factors that can mitigate some of the muscle loss elderly experience especially when hospitalized. Due to this, it is paramount for providers to understand the pathophysiology behind malnutrition and sarcopenia, be able to assess risk factors for malnutrition, and provide appropriate nutrition support. The present review describes the pathophysiology of malnutrition, identifies contributing factors to this condition, discusses tools to assess nutritional status, and proposes key strategies for optimizing enteral nutrition therapy for the elderly.",2018,01/07/2022 10:40,01/07/2022 10:40,,1353-1364,,,13,,,,,,,,,,,,,,WOS:000440495400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UJK7NSUE,journalArticle,2008,"Gur, A; Oktayoglu, P",Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment,CURRENT PHARMACEUTICAL DESIGN,,1381-6128,10.2174/138161208799316348,,"Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are poorly understood disorders that share similar demographic and clinical characteristics. The etiology and pathophysiology of these diseases remain unclear. Because of the similarities between both disorders it was suggested that they share a common pathophysiological mechanisms, namely, central nervous system (CNS) dysfunction. Current hypotheses center on atypical sensory processing in the CNS and dysfunction of skeletal muscle nociception and the hypothalamic-pituitary-adrenal (HPA) axis. Researches suggest that the (CNS) is primarily involved in both disorders in regard to the pain, fatigue and sleep disturbances. Many patients experience difficulty with concentration and memory and many others have mood disturbance, including depression and anxiety. Although fibromyalgia is common and associated with substantial morbidity and disability, there are no US Food and Drug Administration (FDA)-approved treatments except pregabalin. Recent pharmacological treatment studies about fibromyalgia have focused on selective serotonin and norepinephrine (NE) reuptake inhibitors, which enhance serotonin and NE neurotransmission in the descending pain pathways and lack many of the adverse side effects associated with tricyclic medications. CFS is a descriptive term used to define a recognisable pattern of symptoms that cannot be attributed to any alternative condition. The symptoms are currently believed to be the result of disturbed brain function. To date, no pharmacological agent has been reliably shown to be effective treatment for CFS. Management strategies are therefore primarily directed at relief of symptoms and minimising impediments to recovery. This chapter presents data demonstrating CFS, abnormal pain processing and autonomic nervous system (ANS) dysfunction in FM and CFS and concludes by reviewing the new concepts in treatments in CFS and FM.",2008-05,01/07/2022 10:40,01/07/2022 10:40,,1274-1294,,13,14,,,,,,,,,,,,,,WOS:000256618200005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
282X3B8P,journalArticle,2013,"Ryan, DH; Bray, GA",Pharmacologic Treatment Options for Obesity: What Is Old Is New Again,CURRENT HYPERTENSION REPORTS,,1522-6417,10.1007/s11906-013-0343-6,,"After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia (TM) and lorcaserin - BelviqA (R)) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI a parts per thousand yenaEuro parts per thousand 30 kg/m(2)) or in overweight persons (BMI a parts per thousand yenaEuro parts per thousand 27 kg/m(2)) with comorbidities. Another medication, bupropion/naltrexone, is undertaking a cardiovascular outcomes trial and an analysis in 2014 will determine its approval and release. The most widely prescribed drug for obesity, phentermine, used since 1959 for short-term weight management, has been released in a new formulation. This paper reviews these new medications, and other important events in the landscape for management of obesity, with an eye to the interests of physicians who manage hypertension. All the new drugs under discussion are re-fittings of old agents or fresh approaches to old targets; thus, what is old is new again in the pharmacotherapy of obesity.",2013-06,01/07/2022 10:40,01/07/2022 10:40,,182-189,,3,15,,,,,,,,,,,,,,WOS:000318814700009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6WUEREQV,journalArticle,2012,"Kang, EW; Pike, F; Ramer, S; Abdel-Kader, K; Myaskovsky, L; Dew, MA; Unruh, M",The Association of Mental Health over Time with Cardiac Outcomes in HEMO Study Patients,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.06730711,,"Background and objectives Poor mental health over time is significantly associated with cardiovascular morbidity and mortality in the general population, which is the leading cause of death in dialysis patients. Most studies of dialysis patients, however, have investigated the relationship between baseline mental health measurements and all-cause mortality and not mental health measured longitudinally throughout a study and cause-specific mortality. Design, setting, participants, & measurements This study examined the association of changes in mental health over time with all-cause and cause-specific deaths and cardiac hospitalizations in the Hemodialysis study patients. Mental health was assessed at baseline and annually during the study with short form 36 mental health index scores. Poorer mental health was defined by a mental health index score <= 60. Results Patients with poorer mental health at baseline were more likely to have less than a high school education and be unmarried, have significantly higher index of coexistent disease scores, and report taking beta-blockers and sleep medications. Low mental health scores over time were independently associated with a decrease in survival time from all-cause mortality by -0.06 (-0.10, -0.03; P<0.001), and they also significantly hastened time to first cardiac hospitalization by -0.08 (-0.13, -0.02; P=0.01) and composite of first cardiac hospitalization or cardiac death by -0.04 (-0.07, -0.02; P<0.001). Conclusions This study found an independent association between poor mental health over time and all-cause mortality, cardiac hospitalization, and the composite of cardiac death or cardiac hospitalization in hemodialysis patients. The results underscore the importance of attention to mental health related to cardiac complications and even death in dialysis patients. Clin J Am Soc Nephrol 7: 957-964, 2012. doi: 10.2215/CJN.06730711",2012-06,01/07/2022 10:40,01/07/2022 10:40,,957-964,,6,7,,,,,,,,,,,,,,WOS:000304975100013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
895ECAMF,journalArticle,2017,"Abdelaal, M; le Roux, CW; Docherty, NG",Morbidity and mortality associated with obesity,ANNALS OF TRANSLATIONAL MEDICINE,,2305-5839,10.21037/atm.2017.03.107,,"Obesity and its repercussions constitute an important source of morbidity, impaired quality of life and its complications can have a major bearing on life expectancy. The present article summarizes the most important co-morbidities of obesity and their prevalence. Furthermore, it describes classification and grading systems that can be used to assess the individual and combined impact of co-morbid conditions on mortality risk. The literature was screened for assessment tools that can be deployed in the quantification of morbidity and mortality risk in individual patients. Thirteen specific domains have been identified that account for morbidity and mortality in obesity. Cardiovascular disease (CVD) and cancer account for the greatest mortality risk associated with obesity. The King's Criteria and Edmonton Obesity Staging System (EOSS) were identified as useful tools for the detection and monitoring of individual patient mortality risk in obesity care. The stark facts on the complications of obesity should be capitalized on to improve patient management and knowledge and referred to in the wider dissemination of public health messages aimed at improving primary prevention.",2017-04,01/07/2022 10:40,01/07/2022 10:40,,,,7,5,,,,,,,,,,,,,,WOS:000401445600008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UFD8GTEK,journalArticle,2013,"Malarkey, WB; Jarjoura, D; Klatt, M",Workplace based mindfulness practice and inflammation: A randomized trial,BRAIN BEHAVIOR AND IMMUNITY,,0889-1591,10.1016/j.bbi.2012.10.009,,"We have developed a low dose Mindfulness-Based Intervention (MBI-Id) that reduces the time committed to meetings and formal mindfulness practice, while conducting the sessions during the workday. This reduced the barriers commonly mentioned for non-participation in mindfulness programs. In a controlled randomized trial we studied university faculty and staff (n = 186) who were found to have an elevated CRP level,>3.0 mg/ml, and who either had, or were at risk for cardiovascular disease. This study was designed to evaluate if MBI-Id could produce a greater decrease in CRP. IL-6 and cortisol than an active control group receiving a lifestyle education program when measured at the end of the 2 month interventions. We found that MBI-Id significantly enhanced mindfulness by 2-months and it was maintained for up to a year when compared to the education control. No significant changes were noted between interventions in cortisol, IL-6 levels or self-reported measures of perceived stress, depression and sleep quality at 2-months. Although not statistically significant (p=.08), the CRP level at 2-months was one mg/ml lower in the MBI-Id group than in the education control group, a change which may have clinical significance (Ridker et al., 2000; Wassel et al., 2010). A larger MBI-Id effect on CRP (as compared to control) occurred among participants who had a baseline BMI <30 (-2.67 mg/ml) than for those with BMI >30 (-0.18 mg/ml). We conclude that MBI-Id should be more fully investigated as a low-cost self-directed complementary strategy for decreasing inflammation, and it seems most promising for non-obese subjects. (C) 2012 Elsevier Inc. All rights reserved.",2013-01,01/07/2022 10:40,01/07/2022 10:40,,145-154,,,27,,,,,,,,,,,,,,WOS:000312629100018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2K2Y9Z89,journalArticle,2015,"Bass, R; Eneli, I",Severe childhood obesity: an under-recognised and growing health problem,POSTGRADUATE MEDICAL JOURNAL,,0032-5473,10.1136/postgradmedj-2014-133033,,"Childhood obesity is a serious and urgent public health problem. In the last 10 years, there has been a concerted effort in the USA and globally to develop and implement educational, medical and public health interventions designed to attenuate its growth. The success of these efforts was probably responsible for the plateau in the prevalence rate of childhood obesity noted in the last two years. While the attenuation of the overall prevalence of childhood obesity is promising, data from the same cohort reveal a concerning upward trend in the number of children with severe obesity. The consequences of severe childhood obesity can be devastating. When compared to their moderately obese peers, children with severe obesity are at greater risk for adult obesity, early atherosclerosis, hypertension, type 2 diabetes, metabolic syndrome, fatty liver disease and premature death. The determinants for severe obesity include the same lifestyle, environmental, familial and societal risk factors reported for overweight or obesity. While all these risk factors must be screened for, genetic influences are distinct considerations that may have greater bearing especially with early-onset obesity. Treatments for severe childhood obesity include lifestyle intervention, specialised low-calorie diets and bariatric surgery. Outcomes of these treatments vary, with bariatric surgery clearly the most successful of the three for both short-term and long-term weight loss. Severe obesity in children and adolescents remains a challenging health condition. The enormous medical, emotional and financial burden these children and their families endure signals an urgent need to further investigate and standardise treatment modalities and improve outcomes.",2015-11,01/07/2022 10:40,01/07/2022 10:40,,639-645,,1081,91,,,,,,,,,,,,,,WOS:000363846100006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UGTLFZRC,journalArticle,2015,"Welliver, C; Sulaver, R; Whittington, A; Helfand, BT; Cakir, OO; Griffith, JW; McVary, KT",Analyzing Why Men Seek Treatment for Lower Urinary Tract Symptoms and Factors Associated With Nonimprovement,UROLOGY,,0090-4295,10.1016/j.urology.2015.08.006,,"OBJECTIVE To determine the motivating factor for why men seek urologic care and determine persistence of these symptoms and any factors that influence resolution. METHODS Men presenting to an outpatient urology clinic with lower urinary tract symptoms (LUTSs) were prospectively evaluated. At each of 2 visits, surveys were administered including the American Urological Association Symptom Index and a chief LUTS complaint (CLC) identification form. On the CLC identification form, symptoms were considered ""transient"" if only seen at V1 and ""persistent"" if they were selected at both visits. RESULTS Sixty-five percent of the 1240 participants were able to specify a CLC. Among these, nocturia was by far the most common and was found to be persistent in 49% of cases. When comparing the groups of patients who presented with transient verses persistent nocturia, older age (P < .001), diabetes (P = .006), hypertension (P = .033), alpha-blocker use (P = .018), 5-alpha-reductase inhibitor use (P = .008), higher nocturia severity (P < .001), and more severe American Urological Association Symptom Index scores at initial visit (P = .047) were found to be predictors of persistent nocturia. CONCLUSION Most men with LUTS can identify a predominant CLC. Of these, nocturia is the primary CLC of most men and does not improve in almost 50% of those studied. By improving our identification of a predominant CLC and the patient factors that influence both the development and persistence of urinary symptoms, we may start to better evaluate and hopefully focus treatment on the most bothersome urinary symptom. Published by Elsevier Inc.",2015-11,01/07/2022 10:40,01/07/2022 10:40,,862-867,,5,86,,,,,,,,,,,,,,WOS:000366466400006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TU67B3BR,journalArticle,2016,"Zhuang, J; Zhan, YQ; Zhang, F; Tang, Z; Wang, JS; Sun, YH; Ding, RJ; Hu, DY; Yu, JM",Self-reported insomnia and coronary heart disease in the elderly,CLINICAL AND EXPERIMENTAL HYPERTENSION,,1064-1963,10.3109/10641963.2015.1060983,,"Objective: We aimed to investigate the association between self-reported insomnia and coronary heart diseases in the elderly Chinese population. Methods and results: A cross-sectional study was conducted in the Beijing and 2982 participants aged 60 years were recruited. The association between self-reported insomnia and coronary heart diseases (CHD) was determined by multiple logistic regression models. Age, gender, education, obesity, physical activity, current smoking, current drinking, medication, hypertension, diabetes, tea consumption, heart rate, and dyslipidemia were adjusted as confounders. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were reported as effect measurements. The numbers of subjects with no insomnia, occasional insomnia, and frequent insomnia were 2110 (70.76%), 509(17.07%), and 363 (12.17%), respectively. The prevalence of CHD in those with no insomnia, occasional insomnia, and frequent insomnia were 13.65%, 16.31%, and 22.31%. Compared with subjects with no insomnia, the multivariate adjusted ORs and 95% CIs for those with occasional insomnia and frequent insomnia were 1.17 (0.89-1.54) and 1.73 (1.30-2.31), respectively. There was no significant difference of the association between men and women. Conclusions: Self-reported insomnia is associated with high risks of CHD in the elderly Chinese population.",02/01/2016,01/07/2022 10:40,01/07/2022 10:40,,51-55,,1,38,,,,,,,,,,,,,,WOS:000367921300007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
X8VXIYYE,journalArticle,2010,"Nakagawa, H; Niu, K; Hozawa, A; Ikeda, Y; Kaiho, Y; Ohmori-Matsuda, K; Nakaya, N; Kuriyama, S; Ebihara, S; Nagatomi, R; Tsuji, I; Arai, Y",Impact of Nocturia on Bone Fracture and Mortality in Older Individuals: A Japanese Longitudinal Cohort Study,JOURNAL OF UROLOGY,,0022-5347,10.1016/j.juro.2010.05.093,,"Purpose: We evaluated the association of nocturia with fracture and death in a large, community based sample of Japanese individuals 70 years old or older. Materials and Methods: The baseline in this population based study was determined in 2003 by an extensive health interview with each participant. In this study we followed 784 individuals with a mean +/- SD age of 76.0 +/- 4.6 years (range 70 to 97). Information on mortality and fracture during the study period was provided by the National Health Insurance system and details on fractures were collected from medical records. We compared the risk of bone fracture and death with or without nocturia in a multivariate Cox proportional hazard model. Results: Nocturia (2 or greater voids per night) was present in 359 of the 784 participants (45.7%). Fracture was observed in 41 cases, including 32 fall related cases. For all fractures and fall related fractures with nocturia the HR was 2.01 (95% CI 1.04-3.87) and 2.20 (95% CI 1.04-4.68, each p = 0.04). Death occurred in 53 cases. The mortality rate in individuals with nocturia was significantly higher than in those without nocturia. For mortality in patients with nocturia the age-gender adjusted HR was 1.91 (95% CI 1.07-3.43, p = 0.03). Even when further adjusted for diabetes, smoking status, history of coronary disease, renal disease and stroke, tranquilizers, hypnotics and diuretics, the positive relationship was unchanged (HR 1.98, 95% CI 1.09-3.59, p = 0.03). Conclusions: During a 5-year observation period elderly individuals with nocturia were at greater risk for fracture and death than those without nocturia.",2010-10,01/07/2022 10:40,01/07/2022 10:40,,1413-1418,,4,184,,,,,,,,,,,,,,WOS:000282615400059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48KYALF8,journalArticle,2019,"Lisspers, K; Larsson, K; Janson, C; Stallberg, B; Tsiligianni, I; Gutzwiller, FS; Mezzi, K; Bjerregaard, BK; Jorgensen, L; Johansson, G","Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study",NPJ PRIMARY CARE RESPIRATORY MEDICINE,,2055-1010,10.1038/s41533-019-0157-3,,"The present study aimed to generate real-world evidence regarding gender differences among chronic obstructive pulmonary disease (COPD) patients, especially as regards the diagnosis and outcomes in order to identify areas for improvement and management and optimize the associated healthcare resource allocation. ARCTIC is a large, real-world, retrospective cohort study conducted in Swedish COPD patients and a matched reference population from 52 primary care centers in 2000-2014. The incidence of COPD, prevalence of asthma and other comorbidities, risk of exacerbations, mortality rate, COPD drug prescriptions, and healthcare resource utilization were analyzed. In total, 17,479 patients with COPD were included in the study. During the study period, COPD was more frequent among women (53.8%) and women with COPD experienced more exacerbations vs. men (6.66 vs. 4.66). However, the overall mortality rate was higher in men compared with women (45% vs. 38%), but no difference for mortality due to COPD was seen between genders over the study period. Women seemed to have a greater susceptibility to asthma, fractures, osteoporosis, rheumatoid arthritis, rhinitis, depression, and anxiety, but appeared less likely to have diabetes, kidney diseases, and cardiovascular diseases. Furthermore, women had a greater risk of COPD-related hospitalization and were likely to receive a significantly higher number of COPD drug prescriptions compared with men. These results support the need to reduce disease burden among women with COPD and highlight the role of healthcare professionals in primary care who should consider all these parameters in order to properly diagnose and treat women with COPD.",10/12/2019,01/07/2022 10:40,01/07/2022 10:40,,,,,29,,,,,,,,,,,,,,WOS:000502995600001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7SLDTMCE,journalArticle,2013,"Chung, SD; Chen, YK; Liu, SP; Lin, HC",Association between ED in ankylosing spondylitis: a population-based study,INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH,,0955-9930,10.1038/ijir.2013.14,,"Even though a growing number of studies have found that patients with ankylosing spondylitis (AS) suffer from sexual problems, only very few studies have specifically addressed the relationship between AS and ED. Using a population-based data set, this case-control study aimed to examine the association of ED with a prior diagnosis of AS in Taiwan. We selected 2213 ED patients >= 40 years old and 17,704 matched controls. We considered the date of the first diagnosis of ED as the index date for cases. Multivariate logistic regression was performed to calculate the odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between previously diagnosed AS and ED. A total of 224 out of the 19,917 sampled subjects (1.1%) had been diagnosed with AS before the index date. Prior AS was found in 42 (1.9%) cases and 182 (1.0%) controls. After adjusting for geographic location, urbanization level, hypertension, diabetes, coronary heart disease, hyperlipidemia, obesity, depressive disorder and alcohol abuse/alcohol-dependence syndrome, multivariate logistic regression revealed that cases were more likely to have been previously diagnosed with AS than controls (OR = 1.58, 95% CI = 1.09-2.19, P = 0.019). There was an association between ED and AS. We suggest that physicians should be attentive to sexual complaints from AS patients in order to refer them to other specialists for multidisciplinary management.",2013-11,01/07/2022 10:40,01/07/2022 10:40,,229-233,,6,25,,,,,,,,,,,,,,WOS:000327002400007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
56RFKPXW,conferencePaper,2013,"Kozlovszky, M; Bartalis, L; Jokai, B; Ferenczi, J; Bogdanov, P; Meixner, Z; Nemeth, L; Karoczkai, K",Personal health monitoring with Android based mobile devices,,978-953-233-076-2,,,,"We have developed an Android based mobile data acquisition (DAQ) solution, which collects personalized health information of the end-user, store analyze and visualize it on the smart device and optionally sends it towards to the datacenter for further processing. The smart mobile device is capable to collect information from a large set of various wireless (Bluetooth, and WiFi) and wired (USB) sensors. Embedded sensors of the mobile device provide additional useful status information (such as: user location, magnetic or noise level, acceleration, temperature, etc.). The user interface of our software solution is suitable for different skilled users, highly configurable and provides diary functionality to store information (about sleep problems, can act as a diet log, or even can be used as a pain diary). The software enables correlation analysis between the various sensor data sets. The developed system is tested successfully within our Living Lab facility. Sensor data acquisition on the personal mobile device enables both end-users and care givers to provide better and more effective health monitoring and facilitate prevention. The paper describes the internal architecture of the software solution and its main functionalities.",2013,01/07/2022 10:40,01/07/2022 10:40,,326-330,,,,,,,,,,,,,,,,,WOS:000333165800063,,,,,,,,,"Biljanovic, P; Butkovic, Z; Skala, K; Golubic, S; CicinSain, M; Sruk, V; Ribaric, S; Hutinski, Z; Baranovic, M; Tijan, E; Mauher, M; Bombek, I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2013 36TH INTERNATIONAL CONVENTION ON INFORMATION AND COMMUNICATION TECHNOLOGY, ELECTRONICS AND MICROELECTRONICS (MIPRO)",,,,,,,,,,,,,,,
HAUXHFCH,journalArticle,2007,"Norman, RJ; Dewailly, D; Legro, RS; Hickey, TE",Polycystic ovary syndrome,LANCET,,0140-6736,10.1016/S0140-6736(07)61345-2,,"Polycystic ovary syndrome is a heterogeneous endocrine disorder that affects about one in 15 women worldwide. The major endocrine disruption is excessive androgen secretion or activity; and a large proportion of women also have abnormal insulin activity. Many body systems are affected in polycystic ovary syndrome, resulting in several health complications, including menstrual dysfunction, infertility; hirsutism, acne, obesity and metabolic syndrome. Women with this disorder have an established increased risk of developing type 2 diabetes and a still debated increased risk of cardiovascular disease. The diagnostic traits of polycystic ovary syndrome are hyperandrogenism, chronic anovulation, and polycystic ovaries, after exclusion of other conditions that cause these same features. A conclusive definition of the disorder and the importance of the three diagnostic criteria relative to each other remain controversial. The cause of polycystic ovary syndrome is unknown, but studies suggest a strong genetic component that is affected by gestational environment, lifestyle factors, or both.",25/08/2007,01/07/2022 10:40,01/07/2022 10:40,,685-697,,9588,370,,,,,,,,,,,,,,WOS:000249131400033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PVVFVFVW,journalArticle,2021,"Hunter, ML; Knuiman, MW; Musk, B; Hui, JN; Murray, K; Beilby, JP; Hillman, DR; Hung, J; Newton, RU; Bucks, RS; Straker, L; Walsh, JP; Zhu, K; Bruce, DG; Eikelboom, RH; Davis, TME; Mackey, DA; James, AL",Prevalence and patterns of multimorbidity in Australian baby boomers: the Busselton healthy ageing study,BMC PUBLIC HEALTH,,1471-2458,10.1186/s12889-021-11578-y,,"Background and objective Chronic medical conditions accumulate within individuals with age. However, knowledge concerning the trends, patterns and determinants of multimorbidity remains limited. This study assessed the prevalence and patterns of multimorbidity using extensive individual phenotyping in a general population of Australian middle-aged adults. Methods Participants (n = 5029, 55% female), born between 1946 and 1964 and attending the cross-sectional phase of the Busselton Healthy Ageing Study (BHAS) between 2010 and 2015, were studied. Prevalence of 21 chronic conditions was estimated using clinical measurement, validated instrument scores and/or self-reported doctor-diagnosis. Non-random patterns of multimorbidity were explored using observed/expected (O/E) prevalence ratios and latent class analysis (LCA). Variables associated with numbers of conditions and class of multimorbidity were investigated. Results The individual prevalence of 21 chronic conditions ranged from 2 to 54% and multimorbidity was common with 73% of the cohort having 2 or more chronic conditions. (mean +/- SD 2.75 +/- 1.84, median = 2.00, range 0-13). The prevalence of multimorbidity increased with age, obesity, physical inactivity, tobacco smoking and family history of asthma, diabetes, myocardial infarct or cancer. There were 13 pairs and 27 triplets of conditions identified with a prevalence > 1.5% and O/E > 1.5. Of the triplets, arthritis (> 50%), bowel disease (> 33%) and depression-anxiety (> 33%) were observed most commonly. LCA modelling identified 4 statistically and clinically distinct classes of multimorbidity labelled as: 1) ""Healthy"" (70%) with average of 1.95 conditions; 2) ""Respiratory and Atopy"" (11%, 3.65 conditions); 3) ""Non-cardiometabolic"" (14%, 4.77 conditions), and 4) ""Cardiometabolic"" (5%, 6.32 conditions). Predictors of multimorbidity class membership differed between classes and differed from predictors of number of co-occurring conditions. Conclusion Multimorbidity is common among middle-aged adults from a general population. Some conditions associated with ageing such as arthritis, bowel disease and depression-anxiety co-occur in clinically distinct patterns and at higher prevalence than expected by chance. These findings may inform further studies into shared biological and environmental causes of co-occurring conditions of ageing. Recognition of distinct patterns of multimorbidity may aid in a holistic approach to care management in individuals presenting with multiple chronic conditions, while also guiding health resource allocation in ageing populations.",11/08/2021,01/07/2022 10:40,01/07/2022 10:40,,,,1,21,,,,,,,,,,,,,,WOS:000684217000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
U64IYUA2,journalArticle,2019,"Yoshikawa, T; Obayashi, K; Miyata, K; Ueda, T; Kurumatani, N; Saeki, K; Ogata, N",Association between glaucomatous optic disc and depressive symptoms independent of light exposure profiles: a cross-sectional study of the HEIJO-KYO cohort,BRITISH JOURNAL OF OPHTHALMOLOGY,,0007-1161,10.1136/bjophthalmol-2018-312176,,"Background Glaucoma may cause physiological and behavioural circadian misalignment because of the loss of intrinsically photosensitive retinal ganglion cells, the primary receptors of environmental light. Although studies have suggested a high prevalence of depression in patients with glaucoma, it is unclear whether the association is independent of the light exposure profiles as an important confounding factor. Methods In this cross-sectional study of a community-based cohort of 770 elderly individuals (mean age, 70.9 years), glaucomatous optic discs were assessed using fundus photographs and depressive symptoms were assessed using the short version of the Geriatric Depression Scale (GDS). Daytime and night-time ambient light exposures were objectively measured for 2 days. Results Depressive symptoms (GDS score >= 6) were observed in 114 participants (prevalence, 14.8%) and glaucomatous optic discs were detected in 40 participants (prevalence, 5.2%). The prevalence of depressive symptoms was significantly higher in the group with glaucomatous optic disc than in the group without it (30.0% vs 14.0%, respectively; p=0.005). Multivariable logistic regression analysis adjusted for potential confounding factors, including daytime and night-time light exposures, revealed that the OR for depressive symptoms was significantly higher in the group with glaucomatous optic disc than in the group without it (OR 2.45, 95% CI 1.18 to 5.08; p=0.016). Conclusions In this general elderly population, glaucomatous optic disc was significantly associated with higher prevalence of depressive symptoms independent of a number of potential confounding factors, including daily light exposure profiles.",2019-08,01/07/2022 10:40,01/07/2022 10:40,,1119-1122,,8,103,,,,,,,,,,,,,,WOS:000478915300018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8PQFH9IP,journalArticle,2018,"Cozier, YC; Govender, P; Berman, JS",Obesity and sarcoidosis: consequence or contributor?,CURRENT OPINION IN PULMONARY MEDICINE,,1070-5287,10.1097/MCP.0000000000000503,,"Purpose of review Sarcoidosis is a multisystem disease of unknown cause. Obesity can affect many physiological factors. The relationship between obesity and sarcoidosis is unclear, and can been described as posing a 'chicken and egg' scenario for the patient as it is not always clear whether it is a consequence of, or a risk factor for any disease. The purpose of this review is to examine the dual roles of obesity on sarcoidosis morbidity and the incidence. Recent findings Obesity magnifies the symptoms of sarcoidosis and corticosteroid therapy increases BMI. Prospective epidemiologic studies started to explore the role of obesity as a potential risk factor for sarcoidosis. Three studies in the United States, and one study in Denmark, have demonstrated significantly increased risks of sarcoidosis among obese compared with nonobese patients; risk estimates ranged from 1.42 [95% confidence interval (CI), 1.07-1.89] to 3.59 (95% CI, 2.31-5.57). Summary Obesity can be both a consequence of sarcoidosis treatment, and a contributor to disease risk likely through the pro-inflammatory environment of obesity. Prospective epidemiologic cohort studies are needed to explore the cause of sarcoidosis and insight into possible avenues of treatment development and prevention.",2018-09,01/07/2022 10:40,01/07/2022 10:40,,487-494,,5,24,,,,,,,,,,,,,,WOS:000442248700012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32ISGLEW,journalArticle,2014,"Obayashi, K; Saeki, K; Kurumatani, N",Association between Melatonin Secretion and Nocturia in Elderly Individuals: a Cross-Sectional Study of the HEIJO-KYO Cohort,JOURNAL OF UROLOGY,,0022-5347,10.1016/j.juro.2013.12.043,,"Purpose: Nocturnal voids are regulated by circadian biological rhythms, including decreased urine production and increased bladder storage capacity at night. A previous experimental study suggested that exogenous melatonin decreases urine production and increases bladder capacity in rats. However, little is known about whether melatonin secretion, which is considerably lower than exogenous melatonin, is associated with nocturia in humans. We evaluated the association between melatonin secretion and nocturia. Materials and Methods: In this cross-sectional study we examined 861 community based elderly individuals with a mean age of 72.1 years. We measured nocturnal void frequency and overnight urinary 6-sulfatoxymelatonin excretion as an index of melatonin secretion. Nocturia was defined as 2 or more nocturnal voids. Results: Univariate comparisons between the 261 and 600 study participants with and without nocturia, respectively, showed marginal to significant associations of nocturia with age, gender, body mass index, estimated glomerular filtration rate, calcium channel blockers, benign prostatic hyperplasia, total voided urine volume, urinary 6-sulfatoxymelatonin, duration in bed, day length, and daytime and nighttime physical activity. The multivariate logistic regression model adjusted for the former confounding factors revealed that higher urinary 6-sulfatoxymelatonin was significantly associated with a lower nocturia OR (adjusted OR 0.73, 95% CI 0.56-0.96, p = 0.023). After adjustment for age, gender and duration in bed the mean volume of a single voided urine significantly increased with tertiles of increasing urinary 6-sulfatoxymelatonin (p for trend = 0.022). Conclusions: Melatonin secretion is significantly and inversely associated with nocturia in a general elderly population.",2014-06,01/07/2022 10:40,01/07/2022 10:40,,1816-1821,,6,191,,,,,,,,,,,,,,WOS:000336531100063,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F6QFGHSQ,journalArticle,2017,"Kimmel, PL; Fwu, CW; Abbott, KC; Eggers, AW; Kline, PP; Eggers, PW","Opioid Prescription, Morbidity, and Mortality in United States Dialysis Patients",JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1046-6673,10.1681/ASN.2017010098,,"Aggressive pain treatment was advocated for ESRD patients, but new Centers for Disease Control and Prevention guidelines recommend cautious opioid prescription. Little is known regarding outcomes associated with ESRD opioid prescription. We assessed opioid prescriptions and associations between opioid prescription and dose and patient outcomes using 2006-2010 US Renal Data System information in patients on maintenance dialysis with Medicare Part A, B, and D coverage in each study year (n=671,281, of whom 271,285 were unique patients). Opioid prescription was confirmed from Part D prescription claims. In the 2010 prevalent cohort (n=153,758), we examined associations of opioid prescription with subsequent all-cause death, dialysis discontinuation, and hospitalization controlled for demographics, comorbidity, modality, and residence. Overall, >60% of dialysis patients had at least one opioid prescription every year. Approximately 20% of patients had a chronic (>= 90-day supply) opioid prescription each year, in 2010 usually for hydrocodone, oxycodone, or tramadol. In the 2010 cohort, compared with patients without an opioid prescription, patients with short-term(1-89 days) and chronic opioid prescriptions had increased mortality, dialysis discontinuation, and hospitalization. All opioid drugs associated with mortality; most associated with worsened morbidity. Higher opioid doses correlated with death in a monotonically increasing fashion. We conclude that opioid drug prescription is associated with increased risk of death, dialysis discontinuation, and hospitalization in dialysis patients. Causal relationships cannot be inferred, and opioid prescription may be an illness marker. Efforts to treat pain effectively in patients on dialysis yet decrease opioid prescriptions and dose deserve consideration.",2017-12,01/07/2022 10:40,01/07/2022 10:40,,3658-3670,,12,28,,,,,,,,,,,,,,WOS:000416731500024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
VX2KA2M7,journalArticle,2008,"Bush, ZM; Vance, ML",Management of acromegaly: Is there a role for primary medical therapy?,REVIEWS IN ENDOCRINE & METABOLIC DISORDERS,,1389-9155,10.1007/s11154-007-9061-1,,"Acromegaly is a chronic, debilitating disease caused by chronic growth hormone (GH) hypersecretion which results in chronic medical comorbidities, poor quality of life and high mortality rates. Successful treatment can improve clinical signs and symptoms and normalize mortality rates. Over 95% of acromegaly is caused by a somatotroph adenoma of the pituitary, and the first-line treatment is generally transsphenoidal surgery, which can be curative in 50-60% of patients. Nonetheless, high rates of persistent acromegaly following surgery and the limited efficacy of radiation therapy necessitate chronic medical treatment for many patients. Somatostatin analogues have become the preferred first-line medical therapy for many practitioners, as they achieve better biochemical and direct tumor control than the dopamine agonists, and long-acting preparations make once monthly administration possible. Cabergoline, a dopamine agonist, offers a lower-cost option and may be effective in patients with a pituitary tumor that co-secretes GH and prolactin. Pegvisomant is a GH receptor antagonist that produces exceptional biochemical response rates but lacks any direct effects on the tumor, which may limit its effectiveness as life-long monotherapy. Combinations of these three drug classes have not been rigorously studied, and preliminary trials do not suggest improved clinical outcomes. While medical treatment options for acromegaly have significantly improved over the last 30 years, limitations remain, and a multi-specialty team approach is necessary for the effective long-term management of patients with acromegaly.",2008-03,01/07/2022 10:40,01/07/2022 10:40,,83-94,,1,9,,,,,,,,,,,,,,WOS:000252996000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y3L4WGYG,journalArticle,2018,"Valerio, G; Maffeis, C; Saggese, G; Ambruzzi, MA; Balsamo, A; Bellone, S; Bergamini, M; Bernasconi, S; Bona, G; Calcaterra, V; Canali, T; Caroli, M; Chiarelli, F; Corciulo, N; Crino, A; Di Bonito, P; Pietrantonio, V; Di Pietro, M; Di Sessa, A; Diamanti, A; Doria, M; Fintini, D; Franceschi, R; Franzese, A; Giussani, M; Grugni, G; Iafusco, D; Iughetti, L; Lamborghini, A; Licenziati, MR; Limauro, R; Maltoni, G; Manco, M; Reggiani, LM; Marcovecchio, L; Marsciani, A; del Giudice, EM; Morandi, A; Morino, G; Moro, B; Nobili, V; Perrone, L; Picca, M; Pietrobelli, A; Privitera, F; Purromuto, S; Ragusa, L; Ricotti, R; Santamaria, F; Sartori, C; Stilli, S; Street, ME; Tanas, R; Trifiro, G; Umano, GR; Vania, A; Verduci, E; Zito, E","Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics",ITALIAN JOURNAL OF PEDIATRICS,,1720-8424,10.1186/s13052-018-0525-6,,"The Italian Consensus Position Statement on Diagnosis, Treatment and Prevention of Obesity in Children and Adolescents integrates and updates the previous guidelines to deliver an evidence based approach to the disease. The following areas were reviewed: (1) obesity definition and causes of secondary obesity; (2) physical and psychosocial comorbidities; (3) treatment and care settings; (4) prevention. The main novelties deriving from the Italian experience lie in the definition, screening of the cardiometabolic and hepatic risk factors and the endorsement of a staged approach to treatment. The evidence based efficacy of behavioral intervention versus pharmacological or surgical treatments is reported. Lastly, the prevention by promoting healthful diet, physical activity, sleep pattern, and environment is strongly recommended since the intrauterine phase.",31/07/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,44,,,,,,,,,,,,,,WOS:000440429500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
KZZJWII5,journalArticle,2020,"Shakya, PR; Melaku, YA; Page, A; Gill, TK","Association between dietary patterns and adult depression symptoms based on principal component analysis, reduced-rank regression and partial least-squares",CLINICAL NUTRITION,,0261-5614,10.1016/j.clnu.2019.12.011,,"Background & aims: There have been inconsistent findings on the association between dietary patterns and depressive symptoms (DepS). In addition, studies have used single analysis methods to identify dietary patterns. In the current study, we aimed to determine the association between dietary patterns, derived by principal component analysis (PCA), reduced-rank regressions (RRR) and partial least-squares (PLS), and DepS among adults using a cohort study in Australia. Methods: We examined a total of 1743 study participants (>= 4 years, 48.9% males) using cross-sectional and longitudinal data from the North West Adelaide Health Study (NWAHS). The Center for Epidemiological Studies-Depression (CES-D) scale was used to assess DepS and a score >= 16 was considered as having depression. Dietary data were collected using a food frequency questionnaire. Eicosapentaenoic acid (EPA)/Docosahexaenoic acid (DHA), folate, magnesium (Mg) and zinc (Zn) densities were chosen as the response variables for RRR and PLS analyses. Dietary patterns were identified by PCA, RRR and PLS. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated across quartiles (Q) using log binomial logistic regression to assess the association between dietary patterns and DepS. Sensitivity analyses, including a longitudinal association between dietary patterns and DepS among 859 participants, were performed. Multiple imputation was performed to investigate the effect of missing data on the estimates. Results: In this study, 16.9% (14.2% in men and 20.8% in women) of the participants had DepS. We retained two, four and four dietary patterns captured by PCA, RRR and PLS respectively. The 'prudent' pattern determined by PCA [ORQ4VsQ1 = 0.57; 95% CI: 0.35, 0.92] and PLS [ORQ4VsQ1 = 0.66; 95% CI: 0.43, 1.00] together with the 'typical Australian' pattern determined by RRR [ORQ4VsQ1 = 0.60; 95% CI: 0.40, 0.90] were inversely associated with DepS whereas the 'western' pattern derived by PCA [ORQ4VsQ1 = 2.04; 95% CI: 1.12, 3.68] and PLS [ORQ4VsQ1 = 1.62; 95% CI: 1.05, 2.50] was positively associated with DepS. In the longitudinal analysis, the 'prudent' pattern determined by PCA [ORQ4VsQ1 = 0.52; 95% CI: 0.25, 1.09] tended to be inversely associated with DepS whereas 'western' patterns determined by PCA [ORQ4VsQ1 = 3.47; 95% CI: 1.37, 8.78] and PLS [ORQ4VsQ1 = 2.47; 95% CI: 1.24, 4.91] were positively associated with DepS. We found that a dietary pattern characterized by high intakes of fruits, vegetables, medium fat dairy, nuts, legumes, and fish was inversely associated with DepS in this population-based study. Contrary to this, a dietary pattern characterized by high intakes of processed and red meat, fast foods (snacks and takeaway foods), soft drinks, white bread and high-fat dairy products were significantly associated with DepS. Multiple imputation and sensitivity analysis identified similar patterns of association between dietary pattern and DepS. Conclusions: The findings indicate that the 'western' pattern was consistently associated with an increased risk, and the 'prudent' pattern tended to be associated with a reduced risk of DepS. This suggests that dietary interventions may assist with the treatment of DepS. However, current evidence onthe impact of diet on DepS should be supported using further longitudinal studies with extended follow up, larger sample sizes and repeated measures. (c) 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.",2020-09,01/07/2022 10:40,01/07/2022 10:40,,2811-2823,,9,39,,,,,,,,,,,,,,WOS:000577928100021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2FYJ9QU9,journalArticle,2021,"Chen, J; Spracklen, CN; Marenne, G; Varshney, A; Corbin, LJ; Luan, JA; Willems, SM; Wu, Y; Zhang, XS; Horikoshi, M; Boutin, TS; Magi, R; Waage, J; Li-Gao, RF; Chan, KHK; Yao, J; Anasanti, MD; Chu, AY; Claringbould, A; Heikkinen, J; Hong, J; Hottenga, JJ; Huo, SF; Kaakinen, MA; Louie, T; Marz, W; Moreno-Macias, H; Ndungu, A; Nelson, SC; Nolte, IM; North, KE; Raulerson, CK; Ray, D; Rohde, R; Rybin, D; Schurmann, C; Sim, XL; Southam, L; Stewart, ID; Wang, CA; Wang, YJ; Wu, PT; Zhang, WH; Ahluwalia, TS; Appel, EVR; Bielak, LF; Brody, JA; Burtt, NP; Cabrera, CP; Cade, BE; Chai, JF; Chai, XR; Chang, LC; Chen, CH; Chen, BH; Chitrala, KN; Chiu, YF; de Haan, HG; Delgado, GE; Demirkan, A; Duan, Q; Engmann, J; Fatumo, SA; Gayan, J; Giulianini, F; Gong, JH; Gustafsson, S; Hai, Y; Hartwig, FP; He, J; Heianza, Y; Huang, T; Huerta-Chagoya, A; Hwang, MY; Jensen, RA; Kawaguchi, T; Kentistou, KA; Kim, YJ; Kleber, ME; Kooner, IK; Lai, SQ; Lange, LA; Langefeld, CD; Lauzon, M; Li, M; Ligthart, S; Liu, J; Loh, M; Long, JR; Lyssenko, V; Mangino, M; Marzi, C; Montasser, ME; Nag, A; Nakatochi, M; Noce, D; Noordam, R; Pistis, G; Preuss, M; Raffield, L; Rasmussen-Torvik, LJ; Rich, SS; Robertson, NR; Rueedi, R; Ryan, K; Sanna, S; Saxena, R; Schraut, KE; Sennblad, B; Setoh, K; Smith, AV; Sparso, T; Strawbridge, RJ; Takeuchi, F; Tan, JY; Trompet, S; van den Akker, E; van der Most, PJ; Verweij, N; Vogel, M; Wang, HM; Wang, CL; Wang, N; Warren, HR; Wen, WQ; Wilsgaard, T; Wong, A; Wood, AR; Xie, T; Zafarmand, MH; Zhao, JH; Zhao, W; Amin, N; Arzumanyan, Z; Astrup, A; Bakker, SJL; Baldassarre, D; Beekman, M; Bergman, RN; Bertoni, A; Bluher, M; Bonnycastle, LL; Bornstein, SR; Bowden, DW; Cai, QY; Campbell, A; Campbell, H; Chang, YC; de Geus, EJC; Dehghan, A; Du, SF; Eiriksdottir, G; Farmaki, AE; Franberg, M; Fuchsberger, C; Gao, YT; Gjesing, AP; Goel, A; Han, S; Hartman, CA; Herder, C; Hicks, AA; Hsieh, CH; Hsueh, WA; Ichihara, S; Igase, M; Ikram, MA; Johnson, WC; Jorgensen, ME; Joshi, PK; Kalyani, RR; Kandeel, FR; Katsuya, T; Khor, CC; Kiess, W; Kolcic, I; Kuulasmaa, T; Kuusisto, J; Lall, K; Lam, K; Lawlor, DA; Lee, NR; Lemaitre, RN; Li, HL; Lin, SY; Lindstrom, J; Linneberg, A; Liu, JJ; Lorenzo, C; Matsubara, T; Matsuda, F; Mingrone, G; Mooijaart, S; Moon, S; Nabika, T; Nadkarni, GN; Nadler, JL; Nelis, M; Neville, MJ; Norris, JM; Ohyagi, Y; Peters, A; Peyser, PA; Polasek, O; Qi, QB; Raven, D; Reilly, DF; Reiner, A; Rivideneira, F; Roll, K; Rudan, I; Sabanayagam, C; Sandow, K; Sattar, N; Schurmann, A; Shi, JX; Stringham, HM; Taylor, KD; Teslovich, TM; Thuesen, B; Timmers, PRHJ; Tremoli, E; Tsai, MY; Uitterlinden, A; van Dam, RM; van Heemst, D; Vlieg, AV; van Vliet-Ostaptchouk, JV; Vangipurapu, J; Vestergaard, H; Wang, T; van Dijk, KW; Zemunik, T; Abecasis, GR; Adair, LS; Aguilar-Salinas, CA; Alarcon-Riquelme, ME; An, P; Aviles-Santa, L; Becker, DM; Beilin, LJ; Bergmann, S; Bisgaard, H; Black, C; Boehnke, M; Boerwinkle, E; Bohm, BO; Bonnelykke, K; Boomsma, DI; Bottinger, EP; Buchanan, TA; Canouil, M; Caulfield, MJ; Chambers, JC; Chasman, DI; Chen, YDI; Cheng, CY; Collins, FS; Correa, A; Cucca, F; de Silva, HJ; Dedoussis, G; Elmstahl, S; Evans, MK; Ferrannini, E; Ferrucci, L; Florez, JC; Franks, PW; Frayling, TM; Froguel, P; Gigante, B; Goodarzi, MO; Gordon-Larsen, P; Grallert, H; Grarup, N; Grimsgaard, S; Groop, L; Gudnason, V; Guo, XQ; Hamsten, A; Hansen, T; Hayward, C; Heckbert, SR; Horta, BL; Huang, W; Ingelsson, E; James, PS; Jarvelin, MR; Jonas, JB; Jukema, JW; Kaleebu, P; Kaplan, R; Kardia, SLR; Kato, N; Keinanen-Kiukaanniemi, SM; Kim, BJ; Kivimaki, M; Koistinen, HA; Kooner, JS; Korner, A; Kovacs, P; Kuh, D; Kumari, M; Kutalik, Z; Laakso, M; Lakka, TA; Launer, LJ; Leander, K; Li, HX; Lin, X; Lind, L; Lindgren, C; Liu, SM; Loos, RJF; Magnusson, PKE; Mahajan, A; Metspalu, A; Mook-Kanamori, DO; Mori, TA; Munroe, PB; Njolstad, I; O'Connell, JR; Oldehinkel, AJ; Ong, KK; Padmanabhan, S; Palmer, CNA; Palmer, ND; Pedersen, O; Pennell, CE; Porteous, DJ; Pramstaller, PP; Province, MA; Psaty, BM; Qi, L; Raffel, LJ; Rauramaa, R; Redline, S; Ridker, PM; Rosendaal, FR; Saaristo, TE; Sandhu, M; Saramies, J; Schneiderman, N; Schwarz, P; Scott, LJ; Selvin, E; Sever, P; Shu, XO; Slagboom, PE; Small, KS; Smith, BH; Snieder, H; Sofer, T; Sorensen, TIA; Spector, TD; Stanton, A; Steves, CJ; Stumvoll, M; Sun, L; Tabara, Y; Tai, ES; Timpson, NJ; Tonjes, A; Tuomilehto, J; Tusie, T; Uusitupa, M; van der Harst, P; van Duijn, C; Vitart, V; Vollenweider, P; Vrijkotte, TGM; Wagenknecht, LE; Walker, M; Wang, YX; Wareham, NJ; Watanabe, RM; Watkins, H; Wei, WB; Wickremasinghe, AR; Willemsen, G; Wilson, JF; Wong, TY; Wu, JY; Xiang, AH; Yanek, LR; Yengo, L; Yokota, M; Zeggini, E; Zheng, W; Zonderman, AB; Rotter, JI; Gloyn, AL; McCarthy, MI; Dupuis, J; Meigs, JB; Scott, RA; Prokopenko, I; Leong, A; Liu, CT; Parker, SCJ; Mohlke, KL; Langenberg, C; Wheeler, E; Morris, AP; Barroso, I; Lifelines Cohort Study; Metaanal Glucose Insulin Related",The trans-ancestral genomic architecture of glycemic traits,NATURE GENETICS,,1061-4036,10.1038/s41588-021-00852-9,,"Glycemic traits are used to diagnose and monitor type 2 diabetes and cardiometabolic health. To date, most genetic studies of glycemic traits have focused on individuals of European ancestry. Here we aggregated genome-wide association studies comprising up to 281,416 individuals without diabetes (30% non-European ancestry) for whom fasting glucose, 2-h glucose after an oral glucose challenge, glycated hemoglobin and fasting insulin data were available. Trans-ancestry and single-ancestry meta-analyses identified 242 loci (99 novel; P < 5 x 10(-8)), 80% of which had no significant evidence of between-ancestry heterogeneity. Analyses restricted to individuals of European ancestry with equivalent sample size would have led to 24 fewer new loci. Compared with single-ancestry analyses, equivalent-sized trans-ancestry fine-mapping reduced the number of estimated variants in 99% credible sets by a median of 37.5%. Genomic-feature, gene-expression and gene-set analyses revealed distinct biological signatures for each trait, highlighting different underlying biological pathways. Our results increase our understanding of diabetes pathophysiology by using trans-ancestry studies for improved power and resolution. A trans-ancestry meta-analysis of GWAS of glycemic traits in up to 281,416 individuals identifies 99 novel loci, of which one quarter was found due to the multi-ancestry approach, which also improves fine-mapping of credible variant sets.",2021-06,01/07/2022 10:40,01/07/2022 10:40,,840-+,,6,53,,,,,,,,,,,,,,WOS:000656384400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HWUME28N,journalArticle,2019,"Middeldorp, CM; Mahajan, A; Horikoshi, M; Robertson, NR; Beaumont, RN; Bradfield, JP; Bustamante, M; Cousminer, DL; Day, FR; De Silva, NM; Guxens, M; Mook-Kanamori, DO; St Pourcain, B; Warrington, NM; Adair, LS; Ahlqvist, E; Ahluwalia, TS; Almgren, P; Ang, W; Atalay, M; Auvinen, J; Bartels, M; Beckmann, JS; Bilbao, JR; Bond, T; Borja, JB; Cavadino, A; Charoen, P; Chen, ZH; Coin, L; Cooper, C; Curtin, JA; Custovic, A; Das, S; Davies, GE; Dedoussis, GV; Duijts, L; Eastwood, PR; Eliasen, AU; Elliott, P; Eriksson, JG; Estivill, X; Fadista, J; Fedko, IO; Frayling, TM; Gaillard, R; Gauderman, WJ; Geller, F; Gilliland, F; Gilsanz, V; Granell, R; Grarup, N; Groop, L; Hadley, D; Hakonarson, H; Hansen, T; Hartman, CA; Hattersley, AT; Hayes, MG; Hebebrand, J; Heinrich, J; Helgeland, O; Henders, AK; Henderson, J; Henriksen, TB; Hirschhorn, JN; Hivert, MF; Hocher, B; Holloway, JW; Holt, P; Hottenga, JJ; Hypponen, E; Iniguez, C; Johansson, S; Jugessur, A; Kahonen, M; Kalkwarf, HJ; Kaprio, J; Karhunen, V; Kemp, JP; Kerkhof, M; Koppelman, GH; Korner, A; Kotecha, S; Kreiner-Moller, E; Kulohoma, B; Kumar, A; Kutalik, Z; Lahti, J; Lappe, JM; Larsson, H; Lehtimaki, T; Lewin, AM; Li, J; Lichtenstein, P; Lindgren, CM; Lindi, V; Linneberg, A; Liu, XP; Liu, J; Lowe, WL; Lundstrom, S; Lyytikainen, LP; Ma, RCW; Mace, A; Magi, R; Magnus, P; Mamun, AA; Mannikko, M; Martin, NG; Mbarek, H; McCarthy, NS; Medland, SE; Melbye, M; Melen, E; Mohlke, KL; Monnereau, C; Morgen, CS; Morris, AP; Murray, JC; Myhre, R; Najman, JM; Nivard, MG; Nohr, EA; Nolte, IM; Ntalla, I; O'Reilly, P; Oberfield, SE; Oken, E; Oldehinkel, AJ; Pahkala, K; Palviainen, T; Panoutsopoulou, K; Pedersen, O; Pennell, CE; Pershagen, G; Pitkanen, N; Plomin, R; Power, C; Prasad, RB; Prokopenko, I; Pulkkinen, L; Raikkonen, K; Raitakari, OT; Reynolds, RM; Richmond, RC; Rivadeneira, F; Rodriguez, A; Rose, RJ; Salem, R; Santa-Marina, L; Saw, SM; Schnurr, TM; Scott, JG; Selzam, S; Shepherd, JA; Simpson, A; Skotte, L; Sleiman, PMM; Snieder, H; Sorensen, TIA; Standl, M; Steegers, EAP; Strachan, DP; Straker, L; Strandberg, T; Taylor, M; Teo, YY; Thiering, E; Torrent, M; Tyrrell, J; Uitterlinden, AG; van Beijsterveldt, T; van der Most, PJ; van Duijn, CM; Viikari, J; Vilor-Tejedor, N; Vogelezang, S; Vonk, JM; Vrijkotte, TGM; Vuoksimaa, E; Wang, CA; Watkins, WJ; Wichmann, HE; Willemsen, G; Williams, GM; Wilson, JF; Wray, NR; Xu, SJ; Xu, CJ; Yaghootkar, H; Yi, L; Zafarmand, MH; Zeggini, E; Zemel, BS; Hinney, A; Lakka, TA; Whitehouse, AJO; Sunyer, J; Widen, EE; Feenstra, B; Sebert, S; Jacobsson, B; Njolstad, PR; Stoltenberg, C; Smith, GD; Lawlor, DA; Paternoster, L; Timpson, NJ; Ong, KK; Bisgaard, H; Bonnelykke, K; Jaddoe, VWV; Tiemeier, H; Jarvelin, MR; Evans, DM; Perry, JRB; Grant, SFA; Boomsma, DI; Freathy, RM; McCarthy, MI; Felix, JF; EArly Genetics Lifecourse; EGG Consortium; EGG Membership; EAGLE Membership","The Early Growth Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia: design, results and future prospects",EUROPEAN JOURNAL OF EPIDEMIOLOGY,,0393-2990,10.1007/s10654-019-00502-9,,"The impact of many unfavorable childhood traits or diseases, such as low birth weight and mental disorders, is not limited to childhood and adolescence, as they are also associated with poor outcomes in adulthood, such as cardiovascular disease. Insight into the genetic etiology of childhood and adolescent traits and disorders may therefore provide new perspectives, not only on how to improve wellbeing during childhood, but also how to prevent later adverse outcomes. To achieve the sample sizes required for genetic research, the Early Growth Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia were established. The majority of the participating cohorts are longitudinal population-based samples, but other cohorts with data on early childhood phenotypes are also involved. Cohorts often have a broad focus and collect(ed) data on various somatic and psychiatric traits as well as environmental factors. Genetic variants have been successfully identified for multiple traits, for example, birth weight, atopic dermatitis, childhood BMI, allergic sensitization, and pubertal growth. Furthermore, the results have shown that genetic factors also partly underlie the association with adult traits. As sample sizes are still increasing, it is expected that future analyses will identify additional variants. This, in combination with the development of innovative statistical methods, will provide detailed insight on the mechanisms underlying the transition from childhood to adult disorders. Both consortia welcome new collaborations. Policies and contact details are available from the corresponding authors of this manuscript and/or the consortium websites.",2019-03,01/07/2022 10:40,01/07/2022 10:40,,279-300,,3,34,,,,,,,,,,,,,,WOS:000463834200009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RMC3AQTC,journalArticle,2016,"Fritz, M; Klawonn, AM; Nilsson, A; Singh, AK; Zajdel, J; Wilhelms, DB; Lazarus, M; Lofberg, A; Jaarola, M; Kugelberg, UO; Billiar, TR; Hackam, DJ; Sodhi, CP; Breyer, MD; Jakobsson, J; Schwaninger, M; Schuetz, G; Parkitna, JR; Saper, CB; Blomqvist, A; Engblom, D",Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice,JOURNAL OF CLINICAL INVESTIGATION,,0021-9738,10.1172/JCI83844,,"Systemic inflammation causes malaise and general feelings of discomfort. This fundamental aspect of the sickness response reduces the quality of life for people suffering from chronic inflammatory diseases and is a nuisance during mild infections like common colds or the flu. To investigate how inflammation is perceived as unpleasant and causes negative affect, we used a behavioral test in which mice avoid an environment that they have learned to associate with inflammation-induced discomfort. Using a combination of cell-type-specific gene deletions, pharmacology, and chemogenetics, we found that systemic inflammation triggered aversion through MyD88-dependent activation of the brain endothelium followed by COX1-mediated cerebral prostaglandin E-2 (PGE(2)) synthesis. Further, we showed that inflammation-induced PGE(2) targeted EP1 receptors on striatal dopamine D1 receptor-expressing neurons and that this signaling sequence induced aversion through GABA-mediated inhibition of dopaminergic cells. Finally, we demonstrated that inflammation-induced aversion was not an indirect consequence of fever or anorexia but that it constituted an independent inflammatory symptom triggered by a unique molecular mechanism. Collectively, these findings demonstrate that PGE(2)-mediated modulation of the dopaminergic motivational circuitry is a key mechanism underlying the negative affect induced by inflammation.",2016-02,01/07/2022 10:40,01/07/2022 10:40,,695-705,,2,126,,,,,,,,,,,,,,WOS:000370677300029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
PZ9ZNWRD,journalArticle,2013,"Akgun, KM; Gordon, K; Pisani, M; Fried, T; McGinnis, KA; Tate, JP; Butt, AA; Gibert, CL; Huang, L; Rodriguez-Barradas, MC; Rimland, D; Justice, AC; Crothers, K",Risk Factors for Hospitalization and Medical Intensive Care Unit (MICU) Admission Among HIV-Infected Veterans,JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,,1525-4135,10.1097/QAI.0b013e318278f3fa,,"Objective: With improved survival of HIV-infected persons on antiretroviral therapy and growing prevalence of non-AIDS diseases, we asked whether the VACS Index, a composite measure of HIV-associated and general organ dysfunction predictive of all-cause mortality, predicts hospitalization and medical intensive care unit (MICU) admission. We also asked whether AIDS and non-AIDS conditions increased risk after accounting for VACS Index score. Methods: We analyzed data from the Veterans Aging Cohort Study (VACS), a prospective study of HIV-infected Veterans receiving care between 2002 and 2008. Data were obtained from the electronic medical record, VA administrative databases, and patient questionnaires and were used to identify comorbidities and calculate baseline VACS Index scores. The primary outcome was first hospitalization within 2 years of VACS enrollment. We used multivariable Cox regression to determine risk factors associated with hospitalization and logistic regression to determine risk factors for MICU admission, given hospitalization. Results: Of 3410 patients, 1141 were hospitalized within 2 years; 203 (17.8%)/1141 patients included an MICU admission. Median VACS Index scores were 25 (no hospitalization), 34 (hospitalization only), and 51 (MICU). In adjusted analyses, a 5-point increment in VACS Index score was associated with 10% higher risk of hospitalization and MICU admission. In addition to VACS Index score, Hispanic ethnicity, current smoking, hazardous alcohol use, chronic obstructive pulmonary disease, hypertension, diabetes, and prior AIDS-defining event predicted hospitalization. Among those hospitalized, VACS Index score, cardiac disease, and prior cancer predicted MICU admission. Conclusions: The VACS Index predicted hospitalization and MICU admission as did current smoking, hazardous alcohol use, and AIDS and certain non-AIDS diagnoses.",01/01/2013,01/07/2022 10:40,01/07/2022 10:40,,52-59,,1,62,,,,,,,,,,,,,,WOS:000312645400015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2NGX6T4B,journalArticle,2020,"Yang, YH; Reincke, M; Williams, TA","Prevalence, diagnosis and outcomes of treatment for primary aldosteronism",BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM,,1521-690X,10.1016/j.beem.2019.101365,,"Primary aldosteronism (PA) is the most common potentially curable form of hypertension. The overproduction of aldosterone leads to an increased risk of cardiovascular and cerebrovascular events as well as adverse effects to the heart and kidney and psychological disorders. PA is mainly caused by unilateral aldosterone excess due to an aldosterone-producing adenoma or bilateral excess due to bilateral adrenocortical hyperplasia. The diagnostic work-up of PA comprises three steps: screening, confirmatory testing and differentiation of unilateral surgically-correctable forms from medically treated bilateral PA. These specific treatments can mitigate or reverse the increased risks associated with PA. Herein we summarise the prevalence, outcomes and current and future clinical approaches for the diagnosis of primary aldosteronism. (C) 2019 Elsevier Ltd. All rights reserved.",2020-03,01/07/2022 10:40,01/07/2022 10:40,,,,2,34,,,,,,,,,,,,,,WOS:000537836800012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3U5GEI5N,journalArticle,2021,"Wang, YB; Shivappa, N; Hebert, JR; Page, AJ; Gill, TK; Melaku, YA","Association between Dietary Inflammatory Index, Dietary Patterns, Plant-Based Dietary Index and the Risk of Obesity",NUTRIENTS,,2072-6643,10.3390/nu13051536,,"Evidence on the association between various dietary constructs and obesity risk is limited. This study aims to investigate the longitudinal relationship between different diet indices and dietary patterns with the risk of obesity. Non-obese participants (n = 787) in the North West Adelaide Health Study were followed from 2010 to 2015. The dietary inflammatory index (DII(R)), plant-based dietary index (PDI) and factor-derived dietary pattern scores were computed based on food frequency questionnaire data. We found the incidence of obesity was 7.62% at the 5-year follow up. In the adjusted model, results from multivariable log-binomial logistic regression showed that a prudent dietary pattern (RRQ5 vs. (Q1) = 0.38; 95% CI: 0.15-0.96), healthy PDI (RR = 0.31; 95% CI: 0.12-0.77) and overall PDI (RR = 0.56; 95% CI: 0.23-1.33) were inversely associated with obesity risk. Conversely, the DII (RR = 1.59; 95% CI: 0.72-3.50), a Western dietary pattern (RR = 2.16; 95% CI: 0.76-6.08) and unhealthy PDI (RR = 1.94; 95% CI: 0.81-4.66) were associated with increased risk of obesity. Based on the cubic spline analysis, the association between an unhealthy PDI or diet quality with the risk of obesity was non-linear. In conclusion, an anti-inflammatory diet, healthy diet or consumption of healthy plant-based foods were all associated with a lower risk of developing obesity.",2021-05,01/07/2022 10:40,01/07/2022 10:40,,,,5,13,,,,,,,,,,,,,,WOS:000662350100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XGGGW6EP,journalArticle,2021,"Assimon, MM; Flythe, JE",Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis,CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,,1555-9041,10.2215/CJN.10070620,,"Background and objectives Zolpidem, a nonbenzodiazepine hypnotic, and trazodone, a sedating antidepressant, are the most commonmedications used to treat insomnia in theUnited States. Both drugs have side effect profiles (e.g., drowsiness, dizziness, and cognitive andmotor impairment) that can heighten the risk of falls and fractures. Despite widespread zolpidem and trazodone use, little is known about the comparative safety of these medications in patients receiving hemodialysis, a vulnerable population with an exceedingly high fracture rate. Design, setting, participants, & measurements Using data from the United States Renal Data System registry (2013-2016), we conducted a retrospective cohort study to investigate the association between the initiation of zolpidem versus trazodone therapy and the 30-day risk of hospitalized fall-related fractures among Medicare-enrolled patients receiving maintenance hemodialysis. We used an active comparator new-user design and estimated30-day inverse probabilityof treatment-weightedhazardratios andriskdifferences. We treateddeath as a competing event. Results A total of 31,055 patients were included: 18,941 zolpideminitiators (61%) and 12,114 trazodone initiators (39%). During the 30-day follow-up period, 101 fall-related fractures occurred. Zolpidem versus trazodone initiation was associated with a higher risk of hospitalized fall-related fracture (weighted hazard ratio, 1.71; 95% confidence interval, 1.11 to 2.63; weighted risk difference, 0.17%; 95% confidence interval, 0.07% to 0.29%). This association was more pronounced among individuals prescribed higher zolpidem doses (hazard ratio, 1.85; 95% confidence interval, 1.10 to 3.01; andriskdifference, 0.20%; 95% confidence interval, 0.04% to 0.38% forhigher-dose zolpidemversus trazodone; and hazard ratio, 1.60; 95% confidence interval, 1.01 to 2.55 and riskdifference, 0.14%; 95% confidence interval, 0.03% to 0.27% for lower-dose zolpidem versus trazodone). Sensitivity analyses using longer follow-up durations yielded similar results. Conclusions Among individuals receiving maintenance hemodialysis, zolpidem initiators had a higher risk of hospitalized fall- related fracture compared with trazodone initiators.",07/01/2021,01/07/2022 10:40,01/07/2022 10:40,,88-97,,1,16,,,,,,,,,,,,,,WOS:000609872000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
65JWZNJP,journalArticle,2012,"de Salas-Cansado, M; Perez, C; Saldana, MT; Navarro, A; Rejas, J",A Cost-Effectiveness Analysis of the Effect of Pregabalin Versus Usual Care in the Treatment of Refractory Neuropathic Pain in Routine Medical Practice in Spain,PAIN MEDICINE,,1526-2375,10.1111/j.1526-4637.2012.01375.x,,"Objective. The objective of this study was to estimate the cost-effectiveness of pregabalin vs usual care (UC) in outpatients with refractory neuropathic pain (NeP), treated according to routine medical practice in primary care settings in Spain. Methods. Patients were extracted from a 12-week noninterventional prospective study conducted to ascertain the costs of NeP. Pairs of pregabalin-naive patients receiving UC or pregabalin, matched by age, gender, pain intensity, and refractory to previous treatment, were selected in a 1:1 ratio. Refractory was considered a patient with actual pain (scoring >40 in a 100 mm in a pain visual analog scale) after receiving a course of a standard analgesic, at its recommended doses. Perspectives of the Spanish National Healthcare System and society were included in the analysis. Effectiveness was expressed as quality-adjusted life-year (QALY) gain. Results of the cost-effectiveness analysis were expressed as an incremental cost per QALY (ICER) gained. Probabilistic sensitivity analysis using bootstrapping techniques was also carried out. Results. A total of 160 pairs were extracted. Compared with UC, pregabalin was associated with significantly higher QALY gain; 0.0374 +/- 0.0367 vs 0.0224 +/- 0.0313 (P < 0.001). Despite drug acquisition costs being higher for pregabalin (251 pound +/- 125 vs 104 pound +/- 121; P < 0.001), total and health care costs incurred for pregabalin were similar in both groups; 1,335 pound +/- 1,302 vs 1,387 pound +/- 1,489 (P = 0.587) and 529 pound +/- 438 vs 560 pound +/- 672 (P = 0.628), respectively, yielding a dominant ICER for both total and health care costs in the base case scenario; 95% confidence intervals, respectively, dominant to 17,268 pound, and dominant to 6,508 pound. Sensitivity analysis confirmed results of the basecase scenario. Conclusion. This study showed that pregabalin may be cost-effective in the treatment of refractory NeP patients when compared with UC in routine medical practice in Spain.",2012-05,01/07/2022 10:40,01/07/2022 10:40,,699-710,,5,13,,,,,,,,,,,,,,WOS:000304137400013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9PYHG8YV,journalArticle,2006,"Pope, GD; Finlayson, SRG; Kemp, JA; Birkmeyer, JD",Life expectancy benefits of gastric bypass surgery,SURGICAL INNOVATION,,1553-3506,10.1177/1553350606296324,,"Bariatric surgery is the most effective treatment for achieving sustained weight loss in morbidly obese patients. Although the use of gastric bypass is growing rapidly, the potential life expectancy benefits of the procedure are unknown. We created a Markov decision analysis model to examine the effect of gastric bypass surgery on life expectancy in morbidly obese patients (body mass index [BMI] = 40 kg/m(2)). Input assumptions for the model were obtained from published life tables (baseline mortality risks), epidemiologic studies (obesity-related excess mortality), and large case series (surgical outcomes). In our baseline analysis, a 40-year-old woman (BMI = 40 kg/m(2)) would gain 2.6 years of life expectancy by undergoing gastric bypass (38.7 years versus 36.2 years without surgery). In sensitivity analysis, life-years gained with surgery remained substantial when assumptions were varied across reasonable ranges for surgical mortality risk (1.0-3.0 years) and effectiveness (0.9-4.4 years). Life-years gained with gastric bypass surgery did not vary considerably by age and sex subgroups. Relative to other major surgical procedures, gastric bypass for morbid obesity is associated with substantial gains in life expectancy. Longterm data from prospective studies are needed to confirm this finding.",2006-12,01/07/2022 10:40,01/07/2022 10:40,,265-273,,4,13,,,,,,,,,,,,,,WOS:000245205200007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UJDYN7H3,journalArticle,2017,"Raja-Khan, N; Agito, K; Shah, J; Stetter, CM; Gustafson, TS; Socolow, H; Kunselman, AR; Reibel, DK; Legro, RS",Mindfulness-Based Stress Reduction in Women with Overweight or Obesity: A Randomized Clinical Trial,OBESITY,,1930-7381,10.1002/oby.21910,,"Objective: To evaluate the feasibility and cardiometabolic effects of mindfulness-based stress reduction (MBSR) in women with overweight or obesity. Methods: Eighty-six women with BMI >= 25 kg/m(2) were randomized to 8 weeks of MBSR or health education and followed for 16 weeks. The primary outcome was the Toronto Mindfulness Scale. Secondary outcomes included the Perceived Stress Scale-10, fasting glucose, and blood pressure. Results: Compared to health education, the MBSR group demonstrated significantly improved mindfulness at 8 weeks (mean change from baseline, 4.5 vs. -1.0; P=0.03) and significantly decreased perceived stress at 16 weeks (-3.6 vs. -1.3, P=0.01). In the MBSR group, there were significant reductions in fasting glucose at 8 weeks (-8.9 mg/dL, P=0.02) and at 16 weeks (9.3 mg/dL, P=0.02) compared to baseline. Fasting glucose did not significantly improve in the health education group. There were no significant changes in blood pressure, weight, or insulin resistance in the MBSR group. Conclusions: In women with overweight or obesity, MBSR significantly reduces stress and may have beneficial effects on glucose. Future studies demonstrating long-term cardiometabolic benefits of MBSR will be key for establishing MBSR as an effective tool in the management of obesity.",2017-08,01/07/2022 10:40,01/07/2022 10:40,,1349-1359,,8,25,,,,,,,,,,,,,,WOS:000406782600011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
J5UW9367,book,2015,"Worobey, J; Tepper, BJ; Kanarek, RB; Worobey, J; Tepper, BJ; Kanarek, RB",Behavioral Aspects of Overweight and Obesity,,978-1-78064-445-5,,,,,2015,01/07/2022 10:40,01/07/2022 10:40,,,228,,,,,,"NUTRITION AND BEHAVIOR, 2ND EDITION: A MULTIDISCIPLINARY APPROACH",,,,,,,,,,WOS:000477870500015,,,Pages: 252 DOI: 10.1079/9781780644448.0000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MC6RP533,journalArticle,2006,"Smith, AM; Morris, P; Rowell, KO; Clarke, S; Jones, TH; Channer, KS",Junior doctors and the full shift rota - psychological and hormonal changes: a comparative cross-sectional study,CLINICAL MEDICINE,,1470-2118,10.7861/clinmedicine.6-2-174,,"We studied the hormonal and psychological effect of the full shift rota on junior doctors after implementation of the European Working Time Directive, using a comparative, cross-sectional study design of male doctors in South Yorkshire. Cortisol and testosterone levels were measured and subjects completed the general health questionnaire (GHQ-12) and the androgen deficiency in the aging male screening questionnaire (ADAM), after a week of holiday (baseline), a week of nights, and a normal working week. The results showed that cortisol levels decreased from 480.6 +/- 33.1 nmol/l at baseline (after a week of holiday), to 355.7 +/- 29.1 nmol/l post normal working week (p=0.003); to 396.7 +/- 32.5 nmol/l post nights (p=0.03). GHQ-12 scores increased from 0.5 +/- 0.3 at baseline, to 1.8 +/- 0.5 post normal working week (p=0.02) and to 2.3 +/- 0.5 post nights (p=0.005). These results suggest that there are still appreciable physiological consequences with new work patterns.",2006-03,01/07/2022 10:40,01/07/2022 10:40,,174-177,,2,6,,,,,,,,,,,,,,WOS:000237046100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5EIK72Y7,journalArticle,2019,"Kapnadak, SG; Ramos, KJ; Lopriore, AM; Goss, CH; Aitken, ML",A survey identifying nutritional needs in a contemporary adult cystic fibrosis cohort,BMC NUTRITION,,2055-0928,10.1186/s40795-018-0266-3,,"BackgroundCystic fibrosis (CF) is a disease in which nutritional barriers are diverse and common, with malnutrition greatly influencing pulmonary trajectory and overall outcomes. Despite this, the most effective methods to optimize CF nutrition are unknown, and literature describing patients' perspectives on their specific nutritional needs is lacking, particularly in the modern era of CF care. This study aimed to identify the most important nutritional needs and desired health-improvement resources in a contemporary adult CF cohort.MethodsA 14-question investigator-designed survey addressing nutrition concerns, preferred health-improvement resources, and dietary/exercise routines was administered to CF adults. Clinical characteristics and survey responses are presented with descriptive statistics, and responses compared by body mass index (BMI) category (<18.5kg/m(2); 18.5-24.99kg/m(2); 25-29.99kg/m(2); <greater than or equal to>30kg/m(2)), gender, and socioeconomic status using Chi square or Fisher's Exact testing.ResultsOf 66 total patients, nine (13.6%) were underweight (BMI <18.5kg/m(2)), while 19 (28.8%) were overweight or obese (BMI<greater than or equal to>25kg/m(2)). In the overall cohort, the most common primary concern was preventing weight loss [in 20/66 patients (30.3%)], but there were significant differences by BMI (p<0.001), with the most common concern in the overweight subgroup being preventing weight gain. Fifteen (46.9%) men (BMI mean 20.7, range 16.4-29.2kg/m(2)) listed preventing weight loss as the primary concern, compared to only 5 (14.7%) women (BMI mean 18.4, range 16.2-19.9kg/m(2)), representing a trend toward a difference in primary concerns by gender (p=0.066).The most commonly desired health-improvement resource was online CF nutrition and fitness information, found in 26 patients (39.4%) in the overall cohort, without significant differences by BMI (p=0.814) or gender (p=0.199). Financial assistance was the preferred resource in 17 (26.2%), without differences by socioeconomic status (p=0.367).ConclusionsWe identified a wide variety of nutritional needs in CF adults, including a high prevalence of overweight status, many patients desiring weight loss, and many seeking financial resources. Our findings support the individualization of modern-day CF nutrition programs and development of online resources, in an effort to address the heterogeneous barriers that exist in the contemporary CF population and improve outcomes in patients with the disease.",07/01/2019,01/07/2022 10:40,01/07/2022 10:40,,,,1,5,,,,,,,,,,,,,,WOS:000540082500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RT5WINF5,journalArticle,2019,"Elmets, CA; Leonardi, CL; Davis, DMR; Gelfand, JM; Lichten, J; Mehta, NN; Armstrong, AW; Connor, C; Cordoro, KM; Elewski, BE; Gordon, KB; Gottlieb, AB; Kaplan, DH; Kavanaugh, A; Kivelevitch, D; Kiselica, M; Korman, NJ; Kroshinsky, D; Lebwohl, M; Lim, HW; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rupani, R; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ; Hariharan, V; Menter, A",Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities,JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,,0190-9622,10.1016/j.jaad.2018.11.058,,"Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence.",2019-04,01/07/2022 10:40,01/07/2022 10:40,,1073-1113,,4,80,,,,,,,,,,,,,,WOS:000461037700037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MJ5KNZFN,journalArticle,2018,"Bhatt, SP; Bhakta, NR; Wilson, CG; Cooper, CB; Barjaktarevic, I; Bodduluri, S; Kim, YI; Eberlein, M; Woodruff, PG; Sciurba, FC; Castaldi, PJ; Han, MLK; Dransfield, MT; Nakhmani, A",New Spirometry Indices for Detecting Mild Airflow Obstruction,SCIENTIFIC REPORTS,,2045-2322,10.1038/s41598-018-35930-2,,"The diagnosis of chronic obstructive pulmonary disease (COPD) relies on demonstration of airflow obstruction. Traditional spirometric indices miss a number of subjects with respiratory symptoms or structural lung disease on imaging. We hypothesized that utilizing all data points on the expiratory spirometry curves to assess their shape will improve detection of mild airflow obstruction and structural lung disease. We analyzed spirometry data of 8307 participants enrolled in the COPDGene study, and derived metrics of airflow obstruction based on the shape on the volume-time (Parameter D), and flow-volume curves (Transition Point and Transition Distance). We tested associations of these parameters with CT measures of lung disease, respiratory morbidity, and mortality using regression analyses. There were significant correlations between FEV1/FVC with Parameter D (r = -0.83; p < 0.001), Transition Point (r = 0.69; p < 0.001), and Transition Distance (r = 0.50; p < 0.001). All metrics had significant associations with emphysema, small airway disease, dyspnea, and respiratory-quality of life (p < 0.001). The highest quartile for Parameter D was independently associated with all-cause mortality (adjusted HR 3.22, 95% CI 2.42-4.27; p < 0.001) but a substantial number of participants in the highest quartile were categorized as GOLD 0 and 1 by traditional criteria (1.8% and 33.7%). Parameter D identified an additional 9.5% of participants with mild or non-recognized disease as abnormal with greater burden of structural lung disease compared with controls. The data points on the flow-volume and volume-time curves can be used to derive indices of airflow obstruction that identify additional subjects with disease who are deemed to be normal by traditional criteria.",30/11/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,8,,,,,,,,,,,,,,WOS:000451748700006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Z55N3IU3,journalArticle,2018,"Coulter, AA; Rebello, CJ; Greenway, FL","Centrally Acting Agents for Obesity: Past, Present, and Future",DRUGS,,0012-6667,10.1007/s40265-018-0946-y,,"For many years, obesity was believed to be a condition of overeating that could be resolved through counseling and short-term drug treatment. Obesity was not recognized as a chronic disease until 1985 by the scientific community, and 2013 by the medical community. Pharmacotherapy for obesity has advanced remarkably since the first class of drugs, amphetamines, were approved for short-term use. Most amphetamines were removed from the obesity market due to adverse events and potential for addiction, and it became apparent that obesity pharmacotherapies were needed that could safely be administered over the long term. This review of central nervous system (CNS) acting anti-obesity drugs evaluates current therapies such as phentermine/topiramate, which act through multiple neurotransmitter pathways to reduce appetite. In the synergistic mechanism of bupropion/naltrexone, naltrexone blocks the feed-back inhibitory circuit of bupropion to give greater weight loss. Lorcaserin, a selective agonist of a serotonin receptor that regulates food intake, and the glucagon-like-peptide-1 (GLP-1) receptor agonist liraglutide are reviewed. Future drugs include tesofensine, a potent triple reuptake inhibitor in Phase III trials for obesity, and semaglutide, an oral GLP-1 analog approved for diabetes and currently in trials for obesity. Another potential new pharmacotherapy, setmelanotide, is a melanocortin-4 receptor agonist, which is still in an early stage of development. As our understanding of the communication between the CNS, gut, adipose tissue, and other organs evolves, it is anticipated that obesity drug development will move toward new centrally acting combinations and then to drugs acting on peripheral target tissues.",2018-07,01/07/2022 10:40,01/07/2022 10:40,,1113-1132,,11,78,,,,,,,,,,,,,,WOS:000440167900005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
92BVTBVD,journalArticle,2013,"Chang, JJ; Pien, GW; Stamatakis, KA; Brownson, RC","Association Between Physical Activity and Insomnia Symptoms in Rural Communities of Southeastern Missouri, Tennessee, and Arkansas",JOURNAL OF RURAL HEALTH,,0890-765X,10.1111/j.1748-0361.2012.00447.x,,"Purpose The purpose of this study is to examine whether physical activity is associated with less insomnia symptoms in the rural communities. Methods This study used cross-sectional data collected from a 2005 telephone survey for evaluation of a community walking trails intervention to promote physical activity in rural communities including 6 communities in the Missouri Ozark region and 6 communities in Arkansas and Tennessee (n = 1,234). The exposure variable is self-reported regular current physical activity. The outcome includes symptoms of insomnia operationalized as having trouble falling asleep, staying asleep, and waking up too early nearly every day. Logistic regression was used to calculate prevalence odds ratios (PORs) and 95% confidence intervals (95% CI). Findings The study sample includes mostly white (95%), married (62%), overweight/obese (61%) women with a high school degree and a mean age of 54. Fourteen percent of participants reported having insomnia symptoms. Self-report of currently being physically active regularly was associated with decreased odds of insomnia symptoms (adjusted POR: .37; 95% CI, 0.14-0.99) among participants with under or normal body weight, after controlling for age, gender, education level, marital status, and chronic diseases. There was also a negative linear correlation between the number of days and total minutes of vigorous physical activity and insomnia symptoms. Conclusions In these rural communities, we observed a significant relationship between regular physical activity and decreased insomnia symptoms.",2013,01/07/2022 10:40,01/07/2022 10:40,,239-247,,3,29,,,,,,,,,,,,,,WOS:000320936500002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
WFWT2ZBU,book,2007,"Taylor, AE",Clinical Evaluation of Polycystic Ovary Syndrome,,978-1-58829-763-1,,,,"The goals of the clinical evaluation of women with possible polycystic ovary syndrome (PCOS) include: (1) making the proper diagnosis (excluding other more serious diagnoses); (2) determining whether to screen for associated health complications of PCOS in the patient and/or her family members; (3) determining the appropriate current treatment; and (4) discussing a long-term management plan for the patient. The clinical evaluation begins with a complete medical history and physical examination. Although the evaluation will naturally focus on those areas of greatest concern to the patient, the clinician must remember the myriad associated health abnormalities that can occur with PCOS and has a responsibility to evaluate all the health impacts of the condition on the patient, whether or not intervention is currently requested or required.",2007,01/07/2022 10:40,01/07/2022 10:40,,,131,,,,,,"INSULIN RESISTANCE AND POLYCYSTIC OVARIAN SYNDROME: PATHOGENESIS, EVALUATION, AND TREATMENT",,,,,,,,,,WOS:000266909200010,,,Pages: 143,,,,,,"DiamantiKandarakis, E; Nestler, JE; Panidis, D; Pasquali, R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
XSXQGAPM,journalArticle,2014,"Segal, D; MacDonald, JK; Chande, N",Low dose naltrexone for induction of remission in Crohn's disease,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD010410.pub2,,"Background Crohn's disease is a transmural, relapsing inflammatory condition afflicting the digestive tract. Opioid signalling, long known to affect secretion and motility in the gut, has been implicated in the inflammatory cascade of Crohn's disease. Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. Objectives The primary objective was to evaluate the efficacy and safety of low dose naltrexone for induction of remission in Crohn's disease. Search methods A systematic search of MEDLINE, EMBASE, CENTRAL, and the Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group Specialized Register was performed from inception to February 2013 to identify relevant studies. Abstracts from major gastroenterology conferences including Digestive Disease Week and United European Gastroenterology Week and reference lists from retrieved articles were also reviewed. Selection criteria Randomized controlled trials of low dose naltrexone (LDN) for treatment of active Crohn's disease were included. Data collection and analysis Data were analyzed on an intention-to-treat basis using Review Manager (RevMan 5.2). The primary outcome was induction of clinical remission defined by a Crohn's disease activity index (CDAI) of <= 150 or a pediatric Crohn's disease activity index (PCDAI) of <= 10. Secondary outcomes included clinical response (70- or 100-point decrease in CDAI from baseline), endoscopic remission or response, quality of life, and adverse events as defined by the included studies. Risk ratios (RR) and 95% confidence intervals (CI) were calculated for dichotomous outcomes. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting the primary outcome and selected secondary outcomes was assessed using the GRADE criteria. Main results Two studies were identified (46 participants). One study assessed the efficacy and safety of 12 weeks of LDN (4.5 mg/day) treatment compared to placebo in adult patients (N = 34). The other study assessed eight weeks of LDN (0.1 mg/kg, maximum 4.5 mg/day) treatment compared to placebo in pediatric patients (N = 12). The primary purpose of the pediatric study was to assess safety and tolerability. Both studies were rated as having a low risk of bias. The study in adult patients reported that 30% (5/18) of LDN treated patients achieved clinical remission at 12 weeks compared to 18% (3/16) of placebo patients, a difference that was not statistically significant (RR 1.48, 95% CI 0.42 to 5.24). The study in children reported that 25% of LDN treated patients achieved clinical remission (PCDAI <= 10) compared to none of the patients in the placebo group, although it was unclear if this result was for the randomized placebo-controlled trial or for the open label extension study. In the adult study 70-point clinical response rates were significantly higher in those treated with LDN than placebo. Eighty-three per cent (15/18) of LDN patients had a 70-point clinical response at week 12 compared to 38% (6/16) of placebo patients (RR 2.22, 95% CI 1.14 to 4.32). The effect of LDNon the proportion of adult patients who achieved a 100-point clinical response was uncertain. Sixty-one per cent (11/18) of LDN patients achieved a 100-point clinical response compared to 31% (5/16) of placebo patients (RR 1.96, 95% CI 0.87 to 4.42). The proportion of patients who achieved endoscopic response (CDEIS decline >= 5 from baseline) was significantly higher in the LDN group compared to placebo. Seventy-two per cent (13/18) of LDN patients achieved an endoscopic response compared to 25% (4/16) of placebo patients (RR 2.89; 95% CI 1.18 to 7.08). However, there was no statistically significant difference in the proportion of patients who achieved endoscopic remission. Endoscopic remission (CDEIS < 3) was achieved in 22% (4/18) of the LDN group compared to 0% (0/16) of the placebo group (RR 8.05; 95% CI 0.47 to 138.87). Pooled data from both studies show no statistically significant differences in withdrawals due to adverse events or specific adverse events including sleep disturbance, unusual dreams, headache, decreased appetite, nausea and fatigue. No serious adverse events were reported in either study. GRADE analyses rated the overall quality of the evidence for the primary and secondary outcomes (i.e. clinical remission, clinical response, endoscopic response, and adverse events) as low due to serious imprecision (sparse data). Authors' conclusions Currently, there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of LDN used to treat patients with active Crohn's disease. Data from one small study suggests that LDN may provide a benefit in terms of clinical and endoscopic response in adult patients with active Crohn's disease. Data from two small studies suggest that LDN does not increase the rate of specific adverse events relative to placebo. However, these results need to be interpreted with caution as they are based on very small numbers of patients and the overall quality of the evidence was rated as low due to serious imprecision. Further randomized controlled trials are required to assess the efficacy and safety of LDN therapy in active Crohn's disease in both adults and children. One study is currently ongoing (NCT01810185).",2014,01/07/2022 10:40,01/07/2022 10:40,,,,2,,,,,,,,,,,,,,,WOS:000332082900041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UU9W9YGL,journalArticle,2015,"Hsu, A; Nakagawa, S; Walter, LC; Van den Eeden, SK; Brown, JS; Thom, DH; Lee, SJ; Huang, AJ",The Burden of Nocturia Among Middle-Aged and Older Women,OBSTETRICS AND GYNECOLOGY,,0029-7844,10.1097/AOG.0000000000000600,,"OBJECTIVE: To examine the prevalence, predictors, and effects of nocturia in women and evaluate overlaps with established urinary tract disorders. METHODS: This was a cross-sectional analysis of 2,016 women, aged 40 years and older, recruited from Kaiser Permanente Northern California from 2008 to 2012. Nocturia and other urinary symptoms were assessed using structured interviewer-administered questionnaires. Nocturia was defined as patient-reported nocturnal voiding of two or more times per night over a typical week. RESULTS: Thirty-four percent (n=692) reported nocturia, and 40% of women with nocturia reported no other urinary tract symptom. Women with nocturia were older (mean age 58 compared with 55 years) (odds ratio [ OR] per 5-year increase 1.21, 95% confidence interval [CI] 1.12-1.31), more likely black (45%) (OR 1.75, 95% CI 1.30-2.35) or Latina (37%) (OR 1.36, 95% CI 1.02-1.83) compared with non-Latina white (30%), have worse depression (mean Hospital Anxiety and Depression Scale score 3.8 compared with 2.8) (OR per 1-point increase in Hospital Anxiety and Depression Scale score 1.08, 95% CI 1.04-1.12), and worse mobility (mean Timed Up-and-Go 11.3 compared with 10 seconds) (OR per 5-second increase in Timed Up-and-Go 1.29, 95% CI 1.05-1.58). Nocturia occurred more among women with hysterectomy (53% compared with 33%) (OR 1.78, 95% CI 1.08-2.94), hot flushes (38% compared with 32%) (OR 1.49, 95% CI 1.19-1.87), and vaginal estrogen use (42% compared with 34%) (OR 1.50, 95% CI 1.04-2.18). CONCLUSION: Nocturia is common in women and not necessarily attributable to other urinary tract disorders. Factors not linked to bladder function may contribute to nocturia risk, underlining the need for multiorgan prevention and treatment strategies.",2015-01,01/07/2022 10:40,01/07/2022 10:40,,35-43,,1,125,,,,,,,,,,,,,,WOS:000346735600008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
YA4ET7BR,journalArticle,2014,"Criner, GJ; Connett, JE; Aaron, SD; Albert, RK; Bailey, WC; Casaburi, R; Cooper, JAD; Curtis, JL; Dransfield, MT; Han, MK; Make, B; Marchetti, N; Martinez, FJ; Niewoehner, DE; Scanlon, PD; Sciurba, FC; Scharf, SM; Sin, DD; Voelker, H; Washko, GR; Woodruff, PG; Lazarus, SC; COPD Clinical Res Network; Canadian Inst Hlth Res",Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD,NEW ENGLAND JOURNAL OF MEDICINE,,0028-4793,10.1056/NEJMoa1403086,,"BACKGROUND Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. METHODS We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment with glucocorticoids or antibiotic agents, or had had an emergency department visit or hospitalization for COPD within the past year. Patients with diabetes or cardiovascular disease and those who were taking statins or who required statins on the basis of Adult Treatment Panel III criteria were excluded. Participants were treated from 12 to 36 months at 45 centers. RESULTS A total of 885 participants with COPD were enrolled for approximately 641 days; 44% of the patients were women. The patients had a mean (+/-SD) age of 62.2+/-8.4 years, an FEV1 that was 41.6+/-17.7% of the predicted value, and a smoking history of 50.6+/-27.4 pack-years. At the time of study closeout, the low-density lipoprotein cholesterol levels were lower in the simvastatin-treated patients than in those who received placebo. The mean number of exacerbations per person-year was similar in the simvastatin and placebo groups: 1.36+/-1.61 exacerbations and 1.39+/-1.73 exacerbations, respectively (P = 0.54). The median number of days to the first exacerbation was also similar: 223 days (95% confidence interval [CI], 195 to 275) and 231 days (95% CI, 193 to 303), respectively (P = 0.34). The number of nonfatal serious adverse events per person-year was similar, as well: 0.63 events with simvastatin and 0.62 events with placebo. There were 30 deaths in the placebo group and 28 in the simvastatin group (P = 0.89). CONCLUSIONS Simvastatin at a daily dose of 40 mg did not affect exacerbation rates or the time to a first exacerbation in patients with COPD who were at high risk for exacerbations. (Funded by the National Heart, Lung, and Blood Institute and the Canadian Institutes of Health Research; STATCOPE ClinicalTrials.gov number, NCT01061671.)",05/06/2014,01/07/2022 10:40,01/07/2022 10:40,,2201-2210,,23,370,,,,,,,,,,,,,,WOS:000336729900008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
FMH8KB45,journalArticle,2019,"Jhamb, M; Abdel-Kader, K; Yabes, J; Wang, YS; Weisbord, SD; Unruh, M; Steel, JL","Comparison of Fatigue, Pain, and Depression in Patients With Advanced Kidney Disease and Cancer-Symptom Burden and Clusters",JOURNAL OF PAIN AND SYMPTOM MANAGEMENT,,0885-3924,10.1016/j.jpainsymman.2018.12.006,,"Context. Although symptom clusters have been studied in the context of cancer, few data exist in chronic and end-stage kidney disease (CKD/ESKD) patients. Objectives. The objectives of this study were to 1) characterize and compare symptom cluster phenotypes in patients with advanced CKD, ESKD, and cancer and 2) explore predictors of symptom clusters. Methods. We conducted secondary data analysis of three prospective studies in which pain, depression, and fatigue were assessed in patients with Stage 4-5 CKD, ESKD, and gastrointestinal cancer. Tetrachoric correlations between these symptoms were quantified, and partitioning around medoids algorithm was used for symptom cluster analysis. Results. In the 82 CKD, 149 ESKD, and 606 cancer patients, no differences in the average fatigue (P 0.17) or pain levels (P 0.21) were observed. Over 80% of patients in each group had at least one symptom. Moderate or severe depressive symptoms were more common in patients with cancer (31% vs. 19% in ESKD vs. 9% in CKD; P < 0.001). Mild-moderate correlations were observed between the three symptoms in ESKD and cancer patients. Three distinct clusters were observed in each group. In ESKD, the HIGH cluster (with high probability of pain, depression, and fatigue) had higher body mass index (P < 0.001) and antidepressant use (P 0.01). In cancer patients, the HIGH cluster patients were more likely to be female (P 0.04), use antidepressants (P 0.04), and have lower serum albumin (P< 0.001) and hemoglobin (P 0.03) compared to the other two clusters. Conclusion. Although the burden of fatigue, pain, and depressive symptoms for CKD and ESKD patients is similar to patients with gastrointestinal cancer, symptom cluster phenotypes differed between the groups as did the predictors of symptom clusters. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.",2019-03,01/07/2022 10:40,01/07/2022 10:40,,566-+,,3,57,,,,,,,,,,,,,,WOS:000458999300012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HNLCJJAX,journalArticle,2020,"Ng, SK; Martin, SA; Adams, RJ; O'Loughlin, P; Wittert, GA",The Effect of Multimorbidity Patterns and the Impact of Comorbid Anxiety and Depression on Primary Health Service Use: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study,AMERICAN JOURNAL OF MENS HEALTH,,1557-9883,10.1177/1557988320959993,,"This study sought to determine patterns of multimorbidity and quantify their impact on use of primary health services in the presence and absence of anxiety and depression among a cohort of urban community-dwelling men in Australia. The analytic sample consisted of men (n= 2039; age 38-85) from the follow-up wave of a prospective cohort study of all participants of the Florey Adelaide Male Ageing Study (FAMAS; Stage 2 [2007-2010]) and age-matched men from the North-West Adelaide Health Study (NWAHS; Stage 3 [2008-2010]). Self-reported data and linkage with a national universal health coverage scheme (Medicare) provided information on the prevalence of eight chronic conditions and health service utilization information (including annual GP visits). Obesity and cardiovascular disease (CVD) were associated with the highest number of comorbid conditions. Two nonrandom multimorbidity ""clusters"" emerged: ""CVD, Obesity, Diabetes"" and ""CVD, Obesity, Osteoarthritis."" Participants with conditions comorbid with CVD were more likely to have 10 or more annual GP visits, compared to multimorbidity involving other conditions. In comparison to participants without CVD, the presence of CVD increased the chance of having 10 or more annual GP visits (adjusted risk ratio: 3.7; 95% CI [2.8, 4.8]). When CVD was comorbid with anxiety and depression, having 10 or more annual GP visits was more common (adjusted risk ratio: 1.8; 95% CI [1.2, 2.5]). Multimorbidity patterns involving CVD, especially for multimorbidity that includes CVD with comorbid anxiety and depression, should be considered in developing clinical trials to better inform medical decision-making and care for patients with CVD and comorbid conditions.",2020-09,01/07/2022 10:40,01/07/2022 10:40,,,,5,14,,,,,,,,,,,,,,WOS:000582212300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
TISEWRZM,journalArticle,2021,"Shakya, PR; Melaku, YA; Shivappa, N; Hebert, JR; Adams, RJ; Page, AJ; Gill, TK",Dietary inflammatory index (DII (R)) and the risk of depression symptoms in adults,CLINICAL NUTRITION,,0261-5614,10.1016/j.clnu.2020.12.031,,"Background & aims: Findings from observational studies investigating the association between Dietary Inflammatory Index (DII (R)) scores and depression symptoms (DepS) are inconsistent. This study aims to assess the association between energy-adjusted DII (E-DIITM) and DepS using the North West Adelaide Health Study (NWAHS) cohort as well as update a previous meta-analysis. Methods: A total of 1743 (mean +/- SD age: 56.6 +/- 13.6 years, 51% female) study participants from NWAHS were included in the cross-sectional study and 859 (mean +/- SD age: 58.4 +/- 12.1 years, 52.6% female) in the longitudinal analyses. The Center for Epidemiological Studies Depression Scale (CES-D) was used for the measurement of DepS. E-DII scores were calculated from the dietary data collected using a validated food frequency questionnaire (FFQ). Data from two stages [Stage 3 (2008-10) and North West 15 (NW15) (2015)] were used. Log- and negative binomial regression were used to assess the association between quartiles of E-DII and DepS. A recent meta-analysis was updated by including 12 publications (six crosssectional and six cohort studies) on the association between DII and DepS. Results: In the cross-sectional analysis, a higher E-DII score (i.e., more pro-inflammatory diet) was associated with a 79% increase in odds of reporting DepS [ORQuartile4vs1: 1.79; 95% CI: 1.14-2.81; p = 0.01; p for trend (ptrend) = 0.03]. Males with higher E-DII had a more than two-fold higher odds of DepS (ORQuartile4vs1: 2.27; 95% CI: 1.02-5.06; p = 0.045; ptrend = 0.09). Females with higher E-DII had an 81% increase in odds of DepS (ORQuartile4vs1: 1.81; 95% CI: 1.01-3.26; p = 0.046; ptrend = 0.07). These associations were consistent in the longitudinal analysis. Comparing highest to lowest quintiles of E-DII, the updated meta-analysis showed that a pro-inflammatory diet is associated with a 45% increase in odds of having DepS (OR: 1.45; 95% CI: 1.20-1.74; p < 0.01) with higher odds in females (OR: 1.53; 95% CI: 1.16 -2.01; p = 0.01) compared to their male counterparts (OR: 1.29; 95% CI: 0.98-1.69; p = 0.15). Conclusion: The data from the NWAHS and the updated meta-analysis of observational studies provide further evidence that a pro-inflammatory diet is positively associated with increased risk of DepS. These findings support the current recommendation on consuming a less inflammatory diet to improve DepS. 0 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.",2021-05,01/07/2022 10:40,01/07/2022 10:40,,3631-3642,,5,40,,,,,,,,,,,,,,WOS:000654712100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RXVETD7X,journalArticle,2013,"Kelly, AS; Barlow, SE; Rao, G; Inge, TH; Hayman, LL; Steinberger, J; Urbina, EM; Ewing, LJ; Daniels, SR; Council Cardiovasc Dis Young; Council Nutr Phys Activity Metab; Council Clinical Cardiology","Severe Obesity in Children and Adolescents: Identification, Associated Health Risks, and Treatment Approaches A Scientific Statement From the American Heart Association",CIRCULATION,,0009-7322,10.1161/CIR.0b013e3182a5cfb3,,"Severe obesity afflicts between 4% and 6% of all youth in the United States, and the prevalence is increasing. Despite the serious immediate and long-term cardiovascular, metabolic, and other health consequences of severe pediatric obesity, current treatments are limited in effectiveness and lack widespread availability. Lifestyle modification/behavior-based treatment interventions in youth with severe obesity have demonstrated modest improvement in body mass index status, but participants have generally remained severely obese and often regained weight after the conclusion of the treatment programs. The role of medical management is minimal, because only 1 medication is currently approved for the treatment of obesity in adolescents. Bariatric surgery has generally been effective in reducing body mass index and improving cardiovascular and metabolic risk factors; however, reports of long-term outcomes are few, many youth with severe obesity do not qualify for surgery, and access is limited by lack of insurance coverage. To begin to address these challenges, the purposes of this scientific statement are to (1) provide justification for and recommend a standardized definition of severe obesity in children and adolescents; (2) raise awareness of this serious and growing problem by summarizing the current literature in this area in terms of the epidemiology and trends, associated health risks (immediate and long-term), and challenges and shortcomings of currently available treatment options; and (3) highlight areas in need of future research. Innovative behavior-based treatment, minimally invasive procedures, and medications currently under development all need to be evaluated for their efficacy and safety in this group of patients with high medical and psychosocial risks.",08/10/2013,01/07/2022 10:40,01/07/2022 10:40,,1689-1712,,15,128,,,,,,,,,,,,,,WOS:000325345700022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
I424VPD3,journalArticle,2009,"Yurcisin, BM; Gaddor, MM; DeMaria, EJ",Obesity and Bariatric Surgery,CLINICS IN CHEST MEDICINE,,0272-5231,10.1016/j.ccm.2009.05.013,,"Laparoscopic Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding are the most commonly performed weight reduction operations in the United States. Preoperative assessment and selection should be performed by a multidisciplinary team to obtain optimal results. The most devastating complication of bariatric surgery is leak, which can carry a high risk of mortality if not detected and treated expediently. New nationwide databases have been developed to monitor outcomes and facilitate better understanding of the mechanisms of bariatric surgery. New horizons for the advancement of bariatric; surgery are in the realm of surgery in adolescent and geriatric populations, the use of weight-loss surgery in lower body mass index (<35 kg/m(2)) populations, and the use of surgery to cure the comorbidities of obesity.",2009-09,01/07/2022 10:40,01/07/2022 10:40,,539-+,,3,30,,,,,,,,,,,,,,WOS:000270089200011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ZZXEVHCI,journalArticle,2019,"Goss, CH",Acute Pulmonary Exacerbations in Cystic Fibrosis,SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE,,1069-3424,10.1055/s-0039-1697975,,"With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation.",2019-12,01/07/2022 10:40,01/07/2022 10:40,,792-803,,6,40,,,,,,,,,,,,,,WOS:000505070400009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MY3BYC7Q,journalArticle,2005,"Saltzman, E; Anderson, W; Apovian, CM; Boulton, H; Chamberlain, A; Cullum-Dugan, D; Cummings, S; Hatchigian, E; Hodges, B; Keroack, CR; Pettus, M; Thomason, P; Veglia, L; Young, LS",Criteria for patient selection and multidisciplinary evaluation and treatment of the weight loss surgery patient,OBESITY RESEARCH,,1071-7323,10.1038/oby.2005.32,,"Objective: To provide evidence-based guidelines for patient selection and to recommend the medical and nutritional aspects of multidisciplinary care required to minimize perioperative and postoperative risks in patients with severe obesity who undergo weight loss surgery (WLS). Research Methods and Procedures: Members of the Multidisciplinary Care Task Group conducted searches of MEDLINE and PubMed for articles related to WLS in general and medical and nutritional care in particular. Pertinent abstracts' and literature were reviewed for references. Multiple searches were carried out for various aspects of multidisciplinary care published between 1980 and 2004. A total of 3000 abstracts were identified; 242 were reviewed in detail. Results: We recommended multidisciplinary screening of WLS patients to ensure appropriate selection; preoperative assessment for cardiovascular, pulmonary, gastrointestinal, endocrine, and other obesity-related diseases associated with increased risk for complications or mortality; preoperative weight loss and cessation of smoking; perioperative prophylaxis for deep vein thrombosis and pulmonary embolism (PE); preoperative and postoperative education and counseling by a registered dietitian; and a well-defined postsurgical diet progression. Discussion: Obesity-related diseases are often undiagnosed before WLS, putting patients at increased risk for complications and/or early mortality. Multidisciplinary assessment and care to minimize short- and long-term risks include: comprehensive medical screening; appropriate pre-, peri-, and postoperative preparation; collaboration with multiple patient care disciplines (e., anesthesiology, pulmonary medicine, cardiology, and psychology); and long-term nutrition education/counseling.",2005-02,01/07/2022 10:40,01/07/2022 10:40,,234-243,,2,13,,,,,,,,,,,,,,WOS:000228238100004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D6EYF5I3,journalArticle,2021,"Covington, LB; Trude, ACB; Armstrong, B; Black, MM",Regular Bedtime: Implications for Obesity Prevention During the Pandemic and Beyond,CHILDHOOD OBESITY,,2153-2168,10.1089/chi.2021.0063,,,01/10/2021,01/07/2022 10:40,01/07/2022 10:40,,493-495,,7,17,,,,,,,,,,,,,,WOS:000656635700001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L3EM9D2E,journalArticle,2017,"Guekht, A","Epilepsy, Comorbidities and Treatments",CURRENT PHARMACEUTICAL DESIGN,,1381-6128,10.2174/1381612823666171009144400,,"Background: An increasing amount of evidence suggests an association between epilepsy and multiple somatic and psychiatric conditions, which is more significant than in the general population. Furthermore, a bidirectional association has been established between epilepsy and several conditions, notably depression and suicide, cerebrovascular disease, stroke, dementia and migraine, which is best explained by the presence of common underlying mechanisms and risk factors. Gaining knowledge about these common mechanisms can provide insight into new therapeutic targets, screening and preventive measures. Methods: This review discusses several of the more significant somatic and psychiatric comorbidities of epilepsy, the mechanisms and direction of their association, as well as the implications of these comorbidities for treatment. Results: Somatic and psychiatric comorbidity in epilepsy have been investigated in several population-based studies using medical records databases and different survey methods. All show a significantly higher prevalence for a number of medical conditions in people with epilepsy (PWE) compared to the general population. Conclusion: The coexistence of different medical conditions with epilepsy carries important implications for the assessment of the burden of the disease and the outcome and management of these patients, as they often require long-term antiepileptic drug intake.",2017,01/07/2022 10:40,01/07/2022 10:40,,5702-5726,,37,23,,,,,,,,,,,,,,WOS:000425337600014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
UL5ZEVQN,book,2012,"Alexander, S",Health implications of overweight and obesity in children and adolescents,,978-1-920899-85-1,,,,"Overweight and obesity has been associated with a wide range of health and psychosocial problems that impact negatively on quality and length of life. The exact relationship between obesity and premature mortality is controvertible but there are strong and clear associations between increasing weight and risk of most major chronic diseases. Obesity is now the most common chronic disorder of childhood, and may adversely affect a child's health with immediate medical and psychosocial consequences. However the more significant risk in children and adolescents who are obese is the tendency for obesity to persist in adulthood leading to greater potential for the early development of chronic disease and reduced life expectancy.",2012,01/07/2022 10:40,01/07/2022 10:40,,,160,,,,,,MODERN EPIDEMIC: EXPERT PERSPECTIVES ON OBESITY AND DIABETES,,,,,,,,,,WOS:000313584600012,,,Pages: 170,,,,,,"Baur, LA; Twigg, SM; Magnusson, RS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D2VWHJR2,journalArticle,2019,"Middleton, PG; Mall, MA; Drevinek, P; Lands, LC; McKone, EF; Polineni, D; Ramsey, BW; Taylor-Cousar, JL; Tullis, E; Vermeulen, F; Marigowda, G; McKee, CM; Moskowitz, SM; Nair, N; Savage, J; Simard, C; Tian, S; Waltz, D; Xuan, F; Rowe, SM; Jain, R; VX17-445-102 Study Grp",Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele,NEW ENGLAND JOURNAL OF MEDICINE,,0028-4793,10.1056/NEJMoa1908639,,"Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation. In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del-minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clinical outcomes. Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and safety of elexacaftor-tezacaftor-ivacaftor in patients 12 years of age or older with cystic fibrosis with Phe508del-minimal function genotypes. Patients were randomly assigned to receive elexacaftor-tezacaftor-ivacaftor or placebo for 24 weeks. The primary end point was absolute change from baseline in percentage of predicted forced expiratory volume in 1 second (FEV1) at week 4. Results A total of 403 patients underwent randomization and received at least one dose of active treatment or placebo. Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower, a respiratory domain score on the Cystic Fibrosis Questionnaire-Revised (range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; minimum clinically important difference, 4 points) that was 20.2 points higher, and a sweat chloride concentration that was 41.8 mmol per liter lower (P<0.001 for all comparisons). Elexacaftor-tezacaftor-ivacaftor was generally safe and had an acceptable side-effect profile. Most patients had adverse events that were mild or moderate. Adverse events leading to discontinuation of the trial regimen occurred in 1% of the patients in the elexacaftor-tezacaftor-ivacaftor group. Conclusions Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective. (Funded by Vertex Pharmaceuticals; VX17-445-102 ClinicalTrials.gov number, NCT03525444.)",07/11/2019,01/07/2022 10:40,01/07/2022 10:40,,1809-1819,,19,381,,,,,,,,,,,,,,WOS:000496238300006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3BB7R7DH,journalArticle,2019,"Lim, SS; Hutchison, SK; Van Ryswyk, E; Norman, RJ; Teede, HJ; Moran, LJ",Lifestyle changes in women with polycystic ovary syndrome,COCHRANE DATABASE OF SYSTEMATIC REVIEWS,,1469-493X,10.1002/14651858.CD007506.pub4,,"Background Polycystic ovary syndrome (PCOS) affects 8% to 13% of reproductive-aged women and is associated with reproductive and metabolic dysfunction. Obesity worsens the presentation of PCOS and weight management (weight loss, maintenance or prevention of excess weight gain) is proposed as an initial treatment strategy, best achieved through lifestyle changes incorporating diet, exercise and behavioural interventions. Objectives To assess the effectiveness of lifestyle treatment in improving reproductive, anthropometric (weight and body composition), metabolic and quality of life factors in PCOS. Search methods We searched the Cochrane Gynaecology and Fertility Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, CINAHL and AMED (date of last search March 2018). We also searched controlled trials registries, conference abstracts, relevant journals, reference lists of relevant papers and reviews, and grey literature databases, with no language restrictions applied. Selection criteria Randomised controlled trials (RCTs) comparing lifestyle treatment (diet, exercise, behavioural or combined treatments) to minimal or no treatment in women with PCOS. Data collection and analysis Two authors independently selected trials, assessed evidence quality and risk of bias, and extracted data. Our primary outcomes were live birth, miscarriage and pregnancy. We used inverse variance and fixed-effect models in the meta-analyses. We reported dichotomous outcomes as an odds ratio and continuous outcomes as a mean difference (MD) or standardised mean difference (SMD). Main results We included 15 studies with 498 participants. Ten studies compared physical activity to minimal dietary and behavioural intervention or no intervention. Five studies compared combined dietary, exercise and behavioural intervention to minimal intervention. One study compared behavioural intervention to minimal intervention. Risk of bias varied: eight studies had adequate sequence generation, seven had adequate clinician or outcome assessor blinding, seven had adequate allocation concealment, six had complete outcome data and six were free of selective reporting. No studies assessed the fertility primary outcomes of live birth or miscarriage. No studies reported the secondary reproductive outcome of menstrual regularity, as defined in this review. Lifestyle intervention may improve a secondary (endocrine) reproductive outcome, the free androgen index (FAI) (MD -1.11, 95% confidence interval (CI) -1.96 to -0.26, 6 RCTs, N = 204, I-2 = 71%, low-quality evidence).Lifestyle intervention may reduce weight (kg) (MD -1.68 kg, 95% CI -2.66 to -0.70, 9 RCTs, N = 353, I-2 = 47%, low-quality evidence). Lifestyle intervention may reduce body mass index (BMI) (kg/m(2)) (-0.34 kg/m(2), 95% CI -0.68 to -0.01, 12 RCTs, N = 434, I-2 = 0%, low-quality evidence). We are uncertain of the effect of lifestyle intervention on glucose tolerance (glucose outcomes in oral glucose tolerance test) (mmol/L/minute) (SMD 0.02, 95% CI -0.38 to 0.33, 3 RCTs, N = 121, I-2= 0%, low-quality evidence). Authors' conclusions Lifestyle intervention may improve the free androgen index (FAI), weight and BMI in women with PCOS. We are uncertain of the effect of lifestyle intervention on glucose tolerance. There were no studies that looked at the effect of lifestyle intervention on live birth, miscarriage or menstrual regularity. Most studies in this review were of low quality mainly due to high or unclear risk of bias across most domains and high heterogeneity for the FAI outcome.",2019,01/07/2022 10:40,01/07/2022 10:40,,,,3,,,,,,,,,,,,,,,WOS:000462935200003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7AELW7LB,journalArticle,2014,"Abdel-Kader, K; Jhamb, M; Mandich, LA; Yabes, J; Keene, RM; Beach, S; Buysse, DJ; Unruh, ML","Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD",BMC NEPHROLOGY,,1471-2369,10.1186/1471-2369-15-29,,"Background: Many patients on maintenance dialysis experience significant sleepiness and fatigue. However, the influence of the hemodialysis (HD) day and circadian rhythms on patients' symptoms have not been well characterized. We sought to use ecological momentary assessment to evaluate day-to-day and diurnal variability of fatigue, sleepiness, exhaustion and related symptoms in thrice-weekly maintenance HD patients. Methods: Subjects used a modified cellular phone to access an interactive voice response system that administered the Daytime Insomnia Symptom Scale (DISS). The DISS assessed subjective vitality, mood, and alertness through 19 questions using 7-point Likert scales. Subjects completed the DISS 4 times daily for 7 consecutive days. Factor analysis was conducted and a mean composite score of fatigue-sleepiness-exhaustion was created. Linear mixed regression models (LMM) were used to examine the association of time of day, dialysis day and fatigue, sleepiness, and exhaustion composite scores. Results: The 55 participants completed 1,252 of 1,540 (81%) possible assessments over the 7 day period. Multiple symptoms related to mood (e.g., feeling sad, feeling tense), cognition (e. g., difficulty concentrating), and fatigue (e.g., exhaustion, feeling sleepy) demonstrated significant daily and diurnal variation, with higher overall symptom scores noted on hemodialysis days and later in the day. In factor analysis, 4 factors explained the majority of the observed variance for DISS symptoms. Fatigue, sleepiness, and exhaustion loaded onto the same factor and were highly intercorrelated. In LMM, mean composite fatigue-sleepiness-exhaustion scores were associated with dialysis day (coefficient and 95% confidence interval [CI] 0.21 [0.02 - 0.39]) and time of day (coefficient and 95% CI 0.33 [0.25 - 0.41]. Observed associations were minimally affected by adjustment for demographics and common confounders. Conclusions: Maintenance HD patients experience fatigue-sleepiness-exhaustion symptoms that demonstrate significant daily and diurnal variation. The variability in symptoms may contribute to poor symptom awareness by providers and greater misclassification bias of fatigue related symptoms in clinical studies.",06/02/2014,01/07/2022 10:40,01/07/2022 10:40,,,,,15,,,,,,,,,,,,,,WOS:000332128500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SYZWEKXV,journalArticle,2016,"Schwimmer, JB",Clinical advances in pediatric nonalcoholic fatty liver disease,HEPATOLOGY,,0270-9139,10.1002/hep.28441,,,2016-05,01/07/2022 10:40,01/07/2022 10:40,,1718-1725,,5,63,,,,,,,,,,,,,,WOS:000374738000031,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8GSBZXZB,journalArticle,2009,"Sammalisto, S; Hiekkalinna, T; Schwander, K; Kardia, S; Weder, AB; Rodriguez, BL; Doria, A; Kelly, JA; Bruner, GR; Harley, JB; Redline, S; Larkin, EK; Patel, SR; Ewan, AJH; Weber, JL; Perola, M; Peltonen, L",Genome-wide linkage screen for stature and body mass index in 3.032 families: evidence for sex- and population-specific genetic effects,EUROPEAN JOURNAL OF HUMAN GENETICS,,1018-4813,10.1038/ejhg.2008.152,,"Stature (adult body height) and body mass index (BMI) have a strong genetic component explaining observed variation in human populations; however, identifying those genetic components has been extremely challenging. It seems obvious that sample size is a critical determinant for successful identification of quantitative trait loci (QTL) that underlie the genetic architecture of these polygenic traits. The inherent shared environment and known genetic relationships in family studies provide clear advantages for gene mapping over studies utilizing unrelated individuals. To these ends, we combined the genotype and phenotype data from four previously performed family-based genome-wide screens resulting in a sample of 9.371 individuals from 3.032 African-American and European-American families and performed variance-components linkage analyses for stature and BMI. To our knowledge, this study represents the single largest family-based genome-wide linkage scan published for stature and BMI to date. This large study sample allowed us to pursue population- and sex-specific analyses as well. For stature, we found evidence for linkage in previously reported loci on 11q23, 12q12, 15q25 and 18q23, as well as 15q26 and 19q13, which have not been linked to stature previously. For BMI, we found evidence for two loci: one on 7q35 and another on 11q22, both of which have been previously linked to BMI in multiple populations. Our results show both the benefit of (1) combining data to maximize the sample size and (2) minimizing heterogeneity by analyzing subgroups where within-group variation can be reduced and suggest that the latter may be a more successful approach in genetic mapping.",2009-02,01/07/2022 10:40,01/07/2022 10:40,,258-266,,2,17,,,,,,,,,,,,,,WOS:000262499600019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CTSJHJ9H,journalArticle,2014,"Bohm, M; Linz, D; Ukena, C; Esler, M; Mahfoud, F",Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?,CIRCULATION RESEARCH,,0009-7330,10.1161/CIRCRESAHA.115.302522,,"Hypertension imposes a major burden of morbidity and mortality and is associated with sympathetic nervous system overactivity. Renal sympathetic denervation has been shown to reduce office blood pressure, ambulatory blood pressure, and sympathetic activity in patients with resistant hypertension. Therefore, the procedure has attracted a lot of attention. Beyond blood pressure, renal denervation has been shown to improve glucose tolerance, microalbuminuria, and arrhythmias in several experimental models and, in admittedly, often uncontrolled clinical studies. It has been demonstrated to reduce myocardial hypertrophy in a blood pressure-independent and blood pressure-dependent way. The first studies on heart failure with preserved and reduced ejection fraction are ongoing. Renal sympathetic denervation holds promise for future indications in hypertension and related comorbidities and consequences, such as metabolic disease, renal failure, and heart failure. Published data in a placebo-control blinded study, however, are needed. The aim of this review is to provide a critical and comprehensive overview of heretofore generated data on renal denervation in experimental models, in human hypertension, and on early developments in new indications, which should indicate the way to powered and performed, controlled clinical studies appropriately.",18/07/2014,01/07/2022 10:40,01/07/2022 10:40,,400-409,,3,115,,,,,,,,,,,,,,WOS:000339272700011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CGQW63XL,journalArticle,2019,"Tsutsui, H; Isobe, M; Ito, H; Okumura, K; Ono, M; Kitakaze, M; Kinugawa, K; Kihara, Y; Goto, Y; Komuro, I; Saiki, Y; Saito, Y; Sakata, Y; Sato, N; Sawa, Y; Shiose, A; Shimizu, W; Shimokawa, H; Seino, Y; Node, K; Higo, T; Hirayama, A; Makaya, M; Masuyama, T; Murohara, T; Momomura, S; Yano, M; Yamazaki, K; Yamamoto, K; Yoshikawa, T; Yoshimura, M; Akiyama, M; Anzai, T; Ishihara, S; Inomata, T; Imamura, T; Iwasaki, Y; Ohtani, T; Onishi, K; Kasai, T; Kato, M; Kawai, M; Kinugasa, Y; Kinugawa, S; Kuratani, T; Kobayashi, S; Sakata, Y; Tanaka, A; Toda, K; Noda, T; Nochioka, K; Hatano, M; Hidaka, T; Fujino, T; Makita, S; Yamaguchi, O; Ikeda, U; Kimura, T; Kohsaka, S; Kosuge, M; Yamagishi, M; Yamashina, A; Japanese Circulation Soc; Japanese Circulation Soc; Japanese Heart Failure Soc Join",JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version -,CIRCULATION JOURNAL,,1346-9843,10.1253/circj.CJ-19-0342,,,2019-10,01/07/2022 10:40,01/07/2022 10:40,,2084-2184,,10,83,,,,,,,,,,,,,,WOS:000487717600021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6S8EKGV6,journalArticle,2021,"Shakya, PR; Melaku, YA; Page, AJ; Gill, TK",Nutrient patterns and depressive symptoms among Australian adults,EUROPEAN JOURNAL OF NUTRITION,,1436-6207,10.1007/s00394-020-02243-y,,"Purpose Much of the current literature on the associations between diet and depression focus on single nutrients rather than nutrient patterns (NPs). We investigated the association between NPs and depressive symptoms (DepS) in an Australian adult population. Methods DepS were examined at two different time points, in 2010 (Stage 3, n = 1743, 49.0% males) and 2015 [North West 2015 (NW15), n = 1,024, 46.6% males] of the North West Adelaide Health Study (NWAHS). Dietary habits were evaluated using a food frequency questionnaire (FFQ) at Stage 3. DepS were assessed using the Center for Epidemiological Studies Depression (CES-D) scale at Stage 3 and NW15. Principal component analysis was used to identify NPs as well as the factor structure of the CES-D. Log- and negative binomial regression analyses were used to assess the association between NPs and DepS scores. Ordinal logistic regression analysis was undertaken between the NPs and identified factors of the CES-D score. Results Three NPs (from the FFQ) and two-factors (from the CES-D score) were obtained. After adjusting for known confounding variables, a 'plant-sourced' NP (beta-carotene, fibre, vitamin C, potassium and alpha-carotene) was inversely associated with DepS at Stage 3 [prevalence ratio (PR)(Q4VsQ1), 0.78; 95% CI 0.66-0.92; p = 0.003], whereas an 'animal-sourced' (omega-3 fatty acid, monounsaturated fat, vitamin E and cholesterol) or 'mixed-source' (phosphorous, protein, vitamin B2, iodine and zinc) NP was not associated with DepS. There was an inverse relationship between the 'plant-sourced' NP and the '(absence of) positive-affect' factor from the CES-D in both stages. Conclusion The 'plant-sourced' NP is consistently and inversely associated with DepS; however, longitudinal studies are recommended to confirm these results.",2021-02,01/07/2022 10:40,01/07/2022 10:40,,329-343,,1,60,,,,,,,,,,,,,,WOS:000528509600002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCFHTG7V,journalArticle,2020,"Alligier, M; Barres, R; Blaak, EE; Boirie, Y; Bouwman, J; Brunault, P; Campbell, K; Clement, K; Farooqi, IS; Farpour-Lambert, NJ; Fruhbeck, G; Goossens, GH; Hager, J; Halford, JCG; Hauner, H; Jacobi, D; Julia, C; Langin, D; Natali, A; Neovius, M; Oppert, JM; Pagotto, U; Palmeira, AL; Roche, H; Ryden, M; Scheen, AJ; Simon, C; Sorensen, TIA; Tappy, L; Yki-Jarvinen, H; Ziegler, O; Laville, M","OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions",OBESITY FACTS,,1662-4025,10.1159/000505342,,"Heterogeneity of interindividual and intraindividual responses to interventions is often observed in randomized, controlled trials for obesity. To address the global epidemic of obesity and move toward more personalized treatment regimens, the global research community must come together to identify factors that may drive these heterogeneous responses to interventions. This project, called OBEDIS (OBEsity Diverse Interventions Sharing - focusing on dietary and other interventions), provides a set of European guidelines for a minimal set of variables to include in future clinical trials on obesity, regardless of the specific endpoints. Broad adoption of these guidelines will enable researchers to harmonize and merge data from multiple intervention studies, allowing stratification of patients according to precise phenotyping criteria which are measured using standardized methods. In this way, studies across Europe may be pooled for better prediction of individuals' responses to an intervention for obesity - ultimately leading to better patient care and improved obesity outcomes.",2020-02,01/07/2022 10:40,01/07/2022 10:40,,Jan-28,,1,13,,,,,,,,,,,,,,WOS:000518585900001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BV733IRH,journalArticle,2018,"Khoury, P; Akuthota, P; Ackerman, SJ; Arron, JR; Bochner, BS; Collins, MH; Kahn, JE; Fulkerson, PC; Gleich, GJ; Gopal-Srivastava, R; Jacobsen, EA; Leiferman, KM; Francesca, LS; Mathur, SK; Minnicozzi, M; Prussin, C; Rothenberg, ME; Roufosse, F; Sable, K; Simon, D; Simon, HU; Spencer, LA; Steinfeld, J; Wardlaw, AJ; Wechsler, ME; Weller, PF; Klion, AD",Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD),JOURNAL OF LEUKOCYTE BIOLOGY,,0741-5400,10.1002/JLB.5MR0118-028R,,"Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority. Review on eosinophil biology and eosinophil-related disorders (2012-2017) with a focus on continued unmet needs in eosinophil-associated diseases.",2018-07,01/07/2022 10:40,01/07/2022 10:40,,69-83,,1,104,,,,,,,,,,,,,,WOS:000435944300008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
CRBYENDC,journalArticle,2019,"Clifford, SA; Davies, S; Wake, M; Azzopardi, PS; Baur, LA; Burgner, DP; Carlin, JB; Cheung, M; Dwyer, T; Edwards, B; Ellul, S; Gillespie, AN; Gold, L; Grobler, AC; Kerr, JA; Lycett, K; Lange, K; Mensah, FK; Olds, TS; Ranganathan, S; Rogers, H; Saffery, R; Sawyer, M; Simm, PJ; Stevens, L; Wong, TY; Zubrick, SR; Child Hlth CheckPoint Team",Child Health CheckPoint: cohort summary and methodology of a physical health and biospecimen module for the Longitudinal Study of Australian Children,BMJ OPEN,,2044-6055,10.1136/bmjopen-2017-020261,,"Objectives 'Growing Up in Australia: The Longitudinal Study of Australian Children' (LSAC) is Australia's only nationally representative children's longitudinal study, focusing on social, economic, physical and cultural impacts on health, learning, social and cognitive development. LSAC's first decade collected wide-ranging repeated psychosocial and administrative data; here, we describe the Child Health CheckPoint, LSAC's dedicated biophysical module. Design, setting and participants LSAC recruited a cross-sequential sample of 5107 infants aged 0-1 year and a sample of 4983 children aged 4-5 years in 2004, since completing seven biennial visits. CheckPoint was a cross-sectional wave that travelled Australia in 2015-2016 to reach LSAC's younger cohort at ages 11-12 years between LSAC waves 6 and 7. Parent-child pairs participated in comprehensive assessments at 15 Assessment Centres nationwide or, if unable to attend, a shorter home visit. Measures CheckPoint's intergenerational, multidimensional measures were prioritised to show meaningful variation within normal ranges and capture non-communicable disease (NCD) phenotype precursors. These included anthropometry, physical activity, fitness, time use, vision, hearing, and cardiovascular, respiratory and bone health. Biospecimens included blood, saliva, buccal swabs (also from second parent), urine, hair and toenails. The epidemiology and parent-child concordance of many measures are described in separate papers. Results 1874 (54% of eligible) parent-child pairs and 1051 second parents participated. Participants' geographical distribution mirrored the broader Australian population; however, mean socioeconomic position and parental education were higher and fewer reported non-English-speaking or Indigenous backgrounds. Application of survey weights partially mitigates that the achieved sample is less population representative than previous waves of LSAC due to non-random attrition. Completeness was uniformly high for phenotypic data (>92% of eligible), biospecimens (74%-97%) and consent (genetic analyses 98%, accessing neonatal blood spots 97%, sharing 96%). Conclusions CheckPoint enriches LSAC to study how NCDs develop at the molecular and phenotypic levels before overt disease emerges, and clarify the underlying dimensionality of health in childhood and mid-adulthood.",04/07/2019,01/07/2022 10:40,01/07/2022 10:40,,Mar-22,,,9,,,,,,,,,,,,,,WOS:000477729200002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MGNTP44N,journalArticle,2021,"Bousquet, J; Anto, JM; Bachert, C; Haahtela, T; Zuberbier, T; Czarlewski, W; Bedbrook, A; Bosnic-Anticevich, S; Canonica, GW; Cardona, V; Costa, E; Cruz, AA; Erhola, M; Fokkens, WJ; Fonseca, JA; Illario, M; Ivancevich, JC; Jutel, M; Klimek, L; Kuna, P; Kvedariene, V; Le, L; Larenas-Linnemann, DE; Laune, D; Lourenco, OM; Melen, E; Mullol, J; Niedoszytko, M; Odemyr, M; Okamoto, Y; Papadopoulos, NG; Patella, V; Pfaar, O; Pham-Thi, N; Rolland, C; Samolinski, B; Sheikh, A; Sofiev, M; Ulrik, CS; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Tsiligianni, I; Valiulis, A; Valovirta, E; Ventura, MT; Walker, S; Williams, S; Yorgancioglu, A; Agache, I; Akdis, CA; Almeida, R; Ansotegui, IJ; Annesi-Maesano, I; Arnavielhe, S; Basagana, X; Bateman, ED; Bedard, A; Bedolla-Barajas, M; Becker, S; Bennoor, KS; Benveniste, S; Bergmann, KC; Bewick, M; Bialek, S; Billo, NE; Bindslev-Jensen, C; Bjermer, L; Blain, H; Bonini, M; Bonniaud, P; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Boussery, K; Braido, F; Briedis, V; Briggs, A; Brightling, CE; Brozek, J; Brusselle, G; Brussino, L; Buhl, R; Buonaiuto, R; Calderon, MA; Camargos, P; Camuzat, T; Caraballo, L; Carriazo, AM; Carr, W; Cartier, C; Casale, T; Cecchi, L; Sarabia, ACM; Chavannes, NH; Chkhartishvili, E; Chu, DRK; Cingi, C; de Sousa, JC; Costa, DJ; Courbis, AL; Custovic, A; Cvetkosvki, B; D'Amato, G; da Silva, J; Dantas, C; Dokic, D; Dauvilliers, Y; De Feo, G; De Vries, G; Devillier, P; Di Capua, S; Dray, G; Dubakiene, R; Durham, SR; Dykewicz, M; Ebisawa, M; Gaga, M; El-Gamal, Y; Heffler, E; Emuzyte, R; Farrell, J; Fauquert, JL; Fiocchi, A; Fink-Wagner, A; Fontaine, JF; Perez, JMF; Gemicioglu, B; Gamkrelidze, A; Garcia-Aymerich, J; Gevaert, P; Gomez, RM; Diaz, SG; Gotua, M; Guldemond, NA; Guzman, MA; Hajjam, J; Villalobos, YHR; Humbert, M; Iaccarino, G; Ierodiakonou, D; Iinuma, T; Jassem, E; Joos, G; Jung, KS; Kaidashev, I; Kalayci, O; Kardas, P; Keil, T; Khaitov, M; Khaltaev, N; Kleine-Tebbe, J; Kouznetsov, R; Kowalski, ML; Kritikos, V; Kull, I; La Grutta, S; Leonardini, L; Ljungberg, H; Lieberman, P; Lipworth, B; Carlsen, KLC; Lopes-Pereira, C; Loureiro, CC; Louis, R; Mair, A; Mahboub, B; Makris, M; Malva, J; Manning, P; Marshall, GD; Masjedi, MR; Maspero, JF; Carreiro-Martins, P; Makela, M; Mathieu-Dupas, E; Maurer, M; Keenoy, ED; Melo-Gomes, E; Meltzer, EO; Menditto, E; Mercier, J; Micheli, Y; Miculinic, N; Mihaltan, F; Milenkovic, B; Mitsias, DI; Moda, G; Mogica-Martinez, MD; Mohammad, Y; Montefort, S; Monti, R; Morais-Almeida, M; Mosges, R; Munter, L; Muraro, A; Murray, R; Naclerio, R; Napoli, L; Namazova-Baranova, L; Neffen, H; Nekam, K; Neou, A; Nordlund, B; Novellino, E; Nyembue, D; O'Hehir, R; Ohta, K; Okubo, K; Onorato, GL; Orlando, V; Ouedraogo, S; Palamarchuk, J; Pali-Scholl, I; Panzner, P; Park, HS; Passalacqua, G; Pepin, JL; Paulino, E; Pawankar, R; Phillips, J; Picard, R; Pinnock, H; Plavec, D; Popov, TA; Portejoie, F; Price, D; Prokopakis, EP; Psarros, F; Pugin, B; Puggioni, F; Quinones-Delgado, P; Raciborski, F; Rajabian-Soderlund, R; Regateiro, FS; Reitsma, S; Rivero-Yeverino, D; Roberts, G; Roche, N; Rodriguez-Zagal, E; Rolland, C; Roller-Wirnsberger, RE; Rosario, N; Romano, A; Rottem, M; Ryan, D; Salimaki, J; Sanchez-Borges, MM; Sastre, J; Scadding, GK; Scheire, S; Schmid-Grendelmeier, P; Schunemann, HJ; Serpa, FS; Shamji, M; Sisul, JC; Sofiev, M; Sole, D; Somekh, D; Sooronbaev, T; Sova, M; Spertini, F; Spranger, O; Stellato, C; Stelmach, R; Thibaudon, M; To, T; Toumi, M; Usmani, O; Valero, AA; Valenta, R; Valentin-Rostan, M; Pereira, MU; van der Kleij, R; Van Eerd, M; Vandenplas, O; Vasankari, T; Carneiro, AV; Vezzani, G; Viart, F; Viegi, G; Wallace, D; Wagenmann, M; Wang, DY; Waserman, S; Wickman, M; Williams, DM; Wong, G; Wroczynski, P; Yiallouros, PK; Yusuf, OM; Zar, HJ; Zeng, SE; Zernotti, ME; Zhang, L; Shan Zhong, N; Zidarn, M",ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice,ALLERGY,,0105-4538,10.1111/all.14422,,"Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.",2021-01,01/07/2022 10:40,01/07/2022 10:40,,168-190,,1,76,,,,,,,,,,,,,,WOS:000581175300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2F3YD9UA,journalArticle,2013,"Thun, GA; Imboden, M; Ferrarotti, I; Kumar, A; Obeidat, M; Zorzetto, M; Haun, M; Curjuric, I; Alves, AC; Jackson, VE; Albrecht, E; Ried, JS; Teumer, A; Lopez, LM; Huffman, JE; Enroth, S; Bosse, Y; Hao, K; Timens, W; Gyllensten, U; Polasek, O; Wilson, JF; Rudan, I; Hayward, C; Sandford, AJ; Deary, IJ; Koch, B; Reischl, E; Schulz, H; Hui, J; James, AL; Rochat, T; Russi, EW; Jarvelin, MR; Strachan, DP; Hall, IP; Tobin, MD; Dahl, M; Nielsen, SF; Nordestgaard, BG; Kronenberg, F; Luisetti, M; Probst-Hensch, NM",Causal and Synthetic Associations of Variants in the SERPINA Gene Cluster with Alpha1-antitrypsin Serum Levels,PLOS GENETICS,,1553-7404,10.1371/journal.pgen.1003585,,Several infrequent genetic polymorphisms in the SERPINA1 gene are known to substantially reduce concentration of alpha1-antitrypsin (AAT) in the blood. Since low AAT serum levels fail to protect pulmonary tissue from enzymatic degradation these polymorphisms also increase the risk for early onset chronic obstructive pulmonary disease (COPD). The role of more common SERPINA1 single nucleotide polymorphisms (SNPs) in respiratory health remains poorly understood. We present here an agnostic investigation of genetic determinants of circulating AAT levels in a general population sample by performing a genome-wide association study (GWAS) in 1392 individuals of the SAPALDIA cohort. Five common SNPs defined by showing minor allele frequencies (MAFs) >5% reached genome-wide significance all located in the SERPINA gene cluster at 14q32.13. The top-ranking genotyped SNP rs4905179 was associated with an estimated effect of beta = 20.068 g/L per minor allele (P = 1.20*10(-12)). But denser SERPINA1 locus genotyping in 5569 participants with subsequent stepwise conditional analysis as well as exon-sequencing in a subsample (N = 410) suggested that AAT serum level is causally determined at this locus by rare (MAF<1%) and low-frequent (MAF 1-5%) variants only in particular by the well-documented protein inhibitor S and Z (PI S PI Z) variants. Replication of the association of rs4905179 with AAT serum levels in the Copenhagen City Heart Study (N = 8273) was successful (P<0.0001) as was the replication of its synthetic nature (the effect disappeared after adjusting for PI S and Z P = 0.57). Extending the analysis to lung function revealed a more complex situation. Only in individuals with severely compromised pulmonary health (N = 397) associations of common SNPs at this locus with lung function were driven by rarer PI S or Z variants. Overall our meta-analysis of lung function in ever-smokers does not support a functional role of common SNPs in the SERPINA gene cluster in the general population.,2013-08,01/07/2022 10:40,01/07/2022 10:40,,,,8,9,,,,,,,,,,,,,,WOS:000323830300003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
53969TME,journalArticle,2017,"Baumgartner, C; da Costa, BR; Collet, TH; Feller, M; Floriani, C; Bauer, DC; Cappola, AR; Heckbert, SR; Ceresini, G; Gussekloo, J; den Elzen, WPJ; Peeters, RP; Luben, R; Volzke, H; Dorr, M; Walsh, JP; Bremner, A; Iacoviello, M; Macfarlane, P; Heeringa, J; Stott, DJ; Westendorp, RGJ; Khaw, KT; Magnani, JW; Aujesky, D; Rodondi, N; Thyroid Studies Collaboration","Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation",CIRCULATION,,0009-7322,10.1161/CIRCULATIONAHA.117.028753,,"Background: Atrial fibrillation (AF) is a highly prevalent disorder leading to heart failure, stroke, and death. Enhanced understanding of modifiable risk factors may yield opportunities for prevention. The risk of AF is increased in subclinical hyperthyroidism, but it is uncertain whether variations in thyroid function within the normal range or subclinical hypothyroidism are also associated with AF. Methods: We conducted a systematic review and obtained individual participant data from prospective cohort studies that measured thyroid function at baseline and assessed incident AF. Studies were identified from MEDLINE and EMBASE databases from inception to July 27, 2016. The euthyroid state was defined as thyroid-stimulating hormone (TSH) 0.45 to 4.49 mIU/L, and subclinical hypothyroidism as TSH 4.5 to 19.9 mIU/L with free thyroxine (fT4) levels within reference range. The association of TSH levels in the euthyroid and subclinical hypothyroid range with incident AF was examined by using Cox proportional hazards models. In euthyroid participants, we additionally examined the association between fT4 levels and incident AF. Results: Of 30085 participants from 11 cohorts (278955 person-years of follow-up), 1958 (6.5%) had subclinical hypothyroidism and 2574 individuals (8.6%) developed AF during follow-up. TSH at baseline was not significantly associated with incident AF in euthyroid participants or those with subclinical hypothyroidism. Higher fT4 levels at baseline in euthyroid individuals were associated with increased AF risk in age- and sex-adjusted analyses (hazard ratio, 1.45; 95% confidence interval, 1.26-1.66, for the highest quartile versus the lowest quartile of fT4; P for trend <= 0.001 across quartiles). Estimates did not substantially differ after further adjustment for preexisting cardiovascular disease. Conclusions: In euthyroid individuals, higher circulating fT4 levels, but not TSH levels, are associated with increased risk of incident AF.",28/11/2017,01/07/2022 10:40,01/07/2022 10:40,,2100-2116,,22,136,,,,,,,,,,,,,,WOS:000416242600002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
JQJD4VP4,journalArticle,2012,"Wilk, JB; Shrine, NRG; Loehr, LR; Zhao, JH; Manichaikul, A; Lopez, LM; Smith, AV; Heckbert, SR; Smolonska, J; Tang, WB; Loth, DW; Curjuric, I; Hui, J; Cho, MH; Latourelle, JC; Henry, AP; Aldrich, M; Bakke, P; Beaty, TH; Bentley, AR; Borecki, IB; Brusselle, GG; Burkart, KM; Chen, TH; Couper, D; Crapo, JD; Davies, G; Dupuis, J; Franceschini, N; Gulsvik, A; Hancock, DB; Harris, TB; Hofman, A; Imboden, M; James, AL; Khaw, KT; Lahousse, L; Launer, LJ; Litonjua, A; Liu, YM; Lohman, KK; Lomas, DA; Lumley, T; Marciante, KD; McArdle, WL; Meibohm, B; Morrison, AC; Musk, AW; Myers, RH; North, KE; Postma, DS; Psaty, BM; Rich, SS; Rivadeneira, F; Rochat, T; Rotter, JI; Artigas, MS; Starr, JM; Uitterlinden, AG; Wareham, NJ; Wijmenga, C; Zanen, P; Province, MA; Silverman, EK; Deary, IJ; Palmer, LJ; Cassano, PA; Gudnason, V; Barr, RG; Loos, RJF; Strachan, DP; London, SJ; Boezen, HM; Probst-Hensch, N; Gharib, SA; Hall, IP; O'Connor, GT; Tobin, MD; Stricker, BH",Genome-Wide Association Studies Identify CHRNA5/3 and HTR4 in the Development of Airflow Obstruction,AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,,1073-449X,10.1164/rccm.201202-0366OC,,"Rationale: Genome-wide association studies (GWAS) have identified loci influencing lung function, but fewer genes influencing chronic obstructive pulmonary disease (COPD) are known. Objectives: Perform meta-analyses of GWAS for airflow obstruction, a key pathophysiologic characteristic of COPD assessed by spirometry, in population-based cohorts examining all participants, ever smokers, never smokers, asthma-free participants, and more severe cases. Methods: Fifteen cohorts were studied for discovery (3,368 affected; 29,507 unaffected), and a population-based family study and a meta-analysis of case-control studies were used for replication and regional follow-up (3,837 cases; 4,479 control subjects). Airflow obstruction was defined as FEV1 and its ratio to FVC (FEV1/FVC) both less than their respective lower limits of normal as determined by published reference equations. Measurements and Main Results: The discovery meta-analyses identified one region on chromosome 15q25.1 meeting genome-wide significance in ever smokers that includes AGPHD1, IREB2, and CHRNA5/CHRNA3 genes. The region was also modestly associated among never smokers. Gene expression studies confirmed the presence of CHRNA5/3 in lung, airway smooth muscle, and bronchial epithelial cells. A single-nucleotide polymorphism in HTR4, a gene previously related to FEV1/FVC, achieved genome-wide statistical significance in combined meta-analysis. Top single-nucleotide polymorphisms in ADAM19, RARB, PPAP2B, and ADAMTS19 were nominally replicated in the COPD meta-analysis. Conclusions: These results suggest an important role for the CHRNA5/3 region as a genetic risk factor for airflow obstruction that may be independent of smoking and implicate the HTR4 gene in the etiology of airflow obstruction.",01/10/2012,01/07/2022 10:40,01/07/2022 10:40,,622-632,,7,186,,,,,,,,,,,,,,WOS:000309383600013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8PSFKL7J,journalArticle,2017,"Wain, LV; Vaez, A; Jansen, R; Joehanes, R; van der Most, PJ; Erzurumluoglu, AM; O'Reilly, PF; Cabrera, CP; Warren, HR; Rose, LM; Verwoert, GC; Hottenga, JJ; Strawbridge, RJ; Esko, T; Arking, DE; Hwang, SJ; Guo, XQ; Kutalik, Z; Trompet, S; Shrine, N; Teumer, A; Ried, JS; Bis, JC; Smith, AV; Amin, N; Nolte, IM; Lyytikainen, LP; Mahajan, A; Wareham, NJ; Hofer, E; Joshi, PK; Kristiansson, K; Traglia, M; Havulinna, AS; Goel, A; Nalls, MA; Sober, S; Vuckovic, D; Luan, JA; Del Greco, F; Ayers, KL; Marrugat, J; Ruggiero, D; Lopez, LM; Niiranen, T; Enroth, S; Jackson, AU; Nelson, CP; Huffman, JE; Zhang, WH; Marten, J; Gandin, I; Harris, SE; Zemunik, T; Lu, YC; Evangelou, E; Shah, N; de Borst, MH; Mangino, M; Prins, BP; Campbell, A; Li-Gao, RF; Chauhan, G; Oldmeadow, C; Abecasis, G; Abedi, M; Barbieri, CM; Barnes, MR; Batini, C; Beilby, J; Blake, T; Boehnke, M; Bottinger, EP; Braund, PS; Brown, M; Brumat, M; Campbell, H; Chambers, JC; Cocca, M; Collins, F; Connell, J; Cordell, HJ; Damman, JJ; Davies, G; de Geus, EJ; de Mutsert, R; Deelen, J; Demirkale, Y; Doney, ASF; Dorr, M; Farrall, M; Ferreira, T; Franberg, M; Gao, H; Giedraitis, V; Gieger, C; Giulianini, F; Gow, AJ; Hamsten, A; Harris, TB; Hofman, A; Holliday, EG; Hui, JN; Jarvelin, MR; Johansson, A; Johnson, AD; Jousilahti, P; Jula, A; Kahonen, M; Kathiresan, S; Khaw, KT; Kolcic, I; Koskinen, S; Langenberg, C; Larson, M; Launer, LJ; Lehne, B; Liewald, DCM; Lin, L; Lind, L; Mach, F; Mamasoula, C; Menni, C; Mifsud, B; Milaneschi, Y; Morgan, A; Morris, AD; Morrison, AC; Munson, PJ; Nandakumar, P; Nguyen, QT; Nutile, T; Oldehinkel, AJ; Oostra, BA; Org, E; Padmanabhan, S; Palotie, A; Pare, G; Pattie, A; Penninx, BWJH; Poulter, N; Pramstaller, PP; Raitakari, OT; Ren, MX; Rice, K; Ridker, PM; Riese, H; Ripatti, S; Robino, A; Rotter, JI; Rudan, I; Saba, Y; Saint Pierre, A; Sala, CF; Sarin, AP; Schmidt, R; Scott, R; Seelen, MA; Shields, DC; Siscovick, D; Sorice, R; Stanton, A; Stott, DJ; Sundstrom, J; Swertz, M; Taylor, KD; Thom, S; Tzoulaki, I; Tzourio, C; Uitterlinden, AG; Volker, U; Vollenweider, P; Wild, S; Willemsen, G; Wright, AF; Yao, J; Theriault, S; Conen, D; Attia, J; Sever, P; Debette, S; Mook-Kanamori, DO; Zeggini, E; Spector, TD; van der Harst, P; Palmer, CNA; Vergnaud, AC; Loos, RJF; Polasek, O; Starr, JM; Girotto, G; Hayward, C; Kooner, JS; Lindgren, CM; Vitart, V; Samani, NJ; Tuomilehto, J; Gyllensten, U; Knekt, P; Deary, IJ; Ciullo, M; Elosua, R; Keavney, BD; Hicks, AA; Scott, RA; Gasparini, P; Laan, M; Liu, Y; Watkins, H; Hartman, CA; Salomaa, V; Toniolo, D; Perola, M; Wilson, JF; Schmidt, H; Zhao, JH; Lehtimaki, T; van Duijn, CM; Gudnason, V; Psaty, BM; Peters, A; Rettig, R; James, A; Jukema, JW; Strachan, DP; Palmas, W; Metspalu, A; Ingelsson, E; Boomsma, DI; Franco, OH; Bochud, M; Newton-Cheh, C; Munroe, PB; Elliott, P; Chasman, DI; Chakravarti, A; Knight, J; Morris, AP; Levy, D; Tobin, MD; Snieder, H; Caulfield, MJ; Ehret, GB; Alistair, TY; Betholdson, JP; Xiao, LM; BIOS Consortium; Lifelines Cohort Study; Understanding Soc Sci Grp",Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney,HYPERTENSION,,0194-911X,10.1161/HYPERTENSIONAHA.117.09438,,"Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic contribution. Genetic variation influencing blood pressure has the potential to identify new pharmacological targets for the treatment of hypertension. To discover additional novel blood pressure loci, we used 1000 Genomes Project-based imputation in 150 134 European ancestry individuals and sought significant evidence for independent replication in a further 228 245 individuals. We report 6 new signals of association in or near HSPB7, TNXB, LRP12, LOC283335, SEPT9, and AKT2, and provide new replication evidence for a further 2 signals in EBF2 and NFKBIA. Combining large whole-blood gene expression resources totaling 12 607 individuals, we investigated all novel and previously reported signals and identified 48 genes with evidence for involvement in blood pressure regulation that are significant in multiple resources. Three novel kidney-specific signals were also detected. These robustly implicated genes may provide new leads for therapeutic innovation.",2017-09,01/07/2022 10:40,01/07/2022 10:40,,E4-+,,3,70,,,,,,,,,,,,,,WOS:000407241500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49YIA8CZ,journalArticle,2011,"Soler Artigas, M; Loth, DW; Wain, LV; Gharib, SA; Obeidat, M; Tang, WB; Zhai, GJ; Zhao, JH; Smith, AV; Huffman, JE; Albrecht, E; Jackson, CM; Evans, DM; Cadby, G; Fornage, M; Manichaikul, A; Lopez, LM; Johnson, T; Aldrich, MC; Aspelund, T; Barroso, I; Campbell, H; Cassano, PA; Couper, DJ; Eiriksdottir, G; Franceschini, N; Garcia, M; Gieger, C; Gislason, GK; Grkovic, I; Hammond, CJ; Hancock, DB; Harris, TB; Ramasamy, A; Heckbert, SR; Heliovaara, M; Homuth, G; Hysi, PG; Alan, L; Jankovic, S; Joubert, BR; Karrasch, S; Klopp, N; Koch, B; Kritchevsky, SB; Launer, LJ; Liu, YM; Loehr, LR; Lohman, K; Loos, RJF; Lumley, T; Al Balushi, KA; Ang, WQ; Barr, RG; Beilby, J; Blakey, JD; Boban, M; Boraska, V; Brisman, J; Britton, JR; Brusselle, GG; Cooper, C; Curjuric, I; Dahgam, S; Deary, IJ; Ebrahim, S; Eijgelsheim, M; Francks, C; Gaysina, D; Granell, R; Gu, XJ; Hankinson, JL; Hardy, R; Harris, SE; Henderson, J; Henry, A; Hingorani, AD; Hofman, A; Holt, PG; Hui, JN; Hunter, ML; Imboden, M; Jameson, KA; Kerr, SM; Kolcic, I; Kronenberg, F; Liu, JZ; Marchini, J; McKeever, T; Morris, AD; Olin, AC; Porteous, DJ; Postma, DS; Rich, SS; Ring, SM; Rivadeneira, F; Rochat, T; Sayer, AA; Sayers, I; Sly, PD; Smith, GD; Sood, A; Starr, JM; Uitterlinden, AG; Vonk, JM; Wannamethee, SG; Whincup, PH; Wijmenga, C; Williams, OD; Wong, A; Mangino, M; Marciante, KD; McArdle, WL; Meibohm, B; Morrison, AC; North, KE; Omenaas, E; Palmer, LJ; Pietilainen, KH; Pin, I; Polasek, O; Pouta, A; Psaty, BM; Hartikainen, AL; Rantanen, T; Ripatti, S; Rotter, JI; Rudan, I; Rudnicka, AR; Schulz, H; Shin, SY; Spector, TD; Surakka, I; Vitart, V; Volzke, H; Wareham, NJ; Warrington, NM; Wichmann, HE; Wild, SH; Wilk, JB; Wjst, M; Wright, AF; Zgaga, L; Zemunik, T; Pennell, CE; Nyberg, F; Kuh, D; Holloway, JW; Boezen, HM; Lawlor, DA; Morris, RW; Probst-Hensch, N; Kaprio, J; Wilson, JF; Hayward, C; Kahonen, M; Heinrich, J; Musk, AW; Jarvis, DL; Glaser, S; Jarvelin, MR; Stricker, BHC; Elliott, P; O'Connor, GT; Strachan, DP; London, SJ; Hall, IP; Gudnason, V; Tobin, MD; Int Lung Canc Consortium; GIANT Consortium",Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function,NATURE GENETICS,,1061-4036,10.1038/ng.941,,"Pulmonary function measures reflect respiratory health and are used in the diagnosis of chronic obstructive pulmonary disease. We tested genome-wide association with forced expiratory volume in 1 second and the ratio of forced expiratory volume in 1 second to forced vital capacity in 48,201 individuals of European ancestry with follow up of the top associations in up to an additional 46,411 individuals. We identified new regions showing association (combined P < 5 x 10(-8)) with pulmonary function in or near MFAP2, TGFB2, HDAC4, RARB, MECOM (also known as EVI1), SPATA9, ARMC2, NCR3, ZKSCAN3, CDC123, C10orf11, LRP1, CCDC38, MMP15, CFDP1 and KCNE2. Identification of these 16 new loci may provide insight into the molecular mechanisms regulating pulmonary function and into molecular targets for future therapy to alleviate reduced lung function.",2011-11,01/07/2022 10:40,01/07/2022 10:40,,1082-1090,,11,43,,,,,,,,,,,,,,WOS:000296584000011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2VNG2G4K,journalArticle,2015,"Artigas, MS; Wain, LV; Miller, S; Kheirallah, AK; Huffman, JE; Ntalla, I; Shrine, N; Obeidat, M; Trochet, H; McArdle, WL; Alves, AC; Hui, J; Zhao, JH; Joshi, PK; Teumer, A; Albrecht, E; Imboden, M; Rawal, R; Lopez, LM; Marten, J; Enroth, S; Surakka, I; Polasek, O; Lyytikainen, LP; Granell, R; Hysi, PG; Flexeder, C; Mahajan, A; Beilby, J; Bosse, Y; Brandsma, CA; Campbell, H; Gieger, C; Glaser, S; Gonzalez, JR; Grallert, H; Hammond, CJ; Harris, SE; Hartikainen, AL; Heliovaara, M; Henderson, J; Hocking, L; Horikoshi, M; Hutri-Kahonen, N; Ingelsson, E; Johansson, A; Kemp, JP; Kolcic, I; Kumar, A; Lind, L; Melen, E; Musk, AW; Navarro, P; Nickle, DC; Padmanabhan, S; Raitakari, OT; Ried, JS; Ripatti, S; Schulz, H; Scott, RA; Sin, DD; Starr, JM; Vinuela, A; Volzke, H; Wild, SH; Wright, AF; Zemunik, T; Jarvis, DL; Spector, TD; Evans, DM; Lehtimaki, T; Vitart, V; Kahonen, M; Gyllensten, U; Rudan, I; Deary, IJ; Karrasch, S; Probst-Hensch, NM; Heinrich, J; Stubbe, B; Wilson, JF; Wareham, NJ; James, AL; Morris, AP; Jarvelin, MR; Hayward, C; Sayers, I; Strachan, DP; Hall, IP; Tobin, MD; Deloukas, P; Hansell, AL; Hubbard, R; Jackson, VE; Marchini, J; Pavord, I; Thomson, NC; Zeggini, E; UK BiLEVE",Sixteen new lung function signals identified through 1000 Genomes Project reference panel imputation,NATURE COMMUNICATIONS,,2041-1723,10.1038/ncomms9658,,"Lung function measures are used in the diagnosis of chronic obstructive pulmonary disease. In 38,199 European ancestry individuals, we studied genome-wide association of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC with 1000 Genomes Project (phase 1)-imputed genotypes and followed up top associations in 54,550 Europeans. We identify 14 novel loci (P < 5 x 10(-8)) in or near ENSA, RNU5F-1, KCNS3, AK097794, ASTN2, LHX3, CCDC91, TBX3, TRIP11, RIN3, TEKT5, LTBP4, MN1 and AP1S2, and two novel signals at known loci NPNT and GPR126, providing a basis for new understanding of the genetic determinants of these traits and pulmonary diseases in which they are altered.",2015-12,01/07/2022 10:40,01/07/2022 10:40,,,,,6,,,,,,,,,,,,,,WOS:000367589100001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2LPGXWBC,journalArticle,,"Graham, SE; Clarke, SL; Wu, KHH; Kanoni, S; Zajac, GJM; Ramdas, S; Surakka, I; Ntalla, I; Vedantam, S; Winkler, TW; Locke, AE; Marouli, E; Hwang, MY; Han, S; Narita, A; Choudhury, A; Bentley, AR; Ekoru, K; Verma, A; Trivedi, B; Martin, HC; Hunt, KA; Hui, Q; Klarin, D; Zhu, X; Thorleifsson, G; Helgadottir, A; Gudbjartsson, DF; Holm, H; Olafsson, I; Akiyama, M; Sakaue, S; Terao, C; Kanai, M; Zhou, W; Brumpton, B; Rasheed, H; Ruotsalainen, SE; Havulinna, AS; Veturi, Y; Feng, QP; Rosenthal, EA; Lingren, T; Pacheco, JA; Pendergrass, SA; Haessler, J; Giulianini, F; Bradford, Y; Miller, JE; Campbell, A; Lin, K; Millwood, IY; Hindy, G; Rasheed, A; Faul, JD; Zhao, W; Weir, DR; Turman, C; Huang, HY; Graff, M; Mahajan, A; Brown, MR; Zhang, WH; Yu, KT; Schmidt, EM; Pandit, A; Gustafsson, S; Yin, XY; Luan, JA; Zhao, JH; Matsuda, F; Jang, HM; Yoon, K; Medina-Gomez, C; Pitsillides, A; Hottenga, JJ; Willemsen, G; Wood, AR; Ji, YJ; Gao, ZS; Haworth, S; Mitchell, RE; Chai, JF; Aadahl, M; Yao, J; Manichaikul, A; Warren, HR; Ramirez, J; Bork-Jensen, J; Karhus, LL; Goel, A; Sabater-Lleal, M; Noordam, R; Sidore, C; Fiorillo, E; McDaid, AF; Marques-Vidal, P; Wielscher, M; Trompet, S; Sattar, N; Mollehave, LT; Thuesen, BH; Munz, M; Zeng, LY; Huang, JF; Yang, B; Poveda, A; Kurbasic, A; Lamina, C; Forer, L; Scholz, M; Galesloot, TE; Bradfield, JP; Daw, EW; Zmuda, JM; Mitchell, JS; Fuchsberger, C; Christensen, H; Brody, JA; Feitosa, MF; Wojczynski, MK; Preuss, M; Mangino, M; Christofidou, P; Verweij, N; Benjamins, JW; Engmann, J; Kember, RL; Slieker, RC; Lo, KS; Zilhao, NR; Le, P; Kleber, ME; Delgado, GE; Huo, S; Ikeda, DD; Iha, H; Yang, J; Liu, J; Leonard, HL; Marten, J; Schmidt, B; Arendt, M; Smyth, LJ; Canadas-Garre, M; Wang, CL; Nakatochi, M; Wong, A; Hutri-Kahonen, N; Sim, XL; Xia, R; Huerta-Chagoya, A; Fernandez-Lopez, JC; Lyssenko, V; Ahmed, M; Jackson, AU; Irvin, MR; Oldmeadow, C; Kim, HN; Ryu, S; Timmers, PRHJ; Arbeeva, L; Dorajoo, R; Lange, LA; Chai, XR; Prasad, G; Lores-Motta, L; Pauper, M; Long, JR; Li, XH; Theusch, E; Takeuchi, F; Spracklen, CN; Loukola, A; Bollepalli, S; Warner, SC; Wang, YX; Wei, WB; Nutile, T; Ruggiero, D; Sung, YJ; Hung, YJ; Chen, SF; Liu, FC; Yang, JY; Kentistou, KA; Gorski, M; Brumat, M; Meidtner, K; Bielak, LF; Smith, JA; Hebbar, P; Farmaki, AE; Hofer, E; Lin, MX; Xue, C; Zhang, JF; Concas, MP; Vaccargiu, S; van der Most, PJ; Pitkanen, N; Cade, BE; Lee, J; van der Laan, SW; Chitrala, KN; Weiss, S; Zimmermann, ME; Lee, JY; Choi, HS; Nethander, M; Freitag-Wolf, S; Southam, L; Rayner, NW; Wang, CA; Lin, SY; Wang, JS; Couture, C; Lyytikainen, LP; Nikus, K; Cuellar-Partida, G; Vestergaard, H; Hildalgo, B; Giannakopoulou, O; Cai, QY; Obura, MO; van Setten, J; Li, XY; Schwander, K; Terzikhan, N; Shin, JH; Jackson, RD; Reiner, AP; Martin, LW; Chen, ZM; Li, LM; Highland, HM; Young, KL; Kawaguchi, T; Thiery, J; Bis, JC; Nadkarni, GN; Launer, LJ; Li, HX; Nalls, MA; Raitakari, OT; Ichihara, S; Wild, SH; Nelson, CP; Campbell, H; Jager, S; Nabika, T; Al-Mulla, F; Niinikoski, H; Braund, PS; Kolcic, I; Kovacs, P; Giardoglou, T; Katsuya, T; Bhatti, F; de Kleijn, D; de Borst, GJ; Kim, EK; Adams, HHH; Ikram, MA; Zhu, XF; Asselbergs, FW; Kraaijeveld, AO; Beulens, JWJ; Shu, XO; Rallidis, LS; Pedersen, O; Hansen, T; Mitchell, P; Hewitt, AW; Kahonen, M; Perusse, L; Bouchard, C; Tonjes, A; Chen, YDI; Pennell, CE; Mori, TA; Lieb, W; Franke, A; Ohlsson, C; Mellstrom, D; Cho, YS; Lee, H; Yuan, JM; Koh, WP; Rhee, SY; Woo, JT; Heid, IM; Stark, KJ; Volzke, H; Homuth, G; Evans, MK; Zonderman, AB; Polasek, O; Pasterkamp, G; Hoefer, IE; Redline, S; Pahkala, K; Oldehinkel, AJ; Snieder, H; Biino, G; Schmidt, R; Schmidt, H; Chen, YE; Bandinelli, S; Dedoussis, G; Thanaraj, TA; Kardia, SLR; Kato, N; Schulze, MB; Girotto, G; Jung, B; Boger, CA; Joshi, PK; Bennett, DA; De Jager, PL; Lu, XF; Mamakou, V; Brown, M; Caulfield, MJ; Munroe, PB; Guo, XQ; Ciullo, M; Jonas, JB; Samani, NJ; Kaprio, J; Pajukanta, P; Adair, LS; Bechayda, SA; de Silva, HJ; Wickremasinghe, AR; Krauss, RM; Wu, JY; Zheng, W; den Hollander, AI; Bharadwaj, D; Correa, A; Wilson, JG; Lind, L; Heng, CK; Nelson, AE; Golightly, YM; Wilson, JF; Penninx, B; Kim, HL; Attia, J; Scott, RJ; Rao, DC; Arnett, DK; Walker, M; Koistinen, HA; Chandak, GR; Yajnik, CS; Mercader, JM; Tusie-Luna, T; Aguilar-Salinas, CA; Villalpando, CG; Orozco, L; Fornage, M; Tai, ES; van Dam, RM; Lehtimaki, T; Chaturvedi, N; Yokota, M; Liu, J; Reilly, DF; McKnight, AJ; Kee, F; Jockel, KH; McCarthy, MI; Palmer, CNA; Vitart, V; Hayward, C; Simonsick, E; van Duijn, CM; Lu, F; Qu, J; Hishigaki, H; Lin, X; Marz, W; Parra, EJ; Cruz, M; Gudnason, V; Tardif, JC; Lettre, G; 't Hart, LM; Elders, PJM; Damrauer, SM; Kumari, M; Kivimaki, M; van der Harst, P; Spector, TD; Loos, RJF; Province, MA; Psaty, BM; Brandslund, I; Pramstaller, PP; Christensen, K; Ripatti, S; Widen, E; Hakonarson, H; Grant, SFA; Kiemeney, LALM; de Graaf, J; Loeffler, M; Kronenberg, F; Gu, DF; Erdmann, J; Schunkert, H; Franks, PW; Linneberg, A; Jukema, JW; Khera, AV; Mannikko, M; Jarvelin, MR; Kutalik, Z; Cucca, F; Mook-Kanamori, DO; van Dijk, KW; Watkins, H; Strachan, DP; Grarup, N; Sever, P; Poulter, N; Rotter, JI; Dantoft, TM; Karpe, F; Neville, MJ; Timpson, NJ; Cheng, CY; Wong, TY; Khor, CC; Sabanayagam, C; Peters, A; Gieger, C; Hattersley, AT; Pedersen, NL; Magnusson, PKE; Boomsma, DI; de Geus, EJC; Cupples, LA; van Meurs, JBJ; Ghanbari, M; Rsen, PGL; Huang, W; Kim, YJ; Tabara, Y; Wareham, NJ; Langenberg, C; Zeggini, E; Kuusisto, J; Laakso, M; Ingelsson, E; Abecasis, G; Chambers, JC; Kooner, JS; de Vries, PS; Morrison, AC; North, KE; Daviglus, M; Kraft, P; Martin, NG; Whitfield, JB; Abbas, S; Saleheen, D; Walters, RG; Holmes, MV; Black, C; Smith, BH; Justice, AE; Baras, A; Buring, JE; Ridker, PM; Chasman, DI; Kooperberg, C; Wei, WQ; Jarvik, GP; Namjou, B; Hayes, MG; Ritchie, MD; Jousilahti, P; Salomaa, V; Hveem, K; Asvold, BO; Kubo, M; Kamatani, Y; Okada, Y; Murakami, Y; Thorsteinsdottir, U; Stefansson, K; Ho, YL; Lynch, JA; Rader, DJ; Tsao, PS; Chang, KM; Cho, K; O'Donnell, CJ; Gaziano, JM; Wilson, P; Rotimi, CN; Hazelhurst, S; Ramsay, M; Trembath, RC; van Heel, DA; Tamiya, G; Yamamoto, M; Kim, BJ; Mohlke, KL; Frayling, TM; Hirschhorn, JN; Kathiresan, S; Boehnke, M; Natarajan, P; Peloso, GM; Brown, CD; Morris, AP; Assimes, TL; Deloukas, P; Sun, YV; Willer, CJ",The power of genetic diversity in genome-wide association studies of lipids,NATURE,,0028-0836,10.1038/s41586-021-04064-3,,"Increased blood lipid levels are heritable risk factors of cardiovascular disease with varied prevalence worldwide owing to different dietary patterns and medication use(1). Despite advances in prevention and treatment, in particular through reducing low-density lipoprotein cholesterol levels(2), heart disease remains the leading cause of death worldwide(3). Genome-wideassociation studies (GWAS) of blood lipid levels have led to important biological and clinical insights, as well as new drug targets, for cardiovascular disease. However, most previous GWAS(4-23) have been conducted in European ancestry populations and may have missed genetic variants that contribute to lipid-level variation in other ancestry groups. These include differences in allele frequencies, effect sizes and linkage-disequilibrium patterns(24). Here we conduct a multi-ancestry, genome-wide genetic discovery meta-analysis of lipid levels in approximately 1.65 million individuals, including 350,000 of non-European ancestries. We quantify the gain in studying non-European ancestries and provide evidence to support the expansion of recruitment of additional ancestries, even with relatively small sample sizes. We find that increasing diversity rather than studying additional individuals of European ancestry results in substantial improvements in fine-mapping functional variants and portability of polygenic prediction (evaluated in approximately 295,000 individuals from 7 ancestry groupings). Modest gains in the number of discovered loci and ancestry-specific variants were also achieved. As GWAS expand emphasis beyond the identification of genes and fundamental biology towards the use of genetic variants for preventive and precision medicine(25), we anticipate that increased diversity of participants will lead to more accurate and equitable(26) application of polygenic scores in clinical practice.",,01/07/2022 10:40,01/07/2022 10:40,,,,,,,,,,,,,,,,,,,WOS:000728504500001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
929RIDBS,journalArticle,2016,"Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; Arozena, AA; Adachi, H; Adams, CM; Adams, PD; Adeli, K; Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghiso, J; Airoldi, EM; Ait-Si-Ali, S; Akematsu, T; Akporiaye, ET; Al-Rubeai, M; Albaiceta, GM; Albanese, C; Albani, D; Albert, ML; Aldudo, J; Algul, H; Alirezaei, M; Alloza, I; Almasan, A; Almonte-Beceril, M; Alnemri, ES; Alonso, C; Altan-Bonnet, N; Altieri, DC; Alvarez, S; Alvarez-Erviti, L; Alves, S; Amadoro, G; Amano, A; Amantini, C; Ambrosio, S; Amelio, I; Amer, AO; Amessou, M; Amon, A; An, ZY; Anania, FA; Andersen, SU; Andley, UP; Andreadi, CK; Andrieu-Abadie, N; Anel, A; Ann, DK; Anoopkumar-Dukie, S; Antonioli, M; Aoki, H; Apostolova, N; Aquila, S; Aquilano, K; Araki, K; Arama, E; Aranda, A; Araya, J; Arcaro, A; Arias, E; Arimoto, H; Ariosa, AR; Armstrong, JL; Arnould, T; Arsov, I; Asanuma, K; Askanas, V; Asselin, E; Atarashi, R; Atherton, SS; Atkin, JD; Attardi, LD; Auberger, P; Auburger, G; Aurelian, L; Autelli, R; Avagliano, L; Avantaggiati, ML; Avrahami, L; Awale, S; Azad, N; Bachetti, T; Backer, JM; Bae, DH; Bae, JS; Bae, ON; Bae, SH; Baehrecke, EH; Baek, SH; Baghdiguian, S; Bagniewska-Zadworna, A; Bai, H; Bai, J; Bai, XY; Bailly, Y; Balaji, KN; Balduini, W; Ballabio, A; Balzan, R; Banerjee, R; Banhegyi, G; Bao, HJ; Barbeau, B; Barrachina, MD; Barreiro, E; Bartel, B; Bartolome, A; Bassham, DC; Bassi, MT; Bast, RC; Basu, A; Batista, MT; Batoko, H; Battino, M; Bauckman, K; Baumgarner, BL; Bayer, KU; Beale, R; Beaulieu, JF; Beck, GR; Becker, C; Beckham, JD; Bedard, PA; Bednarski, PJ; Begley, TJ; Behl, C; Behrends, C; Behrens, GMN; Behrns, KE; Bejarano, E; Belaid, A; Belleudi, F; Benard, G; Berchem, G; Bergamaschi, D; Bergami, M; Berkhout, B; Berliocchi, L; Bernard, A; Bernard, M; Bernassola, F; Bertolotti, A; Bess, AS; Besteiro, S; Bettuzzi, S; Bhalla, S; Bhattacharyya, S; Bhutia, SK; Biagosch, C; Bianchi, MW; Biard-Piechaczyk, M; Billes, V; Bincoletto, C; Bingol, B; Bird, SW; Bitoun, M; Bjedov, I; Blackstone, C; Blanc, L; Blanco, GA; Blomhoff, HK; Boada-Romero, E; Bockler, S; Boes, M; Boesze-Battaglia, K; Boise, LH; Bolino, A; Boman, A; Bonaldo, P; Bordi, M; Bosch, J; Botana, LM; Botti, J; Bou, G; Bouche, M; Bouchecareilh, M; Boucher, MJ; Boulton, ME; Bouret, SG; Boya, P; Boyer-Guittaut, M; Bozhkov, PV; Brady, N; Braga, VMM; Brancolini, C; Braus, GH; Bravo-San Pedro, JM; Brennan, LA; Bresnick, EH; Brest, P; Bridges, D; Bringer, MA; Brini, M; Brito, GC; Brodin, B; Brookes, PS; Brown, EJ; Brown, K; Broxmeyer, HE; Bruhat, A; Brum, PC; Brumell, JH; Brunetti-Pierri, N; Bryson-Richardson, RJ; Buch, S; Buchan, AM; Budak, H; Bulavin, DV; Bultman, SJ; Bultynck, G; Bumbasirevic, V; Burelle, Y; Burke, RE; Burmeister, M; Butikofer, P; Caberlotto, L; Cadwell, K; Cahova, M; Cai, DS; Cai, JJ; Cai, Q; Calatayud, S; Camougrand, N; Campanella, M; Campbell, GR; Campbell, M; Campello, S; Candau, R; Caniggia, I; Cantoni, L; Cao, LZ; Caplan, AB; Caraglia, M; Cardinali, C; Cardoso, SM; Carew, JS; Carleton, LA; Carlin, CR; Carloni, S; Carlsson, SR; Carmona-Gutierrez, D; Carneiro, LAM; Carnevali, O; Carra, S; Carrier, A; Carroll, B; Casas, C; Casas, J; Cassinelli, G; Castets, P; Castro-Obregon, S; Cavallini, G; Ceccherini, I; Cecconi, F; Cederbaum, AI; Cena, V; Cenci, S; Cerella, C; Cervia, D; Cetrullo, S; Chaachouay, H; Chae, HJ; Chagin, AS; Chai, CY; Chakrabarti, G; Chamilos, G; Chan, EYW; Chan, MTV; Chandra, D; Chandra, P; Chang, CP; Chang, RCC; Chang, TY; Chatham, JC; Chatterjee, S; Chauhan, S; Che, YS; Cheetham, ME; Cheluvappa, R; Chen, CJ; Chen, G; Chen, GC; Chen, GQ; Chen, HZ; Chen, JW; Chen, JK; Chen, M; Chen, MZ; Chen, PW; Chen, Q; Chen, Q; Chen, SD; Chen, S; Chen, SSL; Chen, W; Chen, WJ; Chen, WQ; Chen, WL; Chen, XM; Chen, YH; Chen, YG; Chen, Y; Chen, YY; Chen, YS; Chen, YJ; Chen, YQ; Chen, YJ; Chen, Z; Chen, Z; Cheng, A; Cheng, CHK; Cheng, H; Cheong, HS; Cherry, S; Chesney, J; Cheung, CHA; Chevet, E; Chi, HC; Chi, SG; Chiacchiera, F; Chiang, HL; Chiarelli, R; Chiariello, M; Chieppa, M; Chin, LS; Chiong, M; Chiu, GNC; Cho, DH; Cho, SG; Cho, WC; Cho, YY; Cho, YS; Choi, AMK; Choi, EJ; Choi, EK; Choi, JY; Choi, ME; Choi, SI; Chou, TF; Chouaib, S; Choubey, D; Choubey, V; Chow, KC; Chowdhury, K; Chu, CT; Chuang, TH; Chun, T; Chung, HW; Chung, TJ; Chung, YL; Chwae, YJ; Cianfanelli, V; Ciarcia, R; Ciechomska, IA; Ciriolo, MR; Cirone, M; Claerhout, S; Clague, MJ; Claria, J; Clarke, PGH; Clarke, R; Clementi, E; Cleyrat, C; Cnop, M; Coccia, EM; Cocco, T; Codogno, P; Coers, J; Cohen, EEW; Colecchia, D; Coletto, L; Coll, NS; Colucci-Guyon, E; Comincini, S; Condello, M; Cook, KL; Coombs, GH; Cooper, CD; Cooper, JM; Coppens, I; Corasaniti, MT; Corazzari, M; Corbalan, R; Corcelle-Termeau, E; Cordero, MD; Corral-Ramos, C; Corti, O; Cossarizza, A; Costelli, P; Costes, S; Costes, S; Coto-Montes, A; Cottet, S; Couve, E; Covey, LR; Cowart, LA; Cox, JS; Coxon, FP; Coyne, CB; Cragg, MS; Craven, RJ; Crepaldi, T; Crespo, JL; Criollo, A; Crippa, V; Cruz, MT; Cuervo, AM; Cuezva, JM; Cui, TX; Cutillas, PR; Czaja, MJ; Czyzyk-Krzeska, MF; Dagda, RK; Dahmen, U; Dai, CS; Dai, WJ; Dai, Y; Dalby, KN; Valle, LD; Dalmasso, G; D'Amelio, M; Damme, M; Darfeuille-Michaud, A; Dargemont, C; Darley-Usmar, VM; Dasarathy, S; Dasgupta, B; Dash, S; Dass, CR; Davey, HM; Davids, LM; Davila, D; Davis, RJ; Dawson, TM; Dawson, VL; Daza, P; de Belleroche, J; de Figueiredo, P; de Figueiredo, RCBQ; de la Fuente, J; De Martino, L; De Matteis, A; De Meyer, GRY; De Milito, A; De Santi, M; de Souza, W; De Tata, V; De Zio, D; Debnath, J; Dechant, R; Decuypere, JP; Deegan, S; Dehay, B; Del Bello, B; Del Re, DP; Delage-Mourroux, R; Delbridge, LMD; Deldicque, L; Delorme-Axford, E; Deng, YZ; Dengjel, J; Denizot, M; Dent, P; Der, CJ; Deretic, V; Derrien, B; Deutsch, E; Devarenne, TP; Devenish, RJ; Di Bartolomeo, S; Di Daniele, N; Di Domenico, F; Di Nardo, A; Di Paola, S; Di Pietro, A; Di Renzo, L; DiAntonio, A; Diaz-Araya, G; Diaz-Laviada, I; Diaz-Meco, MT; Diaz-Nido, J; Dickey, CA; Dickson, RC; Diederich, M; Digard, P; Dikic, I; Dinesh-Kumar, SP; Ding, C; Ding, WX; Ding, ZF; Dini, L; Distler, JHW; Diwan, A; Djavaheri-Mergny, M; Dmytruk, K; Dobson, RCJ; Doetsch, V; Dokladny, K; Dokudovskaya, S; Donadelli, M; Dong, XC; Dong, XN; Dong, Z; Donohue, TM; Doran, KS; D'Orazi, G; Dorn, GW; Dosenko, V; Dridi, S; Drucker, L; Du, J; Du, LL; Du, LH; du Toit, A; Dua, P; Duan, L; Duann, P; Dubey, VK; Duchen, MR; Duchosal, MA; Duez, H; Dugail, I; Dumit, VI; Duncan, MC; Dunlop, EA; Dunn, WA; Dupont, N; Dupuis, L; Duran, RV; Durcan, TM; Duvezin-Caubet, S; Duvvuri, U; Eapen, V; Ebrahimi-Fakhari, D; Echard, A; Eckhart, L; Edelstein, CL; Edinger, AL; Eichinger, L; Eisenberg, T; Eisenberg-Lerner, A; Eissa, NT; El-Deiry, WS; El-Khoury, V; Elazar, Z; Eldar-Finkelman, H; Elliott, CJH; Emanuele, E; Emmenegger, U; Engedal, N; Engelbrecht, AM; Engelender, S; Enserink, JM; Erdmann, R; Erenpreisa, J; Eri, R; Eriksen, JL; Erman, A; Escalante, R; Eskelinen, EL; Espert, L; Esteban-Martinez, L; Evans, TJ; Fabri, M; Fabrias, G; Fabrizi, C; Facchiano, A; Faergeman, NJ; Faggioni, A; Fairlie, WD; Fan, CH; Fan, DP; Fan, J; Fang, SY; Fanto, M; Fanzani, A; Farkas, T; Faure, M; Favier, FB; Fearnhead, H; Federici, M; Fei, E; Felizardo, TC; Feng, H; Feng, YB; Feng, YC; Ferguson, TA; Fernandez, AF; Fernandez-Barrena, MG; Fernandez-Checa, JC; Fernandez-Lopez, A; Fernandez-Zapico, ME; Feron, O; Ferraro, E; Ferreira-Halder, CV; Fesus, L; Feuer, R; Fiesel, FC; Filippi-Chiela, EC; Filomeni, G; Fimia, GM; Fingert, JH; Finkbeiner, S; Finkel, T; Fiorito, F; Fisher, PB; Flajolet, M; Flamigni, F; Florey, O; Florio, S; Floto, RA; Folini, M; Follo, C; Fon, EA; Fornai, F; Fortunato, F; Fraldi, A; Franco, R; Francois, A; Francois, A; Frankel, LB; Fraser, IDC; Frey, N; Freyssenet, DG; Frezza, C; Friedman, SL; Frigo, DE; Fu, DX; Fuentes, JM; Fueyo, J; Fujitani, Y; Fujiwara, Y; Fujiya, M; Fukuda, M; Fulda, S; Fusco, C; Gabryel, B; Gaestel, M; Gailly, P; Gajewska, M; Galadari, S; Galili, G; Galindo, I; Galindo, MF; Galliciotti, G; Galluzzi, L; Galluzzi, L; Galy, V; Gammoh, N; Gandy, S; Ganesan, AK; Ganesan, S; Ganley, IG; Gannage, M; Gao, FB; Gao, F; Gao, JX; Nannig, LG; Vescovi, EG; Garcia-Macia, M; Garcia-Ruiz, C; Garg, AD; Garg, PK; Gargini, R; Gassen, NC; Gatica, D; Gatti, E; Gavard, J; Gavathiotis, E; Ge, L; Ge, PF; Ge, SF; Gean, PW; Gelmetti, V; Genazzani, AA; Geng, JF; Genschik, P; Gerner, L; Gestwicki, JE; Gewirtz, DA; Ghavami, S; Ghigo, E; Ghosh, D; Giammarioli, AM; Giampieri, F; Giampietri, C; Giatromanolaki, A; Gibbings, DJ; Gibellini, L; Gibson, SB; Ginet, V; Giordano, A; Giorgini, F; Giovannetti, E; Girardin, SE; Gispert, S; Giuliano, S; Gladson, CL; Glavic, A; Gleave, M; Godefroy, N; Gogal, RM; Gokulan, K; Goldman, GH; Goletti, D; Goligorsky, MS; Gomes, AV; Gomes, LC; Gomez, H; Gomez-Manzano, C; Gomez-Sanchez, R; Goncalves, DAP; Goncu, E; Gong, QQ; Gongora, C; Gonzalez, CB; Gonzalez-Alegre, P; Gonzalez-Cabo, P; Gonzalez-Polo, RA; Goping, IS; Gorbea, C; Gorbunov, NV; Goring, DR; Gorman, AM; Gorski, SM; Goruppi, S; Goto-Yamada, S; Gotor, C; Gottlieb, RA; Gozes, I; Gozuacik, D; Graba, Y; Graef, M; Granato, GE; Grant, GD; Grant, S; Gravina, GL; Green, DR; Greenhough, A; Greenwood, MT; Grimaldi, B; Gros, F; Grose, C; Groulx, JF; Gruber, F; Grumati, P; Grune, T; Guan, JL; Guan, KL; Guerra, B; Guillen, C; Gulshan, K; Gunst, J; Guo, CY; Guo, L; Guo, M; Guo, WJ; Guo, XG; Gust, AA; Gustafsson, AB; Gutierrez, E; Gutierrez, MG; Gwak, HS; Haas, A; Haber, JE; Hadano, S; Hagedorn, M; Hahn, DR; Halayko, AJ; Hamacher-Brady, A; Hamada, K; Hamai, A; Hamann, A; Hamasaki, M; Hamer, I; Hamid, Q; Hammond, EM; Han, F; Han, WD; Handa, JT; Hanover, JA; Hansen, M; Harada, M; Harhaji-Trajkovic, L; Harper, JW; Harrath, AH; Harris, AL; Harris, J; Hasler, U; Hasselblatt, P; Hasui, K; Hawley, RG; Hawley, TS; He, CC; He, CY; He, FT; He, G; He, RR; He, XH; He, YW; He, YY; Heath, JK; Hebert, MJ; Heinzen, RA; Helgason, GV; Hensel, M; Henske, EP; Her, CT; Herman, PK; Hernandez, A; Hernandez, C; Hernandez-Tiedra, S; Hetz, C; Hiesinger, PR; Higaki, K; Hilfiker, S; Hill, BG; Hill, JA; Hill, WD; Hino, K; Hofius, D; Hofman, P; Hoglinger, GU; Hohfeld, J; Holz, MK; Hong, YG; Hood, DA; Hoozemans, JJM; Hoppe, T; Hsu, C; Hsu, CY; Hsu, LC; Hu, D; Hu, GC; Hu, HM; Hu, HB; Hu, MC; Hu, YC; Hu, ZW; Hua, F; Hua, Y; Huang, CH; Huang, HL; Huang, KH; Huang, KY; Huang, SL; Huang, SQ; Huang, WP; Huang, YR; Huang, Y; Huang, YF; Huber, TB; Huebbe, P; Huh, WK; Hulmi, JJ; Hur, GM; Hurley, JH; Husak, Z; Hussain, SNA; Hussain, S; Hwang, JJ; Hwang, SM; Hwang, TIS; Ichihara, A; Imai, Y; Imbriano, C; Inomata, M; Into, T; Iovane, V; Iovanna, JL; Iozzo, RV; Ip, NY; Irazoqui, JE; Iribarren, P; Isaka, Y; Isakovic, AJ; Ischiropoulos, H; Isenberg, JS; Ishaq, M; Ishida, H; Ishii, I; Ishmael, JE; Isidoro, C; Isobe, KI; Isono, E; Issazadeh-Navikas, S; Itahana, K; Itakura, E; Ivanov, AI; Iyer, AKV; Izquierdo, JM; Izumi, Y; Izzo, V; Jaattela, M; Jaber, N; Jackson, DJ; Jackson, WT; Jacob, TG; Jacques, TS; Jagannath, C; Jain, A; Jana, NR; Jang, BK; Jani, A; Janji, B; Jannig, PR; Jansson, PJ; Jean, S; Jendrach, M; Jeon, JH; Jessen, N; Jeung, EB; Jia, KL; Jia, LJ; Jiang, H; Jiang, HC; Jiang, LW; Jiang, T; Jiang, XY; Jiang, XJ; Jiang, Y; Jiang, YJ; Jimenez, A; Jin, C; Jin, HC; Jin, L; Jin, MY; Jin, SK; Jinwal, UK; Jo, EK; Johansen, T; Johnson, DE; Johnson, GVW; Johnson, JD; Jonasch, E; Jones, C; Joosten, LAB; Jordan, J; Joseph, AM; Joseph, B; Joubert, AM; Ju, DW; Ju, JF; Juan, HF; Juenemann, K; Juhasz, G; Jung, HS; Jung, JU; Jung, YK; Jungbluth, H; Justice, MJ; Jutten, B; Kaakoush, NO; Kaarniranta, K; Kaasik, A; Kabuta, T; Kaeffer, B; Kagedal, K; Kahana, A; Kajimura, S; Kakhlon, O; Kalia, M; Kalvakolanu, DV; Kamada, Y; Kambas, K; Kaminskyy, VO; Kampinga, HH; Kandouz, M; Kang, C; Kang, R; Kang, TC; Kanki, T; Kanneganti, TD; Kanno, H; Kanthasamy, AG; Kantorow, M; Kaparakis-Liaskos, M; Kapuy, O; Karantza, V; Karim, MR; Karmakar, P; Kaser, A; Kaushik, S; Kawula, T; Kaynar, AM; Ke, PY; Ke, ZJ; Kehrl, JH; Keller, KE; Kemper, JK; Kenworthy, AK; Kepp, O; Kern, A; Kesari, S; Kessel, D; Ketteler, R; Kettelhut, ID; Khambu, B; Khan, MM; Khandelwal, VKM; Khare, S; Kiang, JG; Kiger, AA; Kihara, A; Kim, AL; Kim, CH; Kim, DR; Kim, DH; Kim, EK; Kim, HY; Kim, HR; Kim, JS; Kim, JH; Kim, JC; Kim, JH; Kim, KW; Kim, MD; Kim, MM; Kim, PK; Kim, SW; Kim, SY; Kim, YS; Kim, Y; Kimchi, A; Kimmelman, AC; Kimura, T; King, JS; Kirkegaard, K; Kirkin, V; Kirshenbaum, LA; Kishi, S; Kitajima, Y; Kitamoto, K; Kitaoka, Y; Kitazato, K; Kley, RA; Klimecki, WT; Klinkenberg, M; Klucken, J; Knaevelsrud, H; Knecht, E; Knuppertz, L; Ko, JL; Kobayashi, S; Koch, JC; Koechlin-Ramonatxo, C; Koenig, U; Koh, YH; Kohler, K; Kohlwein, SD; Koike, M; Komatsu, M; Kominami, E; Kong, DX; Kong, HJ; Konstantakou, EG; Kopp, BT; Korcsmaros, T; Korhonen, L; Korolchuk, VI; Koshkina, NV; Kou, YJ; Koukourakis, MI; Koumenis, C; Kovacs, AL; Kovacs, T; Kovacs, WJ; Koya, D; Kraft, C; Krainc, D; Kramer, H; Kravic-Stevovic, T; Krek, W; Kretz-Remy, C; Krick, R; Krishnamurthy, M; Kriston-Vizi, J; Kroemer, G; Kruer, MC; Kruger, R; Ktistakis, NT; Kuchitsu, K; Kuhn, C; Kumar, AP; Kumar, A; Kumar, A; Kumar, D; Kumar, D; Kumar, R; Kumar, S; Kundu, M; Kung, HJ; Kuno, A; Kuo, SH; Kuret, J; Kurz, T; Kwok, T; Kwon, TK; Kwon, YT; Kyrmizi, I; La Spada, AR; Lafont, F; Lahm, T; Lakkaraju, A; Lam, T; Lamark, T; Lancel, S; Landowski, TH; Lane, DJR; Lane, JD; Lanzi, C; Lapaquette, P; Lapierre, LR; Laporte, J; Laukkarinen, J; Laurie, GW; Lavandero, S; Lavie, L; LaVoie, MJ; Law, BYK; Law, HKW; Law, KB; Layfield, R; Lazo, PA; Le Cam, L; Le Roch, KG; Le Stunff, H; Leardkamolkarn, V; Lecuit, M; Lee, BH; Lee, CH; Lee, EF; Lee, GM; Lee, HJ; Lee, H; Lee, JK; Lee, J; Lee, JH; Lee, JH; Lee, M; Lee, MS; Lee, PJ; Lee, SW; Lee, SJ; Lee, SJ; Lee, SY; Lee, SH; Lee, SS; Lee, SJ; Lee, S; Lee, YR; Lee, YJ; Lee, YH; Leeuwenburgh, C; Lefort, S; Legouis, R; Lei, JZ; Lei, QY; Leib, DA; Leibowitz, G; Lekli, I; Lemaire, SD; Lemasters, JJ; Lemberg, MK; Lemoine, A; Leng, SL; Lenz, G; Lenzi, P; Lerman, LO; Barbato, DL; Leu, JIJ; Leung, HY; Levine, B; Lewis, PA; Lezoualc'h, F; Li, C; Li, FQ; Li, FJ; Li, J; Li, K; Li, L; Li, M; Li, Q; Li, R; Li, S; Li, W; Li, XT; Li, YM; Lian, JQ; Liang, CY; Liang, QR; Liao, YL; Liberal, J; Liberski, PP; Lie, P; Lieberman, AP; Lim, HJ; Lim, KL; Lim, K; Lima, RT; Lin, CS; Lin, CF; Lin, F; Lin, FM; Lin, FC; Lin, K; Lin, KH; Lin, PH; Lin, TW; Lin, WW; Lin, YS; Lin, Y; Linden, R; Lindholm, D; Lindqvist, LM; Lingor, P; Linkermann, A; Liotta, LA; Lipinski, MM; Lira, VA; Lisanti, MP; Liton, PB; Liu, B; Liu, C; Liu, CF; Liu, F; Liu, HJ; Liu, JX; Liu, JJ; Liu, JL; Liu, K; Liu, LY; Liu, L; Liu, QT; Liu, RY; Liu, SM; Liu, SW; Liu, W; Liu, XD; Liu, XG; Liu, XH; Liu, XF; Liu, X; Liu, XQ; Liu, Y; Liu, YL; Liu, ZX; Liu, Z; Liuzzi, JP; Lizard, G; Ljujic, M; Lodhi, IJ; Logue, SE; Lokeshwar, BL; Long, YC; Lonial, S; Loos, B; Lopez-Otin, C; Lopez-Vicario, C; Lorente, M; Lorenzi, PL; Lorincz, P; Los, M; Lotze, MT; Lovat, PE; Lu, BF; Lu, B; Lu, J; Lu, Q; Lu, SM; Lu, SY; Lu, YY; Luciano, F; Luckhart, S; Lucocq, JM; Ludovico, P; Lugea, A; Lukacs, NW; Lum, JJ; Lund, AH; Luo, HL; Luo, J; Luo, SQ; Luparello, C; Lyons, T; Ma, JJ; Ma, Y; Ma, Y; Ma, ZY; Machado, J; Machado-Santelli, GM; Macian, F; MacIntosh, GC; MacKeigan, JP; Macleod, KF; MacMicking, JD; MacMillan-Crow, LA; Madeo, F; Madesh, M; Madrigal-Matute, J; Maeda, A; Maeda, T; Maegawa, G; Maellaro, E; Maes, H; Magarinos, M; Maiese, K; Maiti, TK; Maiuri, L; Maiuri, MC; Maki, CG; Malli, R; Malorni, W; Maloyan, A; Mami-Chouaib, F; Man, N; Mancias, JD; Mandelkow, EM; Mandell, MA; Manfredi, AA; Manie, SN; Manzoni, C; Mao, K; Mao, ZX; Mao, ZW; Marambaud, P; Marconi, AM; Marelja, Z; Marfe, G; Margeta, M; Margittai, E; Mari, M; Mariani, FV; Marin, C; Marinelli, S; Marino, G; Markovic, I; Marquez, R; Martelli, AM; Martens, S; Martin, KR; Martin, SJ; Martin, S; Martin-Acebes, MA; Martin-Sanz, P; Martinand-Mari, C; Martinet, W; Martinez, J; Martinez-Lopez, N; Martinez-Outschoorn, U; Martinez-Velazquez, M; Martinez-Vicente, M; Martins, WK; Mashima, H; Mastrianni, JA; Matarese, G; Matarrese, P; Mateo, R; Matoba, S; Matsumoto, N; Matsushita, T; Matsuura, A; Matsuzawa, T; Mattson, MP; Matus, S; Maugeri, N; Mauvezin, C; Mayer, A; Maysinger, D; Mazzolini, GD; McBrayer, MK; McCall, K; McCormick, C; McInerney, GM; McIver, SC; McKenna, S; McMahon, JJ; McNeish, IA; Mechta-Grigoriou, F; Medema, JP; Medina, DL; Megyeri, K; Mehrpour, M; Mehta, JL; Mei, YD; Meier, UC; Meijer, AJ; Melendez, A; Melino, G; Melino, S; de Melo, EJT; Mena, MA; Meneghini, MD; Menendez, JA; Menezes, R; Meng, LS; Meng, LH; Meng, SS; Menghini, R; Menko, AS; Menna-Barreto, RFS; Menon, MB; Meraz-Rios, MA; Merla, G; Merlini, L; Merlot, AM; Meryk, A; Meschini, S; Meyer, JN; Mi, MT; Miao, CY; Micale, L; Michaeli, S; Michiels, C; Migliaccio, AR; Mihailidou, AS; Mijaljica, D; Mikoshiba, K; Milan, E; Miller-Fleming, L; Mills, GB; Mills, IG; Minakaki, G; Minassian, BA; Ming, XF; Minibayeva, F; Minina, EA; Mintern, JD; Minucci, S; Miranda-Vizuete, A; Mitchell, CH; Miyamoto, S; Miyazawa, K; Mizushima, N; Mnich, K; Mograbi, B; Mohseni, S; Moita, LF; Molinari, M; Molinari, M; Moller, AB; Mollereau, B; Mollinedo, F; Monick, MM; Montagnaro, S; Montell, C; Moore, DJ; Moore, MN; Mora-Rodriguez, R; Moreira, PI; Morel, E; Morelli, MB; Moreno, S; Morgan, MJ; Moris, A; Moriyasu, Y; Morrison, JL; Morrison, LA; Morselli, E; Moscat, J; Moseley, PL; Mostowy, S; Motori, E; Mottet, D; Mottram, JC; Moussa, CEH; Mpakou, VE; Mukhtar, H; Levy, JMM; Muller, S; Munoz-Moreno, R; Munoz-Pinedo, C; Munz, C; Murphy, ME; Murray, JT; Murthy, A; Mysorekar, IU; Nabi, IR; Nabissi, M; Nader, GA; Nagahara, Y; Nagai, Y; Nagata, K; Nagelkerke, A; Nagy, P; Naidu, SR; Nair, S; Nakano, H; Nakatogawa, H; Nanjundan, M; Napolitano, G; Naqvi, NI; Nardacci, R; Narendra, DP; Narita, M; Nascimbeni, AC; Natarajan, R; Navegantes, LC; Nawrocki, ST; Nazarko, TY; Nazarko, VY; Neill, T; Neri, LM; Netea, MG; Netea-Maier, RT; Neves, BM; Ney, PA; Nezis, IP; Nguyen, HTT; Nguyen, HP; Nicot, AS; Nilsen, H; Nilsson, P; Nishimura, M; Nishino, I; Niso-Santano, M; Niu, H; Nixon, RA; Njar, VCO; Noda, T; Noegel, AA; Nolte, EM; Norberg, E; Norga, KK; Noureini, SK; Notomi, S; Notterpek, L; Nowikovsky, K; Nukina, N; Nurnberger, T; O'Donnell, VB; O'Donovan, T; O'Dwyer, PJ; Oehme, I; Oeste, CL; Ogawa, M; Ogretmen, B; Ogura, Y; Oh, YJ; Ohmuraya, M; Ohshima, T; Ojha, R; Okamoto, K; Okazaki, T; Oliver, FJ; Ollinger, K; Olsson, S; Orban, DP; Ordonez, P; Orhon, I; Orosz, L; O'Rourke, EJ; Orozco, H; Ortega, AL; Ortona, E; Osellame, LD; Oshima, J; Oshima, S; Osiewacz, HD; Otomo, T; Otsu, K; Ou, JHJ; Outeiro, TF; Ouyang, DY; Ouyang, HJ; Overholtzer, M; Ozbun, MA; Ozdinler, PH; Ozpolat, B; Pacelli, C; Paganetti, P; Page, G; Pages, G; Pagnini, U; Pajak, B; Pak, SC; Pakos-Zebrucka, K; Pakpour, N; Palkova, Z; Palladino, F; Pallauf, K; Pallet, N; Palmieri, M; Paludan, SR; Palumbo, C; Palumbo, S; Pampliega, O; Pan, HM; Pan, W; Panaretakis, T; Pandey, A; Pantazopoulou, A; Papackova, Z; Papademetrio, DL; Papassideri, I; Papini, A; Parajuli, N; Pardo, J; Parekh, VV; Parenti, G; Park, JI; Park, J; Park, OK; Parker, R; Parlato, R; Parys, JB; Parzych, KR; Pasquet, JM; Pasquier, B; Pasumarthi, KBS; Patschan, D; Patterson, C; Pattingre, S; Pattison, S; Pause, A; Pavenstadt, H; Pavone, F; Pedrozo, Z; Pena, FJ; Penalva, MA; Pende, M; Peng, JX; Penna, F; Penninger, JM; Pensalfini, A; Pepe, S; Pereira, GJS; Pereira, PC; la Cruz, VP; Perez-Perez, ME; Perez-Rodriguez, D; Perez-Sala, D; Perier, C; Perl, A; Perlmutter, DH; Perrotta, I; Pervaiz, S; Pesonen, M; Pessin, JE; Peters, GJ; Petersen, M; Petrache, I; Petrof, BJ; Petrovski, G; Phang, JM; Piacentini, M; Pierdominici, M; Pierre, P; Pierrefite-Carle, V; Pietrocola, F; Pimentel-Muinos, FX; Pinar, M; Pineda, B; Pinkas-Kramarski, R; Pinti, M; Pinton, P; Piperdi, B; Piret, JM; Platanias, LC; Platta, HW; Plowey, ED; Poggeler, S; Poirot, M; Polcic, P; Poletti, A; Poon, AH; Popelka, H; Popova, B; Poprawa, I; Poulose, SM; Poulton, J; Powers, SK; Powers, T; Pozuelo-Rubio, M; Prak, K; Prange, R; Prescott, M; Priault, M; Prince, S; Proia, RL; Proikas-Cezanne, T; Prokisch, H; Promponas, VJ; Przyklenk, K; Puertollano, R; Pugazhenthi, S; Puglielli, L; Pujol, A; Puyal, J; Pyeon, D; Qi, X; Qian, WB; Qin, ZH; Qiu, Y; Qu, ZW; Quadrilatero, J; Quinn, F; Raben, N; Rabinowich, H; Radogna, F; Ragusa, MJ; Rahmani, M; Raina, K; Ramanadham, S; Ramesh, R; Rami, A; Randall-Demllo, S; Randow, F; Rao, H; Rao, VA; Rasmussen, BB; Rasse, TM; Ratovitski, EA; Rautou, PE; Ray, SK; Razani, B; Reed, BH; Reggiori, F; Rehm, M; Reichert, AS; Rein, T; Reiner, DJ; Reits, E; Ren, J; Ren, XC; Renna, M; Reusch, JEB; Revuelta, JL; Reyes, L; Rezaie, AR; Richards, RI; Richardson, DR; Richetta, C; Riehle, MA; Rihn, BH; Rikihisa, Y; Riley, BE; Rimbach, G; Rippo, MR; Ritis, K; Rizzi, F; Rizzo, E; Roach, PJ; Robbins, J; Roberge, M; Roca, G; Roccheri, MC; Rocha, S; Rodrigues, CMP; Rodriguez, CI; de Cordoba, SR; Rodriguez-Muela, N; Roelofs, J; Rogov, VV; Rohn, TT; Rohrer, B; Romanelli, D; Romani, L; Romano, PS; Roncero, MIG; Rosa, JL; Rosello, A; Rosen, KV; Rosenstiel, P; Rost-Roszkowska, M; Roth, KA; Roue, G; Rouis, M; Rouschop, KM; Ruan, DT; Ruano, D; Rubinsztein, DC; Rucker, EB; Rudich, A; Rudolf, E; Rudolf, R; Ruegg, MA; Ruiz-Roldan, C; Ruparelia, AA; Rusmini, P; Russ, DW; Russo, GL; Russo, G; Russo, R; Rusten, TE; Ryabovol, V; Ryan, KM; Ryter, SW; Sabatini, DM; Sacher, M; Sachse, C; Sack, MN; Sadoshima, J; Saftig, P; Sagi-Eisenberg, R; Sahni, S; Saikumar, P; Saito, T; Saitoh, T; Sakakura, K; Sakoh-Nakatogawa, M; Sakuraba, Y; Salazar-Roa, M; Salomoni, P; Saluja, AK; Salvaterra, PM; Salvioli, R; Samali, A; Sanchez, AMJ; Sanchez-Alcazar, JA; Sanchez-Prieto, R; Sandri, M; Sanjuan, MA; Santaguida, S; Santambrogio, L; Santoni, G; dos Santos, CN; Saran, S; Sardiello, M; Sargent, G; Sarkar, P; Sarkar, S; Sarrias, MR; Sarwal, MM; Sasakawa, C; Sasaki, M; Sass, M; Sato, K; Sato, M; Satriano, J; Savaraj, N; Saveljeva, S; Schaefer, L; Schaible, UE; Scharl, M; Schatzl, HM; Schekman, R; Scheper, W; Schiavi, A; Schipper, HM; Schmeisser, H; Schmidt, J; Schmitz, I; Schneider, BE; Schneider, EM; Schneider, JL; Schon, EA; Schonenberger, MJ; Schonthal, AH; Schorderet, DF; Schroder, B; Schuck, S; Schulze, RJ; Schwarten, M; Schwarz, TL; Sciarretta, S; Scotto, K; Scovassi, AI; Screaton, RA; Screen, M; Seca, H; Sedej, S; Segatori, L; Segev, N; Seglen, PO; Segui-Simarro, JM; Segura-Aguilar, J; Seiliez, I; Seki, E; Sell, C; Semenkovich, CF; Semenza, GL; Sen, U; Serra, AL; Serrano-Puebla, A; Sesaki, H; Setoguchi, T; Settembre, C; Shacka, JJ; Shajahan-Haq, AN; Shapiro, IM; Sharma, S; She, H; Shen, CKJ; Shen, CC; Shen, HM; Shen, SB; Shen, WL; Sheng, R; Sheng, XY; Sheng, ZH; Shepherd, TG; Shi, JY; Shi, Q; Shi, QH; Shi, YG; Shibutani, S; Shibuya, K; Shidoji, Y; Shieh, JJ; Shih, CM; Shimada, Y; Shimizu, S; Shin, DW; Shinohara, ML; Shintani, M; Shintani, T; Shioi, T; Shirabe, K; Shiri-Sverdlov, R; Shirihai, O; Shore, GC; Shu, CW; Shukla, D; Sibirny, AA; Sica, V; Sigurdson, CJ; Sigurdsson, EM; Sijwali, PS; Sikorska, B; Silveira, WA; Silvente-Poirot, S; Silverman, GA; Simak, J; Simmet, T; Simon, AK; Simon, HU; Simone, C; Simons, M; Simonsen, A; Singh, R; Singh, SV; Singh, SK; Sinha, D; Sinha, S; Sinicrope, FA; Sirko, A; Sirohi, K; Sishi, BJN; Sittler, A; Siu, PM; Sivridis, E; Skwarska, A; Slack, R; Slaninova, I; Slavov, N; Smaili, SS; Smalley, KSM; Smith, DR; Soenen, SJ; Soleimanpour, SA; Solhaug, A; Somasundaram, K; Son, JH; Sonawane, A; Song, CJ; Song, FY; Song, HK; Song, JX; Song, W; Soo, KY; Sood, AK; Soong, TW; Soontornniyomkij, V; Sorice, M; Sotgia, F; Soto-Pantoja, DR; Sotthibundhu, A; Sousa, MJ; Spaink, HP; Span, PN; Spang, A; Sparks, JD; Speck, PG; Spector, SA; Spies, CD; Springer, W; St Clair, D; Stacchiotti, A; Staels, B; Stang, MT; Starczynowski, DT; Starokadomskyy, P; Steegborn, C; Steele, JW; Stefanis, L; Steffan, J; Stellrecht, CM; Stenmark, H; Stepkowski, TM; Stern, ST; Stevens, C; Stockwell, BR; Stoka, V; Storchova, Z; Stork, B; Stratoulias, V; Stravopodis, DJ; Strnad, P; Strohecker, AM; Strom, AL; Stromhaug, P; Stulik, J; Su, YX; Su, ZL; Subauste, CS; Subramaniam, S; Sue, CM; Suh, SW; Sui, XB; Sukseree, S; Sulzer, D; Sun, FL; Sun, JR; Sun, J; Sun, SY; Sun, Y; Sun, Y; Sun, YJ; Sundaramoorthy, V; Sung, J; Suzuki, H; Suzuki, K; Suzuki, N; Suzuki, T; Suzuki, YJ; Swanson, MS; Swanton, C; Sward, K; Swarup, G; Sweeney, ST; Sylvester, PW; Szatmari, Z; Szegezdi, E; Szlosarek, PW; Taegtmeyer, H; Tafani, M; Taillebourg, E; Tait, SWG; Takacs-Vellai, K; Takahashi, Y; Takats, S; Takemura, G; Takigawa, N; Talbot, NJ; Tamagno, E; Tamburini, J; Tan, CP; Tan, L; Tan, ML; Tan, M; Tan, YJ; Tanaka, K; Tanaka, M; Tang, DL; Tang, DZ; Tang, GM; Tanida, I; Tanji, K; Tannous, BA; Tapia, JA; Tasset-Cuevas, I; Tatar, M; Tavassoly, I; Tavernarakis, N; Taylor, A; Taylor, GS; Taylor, GA; Taylor, JP; Taylor, MJ; Tchetina, EV; Tee, AR; Teixeira-Clerc, F; Telang, S; Tencomnao, T; Teng, BB; Teng, RJ; Terro, F; Tettamanti, G; Theiss, AL; Theron, AE; Thomas, KJ; Thome, MP; Thomes, PG; Thorburn, A; Thorner, J; Thum, T; Thumm, M; Thurston, TLM; Tian, L; Till, A; Ting, JPY; Titorenko, VI; Toker, L; Toldo, S; Tooze, SA; Topisirovic, I; Torgersen, ML; Torosantucci, L; Torriglia, A; Torrisi, MR; Tournier, C; Towns, R; Trajkovic, V; Travassos, LH; Triola, G; Tripathi, DN; Trisciuoglio, D; Troncoso, R; Trougakos, IP; Truttmann, AC; Tsai, KJ; Tschan, MP; Tseng, YH; Tsukuba, T; Tsung, A; Tsvetkov, AS; Tu, SP; Tuan, HY; Tucci, M; Tumbarello, DA; Turk, B; Turk, V; Turner, RFB; Tveita, AA; Tyagi, SC; Ubukata, M; Uchiyama, Y; Udelnow, A; Ueno, T; Umekawa, M; Umemiya-Shirafuji, R; Underwood, BR; Ungermann, C; Ureshino, RP; Ushioda, R; Uversky, VN; Uzcategui, NL; Vaccari, T; Vaccaro, MI; Vachova, L; Vakifahmetoglu-Norberg, H; Valdor, R; Valente, EM; Vallette, F; Valverde, AM; Van den Berghe, G; Van Den Bosch, L; van den Brink, GR; van der Goot, FG; van der Klei, IJ; van der Laan, LJW; van Doorn, WG; van Egmond, M; van Golen, KL; Van Kaer, L; Campagne, MV; Vandenabeele, P; Vandenberghe, W; Vanhorebeek, I; Varela-Nieto, I; Vasconcelos, MH; Vasko, R; Vavvas, DG; Vega-Naredo, I; Velasco, G; Velentzas, AD; Velentzas, PD; Vellai, T; Vellenga, E; Vendelbo, MH; Venkatachalam, K; Ventura, N; Ventura, S; Veras, PST; Verdier, M; Vertessy, BG; Viale, A; Vidal, M; Vieira, HLA; Vierstra, RD; Vigneswaran, N; Vij, N; Vila, M; Villar, M; Villar, VH; Villarroya, J; Vindis, C; Viola, G; Viscomi, MT; Vitale, G; Vogl, DT; Voitsekhovskaja, OV; von Haefen, C; von Schwarzenberg, K; Voth, DE; Vouret-Craviari, V; Vuori, K; Vyas, JM; Waeber, C; Walker, CL; Walker, MJ; Walter, J; Wan, L; Wan, XB; Wang, B; Wang, CH; Wang, CY; Wang, CS; Wang, CR; Wang, CH; Wang, D; Wang, F; Wang, FX; Wang, GH; Wang, HJ; Wang, HC; Wang, HG; Wang, HM; Wang, HD; Wang, J; Wang, JJ; Wang, M; Wang, MQ; Wang, PY; Wang, P; Wang, RC; Wang, S; Wang, TF; Wang, X; Wang, XJ; Wang, XW; Wang, X; Wang, XJ; Wang, Y; Wang, Y; Wang, Y; Wang, YJ; Wang, YP; Wang, Y; Wang, YT; Wang, YQ; Wang, ZN; Wappner, P; Ward, C; Ward, DM; Warnes, G; Watada, H; Watanabe, Y; Watase, K; Weaver, TE; Weekes, CD; Wei, JW; Weide, T; Weihl, CC; Weindl, G; Weis, SN; Wen, LP; Wen, X; Wen, YF; Westermann, B; Weyand, CM; White, AR; White, E; Whitton, JL; Whitworth, AJ; Wiels, J; Wild, F; Wildenberg, ME; Wileman, T; Wilkinson, DS; Wilkinson, S; Willbold, D; Williams, C; Williams, K; Williamson, PR; Winklhofer, KF; Witkin, SS; Wohlgemuth, SE; Wollert, T; Wolvetang, EJ; Wong, E; Wong, GW; Wong, RW; Wong, VKW; Woodcock, EA; Wright, KL; Wu, CL; Wu, DF; Wu, GS; Wu, J; Wu, JF; Wu, M; Wu, M; Wu, SZ; Wu, WKK; Wu, YH; Wu, ZL; Xavier, CPR; Xavier, RJ; Xia, GX; Xia, T; Xia, WL; Xia, Y; Xiao, HY; Xiao, J; Xiao, S; Xiao, WH; Xie, CM; Xie, ZP; Xie, ZL; Xilouri, M; Xiong, YY; Xu, CS; Xu, CF; Xu, F; Xu, HX; Xu, HW; Xu, J; Xu, JZ; Xu, JX; Xu, L; Xu, XL; Xu, YQ; Xu, Y; Xu, ZX; Xu, ZH; Xue, Y; Yamada, T; Yamamoto, A; Yamanaka, K; Yamashina, S; Yamashiro, S; Yan, B; Yan, B; Yan, X; Yan, Z; Yanagi, Y; Yang, DS; Yang, JM; Yang, L; Yang, MH; Yang, PM; Yang, P; Yang, Q; Yang, WN; Yang, WY; Yang, XS; Yang, Y; Yang, Y; Yang, ZF; Yang, ZH; Yao, MC; Yao, PJ; Yao, XF; Yao, ZY; Yao, ZY; Yasui, LS; Ye, MX; Yedvobnick, B; Yeganeh, B; Yeh, ES; Yeyati, PL; Yi, F; Yi, L; Yin, XM; Yip, CK; Yoo, YM; Yoo, YH; Yoon, SY; Yoshida, KI; Yoshimori, T; Young, KH; Yu, HM; Yu, JJ; Yu, JT; Yu, J; Yu, L; Yu, WH; Yu, XF; Yu, ZP; Yuan, JY; Yuan, ZM; Yue, BYJT; Yue, JB; Yue, ZY; Zacks, DN; Zacksenhaus, E; Zaffaroni, N; Zaglia, T; Zakeri, Z; Zecchini, V; Zeng, JS; Zeng, M; Zeng, Q; Zervos, AS; Zhang, DD; Zhang, F; Zhang, G; Zhang, GC; Zhang, H; Zhang, H; Zhang, HB; Zhang, J; Zhang, JW; Zhang, JH; Zhang, JP; Zhang, L; Zhang, L; Zhang, L; Zhang, MY; Zhang, XN; Zhang, XD; Zhang, Y; Zhang, Y; Zhang, YJ; Zhang, YM; Zhang, YJ; Zhao, M; Zhao, WL; Zhao, XN; Zhao, YG; Zhao, Y; Zhao, YC; Zhao, YX; Zhao, ZD; Zhao, ZZJ; Zheng, DX; Zheng, XL; Zheng, XX; Zhivotovsky, B; Zhong, Q; Zhou, GZ; Zhou, GF; Zhou, HP; Zhou, SF; Zhou, XJ; Zhu, HX; Zhu, H; Zhu, WG; Zhu, WH; Zhu, XF; Zhu, YH; Zhuang, SM; Zhuang, XH; Ziparo, E; Zois, CE; Zoladek, T; Zong, WX; Zorzano, A; Zughaier, SM",Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition),AUTOPHAGY,,1554-8627,10.1080/15548627.2015.1100356,,,2016,01/07/2022 10:40,01/07/2022 10:40,,1-222,,1,12,,,,,,,,,,,,,,WOS:000373595400001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GIBY842R,journalArticle,2018,"van Setten, J; Brody, JA; Jamshidi, Y; Swenson, BR; Butler, AM; Campbell, H; Del Greco, FM; Evans, DS; Gibson, Q; Gudbjartsson, DF; Kerr, KF; Krijthe, BP; Lyytikainen, LP; Muller, C; Muller-Nurasyid, M; Nolte, IM; Padmanabhan, S; Ritchie, MD; Robino, A; Smith, AV; Steri, M; Tanaka, T; Teumer, A; Trompet, S; Ulivi, S; Verweij, N; Yin, XY; Arnar, DO; Asselbergs, FW; Bader, JS; Barnard, J; Bis, J; Blankenberg, S; Boerwinkle, E; Bradford, Y; Buckley, BM; Chung, MK; Crawford, D; den Hoed, M; Denny, JC; Dominiczak, AF; Ehret, GB; Eijgelsheim, M; Ellinor, PT; Felix, SB; Franco, OH; Franke, L; Harris, TB; Holm, H; Ilaria, G; Iorio, A; Kahonen, M; Kolcic, I; Kors, JA; Lakatta, EG; Launer, LJ; Lin, HH; Lin, HJ; Loos, RJF; Lubitz, SA; Macfarlane, PW; Magnani, JW; Leach, IM; Meitinger, T; Mitchell, BD; Munzel, T; Papanicolaou, GJ; Peters, A; Pfeufer, A; Pramstaller, PP; Raitakari, OT; Rotter, JI; Rudan, I; Samani, NJ; Schlessinger, D; Aldana, CTS; Sinner, MF; Smith, JD; Snieder, H; Soliman, EZ; Spector, TD; Stott, DJ; Strauch, K; Tarasov, KV; Thorsteinsdottir, U; Uitterlinden, AG; Van Wagoner, DR; Volker, U; Volzke, H; Waldenberger, M; Westra, HJ; Wild, PS; Zeller, T; Alonso, A; Avery, CL; Bandinelli, S; Benjamin, EJ; Cucca, F; Dorr, M; Ferrucci, L; Gasparini, P; Gudnason, V; Hayward, C; Heckbert, SR; Hicks, AA; Jukema, JW; Kaab, S; Lehtimaki, T; Liu, YM; Munroe, PB; Parsa, A; Polasek, O; Psaty, BM; Roden, DM; Schnabel, RB; Sinagra, G; Stefansson, K; Stricker, BH; van der Harst, P; van Duijn, CM; Wilson, JF; Gharib, SA; de Bakker, PIW; Isaacs, A; Arking, DE; Sotoodehnia, N",PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity,NATURE COMMUNICATIONS,,2041-1723,10.1038/s41467-018-04766-9,,"Electrocardiographic PR interval measures atrio-ventricular depolarization and conduction, and abnormal PR interval is a risk factor for atrial fibrillation and heart block. Our genomewide association study of over 92,000 European-descent individuals identifies 44 PR interval loci (34 novel). Examination of these loci reveals known and previously not-yet-reported biological processes involved in cardiac atrial electrical activity. Genes in these loci are overrepresented in cardiac disease processes including heart block and atrial fibrillation. Variants in over half of the 44 loci were associated with atrial or blood transcript expression levels, or were in high linkage disequilibrium with missense variants. Six additional loci were identified either by meta-analysis of similar to 105,000 African and European-descent individuals and/or by pleiotropic analyses combining PR interval with heart rate, QRS interval, and atrial fibrillation. These findings implicate developmental pathways, and identify transcription factors, ionchannel genes, and cell-junction/cell-signaling proteins in atrio-ventricular conduction, identifying potential targets for drug development.",25/07/2018,01/07/2022 10:40,01/07/2022 10:40,,,,,9,,,,,,,,,,,,,,WOS:000439687600002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R7DT3YZK,journalArticle,2016,"Bousquet, J; Farrell, J; Crooks, G; Hellings, P; Bel, EH; Bewick, M; Chavannes, NH; de Sousa, JC; Cruz, AA; Haahtela, T; Joos, G; Khaltaev, N; Malva, J; Muraro, A; Nogues, M; Palkonen, S; Pedersen, S; Robalo-Cordeiro, C; Samolinski, B; Strandberg, T; Valiulis, A; Yorgancioglu, A; Zuberbier, T; Bedbrook, A; Aberer, W; Adachi, M; Agusti, A; Akdis, CA; Akdis, M; Ankri, J; Alonso, A; Annesi-Maesano, I; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Arshad, H; Bai, C; Baiardini, I; Bachert, C; Baigenzhin, AK; Barbara, C; Bateman, ED; Beghe, B; Ben Kheder, A; Bennoor, KS; Benson, M; Bergmann, KC; Bieber, T; Bindslev-Jensen, C; Bjermer, L; Blain, H; Blasi, F; Boner, AL; Bonini, M; Bonini, S; Bosnic-Anticevitch, S; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Burney, PG; Bush, A; Caballero-Fonseca, F; Caimmi, D; Calderon, MA; Calverley, PM; Camargos, PAM; Canonica, GW; Camuzat, T; Carlsen, KH; Carr, W; Carriazo, A; Casale, T; Sarabia, AMC; Chatzi, L; Chen, YZ; Chiron, R; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciprandi, G; Cirule, I; Cox, L; Costa, DJ; Custovic, A; Dahl, R; Dahlen, SE; Darsow, U; De Carlo, G; De Blay, F; Dedeu, T; Deleanu, D; Keenoy, ED; Demoly, P; Denburg, JA; Devillier, P; Didier, A; Dinh-Xuan, AT; Djukanovic, R; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Dykewicz, MS; El-Gamal, Y; Emuzyte, R; Fabbri, LM; Fletcher, M; Fiocchi, A; Wagner, AF; Fonseca, J; Fokkens, WJ; Forastiere, F; Frith, P; Gaga, M; Gamkrelidze, A; Garces, J; Garcia-Aymerich, J; Gemicioglu, B; Gereda, JE; Diaz, SG; Gotua, M; Grisle, I; Grouse, L; Gutter, Z; Guzman, MA; Heaney, LG; Hellquist-Dahl, B; Henderson, D; Hendry, A; Heinrich, J; Heve, D; Horak, F; Hourihane, JOB; Howarth, P; Humbert, M; Hyland, ME; Illario, M; Ivancevich, JC; Jardim, JR; Jares, EJ; Jeandel, C; Jenkins, C; Johnston, SL; Jonquet, O; Julge, K; Jung, KS; Just, J; Kaidashev, I; Kaitov, MR; Kalayci, O; Kalyoncu, AF; Keil, T; Keith, PK; Klimek, L; N'Goran, BK; Kolek, V; Koppelman, GH; Kowalski, ML; Kull, I; Kuna, P; Kvedariene, V; Lambrecht, B; Lau, S; Larenas-Linnemann, D; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Carlsen, KL; Louis, R; MacNee, W; Magard, Y; Magnan, A; Mahboub, B; Mair, A; Majer, I; Makela, MJ; Manning, P; Mara, S; Marshall, GD; Masjedi, MR; Matignon, P; Maurer, M; Mavale-Manuel, S; Melen, E; Melo-Gomes, E; Meltzer, EO; Menzies-Gow, A; Merk, H; Michel, JP; Miculinic, N; Mihaltan, F; Milenkovic, B; Mohammad, GMY; Molimard, M; Momas, I; Montilla-Santana, A; Morais-Almeida, M; Morgan, M; Mosges, R; Mullol, J; Nafti, S; Namazova-Baranova, L; Naclerio, R; Neou, A; Neffen, H; Nekam, K; Niggemann, B; Ninot, G; Nyembue, TD; O'Hehir, RE; Ohta, K; Okamoto, Y; Okubo, K; Ouedraogo, S; Paggiaro, P; Pali-Scholl, I; Panzner, P; Papadopoulos, N; Papi, A; Park, HS; Passalacqua, G; Pavord, I; Pawankar, R; Pengelly, R; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Poethig, D; Pohl, W; Popov, TA; Portejoie, F; Potter, P; Postma, D; Price, D; Rabe, KF; Raciborski, F; Pontal, FR; Repka-Ramirez, S; Reitamo, S; Rennard, S; Rodenas, F; Roberts, J; Roca, J; Manas, LR; Rolland, C; Rodriguez, MR; Romano, A; Rosado-Pinto, J; Rosario, N; Rosenwasser, L; Rottem, M; Ryan, D; Sanchez-Borges, M; Scadding, GK; Schunemann, HJ; Serrano, E; Schmid-Grendelmeier, P; Schulz, H; Sheikh, A; Shields, M; Siafakas, N; Sibille, Y; Similowski, T; Simons, FER; Sisul, JC; Skrindo, I; Smit, HA; Sole, D; Sooronbaev, T; Spranger, O; Stelmach, R; Sterk, PJ; Sunyer, J; Thijs, C; To, T; Todo-Bom, A; Triggiani, M; Valenta, R; Valero, AL; Valia, E; Valovirta, E; Van Ganse, E; van Hage, M; Vandenplas, O; Vasankari, T; Vellas, B; Vestbo, J; Vezzani, G; Vichyanond, P; Viegi, G; Vogelmeier, C; Vontetsianos, T; Wagenmann, M; Wallaert, B; Walker, S; Wang, DY; Wahn, U; Wickman, M; Williams, DM; Williams, S; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zaidi, A; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M; Mercier, J",Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5),CLINICAL AND TRANSLATIONAL ALLERGY,,2045-7022,10.1186/s13601-016-0116-9,,"Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un Vleillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing.",29/07/2016,01/07/2022 10:40,01/07/2022 10:40,,,,,6,,,,,,,,,,,,,,WOS:000390119300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AD6NGMWJ,journalArticle,2017,"Bousquet, J; Farrell, J; Crooks, G; Hellings, P; Bel, EH; Bewick, M; Chavannes, NH; de Sousa, JC; Cruz, AA; Haahtela, T; Joos, G; Khaltaev, N; Malva, J; Muraro, A; Nogues, M; Palkonen, S; Pedersen, S; Robalo-Cordeiro, C; Samolinski, B; Strandberg, T; Valiulis, A; Yorgancioglu, A; Zuberbier, T; Bedbrook, A; Aberer, W; Adachi, M; Agusti, A; Akdis, CA; Akdis, M; Ankri, J; Alonso, A; Annesi-Maesano, I; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Arshad, H; Bai, C; Baiardini, I; Bachert, C; Baigenzhin, AK; Barbara, C; Bateman, ED; Beghe, B; Ben Kheder, A; Bennoor, KS; Benson, M; Bergmann, KC; Bieber, T; Bindslev-Jensen, C; Bjermer, L; Blain, H; Blasi, F; Boner, AL; Bonini, M; Bonini, S; Bosnic-Anticevitch, S; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Burney, PG; Bush, A; Caballero-Fonseca, F; Caimmi, D; Calderon, MA; Calverley, PM; Camargos, PAM; Canonica, GW; Camuzat, T; Carlsen, KH; Carr, W; Carriazo, A; Casale, T; Sarabia, AMC; Chatzi, L; Chen, YZ; Chiron, R; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciprandi, G; Cirule, I; Cox, L; Costa, DJ; Custovic, A; Dahl, R; Dahlen, SE; Darsow, U; De Carlo, G; De Blay, F; Dedeu, T; Deleanu, D; Keenoy, ED; Demoly, P; Denburg, JA; Devillier, P; Didier, A; Dinh-Xuan, AT; Djukanovic, R; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Dykewicz, MS; El-Gamal, Y; Emuzyte, R; Fabbri, LM; Fletcher, M; Fiocchi, A; Wagner, AF; Fonseca, J; Fokkens, WJ; Forastiere, F; Frith, P; Gaga, M; Gamkrelidze, A; Garces, J; Garcia-Aymerich, J; Gemicioglu, B; Gereda, JE; Diaz, SG; Gotua, M; Grisle, I; Grouse, L; Gutter, Z; Guzman, MA; Heaney, LG; Hellquist-Dahl, B; Henderson, D; Hendry, A; Heinrich, J; Heve, D; Horak, F; Hourihane, JOB; Howarth, P; Humbert, M; Hyland, ME; Illario, M; Ivancevich, JC; Jardim, JR; Jares, EJ; Jeandel, C; Jenkins, C; Johnston, SL; Jonquet, O; Julge, K; Jung, KS; Just, J; Kaidashev, I; Khaitov, MR; Kalayci, O; Kalyoncu, AF; Keil, T; Keith, PK; Klimek, L; N'Goran, BK; Kolek, V; Koppelman, GH; Kowalski, ML; Kull, I; Kuna, P; Kvedariene, V; Lambrecht, B; Lau, S; Larenas-Linnemann, D; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Carlsen, KL; Louis, R; MacNee, W; Magard, Y; Magnan, A; Mahboub, B; Mair, A; Majer, I; Makela, MJ; Manning, P; Mara, S; Marshall, GD; Masjedi, MR; Matignon, P; Maurer, M; Mavale-Manuel, S; Melen, E; Melo-Gomes, E; Meltzer, EO; Menzies-Gow, A; Merk, H; Michel, JP; Miculinic, N; Mihaltan, F; Milenkovic, B; Mohammad, GMY; Molimard, M; Momas, I; Montilla-Santana, A; Morais-Almeida, M; Morgan, M; Mosges, R; Mullol, J; Nafti, S; Namazova-Baranova, L; Naclerio, R; Neou, A; Neffen, H; Nekam, K; Niggemann, B; Ninot, G; Nyembue, TD; O'Hehir, RE; Ohta, K; Okamoto, Y; Okubo, K; Ouedraogo, S; Paggiaro, P; Pali-Scholl, I; Panzner, P; Papadopoulos, N; Papi, A; Park, HS; Passalacqua, G; Pavord, I; Pawankar, R; Pengelly, R; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Poethig, D; Pohl, W; Popov, TA; Portejoie, F; Potter, P; Postma, D; Price, D; Rabe, KF; Raciborski, F; Pontal, FR; Repka-Ramirez, S; Reitamo, S; Rennard, S; Rodenas, F; Roberts, J; Roca, J; Manas, LR; Rolland, C; Rodriguez, MR; Romano, A; Rosado-Pinto, J; Rosario, N; Rosenwasser, L; Rottem, M; Ryan, D; Sanchez-Borges, M; Scadding, GK; Schunemann, HJ; Serrano, E; Schmid-Grendelmeier, P; Schulz, H; Sheikh, A; Shields, M; Siafakas, N; Sibille, Y; Similowski, T; Simons, FER; Sisul, JC; Skrindo, I; Smit, HA; Sole, D; Sooronbaev, T; Spranger, O; Stelmach, R; Sterk, PJ; Sunyer, J; Thijs, C; To, T; Todo-Bom, A; Triggiani, M; Valenta, R; Valero, AL; Valia, E; Valovirta, E; Van Ganse, E; van Hage, M; Vandenplas, O; Vasankari, T; Vellas, B; Vestbo, J; Vezzani, G; Vichyanond, P; Viegi, G; Vogelmeier, C; Vontetsianos, T; Wagenmann, M; Wallaert, B; Walker, S; Wang, DY; Wahn, U; Wickman, M; Williams, DM; Williams, S; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zaidi, A; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M; Mercier, J","Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (vol 6, 29, 2016)",CLINICAL AND TRANSLATIONAL ALLERGY,,2045-7022,10.1186/s13601-016-0135-6,,,20/02/2017,01/07/2022 10:40,01/07/2022 10:40,,,,,7,,,,,,,,,,,,,,WOS:000396073300001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HCFI8K4J,journalArticle,2018,"Dicker, D; Nguyen, G; Abate, D; Abate, LH; Abay, SM; Abbafati, C; Abbasi, N; Abbastabar, H; Abd-Allah, F; Abdela, J; Abdelalim, A; Abdel-Rahman, O; Abdi, A; Abdollahpour, I; Abdulkader, RS; Abdurahman, AA; Abebe, HT; Abebe, M; Abebe, Z; Abebo, TA; Aboyans, V; Abraha, HN; Abrham, AR; Abu-Raddad, LJ; Abu-Rmeileh, NM; Mbessi, MMKA; Acharya, P; Adebayo, OM; Adedeji, IA; Adedoyin, RA; Adekanmbi, V; Adetokunboh, OO; Adhena, BM; Adhikari, TB; Adib, MG; Adou, AK; Adsuar, JC; Afaridern, M; Afshin, A; Agarwal, G; Aggarwal, R; Aghayan, SA; Agrawal, S; Agrawal, A; Ahmadi, M; Ahmadi, A; Ahmadieh, H; Ahmed, MLCB; Ahmed, S; Ahmed, MB; Aichour, AN; Aichour, I; Aichour, MTE; Akanda, AS; Akbari, ME; Akibu, M; Akinyemi, RO; Akinyemiju, T; Akseer, N; Alandab, F; Al-Aly, Z; Alam, K; Alebel, A; Aleman, AV; Alene, KA; Al-Eyadhy, A; Ali, R; Alijanzadely, M; Alizadeh-Navaei, R; Aljunid, SM; Alkerwi, A; Alla, F; Allebeck, P; Allen, CA; Alonso, J; Al-Raddadi, RM; Alsharif, U; Altirkawi, K; Alvis-Cituman, N; Amare, AT; Amini, E; Ammar, W; Amoako, YA; Anber, NH; Andrei, CL; Androudi, S; Animut, MD; Anjomshoa, M; Anlay, DZ; Ansari, H; Ansariadi, A; Ansha, MG; Antonio, CAT; Appiah, SCY; Aremu, O; Areri, HA; Arnlov, J; Aroma, M; Artaman, A; Aryal, KK; Asadi-Lari, M; Asayesh, H; Asfaw, ET; Asgedom, SW; Assadi, R; Ataro, Z; Atey, TMM; Athari, SS; Atique, S; Atre, SR; Atteraya, MS; Attia, EF; Ausloos, M; Avila-Burgos, L; Avokpaho, EFGA; Awasthi, AI; Awuah, B; Quintanilla, BPA; Ayele, HT; Ayele, Y; Ayer, R; Ayuk, TBB; Azzopardi, PS; Azzopardi-Muscat, N; Badali, H; Badawi, A; Balakrishnan, K; Bali, AG; Banach, M; Banstola, A; Barac, A; Barboza, MA; Barquera, S; Barrero, LH; Basaleem, H; Bassat, Q; Basu, A; Basu, S; Baune, BT; Bazargan-Hejazi, S; Bedi, N; Beghi, E; Behzadifar, M; Behzadifar, M; Bejot, Y; Bekele, BB; Belachew, AB; Belay, AG; Belay, E; Belay, SA; Belay, YA; Bell, ML; Bello, AK; Bennett, DA; Bensenor, IM; Berhane, A; Berman, AE; Bernabe, E; Bernstein, RS; Bertolacci, GJ; Beuran, M; Beyranvand, T; Bhala, N; Bhatia, E; Bhatt, S; Bhattarai, S; Bhaumik, S; Bhutta, ZA; Biadgo, B; Bijani, A; Bikbov, B; Bililign, N; Bin Sayeed, MS; Birlik, SM; Birungi, C; Bisanzio, D; Biswas, T; Bjorge, T; Bleyer, A; Basara, BB; Bose, D; Bosetti, C; Boufous, S; Bourne, R; Brady, OJ; Bragazzi, NL; Brant, LC; Brazinova, A; Breitborde, NJK; Brenner, H; Britton, G; Brugha, T; Burke, KE; Busse, R; Butt, ZA; Cahuana-Hurtado, L; Callender, CSKH; Campos-Nonato, IR; Rincon, JCC; Cano, J; Car, M; Cardenas, R; Caneras, G; Canero, JJ; Carter, A; Carvalho, F; Casaneda-Orjuela, CA; Rivas, JC; Castro, F; Catala-Lopez, F; Cavlin, A; Cerin, E; Chaiah, Y; Champs, AP; Chang, HY; Chang, JC; Chattopadhyay, A; Chaturvedi, P; Chen, WQ; Chiang, PPC; Chimed-Ochir, O; Chin, KL; Chisumpa, VH; Chitheer, A; Choi, JYJ; Christensen, H; Christopher, DJ; Chung, SC; Cicuttini, FM; Ciobanu, LG; Cirillo, M; Claro, RM; Cohen, AJ; Collado-Mateo, D; Constantin, MM; Conti, S; Cooper, C; Cooper, LT; Cortesi, PA; Cortinovis, M; Cousin, E; Criqui, MH; Cromwell, EA; Crowe, CS; Crump, JA; Cucu, A; Cunningham, M; Daba, AK; Dachew, BA; Dadi, AF; Dandona, L; Dandona, R; Dang, AK; Dargan, PI; Daryani, A; Das, SK; Das Gupta, R; das Neves, J; Dasa, TT; Dash, AP; Weaver, ND; Davitoiu, DV; Davletov, K; Dayama, A; de Courten, B; De la Hoz, FP; De Leo, D; De Neve, JW; Degefa, MG; Degenhardt, L; Degfie, TT; Deiparine, S; Dellavalle, RP; Demoz, GT; Demtsu, BB; Denova-Gutierrez, E; Deribe, K; Dervenis, N; Des Jarlais, DC; Dessie, GA; Dey, S; Dharmaratne, SD; Dhimal, M; Ding, EL; Djalalinia, S; Doku, DT; Dolan, KA; Donnelly, CA; Dorsey, ER; Douwes-Schultz, D; Doyle, KE; Drake, TM; Driscoll, TR; Dubey, M; Dubljanin, E; Duken, EE; Duncan, BB; Duraes, AR; Ebrahimi, H; Ebrahimpour, S; Edessa, D; Edvardsson, D; Eggen, AE; El Bcheraoui, C; Zaki, ME; Elfaramawi, M; El-Khatib, Z; Ellingsen, CL; Elyazar, IRF; Enayati, A; Endries, AYY; Er, B; Ermakov, SP; Eshrati, B; Eskandarieff, S; Esmaeili, R; Esteghamati, A; Esteghamati, S; Fakhar, M; Fakhim, N; Farag, T; Faramarzi, M; Fareed, M; Farhadi, F; Farid, TA; Farinha, CSES; Farioli, A; Faro, A; Farvid, MS; Farzadfar, F; Farzaei, MH; Farzeli, MS; Feigin, VL; Feigl, AB; Feizy, F; Fentahum, N; Fereshtehnejad, SM; Fernandes, E; Fernandes, JC; Feyissa, GT; Fijabi, DO; Filip, I; Finegold, S; Fischer, F; Flor, LS; Foigt, NA; Ford, JA; Foreman, KJ; Harrod, C; Frank, TD; Franklin, RC; Fukumoto, T; Fuller, JE; Fullman, N; Furst, T; Furtado, JM; Futran, ND; Galan, A; Gallus, S; Gambashidze, K; Gamkrelidze, A; Gankpe, FG; Garcia-Basteiro, AL; Garcia-Gordillo, MA; Gebre, T; Gebre, AK; Gebregergs, GB; Gebrehiwot, TT; Gebremedhin, AT; Gelano, TF; Gelaw, YA; Geleijnse, JN; Genova-Maleras, R; Gessner, BD; Getachew, S; Gething, PW; Gezae, KE; Ghadami, MR; Ghadimi, R; Falavarjani, KG; Ghaserni-Kasman, M; Ghiasvand, H; Ghirnire, M; Ghoshal, AG; Gill, PS; Gill, TK; Gillum, RF; Giussani, G; Goenka, S; Coll, S; Gomez, RS; Gomez-Cabrera, MC; Gomez-Dantes, H; Gona, PN; Goodridge, A; Gopalani, SV; Goto, A; Goulart, AC; Goulart, BNG; Grada, A; Grosso, G; Gugnani, HC; Guimaraes, ALS; Guo, YM; Gupta, PC; Gupta, R; Gupta, R; Gupta, T; Gyawali, B; Haagsma, JA; Hachinski, V; Hafezi-Nejad, N; Hagos, TB; Hailegiyorgis, TT; Hailu, GB; Haj-Mirzaian, A; Haj-Mirzaian, A; Hamadeh, RR; Hamidi, S; Handal, AJ; Hankey, GJ; Harb, HL; Harikrishnan, S; Haririan, H; Haro, JM; Hasan, M; Hassankhani, H; Hassen, HY; Havmoeller, R; Hay, RJ; Hay, SI; He, YH; Hedayatizadeh-Omran, A; Hegazy, MI; Heibati, B; Heidari, M; Hendrie, D; Henok, A; Henry, NJ; Heredia-Pi, I; Herteliu, C; Heydarpour, F; Heydarpour, P; Heydarpour, S; Hibstu, DT; Hoek, HW; Hole, MK; Rad, EH; Hoogar, P; Horino, M; Hosgood, HD; Hosseini, SM; Hosseinzadeh, M; Hostiuc, S; Hostiuc, M; Hotez, PJ; Hoy, DC; Hsairi, M; Htet, AS; Hu, GQ; Huang, JJ; Husseini, A; Hussen, MM; Hutfless, S; Iburg, KM; Igumbor, EU; Ikeda, CT; Illesanmi, OS; Iqbal, U; Irvani, SSN; Isehunwa, OO; Islam, SMS; Islam, F; Jahangiry, L; Jahanmehr, N; Jain, R; Jain, SK; Jakovljevic, M; James, SL; Jayanbakht, M; Jayaraman, S; Jayatilleke, AU; Jee, SH; Jeemon, P; Jha, RP; Jha, V; Ji, JS; Johnson, SC; Jonas, JB; Joshi, A; Jozwiak, JJ; Jungari, SB; Jurisson, M; Madhanraj, K; Kabir, Z; Kadel, R; Kahsay, A; Kahssay, M; Kalani, R; Kapil, U; Karami, M; Matin, BK; Karch, A; Karema, C; Karimi, N; Karimi, SM; Karimi-Sari, H; Kasaeian, A; Kassa, GM; Kassa, TD; Kassa, ZY; Kassebaum, NJ; Katibeh, M; Katikireddi, SV; Kaul, A; Kawakami, N; Kazemeini, H; Kazemi, Z; Karyani, AK; Prakash, KC; Kebede, S; Keiyoro, PN; Kemp, GR; Kengne, AP; Keren, A; Keresellidze, M; Khader, YS; Khafaie, MA; Khajavi, A; Khalid, N; Khalil, IA; Khan, EA; Khan, G; Khan, MS; Khan, MA; Khang, YH; Khanna, T; Khater, MM; Khatony, A; Khazaie, H; Khoja, AT; Khosravi, A; Khosravi, MH; Khubchandani, J; Kiadaliri, AA; Kibret, GDD; Kim, CI; Kim, D; Kim, JY; Kim, YE; Kimokoti, RN; Kinfu, Y; Kinra, S; Kisa, A; Kissimova-Skarbek, K; Kissoon, N; Kivimaki, M; Kleber, MF; Knibbs, LD; Knudsen, AKS; Kochhar, S; Kokubo, Y; Kolola, T; Kopec, JA; Kosek, MN; Kosen, S; Koul, PA; Koyanagi, A; Kravchenko, MA; Krishan, K; Krishnaswami, S; Defo, BK; Bicer, BK; Kudom, AA; Kuipers, EJ; Kulikoff, XR; Kumar, GA; Kumar, M; Kumar, P; Kumsa, FA; Kutz, MJ; Lad, SD; Lafranconi, A; Lal, DK; Lalloo, R; Lam, H; Lami, FH; Lan, Q; Langan, SM; Lansingh, V; Torisky, S; Larson, HJ; Laryea, DO; Lassi, ZS; Latifi, A; Lavados, PM; Laxmaiah, A; Lazarus, JV; Lebedev, G; Lee, PH; Leigh, J; Leshargie, CT; Leta, S; Levi, M; Li, SS; Li, YC; Li, XH; Hang, J; Liang, XF; Liben, ML; Lim, LL; Lim, SS; Limenih, MA; Linn, S; Liu, SW; Liu, Y; Lodha, R; Logroscino, G; Lonsdale, C; Lorch, SA; Lorkowski, S; Lotufo, PA; Lozano, R; Lucas, TCD; Lunevicius, R; Lyons, RA; Ma, S; Mabika, C; Macarayam, ERK; Mackay, MT; Maddison, ER; Maddison, R; Madotto, F; Abd El Razek, HM; Abd El Razek, MM; Maghavani, DP; Majdan, M; Majdzadeh, R; Majeed, A; Malekzadeh, R; Malik, MA; Malta, DC; Mamun, AA; Manamo, WA; Manda, AL; Mansoumia, MA; Mantovani, LG; Mapoma, CC; Marami, D; Marayilla, JC; Marcenes, W; Marina, S; Martinez-Raga, J; Martins, SCO; Martins-Melo, FR; Marz, N; Marzan, MB; Mashamba-Thompson, TP; Masiye, F; Massenburg, BB; Maulik, PK; Mazidi, M; McGrath, JJ; McKee, M; Mehata, S; Mehendale, SM; Mehndiratta, MM; Mehrotra, R; Mehta, KM; Mehta, V; Mekonen, T; Mekonnen, TC; Meles, HG; Meles, KG; Melese, A; Melku, M; Memiah, PTN; Memish, ZA; Mendoza, W; Mengistu, DT; Ntengistu, G; Mensah, GA; Mereta, ST; Meretoja, A; Meretoja, TJ; Mestrovic, T; Mezgebe, HB; Miangotar, Y; Miazgowski, B; Miazgowski, T; Miller, TR; Mini, GK; Mirica, A; Mirrakhimov, EM; Misganaw, AT; Moazen, B; Moges, NA; Mohammad, KA; Mohammadi, M; Mohammadifard, N; Mohammadi-Khanaposhtani, M; Mohammadnia-Afrouzi, M; Mohammed, S; Mohammed, MA; Mohan, V; Mokdad, AH; Molokhia, M; Monasta, L; Moradi, G; Moradi, M; Moradi-Lakeh, M; Moradinazar, M; Moraga, P; Morawska, L; Velasquez, TM; Morgado-da-Costa, J; Morrison, SD; Mosapour, A; Moschos, MM; Mousavi, SM; Muche, AA; Muchie, KF; Mueller, UO; Mukhopadhyay, S; Mullany, EC; Muller, K; Murhekar, M; Murphy, TB; Murthy, GVS; Murthy, S; Musa, J; Musa, KI; Mustafa, G; Muthupandian, S; Nachega, JB; Nagel, G; Naghavi, N; Naheed, A; Nahvijou, A; Naik, G; Nair, S; Najafi, F; Nangia, V; Nansseu, JR; Nascimento, BR; Nawaz, H; Ncama, BP; Neamati, N; Negoi, I; Negoi, RI; Neupane, S; Newton, CRJ; Ngalesoni, FN; Ngunjiri, JW; Nguyen, HT; Nguyen, HT; Nguyen, LH; Nguyen, M; Nguyen, TH; Ningrum, DNA; Nirayo, YL; Nisar, MI; Nixon, MR; Nolutshungu, N; Nomura, S; Norheim, OF; Noroozi, M; Norrving, B; Noubiap, JJ; Nouri, HR; Shiadeh, MN; Nowroozi, MR; Nsoesie, EO; Nyasulu, PS; Ofori-Asenso, R; Ogah, OS; Ogbo, FA; Oh, IH; Okoro, A; Oladimeji, O; Olagunju, AT; Olagunju, TO; Olivares, PR; Olusanya, BO; Olusanya, JO; Ong, SK; Opio, JN; Oren, E; Ortiz, JR; Ortiz, A; Ota, E; Otstavnov, SS; Overland, S; Owolabi, MO; Oyekale, AS; Mahesh, PA; Pacella, R; Pakhale, S; Pakhare, AP; Pana, A; Panda, BK; Panda-Jonas, S; Pandey, AR; Pandian, JD; Parisi, A; Park, EK; Parry, CDH; Parsian, H; Patel, S; Patle, A; Patten, SB; Patton, GC; Paudel, D; Pearce, N; Peprah, EK; Pereira, A; Pereira, DM; Perez, KM; Perico, N; Pervaiz, A; Pesudovs, K; Petri, WA; Petzold, M; Phillips, MR; Pigott, DM; Pillay, JD; Pirsaheb, M; Pishgar, F; Plass, D; Polinder, S; Pond, CD; Popova, S; Postma, MJ; Pourmalek, F; Pourshams, A; Poustchi, H; Prabhakaran, D; Prakash, V; Prakash, S; Prasad, N; Qorbani, M; Quistberg, DA; Radfar, A; Rafay, A; Rafiei, A; Rahim, F; Rahimi, K; Rahimi-Movaghar, A; Rahimi-Movaghar, V; Rahman, M; Rahman, MHU; Rahman, MA; Rahman, SU; Rai, RK; Rajati, P; Rajsic, S; Raju, SB; Ram, U; Ranabhat, CL; Ranjan, P; Ranta, A; Rasella, D; Rawaf, DF; Rawaf, S; Ray, SE; Razo-Garcia, C; Rego, MAS; Rehm, J; Reiner, RC; Reinig, N; Reis, C; Remuzzi, G; Renzaho, AMN; Resnikoff, S; Rezaei, S; Rezaeian, S; Rezai, MS; Riahi, SM; Ribeiro, ALP; Riojas, H; Rios-Blancas, MJ; Roba, KT; Robinson, SR; Roever, L; Ronfani, L; Roshandel, G; Roshchin, D; Rostami, A; Rothenbacher, D; Rubagotti, E; Ruhago, GM; Saadat, S; Sabde, YD; Sachder, PS; Saddik, B; Sadeghi, E; Moghaddam, SS; Safari, H; Safari, Y; Safari-Faramani, R; Safdarian, M; Safi, S; Safiri, S; Sagar, R; Sahebkar, A; Sahraian, MA; Sajadi, HS; Salahshoor, M; Salam, N; Salama, JS; Salamati, P; Saldanha, RD; Salimi, Y; Salimzadeh, H; Salz, I; Sambala, EZ; Samy, AM; Sanabria, J; Nino, MDS; Santos, IS; Santos, JV; Milicevic, MMS; Jose, BPS; Sardana, M; Sacker, AR; Sarrafzadegan, N; Sartorius, B; Sarvi, S; Sathian, B; Satpathy, M; Savic, M; Sawant, AR; Sawhney, M; Saxena, S; Sayyah, M; Scaria, V; Schadffner, F; Schelonka, K; Schmidt, MI; Schneider, IJC; Schottker, B; Schutte, AE; Schwebel, DC; Schwendicke, F; Scott, JG; Sekerija, M; Sepanlou, SG; Servan-Mori, E; Shabaninejad, H; Shackelford, KA; Shafieesabet, A; Shaheen, AA; Shaikh, MA; Shakir, RA; Shams-Beyranvand, M; Shamsi, M; Shamsizadeh, M; Sharafi, H; Sharafi, K; Sharit, M; Sharif-Alhoseini, M; Sharma, M; Sharma, J; Sharma, R; She, J; Sheikh, A; Sheth, KN; Shi, PL; Shibuya, K; Shifa, GT; Shiferaw, MS; Shigematsu, M; Shiri, R; Shirkoohi, R; Shiue, I; Shokraneh, F; Shrime, MC; Shukla, SR; Si, S; Siabani, S; Siddiqi, TJ; Sigfusdottir, ID; Sigurvinsdottir, R; Silpakit, N; Silva, DAS; Silva, JP; Silveira, DGA; Singam, NSV; Singh, JA; Singh, V; Sinha, AP; Sinha, DN; Sitas, F; Skirbekk, V; Sliwa, K; Soares, AM; Sobaih, BH; Sobhani, S; Soofi, M; Soriano, JB; Soyiri, IN; Sposato, LA; Sreeramareddy, CT; Srinivasan, V; Srivastava, RK; Starodubov, VI; Stathopoulou, V; Steel, N; Stein, DJ; Steiner, C; Stewart, LG; Stokes, MA; Sudaryanto, A; Sufiyan, MB; Sulo, G; Sunguya, BF; Sur, PJ; Sutradhar, I; Sykes, BL; Sylaja, PN; Sylte, DO; Szoeke, CFI; Tabares-Seisdedos, R; Tabuchi, T; Tadakamadla, SK; Takahashi, K; Tandon, N; Tassew, AA; Tassew, SG; Tavakkoli, M; Taveira, N; Tawye, VY; Tehrani-Banihashemi, A; Tekalign, TG; Tekle, MG; Temesgen, H; Temsah, MH; Temsah, O; Terkawi, AS; Teshale, MY; Tessema, B; Teweldemedhin, M; Thakur, JS; Thankappan, KR; Thinmavukkarasu, S; Thomas, LA; Thomas, N; Thrift, AG; Tilahun, B; To, QG; Tobe-Gai, R; Tonelli, M; Topor-Madry, R; Topouzis, F; Torre, AE; Tortajada-Girbes, M; TIavani-Palone, MR; Towbin, JA; Tran, BX; Tran, KB; Tripathi, S; Tripathy, SP; Truelsen, TC; Truong, NT; Tsadik, AG; Tsilimparis, N; Car, LT; Tuzcu, EM; Tyrovolas, S; Ukwaja, KN; Ullah, I; Usman, MS; Uthman, OA; Uzun, SB; Vaduganathan, M; Vaezi, A; Vaidya, G; Valdez, PR; Varavikova, E; Varughese, S; Vasankari, TJ; Vasconcelos, AMN; Venketasubramanian, N; Vidavalur, R; Villafaina, S; Violante, FS; Vladimirov, SK; Vlassov, V; Vollset, SE; Vos, T; Vosoughi, K; Vujcic, IS; Wagner, GR; Wagnew, FWS; Waheed, Y; Wang, YP; Wang, YP; Wassie, MM; Weiderpass, E; Weintraub, RG; Weiss, DJ; Weiss, J; Weldegebreal, F; Weldegwergs, KG; Werdecker, A; Westerman, R; Whiteford, HA; Widecka, J; Widecka, K; Wijeratne, T; Winkler, AS; Wiysonge, CS; Wolfe, CDA; Wondemagegn, SA; Wu, SL; Wyper, GMA; Xu, GL; Yadav, R; Yakob, B; Yamada, T; Yan, LJL; Yano, Y; Yaseri, M; Yasin, YJ; Ye, PP; Yearwood, JA; Yentur, GK; Yeshaneh, A; Yimer, EM; Yip, P; Yisma, E; Yonemoto, N; Yoon, SJ; York, HW; Yotebieng, M; Younis, MZ; Yousefifard, M; Yu, CH; Zachariah, G; Zadnik, V; Zafar, S; Zaidi, Z; Bin Zaman, S; Zamani, M; Zare, Z; Zeeb, H; Zeleke, MM; Zenebe, ZM; Zerfu, TA; Zhang, K; Zhang, XY; Thou, MG; Zhu, J; Zodpey, S; Zucker, I; Zuhlke, LJJ; Lopez, AD; Gakidou, E; Murray, CJI; GBD 2017 Mortality Collaborators","Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017",LANCET,,0140-6736,10.1016/S0140-6736(18)31891-9,,"Background Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP), the United States Census Bureau, WHO, and as part of previous iterations of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Previous iterations of the GBD used population estimates from UNPOP, which were not derived in a way that was internally consistent with the estimates of the numbers of deaths in the GBD. The present iteration of the GBD, GBD 2017, improves on previous assessments and provides timely estimates of the mortality experience of populations globally. Methods The GBD uses all available data to produce estimates of mortality rates between 1950 and 2017 for 23 age groups, both sexes, and 918 locations, including 195 countries and territories and subnational locations for 16 countries. Data used include vital registration systetns, sample registration systetns, household surveys (complete birth histories, summary birth histories, sibling histories), censuses (summary birth histories, household deaths), and Demographic Surveillance Sites. In total, this analysis used 8259 data sources. Estimates of the probability of death between birth and the age of 5 years and between ages 15 and 60 years are generated and then input into a model life table system to produce complete life tables for all locations and years. Fatal discontinuities and mortality due to HIV/AIDS are analysed separately and then incorporated into the estimation. We analyse the relationship between age-specific mortality and development status using the Socio-demographic Index, a composite measure based on fertility under the age of 25 years, education, and income. There are four main methodological improvements in GBD 2017 compared with GBD 2016: 622 additional data sources have been incorporated; new estimates of population, generated by the GBD study, are used; statistical methods used in different components of the analysis have been further standardised and improved; and the analysis has been extended backwards in time by two decades to start in 1950. Findings Globally, 18.7% (95% uncertainty interval 18.4-19.0) of deaths were registered in 1950 and that proportion has been steadily increasing since, with 58.8% (58.2-59.3) of all deaths being registered in 2015. At the global level, between 1950 and 2017, life expectancy increased from 48.1 years (46.5-49.6) to 70.5 years (70.1-70.8) for men and from 52.9 years (51.7-54.0) to 75.6 years (75.3-75.9) for women. Despite this overall progress, there remains substantial variation in life expectancy at birth in 2017, which ranges from 49.1 years (46.5-51.7) for men in the Central African Republic to 87.6 years (86.9-88.1) among women in Singapore. The greatest progress across age groups was for children younger than 5 years; under-5 mortality dropped from 216.0 deaths (196.3-238.1) per 1000 livebirths in 1950 to 38.9 deaths (35.6-42.83) per 1000 livebirths in 2017, with huge reductions across countries. Nevertheless, there were still 5.4 million (5.2-5.6) deaths among children younger than 5 years in the world in 2017. Progress has been less pronounced and more variable for adults, especially for adult tnales, who had stagnant or increasing mortality rates in several countries. The gap between male and female life expectancy between 1950 and 2017, while relatively stable at the global level, shows distinctive patterns across super-regions and has consistently been the largest in central Europe, eastern Europe, and central Asia, and smallest in south Asia. Performance was also variable across countries and time in observed mortality rates compared with those expected on the basis of development. Interpretation This analysis of age-sex-specific mortality shows that there are remarkably complex patterns in population mortality across countries. The findings of this study highlight global successes, such as the large decline in under-5 mortality, which reflects significant local, national, and global commitment and investment over several decades. However, they also bring attention to mortality patterns that are a cause for concern, particularly among adult men and, to a lesser extent, wotnen, whose mortality rates have stagnated in many countries over the time period of this study, and in some cases are increasing. Copyright C) 2018 The Author(s). Published by Elsevier Ltd.",10/11/2018,01/07/2022 10:40,01/07/2022 10:40,,1684-1735,,10159,392,,,,,,,,,,,,,,WOS:000449710900003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AU68BNF8,journalArticle,2018,"Lozano, R; Fullman, N; Abate, D; Abay, SM; Abbafati, C; Abbasi, N; Abbastabar, H; Abd-Allah, F; Abdela, J; Abdelalim, A; Abdel-Rahman, O; Abdi, A; Abdollahpour, I; Abdulkader, RS; Abebe, ND; Abebe, Z; Abejie, AN; Abera, SP; Abil, OZ; Aboyans, V; Abraha, HN; Abrham, AR; Abu-Raddad, LJ; Abu-Rmeileh, NM; Abyu, GY; Accrombessi, MMK; Acharya, D; Acharya, P; Adamu, AA; Adebayo, OM; Adedeji, IA; Adedoyin, RA; Adekanmbi, V; Adetokunboh, O; Adhena, BM; Adhikari, TR; Adib, MG; Adou, AK; Adsuar, JC; Afarideh, M; Afshari, M; Afshin, A; Agarwal, G; Aghayan, SA; Agius, D; Agrawal, A; Agrawal, S; Ahmadi, A; Ahmadi, M; Ahmadieh, F; Ahmed, MB; Ahmed, S; Akalu, TY; Akanda, AS; Akbari, ME; Akibu, M; Akinyemi, RO; Akinyemiju, T; Akseer, N; Alandab, T; Al-Aly, Z; Alam, K; Alam, T; Abujeer, A; Alebel, A; Alene, KA; Al-Eyadhy, A; Athabib, S; Ali, R; Alijanzadeh, M; Alizadeh-Nayaei, R; Aljunid, SM; Alkerwi, A; Alla, F; Allebeck, P; Allen, CA; Almasi, A; Al-Maskari, F; Al-Mekhlafi, HM; Alonso, J; Al-Raddadi, RM; Alsharif, U; Altirkawi, K; Alvis-Guzman, N; Amare, AT; Amenu, K; Amini, E; Ammar, W; Anber, NH; Anderson, JA; Andrei, CL; Androudi, S; Animut, MD; Anjomshoa, M; Ansari, H; Ansariadi, A; Ansha, MG; Antonio, CAT; Anwari, P; Appiah, LT; Aremu, O; Areri, HA; Arnlov, J; Arora, M; Aryal, KK; Asayesh, H; Asfaw, ET; Asgedom, SW; Asghar, RJ; Assadi, R; Ataro, Z; Atique, S; Atre, SR; Atteraya, MS; Ausloos, M; Avila-Burgos, L; Avokpaho, EFGA; Awasthi, A; Quintanilla, BPA; Ayele, HT; Ayele, Y; Ayer, R; Azarpazhooh, MR; Azzopardi, PS; Azzopardi-Muscat, N; Babalola, TK; Babazadeh, A; Badali, H; Badawi, A; Balakrishnan, K; Bali, AG; Banach, M; Banerjee, A; Banoub, JAM; Banstola, A; Barac, A; Barboza, MA; Barker-Collo, SL; Barnighausen, TW; Barrero, LH; Barthelemy, CM; Bassat, Q; Basu, A; Basu, S; Battista, RJ; Baune, BT; Baynes, HW; Bazargan-Hejazi, S; Bedi, N; Beghi, E; Behzadifar, M; Behzadifar, M; Bejot, Y; Bekele, BB; Belachew, AB; Belay, AG; Belay, SA; Belay, YA; Bell, ML; Bello, AK; Bennett, DA; Bensenor, IM; Benzian, H; Berhane, A; Berhe, AK; Berman, AE; Bernabe, E; Bernstein, RS; Bertolacci, GJ; Beuran, M; Beyranvand, T; Bhala, N; Bhalla, A; Bhansali, A; Bhattarai, S; Bhaumik, S; Bhutta, ZA; Biadgo, B; Biehl, MH; Bijani, A; Rikbov, B; Bililign, N; Bin Sayeed, MS; Birlik, SM; Birungi, C; Bisanzio, D; Biswas, T; Bitew, H; Bizuneh, H; Bjertness, E; Bobasa, EM; Boufous, S; Bourne, R; Bozorgmehr, K; Bragazzi, NL; Brainin, M; Brant, LC; Brauer, M; Brazinova, A; Breitborde, NJK; Briant, PS; Britton, G; Brugha, T; Bukhman, G; Busse, R; Butt, ZA; Cahuana-Hurtado, L; Callender, CSKH; Campos-Nonato, IR; Rincon, JCC; Cano, J; Car, J; Car, M; Cardenas, R; Carrero, JJ; Carter, A; Carvalho, F; Castaneda-Oduela, CA; Rivas, JC; Castro, F; Causey, K; Cavlin, A; Cercy, KM; Cerin, E; Chaiah, Y; Chalek, J; Chang, HY; Chang, JC; Chattopadhyay, A; Chattu, VK; Chaturvedi, P; Chiang, PPC; Chin, KL; Chisumpa, VH; Chitheer, A; Choi, JYJ; Chowdhury, R; Christensen, H; Christopher, DJ; Chung, SC; Cicuttini, FM; Ciobanu, LG; CiriIlo, M; Claro, RM; Classen, TKD; Cohen, AJ; Collado-Mateo, D; Cooper, C; Cooper, LT; Cornaby, L; Cortinovis, M; Costa, M; Cousin, E; Cromwell, EA; Crowe, CS; Cunningham, M; Daba, AK; Dadi, AF; Dandona, L; Dandona, R; Hang, AK; Dargan, PI; Daryani, A; Das, SK; Das Gupta, R; das Neves, J; Dasa, TT; Dash, AP; Davis, AC; Davitoiu, DV; Davletov, K; Dayama, A; de Courten, B; De Leo, D; De Neve, JW; De Steur, H; Degefa, MG; Degenhardt, L; Degfie, TT; Deiparine, S; Dellavalle, RP; Demoz, GT; Demtsu, B; Denova-Gutierrez, E; Deribe, K; Dervenis, N; Dessie, GA; Dey, S; Dharmaratne, SD; Dhimal, M; Dicker, D; Dinberu, MT; Ding, EI; Djalalinia, S; Do, HP; Dokova, K; Doku, DT; Douwes-Schultz, D; Driscoll, TR; Duan, LL; Dubey, M; Dubljanin, E; Duken, EE; Duncan, BB; Duraes, AR; Ebrahimpour, S; Edvardsson, D; El Bcheraoui, C; Eldrenkamp, E; El-Khatib, Z; Elyazar, IRF; Enayati, A; Endries, AY; Eshrati, B; Eskandanieh, S; Esteghamati, A; Esteghamati, S; Estep, K; Fakhar, M; Fakhim, H; Fanzo, J; Faramarzi, M; Fareed, M; Farhadi, F; Farid, TA; Farinha, CSES; Tarioli, A; Faro, A; Farvid, MS; Farzadfar, F; Farzaei, MH; Tarzam, H; Fazaeli, AA; Fazeli, MS; Feigin, VL; Feigl, AB; Fekadu, W; Feldman, R; Fentahun, N; Fereshtehnejad, SM; Fernandes, E; Fernandes, JC; Feyissa, GT; Fijabi, DO; Filip, I; Finegold, S; Finger, JD; Tischer, F; Fitzmaurice, C; Flor, LS; Foigt, NA; Foreman, KJ; Frank, TD; Franklin, RC; Fukumoto, T; Fukutaki, K; Fuller, JE; Furst, T; Furtado, JM; Gakidou, E; Gallus, S; Gankpe, FG; Gansevoort, RT; Garcia, AC; Garcia-Basteiro, AL; Garcia-Gordillo, MA; Gardner, WM; Gebre, AK; Gebre, T; Gebregergs, GB; Gebrehiwot, TT; Gebremedhin, AT; Gebremichael, B; Gebremichael, TG; Gelano, TF; Geleijnse, JM; Geramo, YCD; Getachew, S; Gething, PW; Gezae, KE; Ghadami, MR; Ghadimi, R; Ghadiri, K; Ghasemi-Kasman, M; Ghiasvand, H; Ghimire, M; Choshal, AG; Giampaoli, S; Gill, PS; Gill, TK; Giussani, G; Gnedovskaya, EV; Goldberg, EM; Goli, S; Gona, PN; Goodridge, A; Gopalani, SV; Gorman, TM; Goto, A; Coulart, AC; Coulart, BNG; Grada, A; Griswold, MG; Grosso, G; Gugnani, HCC; Guillemin, F; Guimaraes, ALS; Guo, YM; Gupta, PC; Gupta, R; Gupta, R; Gupta, T; Ha, GH; Haagsma, JA; Hachinski, V; Hafezi-Nejad, N; Bidgoli, HH; Hagos, TB; Haile, MT; Hailegiyorgis, TT; Hailu, GB; Haj-Mirzaian, A; Haj-Mirzaian, A; Hamadeh, RR; Hamidi, S; Hankey, GJ; Harb, HL; Harikrishnan, S; Haririan, H; Haro, JM; Hasan, M; Hassankhani, H; Hassell, HY; Havmoeller, R; Hawley, CN; Hay, SI; He, YH; Hedayatizadeh-Omran, A; Hegazy, MI; Heibati, B; Heidari, B; Heidari, M; Hendrie, D; Henok, A; Heredia-Pi, I; Herteliu, C; Heydarpour, B; Heydarpour, F; Heydarpour, S; Hibstu, DT; Hijar, M; Hoek, HW; Hoffman, DJ; Hole, MK; Rad, EH; Hoogar, P; Horita, N; Hosgood, HD; Hosseini, SM; Hosseinzadeff, M; Hostiuc, A; Hostiuc, S; Hotez, PJ; Hoy, DG; Hsairi, M; Hsiao, T; Hu, GQ; Huang, JJ; Hughes, C; Huynh, CK; Igumbor, EU; Ikeda, CT; Ilesanmi, OS; Iqbal, U; Irvani, SSN; Irvine, CMS; Islam, SMS; Islami, F; Ivers, RQ; Izadi, N; Jacobsen, KH; Jahangiry, L; Jahanmehr, N; Jain, SK; Jakovljevic, M; Jalu, MT; Jamal, AA; James, SI; Jassal, SK; Javanbakht, M; Jayatilleke, AU; Jeemon, P; Jha, RP; Jha, V; Ji, JS; Johnson, CO; Johnson, SC; Jonas, JB; Jonnagaddala, J; Shushtari, ZJ; Joshi, A; Jozwiak, JJ; Jungari, SB; Jurisson, M; Madhanraj, K; Kabir, Z; Kadel, R; Kahsay, A; Kahssay, M; Kalani, R; Kapil, U; Karami, M; Marin, BK; Karanikolos, M; Karimi, N; Karimi, SM; Karimi-Sari, H; Kasaeian, A; Kassa, DH; Kassa, GM; Kassa, TD; Kassa, ZY; Kassebaum, NJ; Katikireddi, SV; Kaul, A; Kawakami, N; Kazemi, Z; Karyani, AK; Kazi, DS; Prakash, KC; Kebede, S; Keiyoro, PN; Kemmer, L; Kemp, GR; Kengne, AP; Keren, A; Kesavachandran, CN; Khader, YS; Khafaei, B; Khafaie, MA; Khajavi, A; Khalid, N; Khalil, IA; Khan, EA; Khan, MS; Khan, MA; Khang, YH; Khanna, T; Khater, MM; Khatony, A; Khazaeipour, Z; Khazaie, H; Khoja, AT; Khosravi, A; Khosravi, MH; Khubchandani, J; Kiadaliri, AA; Kiarie, HW; Kibret, GD; Kiirithio, DN; Kim, D; Kim, JY; Kim, YE; Kim, YJ; Kimokoti, RW; Kinfu, Y; Kinra, S; Kisa, A; Kissimova-Skarbek, K; Kissoon, N; Kivimaki, M; Kocamik, JM; Kochhar, S; Kokubo, Y; Kolola, T; Kopec, JA; Kosek, MN; Kosen, S; Koul, PA; Koyanagi, A; Kravchenko, MA; Krishan, K; Krohn, KJ; Defo, BK; Bicer, BK; Kudom, AA; Kulikoff, XR; Kumar, GA; Kumar, M; Kumar, P; Kutz, MJ; Kyu, HH; Lachat, C; Lad, DP; Lad, SD; Lafranconi, A; Lagat, AK; Lal, DK; Lalloo, R; Lam, H; Lami, FH; Lamichhane, P; Lan, Q; Lang, JJ; Lansingh, V; Lansky, S; Larson, HJ; Larsson, A; Laryea, DO; Lassi, ZS; Latifi, A; Lau, KMM; Laxmaiah, A; Lazarus, JV; Leasher, JL; Lebedev, G; Ledesma, JR; Lee, JB; Lee, PH; Leever, AT; Leigh, J; Leinsalu, M; Leshargie, CT; Leung, J; Lewycka, S; Li, SS; Li, XH; Li, YC; Liang, J; Hang, X; Liben, ML; Lim, LL; Limenih, MA; Linn, S; Liu, SW; Liu, Y; Lodha, R; Logroscino, G; Lopez, AD; Lorkowski, S; Lotufo, PA; Lucchesi, LR; Lyons, RA; Macarayan, ERK; Mackay, MT; Maddison, ER; Madotto, F; Maghavani, DP; Magis-Rodriguez, C; Mahotra, NB; Majdan, M; Majdzadeh, R; Majeed, A; Malekzadeh, R; Malta, DC; Mamun, AA; Manda, AL; Rano, LGM; Mangalam, S; Manguerra, H; Mansournia, MA; Mapoma, CC; Maravilla, JC; Marcenes, W; Marks, A; Martin, RV; Martins, SCO; Martins-Melo, FR; Madopullo, I; Mashamba-Thompson, TP; Massenburg, BB; Mathin, MR; Maulik, PK; Mazidi, M; McAlinden, C; McGrath, JJ; McKee, M; McMahon, BJ; Mehata, S; Mehndiratta, MM; Mehrotra, R; Mehta, KM; Mehta, V; Mejia-Rodriguez, F; Mekonen, T; Mekonnen, TCC; Meles, HG; Melese, A; Melku, M; Memiah, PTN; Memish, ZA; Mendoza, W; Mengistu, DT; Mengistu, G; Mensah, GA; Mensink, GBM; Mereta, ST; Meretoja, A; Meretoja, TJ; Mestrovic, T; Mezgebe, HB; Miazgowski, B; Miazgowski, T; Millear, AI; Miller, TR; Miller-Petrie, MK; Milne, GJ; Mini, GK; Minnig, SP; Mirabi, P; Mirarefin, M; Mintakhimoty, EM; Misganaw, AT; Mitchell, PB; Moazen, B; Moghadamnia, AA; Mohajer, B; Mohammad, KA; Mohammadi, M; Mohammadifard, N; Mohammadnia-Afrouzi, M; Mohammed, MA; Mohammed, S; Mohan, MBV; Mohan, V; Mohebi, F; Moltra, M; Mokdad, AH; Molokhia, M; Monasta, L; Montanez, JC; Moosazadeh, M; Moradi, G; Moradi, M; Moradi-Lakeh, M; Moradinazar, M; Moraga, P; Morawska, L; Morgado-da-Costa, J; Morisaki, N; Morrison, SD; Mosapour, A; Moschos, MM; Mountjoy-Venning, WC; Mouodi, S; Mousavi, SM; Muche, AA; Muchie, KF; Mueller, UO; Muhammed, OSS; Mukhopadhyay, S; Mullany, EC; Muller, K; Mumford, JE; Murhekar, M; Murthy, GVS; Murthy, S; Musa, J; Musa, KI; Mustafa, G; Muthupandian, S; Nabhan, AF; Nachega, JB; Nagarajan, AJ; Nagel, G; Naghavi, M; Naheed, A; Nahvijou, A; Naidoo, K; Naik, G; Naik, N; Najafi, F; Naldi, L; Nam, HS; Nangia, V; Nansseu, JR; Nascimento, BR; Nawaz, H; Neamati, N; Negoi, I; Negoi, RI; Neupane, S; Newton, CRJ; Ngalesoni, FN; Ngunjiri, JW; Nguyen, A; Nguyen, G; Nguyen, H; Nguyen, HLT; Nguyen, HT; Nguyen, M; Nichols, E; Nigatu, SG; Ningrum, DNA; Nirayo, YL; Nisar, MI; Nixon, MR; Nolutshungu, N; Nomura, M; Norheim, OF; Noroozi, M; Norrving, B; Noubiap, JJ; Nouri, HR; Shiadeh, MN; Nowroozi, MR; Nyasulu, PS; Obermeyer, CM; Ofori-Asenso, R; Ogah, OS; Ogbo, FA; Oh, IH; Okoro, A; Oladimeji, KE; Oladimeji, O; Olagunju, AT; Olagunju, T; Olivares, PR; Olsen, HE; Olusanya, BO; Olusanya, JO; Ong, KL; Ong, SK; Oommen, AM; Opio, JN; Oren, E; Oros, A; Ortega-Altamirano, DDV; Ortiz, A; Ortiz, JR; Ortiz-Panozo, E; Ota, E; Otstavnov, SS; Owolabi, MO; Mahesh, PA; Pakhale, S; Pakhare, AP; Pan, WH; Pana, A; Panda, BK; Panda-Jonas, S; Pandian, JD; Papantoniou, N; Park, EK; Parry, CDH; Parsian, H; Patel, S; Pati, S; Patle, A; Patton, GC; Paturi, VR; Paudel, D; Paulson, KR; Pearce, N; Peprah, EK; Pereira, DM; Perico, N; Pervaiz, A; Pesudovs, K; Petri, WA; Petzold, M; Phillips, MR; Pigott, DM; Pillay, JD; Pirsaheb, M; Pletcher, M; Pond, CD; Postma, MJ; Pourshams, A; Poustchi, H; Prabhakaran, D; Prakash, S; Prasad, N; Purcell, CA; Pyakurel, M; Qorbani, M; Quansah, R; Radfar, A; Rafay, A; Rafiei, A; Rahim, F; Rahimi, K; Rahimi-Movaghar, M; Rahimi-Movaghar, V; Rahman, M; Rahman, KS; Rahman, MHU; Rahman, MA; Rahman, SU; Rai, RK; Rajati, F; Rajsic, S; Ram, U; Rana, SM; Ranabhat, CL; Ranjan, P; Rasella, D; Rawaf, DL; Rawaf, S; Razo-Garcia, C; Reddy, KS; Reiner, RC; Reis, C; Reitsma, MB; Remuzzi, G; Renzaho, AMN; Resnikoff, S; Reynales-Shigematsu, LM; Rezaei, S; Rezaeian, S; Rezai, MS; Riahi, SM; Ribeiro, ALP; Rios-Blancas, MJ; Roba, KT; Roberts, NLS; Roever, L; Ronfani, L; Roshandel, G; Rostami, A; Roth, GA; Roy, A; Rubagotti, E; Ruhago, GM; Sabde, YD; Sachdev, PS; Saddik, B; Sadeghi, E; Safari, H; Safari, Y; Safari-Faramani, R; Safdarian, M; Safi, S; Safiri, S; Sagar, R; Sahebkar, A; Sahraian, MA; Sajadi, HS; Salam, N; Salama, JS; Salamati, P; Saldanha, RD; Saleem, Z; Salimi, Y; Salimzadeh, H; Salomon, JA; Salvi, SS; Satz, I; Sambala, EZ; Samy, AM; Sanabria, J; Nino, MDS; Santos, IS; Milicevic, MMS; Jose, BPS; Sardana, M; Sarker, AR; Sarrafzadegan, N; Sartorius, B; Sarvi, S; Sathian, B; Satpathy, M; Savic, M; Sawant, AR; Sawhney, M; Saxena, S; Saylan, M; Sayyah, M; Schaeffner, E; Schmidt, MI; Schneider, IJC; Schotffer, B; Schutte, AE; Schwebel, DC; Schwendicke, F; Seedat, S; Sekerija, M; Sepanlou, SG; Servan-Mori, E; Seyedmousavi, S; Shabaninejad, H; Shackelford, KA; Shafieesabet, A; Shaheen, AA; Shaikh, MA; Shams-Beyranvand, M; Shamsi, MB; Shamsizadeff, M; Sharafi, H; Sharafi, K; Sharif, M; Sharif-Alhoseini, M; Sharma, J; Sharma, R; Sharma, SK; She, J; Sheikh, A; Shey, MS; Shi, PL; Shibuya, K; Shields, C; Shifa, GT; Shiferaw, MS; Shigematsu, M; Shin, R; Shirkoohi, R; Shirude, S; Shishani, K; Shiue, I; Shokraneh, F; Shoman, H; Shrime, MG; Shukla, SR; Si, S; Siabani, S; Sibai, AM; Siddiqi, TJ; Sigfusdottir, TD; Silpakit, N; Silva, DAS; Silva, JP; da Silva, NT; Silveira, DGA; Singh, JA; Singh, NP; Singh, OP; Singh, PK; Singh, V; Sinha, DN; Skiadaresi, E; Sliwa, K; Smith, AE; Smith, M; Soares, AM; Sobaih, BH; Sobhani, S; Soljak, M; Soofi, M; Soosaraei, M; Sorensen, RJD; Soriano, JB; Soshnikov, S; Soyiri, IN; Spinelli, A; Sposato, LA; Sreeramareddy, CT; Srinivasan, RG; Srinivasan, V; Stanaway, JD; Starodubov, VI; Stathopoulou, V; Steckling, N; Stein, DJ; Stewart, LG; Stockfelt, L; Stokes, MA; Straif, K; Sudaryanto, A; Sufiyan, MB; Sunguya, BF; Sur, PJ; Sutradhar, I; Sykes, BL; Sylaja, PN; Sylte, D; Szoeke, CEI; Tabares-Seisdedos, R; Tabuchi, T; Tadakamatha, SK; Tamirat, KS; Tandon, N; Tanser, FC; Tassew, AA; Tassew, SG; Tavakkoli, M; Taveira, N; Tawye, NT; Tehrani-Banihashemi, A; Tekalign, TG; Tekle, MG; Temesgen, H; Temsah, MH; Temsah, O; Terkawi, AS; Teshale, MY; Teshome, DF; Tessema, B; Teweldemedhin, M; Thakur, JS; Thankappan, KR; Theis, A; Thintnavukkarasu, S; Thomas, LA; Thomas, N; Thomson, AJ; Thrift, AC; Tilahun, B; To, QG; Tobe-Gai, R; Tonelli, M; Topor-Madry, R; Torre, AE; Tortajada-Girbes, M; Tovani-Palone, MR; Towbin, JA; Tran, BX; Tran, KB; Tran, TT; Tripathy, SP; Troeger, CE; Truelsen, TC; Tsadik, AG; Car, LT; Tuzcu, EM; Tymeson, HD; Ukwaja, KN; Ullah, I; Updike, RI; Usman, MS; Uthman, OA; Vaduganathan, M; Vaezi, A; Vaidya, G; Valdez, PR; van Donkelaar, A; Varavikova, E; Vasankari, TJ; Venketasubramanian, N; Vidavalur, R; Villafaina, S; Violante, FS; Vladimirov, SK; Vlassov, V; Vollmer, S; Vollset, SE; Vbs, T; Vosoughi, K; Vujcic, IS; Wagner, GR; Wagnew, FS; Waheed, Y; Watson, JI; Wang, YP; Wang, YP; Wassie, MM; Weiderpass, E; Weintraub, RG; Weiss, J; Weldegebreal, F; Weldegwergs, KG; Werdecker, A; Ayaliew, A; West, WTL; Westerman, R; Whisnant, JL; Whiteford, HA; Widecka, J; Widecka, K; Wijeratne, T; Wither, LB; Winkler, AS; Wiyeh, AB; Wiysonge, CS; Wolde, HF; Wolfe, CDA; Wu, SL; Xavier, D; Xu, GL; Xu, RS; Yadollahpour, A; Jabbari, SHY; Yakob, B; Yamada, T; Tan, LJL; Yano, Y; Yaseri, M; Yasin, YJ; Ye, PP; Tearwood, JA; Yeshaneh, A; Yimer, EM; Yip, P; Yirsaw, BD; Yisma, E; Yonemoto, N; Tonga, G; Toon, SJ; Yotebieng, M; Younis, MZ; Yousefifard, M; Yu, CH; Bin Zaman, S; Zamani, M; Zara, Z; Zavala-Arciniega, L; Zegeye, DT; Zegeye, EA; Zeleke, AJ; Zendehdel, K; Zerfit, TA; Zhang, AL; Zhang, XY; Zhou, MG; Zhu, J; Zimsen, SRM; Zodpey, S; Zoeckler, L; Zucker, I; Zuhlke, LJJ; Lim, SS; Murray, CJL; GBD 2017 SDG Collaborators",Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017,LANCET,,0140-6736,10.1016/S0140-6736(18)32281-5,,"Background Efforts to establish the 2015 baseline and monitor early implementation of the UN Sustainable Development Goals (SDGs) highlight both great potential for and threats to improving health by 2030. To fully deliver on the SDG aim of ""leaving no one behind"", it is increasingly important to examine the health-related SDGs beyond national-level estimates. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), we measured progress on 41 of 52 health -related SDG indicators and estimated the health-related SDG index for 195 countries and territories for the period 1990-2017, projected indicators to 2030, and analysed global attainment. Methods We measured progress on 41 health-related S DG indicators from 1990 to 2017, an increase of four indicators since GBD 2016 (new indicators were health worker density, sexual violence by non-intimate partners, population census status, and prevalence of physical and sexual violence [reported separately]). We also improved the measurement of several previously reported indicators. We constructed national-level estimates and, for a subset of health-related SDGs, examined indicator-level differences by sex and Socio-demographic Index (SDI) quintile. We also did subnational assessments of performance for selected countries. To construct the health related SDG index, we transformed the value for each indicator on a scale of 0-100, with 0 as the 2.5th percentile and 100 as the 97.5th percentile of 1000 draws calculated from 1990 to 2030, and took the geometric mean of the scaled indicators by target. To generate projections through 2030, we used a forecasting framework that drew estimates from the broader GBD study and used weighted averages of indicator-specific and country-specific annualised rates of change from 1990 to 2017 to inform future estimates. We assessed attainment of indicators with defined targets in two ways: first, using mean values projected for 2030, and then using the probability of attainment in 2030 calculated from 1000 draws. We also did a global attainment analysis of the feasibility of attaining SDG targets on the basis of past trends. Using 2015 global averages of indicators with defined SDG targets, we calculated the global annualised rates of change required from 2015 to 2030 to meet these targets, and then identified in what percentiles the required global annualised rates of change fell in the distribution of country-level rates of change from 1990 to 2015. We took the mean of these global percentile values across indicators and applied the past rate of change at this mean global percentile to all health-related SDG indicators, irrespective of target definition, to estimate the equivalent 2030 global average value and percentage change from 2015 to 2030 for each indicator. Findings The global median health-related SDG index in 2017 was 59.4 (IQR 35.4-67.3), ranging from a low of 11.6 (95% uncertainty interval 9.6-14.0) to a high of 84.9 (83.1-86.7). SDG index values in countries assessed at the subnational level varied substantially particularly in China and India, although scores in Japan and the UK were more homogeneous. Indicators also varied by SDI quintile and sex, with males having worse outcomes than females for non-communicable disease (NCD) mortality, alcohol use, and smoking, among others. Most countries were projected to have a higher health-related SDG index in 2030 than in 2017, while country-level probabilities of attainment by 2030 varied widely by indicator. Under-5 mortality, neonatal mortality, maternal mortality ratio, and malaria indicators had the most countries with at least 95% probability of target attainment. Other indicators, including NCD mortality and suicide mortality, had no countries projected to meet corresponding SDG targets on the basis of projected mean values for 2030 but showed some probability of attaimnent by 2030. For some indicators, including child malnutrition, several infectious diseases, and most violence measures, the annualised rates of change required to meet SDG targets far exceeded the pace of progress achieved by any country in the recent past. We found that applying the mean global annualised rate of change to indicators without defined targets would equate to about 19% and 22% reductions in global smoking and alcohol consumption, respectively; a 47% decline in adolescent birth rates; and a more than 85% increase in health worker density per 1000 population by 2030. Interpretation The GBD study offers a unique, robust platform for monitoring the health -related SDGs across demographic and geographic dimensions. Our findings underscore the importance of increased collection and analysis of disaggregated data and highlight where more deliberate design or targeting of interventions could accelerate progress in attaining the SDGs. Current projections show that many health -related SDG indicators, NCDs, NCD-related risks, and violence -related indicators will require a concerted shift away from what might have driven past gains curative interventions in the case of NCDs towards multisectoral, prevention -oriented policy action and investments to achieve SDG aims. Notably, several targets, if they are to be met by 2030, demand a pace of progress that no country has achieved in the recent past. The future is fundamentally uncertain, and no model can fully predict what breakthroughs or events might alter the course of the S DGs. What is clear is that our actions or inaction today will ultimately dictate how close the world, collectively, can get to leaving no one behind by 2030. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.",10/11/2018,01/07/2022 10:40,01/07/2022 10:40,,2091-2138,,10159,392,,,,,,,,,,,,,,WOS:000449710900010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3UY7LVTX,journalArticle,2018,"Murray, CJL; Callender, CSKH; Kulikoff, XR; Srinivasan, V; Abate, D; Abate, KH; Abay, SM; Abbasi, N; Abbastabar, H; Abdela, J; Abdelalim, A; Abdel-Rahman, O; Abdi, A; Abdoli, N; Abdollahpour, I; Abdulkader, RS; Abebe, HT; Abebe, M; Abebe, Z; Abebo, TA; Abejie, AN; Aboyans, V; Abraha, HN; Abreu, DMX; Abrham, AR; Abu-Raddad, LJ; Abu-Rmeileh, NME; Accrombessi, MMK; Acharya, P; Adamu, AA; Adebayo, OM; Adedeji, IA; Adekanmbi, V; Adetokunboh, OO; Adhena, BM; Adhikari, TB; Adib, MC; Adou, AK; Adsuar, JC; Afarideh, M; Afshin, A; Agarwal, G; Agesa, KM; Aghayan, SA; Agrawal, S; Ahmadi, A; Ahmadi, M; Ahmed, MB; Ahmed, S; Aichour, AN; Aichour, I; Aichour, MTE; Akanda, AS; Akbari, ME; Akibu, M; Akinyemi, RO; Akinyemiju, T; Akseer, N; Alahdab, F; Al-Aly, Z; Alam, K; Alebel, A; Aleman, AV; Alene, KA; Al-Eyadhy, A; Ali, R; Alijanzadeh, M; Alizadeh-Navaei, R; Aljunid, SM; Alkerwi, A; Alla, F; Allebeck, P; Almasi, A; Alonso, J; Al-Raddadi, RM; Alsharif, U; Altirkawi, K; Alvis-Guzman, N; Amare, AT; Ammar, W; Anber, NF; Andrei, CL; Androudi, S; Animut, MD; Ansari, H; Ansha, MG; Antonio, CAT; Appiah, SCY; Aremu, O; Areri, HA; Arian, N; Arnlov, J; Artaman, A; Aryal, KK; Asayesh, H; Asfaw, ET; Asgedom, SW; Assadi, R; Atey, TMM; Afique, S; Atteraya, MS; Ausloos, M; Avokpaho, EFCA; Awasthi, A; Quintanilla, BPA; Ayele, Y; Ayer, R; Ayuk, TB; Azzopardi, PS; Babalola, TK; Babazadeh, A; Radali, H; Badawi, A; Bali, AG; Ranach, M; Barker-Collo, SL; Barnighausen, TW; Barrero, LH; Basaleem, H; Bassat, Q; Basu, A; Baune, BT; Baynes, HW; Beghi, E; Behzadifar, M; Belazadifar, M; Bekele, BB; Belachew, AB; Belay, AG; Belay, E; Belay, SA; Belay, YA; Bell, ML; Bello, AK; Bennett, DA; Bensenor, IM; Bergeron, G; Berhane, A; Berman, AE; Bernabe, E; Bernstein, RS; Bertolacci, GJ; Beuran, M; Bhattarai, S; Bhaumik, S; Bhutia, ZA; Biadgo, B; Bijani, A; Rikbov, B; Bililign, N; Bin Sayeed, MS; Birlik, SM; Birungi, C; Diswas, T; Bizuneh, H; Bleyer, A; Basara, BB; Bosetti, C; Boufous, S; Brady, OJ; Bragazzi, NL; Brainin, M; Brazinova, A; Breitborde, NJK; Brenner, H; Brewer, JD; Briant, PS; Britton, G; Burstein, R; Busse, R; Riff, ZA; Cahuana-Hurtado, L; Campos-Nonato, IR; Rincon, JCC; Cano, J; Car, M; Cardenas, R; Carrero, JJ; Carvalho, F; Castaneda-Orjuela, CA; Rivas, JC; Castro, F; Catala-Lopez, F; Cavin, A; Cerin, E; Chalek, J; Chang, HY; Chang, JC; Chattopadhyay, A; Chaturvedi, P; Chiang, PPC; Chin, KL; Chisumpa, VH; Chitheer, A; Choi, JYJ; Chowdhury, R; Christopher, DJ; Cicuttini, FM; Ciobanu, LG; Cirillo, M; Claro, RM; Collado-Mateo, D; Constantin, MM; Conti, S; Cooper, C; Cooper, LT; Cornaby, L; Cortesi, PA; Cortinovis, M; Costa, M; Cromwell, EA; Crowe, CS; Cukelj, P; Cunningham, M; Daba, AK; Dachew, BA; Dandona, L; Dandona, R; Dargan, PI; Daryani, A; Das Gupta, RT; Das Neves, J; Dasa, TT; Dash, AP; Weaver, ND; Davitoiu, DV; Davletov, K; De Leo, D; De Neve, JW; Degefa, MG; Degenhardt, L; Degfie, TT; Deiparine, S; Demoz, GT; Demtsu, E; Denova-Gutierrez, E; Deribe, K; Dervenis, N; Des Jarlais, DC; Dessie, GA; Dharniaratne, SD; Dhimal, M; Dicker, D; Ding, EL; Dinsa, GD; Djalalinia, S; Do, HP; Dokova, K; Doku, DT; Dolan, KA; Doyle, KE; Driscoll, TR; Dubey, M; Dubljanin, E; Duken, EN; Duraes, AR; Ebrahimpour, S; Edvardsson, D; El Bcheraoui, C; El-Khatib, Z; Elyazar, IR; Enayati, A; Endries, AY; Ermakov, SP; Eshrati, B; Eskandarieh, S; Esmaeili, R; Esteghamati, A; Esteghamati, S; Estep, K; Fakhim, H; Farag, T; Faramarzi, M; Fareed, M; Farinha, CSES; Faro, A; Farvid, MS; Farzadfar, F; Farzaei, MH; Fay, KA; Fazeli, MS; Feigin, VI; Feigl, AB; Feizy, F; Fenny, AP; Fentahun, N; Fereshtehnejad, SM; Femandes, E; Feyissa, GT; Filip, I; Finegold, S; Fischer, F; Flor, LS; Foigt, NA; Foreman, KJ; Fornari, C; Furst, T; Fukumoto, T; Fuller, JE; Fullman, N; Gakidou, E; Gallus, S; Gamkrelidze, A; Ganji, M; Gankpe, FG; Garcia, GN; Garcia-Gordillo, MA; Gebre, AK; Gebre, T; Gebregergs, GB; Gebrehiwot, TT; Gebremedhin, AT; Gelano, TF; Gelaw, YA; Geleijnse, 'N; Genova-Maleras, R; Gething, P; Gezae, KE; Ghadami, MR; Ghadimi, R; Ghadiri, K; Falavarjani, KG; Ghasemi-Kasman, M; Ghiasvand, H; Ghimire, M; Ghoshal, AG; Gill, PS; Gill, TK; Giussani, G; Gnedovskaya, EV; Goli, S; Gomez, RS; Gomez-Dantes, H; Gona, PN; Goodridge, A; Gopalani, SV; Goulart, AC; Niegia, B; Goulart, G; Grada, A; Grosso, G; Gugnani, HCC; Guo, JW; Guo, YM; Gupta, PC; Gupta, R; Gupta, R; Gupta, T; Haagsma, JA; Hachinski, V; Hafezi-Nejad, N; Hagos, TB; Hailegiyorgis, TT; Hailu, GB; Haj-Mirzaian, A; Haj-Mirzaian, A; Hamadeh, RR; Hamidi, S; Handal, AJ; Hankey, GJ; Hao, YT; Harb, HI; Haririan, H; Haro, JM; Hasan, M; Hassankhani, H; Hassen, HY; Havrnoeller, R; Hay, SI; He, YH; Hedayatizadeh-Omran, A; Hegazy, MI; Heibati, B; Heidari, B; Hendrie, D; Henok, A; Henry, NJ; Herteliu, C; Heydarpour, F; Hibstu, DT; Hole, MK; Rad, EH; Hoogar, P; Hosgood, HD; Hosseini, SM; Chavoshi, MMH; Hosseinzadeh, M; Hostiuc, M; Hostiuc, S; Hsairi, M; Hsiao, T; Hu, GQ; Huang, JJ; Iburg, KM; Igumbor, EU; Ikeda, CT; Ilesanmi, OS; Iqbal, U; Irenso, AA; Irvani, SSN; Isehunwa, OO; Islam, SMS; Jahangiry, L; Jahanmehr, N; Jam, SK; Jakovljevic, M; Jalu, MT; James, SL; Jassal, SK; Javanbakht, M; Jayatilleke, AU; Jeemon, P; Jha, RP; Jha, V; Ji, JS; Jonas, JB; Jozwiak, JJ; Jungari, SB; Jurisson, M; Kabir, Z; Kadel, R; Kahsay, A; Kalani, R; Kapil, U; Karami, M; Martin, BK; Karch, A; Karema, C; Karimi, SM; Kasacian, A; Kassa, DH; Kassa, GM; Kassa, TD; Kassa, ZY; Kassebaum, NJ; Kastor, A; Katikireddi, SV; Kaul, A; Kawakami, N; Karyani, AK; Kebede, S; Keiyoro, PN; Kemp, GR; Kengne, AP; Keren, A; Kereselidze, M; Khader, YS; Khafaie, MA; Khajavi, A; Khalid, N; Khalil, IA; Khan, EA; Khan, MS; Hang, YHK; Khanna, T; Khater, MM; Khatony, A; Khazaeipour, Z; Khazaie, H; Khoja, AT; Khosravi, A; Khosravi, MH; Kibret, GD; Kidenemariam, ZT; Kiirithio, DN; Kilgore, PE; Kim, D; Kim, JY; Kim, YE; Kim, YJ; Kimokoti, RW; Kinfu, Y; Kinra, S; Kisa, A; Kivimaki, M; Kochhar, S; Kokubo, Y; Kolola, T; Kopec, JA; Kosek, MN; Kosen, S; Koul, PA; Koyanagi, A; Krishan, K; Krishnaswami, S; Krohn, KJ; Defo, BK; Bicer, BK; Kumar, GA; Kumar, M; Kumar, P; Kumsa, FA; Kutz, MJ; Lad, SD; Lafranconi, A; Lal, DK; Lalloo, R; Lam, H; Lami, FH; Lang, JJ; Lansky, S; Lansingh, VC; Laryea, DO; Lassi, ZS; Latifi, A; Laxmaiah, A; Lazarus, JV; Lee, JB; Lee, PH; Leigh, J; Leshargie, CT; Leta, S; Levi, M; Li, SS; Li, XH; Li, YC; Liang, J; Liang, XF; Liben, MI; Lim, LL; Limenih, MA; Linn, S; Liu, SW; Lorkowski, S; Lotufo, PA; Lozano, R; Lunevicius, R; Mabika, CM; Macarayan, ERK; Mackay, MT; Madotto, F; Mahmood, TA; Mahotra, NB; Majdan, M; Majdzadeh, R; Majeed, A; Malekzadeh, R; Malik, MA; Mamun, AA; Mariano, WA; Manda, AL; Mangalam, S; Mansournia, MA; Mantovani, LG; Mapoma, CC; Marami, D; Maravilla, JC; Marcenes, W; Marina, S; Martins-Melo, FR; Martz, W; Marzan, MB; Mashamba-Thompson, TP; Masiye, F; Mason-Jones, AJ; Massenburg, BB; Mathur, MR; Main, PK; Mazidi, M; McGrath, JJ; Mehata, S; Mehendale, SM; Mehndiratta, MM; Mehrotra, R; Mehrzadi, S; Mehta, KM; Mehta, V; Mekonnen, TC; Meles, HG; Meles, KG; Melese, A; Melku, M; Memiah, PTN; Memish, ZA; Mendoza, W; Mengesha, MM; Mengistu, DT; Mengistu, G; Mensah, GA; Mereta, ST; Meretoja, A; Meretoja, TJ; Mestrovic, T; Mezgebe, HB; Miangotar, Y; Miazgowski, B; Miazgowski, T; Miller, TR; Miller-Petrie, MK; Mini, GK; Mirabi, P; Mirica, A; Mirrakhimov, EM; Misganaw, AT; Moazen, B; Mohammad, KA; Mohammadi, M; Mohammadifard, N; Mohanmmdi-Khanaposhtani, M; Mohammed, MA; Mohammed, S; Mokdad, AH; Mola, GD; Molokhia, M; Monasta, L; Montanez, JC; Moradi, G; Moradi, M; Moradi-Lakeh, M; Moradinazar, M; Moraga, P; Morgado-Da-Costa, J; Mori, R; Morrison, SD; Mosapour, A; Moschos, MM; Mousavi, SM; Muche, AA; Muchie, KF; Mueller, UO; Mukhopadhyay, S; Murphy, TB; Muller, K; Murthy, GVS; Musa, J; Musa, KI; Mustafa, G; Muthupandian, S; Nachega, JB; Nagel, G; Naghavi, M; Naheed, A; Nahnjou, A; Naik, G; Naik, P; Najafi, F; Naldi, L; Nangia, V; Nansseu, JR; Naschnento, BR; Nawaz, H; Ncama, BP; Neamati, N; Negoi, I; Negoi, RI; Neupane, S; Newton, CRJ; Ngalesoni, FN; Ngunjiri, JW; Nguyen, G; Nguyen, LH; Nguyen, TH; Ningrum, DNA; Nirayo, YL; Nisar, MM; Nixon, MR; Nomura, S; Noroozi, M; Noubiap, JJ; Nouri, HR; Shiadeh, MN; Nowroozi, MR; Nyandwi, A; Nyasulu, PS; Odell, CM; Ofori-Asenso, R; Ogah, OS; Ogbo, FA; Oh, IH; Okoro, A; Oladimeji, O; Olagunju, AT; Olagunju, TO; Olivares, PR; Olusanya, BO; Olusanya, JO; Ong, SK; Ortiz, A; Osgood-Zimmerman, A; Ota, E; Otieno, BA; Otstavnov, SS; Owolabi, MO; Oyekale, AS; Pakhale, MPAS; Pakhare, AP; Pana, A; Panda, BK; Panda-Jonas, S; Pandey, AR; Park, EK; Parsian, H; Patel, S; Patil, ST; Patle, A; Patton, GC; Paturi, VR; Paudel, D; Pedroso, MM; Peprah, EK; Pereira, DM; Perico, N; Pesudovs, K; Petri, WA; Petzold, M; Pierce, M; Pigott, DM; Pillay, JD; Pirsaheb, M; Polanczyk, GV; Postma, MJ; Pourmalek, F; Pourshams, A; Poustchi, H; Prakash, S; Prasad, N; Purcell, CA; Purwar, MB; Qorbani, M; Quansah, R; Radfar, A; Rafay, A; Rafiei, A; Rahim, F; Rahimi-Movaghar, A; Rahimi-Movaghah, V; Rahman, M; Rahman, MS; Rahman, MHU; Rahman, MA; Rahman, SU; Rai, RK; Rajati, F; Rajsic, S; Ram, U; Ranabhat, CL; Ranjan, P; Rawaf, DL; Rawaf, S; Ray, SE; Razo-Garcia, C; Reiner, RC; Reis, C; Remuzzi, G; Renzaho, AMN; Resnikoff, S; Rezaei, S; Rezaeian, S; Rezai, MS; Riahi, SM; Rios-Blancas, MJ; Roba, KT; Roberts, NLS; Roever, L; Ronfani, L; Roshandel, G; Rostami, A; Rubagotti, E; Ruhago, GM; Sabde, YD; Sachdev, PS; Saddik, B; Moghaddam, SS; Safari, H; Safari, Y; Safari-Faramani, R; Safdarian, M; Safi, S; Safiri, S; Sagan, R; Sahebkar, A; Sahraian, MA; Sajadi, HS; Salahshoor, M; Salam, N; Salama, JS; Salamati, P; Saldanha, RDF; Sateen, Z; Salimi, Y; Salimzadeh, H; Salomon, JA; Santosh, S; Salz, I; Sanibala, EZ; Samy, AM; Sanabria, J; Sanchez-Nino, MD; Santos, IS; Milicevic, MMS; Jose, BPS; Sardana, M; Sarker, AR; Sanniento-Suarez, R; Saroshe, S; Sarrafradegan, N; Sartorius, B; Sarvi, S; Sathian, B; Satpathy, M; Sawant, AR; Sawhney, M; Saxena, S; Schaeffner, E; Schelonka, K; Schneider, IJC; Schwebel, DC; Schwendicke, F; Seedat, S; Sekerija, M; Sepanlou, SG; Servan-Mori, E; Shabaninejad, H; Shackelford, KA; Shafieesabet, A; Shaheen, AA; Shaikh, MA; Shakir, RA; Shams-Beyranvand, M; Shamsi, M; Sharnsizadeh, M; Sharafi, H; Sharafi, K; Sharif, M; Sharif-Alhoseini, M; Sharma, J; Sharma, R; She, J; Sheikh, A; Shi, PL; Shibuya, K; Shigematsu, M; Shiri, R; Shirkoohi, R; Shiue, I; Shokraneh, F; Shukla, SR; Si, S; Siabani, S; Sibai, AM; Siddiqi, TJ; Sigfusdottir, ID; Sigurvinsdottir, R; Silpakit, N; Silva, DAS; Silva, JP; Silveira, DGA; Singam, NSV; Singh, JA; Singh, NP; Singh, V; Sinha, DN; Sliwa, K; Soares, AM; Sobaih, BH; Sobhani, S; Soofi, M; Soriano, JB; Soyiri, IN; Sreeramareddy, CT; Starodubov, VI; Steiner, C; Stewart, LG; Stokes, MA; Strong, M; Subart, ML; Sufiyan, MB; Sulo, G; Sunguya, BF; Sur, PJ; Sutradhar, I; Sykes, BL; Sylaja, PN; Sylte, DO; Szoeke, CEI; Tabares-Seisdedos, R; Tabb, KM; Tadakamadla, SK; Tandon, N; Tassew, AA; Tassew, SG; Taveira, N; Tawye, NY; Tehrani-Banihashemi, A; Tekalign, TG; Tekle, MG; Temsah, MH; Terkawi, AS; Teshale, MY; Tessema, B; Teweldemedhin, M; Thakur, JS; Thankappan, KR; Thirunavukkarasu, S; Thomas, N; Thomson, AJ; Tilahun, B; To, QG; Tonelli, M; Topor-Madry, R; Torre, AE; Tortajada-Girbes, M; Tovani-Palone, MR; Toyoshima, H; Tran, BX; Tran, KB; Tripathy, SP; Truelsen, TC; Truong, NT; Tsadik, AG; Tsegay, A; Tsilimparis, N; Car, LT; Ukwaja, KN; Ullah, I; Usman, MS; Uthman, OA; Uzun, SB; Vaduganathan, M; Vaezi, A; Vaidya, G; Valdez, PR; Varavikova, E; Varughese, S; Vasankari, TJ; Vasconcelos, AMN; Venketasubramanian, N; Villafaina, S; Violante, FS; Vladimirov, SK; Vlassov, E; Vollset, SE; Vos, T; Vosoughi, K; Vujcic, IS; Wagnew, FS; Waheed, Y; Walson, JL; Wang, YP; Wang, YP; Weiderpass, E; Weintraub, RG; Weldegwergs, KG; Werdecker, A; Westerman, R; Whiteford, H; Widecka, J; Widecka, K; Wijeratne, T; Winkler, AS; Wiysonge, CS; Wolfe, CDA; Wu, SL; Wyper, GMA; Xu, G; Yamada, T; Yano, Y; Yaseri, M; Yasin, YJ; Ye, PP; Yentur, GK; Yeshaneh, A; Yimer, EM; Yip, P; Yisma, E; Yonemoto, N; Yoon, SJ; Yotebieng, M; Younis, MZ; Yousefifard, M; Yu, C; Zadnik, V; Zaidi, Z; Bin Zaman, S; Zamani, M; Zare, Z; Zeleke, MM; Zenebe, ZM; Zerfu, TA; Zhang, XY; Zhao, XJ; Zhou, MG; Zhu, J; Zimsen, SRM; Zodpey, S; Zoeckler, L; Lopez, AD; Lim, SS; GBD 2017 Population Fertility Coll","Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017",LANCET,,0140-6736,10.1016/S0140-6736(18)32278-5,,"Background Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods. Methods We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10-54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10-14 years and 50-54 years was estimated from data on fertility in women aged 15-19 years and 45-49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-cotnponent method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories. Findings From 1950 to 2017, TFRs decreased by 49.4% (95% uncertainty interval [UI] 46.4-52.0). The TFR decreased from 4.7 livebirths (4.5-4.9) to 2.4 livebirths (2.2-2.5), and the ASFR of mothers aged 10-19 years decreased from 37 livebirths (34-40) to 22 livebirths (19-24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83.8 million people per year since 1985. The global population increased by 197-2% (193.3-200.8) since 1950, from 2.6 billion (2.5-2.6) to 7.6 billion (7.4-7.9) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2.0%; this rate then remained nearly constant until 1970 and then decreased to 1.1% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2.5% in 1963 to O7% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2.7%. The global average age increased from 26.6 years in 1950 to 32.1 years in 2017, and the proportion of the population that is of working age (age 15-64 years) increased from 59.9% to 65.3%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1.0 livebirths (95% UI 0. 9-1.2) in Cyprus to a high of 7.1 livebirths (6.8-7.4) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0.08 livebirths (0.07-0.09) in South Korea to 2.4 livebirths (2.2-2.6) in Niger, and the TFR over age 30 years (I F030; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0.3 livebirths (0.3-0-4) in Puerto Rico to a high of 3.1 livebirths (3.0-3.2) in Niger. TF030 was higher than TFU25 in 145 countries and territories in 2017.33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2.0% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger. Interpretation Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.",10/11/2018,01/07/2022 10:40,01/07/2022 10:40,,1995-2051,,10159,392,,,,,,,,,,,,,,WOS:000449710900008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,